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Public health can be thought of as a series of complex systems. Many things that 
individual living in high income countries take for granted like the control of infectious 
disease, clean, potable water, low infant mortality rates require a high functioning 
systems comprised of numerous actors, locations and interactions to work. Many people 
only notice public health when that system fails. This book explores several systems in 
public health including aspects of the food system, health care system and emerging 
issues including waste minimization in nanosilver. Several chapters address global health 
concerns including non-communicable disease prevention, poverty and health-longevity 
medicine. The book also presents several novel methodologies for better modeling and 
assessment of essential public health issues.
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Preface 
Public health can be thought of as a series of complex systems. Many things that 
individual living in high income countries take for granted like the control of 
infectious disease, clean, potable water, low infant mortality rates require a high
functioning systems comprised of numerous actors, locations and interactions to work.
Many people only notice public health when that system fails. With widespread
globalization occurring, public health issues have become transnational. Infectious
diseases like SARS, H1N1 or the common cold can be transmitted within hours across
national borders via airplane. Pollution and environmental degradation can be
outsourced from high income countries to lower income countries via trade 
imbalances in manufacturing or recycling. Even NCDs can be transmitted via the 
global market for tobacco and fast food. For public health to continue to protect the 
public from these threats clear systems thinking with the development of novel 
methodologies is needed. 
The first section of this book explores novel measurement and methodologies for a 
variety of public health concerns. Chapters include assessing risk and uncertainty, 
measurement of mental health in children, the use of the Ames assay and measuring 
gene by environment interactions. The second section examines issues in the food
system and environmental risks. A safe, reliable food system is essential for public 
health in every country. Issues in this section include the presence of chemical residues
in animal food products, bacteria in food and iron deficiency anemia. The two
environmental health chapters include snakebites, one of the oldest public health
problems and waste minimization in nanosilver productions one of the newest public 
health concerns. The third section of the book reviews some of the major challenges in 
health systems. These include health resources, technology and management of 
medical devices. The role of private business in public health is also explored. The 
final section contains a variety of issues related to global health. This includes the rise 
of NCDs in low and middle income countries, neglected diseases related to poverty
and health and longevity medicine. A chapter of alcoholism and mortality examines
the effects of a public health system breakdown. Final chapters review men’s health,
insomnia and a gendered analysis. 
This book exemplifies the global nature of public health. All six inhabited continents 
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Australia, Turkey, Poland, Mexico, Brazil, Canada, Korea, The Netherlands, Japan, 
Benin, Malaysia, USA, Russia, Romania, Taiwan, Iran, Costa Rica, Columbia, Sweden, 
Germany and Italy. This trans-national list of authors provides an important view of 
the future of public health and the increased need to collaborate with public health 
professionals across the world to address the myriad of public health issues. I hope 
you enjoy reading the following chapters. I find them to be insightful and to provide 
an excellent collection of the ways that methodology advances and systems sciences 
are being used to protect and promote the public’s health. Aloha. 
 
Prof. Jay Maddock 
Department of Public Health Sciences,  
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Measurement and Methodology 
 1 
Potential Risk: A New Approach 
 Handerson J. Dourado Leite and Marcus V. Teixeira Navarro 
Federal Institute of Education, Science and Technology of Bahia 
Brazil 
1. Introduction 
Risk is a polysemic term that has been transformed throughout the historical process, but 
has always been associated to the idea of predicting an unwanted future event. 
The first rudimentary notion of what can be called risk, may have arisen, according to 
Covello and Munpower (1985), around 3200 BC in the valley between the Tigris and 
Euphrates Rivers, where lived a group called “Asipu”. A major function of this group was to 
help people who needed to make difficult decisions. The “Asipus”, when sought, identified 
the scale of the problem, the alternatives and the consequences of each alternative. Then, 
they drew up a table, marking the positive and negative points of each alternative to 
indicate the best decision. 
With the great voyages in the fifteenth century it became necessary to evaluate the damage 
caused by the potential loss of ships. Emerges then the term risk, with connotations similar 
to what is meant today, but the understanding of its causes was related to accidents and, 
therefore, impossible to predict. The development of classical probability theory, in the mid-
seventeenth century, to solve problems related to gambling, allowed the start of the process 
of quantifying the risks, but the causes were still credited to chance. 
Only from the nineteenth century, associated with the dominant thinking of the primacy of 
science and technique and propelled, among other factors, by the discoveries of Pasteur, 
emerged the association of risk with prevention, i.e., if the causes are known and quantified 
one can predict the undesirable effects. 
The advent of modernity has produced and incorporated to the human way of life a variety 
of technologies and the risk became the distinguishing feature of this generated complexity. 
More and more, the sources of hazards1 were associated with daily social practices. In 
today's society, it is difficult to separate the manmade dangers of the "natural" dangers 
(Beck, 2003). A flood for example, that occurred as a completely spontaneous phenomenon, 
today can happen as a consequence of human action on nature. This new concept that the 
term risk assumes defies the human prediction capacity and rationality, because its causes 
are no longer accidental and the causes are not always known, or they are possible effects of 
the technologies generated by man himself. 
                                                 
1 Hazards are “physical, chemical or biological agents or a set of conditions that present a source of 
risk.” (Kolluru, 1996. p. 3-41). 
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2. Risk and probability 
The first report of a quantitative risk evaluation applied to health goes back to Laplace, in the 
late eighteenth century, which calculated the probability of death among people with and 
without vaccination for smallpox. With Pasteur's studies in the late nineteenth century, it was 
possible to use the tools of statistics to evaluate the factors related to communicable diseases, 
giving birth to the concept of epidemiological risk (Covello; Munpower, 1985, Czeresnia, 2004). 
Epidemiological studies about contagious diseases have two very specific characteristics. 
The first refers to the object, which is only a source of damage. The second relates to the 
goals, which aim to determine the relationship between cause and effect, i.e., between 
exposure and disease. So, even with multifactorial determinants, it's an unidimensional 
evaluation. Therefore, in a evaluation between exposed and unexposed, the concept of risk 
approaches the definition of probability. However, when the objective includes the 
judgment about the severity of the injury or the comparison of different injuries in different 
exposures, the probability becomes one of the information that compose the concept of risk. 
Therefore, the development of probability enabled the start of the process of quantifying 
risk. However, it's noteworthy that probability and risk are different concepts to most 
subjects. While the probability it's mathematically defined as the possibility or chance of a 
particular event occurs, and is represented by a number between 0 and 1 (Gelman; Nolan, 
2004, Triola, 2005), the risk is associated with the probability of occurrence of an undesired 
event and its severity and cannot be represented by only one number. 
If two events A and B have, respectively, 0.10 and 0.90 probability of occurring, the event B 
is classified as nine times more likely to occur than the event A. However, one can not say 
that the event B has a greater risk that the event A. For the concept of risk, is fundamental to 
know how much the event will be harmful. The evaluation of the probabilities of occurrence 
of the events A and B is done purely with mathematical analysis, while the risk assessment 
requires judgment of values. Thus, all observers will agree that the event B is more likely to 
happen than the event A, but not all should agree on which event represents a greater risk, 
knowing, or not, the damage. 
As already explained, the notion of risk has been transformed throughout human history, it 
being understood nowadays as a theoretical elaboration that is historically constructed in 
order to mediate the relationship between man and the hazards, in order to minimize losses 
and maximize the benefits. Thus, it is not a greatness that is in nature to be measured, is not 
independent of the observer and his interests. It is formulated and evaluated within a 
political-economical-social context, having a multidimensional and multifactorial character 
(Fischhoff et al., 1983, Covello; Munpower, 1985, Beck, 2003, Hampel, 2006) 
3. The risk in the modern era 
The beginning of the twentieth century was marked by great scientific advances. The 
application of this knowledge produced new technologies such as X-rays, nuclear energy, 
asbestos and formaldehydes. The rapid use of these technologies as if they were only 
sources of benefits brought consequences to public health and to the environment, which 
only came to be perceived and understood by society, from the 70s of the last century. The 
disclosure of these risks led to pressures on governments, to control occupational, 
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environmental, chemical agents and radioactive agents risks. In this context of large social 
movements, the need for State intervention was strengthened, in order to regulate the use of 
products potentially harmful to health and the environment (National Research Council, 
1983, Lippmann; Cohen; Schlesinger, 2003, Omenn; Faustman, 2005) 
The regulation of health risks is understood as a government interference in the market or in 
social processes, in order to control potentially damaging consequences to health (Hood; 
Rothstein; Baldwin, 2004). The model of the regulatory system, deployed in each country 
depends on political, economic and social conjunctures. Therefore, in the 1970s, while 
European countries exerted, initially, its regulatory power, by means of direct 
administration bodies of the State, the United States exercised this power, mainly, through 
independent and specialized agencies. 
Currently, most European Union countries use the model of regulatory agencies (Lucchese, 
2001). In Brazil, this role it's exercised in a hybrid way, because the National System of Sanitary 
Surveillance (Sistema Nacional de Vigilância Sanitária - SNVS) is composed of a regulatory 
agency in the federal sphere, the National Health Surveillance Agency (Agência Nacional de 
Vigilância Sanitária – ANVISA), but in most states and municipalities the regulation is exerted 
by direct administration. 
The new technologies permeate the entire society and, therefore, influence and change the 
established social relations. These technologies are characterized by having intrinsic risks, 
by the possibility of adding new risks throughout their life cycle and by the incomplete 
scientific knowledge about the types of risks they generate and their interactions in different 
situations. Thus, the regulatory process occurs, in most cases, in situations of epistemic 
uncertainty, where risk factors are presented in a diffuse way, requiring from sanitary 
surveillance the use of mutually complementary strategies of health protection. 
As for the economic and social consequences related to the decisions of regulatory actions 
were amplified by the globalization process, as many decisions go beyond national borders 
and bring into play great interests. The first regulatory decisions showed that the process of 
definition and regulation of risk is an exercise of power, full of interests and political, 
economical, and social concepts, and can strongly influence the allocation of public and 
private resources of a nation (Slovic, 2000, Fischhoff; Bostrum e Quadrel, 2005). 
Thus, the risk conceived as the probability of occurrence of an undesired event, calculated 
by specialists and presented to society as an absolute and neutral truth, began to be 
questioned. The conflicts of interest over the division of risk showed that it is not possible to 
separate the technical analysis about the risks from the decisions of who should be 
protected, from the costs and from the available alternatives, because the studies or risk 
evaluations occur, necessarily, to subsidize decision-making. 
4. Other dimensions of risk  
The fact that the calculation of risks undertaken by experts no longer represented the 
absolute truth and, also, the impossibility to eliminate the risks produced by the new 
technologies, because the benefits would also be suppressed, bring up new angles for the 
analysis of the phenomenon. Therefore, come into play other dimensions of risk as 
acceptability, perception and confidence in the regulatory system. 
 
Public Health – Methodology, Environmental and Systems Issues 
 
4 
2. Risk and probability 
The first report of a quantitative risk evaluation applied to health goes back to Laplace, in the 
late eighteenth century, which calculated the probability of death among people with and 
without vaccination for smallpox. With Pasteur's studies in the late nineteenth century, it was 
possible to use the tools of statistics to evaluate the factors related to communicable diseases, 
giving birth to the concept of epidemiological risk (Covello; Munpower, 1985, Czeresnia, 2004). 
Epidemiological studies about contagious diseases have two very specific characteristics. 
The first refers to the object, which is only a source of damage. The second relates to the 
goals, which aim to determine the relationship between cause and effect, i.e., between 
exposure and disease. So, even with multifactorial determinants, it's an unidimensional 
evaluation. Therefore, in a evaluation between exposed and unexposed, the concept of risk 
approaches the definition of probability. However, when the objective includes the 
judgment about the severity of the injury or the comparison of different injuries in different 
exposures, the probability becomes one of the information that compose the concept of risk. 
Therefore, the development of probability enabled the start of the process of quantifying 
risk. However, it's noteworthy that probability and risk are different concepts to most 
subjects. While the probability it's mathematically defined as the possibility or chance of a 
particular event occurs, and is represented by a number between 0 and 1 (Gelman; Nolan, 
2004, Triola, 2005), the risk is associated with the probability of occurrence of an undesired 
event and its severity and cannot be represented by only one number. 
If two events A and B have, respectively, 0.10 and 0.90 probability of occurring, the event B 
is classified as nine times more likely to occur than the event A. However, one can not say 
that the event B has a greater risk that the event A. For the concept of risk, is fundamental to 
know how much the event will be harmful. The evaluation of the probabilities of occurrence 
of the events A and B is done purely with mathematical analysis, while the risk assessment 
requires judgment of values. Thus, all observers will agree that the event B is more likely to 
happen than the event A, but not all should agree on which event represents a greater risk, 
knowing, or not, the damage. 
As already explained, the notion of risk has been transformed throughout human history, it 
being understood nowadays as a theoretical elaboration that is historically constructed in 
order to mediate the relationship between man and the hazards, in order to minimize losses 
and maximize the benefits. Thus, it is not a greatness that is in nature to be measured, is not 
independent of the observer and his interests. It is formulated and evaluated within a 
political-economical-social context, having a multidimensional and multifactorial character 
(Fischhoff et al., 1983, Covello; Munpower, 1985, Beck, 2003, Hampel, 2006) 
3. The risk in the modern era 
The beginning of the twentieth century was marked by great scientific advances. The 
application of this knowledge produced new technologies such as X-rays, nuclear energy, 
asbestos and formaldehydes. The rapid use of these technologies as if they were only 
sources of benefits brought consequences to public health and to the environment, which 
only came to be perceived and understood by society, from the 70s of the last century. The 
disclosure of these risks led to pressures on governments, to control occupational, 
 
Potential Risk: A New Approach 
 
5 
environmental, chemical agents and radioactive agents risks. In this context of large social 
movements, the need for State intervention was strengthened, in order to regulate the use of 
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were amplified by the globalization process, as many decisions go beyond national borders 
and bring into play great interests. The first regulatory decisions showed that the process of 
definition and regulation of risk is an exercise of power, full of interests and political, 
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separate the technical analysis about the risks from the decisions of who should be 
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technologies, because the benefits would also be suppressed, bring up new angles for the 
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In beginning of the 1980, the U.S. Congress, realizing the need to structure a model of risk 
assessment that had wide acceptance, as well as standardizing the realization of studies in 
various areas, established a directive that designated the Food and Drug Administration 
(FDA) as responsible in coordinating a study for the harmonization. The FDA commissioned 
the National Academy of Sciences of the United States, which developed the project, whose 
results were of notorious and acknowledged importance, structuring the foundation for the 
paradigm of risk regulation (National Research Council, 1983, Omenn, Faustman, 2005). 
This study, published in 1983 under the title Risk assessment in the government: managing the 
process, known internationally as the Red Book, establishes a process with seven stages: (1) 
Hazard identification, (2) dose x response assessment, (3) exposure assessment, (4) risk 
characterization; (5) Establishment of regulatory options, (6) Decision and implementation 
of the option of regulation, (7) Evaluation of the regulation. All steps occur with the 
participation of various actors, experts or not. The stages (1 to 4) are classified as risk 
assessment and are of technical and scientifically base. The other stages (5 to 7) are part of 
risk management, which, taking into account the information obtained in the first stage, 
evaluate and implement the best regulatory options, considering economical, political and 
social issues. 
A diagram of the paradigm of risks applied to the area of health surveillance is represented 
in Figure 1. 
 
Fig. 1. Diagram of the paradigm of risks applied to the area of health surveillance. Adapted 
Omenn and Faustman (2005, p. 1084) 
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In the center of the map is the information that characterizes the particularization of the 
model for the health surveillance: the object of study. Objects of action of health 
surveillance, herein referred to as technologies in health care, have three basic 
characteristics: they are of interest to health, produce benefits and have intrinsic risks. It is 
these characteristics that justify the action of health surveillance about the technologies for 
health. 
In this triad, the risk is a feature that mobilizes a wide set of control strategies. As the risk is 
intrinsic to the object, it cannot be eliminated without eliminating the object, it can only be 
minimized. All technologies for health present some kind of risk and, if there is any that 
does not possess risks, it probably will not be object of action of the sanitary surveillance.  
For possessing risks inherent in their nature, the technologies should be used in the 
observance of the bioethical principle of the benefit (Costa, 2003, 2004) 
The diagram of the paradigm of risk, represented in Figure 1, is divided in half, pierced by 
social control and the object of study. The right side represents the field of risk assessment 
and the left side, the field of risk management. Risk assessment is the use of objective 
evidences to define the effects on health due to exposure of individuals or populations to 
hazardous materials or situations. Risk management refers to the process of integrating the 
results of risk assessment with social, economical and political issues, weighing the 
alternatives and selecting the most appropriate to the regulatory action (National Research 
Council, 1983). 
Risk assessment consists of three steps: identifying the source of damage, establishment of 
the dose x response and risk characterization. Risk identification is basically the answer to 
the question: which component of this health technology causes an adverse event? It is a 
question that can be answered based on causal, toxicological, and epidemiological evidence 
or in vitro tests (National Research Council, 1983, Omenn;  Faustman, 2005).  
In the second stage, two questions must be answered: how exposures occur? How is the 
relationship between exposure x effects (dose x response)? At this point, should be 
evaluated the conditions (intensity, frequency, duration, susceptibility and exposure 
period), in which the individuals or the populations are exposed. The second question 
should be answered with epidemiological, toxicological, experimental, and in vitro studies, 
using extrapolations or mathematical modeling, to establish the probability of occurrence 
(National Research Council, 1983, Omenn; Faustman, 2005). 
The last step is the characterization of the risk, in the classic sense. It is a moment of 
synthesis, when setting the damage likely to occur and its probability (P) the severity of the 
damage (D), the lifetime lost (T) and the vulnerabilities of exposure, as the intensity of 
exposure (I), the frequency of exposure (F), the duration of exposure (D), the exposed 
population (N), the populational groups (G) and the accessibility to the geographical 
location of the population (L). 
The risk assessment is a moment eminently technical and scientific, in which the theoretical 
models, the experimental procedures and the validation of the results are the elements of the 
performed studies (epidemiological, toxicological, in vitro and mathematical modeling, 
among others), so they can have rigor and scientific legitimacy. However, the evaluation 
models are not independent of the observers and their objectives (Czeresnia, 2004). 
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Risk assessment is not always possible to be performed quantitatively. In the case of the 
ionizing radiations, for example, the studied populations (Hiroshima and Nagasaki, 
Chernobyl and radiotherapy patients) were exposed to high doses, with high dose rates. 
Thus, it was necessary the use of the precautionary principle to postulate that, by 
extrapolation of the results of exposure at high doses, one must consider the linear 
relationship dose x response, without a threshold of exposure. Similar situations also occur 
in exposures to other physical and chemical elements, reflecting the complexity of the 
processes of risk assessment. 
Based on information from the risk assessment, begins the process of management, 
conducted by the regulatory authority, also composed of three steps: establishment of 
regulatory options and decision making; implementation of control measures and risk 
communication and; assessment of the control actions. 
In the first stage, are raised the possible actions that can minimize the risks, when the 
political-economical-cultural viability of each of the actions should be evaluated. Generally, 
there are several possibilities of regulation, when the best should be chosen. The best option 
is not, necessarily, the one with lowest risk or the one you want, it’s the possible option in 
the evaluated context. The result of the value judgments will be the establishment of the 
limits of acceptability and of the control activities needed to keep the risks within these 
limits (National Research Council, 1983, Omenn; Faustman, 2005). In the case of the sanitary 
surveillance, this is the moment of development and publication of the standards for 
sanitary regulation. 
The next step is the moment to inform society about the risks being regulated and the 
control measures being implemented. Parallel to the communication process, the regulatory 
authority should take the necessary measures, so that the control measures are effectively 
fulfilled by the regulated segment. An autonomous regulatory authority, with financial 
resources and skilled technicians, is a sine qua non condition for the implementation of the 
regulatory actions. However, the tradition of the institutions, of the regulated segment and 
of the society is essential so that risk control actions cease to be just rules and start to be 
practiced (National Research Council, 1983, Omenn; Faustman, 2005). 
The last step is the evaluation of the entire process. It's the end of the first cycle and, 
perhaps, demands the beginning of a new cycle of risk assessment and management. To 
carry out the assessment, understood as a trial on a social practice or any of its components, 
in order to assist in decision-making, it is necessary to formulate strategies, select 
approaches, criteria, indicators and standards (Vieira Da Silva, 2005). 
5. The potential risk 
As seen so far, risk is a theoretical construct, historically grounded and, by the 
characteristics with which it presents itself in modern times, requires a regulatory system 
focused on protecting the health, due to the attributes that present the new technologies. 
In the presented model of regulation of risks, the risk, in the classical sense, no longer has 
the central role, when passing from evaluation to management. In the process of risk 
management, the actions of health surveillance are focused, in general, on the control of 
risks and on the source of risks. In risk evaluation, the hazard is identified, related to the 
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damages and its consequences, thus risk is characterized. In risk management, the forms of 
control are identified, implemented and evaluated; thus control is characterized. 
The sanitary standards generally do not regulate the action of chemical, physical or 
biological substances, they regulate actions, procedures, products and equipments that must 
be used, so that the technologies for health may produce the maximum of benefit with the 
minimum of risk, considering the scientific, ethical, economical, political and social issues.  
The control actions are not related, necessarily, to the sources of risks. They may be related 
to conditions of the environment, of procedures, of human resources or of management of 
the own system of risk management. Since actions of health surveillance are focused, 
generally, on the control of risks and not on the risks itself, it becomes difficult the 
establishment of the cause-effect relationship. 
The sanitary license, for example, is an operating concept that instrumentate the sanitary 
surveillance to control risk, but that is not directly related to any source of risk. A health 
service working without a sanitary license poses a risk to the system control, but may not 
represent a risk in the classical sense. One can not say what are the damages that may occur 
and in which probability. Even because the service can be fulfilling all technical and safety 
requirements. However, the absence of the license represents an unacceptable potential risk 
situation for the system control. Similar reasoning can be used to evaluate the equipment 
registration, the professional certification, among others. 
The luminosity of the view box, used to view radiographic images, is another good example. 
The inadequate luminosity of the view box, despite not causing any direct harm to the 
patient, can hide radiological information and cause a misdiagnosis. In order to display the 
different tones of gray, in a radiography with optical density between 0.5 and 2.2, you need 
a view box with luminance between 2000 and 4000 nit2. So, what is the risk of using a view 
box with a luminance of 500 nit? 
There are so many variables involved that the question becomes difficult to answer. The 
possibility of error or loss of diagnostic information, for example, cannot be understood as a 
harm to the patient. The damage will be done when the decision making of the medical 
procedure, based on incorrect or incomplete diagnostic information, is made effective. Thus, 
one cannot determine the damage that will be caused and what are the probabilities of 
occurrence. One cannot say, even, that damage will occur. However, it is an unacceptable 
potentially hazardous situation, as is known to the minimum necessary light in a view box, 
to produce a reliable diagnosis condition. 
The potential risk concerns the possibility of an injury to health, without necessarily 
describing the injury and its probability of occurrence. It is an concept that expresses a value 
judgment about a potential exposure to a possible risk. It is as if it represents the risk of the 
risk. 
It is observed that the potential risk passes to present itself as a possibility of occurrence, or 
an expectation of the unexpected, therefore, it's related with possibility and not with 
probability. This difference is crucial to be able to clarify the proposed concept, after all, the 
probable is a category of the possible, that is, something is only probable if it's possible, 
                                                 
2 The unit of luminance in the International System is the cd/m2, known as nit. 
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2 The unit of luminance in the International System is the cd/m2, known as nit. 
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because if it's impossible, you cannot talk about probable or improbable. This condition of 
potential risk demonstrates its anteriority in relation to the classic risk. In the examples 
above, one can not calculate the probability of a damaging event for the lack of sanitary 
license or the low luminosity of the negatoscope, but, given what is known, there are 
chances that harmful events may occur due to these conditions. 
Another important feature of the concept of potential risk refers to the temporal dimension 
of causal relationships. While the classic risk has its evaluation basis in occurred events, the 
potential risk has its causal evaluation foundations in the events that are occurring and the 
effects that may, or may not, occur in the future. Thus, allows work with the temporal 
dimension of risk facing the future or for a meta-reality and not for the past.  
It is also possible to differentiate the potential risk from the classical risk according to the 
strategies used in the public health practices. These strategies can be divided into three great 
groups: health promotion in the restricted sense, health prevention (of risks or damages) 
and health protection. 
In the practices of health promotion, strategies are aimed at capacity building and at raising 
awareness of the groups, so that they can take action to improve the quality of life and 
health, without being directed to a disease or injury whatsoever. They are actions of an 
educational nature which are not related to one or another specific risk factor (Almeida 
Filho, 2008). Thus, as their strategies do not involve specific risk factors, remains to discuss 
the concept of risk involving the two other strategies. 
Regarding the preventive health strategy, the search for the determinants or the risk factors 
of a disease or of a specific aggravation on temporally and spatially defined individuals 
characterize their actions.In other words, are destined to act on these factors in order to 
reduce or eliminate new occurrences in the collective.It starts from "the assumption of 
recurrence of events in series, implying in an expectation of stability of the patterns of serial 
occurrence of the epidemiological facts" (Almeida Filho, 2000). As the action is given 
according to specific risk factors, ie, is related to the known behavior of the cause (risk 
factor) according to the probability of occurrence of the unwanted effect, the classical 
concept of risk seems to be the most appropriate. 
On the other hand, health protection is intended to strengthen the individual defenses, 
therefore, is not always directed to known causes and specific risks, or relate to the referred 
events in series. They are used, in most cases, when there is an epistemic uncertainty, ie, 
when it’s unknown or there is little information about the problem to be resolved or a 
decision to make. So, in the case of the health protection strategies, the central element in 
risk management is the potential risk that, despite not, necessarily, representing a defined 
relationship of cause and effect, can be quantified and classified into levels of acceptability, 
as will be discussed further, becoming an important operational concept of the sanitary 
surveillance.  
However, the potential risk, as well as the classic risk, cannot be represented in most 
scientific fields by only a number. It should be understood and evaluated within a context 
and with limits of acceptability established by the technical and social determinants. 
Therefore, the evaluations made by regulatory authorities in the process of risk management 
have as indicators, in most cases, the tools of risk control and, as consequence, a measure of 
potential risk, which will indicate whether the control conditions are acceptable or not. 
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6. Strategy for operationalization of potential risk 
The operationalization of the concept of potential risk has implications for the sanitary 
surveillance, because the quantification, classification and definition of acceptability levels 
of these risks will permit the monitoring and comparison of several objects under the control 
of the sanitary surveillance, such as, the health services. 
A strategy to operationalize this concept is to establish a mathematical function that relates 
potential risk with risk control indicators. These control indicators are present in the rules, 
ie, are the characteristics associated with equipments, procedures, health services etc., that 
should be controlled within the pre-established parameters. 
The control indicators represent elements that, in most cases, you do not know the 
probability of generation of harmful effects, but, if outside of the pre-established 
parameters, there is a possibility that a harmful event may occur. Therefore, there is a causal 
relationship between indicators of control and potential risk, where both are inversely 
proportional, ie, the closer to the predetermined values are the control indicator, the lower 
the potential risk and vice versa. 
Having identified the causal relationship it's possible to establish mathematical formulations 
that describe the behavior of these relationships, through the traditional mathematical 
formalism or using new theoretical contributions to the theory of fuzzy sets which together 
with the theories of evidence and of possibility, constitute a new field of study that aims at 
the treatment of epistemic uncertainties within the possibilities, as will be shown below. 
6.1 A fuzzy logic system to evaluate potential risk 
The theory of fuzzy sets, developed by Zadeh (1965), was born from the observation that in 
the real world certain objects or beings, such as the bacteria, are ambiguous as to which class 
they belong to, ie, have characteristics of animals and also vegetables. The observation of 
this ambiguity has led to the thought that there is no precision in the limits of a set and thus, 
it is possible to establish degrees of belonging of an element X, whatever, to a certain set. 
Taking as an example the bacteria, the number of animals characteristics that they exhibit 
allows us to establish a degree of belonging to the set of the animals, as well as, the amount 
of plant characteristics allows us to establish another degree of belonging to the set of the 
vegetables.This way, although they have a higher number of features of one kind or another, 
the bacterium does not cease to belong to both, though with different degrees of belonging. 
However, in the analysis of the ambiguities present in most of the everyday phenomena, is 
not always possible to quantify the characteristics of an element with precision to determine 
its degree of belonging. In most cases, these characteristics are presented in the form of 
uncertainties. To solve this problem, the modeling of the uncertainties uses the natural 
language (ordinary) and the membership functions express the possible values between 0 
and 1, which each natural term may take. (Weber,2003). 
As in natural language are used variables or linguistic terms, also called inaccurate 
quantifiers , of common use in everyday life, but definers of many decisions, such as, "low," 
"high," "good," "very good"," tolerable "and so on. The membership functions consist of the 
association of each linguistic variable to a standard curve of possibilities (Shaw; Simões, 
1999), which will define the membership degrees between 0 and 1, that the linguistic 
variable may assume. 
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Zadeh (1965) developed operators for the fuzzy sets, enabling the establishment of 
relationships between them, being the most important the operations of maximum (max) 
and minimum (min), which can be easily understood if defined, respectively, as union and 
intersection in the classical set theory. 
A fuzzy logic system (FLS), in a simplified manner, consists of performing logical operations 
with several fuzzy linguistic variables, in order to obtain a single value that represents the 
result of the performed operations. 
To build an FLS, the first step consists of the definition of the input and output variables of 
the FLS, depending on the problem you want solved. When you want to, for example, know 
what is the potential risk indicator of biological contamination of the water for dialysis in 
the realization of the hemodialysis procedure; the output variable of the FLS may already be 
defined as the potential risk indicator of biological contamination of the water for dialysis 
(PRI-BCW) 
To establish the input variables, the first question to be answered is: what are the possible 
causes to make water for dialysis potentially dangerous for biological contamination? 
Loosely, we can say that there are four causes: 1) Inadequacy of the drinking water 
treatment; 2) Inadequacy of the water treatment for dialysis; 3) Lack of knowledge or error 
of an employee who performs the procedure of water treatment for dialysis and 4) 
Inadequacy on the facilities of the water treatment plant. 
The second question, in an attempt to define the input variables, is: how to handle each 
cause defined? Consulting the existing regulations for dialysis services in Brazil, you can 
display at least one control point for each defined cause, as described in Table 1. 
 
Cause Control point 
Inadequacy of the drinking water 
treatment. 
Adequacy of the procedure for drinking water 
treatment, according to the Ordinance MS nº 
518/2004 4 
Inadequacy of the water treatment for 
dialysis. 
Adequacy of the execution of the procedure of 
water treatment for dialysis, according to the 
RDC nº 154/2004 5 
Lack of knowledge or error of an 
employee who performs the procedure 
of water treatment for dialysis. 
Adequacy of the capacity of an employee who 
performs the procedure of water treatment for 
dialysis. 
Inadequacy on the facilities of the water 
treatment plant. 
Adequacy of the constructive aspects and of 
the equipment used in the water treatment 
plant, according to the RDC nº 154/2004 5 
Table 1. Relationship between possible causes and control points of the possibility of 
biological contamination of the water for dialysis. 
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Established the control points of the four possible causes, it is up to define which input 
variables of the FLS will be the results of the verification of the level of control of the set points. 
This level of control is called control indicator (CI) and shall be established by an observer, 
such as, a public health professional with expertise to make a subjective evaluation of each 
item, and may be defined, therefore, for a fuzzy linguistic variable, or inaccurate quantifier. 
Defined the input and output variables of the FLS, it is necessary to establish the universe of 
discourse of each of them, ie, the variation range of the fuzzy linguistic variables of input 
and output. The universe of discourse limits the possible evaluations that the observer can 
present. As is the case of the input variables of the FLS, it is to check its adequacy, we will 
use the universe of discourse in terms of: Inadequate (IND), Shortly Adequate (SAD), 
Tolerable (TOL), Adequate (ADQ) and Very Adequate (VAD). 
For the output variable of the FLS, since it is an indicator of potential risk, the universe of 
discourse adopted will be: Very Low (VL), Low (L), Medium (M), High (H) and Very High 
(VH). Note that in all cases the universe of discourse consists of 5 variables to allow good 
accuracy, since the greater the number of possibilities is, the better the accuracy of the evaluator. 
The next step will be to define the logical operations that must be made in the FLS so that, 
from the input variables, it can be obtained the potential risk indicator of biological 
contamination of the water for dialysis (PRI-BCW) in the output. Being the four input 
variables of the type, verification of the "level of adequacy", and as the output variable 
should represent an indicator of potential risk, two questions must be evaluated: which 
operations should be performed between the four input variables? and what is the 
relationship between control indicator (CI) and potential risk indicator (PRI)?  
The operation between the input variables of the FLS should be held so that it is possible to 
obtain a single value, ie, a value that represents the level of control of all input variables 
(control indicator), ie, an indicator of aggregate control. Therefore, this must be one of the 
logical operations to be performed. 
The control indicators represent the level of control found by the observer and the 'potential 
risk' is the output of the FLS. Thus, the indicator of potential risk is inversely proportional to 
the control indicator, since the greater the observed control indicator, the lower the potential 
risk and vice versa. So, this will be another operation to perform 
To perform these operations, will be used fuzzy logic controllers. A fuzzy logic controller is a 
device that performs logical operations between fuzzy linguistic variables in its three stages: 
fuzzification, fuzzy inference and defuzzification. In this case, you need to build two types of 
fuzzy logic controllers, one for each type of operation you need to perform. 
For each of the fuzzy controllers, it is necessary to develop the three steps referred above 
(fuzzification, fuzzy inference and defuzzification); therefore, it will be demonstrated, 
initially, the operation between the input variables of the FLS, known only as input 
controller. Each controller must perform only the operation between two input variables, so 
there is no explosion of rules, as will be explained later. 
Fuzzification means the process of transforming the possible existing information into fuzzy 
elements; consists in identifying the linguistic variables of input and output that you want to 
operate, defining the universe of discourse and the membership functions for each variable, 
based on the experience and on the nature of the process being fuzzified. 
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To perform the fuzzification of the input controller, some steps have been taken, as the 
identification of the input linguistic variables and the establishment of the universe of 
discourse (Inadequate – IND, Shortly Adequate – SAD, Tolerable – TOL, Adequate – ADQ 
and Very Adequate – VAD). However, it lacks defining the output variable and the universe 
of discourse for this controller, because, as has been identified, it will be required more than 
one logical operation between the fuzzy variables, the output of this input controller, will 
not, necessarily, be equal to the output variable of the FLS. Thus, considering that the 
objective of this controller is to aggregate the control indicators (CI) pointed by the observer 
and thinking about the future composition of the organization of the FLS, it was decided, in 
the example shown, to define the universe of discourse of the output variable as: Very Low 
(VL), Low (L), Medium (M), High (H) and Very High (VH).  
The last step to accomplish the process of fuzzification is to define the membership function 
for each identified fuzzy linguistic variable. In this case, we took the function of trapezoidal 
and symmetrical shape for all the input controller's fuzzy linguistic variables, as can be seen 
in Figure 2. 
A membership function defines the degree of belonging or membership of each fuzzy 
linguistic value, ie, it represents the curve of possibilities of the behavior of the fuzzy 
linguistic variable (Weber, 2003). Note that the membership functions are standard 
functions, ie, in its ordinate axis (Y) it only admits fuzzy values from '0 'to '1', ie, it goes from 
the not belonging (0%) to the total belonging (100%). In the abscissa axis (X) the values 
depend on the problem addressed; in this case, we used '0 'to '1', because those are variables 
that assume this behavior (potential risk and control indicator). 
 
Fig. 2. Input controller's input and output membership functions 
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It is also important to point out, in Figure 2, that each fuzzy linguistic variable was 
associated with a numerical value 0%; 25%, 50%, 75% and 100%, respectively. This fact can 
be identified, by observing that the top of the trapezoids corresponds to one of these values. 
So, if the point 0.5 is taken (50%), in the X-axis (blue dotted line), it will correspond to the 
center of the trapezoid for the fuzzy linguistic variables 'Tolerable', in the input and 
'Medium', in the output. 
We opted for the trapezoidal shape because it was recognized that in the observation made 
there is no accuracy of values; when reporting, for example, that a level of control is 'shortly 
adequate', this does not correspond exactly to 25% but to a range for that value. Now the 
option for the symmetry was made as it was considered that there are an equal number of 
chances of the observer to choose for any of the fuzzy linguistic variables that compose the 
universe of discourse. 
The importance of fuzzification can be understood, when we take a value, for example, 0.35 
in the abscissa axis (red line), note that this value has a degree of membership greater than 
50% for ‘shortly adequate’ and less than 50% for ‘tolerable’. These membership differences 
will generate the sets that will be operationalized. 
Completed the process of fuzzification, it is necessary to perform the fuzzy inference process. 
The fuzzy inference process consists in the processing of the fuzzy variables according to 
specific rules. There are basically two methods, the Mamdani model and the Takagi-Sugeno-
Kang model (Shaw; Simões, 2005). Mamdani's method is the most used and recommended 
for the treatment with inaccurate information. It is based on the elaboration of rules of the 
'IF' <condition>; 'THEN' <consequence> type, using the heuristic method. The rules are the 
knowledge bases, from which, an "inference machine" (software or hardware) acts and 
performs operations of minimum (intersection) between the input fuzzy linguistic variables 
of each rule, and of maximum (union) between the results obtained by the previous 
operation. 
A rule of the 'IF' <condition>; 'THEN' <consequence> type is a simple logic rule and it 
means that for a given situation, 'IF' a condition is met, even partially, 'THEN', a 
consequence will occur. For example, when one states that the potential risk is inversely 
proportional to the level of control, it is possible to say that 'IF' the level of control is high, 
'THEN' the potential risk is low. When two variables (two conditions) are associated, using 
the Mamdani method, we use the operator 'AND' between the two variables to indicate that 
an operation will take place between them. This way, the rule is now stated as: 'IF' a 
condition is met, even partially 'AND' other condition is also met, even partially, 'THEN', 
some consequence will occur. This way, using the heuristic method was constructed the 
rules base for fuzzy logic controller input, shown in Table 2. 
It will be required the construction of twenty-five rules, because for two variables per 
controller and five fuzzy linguistic variables, one needs, therefore, twenty-five combinations 
(52).  
It should be noted, also, that in Table 2 the input variables were treated generically as 
'Adequacy 1' and 'Adequacy 2', because it will be necessary to use more than one input 
controller, since there are four input variables. So, you can use the same set of rules for both 
controllers. 
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The 'inference machine' is a software or hardware that performs logic operations based on 
defined rules.  
 
Rules IF Condition AND Condition THEN Condition 
1 ‘Adequacy 1’ VAD ‘Adequacy 2’ VAD 'Control' VH 
2 ‘Adequacy 1’ VAD ‘Adequacy 2’ ADQ ‘Control’ VH 
3 ‘Adequacy 1’ VAD ‘Adequacy 2’ TOL ‘Control’ M 
4 ‘Adequacy 1’ VAD ‘Adequacy 2’ SAD ‘Control’ L 
5 ‘Adequacy 1’ VAD ‘Adequacy 2’ IND ‘Control’ L 
6 ‘Adequacy 1’ ADQ ‘Adequacy 2’ VAD ‘Control’ VH 
7 ‘Adequacy 1’ ADQ ‘Adequacy 2’ ADQ ‘Control’ H 
8 ‘Adequacy 1’ ADQ ‘Adequacy 2’ TOL ‘Control’ M 
9 ‘Adequacy 1’ ADQ ‘Adequacy 2’ SAD ‘Control’ L 
10 ‘Adequacy 1’ ADQ ‘Adequacy 2’ IND ‘Control’ L 
11 ‘Adequacy 1’ TOL ‘Adequacy 2’ VAD ‘Control’ M 
12 ‘Adequacy 1’ TOL ‘Adequacy 2’ ADQ ‘Control’ M 
13 ‘Adequacy 1’ TOL ‘Adequacy 2’ TOL ‘Control’ M 
14 ‘Adequacy 1’ TOL ‘Adequacy 2’ SAD ‘Control’ L 
15 ‘Adequacy 1’ TOL ‘Adequacy 2’ IND ‘Control’ VL 
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21 ‘Adequacy 1’ IND ‘Adequacy 2’ VAD ‘Control’ L 
22 ‘Adequacy 1’ IND ‘Adequacy 2’ ADQ ‘Control’ L 
23 ‘Adequacy 1’ IND ‘Adequacy 2’ TOL ‘Control’ VL 
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(Inadequate (IND), Shortly Adequate (SAD), Tolerable (TOL), Adequate (ADQ), Very Adequate (VAD), 
Very Low (VL), Low (L), Medium (M), High (H) and Very High (VH)). 
Table 2. Rules ‘IF’...’THEN’ for fuzzy input controller 
As shown in the example above, when it was shown the importance of fuzzification, when 
defining a control indicator for an input variable, it will be associated with a number that 
will produce different degrees of membership for each membership function and, at every 
point where it intercepts the membership function, it will generate fuzzy sets. In the fuzzy 
inference it is verified if there is a point of interception for all defined rules 'IF', 'THEN'. 
Among the sets generated in each variable and in each rule, it is performed an operation of 
minimum (intersection) that corresponds to the operator 'AND'. Among the resulting sets 
from the operation of minimum of every rule, it is performed an operation of maximum 
(union), coming to a set representing the results of the performed fuzzy operations. 
In Figure 3, it is shown what happens in the process of fuzzy inference. It was assigned to 
the ‘adequacy of the procedure for drinking water treatment’ (ADWT) a control indicator 
‘Tolerable’ (0.5) and to the ‘adequacy of the procedure of water treatment for dialysis’ 
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(AWTD), a control indicator ‘Adequate’ (0.75). The red lines represent the values assigned 
to each input variable and the yellow forms, the set generated in each rule. Note  
that operations of minimum (intersection) are performed between the yellow sets of each 
rule, generating as results the blue sets. Among the blue sets, an operation of maximum 
(union) is performed, resulting in the set surrounded by a red line, representing the fuzzy 
result. 
The defuzzification process is translated into the transformation of the fuzzy set resulting 
in a discrete value, seeking to define the value that best represents the distribution of 
possibilities present in the output variable. The three most used methods for 
defuzzification are the center of area (C-O-A), the center of maximum (C-O-M) and the 
mean of maximum (M-O-M). The C-O-A method calculates the centroid of the area 
obtained in the output, or the point that divides this area in half, after the max-min 
operations performed on fuzzy inference. The C-O-M method calculates a weighted 
average of the maximum values present in the exit area, which weights are the results of 
fuzzy inference, the area itself has no influence on the outcome. Finally, the M-O-M 
method, used in this work, calculates an average of the maximum values present in the 
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The 'inference machine' is a software or hardware that performs logic operations based on 
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The second type of fuzzy logic controller to be built is called output controller. As can be 
seen in Figure 4, the input variables of this output controller will be equal to the output 
variables of the input controller and the output variables will be equal to the output 
variables of the FLS. The only difference will be the rule base ‘IF’; ’THEN’, but all other 
steps are identical to the input controller. The difference in the rule base exists, because 
the logical operation to be performed will be the conversion of the indicator of control for 
potential risk indicators that are inversely proportional. Thus, the rule base 'IF', 'THEN' 
was elaborated considering this criterion. 
Finally, for the construction of the FLS the fuzzy logic controllers will be grouped so as to 
produce the desired information, as shown in Figure 4. To carry out the construction and 





Fig. 4. Fuzzy logic system for indication of potential risk of biological contamination of the 
water for dialysis 
Thus, as can be seen in Figure 4, when evaluating a service of dialysis a sanitary inspection 
team should consider the control indicators of the adequacy of the procedure for drinking 
water treatment (CI-ADWT), of the adequacy of the procedure of water treatment for 
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dialysis (CI-AWTD), of the adequacy of the constructive aspects and of the equipment used 
in the water treatment plant (CI-ACEQ) and of the adequacy of the capacity of an employee 
who performs the procedure of water treatment for dialysis (CI-ACET), respectively, ‘TOL’, 
‘ADQ’, ‘SAD’ e ‘VAD’, so, the PRI-BCW of this system will be considered high (H), ie, 0.75; 
indicating that there is a nonconformity at some point in the process under analysis. In this 
case, the inadequacy of the constructive aspects of the water treatment plant and / or of the 
equipment used to perform the process. 
6.2 O PRAM: Potential Risk Assessment Model  
The formulation of the PRAM has been developed generalized so that it could be applied in 
any area of risk governance and possibly, also outside it. 
The PRAM was validated by evaluating potential risks in radiodiagnostic services in the 
State of Bahia, Brazil, enabling advance, in order to better understand the specific problems 
and the possibilities of action of the health surveillance system, as the regulatory authority, 
in control of risks in radiodiagnostic. 
The validation results showed that use of the PRAM model allowed going beyond simple 
situational description, indicating the possible explanatory factors of the health situation 
found. Some advantages of this approach are introduced, in comparison with other works 
that dealt with the theme. One of them concerns the graphical representation of the potential 
risk of each procedure in each of the services. 
This enables the regulatory system to classify and compare the evaluated procedures, so that 
you can plan and direct the actions for the services whose procedures are in unacceptable or 
tolerable level of potential risk , establishing priorities. 
Another advantage relates to the possibility of applying the principle of optimization in the 
risk control system, enabling the continuous evolution of the system, evaluating the 
historical evolution of risk management. The monitoring of time evolution can show an 
advance or a retreat of the potential hazard, alerting the regulatory authority before the 
service moves to a range of higher degree of risk, allowing risks prevention actions, by 
anticipating and stopping a trend.  
So, the Regulatory Authority has the possibility to act in preventing the risk and not just in 
control. The temporal evolution can be used easily, with computational aid, to monitor the 
services individually or collectively. 
However, using PRAM to monitor the temporal evolution of the potential risks, as well as 
for comparison and risk assessment, should be carried out using the same rating scales 
and indicators of the same ranges of acceptability. Otherwise, the PRAM loses 
comparability. 
The PRAM needs to consider important issues of risk governance. The first question refers 
to the range of variation. The PRAM needs to be represented by a mathematical 
formalism, whose values of the potential risk - PR are always within the same range of 
variation, regardless of the number of indicators, and there is no possibility of taking the 
zero value.  
 
Public Health – Methodology, Environmental and Systems Issues 
 
18
The second type of fuzzy logic controller to be built is called output controller. As can be 
seen in Figure 4, the input variables of this output controller will be equal to the output 
variables of the input controller and the output variables will be equal to the output 
variables of the FLS. The only difference will be the rule base ‘IF’; ’THEN’, but all other 
steps are identical to the input controller. The difference in the rule base exists, because 
the logical operation to be performed will be the conversion of the indicator of control for 
potential risk indicators that are inversely proportional. Thus, the rule base 'IF', 'THEN' 
was elaborated considering this criterion. 
Finally, for the construction of the FLS the fuzzy logic controllers will be grouped so as to 
produce the desired information, as shown in Figure 4. To carry out the construction and 





Fig. 4. Fuzzy logic system for indication of potential risk of biological contamination of the 
water for dialysis 
Thus, as can be seen in Figure 4, when evaluating a service of dialysis a sanitary inspection 
team should consider the control indicators of the adequacy of the procedure for drinking 
water treatment (CI-ADWT), of the adequacy of the procedure of water treatment for 
 
Potential Risk: A New Approach 
 
19 
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The issue of the values being within the same range of variation allows the comparison and 
the establishment of limits of acceptability, while the not possibility of assuming the value 
zero is a condition of the problem, because the risks can be as small as possible, but will 
never be nulls. 
The levels of acceptability should not have a direct border between the acceptable and the 
unacceptable. There should be a transition zone, where the condition of risk is tolerable in 
certain conditions or for some time. The levels of acceptability must permit its variation, 
for more or for less, allowing the application of the principle of optimization (Slovic, 
2000). 
On the other hand, the number of indicators should be opened, allowing the inclusion and 
exclusion of as many indicators as may be necessary. The indicators are classified, according 
to the level of potential risk they pose to the system. 
The risk control indicators should be separated into two categories: critical indicators  
and non-critical indicators. Critical indicators are those that are associated, directly, to  
the unacceptable potential risk level. For its severity, they compromise the whole risk 
control system of the procedures. Therefore, report about critical situations, whose 
existence, regardless of the existence of any other, take the potential risk to the 
unacceptable levels. 
The set of the non-critical indicators is formed by all the indicators that, individually, do not 
compromise, in a decisive way, the risk control system. The complete set of the non-critical 
indicators acts like a critical indicator, ie, if all non-critical indicators are null, the set of 
indicators will be null and thus, only then, will represent a critical commitment on the 
potential risks control system. 
Once one can build as many risk indicators as needed or desired and the result must be 
within fixed limits, fundamental to the discussion and establishment of acceptability 
criteria of the potential risks, it was necessary to develop a mathematical formalism to 
represent the mean values of the sets of indicators (critical and noncritical) through a 
single value. 
The set of critical indicators is formed by IC the indicators  
 { }1 2I I I3 INC ; C ; C ;...;C        (1) 
Since the critical indicators have the ability to compromise the entire potential risk control of 
the system, as well as they need to be represented by a mean, the most appropriate way is to 
represent them as a geometric mean. The geometric mean is the nth root of the product of N 








= ∏  (2) 
So, if any of the indicators has zero value, the value of IC will be zero, independent of the 
other indicators. On the other hand, the maximum value is, numerically, equal to the 
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maximum value of an indicator, ie, regardless of the number of indicators that is selected, 
the result will always be in the same range of variation. 
The set of non-critical indicators is formed by the INC indicators. 
 { }1 2 3I I I NNC ; NC ; NC ;...;NC        (3) 
Once the non-critical indicators do not have the ability to, individually, represent the 
commitment of all the system potential risks control, cannot have its mean represented by a 
multiplicand. However, they also need to be represented by a mean, so that the 
representative value of the set is equal, at most, to the maximum value of one of its elements 
and is within a known range of variation. 
Therefore, the best way to represent them is through an arithmetic mean. The non-critical 
indicators (INC) can be represented by a simple arithmetic average, because it can only be 











  (4) 
The function risk control (RC), which represents the result of the indicators of risks control, 
should be represented as the geometric mean, ie: 
 ( ),C I IR C NC C NC= ×                (5) 
Once more, we used the geometric mean, so that the risk control (RC) is in a range of 
variation known in advance and that depends only on the variation of IC and INC. 
Taking the risk control (RC) as the independent variable, the function that best represent the 
relationship of cause and effect between risk control and potential risk is the exponential 
function, with the following form: 
 RP ( ) c
R
CR e−=                (6) 
PR (RC) - Potential risk function, which is dependent on the risk control function, will be 
referred to as PR; RC - Risk control, function that determines the potential risk and that, on 
the other hand, is determined by the indicators of risk control. 
The shape of the exponential function, with a rapid decrease, represents a good model  
for critical phenomena, as is the case of the potential risk for health services. The complex 
relationship between the various factors that influence in the risk control exhibits a  
kind of not extensive sum, where the potential risk for an event, involving the junction 
between two factors, can be greater than the sum of the potential risk of the two factors 
separately.  
This type of behavior ends up generating a sudden increase of the potential risk, when 
adding many elements or some critics, being perfectly represented by the rapid decrease of 
the exponential function. 
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Another important behavior of the exponential function, to represent the potential risk, is 
that it has a finite maximum value and the minimum value tends to zero, without 
necessarily assuming the zero value. The potential risk of a system cannot increase 
indefinitely, and cannot be zero. Its possibility of occurrence is finite and, for bigger and 
better that it is the risk control system, you cannot reach a situation of absence of potential 
risk. 
The function proposed in this article, represented by equation (6), allows the potential risk 
to vary between the maximum value 1 and the minimum value that will be defined by the 
risk control indicator. The minimum value, will never be zero and, regardless of the number 
of indicators that it is used, the potential risk function will have fixed maximum and 
minimum values. 
So, an important issue in this model is to establish the range of variation of the risk control 
indicators, as the maximum scale value defines the minimum value that the potential risk 
function (PR) can take and, consequently, its range of variation. It is worth noting that the 
potential risk assessments with this model can only be compared, if they use the same scale 
of variation of the risk control indicators. 
The IC and INC indicators are evaluated, on a scale of zero to five, where zero represents non-
existent or inadequate risk control and five represents risk control excellent, with the 
following degrees: 0 – absent or inadequate; 1 – poorly; 2 – reasonable; 3 – good; 4 – great 
and 5 – excellent. 
One should consider that the compliance with the rule is associated with the value 3. Thus, 
regardless of the number of critical and non-critical indicators, the risk control function (RC) 
will assume values, necessarily, between 0 and 5. Then, the maximum and minimum values 
of the potential risk (PR) will be: 
 PR(RC=0) = e-0 = 1,000                      (7) 
 PR(RC=5) = e-5 = 0,007                       (8) 
When RC = 0, which means the absence of the set of non-critical risk controls or the absence 
of one of the critical risks controls, the potential risk will be PR (0) = 1, ie, there is a full 
potential risk situation. One can describe the possible potential damage; yet one can not 
specify a damage and its associated probability of occurrence. On the other hand, for greater 
that are the controls, the potential risk (PR) will never assume the zero value.  
So, one can insert or remove as many risk control indicators as may be necessary, whether 
they are critical indicators or not, there will be no change in the variation of the function 
(0.007 ≤ PR ≤ 1.000). 
The exponential function proves to be adequate to describe risk control systems, because it 
reflects well the concept of risks inherent to the technologies, ie, the risk can and should be 
minimized ever more, but can not be totally eliminated, because it is part of the technology 
itself. Ie, even if they have implemented all risk control mechanisms, it has a minimum 
potential risk value (intrinsic), which can not be eliminated, being that the benefits justify 
the use of this technology for health. 
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The RC function can also be understood as the relationship between the macro and micro 
indicators of the service. The means IC and INC contain all the information service, so that 
they behave as if they were the micro systems states, that compose a given health service, 
determined by the individual indicators IC and INC. Through them, we can know the 
situation of the equipment, of the human resources or of the procedures, while RC reports a 
macro value, aggregated, indicating the situation of the total risk control service, but 
nothing about its components, specifically. Both, RC and IC or ICN, are of fundamental 
importance for the understanding of the risk control situation, depending on who is looking 
and what you want to analyze. 
As the potential risk (PR) cannot be understood only as a dimensionless number more 
information are needed to support a decision making. As a way to aggregate the dimension 
acceptability, the potential risk should be represented within an area of potential risk with 





Fig. 5. Risk acceptance space of the PRAM 
The idea of risks space was first proposed by Slovic et al. (1979), to perform a comparison of 
the perception of different types of risks and how experts and lay people perceive risks, by 
using psychometry to quantify the technologies, understood, in the broadest sense, such as 
equipment, products, processes or practices. 
 
Public Health – Methodology, Environmental and Systems Issues 
 
22
Another important behavior of the exponential function, to represent the potential risk, is 
that it has a finite maximum value and the minimum value tends to zero, without 
necessarily assuming the zero value. The potential risk of a system cannot increase 
indefinitely, and cannot be zero. Its possibility of occurrence is finite and, for bigger and 
better that it is the risk control system, you cannot reach a situation of absence of potential 
risk. 
The function proposed in this article, represented by equation (6), allows the potential risk 
to vary between the maximum value 1 and the minimum value that will be defined by the 
risk control indicator. The minimum value, will never be zero and, regardless of the number 
of indicators that it is used, the potential risk function will have fixed maximum and 
minimum values. 
So, an important issue in this model is to establish the range of variation of the risk control 
indicators, as the maximum scale value defines the minimum value that the potential risk 
function (PR) can take and, consequently, its range of variation. It is worth noting that the 
potential risk assessments with this model can only be compared, if they use the same scale 
of variation of the risk control indicators. 
The IC and INC indicators are evaluated, on a scale of zero to five, where zero represents non-
existent or inadequate risk control and five represents risk control excellent, with the 
following degrees: 0 – absent or inadequate; 1 – poorly; 2 – reasonable; 3 – good; 4 – great 
and 5 – excellent. 
One should consider that the compliance with the rule is associated with the value 3. Thus, 
regardless of the number of critical and non-critical indicators, the risk control function (RC) 
will assume values, necessarily, between 0 and 5. Then, the maximum and minimum values 
of the potential risk (PR) will be: 
 PR(RC=0) = e-0 = 1,000                      (7) 
 PR(RC=5) = e-5 = 0,007                       (8) 
When RC = 0, which means the absence of the set of non-critical risk controls or the absence 
of one of the critical risks controls, the potential risk will be PR (0) = 1, ie, there is a full 
potential risk situation. One can describe the possible potential damage; yet one can not 
specify a damage and its associated probability of occurrence. On the other hand, for greater 
that are the controls, the potential risk (PR) will never assume the zero value.  
So, one can insert or remove as many risk control indicators as may be necessary, whether 
they are critical indicators or not, there will be no change in the variation of the function 
(0.007 ≤ PR ≤ 1.000). 
The exponential function proves to be adequate to describe risk control systems, because it 
reflects well the concept of risks inherent to the technologies, ie, the risk can and should be 
minimized ever more, but can not be totally eliminated, because it is part of the technology 
itself. Ie, even if they have implemented all risk control mechanisms, it has a minimum 
potential risk value (intrinsic), which can not be eliminated, being that the benefits justify 
the use of this technology for health. 
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The RC function can also be understood as the relationship between the macro and micro 
indicators of the service. The means IC and INC contain all the information service, so that 
they behave as if they were the micro systems states, that compose a given health service, 
determined by the individual indicators IC and INC. Through them, we can know the 
situation of the equipment, of the human resources or of the procedures, while RC reports a 
macro value, aggregated, indicating the situation of the total risk control service, but 
nothing about its components, specifically. Both, RC and IC or ICN, are of fundamental 
importance for the understanding of the risk control situation, depending on who is looking 
and what you want to analyze. 
As the potential risk (PR) cannot be understood only as a dimensionless number more 
information are needed to support a decision making. As a way to aggregate the dimension 
acceptability, the potential risk should be represented within an area of potential risk with 





Fig. 5. Risk acceptance space of the PRAM 
The idea of risks space was first proposed by Slovic et al. (1979), to perform a comparison of 
the perception of different types of risks and how experts and lay people perceive risks, by 
using psychometry to quantify the technologies, understood, in the broadest sense, such as 
equipment, products, processes or practices. 
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As there is a possibility of more than one evaluation with the same value of potential risk, 
causing a point overlap in the spatial representation, you can add a pie chart, so that you 
can see the number of services / procedures evaluated. 
The IRGC “International Risk Governance Council” in the “white paper nº2”, of 2006, 
proposes a bidimensional graphical representation to classify the risk levels of the 
nanotechnologies, using a non-linear representation, ranges of acceptability and a undefined 
region between the lower limit of the curve and the X-axis. It is a qualitative representation 
without estimation of values, which is meant to represent the shape of risks behavior in 
nanotechnology and its acceptability (IRGC, 2006). The work points to the need for 
quantitative graphical representation, which seems to have bumped in the difficulty to 
mathematically formulate the model. This difficulty was surpassed with the presented 
formulation of potential risk. 
7. Conclusion 
The concept of potential risk regards the possibility of occurrence of a health problem, 
without necessarily describing the injury and its probability of occurrence. It is a concept 
that expresses the value judgment about potential exposure to a possible risk. It's like 
representing the risk of the risk. 
An important aspect of the concept of potential risk refers to the temporal dimension of 
causal relationships. While the classical risk has its basis of evaluation in occurred events, 
the potential risk has its causal bases of evaluation in the events that are occurring and in the 
effects that may, or may not, occur in the future. Thus, allows working with the temporal 
dimension of risk facing the future or a meta-reality and not the past. 
In the case of the inspections of the health regulatory authorities, the central element in risk 
management should be the potential risk that, although not representing, necessarily, a 
defined relation of cause and effect, can be quantified and classified into levels of 
acceptability, as discussed in the presented model. 
However, the potential risk, as the classical risk, can not be represented, only, by a number. 
It should be understood and evaluated within a context and with limits of acceptability 
established by the technical and social determinants. Therefore, the evaluations made by 
regulatory authorities in the process of risk management as indicators have, in most cases, 
the tools of risk control and as a consequence, a measure of potential risk, which will 
indicate whether the control conditions are acceptable or not.  
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Over the course of the past decades, mental health has enjoyed increased interest, 
particularly in research on subjective health and well-being. In 2008, the EU has launched 
the European Pact for Mental Health and Well-being in which European Member States 
declared mental health as an important health issue and recognized it as their responsibility 
to undertake action. The Pact for Mental Health and Well-being recognizes youth and 
education as one of the top priority areas for action and sees prevention and reduction of 
mental disorders (i.e. mental ill-health) as one of the primary objectives (European 
Commission & WHO, 2008).  
According to the World Health Organization’s [WHO] definition, health is not “merely the 
absence of disease or infirmity”, but “a state of complete physical, mental and social well-
being” (WHO Constitution, 1946). Essential to this definition of health is that it has a positive 
slant (through the use of the term well-being) and stresses the equal importance of physical, 
mental and social health. Mental health can further be subdivided into two dimensions: 
Mental ill-health and positive mental health (Lehtinen et al., 2005). Positive mental health is a 
resource and is essential to subjective well-being (Lehtinen et al., 2005). Frequently, however, 
“mental health” is used when actually referring to “positive mental health” and as a 
consequence is also often (mis)understood as mental health problems or even as mental health 
diseases/disorders, and not in the positive sense. The persistence of the negative 
understanding of mental health is largely due to the fact that past and current epidemiological 
research largely was based on mental health problems and/or illness (Zubrick & Kovess-
Masfety, 2005). Many instruments have been developed focusing on mental health problems, 
thus capturing non-positive outcomes rather than mental health, as such.  
 “[W]ith its awareness of human capital and education, [modern society] puts a new 
emphasis on children as the resource of the future, low fertility strengthens children’s 
position as a scarce future resource” (Frønes 2007, p. 7). Upon the background of an 
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increasing prevalence of chronic disease and mental health problems – in adults and youth 
populations alike – research into mental health has become increasingly popular over the 
past years. The term “new morbidity” has been used to describe the changing morbidity 
pattern (from acute to chronic disease) and the rise of mental health problems (Palfrey et al., 
2005). At the present, disabling mental health problems occur worldwide in 20% of children 
and adolescents (WHO, 2001). This is an alarming number, especially knowing that mental 
health problems can have a negative effect on the entire society, with consequences, such as 
loss of productivity and social functioning (Jané-Llopis & Braddick, 2008). The fact that 
children and adolescents are affected as well is particularly worrisome. We know for 
instance that the risk for mental health problems in childhood is higher if there is a lack of 
resources; in the long run this can have effects even later in life (Jané-Llopis & Braddick, 
2008). Many adulthood mental health problems have their roots in childhood (WHO, 2005; 
Jané-Llopis & Braddick, 2008), and therefore monitoring of mental health in children is a 
promising strategy, particularly in times of profound societal changes (Mortimer & Larson, 
2002). Early detection of problem areas is crucial, and therefore, it is essential that 
monitoring systems are established based on sound indicators.  
It is important to stress that despite the above mentioned negative trends, the overall level 
of mental well-being in Europe is still high (Jané-Llopis & Braddick, 2008). And thus, it is 
worthwhile not to limit ourselves to only observing patterns of mental health problems, but 
to look at the positive side as well, in other words: how is the mental health situation in 
children and adolescents? How can it be measured adequately in this population group to 
enable identification (screening) of those with good mental health vs. those who are at risk 
for poor mental health?  
The main objective of this chapter is to give the reader a better understanding and 
appreciation of child mental health measurement, its current state-of-the-art, and 
additionally, to generally raise attention to this important field of public health. Drawing 
upon the authors’ expertise and involvement in child and adolescent mental health research, 
the chapter will briefly go into the history of positive mental health and well-being, 
including important concepts and definitions of mental health, well-being and indicators. 
The heart of the chapter will be on selected indicators of (positive and ill-) mental health and 
subjective well-being. Although surely not comprehensive in all regards, this chapter 
provides a solid background on this research field and the current state-of-the-art of child 
mental health measurement. A brief discussion with an outlook will close the chapter. 
2. Conceptualization of mental health in children and adolescents 
2.1 Concepts of mental health and well-being 
Coming back to the WHO Definition from the introduction which defines health as "a state of 
complete physical, mental and social well-being and not merely the absence of disease or 
infirmity" (WHO, 2001, p. 1), the relationship between health and well-being becomes evident. 
There are two important ideas that emerge from this: first of all, we see that “mental health is 
an integral part of health, mental health is more than the absence of mental illness, and mental 
health is intimately connected with physical health and behaviour” (WHO, 2005, p. 2). From 
this perspective one can also see that “mental health is the foundation for well-being and 
effective functioning for an individual and for a community” (WHO, 2005, p. 2). 
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Common terms often used in association with mental health are “emotional and behaviour 
problems”, “Mental health problems”, “Children’s well-being”, “Psychological health”, 
“Health-related quality of life”, “Behavioural problems”, just to name a few (Ravens-
Sieberer et al., 2008a). However, several of these are synonyms of “ill-mental health” and not 
terms that in any way describe positive mental health. According to the two continua 
model, mental health and mental ill-health (mental illness) are related but distinct 
dimensions (Westerhof & Keyes, 2010). Mental health is a positive phenomenon (Westerhof 
& Keyes, 2010) and is to be distinguished from ill-mental health.  
As a matter of fact, the definition of positive mental health has a long history and goes back to 
the two traditions of well-being (hedonic well-being and eudaimonic well-being). According to 
Keyes (2002), good mental health consists of three components which are: emotional well-
being (e.g. feelings of happiness and satisfaction with life), psychological well-being (e.g. 
positive individual functioning in terms of self-realization), and social well-being (e.g. positive 
societal functioning in terms of being of social value). He extends previous works of Ryff 
(1989) (six dimensions of psychological well-being) by adding five elements of social well-
being which includes “optimal social functioning of inidividuals in terms of their social 
engagement and societal embeddedness” (Westerhof & Keyes, 2010, p. 111). According to 
Keyes, positive mental health consists of hedonic well-being and psychological and societal 
elements of eudaimonic well-being (Keyes, 2005, 2007; Westerhof & Keyes, 2010).  
In the following, when using the term well-being, we use the term subjective well-being 
which is based on self-reports of happiness and life satisfaction (Schwarz & Strack, 1999).  
2.2 Historical development: Positive mental health and well-being 
Today's understanding of mental health and well-being is the result of scientific research 
and political activities over the past decades. Building upon the original definition of health 
(WHO, 1948), the definition of mental health is specified as "a state of well-being in which 
the individual realizes his or her own abilities, can cope with the normal stresses of life, can 
work productively and fruitfully, and is able to make a contribution to his or her 
community" (WHO, 2005, p. 2). This contemporary definition contains also the positive view 
of mental health which is a precondition for well-being. In the eyes of Keyes (2006) the 
science on mental health and subjective well-being has now arrived at - after half a century 
starting with the work of Jahoda (1958) on positive mental health - its "third generation" of 
research which does not merely focus on the absence of illness but "also on the presence of 
subjective well-being" (Keyes, 2006, p. 1).  
The concept of well-being first emerged in Greek philosophical writings. Already ancient 
civilizations considered health and well-being as one of their highest goods and values in life 
(Sigerist, 1941). However, the scientific interest in well-being did not begin until the 1950s, 
when the first indicators for quality of life were defined by social scientists to assess social 
change and to develop social policy (Land, 1975). The theories emerged during the recreation 
period after World War II where the "individual's perceptions and viewpoints, and the 
personal meaning and concerns about life" gained relevance in different scientific fields 
(Keyes, 2006, p. 2). Especially in philosophy (e.g. Phenomenology, cf. Husserl, 1913), sociology 
(e.g. Symbolic Interactionism, cf. Blumer 1962), and psychology (e.g. cognitive Psychology, cf. 
Neisser, 1967), as well as in humanistic theories (cf. Rogers, 1951; Maslow, 1968). 
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enable identification (screening) of those with good mental health vs. those who are at risk 
for poor mental health?  
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additionally, to generally raise attention to this important field of public health. Drawing 
upon the authors’ expertise and involvement in child and adolescent mental health research, 
the chapter will briefly go into the history of positive mental health and well-being, 
including important concepts and definitions of mental health, well-being and indicators. 
The heart of the chapter will be on selected indicators of (positive and ill-) mental health and 
subjective well-being. Although surely not comprehensive in all regards, this chapter 
provides a solid background on this research field and the current state-of-the-art of child 
mental health measurement. A brief discussion with an outlook will close the chapter. 
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2.1 Concepts of mental health and well-being 
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complete physical, mental and social well-being and not merely the absence of disease or 
infirmity" (WHO, 2001, p. 1), the relationship between health and well-being becomes evident. 
There are two important ideas that emerge from this: first of all, we see that “mental health is 
an integral part of health, mental health is more than the absence of mental illness, and mental 
health is intimately connected with physical health and behaviour” (WHO, 2005, p. 2). From 
this perspective one can also see that “mental health is the foundation for well-being and 
effective functioning for an individual and for a community” (WHO, 2005, p. 2). 
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Common terms often used in association with mental health are “emotional and behaviour 
problems”, “Mental health problems”, “Children’s well-being”, “Psychological health”, 
“Health-related quality of life”, “Behavioural problems”, just to name a few (Ravens-
Sieberer et al., 2008a). However, several of these are synonyms of “ill-mental health” and not 
terms that in any way describe positive mental health. According to the two continua 
model, mental health and mental ill-health (mental illness) are related but distinct 
dimensions (Westerhof & Keyes, 2010). Mental health is a positive phenomenon (Westerhof 
& Keyes, 2010) and is to be distinguished from ill-mental health.  
As a matter of fact, the definition of positive mental health has a long history and goes back to 
the two traditions of well-being (hedonic well-being and eudaimonic well-being). According to 
Keyes (2002), good mental health consists of three components which are: emotional well-
being (e.g. feelings of happiness and satisfaction with life), psychological well-being (e.g. 
positive individual functioning in terms of self-realization), and social well-being (e.g. positive 
societal functioning in terms of being of social value). He extends previous works of Ryff 
(1989) (six dimensions of psychological well-being) by adding five elements of social well-
being which includes “optimal social functioning of inidividuals in terms of their social 
engagement and societal embeddedness” (Westerhof & Keyes, 2010, p. 111). According to 
Keyes, positive mental health consists of hedonic well-being and psychological and societal 
elements of eudaimonic well-being (Keyes, 2005, 2007; Westerhof & Keyes, 2010).  
In the following, when using the term well-being, we use the term subjective well-being 
which is based on self-reports of happiness and life satisfaction (Schwarz & Strack, 1999).  
2.2 Historical development: Positive mental health and well-being 
Today's understanding of mental health and well-being is the result of scientific research 
and political activities over the past decades. Building upon the original definition of health 
(WHO, 1948), the definition of mental health is specified as "a state of well-being in which 
the individual realizes his or her own abilities, can cope with the normal stresses of life, can 
work productively and fruitfully, and is able to make a contribution to his or her 
community" (WHO, 2005, p. 2). This contemporary definition contains also the positive view 
of mental health which is a precondition for well-being. In the eyes of Keyes (2006) the 
science on mental health and subjective well-being has now arrived at - after half a century 
starting with the work of Jahoda (1958) on positive mental health - its "third generation" of 
research which does not merely focus on the absence of illness but "also on the presence of 
subjective well-being" (Keyes, 2006, p. 1).  
The concept of well-being first emerged in Greek philosophical writings. Already ancient 
civilizations considered health and well-being as one of their highest goods and values in life 
(Sigerist, 1941). However, the scientific interest in well-being did not begin until the 1950s, 
when the first indicators for quality of life were defined by social scientists to assess social 
change and to develop social policy (Land, 1975). The theories emerged during the recreation 
period after World War II where the "individual's perceptions and viewpoints, and the 
personal meaning and concerns about life" gained relevance in different scientific fields 
(Keyes, 2006, p. 2). Especially in philosophy (e.g. Phenomenology, cf. Husserl, 1913), sociology 
(e.g. Symbolic Interactionism, cf. Blumer 1962), and psychology (e.g. cognitive Psychology, cf. 
Neisser, 1967), as well as in humanistic theories (cf. Rogers, 1951; Maslow, 1968). 
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Sponsored by the Joint Commission on Mental Illness and Health in the United States, Marie 
Jahoda (1958) and Gurin et al. (1960) published two seminal reviews which Keyes categorize 
as the first research generation of subjective well-being (Keyes, 2006). Jahoda’s review 
‘Current Concepts of Positive Mental Health’ (1958) can be seen as pioneer work which 
shaped our current understanding and theories of positive mental health. Her work was 
later continued by other scientists like Carol Ryff (1989) who operationalized her theories on 
well-being (Keyes, 2006). In the first part of this important volume, Jahoda outlines the 
former understanding of mental health and emphasizes “that the absence of disease may 
constitute a necessary, but not a sufficient, criterion for mental health” (Jahoda, 1958, p. 15). 
Further, she investigates throughout a literature research six partly overlapping approaches 
to categorize positive mental health. They can be summarized as “Attitude of an individual 
towards his own self”, “Self-actualization”, “Integration”, “Autonomy”, “Perception of 
reality”, “Environmental mastery”. Yet, there is some criticism especially on the role of 
cultural influences affecting the understanding of mental health. Scientists, e.g. Murphy 
(1978), argued that western cultures are predominated by individualism and so other 
cultures which have a strong collectivistic viewpoint could have a different understanding 
of mental health. Therefore, cultural values have a strong influence on concepts of mental 
health (WHO, 2005). The second influential volume is an interview survey on approximately 
twenty-five hundred Americans conducted by Gurin, Veroff, and Feld (1960) covering the 
subjective dimension of mental health. Additionally, the volume “featured the hedonic 
stream of subjective well-being” (Keyes, 2006, p. 3) which together with the eudaimonic 
stream became more important and dominant in the “second generation” of research 
(Keyes, 2006). Hedonic well-being can be seen as a part of subjective well-being focusing 
predominantly on happiness and interest as well as satisfaction with life (Keyes, 2007). More 
generally contemplated is the existence of positive and the absence of negative affect (Deci & 
Ryan, 2008) and matches up with our everyday understanding of the word happiness 
(Waterman, 1993). In contrast, eudaimonia is a feeling of personal expressiveness, self-
realization and life satisfaction (Waterman, 1993; Deci & Ryan, 2008). The latter tradition has 
lost importance in recent well-being research, but contributes important aspects to the 
concept of well-being (Deci & Ryan, 2008). Three articles stimulated and leveraged the 
research during this time: Schwartz & Clore (1983) studied how current mood states can 
affect judgments of happiness and satisfaction with life; Diener (1984) reviewed the first 
generation of subjective well-being with a focus solely on the hedonic streaming; Ryff (1989) 
operationalized different aspects of well-being. While the well-being theories became more 
and more elaborated, various multidimensional scales were developed to measure different 
aspects of the concept. Early scales for adults included, e.g. the Bradburn Schedule (1969) 
and the General Well-Being Scale (GWBS) (1969). The first signs of child and adolescent 
well-being measurement can be found in the “social indicators movement” in the 1960s. 
Seminal work published by Campbell and Converse (1972) deals with the development of 
subjective indicators of the quality of life (e.g. aspiration, expectations, and life satisfaction) 
and Sheldon and Moore’s (1968) volume “Indicators of Social Change” conceptualized 
“objective measures, reviewing available data, and recommending data needs that would 
enable descriptive reporting on the status of society across domains” (Lippman, 2007, p. 40; 
Aborn, 1985). In later years, theoretical, normative and methodical changes in science 
spurred and formed the development of child indicators. Of particular relevance were the 
United Nation’s Convention on the Rights of the Child (CRC) which raised a normative 
framework for an integral view on children; the “new” sociology of childhood considered it 
as an independent stage in and of his self and child development theories became more 
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dynamic processes interacting with the environment (Ben-Arieh, 2008). These theoretical 
changes gave rise to new methodological perspectives. To better capture children’s own 
living conditions, especially on terms like mental well-being or peer-relations, subjective 
reports and child-centred indicators became necessary (Ben-Arieh, 2008).  
Efforts to synthesize data into national and international “state of the child” reports began 
during the 1970s. At the international level, UNICEF published in 1979 the State of the World’s 
Children Report (United Nations International Children’s Emergency Fund [UNICEF], 1979) – 
at that time only basic survival indicators were included (e.g. infant and child mortality). In the 
1990s, significant developments were made in the reporting. For instance, the Census Bureau 
published the first comparable report at an international level including domains on family 
structure, economic status, health and education (Lippman, 2007). Of particular note is the 
work of an international group of child health experts on a project called “Measuring and 
Monitoring Child Well-being: Beyond Survival” (Ben-Arieh & Wintersburger, 1997) with the 
intention to create international indicators which measure quality of life from a child’s 
perspective, including indicators which go beyond the traditionally used survival indicators, 
such as social connectedness, civic and personal life skills and children’s subculture (Lippman, 
2007). Until now, a varying set of indicators exist to measure different aspects of child well-
being. Crucial factors for the development of mental health indicators were obtained in the 
child indicators movement: Indicators for negative or risk factor were complemented by 
indicators for protective factors. Also, the indicators shifted from “well-becoming” (e.g. 
preparing children to be productive and happy adults) to “well-being” (Ben-Arieh, 2008).   
As this short historical overview shows, there have been groundbreaking developments on 
the understanding and conceptualization of mental well-being. In the next two sections we 
will take a closer look at mental health measurement in children and adolescents. We will 
begin by briefly highlighting the importance of indicators in health monitoring while also 
pointing out the conceptual and methodological challenges. 
3. Indicators as tools for health monitoring 
The term indicator originates from the Latin word “indicator” which means “one who points 
out” or “indico” (=to point out). Indicators can cover anything from “indices, signs, and 
symptoms” to “calculated probabilities and systematic measurements” (Frønes 2007, p. 8), and 
include time and space. Bauer (1966) has referred to (social) indicators as “statistics, statistical 
series, and all other forms of evidence […] that enable us to assess where we stand and are 
going with respect to our values and goals” (p. 1). For policy makers, indicators provide 
valuable information on relevant public health issues, including their trend and direction of 
change (improvement or worsening) (Lippman, 2007). But also other groups, such as child 
advocacy groups, researchers, and media use them for various purposes (Ben-Arieh, 2008).  
A good example of a widely-known and politically very influential programme is the OECD 
Programme for International Student Assessment [PISA]. PISA assesses to what extend 
knowledge and skills essential for participation in society have been acquired by 15-year-
olds at the end of their compulsory education (www.pisa.oecd.org/). The PISA indicators of 
educational success and marginalization are “perhaps the most well-known example of 
highly elaborated comparative research indicators related to children” (Frønes, 2007, p. 7). 
The first PISA report in 2000 had a substantial national and international impact and PISA 
assessment continues to be an important strategy to benchmark improvements in education 
at international level. 
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dynamic processes interacting with the environment (Ben-Arieh, 2008). These theoretical 
changes gave rise to new methodological perspectives. To better capture children’s own 
living conditions, especially on terms like mental well-being or peer-relations, subjective 
reports and child-centred indicators became necessary (Ben-Arieh, 2008).  
Efforts to synthesize data into national and international “state of the child” reports began 
during the 1970s. At the international level, UNICEF published in 1979 the State of the World’s 
Children Report (United Nations International Children’s Emergency Fund [UNICEF], 1979) – 
at that time only basic survival indicators were included (e.g. infant and child mortality). In the 
1990s, significant developments were made in the reporting. For instance, the Census Bureau 
published the first comparable report at an international level including domains on family 
structure, economic status, health and education (Lippman, 2007). Of particular note is the 
work of an international group of child health experts on a project called “Measuring and 
Monitoring Child Well-being: Beyond Survival” (Ben-Arieh & Wintersburger, 1997) with the 
intention to create international indicators which measure quality of life from a child’s 
perspective, including indicators which go beyond the traditionally used survival indicators, 
such as social connectedness, civic and personal life skills and children’s subculture (Lippman, 
2007). Until now, a varying set of indicators exist to measure different aspects of child well-
being. Crucial factors for the development of mental health indicators were obtained in the 
child indicators movement: Indicators for negative or risk factor were complemented by 
indicators for protective factors. Also, the indicators shifted from “well-becoming” (e.g. 
preparing children to be productive and happy adults) to “well-being” (Ben-Arieh, 2008).   
As this short historical overview shows, there have been groundbreaking developments on 
the understanding and conceptualization of mental well-being. In the next two sections we 
will take a closer look at mental health measurement in children and adolescents. We will 
begin by briefly highlighting the importance of indicators in health monitoring while also 
pointing out the conceptual and methodological challenges. 
3. Indicators as tools for health monitoring 
The term indicator originates from the Latin word “indicator” which means “one who points 
out” or “indico” (=to point out). Indicators can cover anything from “indices, signs, and 
symptoms” to “calculated probabilities and systematic measurements” (Frønes 2007, p. 8), and 
include time and space. Bauer (1966) has referred to (social) indicators as “statistics, statistical 
series, and all other forms of evidence […] that enable us to assess where we stand and are 
going with respect to our values and goals” (p. 1). For policy makers, indicators provide 
valuable information on relevant public health issues, including their trend and direction of 
change (improvement or worsening) (Lippman, 2007). But also other groups, such as child 
advocacy groups, researchers, and media use them for various purposes (Ben-Arieh, 2008).  
A good example of a widely-known and politically very influential programme is the OECD 
Programme for International Student Assessment [PISA]. PISA assesses to what extend 
knowledge and skills essential for participation in society have been acquired by 15-year-
olds at the end of their compulsory education (www.pisa.oecd.org/). The PISA indicators of 
educational success and marginalization are “perhaps the most well-known example of 
highly elaborated comparative research indicators related to children” (Frønes, 2007, p. 7). 
The first PISA report in 2000 had a substantial national and international impact and PISA 
assessment continues to be an important strategy to benchmark improvements in education 
at international level. 
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The European Community Health Indicators Project (ECHI) is a similar effort, but has a 
different focus. Its aim is to lay the foundation for further development of health indicators 
targeting all population groups, not just school children. The initial projects on European 
Community Health Indicators (ECHI and ECHI-2) which were conducted between 1998 and 
2005 developed ECHI indicator lists which formed the basis for the follow-up work in the 
ECHIM project. The ECHIM project is part of the European Health Strategy and builds upon 
the works of ECHI and ECHI-2. It has three main objectives (Kilpeläinen, Aromaa & the 
ECHIM project, 2008):  
• to further develop health indicators (based on ECHI short list),  
• to initiate implementation in the EU countries, and  
• to enable the establishment of a Health Monitoring System.  
Within ECHI, an indicator was defined as a characteristic of an individual, population or 
environment which is subject to measurement (directly or indirectly) and can be used to 
describe one or more aspects of the health of an individual or population (quantity, quality 
and time). According to ECHI recommendations, indicators must fulfil the criteria of 
validity, sensitivity, comparability (Kramers, 2003). 
Despite advances in indicator development through projects such as ECHI, the development 
of positive mental health indicators for children and young people is really only beginning 
(Maher & Waters, 2005). While we seek to gain a better understanding of the magnitude of 
mental health problems in children, we seem to oversee the importance of measurement 
tools and indicators to facilitate this process. Monitoring of both positive mental health and 
mental ill-health (i.e. mental health problems) is essential for human development (Zubrick 
& Kovess-Masfety, 2005). Unfortunately, mental health research in children and adolescents 
currently lacks well-established indicators. It is primarily “needs driven”, focusing on 
“illness” rather than “wellness”, and in consequence, aimed at physical rather than mental 
health (Zubrick & Kovess-Masfety, 2005). Furthermore, it is too focussed on distress, and 
mental health problems, such as delinquency, suicide, depression (Maher & Waters, 2005), 
rather than positive mental health. 
Presently, existing indicators on health are available through organisations, such as the 
European Union [EU], the Organisation for Economic Co-Operation and Development 
[OECD], and the World Health Organisation [WHO]. The EU sustainable development 
indicators provide 120 indicators, the OECD social indicators have 34 indicators on 
employment, society, general health and social cohesion, and the EU social protection 
indicators comprise 11 primary social protection indicators (whereby none on mental 
health). In 2009, the Innocenti Research Centre of the UNICEF has published a working 
paper on “Positive indicators of child well-being: a conceptual framework, measures and 
methodological issues” outlining frameworks for further development of positive indicators 
of well-being of children as well as the challenges involved (Lippman et al., 2009).  
4. Child mental health measurement 
4.1 Indicators of mental health 
As mentioned in the introduction of this chapter, we have limited ourselves to a narrow 
selection of indicators which we consider suitable for several reasons. First of all, all of the 
indicators presented here are based on tools/instruments assessing the subjective 
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perspective of the child itself. Secondly, and this is perhaps even more important, the 
indicators are based on robust, scientifically valid measurement tools. Apart from having 
been frequently used in research studies in Europe (as well as internationally), the measures 
also fulfil the scientific criteria for indicators (as proposed by the ECHI group).  
When child well-being is of interest, the preferred method of assessment is via the child’s own 
subjective perspective (Lippman et al., 2009). How children and adolescents reflect and perceive 
their world and life may differ quite substantially today from adult’s reality (Bradshaw et al. 
2006). Increasing their participation and asking for their insight and view is an indispensable 
component of present and future research. “Current attempts to measure children’s well-being 
are problematic because they fail to incorporate an analysis of broader contextual structural and 
political factors” (Morrow & Mayall, 2010, p. 162). Subjective indicators reflecting the “voice of 
the child” need to be complemented by objective models on well-being and indicators (Frønes, 
2007, p. 11). Furthermore, indicators should be based on measurement tools, which have 
undergone extensive piloting and ideally have been used previously in surveys. Measurement 
tools need to be age-, gender-, and culturally-sensitive and should also take the individual’s 
socioeconomic background into account (Erhart et al., 2006).  
Many of the indicators which will be presented here originate from the KIDSCREEN survey 
[“Screening for and Promotion of Health-Related Quality of Life in Children and 
Adolescents - A European Public Health Perspective”] and the Health Behaviour in School-
aged Children [HBSC] Survey.  
4.1.1 The KIDSCREEN survey 
The European KIDSCREEN project titled “Screening for and promotion of health-related 
well-being in children and adolescents: a European public health perspective 
(KIDSCREEN)” took place between 2001 and 2004 in 13 European countries (Austria, the 
Czech Republic, France, Germany, Greece, Hungary, Ireland, Poland, Spain, Sweden, 
Switzerland, the Netherlands and the United Kingdom) and had the aim to develop a 
standardised screening instrument for quality of life in children and adolescents. This 
instrument should be suitable for representative national and European health surveys 
and enable cross-cultural comparisons. The project, which also comprised data collection 
from large population-based samples in each of the participating countries, was part of 
the Quality of life and Management of Living Resources programme and was funded by 
the European Commission (EC) within the Fifth Framework Programme (EC Grant 
Number: QLG-CT-2000- 00751) (Ravens-Sieberer et al., 2001). The data collection targeted 
children between 8 and 18 years of age using both parents as well as children as 
information sources. The same kind of data collection tools (questionnaires) and the same 
assessment tools were used in all participating countries (Ravens-Sieberer et al., 2005). 
Data on physical health, mental health and socioeconomic status in children and 
adolescents in Europe was collected and the distribution of mental ill health and poor 
mental well-being estimated. Thee important instruments came out of the KIDSCREEN 
project: KIDSCREEN-52, KIDSCREEN-27 and KIDSCREEN-10. Single dimensions of these 
instruments and the global HRQoL score (KIDSCREEN-10) can be used as suitable 
indicators for quality of life resp. positive mental health. The KIDSCREEN-10 Mental 
Health Index assesses the child's perspective on his or her physical, mental and social 
well-being, identifies children at risk and suggests suitable early interventions. For this 
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perspective of the child itself. Secondly, and this is perhaps even more important, the 
indicators are based on robust, scientifically valid measurement tools. Apart from having 
been frequently used in research studies in Europe (as well as internationally), the measures 
also fulfil the scientific criteria for indicators (as proposed by the ECHI group).  
When child well-being is of interest, the preferred method of assessment is via the child’s own 
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and enable cross-cultural comparisons. The project, which also comprised data collection 
from large population-based samples in each of the participating countries, was part of 
the Quality of life and Management of Living Resources programme and was funded by 
the European Commission (EC) within the Fifth Framework Programme (EC Grant 
Number: QLG-CT-2000- 00751) (Ravens-Sieberer et al., 2001). The data collection targeted 
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indicators for quality of life resp. positive mental health. The KIDSCREEN-10 Mental 
Health Index assesses the child's perspective on his or her physical, mental and social 
well-being, identifies children at risk and suggests suitable early interventions. For this 
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reason it is particularly useful for identifying children with positive mental health. Section 
4.4 of this chapter will present empirical results from the KIDSCREEN survey detailing 
the distribution of children with positive mental health in thirteen European countries. 
Further information on the KIDSCREEN instruments is available at  
http://www.kidscreen.org. 
4.1.2 The Health Behaviour in School-aged Children (HBSC) survey 
The HBSC Study is a WHO-collaborative study dedicated to the study of adolescent health. 
The overall aim is to gain a better understanding of health behaviours, health, and well-
being in children and adolescents at the age of 11, 13 and 15 years. HBSC is a cross-national 
study covering over 40 countries in Europe, North America and Israel. The design of the 
survey is cross-sectional and data collection is carried out every four years. The basis for 
each survey is a standardized research protocol which is renewed for each survey round. 
The survey is based on a questionnaire which consists of mandatory items (required from 
each country), and optional items which focus on topics of national interest. Mandatory 
items are part of the international file and enable cross-country comparisons. Data is 
collected in schools and the primary sampling unit is school class (or entire school in case 
this is not possible). Data is collected within a class period via questionnaire.  
Further information on the HBSC Survey is available at: http://www.hbsc.org . 
Collection of data on positive mental health is in line with the health definition of the WHO 
(Ravens-Sieberer et al., 2008a). Assessment of mental health is possible in one of two ways: 
positive mental health and negative (ill) mental health, and the HBSC and KIDSCREEN 
Surveys provide suitable instruments for both.  
4.2 Positive mental health indicators 
4.2.1 Quality of life and positive mental health indicator 
One of the outputs of the European KIDSCREEN survey was the development of a 
screening tool for mental health. The KIDSCREEN-10 instrument is an index which assesses 
the child’s perspective on his or her physical, mental and social well-being, thus enabling 
the identification of children at risk. As previously stated, the KIDSCREEN-10 Mental 
Health Index is a non-clinical measure of quality of life and positive mental health status 
and enables the assessment of school-aged children’s general well-being. The index is 
especially sensitive for affective, cognitive, and psychovegetative, as well as psychosocial 
aspects of mental health. 
The short instrument consists of ten items covering six aspects of quality of life (physical 
well-being, moods & emotions, autonomy, parent relation & home life, peers & social 
support, school environment). The short instrument consists of the following ten items and 
only takes a few minutes to complete:   
• “Have you felt fit and well?”  
• “Have you felt full of energy?” 
• “Have you felt sad?”  
• “Have you felt lonely?” 
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• “Have you had enough time for yourself?” 
• “Have you been able to do the things that you want to do in your free time?” 
• “Have your parent(s) treated you fairly?” 
• “Have you had fun with your friends?” 
• “Have you got on well at school?” 
• “Have you been able to pay attention?” 
Children at risk of poor quality of life are identified by coding of responses so that higher 
values indicate better quality of life. The KIDSCREEN-10 Mental Health Index was 
developed by means of a Rasch analysis which ensured that only those items which 
represented a global, unidimensional latent trait were included. The values on the 
individual items are summed up, Rasch person parameters (PP) are assigned to each 
possible sum score, and then the PP are transformed into values with a mean of 50 and 
standard deviation of approximately 10 (Ravens-Sieberer et al., 2006). A better 
differentiation between the children is made possible by the distribution of the Rasch scores 
that resemble the expected theoretical normal distribution. The index provides a good 
discriminatory power and shows only few ceiling or floor effects. 
Validation work on this instrument indicates that it is a valid and well-tested stable child 
centred self-report measure (indicator) for child and adolescent general quality of life and 
mental well-being status. It has good psychometric properties, with high reliability and 
Rasch-scale properties. The index provides a good discriminatory power and shows only 
few ceiling or floor effects. The strong internal consistency reliability (Cronbach’s Alpha = 
.82) and test-retest reliability (r = .73) allow precise and stable measurements (Ravens-
Sieberer et al., 2006; Ravens-Sieberer et al., 2010).  
The cut-off at T-value below 38 (which represents the lowest 10%) indicates lower quality of life 
resp. higher risk for poor mental health (Ravens-Sieberer et al., 2006). Comparisons with the 
European Community Health Indicators (ECHI) show that the Kidscreen-10 Index for children 
and adolescents corresponds well with the “General Quality of Life Indicator”. The ECHI group 
proposes to use the Euroqol score from the Euroqol 5D instrument (Eurociss project) or 
alternatively the WHOQOL of the WHO (Kramers & the ECHI team, 2005) for adults. 
Since its development, the instrument has been employed in several EU funded European 
research projects (KIDSCREEN, DISABKIDS, MHADIE, SPARCLE), in the Flash 
Eurobarometer and in the PROMIS roadmap initiative of the US NIH (National Institutes of 
Health) to develop a patient reported outcome measurement information system. The 
instrument is also used in the Health Behaviour in School-aged Children (HBSC) study as an 
indicator of positive mental health and has been translated into a variety of languages.  
4.2.2 Psychological well-being indicator 
Another positive mental health indicator is psychological well-being which refers to a 
child’s or adolescents’ positive emotions and perceptions, his/her satisfaction with life, 
covering various areas of his/her inner feelings and thus provides insight into an 
individual’s mental health state. The psychological well-being dimension is one of ten 
dimensions of KIDSCREEN-52 and one of the five dimensions of KIDSCREEN-27 as shown 
in the figure below. In the latter, it also encompasses the Moods and Emotions and the Self-
Perception scale of KIDSCREEN-52. 
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• “Have you had enough time for yourself?” 
• “Have you been able to do the things that you want to do in your free time?” 
• “Have your parent(s) treated you fairly?” 
• “Have you had fun with your friends?” 
• “Have you got on well at school?” 
• “Have you been able to pay attention?” 
Children at risk of poor quality of life are identified by coding of responses so that higher 
values indicate better quality of life. The KIDSCREEN-10 Mental Health Index was 
developed by means of a Rasch analysis which ensured that only those items which 
represented a global, unidimensional latent trait were included. The values on the 
individual items are summed up, Rasch person parameters (PP) are assigned to each 
possible sum score, and then the PP are transformed into values with a mean of 50 and 
standard deviation of approximately 10 (Ravens-Sieberer et al., 2006). A better 
differentiation between the children is made possible by the distribution of the Rasch scores 
that resemble the expected theoretical normal distribution. The index provides a good 
discriminatory power and shows only few ceiling or floor effects. 
Validation work on this instrument indicates that it is a valid and well-tested stable child 
centred self-report measure (indicator) for child and adolescent general quality of life and 
mental well-being status. It has good psychometric properties, with high reliability and 
Rasch-scale properties. The index provides a good discriminatory power and shows only 
few ceiling or floor effects. The strong internal consistency reliability (Cronbach’s Alpha = 
.82) and test-retest reliability (r = .73) allow precise and stable measurements (Ravens-
Sieberer et al., 2006; Ravens-Sieberer et al., 2010).  
The cut-off at T-value below 38 (which represents the lowest 10%) indicates lower quality of life 
resp. higher risk for poor mental health (Ravens-Sieberer et al., 2006). Comparisons with the 
European Community Health Indicators (ECHI) show that the Kidscreen-10 Index for children 
and adolescents corresponds well with the “General Quality of Life Indicator”. The ECHI group 
proposes to use the Euroqol score from the Euroqol 5D instrument (Eurociss project) or 
alternatively the WHOQOL of the WHO (Kramers & the ECHI team, 2005) for adults. 
Since its development, the instrument has been employed in several EU funded European 
research projects (KIDSCREEN, DISABKIDS, MHADIE, SPARCLE), in the Flash 
Eurobarometer and in the PROMIS roadmap initiative of the US NIH (National Institutes of 
Health) to develop a patient reported outcome measurement information system. The 
instrument is also used in the Health Behaviour in School-aged Children (HBSC) study as an 
indicator of positive mental health and has been translated into a variety of languages.  
4.2.2 Psychological well-being indicator 
Another positive mental health indicator is psychological well-being which refers to a 
child’s or adolescents’ positive emotions and perceptions, his/her satisfaction with life, 
covering various areas of his/her inner feelings and thus provides insight into an 
individual’s mental health state. The psychological well-being dimension is one of ten 
dimensions of KIDSCREEN-52 and one of the five dimensions of KIDSCREEN-27 as shown 
in the figure below. In the latter, it also encompasses the Moods and Emotions and the Self-
Perception scale of KIDSCREEN-52. 
 




































Fig. 1. Dimensions of the KIDSCREEN-52, -27, -10 (http://www.kidscreen.org/) 
The KIDSCREEN-52 is part of a family of health-related quality of life instruments which were 
developed in several stages, beginning with literature searches, expert consultations (Delphi 
method)  and focus groups with children and adolescents (Herdman et al., 2002; Ravens-
Sieberer et al., 2006, 2008b). Using this approach, relevant health-related quality of life (HRQoL) 
dimensions and items could be identified (Ravens-Sieberer et al., 2006, 2008b). Reduction of 
items gathered in focus groups were done following EUROHIS guidelines (Nosikov & Gudex, 
2003). Following this, a procedure of forward-backward-forward translation and harmonization 
was applied, followed by a pilot study and an item reduction analysis, which finally yielded a 
questionnaire comprising 52 items (Ravens-Sieberer et al., 2006, 2008b).  
The KIDSCREEN-52 Psychological Well-being dimension assesses the psychological well-
being of the child, which covers positive emotions and life satisfaction, including the child’s 
or adolescents’ positive perceptions and emotions, and positive feelings, such as happiness, 
joy and cheerfulness (Ravens-Sieberer et al., 2006). A low score on this dimension implies no 
pleasure in life/high dissatisfaction with life while a high score indicates happiness, positive 
view of life, life satisfaction and cheerfulness. The cut-off is at T-value of 36.91 and identifies 
the lowest 10% (Ravens-Sieberer et al., 2006). This dimension of the KIDSCREEN-52 (for 
children and adolescents) is comparable to the psychological well-being dimension for 
adults which is used as an indicator for general mental health in the ECHI report, and is 
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defined as the percent of the population below the cut-point of the energy-vitality scale from 
the SF-36 questionnaire (see ECHI long list, 2005). 
4.2.3 Self-rated health (subjective health indicator) 
The building blocks for good health are laid early in life, and therefore evaluation of health 
does not begin in adulthood but much earlier. Health is an important resource and poor 
health early in life can have long-term negative effects which may continue throughout 
adulthood (WHO, 2006). Being in good health – physically, emotionally and socially – helps 
young people deal productively with challenges in their development (Burt, 2002). In recent 
years, self-assessments of health have come more into use as they are based on an 
individual’s perception and evaluation of his or her health. Focusing on the subjective 
perspective, self-rated health is usually founded on age-peer comparisons either consciously 
or unconsciously (Bjorner et al., 1996). It can be distinguished from more specific health 
constructs in that it captures an overall conception of health, rather than a summation across 
specific domains of health. Empirical studies have shown that self-reported health is an 
independent predictor of mortality (Idler & Benyamini, 1997). Benjamins et al. (2004) could 
also identify a relationship between self-reported health and cause-specific mortality, and 
moreover, also found gender effects for some causes of mortality. A gender effect in self-
rated health was confirmed in a sample of children, whereby girls reported poorer health 
than boys (Cavallo et al., 2006). Another study on psychosocial, demographic, and health-
related correlates of self-rated health showed that daily smoking, alcohol intoxication on at 
least one occasion, infrequent physical activity, and difficulty making friends were 
predictors of poor self-rated health (Kelleher et al., 2007). Seemingly, multiple independent 
correlates of adolescent self-rated health exist (Breidablik et al., 2009), whereby poor health 
increases by age and throughout adolescence (Wade & Vingilis, 1999). 
The single item question on health is a suitable indicator of subjective health. Individuals are 
asked to indicate how they perceive their general health on a Likert scale. The answer 
categories are either four or five scaled. The Health Behaviour in School-aged Children 
(HBSC) study uses the four point Likert scale with answer categories: “excellent”, “good”, 
“fair”, “poor”. Those with either “fair” or “poor” health respectively “excellent” and “good” 
health are then combined into subgroups of individuals with “poorer health” resp. “better 
health” (Currie et al., 2004). Other studies, such as e.g. the European KIDSCREEN survey 
(Ravens-Sieberer et al., 2006), use the five-scaled answer categories: “excellent”, “very 
good”, “good”, “fair”, “poor”. The main difference is the extra answer category “very good” 
which enables more differentiation on the positive end of the scale.   
According to ECHI recommendations, preference should be given to the five answer 
categories (Kramers & the ECHI team, 2005). In the ECHI report, the WHO recommended 
instrument is proposed which is based on a five response category item: “How is your 
health in general?” (Answer options are: very good/good/fair/bad/very bad). The ECHI 
report further proposes to set the cut-off for perceived health at the % (very) good/less than 
good/less than fair. As noted in the ECHI report, very little focus was placed on the specific 
situation of children (ECHI long list 2005, p. 50).  
Although no specific validation has been done on the self-rated health item in HBSC, 
several studies support its validity. It has shown multiple independent health-related 
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4.2.3 Self-rated health (subjective health indicator) 
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which enables more differentiation on the positive end of the scale.   
According to ECHI recommendations, preference should be given to the five answer 
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correlates, including medical diagnosis, and health complaints. The self-rated health item 
shows a certain degree of stability across time, suggesting that these self-reports are not 
simply a fluctuating subjective impression. Cavallo et al. (2006) analyzed the item in terms 
of its feasibility and psychometric robustness using the HBSC 2001/2002 data from all 
countries involved. The results confirm the trend of an increasing perception of poor 
health with increasing age in the pre-adolescence phase and a higher risk for perceived 
poorer health in girls, (Cavallo et al., 2006). HBSC showed this was a consistent finding 
across a large number of countries in Europe and North America (see also Currie et al., 
2008). 
4.2.4 Life satisfaction indicator 
Well-being is a multi-faceted concept (Diener, 1984; Wilkinson & Walford, 1998) and 
comprises the individual’s own evaluation of life, i.e. life satisfaction. It was not until the 
early 1990s that determinants of life satisfaction were studied (Suldo et al., 2006). Unlike 
other concepts, life satisfaction is relatively stable over time (Pavot & Diener, 1993). It is 
associated with depression, anxiety, suicide, work disability, fatal accidents and all cause 
mortality in adults (Fiscella & Franks, 1997; Helliwell, 2007; Koivumaa-Honkanen et al., 
2001; Koivumaa-Honkanen et al., 2002; Koivumaa-Honkanen et al., 2004a; Koivumaa-
Honkanen et al., 2004b). During adolescence, life satisfaction is influenced by life 
experiences and relationships, especially within the family context (Edwards & Lopez, 2006; 
Gohm et al., 1998; Rask et al., 2003) and school (Samdal et al., 1998). Psychosocial resources 
and school satisfaction, especially perceptions of feeling treated fairly, feeling safe and 
perceiving teachers as supportive (Samdal et al., 1998), are linked with high life satisfaction. 
School-related resources and their impact on overall life satisfaction are a central issue as the 
acquirement of academic competence constitutes one of the developmental goals in 
adolescence (Hurrelmann & Lösel, 1990). Moreover, school creates a social environment for 
young people which can provide them with additional resources. At the certain time, some 
social factors, such as bullying, can pose a risk as they may be associated with low life 
satisfaction and low subjective health (Gobina et al., 2008). 
The Cantril Ladder is a measure of life satisfaction which has been widely used in the 
Health Behaviour in School-aged Children (HBSC) study. The measure is also a suitable 
indicator for life satisfaction in children and adolescents (Cantril, 1965). The measure 
consists of a Visual Analogue Scale with 11 positions (0 through 10) where children can 
mark the position on the scale demonstrating how satisfied they are with their life: “Here is 
a picture of a ladder. The top of the ladder “10” is the best possible life for you and the 
bottom “0” is the worst possible life for you. In general, where on the ladder do you feel you 
stand at the moment? Tick the box next to the number that best describes where you stand.” 
The Health Behaviour in School-aged Children (HBSC) study uses the cut-off at “6 or 
above” to identify children and adolescents with a positive level of life satisfaction (normal 
to high life satisfaction) (Currie et al., 2004). 
The Cantril Ladder has not been subject to structured validation studies at the international 
level, but observed relationships with quality of life and with self-rated health are in the 
expected range, and support claims about its validity. Analyses using data from the HBSC 
study show that the item is associated with the general health item and the Symptom 
Checklist (HBSC-SCL) (Cavallo et al., 2006). 
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4.3 Ill-mental health indicators 
4.3.1 Psychological distress indicator 
In the past, assessment of mental health was for the most part aimed at assessing mental ill 
health, with the focus being placed on mental health disorders and -problems. This has the 
disadvantage that the information gathered only enables separation between individuals 
with (signs of) mental disorders and healthy individuals (without any signs of mental health 
problems). No information is available on individuals “in-between”, in other words about 
the position of the individual on a mental health continuum (Ravens-Sieberer et al., 2008a). 
Moreover, earlier instruments for measuring mental health problems in children were based 
and validated on experiences with child psychiatric patients and were often developed as 
screening instruments for patients in care. KIDSCREEN instruments overcome this 
drawback as they have been developed to measure mental health in the general population 
and have been validated in large population studies. 
The KIDSCREEN-52 “Moods & Emotions” Dimension provides an important indicator of 
psychological distress which can be used to identify children with depressiveness, as well as 
those feeling lonely, sad, and unhappy (Ravens-Sieberer et al., 2006). This dimension of the 
KIDSCREEN-52 examines experiences of depressive moods and emotions, including 
stressful feelings, and how distressing these are to the individual. A low score indicates that 
the child or adolescent feels depressed, is unhappy and/or in bad mood. A high score in 
contrast, implies feeling good and being in a good mood. The cut-off identifying the lowest 
10% is at a T-value of 37.76 (Ravens-Sieberer et al., 2006).  
The “moods & emotions” dimension of KIDSCREEN-52 for children and adolescents 
corresponds to the indicator of psychological distress for adults in the general mental health 
section as published in the ECHI indicator list. In the ECHI report, psychological distress is 
defined as the percent of the population below the cut-point of MHI-5 score from the SF-36 
questionnaire (see ECHI report, long list: http://www.echim.org/docs/echi_longlist.pdf).  
The KIDSCREEN instruments are robust and psychometrically sound instruments suitable for 
the assessment of the health-related quality of life and mental health in children and adolescents 
between 8 and 18 years of age. The internal consistency reliability (Cronbach’s Alpha) for the 
individual dimensions show for the “Moods & Emotions” dimension a value of 0.86 and for the 
“Psychological Well-being” dimension a Cronbach’s Alpha of 0.89 (Ravens-Sieberer et al., 
2008b; Ravens-Sieberer et al., 2006), both of which can be considered sufficiently high. 
Both, the “Moods & Emotions”, as well as the “Psychological Well-being” dimension of 
KIDSCREEN-52, correspond well with the published indicators of general mental health in 
the ECHI report (Kramers & the ECHI team, 2005), and are thus suitable indicators. 
4.3.2 Subjective health complaints index 
The presence of subjective health complaints and the frequency of their occurrence can serve as 
a good approximation for the individual’s physical well-being. Health complaints tend to 
cluster together (Alfven, 1993; Mikkelsson et al., 1997; Starfield et al., 1984; WHO, 2006) and in 
this way cause immense burden – not only on the individual, but also on the health care system.  
Within the international HBSC Study, the Symptom Checklist (HBSC-SCL) was developed 
to assess the various health complaints that might occur in children and adolescents. The 
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correlates, including medical diagnosis, and health complaints. The self-rated health item 
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4.3 Ill-mental health indicators 
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HBSC-SCL has proven to be a suitable and effective screening tool for the assessment of 
physical well-being. The Checklist includes symptoms, such as headache, abdominal pain, 
backache, feeling low, irritability or bad mood, feeling nervous, sleeping difficulties and 
dizziness (Haugland et al., 2001). The advantage of the HBSC-SCL is that it is not limited to 
somatic symptoms, but also contains a number of psychological symptoms and hence 
constitutes an instrument suitable for detecting psychosomatic complaints.  
The HBSC-SCL assesses the occurrence of health complaints in children and adolescents and 
is a useful indicator for identifying individuals at risk for impaired health. The HBSC-SCL 
asks about the occurrence of the following symptoms in the last 6 months: Headache, 
Stomach ache, Back ache, Feeling low, Irritability or bad temper, Feeling nervous, 
Difficulties in getting to sleep, Feeling dizzy. Ravens-Sieberer et al. (2008c) developed an 
international scoring system for the HBSC-SCL which enables a cross-cultural and interval-
scaled assessment of subjective health complaints and which can further be used to identify 
individuals at a greater risk of health complaints. This uni-dimensional scoring algorithm is 
based on seven of the eight items. A score below 41 indicates a “higher risk” for health 
complaints (Ravens-Sieberer et al., 2008c).  
A number of validation studies have been made on the HBSC-SCL (Haugland & Wold, 2001; 
Haugland et al., 2001). Qualitative semi-structured interviews with early adolescents 
revealed that adolescents perceive the symptoms to be aversive physical and psychological 
states that interfere with daily functional ability and well-being. Consistent accounts as to 
how the different symptoms were defined were given, suggesting that adolescents have a 
common frame of reference when they rate their frequency of symptoms (Haugland & 
Wold, 2001). Differences emerged in their lay perspectives on the causes of such symptoms. 
While some explanations were consistent with a stress-model of health complaints, others 
were associated with developmental processes, such as growing pain, or ergonomic factors, 
such as low quality of air in classrooms etc. 
4.4 Application of the mental health indicator (KIDSCREEN-10) 
As previously mentioned, the mental health index (KIDSCREEN-10) is a non-clinical measure of 
mental health status. It does not permit identification of groups with defined burden of mental 
health problems, but allows measurement along a continuum (Ravens-Sieberer et al. 2008a).  
As stated previously, KIDSCREEN-10 is an indicator of quality of life and (positive) mental 
health and in the following, we will apply it on a European sample of adolescents from 13 
countries. The overall mean score is 48 with a standard deviation of 10. The results in Figure 
2 show that some countries fall above and some below the European mean. Countries 
towards the left side of the figure tend to show better positive mental health compared to 
the countries at the right end of the figure which fall below the European average. 
Additional results show that variation in mental health scores was generally lower in 
countries with lower positive mental health scores (results not shown).  
To gain a better understanding of the distribution of mental health, we will now look at 
selected sociodemographic characteristics, such as gender and socioeconomic status 
(approximated by family affluence [FAS]). Table 1 below shows the distribution of positive 
mental health across the 13 countries by gender. Comparisons across gender groups show 
that boys report better mental health across all countries than girls. This difference is 
significant in all but one country, and the effect sizes are generally small.  
 






































































Fig. 2. Positive mental health index (KIDSCREEN-10) across 13 European countries1,2 
 
 
Country Girls m(SD) Boys m(SD) Effect (d) 
Austria (n=878) 49.6 (8.9) 52.6 (9.4) 0.3*** 
Czech Republic (n=1016) 45.0 (7.1) 47.3 (7.8) 0.3*** 
France (n=622) 45.0 (8.4) 46.1 (8.0) n.s. 
Germany (n=1079) 49.3 (8.4) 51.0 (8.4) 0.2*** 
Greece (n=1146) 44.2 (7.6) 47.2 (8.0) 0.4*** 
Hungary (n=1839) 43.6 (7.6) 46.2 (8.9) 0.3*** 
Ireland (n=894) 45.5 (7.9) 48.1 (7.6) 0.3*** 
The Netherlands (n=1168) 50.2 (8.2) 53.6 (10.0) 0.4*** 
Poland (n=1120) 43.9 (7.9) 45.3 (7.3) 0.2** 
Spain (n=522) 48.4 (9.6) 50.9 (8.7) 0.3** 
Sweden (n=3097) 49.2 (10.0) 52.4 (10.0) 0.3*** 
Switzerland (n=1078) 49.6 (8.0) 52.6 (8.5) 0.4*** 
United Kingdom (n=883) 45.5 (8.3) 47.8 (8.5) 0.3*** 
** p<.01   
*** p<.001 
Table 1. Positive mental health (KIDSCREEN-10) in different countries according to 
gender3,4 
Next, the analysis of positive mental health by family affluence shows that higher family 
affluence, i.e. growing up a in a better-situated family, is generally associated with a higher 
level of positive mental health (i.e. above the European average). This is depicted in Figure 3 
by the increasing line (with one or two exceptions) and also in the distribution of % of 
children in low, middle and high FAS group per country (results not shown). Countries 
with higher mental health score means are also those with the least number of adolescents in 
the low FAS group.  
                                                 
1 Mean scores of the KIDSCREEN-10 are depicted  
2 This figure was previously published in Ravens-Sieberer et al. (2008a). 
3 Effect size calculation was based on dividing the mean difference by the overall standard deviation 
(according to Cohen 1988). 
4 This figure was previously published in Ravens-Sieberer et al. (2008a). 
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Fig. 3. Adolescent positive mental health (KIDSCREEN-10) and FAS in the participating 
countries (without Ireland and Sweden)5  
The results that were presented here serve the purpose to exemplify the application of a 
robust measure of mental health in a European sample of children and adolescents. Results 
show the associations between the outcome (mental health) and various sociodemographic 
factors (age, gender, FAS) and in this way provide the basis for more comprehensive 
analyses of mental health status in children and adolescents in Europe.  
5. Closing comments  
The objective of this chapter was to give interested readers an insight into the state-of-the-art 
in child mental health measurement. Our aim was to show that progress has indeed been 
made in this vast field, and although we still do not have all the tools and information for a 
complete assessment of mental health in children and adolescents, we have been able to 
identify useful measures and important surveys at the European level which enable a good 
approximation. The complexity of the field has made it necessary for us to concentrate on a 
few indicators which in our view are good representatives of the respective constructs. The 
indicators and the results we have described in this chapter come from the HBSC and 
KIDSCREEN Studies and also reflect our insights from within the RICHE project. 
The original idea for a publication on mental health measurement came up during the 
course of working in the RICHE project. RICHE stands for “Research into Child Health in 
Europe” and is an international project focusing on child health research in Europe. The 
project is funded within the EU 7th Framework Programme. RICHE embraces the full multi-
disciplinary diversity of European research and addresses its fragmentation by making the 
parts visible. This is done in part via a platform which provides the opportunity for open 
exchange (http://www.childhealthresearch.eu/). The aims of the project are: to provide an 
inventory of current research; to identify research into child health measurement, statistics, 
                                                 
5 The Figure was previously published in Ravens-Sieberer et al. (2008a). 
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and indicators; to identify gaps in child health research as perceived by stakeholders; and 
lastly, to develop roadmaps for the future of child health research in Europe based on all 
these findings. One of the objectives of the RICHE project is to produce an inventory of 
measurement and indicators to facilitate the implementation of existing methods and at the 
same time to initiate new developments through exchange and networking. Based on the 
notion that development and implementation of sound indicators is essential for developing 
child health with the European Union (Rigby et al., 2003), it is important that high quality 
indicators are available for analyses and political decision making. Health measurement is 
the core for developing prevention strategies in a life course perspective.  
The review of research into child mental health measurement has revealed important 
advances, such as the development of quality of life and positive mental health indicators in 
the KIDSCREEN project, while on the other hand, also pointed out several shortcomings. 
The main shortcomings relate to the age-specification and the cultural adaptation of 
measurement tools. With regard to the age issue, our evaluation of measures of child mental 
health revealed that measurement tools generally target older children and adolescents, i.e. 
eight years and older. Many of the measurement tools come from the HBSC survey and all 
of these have originally been designed for 11-, 13-, and 15-year old children. Any application 
of these instruments on younger children would require further validation which to date 
has not been done. Although indicators based on KIDSCREEN measures are suitable for 
slightly younger children (beginning with age seven), they are not available for the very 
young children (0-6 year olds). For this young group, there is a clear gap on measurement 
tools, especially those enabling a valid and cross-cultural assessment of quality of life and 
well-being for the age group 0-3 years and for the age group 4-6 years. Generally, very 
young and young children are underrepresented in international data sources, and “a 
portrait of positive well-being among young children is not available, and in many cases, 
measures are lacking that are appropriate for their age” (Lippman et al., 2009, p. 24). This 
implies that many indicators are adolescent-focused and hence may point attention to 
matters relevant for adolescents which may be quite different from those that are essential 
for children (Bradshaw et al., 2006). 
Another shortcoming of current research on indicators for child well-being lies in the 
cultural adaptation of the measurement tools. As mentioned above, all of the indicators 
presented here are based on measurement tools which have been developed within the 
European and North American context. In order to compare child well-being and quality of 
life in different cultural contexts outside of Europe (e.g. in Africa, Asia), cultural adaptations 
would need to be done with the instruments. Currently, this is a research challenge in this 
field and needs to be addressed in the near future.   
6. Outlook 
To end on a positive note, it is important to acknowledge that there are already a number of 
programmes on mental health and well-being in children and adolescents underway. A 
good example of a promising strategy is Scotland’s “National Programme for Improving 
Mental Health and Wellbeing” which was launched in April 2008 with the purpose to 
identify a core set of indicators on mental health to support the national action plan on 
mental health (“mental health profile for Scotland”; Parkinson, 2009). Building upon the 
experience from the establishment of a mental health indicator set for adults (Parkinson, 
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To end on a positive note, it is important to acknowledge that there are already a number of 
programmes on mental health and well-being in children and adolescents underway. A 
good example of a promising strategy is Scotland’s “National Programme for Improving 
Mental Health and Wellbeing” which was launched in April 2008 with the purpose to 
identify a core set of indicators on mental health to support the national action plan on 
mental health (“mental health profile for Scotland”; Parkinson, 2009). Building upon the 
experience from the establishment of a mental health indicator set for adults (Parkinson, 
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2007), the same is now being done for the age group 18 years and younger. The goal is to 
“support and promote consistent and sustainable national monitoring of the state of mental 
health and associated contextual factors for children and young people in Scotland” 
(Parkinson, 2009, n.p.). Using different methods, such as a comprehensive review of 
literature on children’s own views of mental health (Shucksmith et al., 2009), and wider 
consultations with researchers, policy makers and practitioners, as well as advisory groups 
will be used to inform the development of a framework on mental health and well-being. 
Direct consultations with children and young people on mental health indicators and the 
proposed framework will complement this information (Parkinson, 2009).  
NHS Scotland is a good example of how research and policy making can work together to 
more forward on an important public health issue with high relevance not just in Scotland, 
but also at the European level. It highlights the importance of epidemiological data which 
delivers information relevant for development of policy making (Remschmidt & Belfer, 
2005). HBSC and KIDSCREEN are good examples of this. Through regular, standardized 
data collection (such as through monitoring), health indicators can further help in the 
problem identification process as well as in its prioritization (Korkeila et al., 2006). By 
“screening” for certain (risk) groups or health problems, they are valuable tools for 
preventive action which requires early detection of hidden or manifest mental health 
problems (Erhart et al., 2009). In this sense, indicators are an important “bridge between 
health policy and scientific information” (Korkeila et al., 2006, p. 13). 
7. Acknowledgement 
The RICHE Project (Title: A platform and inventory for child health research in Europe) is 
financed by a grant from the European Commission within the EC Seventh Framework 
Programme (HEALTH-2009-3.3-5 European child health research platform).  
Participants of the RICHE project are: 
Prof Anthony Staines, Dublin City University (Coordinator) 
Dr Giorgio Tamburlini, Burlo Garofolo 
Ms Csilla Kaposvari, Egészség Monitor 
Prof Hein Raat, Erasmus Universitair Medisch Centrum Rotterdam 
Dr Else-Karin Groholt, Nasjonalt Folkehelseinstitutt 
Prof Margarida Gaspar de Matos, Faculdade de Motricidade Humana 
Dr Anne McCarthy, The Health Research Board 
Dr Mitch Blair, Imperial College of Science, Technology and Medicine 
Dr Matilde Leonardi, Fondazione IRCCS Istituto Neurologico Carlo Besta 
Dr Polonca Truden-Dobrin, Institute of Public Health of the Republic of Slovenia 
Dr Reli Mechtler, Johannes Kepler University Linz, Institute of Health System Research 
Prof Michael Rigby, Nordic School for Public Health 
Prof Anders Hjern, Nordic School for Public Health 
Dr Polanska Kinga, Nofer Institute of Occupational Medicine 
Mr Con Hennessy, Open Applications Consulting Limited 
Prof Geir Gunnlaugsson, Reykjavik University 
Prof Mika Gissler, National Institute for Health and Welfare 
Prof Toomas Veidebaum, National Institute for Health Development 
 
Child Mental Health Measurement: Reflections and Future Directions 
 
45 
Dr Ales Bourek, Masarykova Univerzita 
Prof Candace Currie, The University of Edinburgh, National Institute for Health and 
Clinical Excellence 
Prof Ulrike Ravens-Sieberer, Universitätsklinikum Hamburg-Eppendorf 
Prof Allan Colver, University of Newcastle upon Tyne 
Prof Livia Popescu, Universitatea Babeş-Bolyai 
Prof Angela Brand, Universiteit Maastricht, European Centre for Public Health Genomics 
8. References  
Aborn, M. (1985). Statistical legacies of the social indicators movement. Paper presented at the 
annual meeting of the American Statistical Association, Las Vegas, Nevada 
Alfven, G. (1993). The covariation of common psychosomatic symptoms among children 
from socio-economically differing residential areas: an epidemiological study. Acta 
Paediatr, 82, pp. 484-487 
Bauer, R. A. (Ed.) (1966). Social Indicators, MIT Press, Cambridge 
Ben-Arieh, A. & Wintersberger, H. (Eds.) (1997). Monitoring and Measuring the State of 
Children – Beyond Survival. Eurosocial Report No. 62, European Centre for Social 
Welfare Policy and Research, Vienna 
Ben-Arieh, A. (2008). The Child Indicators Movement: Past, Present, and Future. Child 
Indicators Research, 1, pp. 3-16, 1874-8988 
Benjamins, M. R., Hummer, R. A., Eberstein, I. W. & Nam, C. B. (2004). Self-report health 
and adult mortality risk: an analysis of cause-specific mortality. Social Science & 
Medicine, 59, pp. 1297-1306 
Bjorner, J. P, Kristensen, T. O., Orth-Gomer, K., Tibblin, G., Sullivan, M. & Westerholm, P. 
(1996). Self-rated health. A useful concept in research, prevention and clinical medicine, 
Forskningsradsnämnden, Ord & Form AB, Uppsala  
Breidablik, H. J., Meland, E. & Lydersen, S. (2009). Self-rated health during adolescence: 
stability and predictors of change (Young-Hunt study, Norway). European Journal of 
Public Health, 91, 1, pp. 73-78 
Blumer, H. (1962). Society as Symbolic Interaction, In: Human Behavior and Social Process: An 
Interactionist Approach, Arnold M. Rose,  pp. 179-192, Houghton-Mifflin, Boston 
Bradburn, N. M. (1969). The structure of psychological well-being, Aldine, Chicago 
Bradshaw, J., Hoelscher, P., Richardson, D. & UNICEF (2006). Comparing Child Well-Being in 
OECD Countries: Concepts and methods. Innocenti Working Paper No. 2006-03, UNICEF 
Innocenti Research Centre, 1014-7837, Florence. 
Burt, M.R. (2002). Reasons to invest in adolescents. Journal of Adolescent Health, 31, 2, pp. 136-
152  
Cameron, E., Mathers, J. & Parry, J (2006). Health and well-being: questioning the use of 
health concepts in public health policy and practice. Critical Public Health, 16, 4, pp. 
347-354, 1469-3682 
Campbell, A. & Converse, P.E. (Eds.) (1972). The Human Meaning of Social Change, Russell 
Sage Foundation, New York 
Cantril, H. (1965). The pattern of human concern, Rutgers University Press, New York 
Cavallo, F., Zambon, A., Borraccino, A., Ravens-Sieberer, U., Torsheim, T. & Lemma, P. 
(2006). Girls growing through adolescence have a higher risk of poor health. 
Quality of Life Research, 15, 10, pp. 1577-1585, 1573-2649  
Cohen, J. (1988). Statistical power analysis for the behavioral science, Lawrence Erlbaum, New 
York  
 
Public Health – Methodology, Environmental and Systems Issues 
 
44
2007), the same is now being done for the age group 18 years and younger. The goal is to 
“support and promote consistent and sustainable national monitoring of the state of mental 
health and associated contextual factors for children and young people in Scotland” 
(Parkinson, 2009, n.p.). Using different methods, such as a comprehensive review of 
literature on children’s own views of mental health (Shucksmith et al., 2009), and wider 
consultations with researchers, policy makers and practitioners, as well as advisory groups 
will be used to inform the development of a framework on mental health and well-being. 
Direct consultations with children and young people on mental health indicators and the 
proposed framework will complement this information (Parkinson, 2009).  
NHS Scotland is a good example of how research and policy making can work together to 
more forward on an important public health issue with high relevance not just in Scotland, 
but also at the European level. It highlights the importance of epidemiological data which 
delivers information relevant for development of policy making (Remschmidt & Belfer, 
2005). HBSC and KIDSCREEN are good examples of this. Through regular, standardized 
data collection (such as through monitoring), health indicators can further help in the 
problem identification process as well as in its prioritization (Korkeila et al., 2006). By 
“screening” for certain (risk) groups or health problems, they are valuable tools for 
preventive action which requires early detection of hidden or manifest mental health 
problems (Erhart et al., 2009). In this sense, indicators are an important “bridge between 
health policy and scientific information” (Korkeila et al., 2006, p. 13). 
7. Acknowledgement 
The RICHE Project (Title: A platform and inventory for child health research in Europe) is 
financed by a grant from the European Commission within the EC Seventh Framework 
Programme (HEALTH-2009-3.3-5 European child health research platform).  
Participants of the RICHE project are: 
Prof Anthony Staines, Dublin City University (Coordinator) 
Dr Giorgio Tamburlini, Burlo Garofolo 
Ms Csilla Kaposvari, Egészség Monitor 
Prof Hein Raat, Erasmus Universitair Medisch Centrum Rotterdam 
Dr Else-Karin Groholt, Nasjonalt Folkehelseinstitutt 
Prof Margarida Gaspar de Matos, Faculdade de Motricidade Humana 
Dr Anne McCarthy, The Health Research Board 
Dr Mitch Blair, Imperial College of Science, Technology and Medicine 
Dr Matilde Leonardi, Fondazione IRCCS Istituto Neurologico Carlo Besta 
Dr Polonca Truden-Dobrin, Institute of Public Health of the Republic of Slovenia 
Dr Reli Mechtler, Johannes Kepler University Linz, Institute of Health System Research 
Prof Michael Rigby, Nordic School for Public Health 
Prof Anders Hjern, Nordic School for Public Health 
Dr Polanska Kinga, Nofer Institute of Occupational Medicine 
Mr Con Hennessy, Open Applications Consulting Limited 
Prof Geir Gunnlaugsson, Reykjavik University 
Prof Mika Gissler, National Institute for Health and Welfare 
Prof Toomas Veidebaum, National Institute for Health Development 
 
Child Mental Health Measurement: Reflections and Future Directions 
 
45 
Dr Ales Bourek, Masarykova Univerzita 
Prof Candace Currie, The University of Edinburgh, National Institute for Health and 
Clinical Excellence 
Prof Ulrike Ravens-Sieberer, Universitätsklinikum Hamburg-Eppendorf 
Prof Allan Colver, University of Newcastle upon Tyne 
Prof Livia Popescu, Universitatea Babeş-Bolyai 
Prof Angela Brand, Universiteit Maastricht, European Centre for Public Health Genomics 
8. References  
Aborn, M. (1985). Statistical legacies of the social indicators movement. Paper presented at the 
annual meeting of the American Statistical Association, Las Vegas, Nevada 
Alfven, G. (1993). The covariation of common psychosomatic symptoms among children 
from socio-economically differing residential areas: an epidemiological study. Acta 
Paediatr, 82, pp. 484-487 
Bauer, R. A. (Ed.) (1966). Social Indicators, MIT Press, Cambridge 
Ben-Arieh, A. & Wintersberger, H. (Eds.) (1997). Monitoring and Measuring the State of 
Children – Beyond Survival. Eurosocial Report No. 62, European Centre for Social 
Welfare Policy and Research, Vienna 
Ben-Arieh, A. (2008). The Child Indicators Movement: Past, Present, and Future. Child 
Indicators Research, 1, pp. 3-16, 1874-8988 
Benjamins, M. R., Hummer, R. A., Eberstein, I. W. & Nam, C. B. (2004). Self-report health 
and adult mortality risk: an analysis of cause-specific mortality. Social Science & 
Medicine, 59, pp. 1297-1306 
Bjorner, J. P, Kristensen, T. O., Orth-Gomer, K., Tibblin, G., Sullivan, M. & Westerholm, P. 
(1996). Self-rated health. A useful concept in research, prevention and clinical medicine, 
Forskningsradsnämnden, Ord & Form AB, Uppsala  
Breidablik, H. J., Meland, E. & Lydersen, S. (2009). Self-rated health during adolescence: 
stability and predictors of change (Young-Hunt study, Norway). European Journal of 
Public Health, 91, 1, pp. 73-78 
Blumer, H. (1962). Society as Symbolic Interaction, In: Human Behavior and Social Process: An 
Interactionist Approach, Arnold M. Rose,  pp. 179-192, Houghton-Mifflin, Boston 
Bradburn, N. M. (1969). The structure of psychological well-being, Aldine, Chicago 
Bradshaw, J., Hoelscher, P., Richardson, D. & UNICEF (2006). Comparing Child Well-Being in 
OECD Countries: Concepts and methods. Innocenti Working Paper No. 2006-03, UNICEF 
Innocenti Research Centre, 1014-7837, Florence. 
Burt, M.R. (2002). Reasons to invest in adolescents. Journal of Adolescent Health, 31, 2, pp. 136-
152  
Cameron, E., Mathers, J. & Parry, J (2006). Health and well-being: questioning the use of 
health concepts in public health policy and practice. Critical Public Health, 16, 4, pp. 
347-354, 1469-3682 
Campbell, A. & Converse, P.E. (Eds.) (1972). The Human Meaning of Social Change, Russell 
Sage Foundation, New York 
Cantril, H. (1965). The pattern of human concern, Rutgers University Press, New York 
Cavallo, F., Zambon, A., Borraccino, A., Ravens-Sieberer, U., Torsheim, T. & Lemma, P. 
(2006). Girls growing through adolescence have a higher risk of poor health. 
Quality of Life Research, 15, 10, pp. 1577-1585, 1573-2649  
Cohen, J. (1988). Statistical power analysis for the behavioral science, Lawrence Erlbaum, New 
York  
 
Public Health – Methodology, Environmental and Systems Issues 
 
46
Currie, C., Roberts, C., Morgan, A., Smith, R., Settertobulte, W., Samdal, O. & Rasmussen, V. 
B. (Eds.) (2004). Young People's Health in Context: international report from the HBSC 
2001/02 survey, (Health Policy for Children and Adolescents, No.4), WHO Regional 
Office for Europe, 92 890 1372 9, Copenhagen 
Currie, C., Nic Gabhainn, S. Godeau, E., Roberts, C. Smith, R. Currie, D., Pickett, W. Richter, 
M., Morgan, A. & Barnekow, V. (Eds.) (2008). Inequalities in young people‘s health: 
HBSC international report from the 2005/2006 Survey, WHO Regional Office for 
Europe, Copenhagen 
Deci, E. L. & Ryan, R. M. (2008). Hedonia, Eudaimonia, and Well-Being: An Introduction. 
Journal of Happiness Studies, 9, pp. 1-11, 1573-7780 
Diener, E. (1984). Subjective well-being. Psychological Bulletin, 95, pp. 542–575, 0033-2909 
Dupuy, H. J. (1977). The General Well-being Schedule, In: Measuring health: a guide to rating 
scales and questionnaire (2nd ed), McDowell & Newell, pp. 206-213, Oxford 
University Press, Oxford 
ECHI long list (2005). Annex 5, In: The ECHI comprehensive indicators list (Long List), 
31.10.2011,   Available from:  
 <http://www.healthindicators.eu/healthindicators/object_binary/o2701_ECHI_ 
longlist.pdf> 
Edwards, L. M. & Lopez, S. J. (2006). Perceived family support, acculturation, and life 
satisfaction in Mexican American youth: A mixed-methods exploration. Journal of 
Counselling Psychology, 53, pp. 279-287, 1939-2168 
Ehrlich, D. (1961). Americans View Their Mental Health (Review). Archives of General 
Psychiatry, 5, 6, pp. 616-a-618, 0003-990X 
Erhart, M., Wille, N., Ravens-Sieberer, U. (2006). Die Messung der subjektiven Gesundheit: 
Stand der Forschung und Herausforderungen, In: Gesundheitliche Ungleichheit. 
Grundlagen, Probleme, Perspektiven, Richter, Hurrelmann, pp. 321-338, VS Verlag für 
Sozialwissenschaften, 3531160842, Wiesbaden 
Erhart, M. , Ottova, V., Gaspar, T., Jericek, H., Schnohr, C., Alikasifoglu, M., Morgan, A., 
Ravens-Sieberer,  U. & HBSC Positive Health Focus Group (2009). Measuring 
mental health and well-being of school-children in 15 European countries using the 
KIDSCREEN-10 Index. International Journal of Public Health, 54, 2, pp. 160-166 
European Commission & WHO (2008). European Pact for Mental Health and Well-being, 
Proceeding of EU High-level Conference: Together for Mental Health and Well-Being, 
Brussels, June 2008 
Fiscella, K. & Franks, P. (1997). Does psychological distress contribute to racial and 
socioeconomic disparities in mortality? Social Science & Medicine, 45, pp. 1805–1809, 
0277-9536 
Frønes, I. (2007). Theorizing indicators. On Indicators, Signs and Trends. Social Indicators 
Research, 83, pp. 5-23, pp. 1573-0921, 1573-0921   
Gobina, I., Zaborskis, A., Pudule, I., Kalnins, I. & Villerusa, A. (2008). Bullying and 
subjective health among adolescents at schools in Latvia and Lithuania. 
International Journal of Public Health, 53, 5, pp. 272-276, 1661-8556 
Gohm, C., Oishi, S., Darlington, J. & Diener, E. (1998). Culture, parental conflict, parental 
marital status, and the subjective well-being of young adults. Journal of Marriage and 
the Family, 60, pp. 319–334, 1741-3737 
Gurin, G., Veroff, J. & Feld, S. (1960). Americans View Their Mental Health, Basic Books, New 
York 
Helliwell, J. F. (2007). Well-being and social capital: Does suicide pose a puzzle? Social 
Indicators Research, 81, pp. 455-496, 1573-0921 
 
Child Mental Health Measurement: Reflections and Future Directions 
 
47 
Herdman, M., Rajmil, L., Ravens-Sieberer, U., Bullinger, M., Power, M., Alonso, J., the 
European KIDSREEN Group & DISABKIDS Group (2002). Expert consensus in the 
development of a European health-related quality of life measure for children and 
adolescents: a Delphi study. Acta Paediatrica, 91, 12, pp. 1385–90, 1651-2227 
Hurrelmann, K. & Lösel F. (1990). Basic issues and problem of health in adolescence, In: 
Health hazards in adolescence, Hurrelmann & Lösel, pp. 1-21, Walter de Gruyter, 
Berlin 
Husserl, E. (1913). Ideen zu einer reinen Phänomenologie und phänomenologischen Philosophie. 
Erstes Buch: Allgemeine Einführung in die reine Phänomenologie, Max Niemeyer 
Verlag, Halle 
Idler, E.L. & Benyamini, Y. (1997). Self-related health and mortality: A review of twenty-
seven community studies. Journal of Health and Behavior, 38, pp. 21-37, 2150-6000 
Jahoda, M. (1958). Current Concepts of Positive Mental Health, Basic Books, New York 
Jané-Llopis, E. & Braddick, F. (Eds). (2008). Mental Health in Youth and Education. Consensus 
paper, European Communities, Luxembourg, 978-92-79-09526-9 
Keyes, C. L. M. (2002). The mental health continuum: From languishing to flourishing in life. 
Journal of Health and Social Behavior, 43, pp. 207-222, 2150-6000 
Keyes, C. L. M. (2005). Mental illness and/or mental health? Investigating axioms of the 
complete state model of health. Journal of Consulting and Clinical Psychology, 73, pp. 
539–548, 0022-006X 
Keyes, C. L. M. (2006). Subjective Well-Being in Mental Health and Human Development 
Research Worldwide: An Introduction. Social Indicators Research, 77, 1, pp. 1-10, 
1573-0921  
Keyes, C. L. M. (2007). Promoting and protecting mental health as flourishing: A 
complementary strategy for improving national mental health. American 
Psychologist, 62, pp. 95–108, 0003-066X 
Kilpeläinen, K., Aromaa, A. & the ECHIM project  (Eds.) (2008). European Health Indicators: 
Development and Initial Implementation. Final Report of the ECHIM project, National 
Public Health Institute, 978-951-740-858-5, Helsinki 
Koivumaa-Honkanen, H., Honkanen, R., Viinamaki, H., Heikkila, K., Kaprio, J. & 
Koskenvuo, M. (2001). Life satisfaction and suicide: A 20-year follow-up study. 
American Journal of Psychiatry, 158, pp. 433-439, 1535-7228 
Koivumaa-Honkanen, H.T., Honkanen, R., Koskenvuo, M., Viinamaki, H. & Kaprio, J. 
(2002). Life satisfaction as a predictor of fatal injury in a 20-year follow-up. Acta 
Psychiatrica Scandinavica, 105, pp. 444–450, 1600-0447 
Koivumaa-Honkanen, H. T., Kaprio, J., Honkanen, R., Viinamaki, H. & Koskenvuo, M. 
(2004a). Life satisfaction and depression in a 15-year follow-up of healthy adults. 
Social Psychiatry and Psychiatric Epidemiology, 39, pp. 994-999, 1433-9285 
Koivumaa-Honkanen, H.T., Koskenvuo, M., Honkanen, R., Viinamaki, H., Heikkila, K. & 
Kaprio, J. (2004b). Life dissatisfaction and subsequent work disability in an 11-year 
follow-up. Psychological Medicine, 34, pp. 221-228,  
Korkeila, J., Tuomi-Nikula, A., Wahlbeck, K., Lehtinen, V. & Lavikainen J. (2006). Proposal 
for a harmonised set of mental health indicators, In: Improving Mental Health 
Information in Europe, Lavikainen, Fryers & Lehtinen, pp. 107-116, Stakes and 
European Union, Helsinki 
Kramers, P.G.N. (2003). The ECHI project. Health indicators for the European Community. 
European Journal of Public Health, 13, pp. 101-106, 1464-360X 
Kramers, P.G.N. & the ECHI team (2005). Public Health indicators for the European Union: 
Context, selection, definition. Final Report by the ECHI Project Phase II, National 
 
Public Health – Methodology, Environmental and Systems Issues 
 
46
Currie, C., Roberts, C., Morgan, A., Smith, R., Settertobulte, W., Samdal, O. & Rasmussen, V. 
B. (Eds.) (2004). Young People's Health in Context: international report from the HBSC 
2001/02 survey, (Health Policy for Children and Adolescents, No.4), WHO Regional 
Office for Europe, 92 890 1372 9, Copenhagen 
Currie, C., Nic Gabhainn, S. Godeau, E., Roberts, C. Smith, R. Currie, D., Pickett, W. Richter, 
M., Morgan, A. & Barnekow, V. (Eds.) (2008). Inequalities in young people‘s health: 
HBSC international report from the 2005/2006 Survey, WHO Regional Office for 
Europe, Copenhagen 
Deci, E. L. & Ryan, R. M. (2008). Hedonia, Eudaimonia, and Well-Being: An Introduction. 
Journal of Happiness Studies, 9, pp. 1-11, 1573-7780 
Diener, E. (1984). Subjective well-being. Psychological Bulletin, 95, pp. 542–575, 0033-2909 
Dupuy, H. J. (1977). The General Well-being Schedule, In: Measuring health: a guide to rating 
scales and questionnaire (2nd ed), McDowell & Newell, pp. 206-213, Oxford 
University Press, Oxford 
ECHI long list (2005). Annex 5, In: The ECHI comprehensive indicators list (Long List), 
31.10.2011,   Available from:  
 <http://www.healthindicators.eu/healthindicators/object_binary/o2701_ECHI_ 
longlist.pdf> 
Edwards, L. M. & Lopez, S. J. (2006). Perceived family support, acculturation, and life 
satisfaction in Mexican American youth: A mixed-methods exploration. Journal of 
Counselling Psychology, 53, pp. 279-287, 1939-2168 
Ehrlich, D. (1961). Americans View Their Mental Health (Review). Archives of General 
Psychiatry, 5, 6, pp. 616-a-618, 0003-990X 
Erhart, M., Wille, N., Ravens-Sieberer, U. (2006). Die Messung der subjektiven Gesundheit: 
Stand der Forschung und Herausforderungen, In: Gesundheitliche Ungleichheit. 
Grundlagen, Probleme, Perspektiven, Richter, Hurrelmann, pp. 321-338, VS Verlag für 
Sozialwissenschaften, 3531160842, Wiesbaden 
Erhart, M. , Ottova, V., Gaspar, T., Jericek, H., Schnohr, C., Alikasifoglu, M., Morgan, A., 
Ravens-Sieberer,  U. & HBSC Positive Health Focus Group (2009). Measuring 
mental health and well-being of school-children in 15 European countries using the 
KIDSCREEN-10 Index. International Journal of Public Health, 54, 2, pp. 160-166 
European Commission & WHO (2008). European Pact for Mental Health and Well-being, 
Proceeding of EU High-level Conference: Together for Mental Health and Well-Being, 
Brussels, June 2008 
Fiscella, K. & Franks, P. (1997). Does psychological distress contribute to racial and 
socioeconomic disparities in mortality? Social Science & Medicine, 45, pp. 1805–1809, 
0277-9536 
Frønes, I. (2007). Theorizing indicators. On Indicators, Signs and Trends. Social Indicators 
Research, 83, pp. 5-23, pp. 1573-0921, 1573-0921   
Gobina, I., Zaborskis, A., Pudule, I., Kalnins, I. & Villerusa, A. (2008). Bullying and 
subjective health among adolescents at schools in Latvia and Lithuania. 
International Journal of Public Health, 53, 5, pp. 272-276, 1661-8556 
Gohm, C., Oishi, S., Darlington, J. & Diener, E. (1998). Culture, parental conflict, parental 
marital status, and the subjective well-being of young adults. Journal of Marriage and 
the Family, 60, pp. 319–334, 1741-3737 
Gurin, G., Veroff, J. & Feld, S. (1960). Americans View Their Mental Health, Basic Books, New 
York 
Helliwell, J. F. (2007). Well-being and social capital: Does suicide pose a puzzle? Social 
Indicators Research, 81, pp. 455-496, 1573-0921 
 
Child Mental Health Measurement: Reflections and Future Directions 
 
47 
Herdman, M., Rajmil, L., Ravens-Sieberer, U., Bullinger, M., Power, M., Alonso, J., the 
European KIDSREEN Group & DISABKIDS Group (2002). Expert consensus in the 
development of a European health-related quality of life measure for children and 
adolescents: a Delphi study. Acta Paediatrica, 91, 12, pp. 1385–90, 1651-2227 
Hurrelmann, K. & Lösel F. (1990). Basic issues and problem of health in adolescence, In: 
Health hazards in adolescence, Hurrelmann & Lösel, pp. 1-21, Walter de Gruyter, 
Berlin 
Husserl, E. (1913). Ideen zu einer reinen Phänomenologie und phänomenologischen Philosophie. 
Erstes Buch: Allgemeine Einführung in die reine Phänomenologie, Max Niemeyer 
Verlag, Halle 
Idler, E.L. & Benyamini, Y. (1997). Self-related health and mortality: A review of twenty-
seven community studies. Journal of Health and Behavior, 38, pp. 21-37, 2150-6000 
Jahoda, M. (1958). Current Concepts of Positive Mental Health, Basic Books, New York 
Jané-Llopis, E. & Braddick, F. (Eds). (2008). Mental Health in Youth and Education. Consensus 
paper, European Communities, Luxembourg, 978-92-79-09526-9 
Keyes, C. L. M. (2002). The mental health continuum: From languishing to flourishing in life. 
Journal of Health and Social Behavior, 43, pp. 207-222, 2150-6000 
Keyes, C. L. M. (2005). Mental illness and/or mental health? Investigating axioms of the 
complete state model of health. Journal of Consulting and Clinical Psychology, 73, pp. 
539–548, 0022-006X 
Keyes, C. L. M. (2006). Subjective Well-Being in Mental Health and Human Development 
Research Worldwide: An Introduction. Social Indicators Research, 77, 1, pp. 1-10, 
1573-0921  
Keyes, C. L. M. (2007). Promoting and protecting mental health as flourishing: A 
complementary strategy for improving national mental health. American 
Psychologist, 62, pp. 95–108, 0003-066X 
Kilpeläinen, K., Aromaa, A. & the ECHIM project  (Eds.) (2008). European Health Indicators: 
Development and Initial Implementation. Final Report of the ECHIM project, National 
Public Health Institute, 978-951-740-858-5, Helsinki 
Koivumaa-Honkanen, H., Honkanen, R., Viinamaki, H., Heikkila, K., Kaprio, J. & 
Koskenvuo, M. (2001). Life satisfaction and suicide: A 20-year follow-up study. 
American Journal of Psychiatry, 158, pp. 433-439, 1535-7228 
Koivumaa-Honkanen, H.T., Honkanen, R., Koskenvuo, M., Viinamaki, H. & Kaprio, J. 
(2002). Life satisfaction as a predictor of fatal injury in a 20-year follow-up. Acta 
Psychiatrica Scandinavica, 105, pp. 444–450, 1600-0447 
Koivumaa-Honkanen, H. T., Kaprio, J., Honkanen, R., Viinamaki, H. & Koskenvuo, M. 
(2004a). Life satisfaction and depression in a 15-year follow-up of healthy adults. 
Social Psychiatry and Psychiatric Epidemiology, 39, pp. 994-999, 1433-9285 
Koivumaa-Honkanen, H.T., Koskenvuo, M., Honkanen, R., Viinamaki, H., Heikkila, K. & 
Kaprio, J. (2004b). Life dissatisfaction and subsequent work disability in an 11-year 
follow-up. Psychological Medicine, 34, pp. 221-228,  
Korkeila, J., Tuomi-Nikula, A., Wahlbeck, K., Lehtinen, V. & Lavikainen J. (2006). Proposal 
for a harmonised set of mental health indicators, In: Improving Mental Health 
Information in Europe, Lavikainen, Fryers & Lehtinen, pp. 107-116, Stakes and 
European Union, Helsinki 
Kramers, P.G.N. (2003). The ECHI project. Health indicators for the European Community. 
European Journal of Public Health, 13, pp. 101-106, 1464-360X 
Kramers, P.G.N. & the ECHI team (2005). Public Health indicators for the European Union: 
Context, selection, definition. Final Report by the ECHI Project Phase II, National 
 
Public Health – Methodology, Environmental and Systems Issues 
 
48
Institute for Public Health and the Environment, Bilthoven, 31.10.2011, Available 
from: < 
http://rivm.openrepository.com/rivm/bitstream/10029/7294/1/271558006.pdf> 
Land, K. C. (1975). Social indicators models: An overview, In: Social Indicator Models, Land & 
Spilerman, pp. 5-36, Russell Sage Foundation, New York 
Lehtinen, V. Ozamiz, A., Underwood, L. & Weiss, M. (2005). The Intrinsic Value of Mental 
Health, In: Promoting Mental Health: Concepts, Emerging Evidence, Practice, Herrman, 
Saxena & Moodie, pp. 46-57, World Health Organization, 92 4 156294 3, Geneva 
Lippman, L. H. (2007). Indicators and Indices of Child Well-Being: A Brief American 
History. Social Indicators Research, 83, pp. 39-53, 1573-0921 
Lippmann, L.H., Moore, K.A., McIntosh, H. (2009). Positive indicators of child well-being: a 
conceptual framework, measures and methodological issues. Innocenti Working Paper No. 
2009-21, UNICEF Innocenti Research Centre, 1014-7837, Florence 
Maher, I. & Waters, E. (2005). Indicators of Positive Mental Health for Children, In: 
Promoting Mental Health: Concepts, Emerging Evidence, Practice, Herrman, Saxena & 
Moodie, pp. 159-168, World Health Organization, 92 4 156294 3, Geneva 
Maslow, A. H. (1968). Toward a psychology of being (2th editon), John Wiley & Son, 
0471293091, New York  
Mikkelsson, M., Salminen, J. & Kautiainen, H. (1997). Non-specific muskuloskeletal pain in 
preadolescents: prevalence and 1-year persistence. Pain, 73, pp. 29-35, 0304-3959 
Morrow, V. & Mayall, B. (2010). Measuring Children’s Well-Being: Some Problems and 
Possibilities, In: Health Assets in a Global Context, Morgan, Davies & Ziglio, pp. 145-
167, Springer, 978-1-4419-5920-1, New York 
Mortimer, J. & Larson, R. (2002). The Changing Adolescent Experience: Societal trends and the 
Transition to Adulthood, Cambridge University Press, Cambridge 
Murphy, H.B.M. (1978). The meaning of symptom-checklist scores in mental health surveys: 
a testing of multiple hypotheses. Social Science & Medicine, 12, pp. 67-75, 0277-9536 
Neisser, U. (1967). Cognitive Psychology, Appleton-Century-Crofts, New York 
Nosikov, A. & Gudex, C. (2003). EUROHIS: Developing Common Instruments for Health 
Surveys. Biomedical and Health Research, 57, 1586033220 
Palfrey, J. S., Tonniges, T.F., Green, M. & Richmond, J. (2005). Introduction: Addressing the 
Millennial Morbidity − The Context of Community Pediatrics. Pediatrics, 115,  
pp. 1121-1123, 1098-4275 
Parkinson, J. (2007). Establishing a core set of national, sustainable mental health indicators for 
adults in Scotland: Final report, Public Health Adviser and NHS Health Scotland, 
Edinburgh, 31.10.2011, Available from:  
 http://www.healthscotland.com/uploads/documents/5798-
Adult%20mental%20health%20indicators%20-%20final%20report.pdf 
Parkinson, J. (2009). Children and Young People’s Mental Health Indicators: Background Briefing, 




Pavot, W. G. & Diener, E. (1993). Review of the Satisfaction with Life Scale. Psychological 
Assessment, 5, pp. 164-172, 1040-3590 
Rask, K., Asted-Kurki, P., Paavilainen, E. & Laippala, P. (2003). Adolescent subjective well-
being and family dynamics. Scandinavian Journal of Caring Sciences, 17, pp. 129–138, 
1471-6712 
 
Child Mental Health Measurement: Reflections and Future Directions 
 
49 
 Ravens-Sieberer, U., Gosch, A., Abel, T., Auquier, P., Bellach, B.M., Bruil, J., Dür, W., Power, 
M., Rajmil, L., & European KIDSCREEN Group (2001). Quality of Life in children 
and adolescents – a European public health perspective. Sozial- und 
Präventivmedizin, 46, pp. 297-302, 1420-911X 
Ravens-Sieberer, U., Gosch, A., Rajmil, L., Erhart, M., Bruil, J., Duer, W., Auquier, P., Power, 
M., Abel, T., Czemy, L., Mazur, J., Czimbalmos, A., Tountas, Y., Hagquist, C., 
Kilroe, J. & Kidscreen Group Europe (2005). The KIDSCREEN-52 Quality of life 
measure for children and adolescents: development and first results from a 
European survey. Expert Review in Pharmacoeconomics & Outcomes Research, 5, pp. 
353-364, 1473-7167 
Ravens-Sieberer, U., et al. & the European KIDSCREEN Group. (2006). The KIDSCREEN 
questionnaires—Quality of life questionnaires for children and adolescents—Handbook, 
Pabst Science Publisher, Lengerich 
Ravens-Sieberer, U., Wille, N., Erhart, M., Nickel, J. & Richter, M. (2008a). Socioeconomic 
inequalities in mental health among adolescents in Europe, In: Social cohesion for 
mental well-being among adolescents, pp. 26-42, WHO Regional Office for Europe, 978 
92 890 4288 8, Copenhagen 
Ravens-Sieberer, U., Gosch, A., Rajmil, L., Erhart, M., Bruil, J., Power, M., Duer, W., 
Auquier, P., Cloetta, B., Czemy, L., Mazur, J., Czimbalmos, A., Tountas, Y., 
Hagquist, C., Kilroe, J., & KIDSCREEN Group (2008b). The KIDSCREEN-52 Quality 
of Life Measure for Children and Adolescents: Psychometric Results from a Cross-
Cultural Survey in 13 European Countries. Value in Health, 11, 4, pp. 645-658 
Ravens-Sieberer, U., Erhart, M., Torsheim, T., Hetland, J., Freeman, J., Danielson, M., 
Thomas, C. and The HBSC Positive Health Group (2008c). An international scoring 
system for self-reported health complaints in adolescents. European Journal of Public 
Health, 18, pp. 294-299, 1101-1262  
Ravens-Sieberer, U., Erhart, M., Rajmil, L., Herdman, M., Auquier, P., Bruil, J., Power, M., 
Duer, W., Abel, T., Czemy, L., Mazur, J., Czimbalmos, A., Tountas, Y., Hagquist, C., 
Kilroe, J. & European KIDSCREEN Group (2010). Reliability, construct and 
criterion validity of the KIDSCREEN-10 score: a short measure for children and 
adolescents' well-being and health-related quality of life. Quality of Life Research, 19, 
10, pp. 1487-1500  
Remschmidt, H. & Belfer, M. (2005). Mental health care for children and adolescents 
worldwide: a review. World Psychiatry, 4, 3, pp. 147-153 
Rigby, M. J., Köhler, L. I., Blair, M. E. & Metchler, R. (2003). Child Health Indicators for 
Europe. A priority for a caring society. European Journal of Public Health, 1, 1, pp. 38-
46, 1464-360X 
Rogers, C. (1951). Client-centered therapy: Its current practice, implications and theory, Constable, 
1-84119-840-4, London 
Ryff, C.D. (1989). Happiness is everything, or is it? Explorations on the meaning of 
psychological well-being. Journal of Personality and Social Psychology, 57, pp. 1069–
1081, 0022-3514  
Samdal, O., Nutbeam, D., Wold, B. & Kannas, L. (1998). Achieving health and educational 
goals through schools: A study of the importance of school climate and students' 
satisfaction with school. Health Education Research, 13, 3, pp. 383-397, 1465-3648 
Schwarz, N. & Clore G.L. (1983). Mood, misattribution, and judgments of well-being: 
Informative and directive functions of affective states. Journal of Personality and 
Social Psychology, 45, pp. 513–523, 0022-3514 
 
Public Health – Methodology, Environmental and Systems Issues 
 
48
Institute for Public Health and the Environment, Bilthoven, 31.10.2011, Available 
from: < 
http://rivm.openrepository.com/rivm/bitstream/10029/7294/1/271558006.pdf> 
Land, K. C. (1975). Social indicators models: An overview, In: Social Indicator Models, Land & 
Spilerman, pp. 5-36, Russell Sage Foundation, New York 
Lehtinen, V. Ozamiz, A., Underwood, L. & Weiss, M. (2005). The Intrinsic Value of Mental 
Health, In: Promoting Mental Health: Concepts, Emerging Evidence, Practice, Herrman, 
Saxena & Moodie, pp. 46-57, World Health Organization, 92 4 156294 3, Geneva 
Lippman, L. H. (2007). Indicators and Indices of Child Well-Being: A Brief American 
History. Social Indicators Research, 83, pp. 39-53, 1573-0921 
Lippmann, L.H., Moore, K.A., McIntosh, H. (2009). Positive indicators of child well-being: a 
conceptual framework, measures and methodological issues. Innocenti Working Paper No. 
2009-21, UNICEF Innocenti Research Centre, 1014-7837, Florence 
Maher, I. & Waters, E. (2005). Indicators of Positive Mental Health for Children, In: 
Promoting Mental Health: Concepts, Emerging Evidence, Practice, Herrman, Saxena & 
Moodie, pp. 159-168, World Health Organization, 92 4 156294 3, Geneva 
Maslow, A. H. (1968). Toward a psychology of being (2th editon), John Wiley & Son, 
0471293091, New York  
Mikkelsson, M., Salminen, J. & Kautiainen, H. (1997). Non-specific muskuloskeletal pain in 
preadolescents: prevalence and 1-year persistence. Pain, 73, pp. 29-35, 0304-3959 
Morrow, V. & Mayall, B. (2010). Measuring Children’s Well-Being: Some Problems and 
Possibilities, In: Health Assets in a Global Context, Morgan, Davies & Ziglio, pp. 145-
167, Springer, 978-1-4419-5920-1, New York 
Mortimer, J. & Larson, R. (2002). The Changing Adolescent Experience: Societal trends and the 
Transition to Adulthood, Cambridge University Press, Cambridge 
Murphy, H.B.M. (1978). The meaning of symptom-checklist scores in mental health surveys: 
a testing of multiple hypotheses. Social Science & Medicine, 12, pp. 67-75, 0277-9536 
Neisser, U. (1967). Cognitive Psychology, Appleton-Century-Crofts, New York 
Nosikov, A. & Gudex, C. (2003). EUROHIS: Developing Common Instruments for Health 
Surveys. Biomedical and Health Research, 57, 1586033220 
Palfrey, J. S., Tonniges, T.F., Green, M. & Richmond, J. (2005). Introduction: Addressing the 
Millennial Morbidity − The Context of Community Pediatrics. Pediatrics, 115,  
pp. 1121-1123, 1098-4275 
Parkinson, J. (2007). Establishing a core set of national, sustainable mental health indicators for 
adults in Scotland: Final report, Public Health Adviser and NHS Health Scotland, 
Edinburgh, 31.10.2011, Available from:  
 http://www.healthscotland.com/uploads/documents/5798-
Adult%20mental%20health%20indicators%20-%20final%20report.pdf 
Parkinson, J. (2009). Children and Young People’s Mental Health Indicators: Background Briefing, 




Pavot, W. G. & Diener, E. (1993). Review of the Satisfaction with Life Scale. Psychological 
Assessment, 5, pp. 164-172, 1040-3590 
Rask, K., Asted-Kurki, P., Paavilainen, E. & Laippala, P. (2003). Adolescent subjective well-
being and family dynamics. Scandinavian Journal of Caring Sciences, 17, pp. 129–138, 
1471-6712 
 
Child Mental Health Measurement: Reflections and Future Directions 
 
49 
 Ravens-Sieberer, U., Gosch, A., Abel, T., Auquier, P., Bellach, B.M., Bruil, J., Dür, W., Power, 
M., Rajmil, L., & European KIDSCREEN Group (2001). Quality of Life in children 
and adolescents – a European public health perspective. Sozial- und 
Präventivmedizin, 46, pp. 297-302, 1420-911X 
Ravens-Sieberer, U., Gosch, A., Rajmil, L., Erhart, M., Bruil, J., Duer, W., Auquier, P., Power, 
M., Abel, T., Czemy, L., Mazur, J., Czimbalmos, A., Tountas, Y., Hagquist, C., 
Kilroe, J. & Kidscreen Group Europe (2005). The KIDSCREEN-52 Quality of life 
measure for children and adolescents: development and first results from a 
European survey. Expert Review in Pharmacoeconomics & Outcomes Research, 5, pp. 
353-364, 1473-7167 
Ravens-Sieberer, U., et al. & the European KIDSCREEN Group. (2006). The KIDSCREEN 
questionnaires—Quality of life questionnaires for children and adolescents—Handbook, 
Pabst Science Publisher, Lengerich 
Ravens-Sieberer, U., Wille, N., Erhart, M., Nickel, J. & Richter, M. (2008a). Socioeconomic 
inequalities in mental health among adolescents in Europe, In: Social cohesion for 
mental well-being among adolescents, pp. 26-42, WHO Regional Office for Europe, 978 
92 890 4288 8, Copenhagen 
Ravens-Sieberer, U., Gosch, A., Rajmil, L., Erhart, M., Bruil, J., Power, M., Duer, W., 
Auquier, P., Cloetta, B., Czemy, L., Mazur, J., Czimbalmos, A., Tountas, Y., 
Hagquist, C., Kilroe, J., & KIDSCREEN Group (2008b). The KIDSCREEN-52 Quality 
of Life Measure for Children and Adolescents: Psychometric Results from a Cross-
Cultural Survey in 13 European Countries. Value in Health, 11, 4, pp. 645-658 
Ravens-Sieberer, U., Erhart, M., Torsheim, T., Hetland, J., Freeman, J., Danielson, M., 
Thomas, C. and The HBSC Positive Health Group (2008c). An international scoring 
system for self-reported health complaints in adolescents. European Journal of Public 
Health, 18, pp. 294-299, 1101-1262  
Ravens-Sieberer, U., Erhart, M., Rajmil, L., Herdman, M., Auquier, P., Bruil, J., Power, M., 
Duer, W., Abel, T., Czemy, L., Mazur, J., Czimbalmos, A., Tountas, Y., Hagquist, C., 
Kilroe, J. & European KIDSCREEN Group (2010). Reliability, construct and 
criterion validity of the KIDSCREEN-10 score: a short measure for children and 
adolescents' well-being and health-related quality of life. Quality of Life Research, 19, 
10, pp. 1487-1500  
Remschmidt, H. & Belfer, M. (2005). Mental health care for children and adolescents 
worldwide: a review. World Psychiatry, 4, 3, pp. 147-153 
Rigby, M. J., Köhler, L. I., Blair, M. E. & Metchler, R. (2003). Child Health Indicators for 
Europe. A priority for a caring society. European Journal of Public Health, 1, 1, pp. 38-
46, 1464-360X 
Rogers, C. (1951). Client-centered therapy: Its current practice, implications and theory, Constable, 
1-84119-840-4, London 
Ryff, C.D. (1989). Happiness is everything, or is it? Explorations on the meaning of 
psychological well-being. Journal of Personality and Social Psychology, 57, pp. 1069–
1081, 0022-3514  
Samdal, O., Nutbeam, D., Wold, B. & Kannas, L. (1998). Achieving health and educational 
goals through schools: A study of the importance of school climate and students' 
satisfaction with school. Health Education Research, 13, 3, pp. 383-397, 1465-3648 
Schwarz, N. & Clore G.L. (1983). Mood, misattribution, and judgments of well-being: 
Informative and directive functions of affective states. Journal of Personality and 
Social Psychology, 45, pp. 513–523, 0022-3514 
 
Public Health – Methodology, Environmental and Systems Issues 
 
50
Schwarz, N. & Strack, F. (1999). Reports of Subjective Well-Being: Judgmental Processes and 
Their Methodological Implications, In: Well-Being: The Foundations of Hedonic 
Psychology, Kahneman, Diener & Schwarz, pp. 61-84, Russell Sage Foundation, 7 
0871544237, New York 
Sheldon, E.B. & Moore, W.E. (Eds.) (1968). Indicators of Social Change: Concepts and 
Measurements, Russell Sage Foundation, New York 
Shucksmith, J., Spratt, J., Philip, K. & McNaughton, R. (2009). A critical review of the literature 
on children and young people’s views of the factors that influence their mental health, NHS 




Sigerist, H.E. (1941). Medicine and Human Welfare, Yale University Press, New Haven  
Starfield, B., Katz, H., Gabriel, A., Livingston, G., Benson, P., Hankin, J., Horn, S., 
Steinwachs, D. (1984). Morbidity in childhood: a longitudinal view. New England 
Journal of Medicine, 310, pp. 824-829 
Suldo, S. M., Riley, K. N. & Shaffer, E. J. (2006). Academic Correlates of Children 
Adolescents’ Life Satisfaction. School Psychology International, 27, 5, pp. 567-582, 
1461-7374 
UN General Assembly (1989). Convention on the Rights of the Child 
UNICEF (1979). The State of the World’s Children, Oxford University Press, New York   
Wade, T. J. & Vingilis, E. (1999). The development of self-rated health during adolescence: 
An exploration of inter- and intra-cohort effect. Canadian Journal of Public Health-
Revue Canadienne De Sante Publique, 90, 2, pp. 90-94 
Waterman, A. S. (1993). Two Conceptions of Happiness: Contrasts of Personal 
Expressiveness (Eudaimonia) and Hedonic Enjoyment. Journal of Personality and 
Social Psychology, 46, 4, pp. 678-691, 0022-3514 
Westerhof, G., J. & Keyes, C. L. M. (2010). Mental Illness and Mental Health: The Two 
Continua Model Across the Lifespan. Journal of Adult Development, 17, pp. 110-119, 
1573-3440, 1573-3440 
Wilkinson, R.B. & Walford, W. (1998). The measurement of adolescent psychological health: 
One or two dimensions? Journal of Youth and Adolescence, 27, pp. 443-455, 1573-6601 
World Health Organization (1946). Constitution of the World Health Organization, 
Proceedings of  International Health Conference,  New York, June-July 1964 
World Health Organization (2001). The world health report 2001 - Mental Health: New 
Understanding, New Hope, WHO, 92 4 156201 3, Geneva 
World Health Organization (2005). Promoting mental health: Concepts, emerging evidence, 
practice, WHO, 92 4 156294 3, Geneva 
World Health Organization (2006). Addressing the socioeconomic determinants of healthy eating 
habits and physical activity levels among adolescents: Report from the 2006 HBSC/WHO 
Forum, WHO Regional Office for Europe, Copenhagen  
Zubrick, S. R. & Kovess-Masfety, V. (2005). Indicators of Mental Health, In: Promoting Mental 
Health: Concepts, Emerging Evidence, Practice, Herrman, Saxena & Moodie, pp. 146-
166, World Health Organization, 92 4 156294 3, Geneva 
0
Assessing the Outline Uncertainty
of Spatial Disease Clusters
Fernando L. P. Oliveira1, André L. F. Cançado2,
Luiz H. Duczmal3 and Anderson R. Duarte1
1Departament of Mathematics, Universidade Federal de Ouro Preto
2Departament of Statistics, Universidade de Brasília
3Departament of Statistics, Universidade Federal de Minas Gerais
Brazil
1. Introduction
The spatial analysis of disease incidence is a fundamental tool in public health monitoring
(Lawson et al., 1999). Suppose that a geographic study area is divided into administrative
areas, with known populations at risk and observed cases of disease within a certain period
of time. An interesting question is the possible existence of spatial anomalies in the study
area: are there localized regions within the map for which the relative concentration of cases
among the population at risk is significantly higher than would be expected if the cases were
distributed at random? Such anomalies, known as spatial clusters, are inherently difficult to
delineate, for several reasons (Cancado et al., 2010; Lawson, 2009). Due to the stochastic nature
of the number of observed cases of disease, the uncertainty may be elevated in the disease rate
estimation for aggregated area maps, especially for small population areas. Thus the most
likely disease cluster produced by any given method for the detection and inference of spatial
clusters (like SaTScan (Kulldorff, 1999) or any other irregularly shaped scan) is subject to a
lot of variation. If it is found to be statistically significant, what could be said of the external
areas adjacent to the cluster? Do we have enough information to exclude them from a health
program of prevention?
A criterion was proposed (Goovaerts, 2006) to measure the uncertainty of each area being
part of a possible localized anomaly in the map, finding error bounds for the delineation of
spatial clusters in maps of areas with known populations and observed number of cases. A
given map with the vector of real data (the number of observed cases for each area) was
considered as just one of the possible realizations of the random variable vector with an
unknown expected number of cases. In this methodology, m Monte Carlo replications were
performed, considering that the simulated number of cases for each area is the realization of
a random variable with average equal to the observed number of cases of the original map.
Then the most likely cluster for each replicated map was detected. Finally, to each area ai
it was assigned the number of simulations that ai was included in a most likely cluster. If
an area belonged to the most likely cluster on all the m replications, it was colored as black;
3
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an area belonged to the most likely cluster on all the m replications, it was colored as black;
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otherwise, if it never was part of a most likely cluster, then it was colored as white, with
intermediate shades of gray in-between. A Bayesian variant along these lines, to detect and
represent spatial clusters, was also proposed recently Neill (2011).
Another approach to represent the uncertainty in the delineation of spatial clusters appeared
recently (Oliveira et al., 2011), employing a ranking based scheme known as intensity function.
That procedure uses the circular spatial scan statistic (Kulldorff, 1999) to find the circularly
shaped most likely cluster for each replicated map. The corresponding m likelihood values
(obtained by means of the m Monte Carlo replications) are ranked. For each area ai , the
maximum likelihood value, obtained among the most likely clusters containing the area ai, is
determined. Finally, the intensity function associated to each areaŠs ranking of its respective
likelihood value among the m obtained values is constructed. The latest procedure generally
produce less biased results when compared with the two previous schemes.
However, the circular spatial scan has several limitations, which were discussed in the
literature (Duczmal et al., 2006; Kulldorff et al., 2006). Particularly, the circular window is not
suitable to make the correct delineation of irregularly shaped clusters because it either chooses
a proper subset of the true cluster (underestimation) or chooses a large circle containing the
cluster as a proper subset (overestimation). One important consequence is the reduction
of the power of detection (Duczmal et al., 2006). In order to overcome this limitation,
many algorithms were recently proposed to detect irregularly shaped clusters, replacing the
circularly shaped window scheme for any strategy of finding irregularly shaped solutions.
Usually, the only limitation in shape for those clusters is a connectivity requirement. In this
work, we will analyze the utilization of irregularly shaped algorithms for the application of
the intensity function (Oliveira et al., 2011), compared to the use of the simple circular scan,
which was employed as the standard method. Due to the regular shape of the most likely
cluster found, a question was left, at least in part unanswered: do all the areas inside the
cluster have the same importance from a practitioner perspective? In this work is proposed
an application of the intensity function for irregularly shaped algorithms, thus avoiding a
potential problem inherent in the use of the circular spatial scan, which may described as the
lack of resolution inside the circular cluster. As a consequence, it may be difficult or impossible
to distinguish the relative importance of the areas inside the detected circular cluster. As
we shall see, this problem does not occur when using irregularly shaped scans. Besides, the
maximum allowed size for the most likely cluster has a large influence in the result of the
cluster search (Chen J, 2008).
In this work novel results are presented, applying the multi-objective genetic algorithm scan
(Duarte et al., 2010; Duczmal et al., 2008; 2007), adapted for the weighted non-connectivity
penalty function (Cancado et al., 2010). Also, by allowing several different maximum sizes
for the most likely cluster, the possible anomaly could be identified with greater precision. As
will be demonstrated in the following sections, much better delineated cluster maps of the
intensity function will be generated, as compared with the previous version using the simpler
circular scan. As a consequence, the relative importance of individual regions composing
the spatial anomalies may be assessed, and several interesting phenomena related to the
geographical distribution of chronic and acute diseases may be visualized.
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2. The intensity function
In this section we define a criterion to measure the plausibility of each area being part of a
possible localized anomaly in the map. Following Oliveira et al. (2011), instead of finding the
most likely cluster in the original map with the observed number of cases for each area, we
consider maps where the number of cases are replications of a vector of random variables,
whose averages are defined based on the observed number of cases of the original map. We
formalize this procedure in the following.
The original map has ci observed cases in the area ai, i = 1, . . . , K. Now we construct a
Monte Carlo replication distributing randomly the C = ∑Ki=1 ci cases among the K areas
a1, . . . , aK according to a multinomial distribution where the probability associated to the area
ai is ci/C. Let V = (s1, . . . , sK) the realization of the multinomial random vector where si is
the number of simulated cases in the area ai, i = 1, . . . , K, where ∑
K
i=1 si = C. The cluster
finder algorithm (in our setting we use the circular scan or we use the elliptic scan) now finds
the most likely cluster MLC1 with likelihood ratio value LLR1. The Monte Carlo procedure
above is repeated m times, generating a set of m likelihood ratio values {LLR1, . . . , LLRm}
corresponding to the most likely clusters {MLC1, . . . , MLCm}. The likelihood ratio values are
sorted in increasing order as {LLR(1), . . . , LLR(m)} for the corresponding most likely clusters
found {MLC(1), . . . , MLC(m)}. We now define the intensity f unction f : {1, . . . , m} −→ R by
f (j) = LLR(j), j = 1, . . . , m.






f (j), i = 1, . . . , K
If the area ai does not belong to any of the sets MLC(1), . . . , MLC(m) then we set q(ai) = 0. The
value q(ai) represents the quantile of the highest likelihood ratio among the ranked values
of the likelihood ratios of the most likely clusters found in the m Monte Carlo replications,
which take into account the variability of the number of cases in each area. In this sense, the
value q(ai) may be interpreted as the relative importance of the area ai as part of the anomaly
of the map, where the value f (ai) represents the maximum likelihood ratio found for the
most likely clusters which contain the area ai. This concept gives more information about the
anomaly than the clear-cut division between cluster and non-cluster areas, as given by the
usual process of finding the most likely cluster in the original map. See Oliveira et al. (2011)
for further details.
3. Genetic algorithm for spatial cluster finding
3.1 Introduction
Genetic algorithms (GA’s) constitute an important class of optimization methods. Its
importance comes from the fact that the GA’s are robust algorithms, in the sense that they
are able to treat a wide variety of problems. While some optimization methods require certain
assumptions about the problem to be solved, without which these methods fail, the GA’s do
not require any assumption of continuity, convexity, differentiability and unimodality. In fact,
5essing the Outline Uncert inty of Spatial Disease Clusters
2 Will-be-set-by-IN-TECH
otherwise, if it never was part of a most likely cluster, then it was colored as white, with
intermediate shades of gray in-between. A Bayesian variant along these lines, to detect and
represent spatial clusters, was also proposed recently Neill (2011).
Another approach to represent the uncertainty in the delineation of spatial clusters appeared
recently (Oliveira et al., 2011), employing a ranking based scheme known as intensity function.
That procedure uses the circular spatial scan statistic (Kulldorff, 1999) to find the circularly
shaped most likely cluster for each replicated map. The corresponding m likelihood values
(obtained by means of the m Monte Carlo replications) are ranked. For each area ai , the
maximum likelihood value, obtained among the most likely clusters containing the area ai, is
determined. Finally, the intensity function associated to each areaŠs ranking of its respective
likelihood value among the m obtained values is constructed. The latest procedure generally
produce less biased results when compared with the two previous schemes.
However, the circular spatial scan has several limitations, which were discussed in the
literature (Duczmal et al., 2006; Kulldorff et al., 2006). Particularly, the circular window is not
suitable to make the correct delineation of irregularly shaped clusters because it either chooses
a proper subset of the true cluster (underestimation) or chooses a large circle containing the
cluster as a proper subset (overestimation). One important consequence is the reduction
of the power of detection (Duczmal et al., 2006). In order to overcome this limitation,
many algorithms were recently proposed to detect irregularly shaped clusters, replacing the
circularly shaped window scheme for any strategy of finding irregularly shaped solutions.
Usually, the only limitation in shape for those clusters is a connectivity requirement. In this
work, we will analyze the utilization of irregularly shaped algorithms for the application of
the intensity function (Oliveira et al., 2011), compared to the use of the simple circular scan,
which was employed as the standard method. Due to the regular shape of the most likely
cluster found, a question was left, at least in part unanswered: do all the areas inside the
cluster have the same importance from a practitioner perspective? In this work is proposed
an application of the intensity function for irregularly shaped algorithms, thus avoiding a
potential problem inherent in the use of the circular spatial scan, which may described as the
lack of resolution inside the circular cluster. As a consequence, it may be difficult or impossible
to distinguish the relative importance of the areas inside the detected circular cluster. As
we shall see, this problem does not occur when using irregularly shaped scans. Besides, the
maximum allowed size for the most likely cluster has a large influence in the result of the
cluster search (Chen J, 2008).
In this work novel results are presented, applying the multi-objective genetic algorithm scan
(Duarte et al., 2010; Duczmal et al., 2008; 2007), adapted for the weighted non-connectivity
penalty function (Cancado et al., 2010). Also, by allowing several different maximum sizes
for the most likely cluster, the possible anomaly could be identified with greater precision. As
will be demonstrated in the following sections, much better delineated cluster maps of the
intensity function will be generated, as compared with the previous version using the simpler
circular scan. As a consequence, the relative importance of individual regions composing
the spatial anomalies may be assessed, and several interesting phenomena related to the
geographical distribution of chronic and acute diseases may be visualized.
52 Public Health – Methodology, Environmental and Syst ms Issues Assessing the Outline Uncertainty of Spatial Disease Clusters 3
2. The intensity function
In this section we define a criterion to measure the plausibility of each area being part of a
possible localized anomaly in the map. Following Oliveira et al. (2011), instead of finding the
most likely cluster in the original map with the observed number of cases for each area, we
consider maps where the number of cases are replications of a vector of random variables,
whose averages are defined based on the observed number of cases of the original map. We
formalize this procedure in the following.
The original map has ci observed cases in the area ai, i = 1, . . . , K. Now we construct a
Monte Carlo replication distributing randomly the C = ∑Ki=1 ci cases among the K areas
a1, . . . , aK according to a multinomial distribution where the probability associated to the area
ai is ci/C. Let V = (s1, . . . , sK) the realization of the multinomial random vector where si is
the number of simulated cases in the area ai, i = 1, . . . , K, where ∑
K
i=1 si = C. The cluster
finder algorithm (in our setting we use the circular scan or we use the elliptic scan) now finds
the most likely cluster MLC1 with likelihood ratio value LLR1. The Monte Carlo procedure
above is repeated m times, generating a set of m likelihood ratio values {LLR1, . . . , LLRm}
corresponding to the most likely clusters {MLC1, . . . , MLCm}. The likelihood ratio values are
sorted in increasing order as {LLR(1), . . . , LLR(m)} for the corresponding most likely clusters
found {MLC(1), . . . , MLC(m)}. We now define the intensity f unction f : {1, . . . , m} −→ R by
f (j) = LLR(j), j = 1, . . . , m.






f (j), i = 1, . . . , K
If the area ai does not belong to any of the sets MLC(1), . . . , MLC(m) then we set q(ai) = 0. The
value q(ai) represents the quantile of the highest likelihood ratio among the ranked values
of the likelihood ratios of the most likely clusters found in the m Monte Carlo replications,
which take into account the variability of the number of cases in each area. In this sense, the
value q(ai) may be interpreted as the relative importance of the area ai as part of the anomaly
of the map, where the value f (ai) represents the maximum likelihood ratio found for the
most likely clusters which contain the area ai. This concept gives more information about the
anomaly than the clear-cut division between cluster and non-cluster areas, as given by the
usual process of finding the most likely cluster in the original map. See Oliveira et al. (2011)
for further details.
3. Genetic algorithm for spatial cluster finding
3.1 Introduction
Genetic algorithms (GA’s) constitute an important class of optimization methods. Its
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the only assumption a GA requires is that the function to be optimized presents a “global
trend” that can be captured or learned by the algorithm. Of course, not making any kind
of assumption and, consequently, not using these characteristics in favor, GA’a tend to be
computationally intensive, so its usage is justified for difficult problems.
When looking for a most likely cluster, one faces a challenging otimization problem: given a
set R of n regions in a map, some of which are neighbors, find the connected subset S of R
that assumes the highest LLR value. By “connected” we mean that, starting from any region
in S there’s always a path to any other region of S formed by a chain of neighbors, all of them
inside S.
Solving this problem exactly means that we would have to look at all of the 2n subsets of R,
test which ones are connected, evaluate their LLR values and pick up the most likely one.
For maps with just a few dozens of regions this problem is already intractable. So we need
another strategy to find such optimal solution. GA’s showed to be a good alternative for the
spatial cluster finding problem (Duczmal et al., 2008; 2007).
3.2 The genetic algorithm
The natural evolution of living beings can be compared to an optimization process. In
fact, if individuals who are best adapted survive - in the sense of transmitting their genetic
information - while less adapted individuals tend to disappear, it is expected that after a
number of generations the population is composed of individuals who are generally better
adapted than those of earlier generations. This is also the idea behind a genetic algorithm.
It tries to simulate the mechanisms of random variation and selection of adaptive evolution.
The mechanisms (or genetic operators) that form the basis of a genetic algorithm are:
• crossover operator, which combines the information of two or more individuals - called
parents - generating new individuals - called children;
• mutation operator, which applies a random perturbation to the information of an
individual, generating a new one;
• selection operator, which defines the probability of an individual to transmit its genetic
information (generate children) based on its adaptation level.
In this context, an individual is a candidate-solution to the optimization problem and a
population is a set of individuals. For the spatial cluster detection problem a solution - or
individual - is a set of connected regions of the map (the candidate cluster). So, the population
is a set of lists, each list being a set of regions that form the solution.
Starting with an initial population the GA forms a sequence of generations. At each iteration it
applies the selection, crossover and mutation operators to the current population, generating
a new population. The GA used in this work was primarily described in Duczmal et al. (2007)
and its biobjective versions were used by Duczmal et al. (2008), Cancado et al. (2010) and
Duarte et al. (2010).
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3.2.1 Generating the initial population
The initial population is generated by a greedy procedure. Given a map with n regions we
generate a population of n individuals, each of which is generated from one region of the
map. So, starting with a region, the solution incorporates more regions, choosing at each step
to aggregate, among all the regions that are neighbors of some region in the actual solution, the
one that makes the LLR value to increase the most when added to the solution. The individual
grows until it reaches a maximum size set by the user.
3.2.2 The selection operator
Each solution is evaluated by means of its LLR value and this is the adaptation indicator:
higher LLR-valued individuals are more adapted. The selection operator will then give
more chances to the more adapted individuals to generate offspring. This is done through
a mechanism called binary tournment. For each tournment two individuals are chosen from
the current population, each individual having the same probability of being chosed. Then
we compare the two solutions and the one with higher LLR value is selected. This procedure
is repeated n times, thus producing a set of n selected individuals.
3.2.3 The crossover operator
Now, selected individuals have the chance to trasmit their genetic information to new
individuals by generating offspring. Crossover is applied to pairs of parents randomly chosen
from the list of selected individuals. The offspring is generated in a way that the children
inherit characteristis from both parents. In addition, it is well known that GA’s particularly
designed for a specific problem perform much better than multiple-purpose generic GA’s.
Thus, it is highly recommended that operators are designed so that they can take advantage
of the intrinsic structure of the problem. For example, in our case we would discard any
disconnected cluster candidate because it is an infeasible solution. While a generic crossover
operator could, most of the time, generate infeasible clusters, we chose to use a crossover
operator that ensures that every generated solution is feasible.
The crossover operator described by Duczmal et al. (2007) presents all these features, being
capable of efficiently generating feasible offspring having characteristics of both parents.
The operator is implemented in sucha a way that it is only possible to perform a crossover
between two parents if they share a nonempty intersection. Once this condition is verified,
the offspring is generated. Figure 1 shows an example with two parents (A and B) and
the generated offspring 1-5. Note that the offspring constitutes a “path” from one parent
to another, with child 1 being more like parent A, while child 5 is almost like parent B. In the
middle of the figure we can see parents inside the map with the two intersection regions (in
gray).
3.2.4 The mutation operator
Each individual generated by the crossover process has a probability of suffering a mutation.
Mutation consistis in introducing a random perturbation in the genetic code of the individual.
In our case, the mutation consists of adding to or removing from the cluster a randomly chosen
region, provided the cluster’s connectivity.
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Fig. 1. A splitted vision of parents A and B (left), parents A and B inside the map (middle)
and offspring (right).
3.3 The biobjective genetic algorithm
Many times one wants to find a solution that simultaneously optimizes two or more
functionals. For example, a costumer may want to buy a car which is powerful and cheap.
Of course, it is very unlikely that, say, the most powerful is also the cheaper car, because these
two criteria are conflicting. Based on these two criteria, a whole set of cars can be of interest for
this costumer: powerful (but expensive) cars and cheap (but underpowered) cars. Of course,
a costumer (again, based on just these criteria) will reject cars that cost too much and are low
powered.
Following the same reasoning, a biobjective GA was proposed (Cancado et al., 2010; Duarte
et al., 2010; Duczmal et al., 2008) to deal with the problem of spatial cluster detection. Using
the LLR as the only objective to be maximized would lead to geographically meaningless
tree-shaped solutions and it is necessary to consider some shape regularity measure, such
as geometric compactness (Duczmal et al., 2008) or topological corrections (Cancado et al.,
2010; Yiannakoulias et al., 2007). This regularity measure works as a second objective to be
maximized. As in the power/price car example, LLR and regularity are conflicting objectives,
because high values of LLR are associated to very irregular clusters, while regular solutions
tend to
Instead of an optimal solution, a biobjective maximization problem will lead, in general, to
a set of optimal solutions, called the Pareto-set. This set is composed by all solutions that
are not worse than any other solution in both objectives simulteanously. Such solution is
called nondominated solution. Because GA’s work with a population of candidate-solutions
they can find the Pareto-set in one execution with almost the same effort spent by its
mono-objective version. Figure 2 illustrates a set of solutions in the objectives space.
Nondominated solutions are indicated by black dots.




Fig. 2. A set of solutions in the objectives space: dominated solutions (×) and Pareto-set (•).
3.4 Inference and the attainment function
Once the most likely cluster is identified, we want to check its significace. This will allow
the practitioner to verify if the cluster can be considered a disease outbreak or if the disease
cases are randomly spreaded over the map. Since the distribution of LLR under H0 is not
known we must perform a Monte Carlo simulation. For the mono-objective case, the LLR
value is calculated for the most likely cluster in each Monte Carlo replication under H0 and
the p-value is computed comparing the value of LLR for the observed data and the empirical
distribution obtained through the Monte Carlo procedure.
For the biobjective case, we consider the attainment function (da Fonseca et al., 2001; Fonseca
et al., 2005), as also used by Cancado et al. (2010). A single run of the biobjective GA would
produce a Pareto-set, defining two distinct regions in the objectives space: points that are
dominated by the Pareto-set and points that are not dominated by it. Then, for inference
purposes we can consider, for each point of the Pareto-set obtained for the observed data, the
proportion times that the point is dominated by the Pareto-sets under H0. This is exactly the
p-value for that point.
3.5 The geometric penalty function
One of the possible penalties that takes in account the cluster geometric shape is the called
compactness geometric penalty function. This penalty function introduced in Duczmal et al.
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(2006) aims to penalize zones in the map that have very irregular shape. The compactness
geometric function k(z) of a zone z is given by the area of z divided by the area of a circle
with the same perimeter as the convex hull of z. The compactness geometric function takes
values between zero and one, the circle has the most compact shape (k(z) = 1). Compactness





where A(z) is the area of the zone z and H(z) the perimeter of the convex hull of z. The
compactness penalyzed scan statistic is defined as maxz∈Zk(z).LLR(z).
3.6 The non-connectivity penalty function
Yiannakoulias et al. (2007) proposed a greedy algorithm to scan the set Z of all possible zones
z. A new penalty function called non-connectivity was proposed. It was based on the ratio of
the number of nodes v(z) to the number of edges e(z) of the subgraph associated with the zone
z. The non-connectivity penalty was used as a multiplier for the LLR(z). The non-connectivity
penalty function of a zone z is defined by:
nc(z) =
e(z)
[3 (v(z)− 2)] (2)
the expression in the denominator represents the maximum number of edges of a planar
graph given its number of vertices. The most penalized zones are the ones whith tree-like
associated graphs, meaning that they have a small number of nodes compared with the
number of edges. Although there is some similarity between the non-connectivity penalty
to the geometric compactness penalty, there is an important difference: the non-connectivity
penalty does not rely on the geometric shape of the candidate cluster, which could be an
interesting feature when searching for real clusters which are highly irregularly shaped, but
present good connectivity properties.
3.7 Evaluation of the candidate solutions
Differently from the previous procedure employing the circular scan, each run of the
multiobjective genetic scan produces a set of several non-dominated solutions.
In the circular scan, the scan statistic value for the most likely cluster was assigned to each area
of the solution cluster, and later the maximum value of this quantity was obtained for all the
executions. However, in the multiobjective procedure, the scan statistic value will be assigned
for each component area of each solution cluster of the non-dominated solution set. In the
event that a given area belongs to more than one solution cluster, the largest scan statistic
value is assigned to the area. The remaining of the process is identical to the usual procedure
using the circular scan, obtaining the maximum value of this quantity for all the executions,
and building the intensity function as usual.
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4. Results and discussion
Epidemiological surveillance is essential to monitoring possible changes in the geographical
distribution pattern of both acute and chronic diseases. To illustrate the techniques presented
in this chapter, four diseases (dengue fever, tuberculosis, diabetes and hypertension) are
analyzed. Those four diseases are currently among the most serious health threats to the
Brazilian population. Our studies were concentrated in the Minas Gerais state in southeast
Brazil, with 853 municipalities and total population of 19,597,330 (2010 census). For each
disease, only the specific population at risk at each municipality was considered. Population
data was available at Instituto Brasileiro de Geografia e Estatística (www.ibge.gov.br), and
disease data was obtained through DATASUS, the Brazilian Ministry of Health’s central data
system (www.datasus.gov.br). Dengue fever data was collected by SINAN/MS system from
the Brazilian Ministry of Health (www.sinam.org.br). During the period 2007-2010, 349.005
cases were registered, and the population at risk was assumed to be the total population of
the 2010 census. Tuberculosis disease cases, using SINAN/MS data, were considered for the
2001-2010 period for the following age groups (years): 15-19, 20-39 and 40-59, making a total
of 41,824 cases for a population at risk of 12,892,744. Hypertension data was obtained through
the Hiperdia program of Brazilian Ministry of Health from January 2002 to January 2011.
Data was available to the following age groups (years): 50-59, 60-69, 70-79 and 80+, with a
total population at risk of 4,365,352 individuals and 941,710 cases. Diabetes types 1 and 2 data
were also obtained through the Hiperdia program from January 2002 to May 2011. The age
groups were: 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79 and 80+ years, with 28.039 cases.
Diabetes mellitus and hypertension are considered chronic diseases and their control and
treatment depend on the individuals behavior in relation to their lifestyle: healthy eating,
physical activity, and weight control. These diseases are responsible for high rates of hospital
expenses, so the investment in shares of health promotion and prevention is potentially very
cost effective. The importance of dengue in our study lies in the fact that it is an infectious
disease and even in regions with previous low incidence rates are subject to outbreaks. This
disease is subject to major public health campaigns in Brazil. The report on the epidemiology
of dengue published by the Secretariat of Health Surveillance in 2010 indicates Minas Gerais
state as one of the critical states in need of stricter monitoring. Hypertension and diabetes
are very common chronic diseases, and hypertension is a major public health problem in
Brazil. Tuberculosis has become relevant to this study due to its high incidence, and its
early diagnosis and effective treatment are of great importance to public health. The biggest
challenge for public health professionals has been to promote action to encourage compliance
and continuity of care, since many individuals do not join or do not follow the prescribed
treatment.
4.1 Real data case studies
In what follows, we present the obtained sets of intensity function maps for dengue
fever, tuberculosis, diabetes and hypertension in Minas Gerais state (Figures 3, 4, 5 and 6,
respectively). North is up for all the maps. For each disease set we present six maps: (a)
the quantiles of population at risk, (b) the quantiles of disease rate and the intensity function
maps based on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30
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(2006) aims to penalize zones in the map that have very irregular shape. The compactness
geometric function k(z) of a zone z is given by the area of z divided by the area of a circle
with the same perimeter as the convex hull of z. The compactness geometric function takes
values between zero and one, the circle has the most compact shape (k(z) = 1). Compactness
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of 41,824 cases for a population at risk of 12,892,744. Hypertension data was obtained through
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Data was available to the following age groups (years): 50-59, 60-69, 70-79 and 80+, with a
total population at risk of 4,365,352 individuals and 941,710 cases. Diabetes types 1 and 2 data
were also obtained through the Hiperdia program from January 2002 to May 2011. The age
groups were: 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79 and 80+ years, with 28.039 cases.
Diabetes mellitus and hypertension are considered chronic diseases and their control and
treatment depend on the individuals behavior in relation to their lifestyle: healthy eating,
physical activity, and weight control. These diseases are responsible for high rates of hospital
expenses, so the investment in shares of health promotion and prevention is potentially very
cost effective. The importance of dengue in our study lies in the fact that it is an infectious
disease and even in regions with previous low incidence rates are subject to outbreaks. This
disease is subject to major public health campaigns in Brazil. The report on the epidemiology
of dengue published by the Secretariat of Health Surveillance in 2010 indicates Minas Gerais
state as one of the critical states in need of stricter monitoring. Hypertension and diabetes
are very common chronic diseases, and hypertension is a major public health problem in
Brazil. Tuberculosis has become relevant to this study due to its high incidence, and its
early diagnosis and effective treatment are of great importance to public health. The biggest
challenge for public health professionals has been to promote action to encourage compliance
and continuity of care, since many individuals do not join or do not follow the prescribed
treatment.
4.1 Real data case studies
In what follows, we present the obtained sets of intensity function maps for dengue
fever, tuberculosis, diabetes and hypertension in Minas Gerais state (Figures 3, 4, 5 and 6,
respectively). North is up for all the maps. For each disease set we present six maps: (a)
the quantiles of population at risk, (b) the quantiles of disease rate and the intensity function
maps based on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30
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and 40 (c, d, e and f respectively). The population at risk was different for each disease in our
study.
As can be noted on all four disease sets, the probability that each area belongs to the "‘true"’
cluster decreases as the maximum cluster size increases from 10 to 40. For instance, in the
dengue fever set, the dark brown areas have probability of belonging to the "‘true cluster"’
greater than 94%, 88%, 83% and 76%, as the maximum cluster size increases from 10, 20, 30
and 40, respectively. It means that the intensity function maps produced with the smaller
maximum cluster sizes (10 and 20)indicate inner "‘core"’ regions within the "‘true cluster"’.
On the other hand, the intensity function maps produced with the larger maximum cluster
sizes (30 and 40)indicate "‘borderline"’ regions with respect of the "‘true cluster"’.
Another important feature is the complexity of the shapes displayed in the sequence of
intensity function maps as the maximum cluster size increases.
4.1.1 Dengue fever
In Figure 3c, the maximum size 10 inner core region of dengue fever includes the
municipalities arround the state capital Belo Horizonte urban area (population 4 million) in
the central part of the state. The maximum sizes 20 and 30 intensity function maps (Figures
3d and 3e respectively) show the anomaly spreading northward following the São Francisco
river basin, a region with elevated humidity and high mosquito incidence. Finally, the larger
maximum size 40 anomaly (Figure 3f) spreads along the highway joining the cities of Ipatinga,
Valadares and Teofilo Otoni in the eastern part of the state.
4.1.2 Tuberculosis
In Figure 4c, the maximum size 10 inner core region of tuberculosis includes the
predominantly urban area of Belo Horizonte (in the central part of the state) and two weaker
urban regions: (i) the highway joining the cities of Ipatinga, Valadares and Teofilo Otoni in
the eastern part of the state, and (ii) the areas surrounding the city of Juiz de Fora, the second
largest city of the state in the south. As the maximum cluster size increases (Figures 4d, 4e
and 4f), the tuberculosis anomaly is reinforced to include the surrounding municipalities, and
also the neighbors of the populous Montes Claros city in the northern part of the state.
4.1.3 Diabetes
In Figure 5c, the maximum size 10 inner core region of diabetes includes the southwest part
of the state and the weaker urban region of Valadares city in the east. As the maximum
cluster size increases (Figures 5d, 5e and 5f), the diabetes anomaly is reinforced to include
the surrounding municipalities.
4.1.4 Hypertension
In Figure 6c, the maximum size 10 inner core region of hypertension includes several scattered
regions in the center and mid southeast parts of the state. As the maximum cluster size
increases (Figures 6d, 6e and 6f), the hypertension anomaly is reinforced to include the
surrounding municipalities.













































Fig. 3. Population at risk quantiles (a), dengue fever rates (b), and intensity function maps
based on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30 and
40 (c, d, e and f respectively)
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the central part of the state. The maximum sizes 20 and 30 intensity function maps (Figures
3d and 3e respectively) show the anomaly spreading northward following the São Francisco
river basin, a region with elevated humidity and high mosquito incidence. Finally, the larger
maximum size 40 anomaly (Figure 3f) spreads along the highway joining the cities of Ipatinga,
Valadares and Teofilo Otoni in the eastern part of the state.
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In Figure 4c, the maximum size 10 inner core region of tuberculosis includes the
predominantly urban area of Belo Horizonte (in the central part of the state) and two weaker
urban regions: (i) the highway joining the cities of Ipatinga, Valadares and Teofilo Otoni in
the eastern part of the state, and (ii) the areas surrounding the city of Juiz de Fora, the second
largest city of the state in the south. As the maximum cluster size increases (Figures 4d, 4e
and 4f), the tuberculosis anomaly is reinforced to include the surrounding municipalities, and
also the neighbors of the populous Montes Claros city in the northern part of the state.
4.1.3 Diabetes
In Figure 5c, the maximum size 10 inner core region of diabetes includes the southwest part
of the state and the weaker urban region of Valadares city in the east. As the maximum
cluster size increases (Figures 5d, 5e and 5f), the diabetes anomaly is reinforced to include
the surrounding municipalities.
4.1.4 Hypertension
In Figure 6c, the maximum size 10 inner core region of hypertension includes several scattered
regions in the center and mid southeast parts of the state. As the maximum cluster size
increases (Figures 6d, 6e and 6f), the hypertension anomaly is reinforced to include the
surrounding municipalities.













































Fig. 3. Population at risk quantiles (a), dengue fever rates (b), and intensity function maps
based on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30 and
40 (c, d, e and f respectively)














































Fig. 4. Population at risk quantiles (a), tuberculosis rates (b), and intensity function maps
based on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30 and
40 (c, d, e and f respectively)













































Fig. 5. Population at risk quantiles (a), diabetes rates (b), and intensity function maps based
on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30 and 40 (c, d,
e and f respectively)














































Fig. 4. Population at risk quantiles (a), tuberculosis rates (b), and intensity function maps
based on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30 and
40 (c, d, e and f respectively)













































Fig. 5. Population at risk quantiles (a), diabetes rates (b), and intensity function maps based
on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30 and 40 (c, d,
e and f respectively)














































Fig. 6. Population at risk quantiles (a), hypertension rates (b), and intensity function maps
based on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30 and
40 (c, d, e and f respectively)
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5. Conclusion
Our methodology takes into account the variability in the observed number of disease cases on
area aggregated maps to nonparametrically infer the uncertainty in the delineation of spatial
clusters. A given real data map is regarded as just one possible realization of an unknown
random variable vector with expected number of cases. The real data vector of the number of
observed cases in each area is used to construct a new vector of expected values of random
variables, considering the count of cases as the average of the random variables. This vector is
now an estimate of the unknown random variable vector with expected number of cases. Our
methodology performs m Monte Carlo replications based on this estimated vector of averages.
The most likely cluster of each replicated map is detected and the m corresponding likelihood
values obtained in the replications are ranked. For each area we determine the maximum
likelihood value among the most likely clusters containing that area. Thus, we obtain the
intensity function associated to each area’s ranking of their respective likelihood value among
the m values. The intensity of each area can be interpreted as the importance of that area in
the delineation of the possibly existing anomaly on the map, considering only the initially
given information of the observed number of cases. This procedure, based on the empirical
distribution, takes into account the intrinsic variability of the observed number of cases, which
generally is not considered directly in the existing algorithms used to detect spatial clusters.
In our case studies we could see different situations with respect to the intrinsic variability
of the existing spatial anomaly. When the most likely cluster is quite prominent, as in the
diabetes case study, the intensity function is such that almost all areas associated with the
most likely clusters found in the m replications coincides with those areas composing the
most likely cluster detected for the original observed cases. In this situation the geographic
anomaly is highly focused. However, in a different scenario, a disease map may present an
intrinsically wide variability of data. Many areas near or adjacent to the most likely cluster
have values of the intensity function close to the values corresponding to areas of the most
likely cluster. In the case study of hypertension, this intrinsic variability produces a map with
clearly unrelated areas, but with rather close probability ranking, indicating a situation of
multiplicity of clusters, i. e., the most likely cluster is clearly poorly delineated.
In this work we included two new features that extended the original ideas of the previous
paper Oliveira et al. (2011). First, instead of the circular scan, we have used an irregularly
shaped cluster finder based on a multiobjective genetic algorithm. It allowed a much better
delineation of the complex shapes found in the real data clusters. As a consequence, several
new phenomena could be distinguished in the spatial distribution of disease, which could
not be observed with the simples spatial scan. The second modification was the sequential
execution of runs with different sizes for the maximum allowed cluster to composing the
intensity function maps. With this modified procedure, instead of only one map, it was
obtained a sequence of intensity function maps: as the maximum cluster size increased, larger
anomalies of lesser intensity were displayed. This allowed the identification of "‘core"’ and
"‘borderline"’ regions, with different levels of uncertainty.
The visualization tool developed in this work may serve as a support for the decision making
process to prioritize areas of public health intervention, in a more precise manner than
provided by ordinary methods of cluster finding.














































Fig. 6. Population at risk quantiles (a), hypertension rates (b), and intensity function maps
based on the genetic multi-objective algorithm for maximum clusters of sizes 10, 20, 30 and
40 (c, d, e and f respectively)
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most likely clusters found in the m replications coincides with those areas composing the
most likely cluster detected for the original observed cases. In this situation the geographic
anomaly is highly focused. However, in a different scenario, a disease map may present an
intrinsically wide variability of data. Many areas near or adjacent to the most likely cluster
have values of the intensity function close to the values corresponding to areas of the most
likely cluster. In the case study of hypertension, this intrinsic variability produces a map with
clearly unrelated areas, but with rather close probability ranking, indicating a situation of
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intensity function maps. With this modified procedure, instead of only one map, it was
obtained a sequence of intensity function maps: as the maximum cluster size increased, larger
anomalies of lesser intensity were displayed. This allowed the identification of "‘core"’ and
"‘borderline"’ regions, with different levels of uncertainty.
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process to prioritize areas of public health intervention, in a more precise manner than
provided by ordinary methods of cluster finding.
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1. Introduction 
This chapter we refer to mutagenicity activity in the urine samples of persons who are 
exposed to carcinogenic materials in their occupations, and so some studies evaluated 
mutagenicity determination in individuals who worked with and are exposed to active 
potential mutagenic materials. There are some mutagenic compounds present in workplaces 
such as among nursing personnel in oncology hospitals, farmers' fields, clinical pathology 
laboratories, clinical forensic laboratories and pharmacology investigation laboratories etc. 
Also, clinical forensic laboratory personnel use some dangerous solvents such as chloroform 
which is mixed with other solvents in solutions of preparations of tank thin layer 
chromatography. They are also exposed to some mutagenic compounds such as 
formaldehyde, benzene and some solvents and colour regents. We refer to some of the 
below mentioned compounds, such as benzene, formaldehyde, paraffin, colour regents, 
organochlorin, smear fixators and so on. The colour regent might be contained in heavy 
metal carcinogenic substances which were used for smear colouring in clinical pathology 
laboratories by technicians and clinical forensic laboratories. According to review of some 
studies, after the filling out of questionnaire forms by these individuals, urine samples were 
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1. Introduction 
This chapter we refer to mutagenicity activity in the urine samples of persons who are 
exposed to carcinogenic materials in their occupations, and so some studies evaluated 
mutagenicity determination in individuals who worked with and are exposed to active 
potential mutagenic materials. There are some mutagenic compounds present in workplaces 
such as among nursing personnel in oncology hospitals, farmers' fields, clinical pathology 
laboratories, clinical forensic laboratories and pharmacology investigation laboratories etc. 
Also, clinical forensic laboratory personnel use some dangerous solvents such as chloroform 
which is mixed with other solvents in solutions of preparations of tank thin layer 
chromatography. They are also exposed to some mutagenic compounds such as 
formaldehyde, benzene and some solvents and colour regents. We refer to some of the 
below mentioned compounds, such as benzene, formaldehyde, paraffin, colour regents, 
organochlorin, smear fixators and so on. The colour regent might be contained in heavy 
metal carcinogenic substances which were used for smear colouring in clinical pathology 
laboratories by technicians and clinical forensic laboratories. According to review of some 
studies, after the filling out of questionnaire forms by these individuals, urine samples were 
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collected from candidates in all occupations at the end of the week and they were then held 
in a refrigerator for the urine extraction process. Special instruments – such as vacuum – and 
special materials such as MilliQ water and some solvents  such as methanol and acetonitrile 
were used for urine solid phase extraction. Some relationship studies showed that urine extracts 
were prepared by resins of C18 and amberlite XAD-2 because they are particularly absorbent of 
the carcinogenic compounds of urine; the importance of the above mentioned resins and the 
sterilisation of urine extracts will be described in this chapter as well. The personnel who 
work for a long time in these fields are exposed to these potentially carcinogenic materials. 
According to the review studies, we will show the mutagenic activity evaluation of the urine of 
some professional personnel by Ames monitoring. After the preparation of the sterile urine 
extracts of these personnel, they were exposed to salmonella strains of bacteria for the 
determination of mutagenic activity. The function of salmonella typhimorium strains such as: 
TA98,TA100, and the overnight culture of these bacteria show the importance of suspension 
preparation in the Ames test ratio and all kinds of bacterial environment cultures and the holding 
of the above mentioned bacteria will be considered in this chapter too.  All methods of Ames 
assay application in these work places will be explained in detail in this chapter. And finally, a 
risk-benefit assessment and the conditions of healthy work places and individuals’ protection 
will be described as well at the end of this chapter. 
2. Mutagenic or carcinogenic material 
Some compounds are present in the occupations of clinical pathology and forensic 
laboratory personnel and other occupations, such as oncology hospitals. Others in this 
review are: hamatoxilene, eosin and some solvents and colour reagent. Benzene, 
formaldehyde, paraffin, colour reagents, organochlorin, smear fixators, antineoplastic drugs 
etc. So the personal of these places might absorb these materials in their work environment 
through the lungs, the skin, orally etc. These compounds are metabolised in their liver by 




Fig. 1. Mutagenic or Carcinogenic material in laboratory, oxide metabolites of these 
compounds cause genotoxic effects. 
3. Samples and Ames test history   
For the mutagenicity activity evaluation of biological fluids in different job environments in 
previous decades, numerous studies of the founder of mutagenicity have a review up 
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technique called Ames assay. The first experiments by professor Ames and his co-workers 
were conducted in the 1960s and 1970s and they were accepted by international agencies, 
including the American FDA. The test has its own specific conditions because it shows that 
mutagenicity activities with cost less and the samples of tested results would be expressed 
in a few days. As well as this, it can simultaneously test up some carcinogenic material over 
the same time in less than three days. It is held that it also tested for ease of mutagenicity 
activities which are available for review, of which there may be more in the future. 
However, in many work environments there are promutagenic and carcinogenic 
compounds that are present to which workers are exposed. The review of studies of more 
jobs and environments globally show that using this test for biological fluids – including the 
urine of personnel – proves potential mutagenic activities. It is also held that the assessment 
of them in all jobs as well as review by the study process  including the preparation of urine 
samples, extraction of urine mutagenic compounds and the Ames test performed on the 
samples and biological extracted compounds  have similarities processes. [1,2,3,6,12,13,17]    
4. Sampling of volunteers and urine extraction 
All of the urine samples were collected at the end of the week from the Iranian forensic 
organisation’s laboratories and other relationship laboratories personnel and stored in a 
refrigerator, although some appropriate methods are accessible for the urine extracts’ 
preparation, but in this review we almost see solid phase extraction methods. Extraction 
columns were filled with 1 g from one kind of C18 or XAD-2 resins between two layers of 
cotton, depending on studies’ strategies. First, the resins were activated by Milli-Q water 
and methanol then the volunteer’s clear urine was passed through a column by vacuum and 
the mutagenic substances were concentrated with V/V of methanol/Acetonitrile in tubes. 
[3,4,6,12,17] 
5. Ames assay 
In these studies, mutagenicity was followed by the plates’ incorporated procedures, as 
described by Mortelmans and Zeiger (2000), in overnight cultures of TA98 and TA100 
salmonella typhymorium tester strains with and without the S9 mix fraction in the forensic 
organisation’s personnel and just TA100 in the clinical laboratory technicians in Iranian 
laboratories. For this strain, the spontaneous background number of the revertant was 
approximately 20-50 for TA98 and 75-200 for TA100 salmonella typhymorium tester strains. In 
this study, Sodium azide was used as a positive control without using the S-9 mix buffer and 
the 2-amino anthracene as a positive control  with the S-9 mix buffer. DMSO and distilled 
water were considered as negative controls and were used in this study. [1,2,3,6,12,13,17] 
6. Ames assay protocol 
The first dose/response was determined for all urine extract samples. In our studies, the 
appropriate dose of urine extracts was 1/100 for exposed bacterial strains and 0.05ml of 
overnight bacterial culture (TA98 or TA100) was added in 2ml of melting top agar 
containing trace amounts of biotin and histidine then, and 0.05ml 1/100 of diluted urine 
extract with DMSO solvent was added in the melting top agar tube as well; after shaking the 
tube’s contents were transferred in Glucose minimum agar plates which were incubated at 
37C for 48 hours. The above mentioned protocols were repeated with the addition of 0.5ml 
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of the S-9mix buffer with the contents of the rat liver p450 enzyme. After the incubation of 
all plates with and without S-9mix buffer, the colony counts of all the plates were reported 
for data collection. [1,2,3,4,6,12,13,17] 
7. Ames assay on urine samples of hospitals nursings 
Most of the anti-neoplastic drugs are cytotoxic as well as nephrotoxic and cause DNA 
damage. For example, some of them are: doxorubicin, bleomycin, vinblastine, dacarbazine, 
methotrexate, fluorouracil , prednisone , epirubicin , irinotecan , leucoverin, prednisone,  
6-mercaptopurine, procarbazine, lomustine, cisplatin (platinum), etoposide, 6-thioguanine, 
dexamethasone. According to figure.2, these drugs (such as cycloposphamide, 
mechlortamine, melphalan, chlorambucil) are nitrogen mustard group and so they have 
genotoxic effects because they will link to DNA, and they have carcinogenic effects on 
individuals who are exposed to them in their occupations. They involve a rapid 
proliferation of normal tissues (bone marrow, hair follicles and the intestinal epithelium). 
Therefore, most hospital nursing personnel are chronically exposed to anti-neoplastic drugs, 
especially during the course of giving therapeutic doses to cancer patients. Some studies 




Fig. 2. Some antineoplastic drugs with nitrogen mustard groups. 
8. Studies’ results 
The data was collected from all the occupational personnel and their negative group 
control urine extracts were exposed to salmonella bacteria tester strains, such as TA98 and 
TA100 in these review studies; then, according to the below mentioned results and data 
from the Iranian clinical pathology and medicinal forensic laboratories, they show the 
colony counts of all the tester strains of salmonella typhymorium bacteria (such as TA 98 
and TA100) as being more than 400 for the positive samples of personnel. On the other 
hand, the colony count of these individuals’ urine samples in the bacterial culture shows 
that these personnel excrete mutagenic compounds in their urine. Each ratio is 
determined from individuals’ urine samples colony counts per negative group of control 
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persons’ urine sample colony counts, so the ratio of all the samples was more than 2 and 
significant for the description of mutagenic compounds in all occupations. According to 
figure.3, in these studies we used a 0.05ml DMSO solvent and diluted water for negative 
control plates with and without using the S-9mix buffer, and we also used sodium azide 
for positive control plates without using the S-9mix buffer and 2-amino anthracene for 
positive control plates with the S-9mix buffer.  
 
            
Fig. 3a. Diluted water (D.W) for the negative control colony count plate without using the  
S-9 mix buffer. Rezai-basiri et al., 2008. 
 
 
Fig. 3b. Sodium azide (5µg/plate) for the positive control colony count plate (and TA100 
Salmonella typhymorium tester strain) without using the S-9 mix buffer. Rezai-basiri et al., 2008. 
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Fig. 3c. DMSO for the positive control colony count plate (and TA100 Salmonella 
typhymorium tester strain) with using the S-9 mix buffer. Rezai-basiri et al., 2008. 
9. Statistical analysis methods 
In the Ames assay on the Iranian forensic organisation’s laboratory personnel’s urines with 
two bacterial tester strains of TA98, TA100 for colony counts in exposure to urine extract 
samples, and positive or negative samples the Anova two-way statistical method was used. 
10. Evaluation of mutagenic compounds the in urine of medicinal forensic 
laboratory personnel 
 
Control group Colony count TA100 Colony countTA98 
 without-S-9mix with+S-9mix without-S-9mix with+S-9mix 
Male 86 65 26 25 
Male 106 72 23 27 
Male 100 77 27 21 
Male 85 75 19 24 
Male 88 68 22 25 
Male 98 65 21 14 
Male 95 85 23 29 
Female 91 85 20 20 
Female 102 86 24 28 
Female 98 76 18 24 
Average 94.9 75.4 22.2 24.7 
Partoazr, et al., 2009. 
Table 1. Results of the control group of the mutagenicity assay in the urine of medicinal 
forensic laboratory personnel with the use of TA98 and TA100 bacteria strains both with and 
without the S-9mix. 
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Samples Colony count TA100 Ratio of TA100 
 with+S-9mix without-S-9mix without-S-9mix with+S-9mix 
1* 95 95 1 1.26 
2* 95 78 1 1.04 
3** 85 74 0.89 0.98 
*=The samples belonged to the  pathology personnel of the medicinal forensic organisation. 
**=The samples belonged to the anatomy personnel of the medicinal forensic organisation. Partoazr, et al., 2009. 
Table 2. Positive and doubtful cases. The results of the mutagenicity assay in the urine of 
medicinal forensic laboratory personnel with the use of TA100 salmonella typhymorium 
bacteria strains both with and without the S-9mix (cell of rat liver). 
 
Samples Colony count TA98 Ratio of TA98 
 with+S-9mix without-S-9mix without-S-9mix with+S-9mix 
1** 550 55 20 2.2 
2* 340 30 15 1.2 
3* 41 31 1.86 1.24 
**=Positive cases in the personnel of the medicinal forensic organisation. 
*=Doubtful cases in the personnel of the medicinal forensic organisation. Partoazr, et al., 2009. 
Table 3. Positive and doubtful cases. The results of the mutagenicity assay in the urine of 
medicinal forensic laboratory personnel with the use of TA98 salmonella typhymorium 
bacteria strains both with and without the S-9mix (cell of rat liver). 
11. Evaluation of mutagenic compound in urine of clinical pathology 
laboratory technicians 
At least four clinical pathology laboratories witnessed the evaluation of the mutagenicity  
of the urine of technicians by the Ames assay. That the ratio would be more than two  
was significant for the potential of the mutagenic activity of the urine of technician.  
 
 
Fig. 4. The plates of positive cases of the TA100 salmonella tester strain cultures at 37C for 
48hours for the Ames assay on the urine extracts of the clinical pathology laboratory 
technicians. Rezai-basiri et al., 2008. 
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The number of personnel who had greater than two ratios was five people in this study. 
According to the below mentioned, we see some significant results showing mutagenic 
excretions in the urine of clinical pathology laboratory technicians:   
The ratios without the S-9mix for two of the technicians were 2.01 and 2.0, and the ratio with 
the S-9mix for these individuals was 2.05 and 2.01. [3,6,12,13,17] 
12. Conclusion and recommendation 
In this review study, we observed mutagenic activity in the urine extracts of some of the 
technicians of clinical pathology laboratories and the forensic organisation laboratories. 
According to these studies, in order to reduce mutagenicity in technicians it was suggested 
to all of them to use masks, gloves and work under laminar flu and avoid drinking in the 
laboratories. Considering the contamination of all personnel with mutagenic substances 
such as colour reagents contained in carcinogenic heavy metals, formaldehyde, benzene, 
hamatoxilen-Eosin and so on in these laboratories, the observation of the principles of health 
conditions in clinical pathology laboratories and forensic organisation laboratories is 
recommended. According to this review study, it is held that the long duration of working 
and exposure to mutagenic and carcinogenic substances in high risk conditions leads to the 
excreting of mutagenic compounds in the urine of these individuals and so they should 
decrease their time spent working over the week. The some studies showed which 
personnel has used antioxidant compounds, such as thiol group drugs; they had decreased 
the mutagenic activity in their urine. Also these results were shown to smokers who have 
used thiol group drugs such as acetyl cystein, had low mutagenic activity in urine samoles. 
As such, it considers the consumption of vitamins with antioxidant effects which are useful 
to individuals who are exposed to mutagenic compounds in their occupations. [3,6,12,13,16]. 
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used thiol group drugs such as acetyl cystein, had low mutagenic activity in urine samoles. 
As such, it considers the consumption of vitamins with antioxidant effects which are useful 
to individuals who are exposed to mutagenic compounds in their occupations. [3,6,12,13,16]. 
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1. Introduction 
Genetics and Social Sciences are divergent disciplines for whom it is customary to compete 
to explain the greater part of Schizophrenia risk 1. These days, a convincing case can be 
made for the prospective public health value of either discipline 2,3. However the practical 
implementation of such knowledge continues to prove challenging for either field alone: 
From a genetic perspective, progress was traditionally hindered by the inconsistent nature 
of discoveries made in the pre-GWAS (Genome-wide Association Study) era. It is now held 
back by the fact that the heritability attributed to this disorder remains largely impermeable 
to GWAS and other genomic approaches. 
Socio-environmental research, on the other hand, has not progressed to the point of being 
able to pinpoint the precise origins of the high attributable risk fractions repeatedly 
encountered 2.  
However ongoing progress on two fronts is fuelling hopes that a successful marriage of the 
two fields will benefit both the rate and the integrity of new discoveries, so that clinical 
interventions can eventually be targeted to patient sub-groups on the basis of their 
combined genetic and environmental risk profile: 
i. Firstly, the credibility of Schizophrenia genetics is benefiting from a recent upswing in 
the generation of verifiable new findings. This has led to a palpable mood change 
within the psychiatric genetics community 4. 
ii. Secondly, it is anticipated that social science research will benefit from an 
unprecedented program of investment that will stimulate the emergence of newer 
methodologies designed to improve the resolution with which social risk factors are 
measured 5,6. 
There are high hopes that the formal integration of these two fields will help to invigorate 
the search for tailored clinical interventions, whether they be therapeutic or prophylactic in 
nature. Thus it seems an opportune time to consider the potential obstacles that lie ahead for 
Schizophrenia research in the newly revitalised era of translational research. We do this by 
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taking a fresh look through a retrospective lens, at the historical stumbling blocks for the 
GxE field. We discuss some of the new opportunities (horizons) at the disposal of GxE 
researchers designed to circumvent them. Some of these hail from recent advances in 
biobanking, meanwhile new bioinformatic initiatives are helping to transform electronic 
clinical databases into similarly powerful research tools.  
We also highlight the potential pitfalls of an over-regulated clinical trial environment and 
the detrimental consequences this may eventually have on the pipeline for new drugs. 
Currently there are fears that an over-burdensome European regulatory legislature is 
responsible for the recent efflux of companies away from the European clinical trial market. 
This may create an unwanted bottleneck (or worse still, a precipice) within the new and 
fully-functional formal framework designed to shepherd only the most robust GxE 
discoveries into the clinic. We begin this chapter with a brief review of some important 
concepts central to a discussion on Gene-Environment inter-dependency. 
2. The enigma surrounding heritability 
Heritability is defined as the proportion of phenotypic variance due to genetic variance. The 
concept of Schizophrenia as a heritable disorder was once considered to be controversial, 
though this is no longer the case. From a scientific perspective it is well worth knowing 
beforehand that a phenotype of potential interest is heritable enough to merit the effort of 
dissecting genetically. Thus, establishing that this is the case, is a prerequisite first step in 
genetic research. 
Formal estimates of heritability can be obtained through a number of different methods. The 
archetypal approach uses twins 7. Twin studies suggest that susceptibility to Schizophrenia 
is predominantly a genetic phenomenon that accounts for 65-80% of overall risk 7,8. But that 
upper estimate is likely to understate the true importance of the environment. Even highly 
penetrant genetic risk factors (such as a syndromic deletion on chromosome 22q11), are not 
always sufficient to elicit Schizophrenia on their own 9. This is confirmed by the fact that 
pathogenic genetic anomalies are often harboured by asymptomatic controls, as well as 
cases 10. This suggests that the underlying risk conferred is heavily mitigated by the 
environment and other background genetic modifiers of main effects. 
Heritability studies estimate that the environmental contribution to Schizophrenia is 
between 15-35% of the phenotypic variance. The issue of which science explains the greater 
part of risk is contentious; social science research bases its own claims of dominance on 
larger explained effects, and also recent calculations which suggest that the burden of cases 
occurring in the general population could be averted through social interventions 2. In truth, 
methodological biases in both fields mean attempting to delineate between the effects of 
genes and environment is a somewhat arbitrary exercise. This is because classical 
approaches to heritability estimation do not automatically factor-in the dependency which 
may occur between genes and environment. Meanwhile, one all-important confounder not 
accounted for by the social risk liability models of Kirkbride et al 2, is a family history of 
psychiatric disorder, (a proxy for genetic influence). It is important to keep in mind that 
these methodological limitations mean that a disorder caused by GxE will be attributed to 
Genes in a twin study and Environment in an epidemiological study. 
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This ambiguity probably explains why heritability estimates for Schizophrenia have 
historically been so variable; the value of each estimate is affected by parameters defined by 
the population under study, and also the degree to which characteristics such as gender, 
age, and environment exposure profile have been averaged-over 11. Therefore it comes as no 
surprise that genetic epidemiology research in Psychiatry is fast becoming preoccupied with 
redefining heritability itself 11. Some principle areas of interest emerging from such work 
include;  
- the stability of heritability over time 
- genetic determination of sensitivity to exposure  
Twin studies and other methods impose a fixed-point approximation of heritability. But this 
fails to adequately capture the inherent mobility of heritability over time. Evidence for this 
drift comes from longitudinal studies of both Substance Misuse and Depression. These 
demonstrate a tendency for heritability to increase across the developmental period between 
adolescence and adulthood 12, and also with later stages of decline 13. These studies show that 
the initiation of cannabis use is predominantly an environmental phenomenon, although 
genetic influences become increasingly important as the level of usage progresses towards 
substance abuse and drug dependency 14. In extreme scenarios within polygenic disorders, 
heritability may reach a higher level during earlier neuro-developmental stages. Such cases 
tend to result in earlier onset. For Schizophrenia, the earliest cases are known to occur during 
childhood 15. 
3. Multifactorial risk factors for Schizophrenia 
Table 1 lists some of the important exposures known to affect the risk of Schizophrenia. The 
main origins are social, socio-economic and neuro-developmental. As well as being very 
common many of these risk factors are associated with large effects. Odds ratios (ORs), reflect 
the odds of exposure to a risk factor in cases relative to controls (expressed as a fold-difference).  
 
Table 1.  Environmental Risk factors for Schizophrenia - a non-exhaustive list 
Context Environmental Risk Factor Recent Review Recent meta-analysis 
  Urban-Rural dwelling March et al, 2008 16 - 
  
Social Context - Neighbourhood 
effects - - 
Social Social Discrimination- Discrimination - Allardyce et al, 2005 17 
 Migration 
Cantor-Graae and Selten, 
2005 18 DeAlberto et al, 2010 19 
  Cannabis Use  Henquet et al, 2008 20 
Arsenault et al, 2002 21; Henquet et al, 2005 22; Moore et 
al, 2007 23 
  Childhood Trauma Morgan and Fisher, 2007 24 - 
Familial Advancing Paternal age Miller et al, 2010 25 Miller et al 2011 26 




complications - - 
  Seasonal birth - - 
 Vitamin D - - 
Economic Developed vs Developing Country - Saha et al, 2005 25  (25) 
 Socio-Economic status Cohen et al, 2008 (22) - 
      - 
    - - 
Other Gender - Aleman et al, 2003  23 (23) McGrath et al, 2004  24 (24) 
    - - 
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  Urban-Rural dwelling March et al, 2008 16 - 
  
Social Context - Neighbourhood 
effects - - 
Social Social Discrimination- Discrimination - Allardyce et al, 2005 17 
 Migration 
Cantor-Graae and Selten, 
2005 18 DeAlberto et al, 2010 19 
  Cannabis Use  Henquet et al, 2008 20 
Arsenault et al, 2002 21; Henquet et al, 2005 22; Moore et 
al, 2007 23 
  Childhood Trauma Morgan and Fisher, 2007 24 - 
Familial Advancing Paternal age Miller et al, 2010 25 Miller et al 2011 26 




complications - - 
  Seasonal birth - - 
 Vitamin D - - 
Economic Developed vs Developing Country - Saha et al, 2005 25  (25) 
 Socio-Economic status Cohen et al, 2008 (22) - 
      - 
    - - 
Other Gender - Aleman et al, 2003  23 (23) McGrath et al, 2004  24 (24) 
    - - 
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The typical effect range of the risk factors shown in table 1 typically range from 1.5 to 11. In 
contrast, common genetic risk factors for Schizophrenia are much smaller, typically with 
Odds ratios of between 1.1 – 1.4. See table 2 for a summary of genetic risk factors for 
Schizophrenia deriving from large-scale (genome-wide) genetic studies. 
 
Table 2.    Genetic Risk factors for Schizophrenia 
Chromosome Gene/Region Symbol Full Gene Name GWAS Significance threshold Reference 
 1 
1q21.1 
deletion    Too rare to compute 28-36 
 1q21.1 BCL9 B-cell CLL/lymphoma 9 Strongly suggestive 37 
 1p21.3 
MIR137 (intron 3 of 
miRNA transcript)   Significant 4 
  1q24    Significant 38 
  1q32.2 PLXNA2 plexin A2 Strongly suggestive 39 





neurexin 1 Too rare to compute 28,31-35,42-44 
  2p22.2 
SULT6B1 sulfotransferase family, cytosolic, 6B, 
member 1 Strongly suggestive 45 
  2q32.1 ZNF804A zinc finger protein 804A Strongly suggestive 46-48 
  2q32.3 
PCGEM1(non-coding 
RNA transcript) (prostate-specific transcript 1 Significant 4 
 2q33.3-q34 
ERBB4 v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) Strongly suggestive 49 
  2q34-q35 
ACSL3-KCNE4 acyl-CoA synthetase long-chain family 
member 3 Significant 50 
  2q37 
CENTG2/AGAP1 ArfGAP with GTPase domain, ankyrin 
repeat and PH domain 1 Strongly suggestive 49 
  2q37.1 
UGT1A1-HJURP 
(intergenic) Holliday junction recognition protein Significant 50 
  2q37.3 
AK573765-TWIST2 
(intergenic) twist homolog 2 (Drosophila) Significant 50 
  2q37.3 
LRRFIP1 leucine rich repeat (in FLII) interacting 
protein 1 Significant 50 
  3p21.1  PBRM1 Polybromo 1 Strongly suggestive 51 
3 3q21-q23 RELN reelin Strongly suggestive 52 
 3q21-q23 RBP1 retinol binding protein 1, cellular Strongly suggestive 53 
  3q39 deletion 
 
  Too rare to compute 
28,32,34,35,43,
54 
5 5q14.1 CMYA5 cardiomyopathy associated 5 Strongly suggestive 55 
 6 6p21 
ZKSCAN4 zinc finger with KRAB and SCAN 
domains 4 Significant 56 
  6p21.3 NOTCH4 notch 4  Strongly suggestive 45,57 
  6p22.1 MHC region   Significant 49,57,58 
 6p22.1 NKAPL NFKB activating protein-like Significant 56 
  6p22.1 
PGBD1 piggyBac transposable element derived 
1 Significant 56,57 
  6q21-qter 
LOC645434-NMBR 
(intergenic) neuromedin B receptor Significant 50 
  6q23.2 AHI1 Abelson helper integration site 1 Strongly suggestive 59 
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Chromosome Gene/Region Symbol Full Gene Name GWAS Significance threshold Reference 
7 
7q11.23-q21.3 PCLO piccolo (presynaptic cytomatrix protein) Strongly suggestive 60 
7q36.3 
duplication VIPR2 vasoactive intestinal peptide receptor 2 Too rare to compute 28,32,53,61,62 
 8 8p12    Significant 38 
 8p21-p12 NRG1 neuregulin 1 Strongly suggestive 49 
 8q21 MMP16 matrix metallopeptidase 16 Significant 4 
 8p23.2 CSMD1 CUB and Sushi multiple domains 1 Significant 4 
11 11q24.2   NRGN 
neurogranin (protein kinase C substrate, 
RC3)  Significant  41,57 
12 12p13.3   CACNA1C 
calcium channel, voltage-dependent, L 
type, alpha 1C subunit Suggestive  63 
15 
15q13.2 
deletion    Too rare to compute 28,32,34 
16 
16p11.2 
duplication    Too rare to compute 28,32,35 
 
16p13.11 
duplication    Too rare to compute 28,30,31,34 
17 17q12 deletion    Too rare to compute 32,34 











interleukin 3 receptor, alpha (low 
affinity) Strongly suggestive 64 
Xp22.32 & 
Yp11.3 CSF2RA 
colony stimulating factor 2 receptor, 
alpha Strongly suggestive 64 
 
Table 2. CNVs (Copy Number Variants) are sub-microscopic deletions and duplications 
of DNA (typically greater than 100kb in size). SNP (Single Nucleotide Polymorphism) 
refers to a single subnit (base) change in the DNA sequence. CACNA1C, ZNF804A, 
NRGN, MHC and PBRM1, all overlap with Bipolar Disorder. *Genome-wide  
significant = P<5x10-8; Strong significance is defined as a P value of between 5x10-4  
and 5x10-8. **Notes the pre-existence of this gene as a commonly-researched candidate 
in Schizophrenia research prior to GWAS. Note within table 2 the high occurence  
of findings validated by more than one study. This is particularly obvious for CNVs, 
but is also evident for SNP variants, including those not reaching overall  
significance. 
The effects of Environmental risk factors are on a par with those of the structural variants 9, 
catalogued in Table 2, but the latter occur much too infrequently to explain the fact that 
Schizophrenia is common mental disorder, affecting 1% of the global population. In fact, the 
molecular modalities identified so far for Schizophrenia (namely copy number and common 
variation) currently account for no more than 3% of the total phenotypic variance of 
Schizophrenia 65.  
The discrepancy between theoretical and observed heritability estimates has led many to 
speculate on possible reasons why the ‘missing’ component is so elusive 66. The possibilities 
span a wide array of plausible theories, most of which are based on the premise that the 
additive component of heritability is probably exaggerated. eg 67.  
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4. The fundamental models of gene-environment dependency 
Nowadays, it is possible to examine the theory that heritability has been overstated, by 
testing the significance of the difference in heritability between exposure and non-exposure 
twin models 11. This is an appropriate way to empirically test the dependency between 
genes and environment. 
The risk factors shown in table 1, while very common, are mitigated by the genetic make-up 
of the individual, such that the overall effect on risk is relatively small. At a population level 
this means that only a small proportion of those encountering these exposures will ever go 
on to develop clinical symptoms. This example of inter-dependency is known as Gene-
Environment interaction. Cumulatively it may have a large impact on psychosis risk at the 
population level.  
4.1 G-E correlation (rGE) 
Analytically, GxE is difficult to distinguish from gene-environment correlation (rGE), a 
phenomena whereby exposure to exogenous risk factors is encoded within the DNA of the 
individual. rGE represents the social manifestation of one’s genetic heritage, and its 
influence on subsequent lifestyle choices. If not properly accounted for, rGE can quietly 
confound the apparent interaction between genes and the environment.  
There are many behavioural examples of this phenomenon in the psychiatric literature 
(reviewed in 68). For instance, genes can have an indirect influence on adolescent substance 
misuse, through a mechanism in which genes drive the selection of friends who facilitate 
this behaviour. In this example, peer-group choice can be redefined as a lifestyle trait with a 
strong genetic component 69. An equally compelling case can be made for rGE in 
Depression, as there is an indication that genetic susceptibility to Depression may also 
partly reflect a person’s tendency to experience stressful experiences, such as interpersonal 
and romantic difficulties 70. 
The evidence used to discuss G-E dependency in the context of Schizophrenia is drawn 
almost exclusively from the cannabis literature, as it is one of the most commonly 
investigated risk factors in GxE research. Its popularity probably reflects the relative ease 
with which data on this exposure may be obtained and verified, with good sensitivity and 
specificity. This makes it comparatively easy to derive a fairly accurate profile of exposure 
using retrospective assessments 71,72. 
While there is little in the way of direct experimental evidence to support the occurrence 
of rGE in Schizophrenia, it would be surprising if Schizophrenia were shown to be 
completely devoid of the phenomenon, given its demonstration in other areas of 
behavioural research 68. Only one study has purported to show evidence of the rGE 
mechanism in Schizophrenia 73. Meanwhile the evidence that contradicts this finding has 
withstood the many different experimental designs applied to re-address the same 
question eg. 21,74,75. The most recent of these used a case-control design 75, and also 
included a comparison of lifetime cannabis consumption between the siblings of cases 
(who have a higher genetic propensity for Schizophrenia) and healthy controls. It found 
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no difference between these two groups and thus does not find support a role for 
Schizophrenia genes in the initiation of cannabis use. 
4.2 G-E interaction (GxE) 
Interaction is a more solidly supported mechanism of G-E dependency in Schizophrenia, 
whose influence clearly extends to cannabis use. For example, early studies have suggested 
that familial (presumably genetic) influences on SZ risk also augment the psychotogenetic 
effects of this drug 76. Another study finds that the same level of familial liability is reached 
among cases of cannabis-induced psychosis, as that found among Schizophrenia patients; a 
strong indication that the enhanced responsiveness to cannabis in these hospitalised users is 
enabled by Schizophrenia genes 77. Cannabis use can thus be said to advance the genetic risk 
of Schizophrenia onset. The same can be said of urbanicity 78 and prenatal exposure to 
infection 79, but seemingly not of obstetric complications 80.  
One drawback of the familial liability study design is that genetic and environmental effects 
cannot so easily be discerned within the construct of ‘familiality’, which is inferred as being 
predominantly genetic in origin, but which also incorporates an element of shared 
environmental risk. The adoption study design therefore, is a convenient way to disentangle 
the components of this construct, by allowing the genetic component to be assessed in 
isolation of shared environmental influences. 
The adoption study design has been widely used for this purpose in Schizophrenia research. 
A recent exemplar for the approach investigated psychosis in 13,000 entrants on the Swedish 
National Adoption Register. Using an empirical approach, the study confirmed the 
relevance of early life parental employment status, parental separation and housing status to 
underlying Schizophrenia risk. Importantly this occurred both dependently and 
independently of underlying genetic liability. The synergism between genes and 
environment was many times greater than either additive or multiplicative risk thresholds, 
indicating a strong interaction. The findings were later validated in 26,000 individuals 
derived from the general population 81.  
5. Candidate gene studies of gene-environment interaction  
Currently, Gene-Environment interaction is one of a few areas of genetic research in which 
the candidate-gene design has had the upper hand over the more systematic approach 
represented by Genome-wide Association studies (GWAS). A favoured approach uses 
biological plausibility to guide the formulation of coherent hypotheses 82. This strategy has 
several high profile discoveries to its credit. Table 3 Lists the GxE studies performed to date 
in psychosis and summarises the individual outcome of each. Heterogeneity among 
hypotheses and methodological approaches precludes a more formal assessment of current 
experimental evidence (ie. by meta-analysis). 
Universal acknowledgement of the GxE concept in Schizphrenia alone 78-81,83-86 tends to 
suggest that its pervasiveness across psychiatry should be on a par with the rest of nature. 
However the paradox of GxE in Psychiatry is that though generally acknowledged, the 
interactions themselves are proving difficult to individually identify. 
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Table 3. Studies investigating interactions between candidate susceptibility genes         
        and candidate environmental pathogens in relation to psychosis.  
Author Sample size Candidate G Candidate E Outcome Variable Results Statistics 
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p=0.004; =0.27, SE=0.10 
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Table 3. AKT1 = Serine-threonine protein kinase; BDNF = Brain-derived neurotrophic factor; 
CB1 = Cannabinoid receptor type 1; CAPON = Carboxyl-terminal PDZ ligand of neuronal 
nitric oxide; CHRNA7 = Neuronal acetylcholine receptor subunit alpha-7; COMT = Catechol-
O-methyltransferase; DTNBP1 = dystrobrevin-binding protein 1; ESM = Experience 
Sampling Method. GAD1 = Glutamate decarboxylase 1; GRM3  = Metabotropic glutamate 
receptor 3; HC = Healthy Controls; HLA = Human Leukocyte Antigen; MTHFR = 
Methylenetetrahydrofolatereductase; NOTCH4 = Neurogenic locus notch homolog protein 
4; NOS1AP = Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein; 
NRG1 = Neuregulin; PRODH = Prolinedehydrogenase; RGS4 = Regulator of G protein 
signaling 4; SZ = Patients with Schizophrenia; TNF-alpha = Tumor necrosis factor. 
The particulate nature of the molecular element to GxE interaction means that genetically 
pre-ordained outcomes could in theory be averted. The extent to which this is true depends 
on the effect sizes involved and whether the proposed intervention can be made in timely 
fashion. This has positive implications for public health. For example in some circumstances, 
it may be preferable to eliminate the environmental risk component altogether, rather than 
attempt the more tedious task of targeting genetic risk groups for a given intervention. 
Phenotype expression is normally suppressed as risk-inducing environmental exposures 
become scarce; this correlates with a decline in heritability and impacts on the number of 
diagnosed cases. The contextual nature of heritability can be exploited through use of the 
‘exposure only’ study design 87, which facilitates the detection of environmentally-sensitive 
genetic variation. This approach is particularly powerful at the genome-wide level. The 
success of such strategies is determined by the extent of GxE contribution to the heritability 
of a given disorder. 
A good illustration of the relationship between exposure and heritability comes from a US 
study that compared interstate influences on the heritability of teenage nicotine use. It was 
found that heavier state control of tobacco availability, through a combination of higher 
taxation, lower advertising and controlled vending machine supply, resulted in lower levels 
of detectable genetic influence on daily smoking 88. The high incidence of Schizophrenia 
could benefit from interventions in several areas of public policy. First and foremost would 
be those policies that made it more difficult to acquire cannabis, as this could reduce rates of 
Schizophrenia within genetically-prone sub-populations. 
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6. Methodological constraints in GxE research 
There are lingering doubts about the experimental validity of many GxE findings reported 
in the literature. This is in contrast to the renewed sense of optimism about genetic 
association, a method which focuses on direct gene effects rather than the consequences of 
their interactions. Genetic association studies now have GWAS to look to as a 
methodological reference point 4,38,40,41,50,56,89, and it is out of the technological infrastructure 
supporting GWAS, that two competing theories (they may not be mutually exclusive) 
regarding the genetic architecture of Schizophrenia have emerged: The Common Disease-
Common Variant and Multiple Rare Variant hypotheses 4,9,10,58. The latter of these will be 
explored in great detail through new sequencing initiatives already underway for 
Schizophrenia (for example, the UK10K study: www.uk10k.org/goals.html).  
A combination of meticulous study design, unprecedented sample sizes and good 
governance over methodological practice 90, now mean that replication is no longer the 
rarity it once was for genetic association studies (see table 3). This is in part due to the fact 
that genetic association studies are becoming more methodologically homogeneous; many 
of the rigorous methodological practices and standards routinely implemented in GWAS 
research (internally validated findings, population stratification, etc) have also been widely 
adopted by studies whose scope does not extend beyond individual candidate genes.  
In contrast, the diversity of methodologies and standards used in GxE research has 
remained stubbornly heterogeneous to date; the multitude of study designs used to follow-
up new discoveries, has seen only varying levels of success 91. Longitudinal studies sit very 
high within the complex methodological hierarchy of epidemiological designs, but even 
they are failing to provide the swift resolutions hoped for, to ongoing research questions of 
high importance (eg. Caspi vs Zammit) 92,93. 
Several recurring factors limit the success rate of replication attempts in GxE research. These 
include: 
- Measurement error 
- The distribution of genotypes and exposure 
- The effect size 
- Sample size  
The next section is dedicated to exploring each of these aspects in greater detail. 
6.1 Measurement error 
Arguably the most replicated GxE finding in Psychiatry belongs to the field of Depression, 
and involves the short allele of the Serotonin transporter gene (5HTTLPR) and Stressful Life 
Events (SLE), which interactively augment the risk of Depression 94. Reviews that have 
delved into the matter of how consistently the finding can be reproduced, have noted that 
there is an inverse relationship between sample sizes and the associated likelihood of 
replication. This appears to be due to the larger degree of measurement error (associated 
with exposure) inherent to large studies 95. Small studies, which have fewer resources, shun 
large-scale recruitment, but place greater importance instead on maximising the accuracy 
with which environmental exposures are measured.  
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‘exposure only’ study design 87, which facilitates the detection of environmentally-sensitive 
genetic variation. This approach is particularly powerful at the genome-wide level. The 
success of such strategies is determined by the extent of GxE contribution to the heritability 
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A good illustration of the relationship between exposure and heritability comes from a US 
study that compared interstate influences on the heritability of teenage nicotine use. It was 
found that heavier state control of tobacco availability, through a combination of higher 
taxation, lower advertising and controlled vending machine supply, resulted in lower levels 
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Events (SLE), which interactively augment the risk of Depression 94. Reviews that have 
delved into the matter of how consistently the finding can be reproduced, have noted that 
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large-scale recruitment, but place greater importance instead on maximising the accuracy 
with which environmental exposures are measured.  
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Studies in which the SLE represents a single specific source of adversity, tend to extend the 
interaction trend, (even if they do not strictly reach the criteria of a ’replication’ study) 91. 
This reaffirms the statistical importance of maintaining measurement error at low levels 96,97. 
Opportunistic replication studies, typically performed using cohorts not primarily intended 
to address the original research question, tend to be more detrimental to replication efforts, 
as even variables with the same name can reflect either subtly, or grossly different 
constructs. 
6.2 The distribution of genotypes and exposure 
The issue of replication is further complicated by the fact that, depending on the frequency 
of the exposure, the same GxE construct may range from having: 
i. no effect when the exposure is low, 
ii. statistical interaction when the exposure is moderate, or  
iii. a main effect when the exposure is high 91.  
As genotypic frequency has a similar influence on interaction detection, it is only 
recommendable to attempt the reproduction of an interaction in samples where exposure 
and allelic frequencies compare with the original study. Additionally, power to detect 
interactions is optimal only when both minor allele frequencies and exposure rates are at the 
50% level. Idealised distributions such as these are unlikely to occur under normal 
recruitment conditions, although they can be ensured by the use of selective sampling 98. 
Deviation away from these two statistical optima may, along with other methodological 
deficiencies, compromise the overall power of a GxE study.  
6.3 Effect sizes 
Biological interactions need not give any statistical clues to their existence. This is 
demonstrated by the example of Phenylketonuria (PKU), (a syndrome that gives rise to 
neurodevelopmental and psychiatric symptomatologies). PKU results from a combination of 
allelic deficiency in the gene encoding the phenylalanine hydroxylase enzyme, and dietary 
exposure to phenylalanine. In this case, any statistical trace of this biological interaction is 
obfuscated by the ubiquitous nature of phenylalanine in the human diet. 
A typical GxE analysis requires large samples to facilitate the detection of targeted effects. A 
wider debate surrounds how these interactions should be scaled. In order to determine the 
presence of an interaction, a product term is added to the regression model. In linear regression, the 
regression coefficient of the product term defines interaction as departure from additivity, whereas an 
interaction using logistic regression indicates a departure from multiplicativity 99. An additive 
model is thought to best approximate the concept of biological interaction 100, though this 
view is heavily contentious. Meanwhile multiplicative effects, though more difficult to 
interpret, generally allude to larger effects on risk, and so are still predictively useful. 
Biological validity remains a panacea for all GxE research, as the concept of a purely 
biological interaction is easy to understand and design interventions around (assuming the 
consequences of the interaction is large enough to merit this course of action). In contrast, 
inferring a mechanistic relationship out of a statistical effect, relies on conditions and 
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assumptions 101 that may not necessarily hold true for Schizophrenia 85. A statistical 
interaction may still have great predictive value nonetheless.  
The difference between these two definitions (of Biological versus Statistical Interaction) 
can be problematic, as there remains plenty of scope for conflict between the two. In 
some cases discrepancies between the two may be artefactual. For example, the 
logarithmic transformation inherent to the multiplicative model can cause bona fide 
interactions to disappear, or else induce them spuriously 86, (an important caveat of this 
strategy). 
These issues have fuelled a debate about the more appropriate way to scale interaction 
effects eg.85,86. Some of the rhetoric surrounding this issue is seemingly prejudicial to the 
question of whether GxE research can make a positive contribution towards Schizophrenia’s 
translational goals 85. A key step to obtaining a definitive answer to this question will be the 
introduction of more systematic approaches to GxE discovery. The model for the type of 
approach needed is epitomised by GWAS 102,103. In the future this will be further 
complemented by the genome sequencing projects now underway in Schizophrenia 104 (also 
see details of the UK MRC’s cross-disorder sequencing initiative, the UK10K study; 
http://www.uk10k.org/). 
6.4 Sample size 
The tendency to overstate initial effect sizes results in a phenomenon known as ‘winners’ 
curse’ 105.  
Sample sizes in a replication study must accordingly be adjusted (upwards) to compensate 
for this associated loss of power. This is a practice embraced by the genetic association field 
of late, due to a combination of good governance 90 and a ‘trickle down’ of good research 
etiquette from GWAS, through to mainstream (candidate gene) genetic research. 
A similar level of rigour is lacking from GxE research. This is worrying on two counts. 
Firstly, because from the outset, the power of an interaction analysis is typically lower than 
it is for a study of main effects 106, and secondly, the GxE field has tended to avoid facing 
such issues head on. This is typified by a reluctance among researchers to divulge vital 
information regarding statistical power in many instances 84. Such faux pas are propagated 
by the willingness of reviewers to accept such work, without enforcing appropriate 
disclosure of this information. 
7. 10 years of GxE research in psychiatry – A post-assessment review 
A recent critical appraisal shines a spotlight on the immediate shortcomings of GxE 
research in the psychiatric field 84. Its findings are still being digested by the psychiatric 
research community 107. A main accusation again centres on underpowering, (described 
by its authors to have skewed a decade’s worth of research). Face value interpretation of 
their calculations suggests that average effect sizes would have to be 10 times larger than 
those normally found in GWAS, for the small sample sizes used to be even remotely 
credible 84.  
The problem of underpowering was found to have a bi-directional relationship with 
publication bias, (the tendency to only report trends that support a given hypothesis). The 
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authors’ report outlines an interesting chain of events, initiated by the instinctive preference 
among journal editors for novel findings. This distortion of the literature is sustained by 
additional biases that favour the publication of corroborating evidence, at which point 
statistical considerations such as power and study design are less rigorously enforced 84. 
Leniency in areas such as sample size and study design has long been self-evident in GxE 
research 91,95 but can, for the first time, be quantified; studies which have failed to replicate 
an existing discovery are, on average, 6 times larger than studies that did manage to 
replicate. This suggests that the sample-size threshold required for a negative finding to be 
published is 6x higher than that of a positive study 84.  
One non-intuitive factor that such appraisals have failed to acknowledge is that samples 
characterised by a low n may also be those most immune from measurement error 91. For the 
5HTTLPR x SLE interaction alone, low measurement error has been qualitatively shown to 
be the single most important determinant of a successful replication 91,95. Simulations of 
measurement error by Wong et al help to qualify this point 96. They suggest that an increase 
in correlation with true values of ‘E’ from .4 to .7 can equate to as much as a 20-fold gain in 
sample size. It is apparent therefore, that any review of the field must take into account the 
fact that the problem of a small sample can, to an extent, be overcome by maximising the 
precision of environmental measures. These days purposefully-designed tools (eg. 
http://www.hsph.harvard.edu/faculty/peter-kraft/software/ or the ESPRESSO power 
calculator at http://www.p3gobservatory.org/powercalculator.htm ) allow one to factor-in 
the variable precision of exposure measurement to estimations of power. 
But in its defence, the Duncan-Keller assessment (a systematic assessment of 103 studies 
over a 10-year period) extends way beyond the Serotonin transporter. Therefore the critique 
is a formulation which applies to the field as a whole. Its take home message suggests that 
replication studies in Psychiatry currently only rarely achieve what they purport to, to a 
satisfactory standard.  
This message is resounding, and also provides a convenient narrative for the poor progress 
made in bringing new findings to the clinic. At present it is largely explained by the 
shortage of high quality evidence entering the translational pipeline.  
The crystallisation of lessons learned over the past 10 years 84 should be capitalised upon to 
make this a watershed moment for the application of GxE methodology in Psychiatry. 
However the type of cultural revolution needed can only be prompted by:  
i. An all-encompassing redefinition of what constitutes methodological good practice in 
GxE research 107 (this could be achieved by developing something equivalent to the 
STREGA (STrengthening the REporting of Genetic Associations) principles, specifically 
for the GxE research. 
ii. A consensus between journal editors, reviewers and researchers that these guidelines 
should be adhered to.  
8. New horizons in GxE research 
8.1 GxEWAS: The systematically tractable meets the biologically plausible  
The archetypal approach to identifying potential GxE candidates avoids the statistical 
pitfalls of multiple testing, and is instead guided towards appropriate candidate regions 
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through a combination of biological theory and functional evidence 82. Given our 
rudimentary understanding of the complexity encoded at the genomic level, it is perhaps 
not so surprising that the doctrine of ‘biological plausibility’ is often questioned. Additional 
scepticism is reserved for the notion that the molecular dissection of psychiatric phenotypes 
can be formularised 82. This is a pertinent point, given that GWAS has shown us that the 
underlying biological basis of many complex and Mendelian traits is largely abstract in 
nature. 
Advocates of the biological plausibility doctrine can rightly point to the robust experimental 
and analytical settings in which several of these discoveries have been made 93,94,108. 
However detractors often cite the peculiarly low level of GWAS support for traditional 
Schizophrenia candidate gene favourites, (all of which are ‘plausible’ in one way or 
another), 109,110 to suggest the perils of a religious fixation on biological dogma 84.  
The apparent discord between candidate-gene and GWAS findings is typical for most of 
Psychiatry, with very few exceptions 111 (convergent GWAS and candidate-gene findings 
in Schizophrenia are noted in table 2). If anything, GWAS has diverted attention towards 
less-obvious genomic points of interest, many of which lie within the non-coding 
domain.  
Thus the non-coding genome has proved to be a rich source of pathogenic variation; 
approximately 90% of all GWAS findings (across disorders) originate from there. But for 
now, the jury is still out regarding the possible contribution of first-generation candidate 
genes to the risk, pathology and outcome of Schizophrenia. The delay in implementing 
GxEWAS studies of Schizophrenia means that the relevance of historical genetic candidates 
to the GxE paradigm remains untested in modern-day genome-wide protocols. It is still 
premature therefore, to exclude a possible wider role for some of these genes in the 
aetiological or pathological course of Schizophrenia. 
GxEWAS studies are steadily becoming entrenched in the literature. A number of neuro-
developmental and neurological phenotypes have already been investigated. These 
highlight interactions ranging from the effect of coffee-drinking on Parkinson’s Disease, 
to the effect of adverse intrauterine environments on brain growth 112-114. As this 
innovative branch of genomics is yet to take off in Schizophrenia, the current crop of GxE 
findings both in table 3 and in other areas of Psychiatry, are still yet to face the same acid 
test used to put the previous generation of association candidates on trial 109,110. GxEWAS 
is currently one of many longer-term aspirations for policymakers in the Psychiatric 
Genetics community 115.  
Several alternatives to standard Case-Control analysis methods will be at the disposal of 
the community by the time this occurs. Bayesian Case-control approaches already feature 
among them 116. However the Case-only model is currently considered to be the most 
effective (in terms of power and efficiency) methodology for this branch of research 
117,118. The one proviso of the approach is that genes and exposure must be independent 
in the population from which cases are drawn 117,119. This condition can be tested 
directly, by repeating the GxE analytical procedure on controls, and appropriately 
filtering out signals (that cross the designated threshold of significance) from the case-
only study. 
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through a combination of biological theory and functional evidence 82. Given our 
rudimentary understanding of the complexity encoded at the genomic level, it is perhaps 
not so surprising that the doctrine of ‘biological plausibility’ is often questioned. Additional 
scepticism is reserved for the notion that the molecular dissection of psychiatric phenotypes 
can be formularised 82. This is a pertinent point, given that GWAS has shown us that the 
underlying biological basis of many complex and Mendelian traits is largely abstract in 
nature. 
Advocates of the biological plausibility doctrine can rightly point to the robust experimental 
and analytical settings in which several of these discoveries have been made 93,94,108. 
However detractors often cite the peculiarly low level of GWAS support for traditional 
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another), 109,110 to suggest the perils of a religious fixation on biological dogma 84.  
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now, the jury is still out regarding the possible contribution of first-generation candidate 
genes to the risk, pathology and outcome of Schizophrenia. The delay in implementing 
GxEWAS studies of Schizophrenia means that the relevance of historical genetic candidates 
to the GxE paradigm remains untested in modern-day genome-wide protocols. It is still 
premature therefore, to exclude a possible wider role for some of these genes in the 
aetiological or pathological course of Schizophrenia. 
GxEWAS studies are steadily becoming entrenched in the literature. A number of neuro-
developmental and neurological phenotypes have already been investigated. These 
highlight interactions ranging from the effect of coffee-drinking on Parkinson’s Disease, 
to the effect of adverse intrauterine environments on brain growth 112-114. As this 
innovative branch of genomics is yet to take off in Schizophrenia, the current crop of GxE 
findings both in table 3 and in other areas of Psychiatry, are still yet to face the same acid 
test used to put the previous generation of association candidates on trial 109,110. GxEWAS 
is currently one of many longer-term aspirations for policymakers in the Psychiatric 
Genetics community 115.  
Several alternatives to standard Case-Control analysis methods will be at the disposal of 
the community by the time this occurs. Bayesian Case-control approaches already feature 
among them 116. However the Case-only model is currently considered to be the most 
effective (in terms of power and efficiency) methodology for this branch of research 
117,118. The one proviso of the approach is that genes and exposure must be independent 
in the population from which cases are drawn 117,119. This condition can be tested 
directly, by repeating the GxE analytical procedure on controls, and appropriately 
filtering out signals (that cross the designated threshold of significance) from the case-
only study. 
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Post-genomic technological advances, namely the advent of micro-array technology, have 
led to huge increases in the scale at which genetic variation can be sampled from a genome 
by a single study. The abundance of this data can propel the formulation of post-hoc 
hypotheses based on biological plausibility. Useful resources that can help to inform the 
decision-making process include tools such as the UCSC and ENSEMBL genome browsers 
(http://genome.ucsc.edu/cgi-bin/hgGateway and http://www.ensembl.org/index.html). 
These contain a wealth of information highlighting the organisation, structure and function 
of the genome. Other specialist resources provide a dense functional annotation of regions 
that border GWAS hits (http://jjwanglab.org:8080/gwasdb/) 120.  
One area in which Schizophrenia genetic research has been slow (compared to other fields 
such as Alzheimer’s Disease), is its readiness to combine genetics with other flavours of 
system biology that can now be feasibly explored. This multi-level approach could provide 
insights about fundamental bio-mechanic processes that lie at the heart of gene-environment 
interaction. 
One potential class of mediaries are known as Quantitative Trait Loci (QTLs). These are 
regulatory variants associated with control of gene-expression (eQTLs), protein levels 
(pQTLs) and gene activation status (methQTLs). 
The ever-decreasing cost of implementing these system-based biological approaches 
continues to increase their accessibility. Meanwhile, whole-genome sequencing provides the 
means to increase both the resolution of regulatory variants across the genome, and the fuel 
for further biological hypotheses. 
A key objective within the universal objectives of personalised medicine (to which the 
field of Psychiatric Genetics is also subscribed) is to enhance both the visibility and 
efficiency with which promising new evidence is vetted and then turned into new 
diagnostics and treatments. Crucially however, neither a purely biological, nor a purely 
systematic approach, (such as GxEWAS) can secure these goals alone. This is due to two 
main reasons: 
- Exhausting the investigation of all plausible biological hypotheses using available 
genomic and enviromic data, is a slow, painstaking process that is difficult to fully 
automate. In any case we lack the fundamental insight about underlying biological 
mechanisms to assume we can become routinely successful at this.  
- Meanwhile systematic methods such as GxEWAS may be too cursory. They must in any 
case, first confront the reasons why smaller candidate-based studies of GxE so regularly 
out-perform larger ones, lest the same mistakes of candidate GxE research simply end 
up being repeated, on a yet grander scale 91. 
The many lines of derivative research resulting from GWAS in Schizophrenia collectively 
demonstrate how both systematic and biological candidate approaches can work in 
tandem 55,103,115,121,122. Thus, an emphasis on post-hoc explorations of candidate pathways, 
genes and variants may be the best bet for turning a cursory screen of the genome (such 
as GxEWAS) into something that is potentially much more substantive. This kind of 
combinatorial approach, which marries systematic and hypothesis-led discovery through 
data-mining, may one day reveal (and explain) the true pervasiveness of GxE in 
Schizophrenia.  
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8.2 Strategies for data harmonisation and how this will help 
Observations by Caspi 91, Uher and McGuffin 95, Vineis 97 and Wong 96 collectively highlight 
the challenge of balancing sample size and measurement error for optimal statistical benefit. 
It is in this respect that the Dunedin study (to which a disproportionate number of GxE 
discoveries belong) enjoys an unparalleled advantage over many of the cohorts that have 
since revisited the original 5HTTLPR finding. The study combines the higher accuracy of 
exposure measurement often found in smaller studies, with a large sample size that is so 
often elusive.  
A large number of replication studies do not share this same rare-but-optimal combination 
of properties 91,96,97. It is this variability which may be incapacitating to the field as a whole. 
Such problems can be addressed by applying greater epidemiological rigour to the 
collection, storage and power of genetic datasets. The rapid proliferation of biobanks in 
biomedical research is accompanied by the expectation that this will directly improve the 
quality of translational research, (and not just for Schizophrenia). Biobanks provide a means 
to satisfy the growing demand for high quality population data, thus they will be a key 
driver of genetic discovery in the future. They will also be an essential resource for 
validating discoveries made elsewhere.  
Of course genetics is just one of many important biological areas that can be served by such 
resources. This is why the rapid proliferation of biobanks is vital, even for the many non-
psychiatric traits that have, to a large degree, already profited from GWAS. This includes 
traits such as Age-related Macular Degeneration, Prostate Cancer, Coronary Heart disease 
and type 2 Diabetes 65. 
The primary functions of a biobank include: 
- Processing and storage of biological samples. 
- Collection of phenotype and other data 
- Facilitating statistical analysis. 
A recurrent concern among commentators in the GxE field is the increased scope for 
measurement error in these heterogeneously-assembled datasets 91. Additional problems 
may occur due to the fact that geneticists, epidemiologists, biologists and biostatisticians, 
often use different vocabularies 123. Extrapolating these issues to the large number of 
biobanks in existence around the globe suggests that there is a need for overall governance 
to maximise data harmonisation. A large number of international bodies have been created 
for this purpose, many with overlapping functions. For example in Europe, PHOEBE 
(Promoting Harmonisation Of Epidemiological Biobanks in Europe), ENGAGE (European 
Network of Genomic and Genetic Epidemiology) P3G (Public Population Project in 
Genomics), are three independent organisations that provide a continent-wide consensus on 
procedures ranging from collection, storage and format of biological samples and associated 
data. 
Perhaps this overlap is needed to counteract the organisational absence of other major 
institutions from this exercise. Regulatory bodies such as the European Medicines Agency 
(EMA) and The Food and Drug Administration (FDA) were at some point considered, but 
ultimately deemed too inherently conservative to oversee such a task 124. Top-down 
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implementation of new and emerging international standards and protocols for data collection, 
sample acquisition, etc is managed by national biobanking initiatives, such as the UK Biobank. 
Policies may then be channelled down to a set of regional hubs such as the National Institute for 
Health Research’s Biomedical Research Centres (UK). It is encouraging that Schizophrenia 
research is now beginning to derive the benefits of biobank-based research 125-127. 
8.3 A note on methods for research synthesis 
Such initiatives inevitably generate an abundance of data. A critical mass of high quality 
data is usually the trigger for the synthesisation of this evidence to begin. This typically uses 
meta-analysis, whose conventional format uses the null hypothesis (a construct of 
frequentist statistical theory) as its reference point. However the rationale for this becomes 
increasingly questionable as new evidence is added to an existing literature 128,129. A 
Bayesian approach (ie. one that would allow the posterior probability of a hypothesis to be 
derived from prior knowledge, after taking into account new data), would allow any 
uncertainty about a hypothesis, to be acknowledged in an adaptive way.  
The conspicuous absence of Bayesian methods from the science of data synthesis was only 
recently lamented, by key stakeholders involved in the process of evaluating new drugs for 
the UK’s National Health Service 128. Such messages may yet help to expedite the uptake of 
these methods, although there is already evidence of their adoption in clinical trial research 
128. These methods could widen the net used to gather new evidence, by allowing the 
incorporation of data from in vivo and cellular studies into the evaluation process. Thus 
Bayesian methodologies could provide an important means of channelling a wide range of 
functional evidence into synthesised data 130, as well as providing an alternative set of rules 
for assessing the validity of a hypothesis. 
8.4 The future of clinical databases in psychiatric GxE research 
It will soon be much easier to harvest the valuable clinical data derived out of even routine 
patient contact with clinical services, given that a switch-over to electronic medical records 
(EMRs) is now underway. The integrative blueprint for the new digital clinical age would 
allow a comprehensive (clinical, molecular and environmental risk profile) to be compiled 
for each patient. The front-end portal for this is as a personal record that follows the 
individual around as they move between different mental health institutions. Back-end 
access to such data is possible (for research purposes), but necessarily anonymised. The 
information itself can be processed in a way that allows even the interrogation of 
unstructured data (eg. clinical notes) to now be formularised (eg. see 131). The huge potential 
of EMRs represents great scope for integrative research. It is anticipated that such resources 
will: 
- Continue to drive understanding of molecular aetiology, by harnessing patients for in 
silico (bioinformatically-oriented) studies. 
- Allow more efficient stratification of patients for interventions or clinical trials 
- Improve the quality of genetic counselling, which will be based on a fuller, all-
encompassing profile on which to base evaluations of risk, treatment outcomes and 
prognoses. 
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The true potential of the EMR model will become more apparent only when high-
dimensional genetic and molecular profiling becomes economically feasible and clinically 
routine. This will make it practically possible to integrate a whole manner of clinical data 
into diagnostic/prognostic genetic research. But such times are almost already upon us, 
thus we do not have far to search, to find examples of how an integrative approach may 
work in practice. One such model is that of Ashley and colleagues 132, who recently 
reported a far-reaching genomic health assessment of a patient showing a strong familial 
indication of Coronary Heart Disease and Sudden Death Syndrome. A graphical account of 
the relative genetic liability for other disorders (Coronary Artery Disease, Obesity, 
Osteoarthritis and Type 2 Diabetes) depicts the genetic relationship between these 
disorders and several conditional environmental risk exposures, (stress, smoking, exercise 
and diet).  
For Schizophrenia, a more precise account of the relationship with environmental risk 
factors could be achieved with the help of a new generation of instruments (questionnaires) 
and devices that will enable their measurement to be conducted with greater sensitivity than 
ever. Many examples of these have been devised for a large multi-centre study: The 
European network study of Gene-Environment Interaction (EUGEI) 5. Of particular 
relevance is a work package entitled ‘Functional Enviromics’, which aims to take the 
elucidation of socio-environmental risk factors for Schizophrenia to a level of resolution not 
previously reached. 
9. New horizons in pharmacogenomic research 
9.1 Background 
One consequence of GxE interaction is that any undesired outcomes can be averted through 
interventions targeted at the level of the individual, or the population, through changes in 
wider socio-economic policy. Primary avenues of social intervention for Schizophrenia 
would include redressing social inequalities 2, as well as challenging permissive attitudes to 
the use of illegal psychotogenic substances which, in tandem with other risk factors, help to 
sustain the high level of psychosis in the general population.  
Meanwhile, molecular strategies for moderating or ameliorating the detrimental 
consequences of GxE interaction, fall within an area of personalised medicine known as 
Pharmacogenomics. This discipline is concerned with devising optimal therapeutic 
treatments for genetic sub-groups of patients. A competing goal is to minimise the risk of ill 
effects resulting from such treatments. Large inter-individual variability in both drug 
response and side-effects are the main foundation for this branch of research 133. Much of 
this variability can be traced to genetic variation within key liver enzymes (the cytochrome 
P450 complex). It is the fate of all antipsychotic drugs to be channelled to this biological 
complex for breakdown (see table 4).  
Of all the enzymes known to have a role in the metabolism of antipsychotic drugs, CYP2D6 
has been the most extensively characterised. This is not a great surprise, given that the 
protein product of this gene catalyses the breakdown of up to 25% of all pharmacological 
compounds. Current knowledge about functional variation within this gene alone is enough 
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to explain inter-individual differences in drug efficacy. For example, 2% of Caucasians and 
25% of East Africans who express multiple functional CYP2D6 alleles, (ultra-rapid 
metabolisers) can be phenotypically distinguished on account of having the poorest levels of 
response to specific treatments 134,135. Unfortunately however, current assessments of the 
clinical utility of pharmacogenetic testing in Schizophrenia, suggest that a heavy reliance on 
CYP2D6 genotyping is currently not the most beneficial way to formulate pescribing 
guidelines regarding the use of antipsychotic drugs 134. A similar study of CYP2D6 (looking 
at Selective Serotonin Re-uptake Inhibitor treatments in Depression), recently came to a 
similar conclusion 136.  
 
Table 4.  Commonly used antipsychotics metabolised by CYP enzymes 
Enzyme Typical Antipsychotics Atypical Antipsychotics 
CYP2D6 Primary metabolism Primary metabolism 
  Chlorpromazine Risperidone 
  Haloperidol   
  Perphenazine Secondary Metabolism 
  Thioridazine Olanzapine 
    Quetiapine 
  Secondary Metabolism   
  Zuclopenthixol   
CYP1A2 Primary metabolism Primary metabolism 
  Chlorpromazine Clozapine 
  Perphenazine Olanzapine 
  Thioridazine   
      
  Secondary Metabolism   
  Haloperidol   
  Perphenazine   
CYP3A4 Primary metabolism Primary metabolism 
  Haloperidol Quetiapine 
    Ziprasidone 
    Secondary Metabolism 
    Clozapine 
    Olanzapine 
    Risperidone 
Table 4. (Adapted from reference 134) 
9.2 A generalisable translation framework for GxE discovery 
Poor performance of novel findings across different formulations of synthesised data 
represents an obvious barrier to clinical translation. But even if this obstacle can be 
overcome, a further series of hurdles may replace it. A clear framework now exists to 
prompt and signpost the long path between discovery and clinical application 137. 
Implementation of the framework is marshalled by the Human Genome Epidemiology 
Network (HUGENET), a global collaboration of individuals and organisations whose 
remit is to assess the impact of genomic variation on population health. According to 
HUGENET, the pathway to clinical translation can be divided into four key stages (see 
table 5). 
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Table 5.   The 4 phases of clinical translation 
Translation Research Phase  Example Study Approach to overcoming phase 
Phase 1: Discovery and Clinical validity 
eg. Reliable series of 
associations between a SNP 
and drug response 
Phases I and II clinical trials; observational studies 
Phase 2: Clinical Utility to Clinical guidelines 
Does SNP improve drug 
response and what is its 
predictive accuracy? 
Phase III clinical trials; observational studies; 
evidence synthesis and guidelines development 
Phase 3: Implementation in Clinical practice 
Explore data regarding the 
uptake of the SNP test in 
clinical settings - explore 
potential barriers 
Dissemination and implementation research; Phase 
IV clinical trials 
Phase 4: Public Health Impact Does SNP improve clinical outcome in the population? 
Outcomes research; Population monitoring; Phase IV 
clinical trials 
Table 5. Table 4 shows the 4 phases of clinical translation and the critical approaches 
required to negotiate each one. Though initially designed to provide a translational model 
for pharmacogenetic research, it can also be applied in the context of GxE research.  
(Adapted from references 138,139) 
Although this framework has been developed to support emerging new pharmacogenomic 
technologies, devices and treatments, its generic nature means it provides a model that is 
also extrapolable across genetic research (including GxE). The model adopts the ACCE 
(Analytical validity, Clinical Validity, Clinical Utility) and ELSI (Ethical, legal, social issues) 
criteria to ensure a rigorously vetted transition between phases 139. The solid foundation 
provided by the framework will help to ensure that promising findings do not become ‘lost 
in translation’ 140, a problem that has characterised the last 60 years of drug development. 
This issue still continues to affect the industry acutely: It takes an average of 17 years for just 
14% of new scientific discoveries to enter day-to-day clinical practice 137, while the cost per 
successful drug exceeds $1billion, after adjusting for all the failures 141. 
9.3 Regulation and decision-making 
Regulatory governance fulfils several objectives, the most important of which is to ensure 
that patients and research subjects are protected from any undesired consequences (‘adverse 
events’) of new drugs intended for the market. GxE discoveries that make it into clinical 
evaluation phases fall under the jurisdiction of various geographical regulatory institutions 
such as the European Medicines Agency (EMA) in Europe, the Medicines and Healthcare 
products Regulatory Agency (MHRA) in the UK, and the Food and Drug Administration 
(FDA) in the US. 
Adherence to the process of regulation is essential for ensuring a smooth progression 
through the translation scheme outlined in table 5. For instance, failing to procure 
accreditation for genetic tests and therapies from decision-making bodies such as the EMA 
and the FDA tends to adversely affect the uptake of these innovations in other global 
regions. This may partly explain the poor uptake of CYP2D6 and CYP2C19 genetic tests 
observed in a recent Danish study 142.  
However, over-zealous regulation can itself create obstacles, particularly if perceived to be 
of no discernible benefit to patients 143. This has potentially been the case in Europe, where 
the much-criticised 2001 European Union Clinical Trial Directive has caused the cost of 
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to explain inter-individual differences in drug efficacy. For example, 2% of Caucasians and 
25% of East Africans who express multiple functional CYP2D6 alleles, (ultra-rapid 
metabolisers) can be phenotypically distinguished on account of having the poorest levels of 
response to specific treatments 134,135. Unfortunately however, current assessments of the 
clinical utility of pharmacogenetic testing in Schizophrenia, suggest that a heavy reliance on 
CYP2D6 genotyping is currently not the most beneficial way to formulate pescribing 
guidelines regarding the use of antipsychotic drugs 134. A similar study of CYP2D6 (looking 
at Selective Serotonin Re-uptake Inhibitor treatments in Depression), recently came to a 
similar conclusion 136.  
 
Table 4.  Commonly used antipsychotics metabolised by CYP enzymes 
Enzyme Typical Antipsychotics Atypical Antipsychotics 
CYP2D6 Primary metabolism Primary metabolism 
  Chlorpromazine Risperidone 
  Haloperidol   
  Perphenazine Secondary Metabolism 
  Thioridazine Olanzapine 
    Quetiapine 
  Secondary Metabolism   
  Zuclopenthixol   
CYP1A2 Primary metabolism Primary metabolism 
  Chlorpromazine Clozapine 
  Perphenazine Olanzapine 
  Thioridazine   
      
  Secondary Metabolism   
  Haloperidol   
  Perphenazine   
CYP3A4 Primary metabolism Primary metabolism 
  Haloperidol Quetiapine 
    Ziprasidone 
    Secondary Metabolism 
    Clozapine 
    Olanzapine 
    Risperidone 
Table 4. (Adapted from reference 134) 
9.2 A generalisable translation framework for GxE discovery 
Poor performance of novel findings across different formulations of synthesised data 
represents an obvious barrier to clinical translation. But even if this obstacle can be 
overcome, a further series of hurdles may replace it. A clear framework now exists to 
prompt and signpost the long path between discovery and clinical application 137. 
Implementation of the framework is marshalled by the Human Genome Epidemiology 
Network (HUGENET), a global collaboration of individuals and organisations whose 
remit is to assess the impact of genomic variation on population health. According to 
HUGENET, the pathway to clinical translation can be divided into four key stages (see 
table 5). 
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and the FDA tends to adversely affect the uptake of these innovations in other global 
regions. This may partly explain the poor uptake of CYP2D6 and CYP2C19 genetic tests 
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running clinical trials to spiral. Other knock-on effects attributed to the legislation include a 
30% decline in the numbers of participants agreeing to take part in trials across Europe, over 
the last few years 144. As clinical trials are an integral component within any translation 
scheme, such problems threaten to create a fatal bottle-neck in the pipeline, for discoveries 
that might otherwise have made it through the process relatively unscathed. 
An overhaul of regulatory governance at national level has been proposed to circumvent 
this problem. In the UK, it is being done in conjunction with The National Institute for 
Health and Clinical Excellence (NICE), an organisation primarily responsible for assessing 
the cost-effectiveness, on behalf of the National Health Service (NHS), of providing new 
therapies and treatments. However the change of UK government means it is not even clear 
that there is a timetable for putting such proposals into practice 143. 
As just hinted at, all novel genetic disoveries (including GxE interactions) that have safely 
negotiated the rigours of the validation stages shown in table 5, must still run the gauntlet of 
proving their overall cost-effectivenesss, before they can progress beyond validity, into 
utility. But new technology and treatments can only be considered to be cost-effective if 
their health benefits can be shown to outweigh the opportunity costs of services or 
treatments that they may displace 145. When viewed in the context of the many benefits that 
personalised health care will bring, the additional expenses inherent to many new genomic 
technologies, are unlikely to present much of a barrier to widespread uptake. 
10. Conclusion 
Lessons of the past decade of GxE research in psychiatry (and more specifically, 
Schizophrenia) mean that the focus of the next should be to ensure that effort and resources 
already spent, or else earmarked for future investment, do not go wasted. In order to ensure 
this a course of greater methodological rigour should be pursued. 
It would be advantageous to complement this with the encouraging array of new specialist 
tools, methodologies and infrastructures available, some of which are highlighted in this 
article. A combination of falling economic costs and increasing accessibility make this 
proposition the most practical and logical way forward. In the category of ‘methodologies’ 
we additionally include innovations that enable the epigenomes, transcriptomes and 
proteomes of Schizophrenic patients to be characterised in high-dimension. Each of these 
domains reflects a different dynamic (and environmentally-responsive) element within a 
broader biological scheme. But each also remains curiously under-represented in 
mainstream GxE research today. This is despite evidence to suggest they may serve a 
functional purpose as biomarkers of environmentally-induced pathogenesis, susceptibility, 
illness progression and treatment outcome 146-152. Despite these documented examples, each 
discipline also faces thematic questions about how to achieve methodological best practice, 
given their various respective constraints 147,153,154. 
Thus the current outlook would suggest that no single biological domain will have a 
monopoly on the clinical insights that may yet emerge out of future studies that may link 
genes, environment and Schizophrenia. The option to harness the various biological 
domains collectively, with genetics as the focal point, is promising, but currently under-
resourced 155-157. But this type of expansive approach is additionally attractive and may 
propel us towards fulfilling the unrealised clinical ambitions of GxE research. 
Old Obstacles on New Horizons:  
The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research 99 
11. References 
[1] McGrath, J.J. & Selten, J.P. Mental health: don't overlook environment and its risk factors. 
Nature 454, 824 (2008). 
[2] Kirkbride, J., et al. Translating the epidemiology of psychosis into public mental health: 
evidence, challenges and future prospects. J Public Ment Health 9, 4-14 (2010). 
[3] Rujescu, D., Genius, J., Benninghoff, J. & Giegling, I. Current progress in the genetic 
research of schizophrenia: relevance for drug discovery? Curr Pharm 
Biotechnol.(2012) 
[4] Ripke, S., et al. Genome-wide association study identifies five new schizophrenia loci. 
Nat Genet 43, 969-976 (2011). 
[5] van Os, J., Rutten, B.P. & Poulton, R. Gene-environment interactions in schizophrenia: 
review of epidemiological findings and future directions. Schizophr Bull 34, 1066-
1082 (2008). 
[6] Weis, B.K., et al. Personalized exposure assessment: promising approaches for human 
environmental health research. Environ Health Perspect 113, 840-848 (2005). 
[7] Cardno, A.G., et al. Heritability estimates for psychotic disorders: the Maudsley twin 
psychosis series. Arch Gen Psychiatry 56, 162-168 (1999). 
[8] Lichtenstein, P., et al. Common genetic determinants of schizophrenia and bipolar 
disorder in Swedish families: a population-based study. Lancet 373, 234-239 (2009). 
[9] Vassos, E., et al. Penetrance for copy number variants associated with schizophrenia. 
Hum Mol Genet 19, 3477-3481 (2010). 
[10] Grozeva, D., et al. Independent estimation of the frequency of rare CNVs in the UK 
population confirms their role in schizophrenia. Schizophr Res (2011). 
[11] Dick, D.M., Riley, B. & Kendler, K.S. Nature and nurture in neuropsychiatric genetics: 
where do we stand? Dialogues Clin Neurosci 12, 7-23 (2010). 
[12] Bergen, S.E., Gardner, C.O. & Kendler, K.S. Age-related changes in heritability of 
behavioral phenotypes over adolescence and young adulthood: a meta-analysis. 
Twin Res Hum Genet 10, 423-433 (2007). 
[13] Pagan, J.L., et al. Genetic and environmental influences on stages of alcohol use across 
adolescence and into young adulthood. Behav Genet 36, 483-497 (2006). 
[14] Agrawal, A. & Lynskey, M.T. The genetic epidemiology of cannabis use, abuse and 
dependence. Addiction 101, 801-812 (2006). 
[15] Scherr, M., et al. Environmental risk factors and their impact on the age of onset of 
schizophrenia: Comparing familial to non-familial schizophrenia. Nord J 
Psychiatry (2011). 
[16] March, D., et al. Psychosis and place. Epidemiol Rev 30, 84-100 (2008). 
[17] Allardyce, J. & Boydell, J. Review: the wider social environment and schizophrenia. 
Schizophr Bull 32, 592-598 (2006). 
[18] Cantor-Graae, E. & Selten, J.P. Schizophrenia and migration: a meta-analysis and 
review. Am J Psychiatry 162, 12-24 (2005). 
[19] Dealberto, M.J. Ethnic origin and increased risk for schizophrenia in immigrants to 
countries of recent and longstanding immigration. Acta Psychiatr Scand 121, 325-
339 (2010). 
[20] Henquet, C., Di Forti, M., Morrison, P., Kuepper, R. & Murray, R.M. Gene-environment 
interplay between cannabis and psychosis. Schizophr Bull 34, 1111-1121 (2008). 
[21] Arseneault, L., Cannon, M., Witton, J. & Murray, R.M. Causal association between 
cannabis and psychosis: examination of the evidence. Br J Psychiatry 184, 110-117 
(2004). 
Public Health – Methodology, Environmental and Systems Issues 98
running clinical trials to spiral. Other knock-on effects attributed to the legislation include a 
30% decline in the numbers of participants agreeing to take part in trials across Europe, over 
the last few years 144. As clinical trials are an integral component within any translation 
scheme, such problems threaten to create a fatal bottle-neck in the pipeline, for discoveries 
that might otherwise have made it through the process relatively unscathed. 
An overhaul of regulatory governance at national level has been proposed to circumvent 
this problem. In the UK, it is being done in conjunction with The National Institute for 
Health and Clinical Excellence (NICE), an organisation primarily responsible for assessing 
the cost-effectiveness, on behalf of the National Health Service (NHS), of providing new 
therapies and treatments. However the change of UK government means it is not even clear 
that there is a timetable for putting such proposals into practice 143. 
As just hinted at, all novel genetic disoveries (including GxE interactions) that have safely 
negotiated the rigours of the validation stages shown in table 5, must still run the gauntlet of 
proving their overall cost-effectivenesss, before they can progress beyond validity, into 
utility. But new technology and treatments can only be considered to be cost-effective if 
their health benefits can be shown to outweigh the opportunity costs of services or 
treatments that they may displace 145. When viewed in the context of the many benefits that 
personalised health care will bring, the additional expenses inherent to many new genomic 
technologies, are unlikely to present much of a barrier to widespread uptake. 
10. Conclusion 
Lessons of the past decade of GxE research in psychiatry (and more specifically, 
Schizophrenia) mean that the focus of the next should be to ensure that effort and resources 
already spent, or else earmarked for future investment, do not go wasted. In order to ensure 
this a course of greater methodological rigour should be pursued. 
It would be advantageous to complement this with the encouraging array of new specialist 
tools, methodologies and infrastructures available, some of which are highlighted in this 
article. A combination of falling economic costs and increasing accessibility make this 
proposition the most practical and logical way forward. In the category of ‘methodologies’ 
we additionally include innovations that enable the epigenomes, transcriptomes and 
proteomes of Schizophrenic patients to be characterised in high-dimension. Each of these 
domains reflects a different dynamic (and environmentally-responsive) element within a 
broader biological scheme. But each also remains curiously under-represented in 
mainstream GxE research today. This is despite evidence to suggest they may serve a 
functional purpose as biomarkers of environmentally-induced pathogenesis, susceptibility, 
illness progression and treatment outcome 146-152. Despite these documented examples, each 
discipline also faces thematic questions about how to achieve methodological best practice, 
given their various respective constraints 147,153,154. 
Thus the current outlook would suggest that no single biological domain will have a 
monopoly on the clinical insights that may yet emerge out of future studies that may link 
genes, environment and Schizophrenia. The option to harness the various biological 
domains collectively, with genetics as the focal point, is promising, but currently under-
resourced 155-157. But this type of expansive approach is additionally attractive and may 
propel us towards fulfilling the unrealised clinical ambitions of GxE research. 
Old Obstacles on New Horizons:  
The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research 99 
11. References 
[1] McGrath, J.J. & Selten, J.P. Mental health: don't overlook environment and its risk factors. 
Nature 454, 824 (2008). 
[2] Kirkbride, J., et al. Translating the epidemiology of psychosis into public mental health: 
evidence, challenges and future prospects. J Public Ment Health 9, 4-14 (2010). 
[3] Rujescu, D., Genius, J., Benninghoff, J. & Giegling, I. Current progress in the genetic 
research of schizophrenia: relevance for drug discovery? Curr Pharm 
Biotechnol.(2012) 
[4] Ripke, S., et al. Genome-wide association study identifies five new schizophrenia loci. 
Nat Genet 43, 969-976 (2011). 
[5] van Os, J., Rutten, B.P. & Poulton, R. Gene-environment interactions in schizophrenia: 
review of epidemiological findings and future directions. Schizophr Bull 34, 1066-
1082 (2008). 
[6] Weis, B.K., et al. Personalized exposure assessment: promising approaches for human 
environmental health research. Environ Health Perspect 113, 840-848 (2005). 
[7] Cardno, A.G., et al. Heritability estimates for psychotic disorders: the Maudsley twin 
psychosis series. Arch Gen Psychiatry 56, 162-168 (1999). 
[8] Lichtenstein, P., et al. Common genetic determinants of schizophrenia and bipolar 
disorder in Swedish families: a population-based study. Lancet 373, 234-239 (2009). 
[9] Vassos, E., et al. Penetrance for copy number variants associated with schizophrenia. 
Hum Mol Genet 19, 3477-3481 (2010). 
[10] Grozeva, D., et al. Independent estimation of the frequency of rare CNVs in the UK 
population confirms their role in schizophrenia. Schizophr Res (2011). 
[11] Dick, D.M., Riley, B. & Kendler, K.S. Nature and nurture in neuropsychiatric genetics: 
where do we stand? Dialogues Clin Neurosci 12, 7-23 (2010). 
[12] Bergen, S.E., Gardner, C.O. & Kendler, K.S. Age-related changes in heritability of 
behavioral phenotypes over adolescence and young adulthood: a meta-analysis. 
Twin Res Hum Genet 10, 423-433 (2007). 
[13] Pagan, J.L., et al. Genetic and environmental influences on stages of alcohol use across 
adolescence and into young adulthood. Behav Genet 36, 483-497 (2006). 
[14] Agrawal, A. & Lynskey, M.T. The genetic epidemiology of cannabis use, abuse and 
dependence. Addiction 101, 801-812 (2006). 
[15] Scherr, M., et al. Environmental risk factors and their impact on the age of onset of 
schizophrenia: Comparing familial to non-familial schizophrenia. Nord J 
Psychiatry (2011). 
[16] March, D., et al. Psychosis and place. Epidemiol Rev 30, 84-100 (2008). 
[17] Allardyce, J. & Boydell, J. Review: the wider social environment and schizophrenia. 
Schizophr Bull 32, 592-598 (2006). 
[18] Cantor-Graae, E. & Selten, J.P. Schizophrenia and migration: a meta-analysis and 
review. Am J Psychiatry 162, 12-24 (2005). 
[19] Dealberto, M.J. Ethnic origin and increased risk for schizophrenia in immigrants to 
countries of recent and longstanding immigration. Acta Psychiatr Scand 121, 325-
339 (2010). 
[20] Henquet, C., Di Forti, M., Morrison, P., Kuepper, R. & Murray, R.M. Gene-environment 
interplay between cannabis and psychosis. Schizophr Bull 34, 1111-1121 (2008). 
[21] Arseneault, L., Cannon, M., Witton, J. & Murray, R.M. Causal association between 
cannabis and psychosis: examination of the evidence. Br J Psychiatry 184, 110-117 
(2004). 
Public Health – Methodology, Environmental and Systems Issues 100 
[22] Henquet, C., Murray, R., Linszen, D. & van Os, J. The environment and schizophrenia: 
the role of cannabis use. Schizophr Bull 31, 608-612 (2005). 
[23] Moore, T.H., et al. Cannabis use and risk of psychotic or affective mental health 
outcomes: a systematic review. Lancet 370, 319-328 (2007). 
[24] Morgan, C. & Fisher, H. Environment and schizophrenia: environmental factors in 
schizophrenia: childhood trauma--a critical review. Schizophr Bull 33, 3-10 (2007). 
[25] Miller, B., et al. Paternal age and mortality in nonaffective psychosis. Schizophr Res 121, 
218-226 (2010). 
[26] Miller, B., et al. Meta-analysis of paternal age and schizophrenia risk in male versus 
female offspring. Schizophr Bull 37, 1039-1047 (2011). 
[27] Davies, G., Welham, J., Chant, D., Torrey, E.F. & McGrath, J. A systematic review and 
meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. 
Schizophr Bull 29, 587-593 (2003). 
[28] Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 
455, 237-241 (2008). 
[29] Glessner, J.T., et al. Strong synaptic transmission impact by copy number variations in 
schizophrenia. Proc Natl Acad Sci U S A 107, 10584-10589 (2010). 
[30] Ikeda, M., et al. Copy number variation in schizophrenia in the Japanese population. 
Biol Psychiatry 67, 283-286 (2010). 
[31] Kirov, G., et al. Support for the involvement of large copy number variants in the 
pathogenesis of schizophrenia. Hum Mol Genet 18, 1497-1503 (2009). 
[32] Levinson, D.F., et al. Copy number variants in schizophrenia: confirmation of five 
previous findings and new evidence for 3q29 microdeletions and VIPR2 
duplications. Am J Psychiatry 168, 302-316 (2011). 
[33] Need, A.C., et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. 
PLoS Genet 5, e1000373 (2009). 
[34] Stefansson, H., et al. Large recurrent microdeletions associated with schizophrenia. 
Nature 455, 232-236 (2008). 
[35] Walsh, T., et al. Rare structural variants disrupt multiple genes in neurodevelopmental 
pathways in schizophrenia. Science 320, 539-543 (2008). 
[36] Xu, B., et al. Strong association of de novo copy number mutations with sporadic 
schizophrenia. Nat Genet 40, 880-885 (2008). 
[37] Li, J., et al. Common variants in the BCL9 gene conferring risk of schizophrenia. Arch 
Gen Psychiatry 68, 232-240 (2011). 
[38] Shi, Y., et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat 
Genet 43, 1224-1227 (2011). 
[39] Mah, S., et al. Identification of the semaphorin receptor PLXNA2 as a candidate for 
susceptibility to schizophrenia. Mol Psychiatry 11, 471-478 (2006). 
[40] Rietschel, M., et al. Association between genetic variation in a region on chromosome 11 
and schizophrenia in large samples from Europe. Mol Psychiatry (2011). 
[41] Steinberg, S., et al. Common variants at VRK2 and TCF4 conferring risk of 
schizophrenia. Hum Mol Genet 20, 4076-4081 (2011). 
[42] Kirov, G., et al. Comparative genome hybridization suggests a role for NRXN1 and 
APBA2 in schizophrenia. Hum Mol Genet 17, 458-465 (2008). 
[43] Magri, C., et al. New copy number variations in schizophrenia. PLoS One 5, e13422 
(2010). 
[44] Vrijenhoek, T., et al. Recurrent CNVs disrupt three candidate genes in schizophrenia 
patients. Am J Hum Genet 83, 504-510 (2008). 
Old Obstacles on New Horizons:  
The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research 101 
[45] Ikeda, M., et al. Genome-wide association study of schizophrenia in a Japanese 
population. Biol Psychiatry 69, 472-478 (2010). 
[46] O'Donovan, M.C., et al. Identification of loci associated with schizophrenia by genome-
wide association and follow-up. Nat Genet 40, 1053-1055 (2008). 
[47] Riley, B., et al. Replication of association between schizophrenia and ZNF804A in the 
Irish Case-Control Study of Schizophrenia sample. Mol Psychiatry 15, 29-37 (2010). 
[48] Williams, H.J., et al. Fine mapping of ZNF804A and genome-wide significant evidence 
for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 16, 429-
441 (2011). 
[49] Shi, J., et al. Common variants on chromosome 6p22.1 are associated with 
schizophrenia. Nature 460, 753-757 (2009). 
[50] Alkelai, A., et al. Identification of new schizophrenia susceptibility loci in an ethnically 
homogeneous, family-based, Arab-Israeli sample. FASEB J 25, 4011-4023 (2011). 
[51] Williams, H.J., et al. Most genome-wide significant susceptibility loci for schizophrenia 
and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum 
Mol Genet 20, 387-391 (2011) . 
[52] Shifman, S., et al. Genome-wide association identifies a common variant in the reelin 
gene that increases the risk of schizophrenia only in women. PLoS Genet 4, e28 
(2008). 
[53] Kirov, G., et al. A genome-wide association study in 574 schizophrenia trios using DNA 
pooling. Mol Psychiatry 14, 796-803 (2009). 
[54] Mulle, J.G., et al. Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum 
Genet 87, 229-236 (2010). 
[55] Chen, X., et al. GWA study data mining and independent replication identify 
cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol 
Psychiatry 16, 1117-1129 (2011). 
[56] Yue, W.H., et al. Genome-wide association study identifies a susceptibility locus for 
schizophrenia in Han Chinese at 11p11.2. Nat Genet 43, 1228-1231 (2011) . 
[57] Stefansson, H., et al. Common variants conferring risk of schizophrenia. Nature 460, 
744-747 (2009). 
[58] Purcell, S.M., et al. Common polygenic variation contributes to risk of schizophrenia 
and bipolar disorder. Nature 460, 748-752 (2009). 
[59] Ingason, A., et al. A large replication study and meta-analysis in European samples 
provides further support for association of AHI1 markers with schizophrenia. Hum 
Mol Genet 19, 1379-1386 (2010) 
[60] Athanasiu, L., et al. Gene variants associated with schizophrenia in a Norwegian 
genome-wide study are replicated in a large European cohort. J Psychiatr Res 44, 
748-753 (2010) 
[61] Shi, Y.Y., et al. A study of rare structural variants in schizophrenia patients and normal 
controls from Chinese Han population. Mol Psychiatry 13, 911-913 (2008). 
[62] Vacic, V., et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant 
risk for schizophrenia. Nature 471, 499-503 (2011) 
[63] Green, E.K., et al. The bipolar disorder risk allele at CACNA1C also confers risk of 
recurrent major depression and of schizophrenia. Mol Psychiatry 15, 1016-1022 
(2010). 
[64] Lencz, T., et al. Converging evidence for a pseudoautosomal cytokine receptor gene 
locus in schizophrenia. Mol Psychiatry 12, 572-580 (2007). 
Public Health – Methodology, Environmental and Systems Issues 100 
[22] Henquet, C., Murray, R., Linszen, D. & van Os, J. The environment and schizophrenia: 
the role of cannabis use. Schizophr Bull 31, 608-612 (2005). 
[23] Moore, T.H., et al. Cannabis use and risk of psychotic or affective mental health 
outcomes: a systematic review. Lancet 370, 319-328 (2007). 
[24] Morgan, C. & Fisher, H. Environment and schizophrenia: environmental factors in 
schizophrenia: childhood trauma--a critical review. Schizophr Bull 33, 3-10 (2007). 
[25] Miller, B., et al. Paternal age and mortality in nonaffective psychosis. Schizophr Res 121, 
218-226 (2010). 
[26] Miller, B., et al. Meta-analysis of paternal age and schizophrenia risk in male versus 
female offspring. Schizophr Bull 37, 1039-1047 (2011). 
[27] Davies, G., Welham, J., Chant, D., Torrey, E.F. & McGrath, J. A systematic review and 
meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. 
Schizophr Bull 29, 587-593 (2003). 
[28] Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 
455, 237-241 (2008). 
[29] Glessner, J.T., et al. Strong synaptic transmission impact by copy number variations in 
schizophrenia. Proc Natl Acad Sci U S A 107, 10584-10589 (2010). 
[30] Ikeda, M., et al. Copy number variation in schizophrenia in the Japanese population. 
Biol Psychiatry 67, 283-286 (2010). 
[31] Kirov, G., et al. Support for the involvement of large copy number variants in the 
pathogenesis of schizophrenia. Hum Mol Genet 18, 1497-1503 (2009). 
[32] Levinson, D.F., et al. Copy number variants in schizophrenia: confirmation of five 
previous findings and new evidence for 3q29 microdeletions and VIPR2 
duplications. Am J Psychiatry 168, 302-316 (2011). 
[33] Need, A.C., et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. 
PLoS Genet 5, e1000373 (2009). 
[34] Stefansson, H., et al. Large recurrent microdeletions associated with schizophrenia. 
Nature 455, 232-236 (2008). 
[35] Walsh, T., et al. Rare structural variants disrupt multiple genes in neurodevelopmental 
pathways in schizophrenia. Science 320, 539-543 (2008). 
[36] Xu, B., et al. Strong association of de novo copy number mutations with sporadic 
schizophrenia. Nat Genet 40, 880-885 (2008). 
[37] Li, J., et al. Common variants in the BCL9 gene conferring risk of schizophrenia. Arch 
Gen Psychiatry 68, 232-240 (2011). 
[38] Shi, Y., et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat 
Genet 43, 1224-1227 (2011). 
[39] Mah, S., et al. Identification of the semaphorin receptor PLXNA2 as a candidate for 
susceptibility to schizophrenia. Mol Psychiatry 11, 471-478 (2006). 
[40] Rietschel, M., et al. Association between genetic variation in a region on chromosome 11 
and schizophrenia in large samples from Europe. Mol Psychiatry (2011). 
[41] Steinberg, S., et al. Common variants at VRK2 and TCF4 conferring risk of 
schizophrenia. Hum Mol Genet 20, 4076-4081 (2011). 
[42] Kirov, G., et al. Comparative genome hybridization suggests a role for NRXN1 and 
APBA2 in schizophrenia. Hum Mol Genet 17, 458-465 (2008). 
[43] Magri, C., et al. New copy number variations in schizophrenia. PLoS One 5, e13422 
(2010). 
[44] Vrijenhoek, T., et al. Recurrent CNVs disrupt three candidate genes in schizophrenia 
patients. Am J Hum Genet 83, 504-510 (2008). 
Old Obstacles on New Horizons:  
The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research 101 
[45] Ikeda, M., et al. Genome-wide association study of schizophrenia in a Japanese 
population. Biol Psychiatry 69, 472-478 (2010). 
[46] O'Donovan, M.C., et al. Identification of loci associated with schizophrenia by genome-
wide association and follow-up. Nat Genet 40, 1053-1055 (2008). 
[47] Riley, B., et al. Replication of association between schizophrenia and ZNF804A in the 
Irish Case-Control Study of Schizophrenia sample. Mol Psychiatry 15, 29-37 (2010). 
[48] Williams, H.J., et al. Fine mapping of ZNF804A and genome-wide significant evidence 
for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 16, 429-
441 (2011). 
[49] Shi, J., et al. Common variants on chromosome 6p22.1 are associated with 
schizophrenia. Nature 460, 753-757 (2009). 
[50] Alkelai, A., et al. Identification of new schizophrenia susceptibility loci in an ethnically 
homogeneous, family-based, Arab-Israeli sample. FASEB J 25, 4011-4023 (2011). 
[51] Williams, H.J., et al. Most genome-wide significant susceptibility loci for schizophrenia 
and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum 
Mol Genet 20, 387-391 (2011) . 
[52] Shifman, S., et al. Genome-wide association identifies a common variant in the reelin 
gene that increases the risk of schizophrenia only in women. PLoS Genet 4, e28 
(2008). 
[53] Kirov, G., et al. A genome-wide association study in 574 schizophrenia trios using DNA 
pooling. Mol Psychiatry 14, 796-803 (2009). 
[54] Mulle, J.G., et al. Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum 
Genet 87, 229-236 (2010). 
[55] Chen, X., et al. GWA study data mining and independent replication identify 
cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol 
Psychiatry 16, 1117-1129 (2011). 
[56] Yue, W.H., et al. Genome-wide association study identifies a susceptibility locus for 
schizophrenia in Han Chinese at 11p11.2. Nat Genet 43, 1228-1231 (2011) . 
[57] Stefansson, H., et al. Common variants conferring risk of schizophrenia. Nature 460, 
744-747 (2009). 
[58] Purcell, S.M., et al. Common polygenic variation contributes to risk of schizophrenia 
and bipolar disorder. Nature 460, 748-752 (2009). 
[59] Ingason, A., et al. A large replication study and meta-analysis in European samples 
provides further support for association of AHI1 markers with schizophrenia. Hum 
Mol Genet 19, 1379-1386 (2010) 
[60] Athanasiu, L., et al. Gene variants associated with schizophrenia in a Norwegian 
genome-wide study are replicated in a large European cohort. J Psychiatr Res 44, 
748-753 (2010) 
[61] Shi, Y.Y., et al. A study of rare structural variants in schizophrenia patients and normal 
controls from Chinese Han population. Mol Psychiatry 13, 911-913 (2008). 
[62] Vacic, V., et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant 
risk for schizophrenia. Nature 471, 499-503 (2011) 
[63] Green, E.K., et al. The bipolar disorder risk allele at CACNA1C also confers risk of 
recurrent major depression and of schizophrenia. Mol Psychiatry 15, 1016-1022 
(2010). 
[64] Lencz, T., et al. Converging evidence for a pseudoautosomal cytokine receptor gene 
locus in schizophrenia. Mol Psychiatry 12, 572-580 (2007). 
Public Health – Methodology, Environmental and Systems Issues 102 
[65] So, H.C., Gui, A.H., Cherny, S.S. & Sham, P.C. Evaluating the heritability explained by 
known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol 
35, 310-317 (2011) 
[66] Eichler, E.E., et al. Missing heritability and strategies for finding the underlying causes 
of complex disease. Nat Rev Genet 11, 446-450 (2010) 
[67] Zuk, O., Hechter, E., Sunyaev, S.R. & Lander, E.S. The mystery of missing heritability: 
Genetic interactions create phantom heritability. Proc Natl Acad Sci U S A (2012) 
[68] Jaffee, S.R. & Price, T.S. Genotype-environment correlations: implications for 
determining the relationship between environmental exposures and psychiatric 
illness. Psychiatry 7, 496-499 (2008). 
[69] Dick, D.M., et al. Gender differences in friends' influences on adolescent drinking: a 
genetic epidemiological study. Alcohol Clin Exp Res 31, 2012-2019 (2007). 
[70] Kendler, K.S. & Karkowski-Shuman, L. Stressful life events and genetic liability to major 
depression: genetic control of exposure to the environment? Psychol Med 27, 539-
547 (1997). 
[71] Di Forti, M., et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 195, 
488-491 (2009). 
[72] Barkus, E.J., Stirling, J., Hopkins, R.S. & Lewis, S. Cannabis-induced psychosis-like 
experiences are associated with high schizotypy. Psychopathology 39, 175-178 
(2006). 
[73] Ferdinand, R.F., et al. Cannabis use predicts future psychotic symptoms, and vice versa. 
Addiction 100, 612-618 (2005). 
[74] Fergusson, D.M., Horwood, L.J. & Ridder, E.M. Tests of causal linkages between 
cannabis use and psychotic symptoms. Addiction 100, 354-366 (2005). 
[75] Veling, W., Mackenbach, J.P., van Os, J. & Hoek, H.W. Cannabis use and genetic 
predisposition for schizophrenia: a case-control study. Psychol Med 38, 1251-1256 
(2008). 
[76] McGuire, P.K., et al. Morbid risk of schizophrenia for relatives of patients with 
cannabis-associated psychosis. Schizophr Res 15, 277-281 (1995). 
[77] Arendt, M., Mortensen, P.B., Rosenberg, R., Pedersen, C.B. & Waltoft, B.L. Familial 
predisposition for psychiatric disorder: comparison of subjects treated for cannabis-
induced psychosis and schizophrenia. Arch Gen Psychiatry 65, 1269-1274 (2008). 
[78] van Os, J., Hanssen, M., Bak, M., Bijl, R.V. & Vollebergh, W. Do urbanicity and familial 
liability coparticipate in causing psychosis? Am J Psychiatry 160, 477-482 (2003). 
[79] Clarke, M.C., Tanskanen, A., Huttunen, M., Whittaker, J.C. & Cannon, M. Evidence for 
an interaction between familial liability and prenatal exposure to infection in the 
causation of schizophrenia. Am J Psychiatry 166, 1025-1030 (2009). 
[80] Margari, F., et al. Familial liability, obstetric complications and childhood development 
abnormalities in early onset schizophrenia: a case control study. BMC Psychiatry 
11, 60 (2011) 
[81] Wicks, S., Hjern, A. & Dalman, C. Social risk or genetic liability for psychosis? A study 
of children born in Sweden and reared by adoptive parents. Am J Psychiatry 167, 
1240-1246 (2010) 
[82] Moffitt, T.E., Caspi, A. & Rutter, M. Strategy for investigating interactions between 
measured genes and measured environments. Arch Gen Psychiatry 62, 473-481 
(2005). 
[83] Tienari, P., et al. Genetic boundaries of the schizophrenia spectrum: evidence from the 
Finnish Adoptive Family Study of Schizophrenia. Am J Psychiatry 160, 1587-1594 
(2003). 
Old Obstacles on New Horizons:  
The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research 103 
[84] Duncan, L.E. & Keller, M.C. A critical review of the first 10 years of candidate gene-by-
environment interaction research in psychiatry. Am J Psychiatry 168, 1041-
1049(2011) 
[85] Zammit, S., Lewis, G., Dalman, C. & Allebeck, P. Examining interactions between risk 
factors for psychosis. Br J Psychiatry 197, 207-211(2010) 
[86] Kendler, K.S. & Gardner, C.O. Interpretation of interactions: guide for the perplexed. Br 
J Psychiatry 197, 170-171 (2010) 
[87] Kotb, M., et al. An immunogenetic and molecular basis for differences in outcomes of 
invasive group A streptococcal infections. Nat Med 8, 1398-1404 (2002). 
[88] Boardman, J.D. State-level moderation of genetic tendencies to smoke. Am J Public 
Health 99, 480-486 (2009). 
[89] Carrera, N., et al. Association study of nonsynonymous single nucleotide 
polymorphisms in schizophrenia. Biol Psychiatry 71, 169-177 (2012) 
[90] Little, J., et al. STrengthening the REporting of Genetic Association Studies (STREGA): 
an extension of the STROBE statement. PLoS Med 6, e22 (2009). 
[91] Caspi, A., Hariri, A.R., Holmes, A., Uher, R. & Moffitt, T.E. Genetic sensitivity to the 
environment: the case of the serotonin transporter gene and its implications for 
studying complex diseases and traits. Am J Psychiatry 167, 509-527 (2011) 
[92] Zammit, S., Owen, M.J., Evans, J., Heron, J. & Lewis, G. Cannabis, COMT and psychotic 
experiences. Br J Psychiatry 199, 380-385 (2011) 
[93] Caspi, A., et al. Moderation of the effect of adolescent-onset cannabis use on adult 
psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: 
longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57, 
1117-1127 (2005). 
[94] Caspi, A., et al. Influence of life stress on depression: moderation by a polymorphism in 
the 5-HTT gene. Science 301, 386-389 (2003). 
[95] Uher, R. & McGuffin, P. The moderation by the serotonin transporter gene of 
environmental adversity in the aetiology of mental illness: review and 
methodological analysis. Mol Psychiatry 13, 131-146 (2008). 
[96] Wong, M.Y., Day, N.E., Luan, J.A. & Wareham, N.J. Estimation of magnitude in gene-
environment interactions in the presence of measurement error. Stat Med 23, 987-
998 (2004). 
[97] Vineis, P. A self-fulfilling prophecy: are we underestimating the role of the environment 
in gene-environment interaction research? Int J Epidemiol 33, 945-946 (2004). 
[98] Boks, M.P., et al. Investigating gene environment interaction in complex diseases: 
increasing power by selective sampling for environmental exposure. Int J 
Epidemiol 36, 1363-1369 (2007). 
[99] Knol, M.J., van der Tweel, I., Grobbee, D.E., Numans, M.E. & Geerlings, M.I. Estimating 
interaction on an additive scale between continuous determinants in a logistic 
regression model. Int J Epidemiol 36, 1111-1118 (2007). 
[100] Darroch, J. Biologic synergism and parallelism. Am J Epidemiol 145, 661-668 (1997). 
[101] VanderWeele, T.J., Hernandez-Diaz, S. & Hernan, M.A. Case-only gene-environment 
interaction studies: when does association imply mechanistic interaction? Genet 
Epidemiol 34, 327-334 (2010) 
[102] Engelman, C.D., et al. Detecting gene-environment interactions in genome-wide 
association data. Genet Epidemiol 33 Suppl 1, S68-73 (2009). 
[103] Thomas, D. Gene--environment-wide association studies: emerging approaches. Nat 
Rev Genet 11, 259-272 (2010) 
Public Health – Methodology, Environmental and Systems Issues 102 
[65] So, H.C., Gui, A.H., Cherny, S.S. & Sham, P.C. Evaluating the heritability explained by 
known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol 
35, 310-317 (2011) 
[66] Eichler, E.E., et al. Missing heritability and strategies for finding the underlying causes 
of complex disease. Nat Rev Genet 11, 446-450 (2010) 
[67] Zuk, O., Hechter, E., Sunyaev, S.R. & Lander, E.S. The mystery of missing heritability: 
Genetic interactions create phantom heritability. Proc Natl Acad Sci U S A (2012) 
[68] Jaffee, S.R. & Price, T.S. Genotype-environment correlations: implications for 
determining the relationship between environmental exposures and psychiatric 
illness. Psychiatry 7, 496-499 (2008). 
[69] Dick, D.M., et al. Gender differences in friends' influences on adolescent drinking: a 
genetic epidemiological study. Alcohol Clin Exp Res 31, 2012-2019 (2007). 
[70] Kendler, K.S. & Karkowski-Shuman, L. Stressful life events and genetic liability to major 
depression: genetic control of exposure to the environment? Psychol Med 27, 539-
547 (1997). 
[71] Di Forti, M., et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 195, 
488-491 (2009). 
[72] Barkus, E.J., Stirling, J., Hopkins, R.S. & Lewis, S. Cannabis-induced psychosis-like 
experiences are associated with high schizotypy. Psychopathology 39, 175-178 
(2006). 
[73] Ferdinand, R.F., et al. Cannabis use predicts future psychotic symptoms, and vice versa. 
Addiction 100, 612-618 (2005). 
[74] Fergusson, D.M., Horwood, L.J. & Ridder, E.M. Tests of causal linkages between 
cannabis use and psychotic symptoms. Addiction 100, 354-366 (2005). 
[75] Veling, W., Mackenbach, J.P., van Os, J. & Hoek, H.W. Cannabis use and genetic 
predisposition for schizophrenia: a case-control study. Psychol Med 38, 1251-1256 
(2008). 
[76] McGuire, P.K., et al. Morbid risk of schizophrenia for relatives of patients with 
cannabis-associated psychosis. Schizophr Res 15, 277-281 (1995). 
[77] Arendt, M., Mortensen, P.B., Rosenberg, R., Pedersen, C.B. & Waltoft, B.L. Familial 
predisposition for psychiatric disorder: comparison of subjects treated for cannabis-
induced psychosis and schizophrenia. Arch Gen Psychiatry 65, 1269-1274 (2008). 
[78] van Os, J., Hanssen, M., Bak, M., Bijl, R.V. & Vollebergh, W. Do urbanicity and familial 
liability coparticipate in causing psychosis? Am J Psychiatry 160, 477-482 (2003). 
[79] Clarke, M.C., Tanskanen, A., Huttunen, M., Whittaker, J.C. & Cannon, M. Evidence for 
an interaction between familial liability and prenatal exposure to infection in the 
causation of schizophrenia. Am J Psychiatry 166, 1025-1030 (2009). 
[80] Margari, F., et al. Familial liability, obstetric complications and childhood development 
abnormalities in early onset schizophrenia: a case control study. BMC Psychiatry 
11, 60 (2011) 
[81] Wicks, S., Hjern, A. & Dalman, C. Social risk or genetic liability for psychosis? A study 
of children born in Sweden and reared by adoptive parents. Am J Psychiatry 167, 
1240-1246 (2010) 
[82] Moffitt, T.E., Caspi, A. & Rutter, M. Strategy for investigating interactions between 
measured genes and measured environments. Arch Gen Psychiatry 62, 473-481 
(2005). 
[83] Tienari, P., et al. Genetic boundaries of the schizophrenia spectrum: evidence from the 
Finnish Adoptive Family Study of Schizophrenia. Am J Psychiatry 160, 1587-1594 
(2003). 
Old Obstacles on New Horizons:  
The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research 103 
[84] Duncan, L.E. & Keller, M.C. A critical review of the first 10 years of candidate gene-by-
environment interaction research in psychiatry. Am J Psychiatry 168, 1041-
1049(2011) 
[85] Zammit, S., Lewis, G., Dalman, C. & Allebeck, P. Examining interactions between risk 
factors for psychosis. Br J Psychiatry 197, 207-211(2010) 
[86] Kendler, K.S. & Gardner, C.O. Interpretation of interactions: guide for the perplexed. Br 
J Psychiatry 197, 170-171 (2010) 
[87] Kotb, M., et al. An immunogenetic and molecular basis for differences in outcomes of 
invasive group A streptococcal infections. Nat Med 8, 1398-1404 (2002). 
[88] Boardman, J.D. State-level moderation of genetic tendencies to smoke. Am J Public 
Health 99, 480-486 (2009). 
[89] Carrera, N., et al. Association study of nonsynonymous single nucleotide 
polymorphisms in schizophrenia. Biol Psychiatry 71, 169-177 (2012) 
[90] Little, J., et al. STrengthening the REporting of Genetic Association Studies (STREGA): 
an extension of the STROBE statement. PLoS Med 6, e22 (2009). 
[91] Caspi, A., Hariri, A.R., Holmes, A., Uher, R. & Moffitt, T.E. Genetic sensitivity to the 
environment: the case of the serotonin transporter gene and its implications for 
studying complex diseases and traits. Am J Psychiatry 167, 509-527 (2011) 
[92] Zammit, S., Owen, M.J., Evans, J., Heron, J. & Lewis, G. Cannabis, COMT and psychotic 
experiences. Br J Psychiatry 199, 380-385 (2011) 
[93] Caspi, A., et al. Moderation of the effect of adolescent-onset cannabis use on adult 
psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: 
longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57, 
1117-1127 (2005). 
[94] Caspi, A., et al. Influence of life stress on depression: moderation by a polymorphism in 
the 5-HTT gene. Science 301, 386-389 (2003). 
[95] Uher, R. & McGuffin, P. The moderation by the serotonin transporter gene of 
environmental adversity in the aetiology of mental illness: review and 
methodological analysis. Mol Psychiatry 13, 131-146 (2008). 
[96] Wong, M.Y., Day, N.E., Luan, J.A. & Wareham, N.J. Estimation of magnitude in gene-
environment interactions in the presence of measurement error. Stat Med 23, 987-
998 (2004). 
[97] Vineis, P. A self-fulfilling prophecy: are we underestimating the role of the environment 
in gene-environment interaction research? Int J Epidemiol 33, 945-946 (2004). 
[98] Boks, M.P., et al. Investigating gene environment interaction in complex diseases: 
increasing power by selective sampling for environmental exposure. Int J 
Epidemiol 36, 1363-1369 (2007). 
[99] Knol, M.J., van der Tweel, I., Grobbee, D.E., Numans, M.E. & Geerlings, M.I. Estimating 
interaction on an additive scale between continuous determinants in a logistic 
regression model. Int J Epidemiol 36, 1111-1118 (2007). 
[100] Darroch, J. Biologic synergism and parallelism. Am J Epidemiol 145, 661-668 (1997). 
[101] VanderWeele, T.J., Hernandez-Diaz, S. & Hernan, M.A. Case-only gene-environment 
interaction studies: when does association imply mechanistic interaction? Genet 
Epidemiol 34, 327-334 (2010) 
[102] Engelman, C.D., et al. Detecting gene-environment interactions in genome-wide 
association data. Genet Epidemiol 33 Suppl 1, S68-73 (2009). 
[103] Thomas, D. Gene--environment-wide association studies: emerging approaches. Nat 
Rev Genet 11, 259-272 (2010) 
Public Health – Methodology, Environmental and Systems Issues 104 
[104] Bickeboller, H., Houwing-Duistermaat, J.J., Wang, X. & Yan, X. Dealing with high 
dimensionality for the identification of common and rare variants as main effects 
and for gene-environment interaction. Genet Epidemiol 35 Suppl 1, S35-40 (2011) 
[105] Kraft, P. Curses--winner's and otherwise--in genetic epidemiology. Epidemiology 19, 
649-651; discussion 657-648 (2008). 
[106] Kraft, P. & Hunter, D. Integrating epidemiology and genetic association: the challenge 
of gene-environment interaction. Philos Trans R Soc Lond B Biol Sci 360, 1609-1616 
(2005). 
[107] Hewitt, J.K. Editorial Policy on Candidate Gene Association and Candidate Gene-by-
Environment Interaction Studies of Complex Traits. Behav Genet 42, 1-2 (2012) 
[108] Caspi, A., et al. Role of genotype in the cycle of violence in maltreated children. Science 
297, 851-854 (2002). 
[109] Collins, A.L., Kim, Y., Sklar, P., O'Donovan, M.C. & Sullivan, P.F. Hypothesis-driven 
candidate genes for schizophrenia compared to genome-wide association results. 
Psychol Med 42, 607-616 (2012) 
[110] Sanders, A.R., et al. No significant association of 14 candidate genes with 
schizophrenia in a large European ancestry sample: implications for psychiatric 
genetics. Am J Psychiatry 165, 497-506 (2008). 
[111] Lasky-Su, J., et al. Genome-wide association scan of quantitative traits for attention 
deficit hyperactivity disorder identifies novel associations and confirms candidate 
gene associations. Am J Med Genet B Neuropsychiatr Genet 147B, 1345-1354 (2008). 
[112] Hamza, T.H., et al. Genome-wide gene-environment study identifies glutamate 
receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with 
coffee. PLoS Genet 7, e1002237 (2011) 
[113] Paus, T., et al. KCTD8 Gene and Brain Growth in Adverse Intrauterine Environment: A 
Genome-wide Association Study. Cereb Cortex (2011) 
[114] Tan, A., et al. A genome-wide association and gene-environment interaction study for 
serum triglycerides levels in a healthy Chinese male population. Hum Mol Genet 
(2012) 
[115] A framework for interpreting genome-wide association studies of psychiatric 
disorders. Mol Psychiatry 14, 10-17 (2009). 
[116] Mukherjee, B., Ahn, J., Gruber, S.B., Ghosh, M. & Chatterjee, N. Case-control studies of 
gene-environment interaction: Bayesian design and analysis. Biometrics 66, 934-948 
(2010). 
[117] Mukherjee, B., Ahn, J., Gruber, S.B. & Chatterjee, N. Testing gene-environment 
interaction in large-scale case-control association studies: possible choices and 
comparisons. Am J Epidemiol 175, 177-190 (2012) . 
[118] Pierce, B.L. & Ahsan, H. Case-only genome-wide interaction study of disease risk, 
prognosis and treatment. Genet Epidemiol 34, 7-15 (2010). 
[119] Piegorsch, W.W., Weinberg, C.R. & Taylor, J.A. Non-hierarchical logistic models and 
case-only designs for assessing susceptibility in population-based case-control 
studies. Stat Med 13, 153-162 (1994). 
[120] Li, M.J., et al. GWASdb: a database for human genetic variants identified by genome-
wide association studies. Nucleic Acids Res 40, D1047-1054 (2012). 
[121] Chen, J., et al. Two non-synonymous markers in PTPN21, identified by genome-wide 
association study data-mining and replication, are associated with schizophrenia. 
Schizophr Res 131, 43-51(2011). 
[122] Havik, B., et al. The complement control-related genes CSMD1 and CSMD2 associate 
to schizophrenia. Biol Psychiatry 70, 35-42 (2011). 
Old Obstacles on New Horizons:  
The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research 105 
[123] Zuvich, R.L., et al. Pitfalls of merging GWAS data: lessons learned in the eMERGE 
network and quality control procedures to maintain high data quality. Genet 
Epidemiol 35, 887-898 (2011). 
[124] WellcomeTrust. Translating the potential of human population genetics research to 
improve the quality of health of the EU citizen. in From Biobanks to biomarkers 
(Wellcome Trust, 2006). 
[125] Inczedy-Farkas, G., et al. [SCHIZOBANK - The Hungarian national schizophrenia 
biobank and its role in schizophrenia research and in personalized medicine]. Orv 
Hetil 151, 1403-1408 (2010). 
[126] McGrath, J.J., et al. Neonatal vitamin D status and risk of schizophrenia: a population-
based case-control study. Arch Gen Psychiatry 67, 889-894 (2010). 
[127] Mortensen, P.B., et al. A Danish National Birth Cohort study of maternal HSV-2 
antibodies as a risk factor for schizophrenia in their offspring. Schizophr Res 122, 
257-263 (2010). 
[128] Rawlins, M. De testimonio: on the evidence for decisions about the use of therapeutic 
interventions. Lancet 372, 2152-2161 (2008). 
[129] Uher, R. Forum: The case for gene-environment interactions in psychiatry. Curr Opin 
Psychiatry 21, 318-321 (2008). 
[130] Inselman, A.L., et al. Assessment of research models for testing gene-environment 
interactions. Eur J Pharmacol 668 Suppl 1, S108-116. 
[131] Stewart, R., et al. The South London and Maudsley NHS Foundation Trust Biomedical 
Research Centre (SLAM BRC) case register: development and descriptive data. 
BMC Psychiatry 9, 51 (2009). 
[132] Ashley, E.A., et al. Clinical assessment incorporating a personal genome. Lancet 375, 
1525-1535 (2010). 
[133] Wilson, J.F., et al. Population genetic structure of variable drug response. Nat Genet 29, 
265-269 (2001). 
[134] Fleeman, N., et al. Cytochrome P450 testing for prescribing antipsychotics in adults 
with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 11, 
1-14 (2011) . 
[135] Johansson, I., et al. Inherited amplification of an active gene in the cytochrome P450 
CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad 
Sci U S A 90, 11825-11829 (1993). 
[136] Thakur, M., et al. Review of evidence for genetic testing for CYP450 polymorphisms in 
management of patients with nonpsychotic depression with selective serotonin 
reuptake inhibitors. Genet Med 9, 826-835 (2007). 
[137] Khoury, M.J., et al. The continuum of translation research in genomic medicine: how 
can we accelerate the appropriate integration of human genome discoveries into 
health care and disease prevention? Genet Med 9, 665-674 (2007). 
[138] Pirmohamed, M. Acceptance of biomarker-based tests for application in clinical 
practice: criteria and obstacles. Clin Pharmacol Ther 88, 862-866 (2010). 
[139] Zimmern, R.L. Testing challenges: evaluation of novel diagnostics and molecular 
biomarkers. Clin Med 9, 68-73 (2009). 
[140] Lenfant, C. Shattuck lecture--clinical research to clinical practice--lost in translation? N 
Engl J Med 349, 868-874 (2003). 
[141] Collins, F.S. Reengineering translational science: the time is right. Sci Transl Med 3, 
(2011). 
[142] Jurgens, G., et al. Utility and adoption of CYP2D6 and CYP2C19 genotyping and its 
translation into psychiatric clinical practice. Acta Psychiatr Scand (2011). 
Public Health – Methodology, Environmental and Systems Issues 104 
[104] Bickeboller, H., Houwing-Duistermaat, J.J., Wang, X. & Yan, X. Dealing with high 
dimensionality for the identification of common and rare variants as main effects 
and for gene-environment interaction. Genet Epidemiol 35 Suppl 1, S35-40 (2011) 
[105] Kraft, P. Curses--winner's and otherwise--in genetic epidemiology. Epidemiology 19, 
649-651; discussion 657-648 (2008). 
[106] Kraft, P. & Hunter, D. Integrating epidemiology and genetic association: the challenge 
of gene-environment interaction. Philos Trans R Soc Lond B Biol Sci 360, 1609-1616 
(2005). 
[107] Hewitt, J.K. Editorial Policy on Candidate Gene Association and Candidate Gene-by-
Environment Interaction Studies of Complex Traits. Behav Genet 42, 1-2 (2012) 
[108] Caspi, A., et al. Role of genotype in the cycle of violence in maltreated children. Science 
297, 851-854 (2002). 
[109] Collins, A.L., Kim, Y., Sklar, P., O'Donovan, M.C. & Sullivan, P.F. Hypothesis-driven 
candidate genes for schizophrenia compared to genome-wide association results. 
Psychol Med 42, 607-616 (2012) 
[110] Sanders, A.R., et al. No significant association of 14 candidate genes with 
schizophrenia in a large European ancestry sample: implications for psychiatric 
genetics. Am J Psychiatry 165, 497-506 (2008). 
[111] Lasky-Su, J., et al. Genome-wide association scan of quantitative traits for attention 
deficit hyperactivity disorder identifies novel associations and confirms candidate 
gene associations. Am J Med Genet B Neuropsychiatr Genet 147B, 1345-1354 (2008). 
[112] Hamza, T.H., et al. Genome-wide gene-environment study identifies glutamate 
receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with 
coffee. PLoS Genet 7, e1002237 (2011) 
[113] Paus, T., et al. KCTD8 Gene and Brain Growth in Adverse Intrauterine Environment: A 
Genome-wide Association Study. Cereb Cortex (2011) 
[114] Tan, A., et al. A genome-wide association and gene-environment interaction study for 
serum triglycerides levels in a healthy Chinese male population. Hum Mol Genet 
(2012) 
[115] A framework for interpreting genome-wide association studies of psychiatric 
disorders. Mol Psychiatry 14, 10-17 (2009). 
[116] Mukherjee, B., Ahn, J., Gruber, S.B., Ghosh, M. & Chatterjee, N. Case-control studies of 
gene-environment interaction: Bayesian design and analysis. Biometrics 66, 934-948 
(2010). 
[117] Mukherjee, B., Ahn, J., Gruber, S.B. & Chatterjee, N. Testing gene-environment 
interaction in large-scale case-control association studies: possible choices and 
comparisons. Am J Epidemiol 175, 177-190 (2012) . 
[118] Pierce, B.L. & Ahsan, H. Case-only genome-wide interaction study of disease risk, 
prognosis and treatment. Genet Epidemiol 34, 7-15 (2010). 
[119] Piegorsch, W.W., Weinberg, C.R. & Taylor, J.A. Non-hierarchical logistic models and 
case-only designs for assessing susceptibility in population-based case-control 
studies. Stat Med 13, 153-162 (1994). 
[120] Li, M.J., et al. GWASdb: a database for human genetic variants identified by genome-
wide association studies. Nucleic Acids Res 40, D1047-1054 (2012). 
[121] Chen, J., et al. Two non-synonymous markers in PTPN21, identified by genome-wide 
association study data-mining and replication, are associated with schizophrenia. 
Schizophr Res 131, 43-51(2011). 
[122] Havik, B., et al. The complement control-related genes CSMD1 and CSMD2 associate 
to schizophrenia. Biol Psychiatry 70, 35-42 (2011). 
Old Obstacles on New Horizons:  
The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research 105 
[123] Zuvich, R.L., et al. Pitfalls of merging GWAS data: lessons learned in the eMERGE 
network and quality control procedures to maintain high data quality. Genet 
Epidemiol 35, 887-898 (2011). 
[124] WellcomeTrust. Translating the potential of human population genetics research to 
improve the quality of health of the EU citizen. in From Biobanks to biomarkers 
(Wellcome Trust, 2006). 
[125] Inczedy-Farkas, G., et al. [SCHIZOBANK - The Hungarian national schizophrenia 
biobank and its role in schizophrenia research and in personalized medicine]. Orv 
Hetil 151, 1403-1408 (2010). 
[126] McGrath, J.J., et al. Neonatal vitamin D status and risk of schizophrenia: a population-
based case-control study. Arch Gen Psychiatry 67, 889-894 (2010). 
[127] Mortensen, P.B., et al. A Danish National Birth Cohort study of maternal HSV-2 
antibodies as a risk factor for schizophrenia in their offspring. Schizophr Res 122, 
257-263 (2010). 
[128] Rawlins, M. De testimonio: on the evidence for decisions about the use of therapeutic 
interventions. Lancet 372, 2152-2161 (2008). 
[129] Uher, R. Forum: The case for gene-environment interactions in psychiatry. Curr Opin 
Psychiatry 21, 318-321 (2008). 
[130] Inselman, A.L., et al. Assessment of research models for testing gene-environment 
interactions. Eur J Pharmacol 668 Suppl 1, S108-116. 
[131] Stewart, R., et al. The South London and Maudsley NHS Foundation Trust Biomedical 
Research Centre (SLAM BRC) case register: development and descriptive data. 
BMC Psychiatry 9, 51 (2009). 
[132] Ashley, E.A., et al. Clinical assessment incorporating a personal genome. Lancet 375, 
1525-1535 (2010). 
[133] Wilson, J.F., et al. Population genetic structure of variable drug response. Nat Genet 29, 
265-269 (2001). 
[134] Fleeman, N., et al. Cytochrome P450 testing for prescribing antipsychotics in adults 
with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 11, 
1-14 (2011) . 
[135] Johansson, I., et al. Inherited amplification of an active gene in the cytochrome P450 
CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad 
Sci U S A 90, 11825-11829 (1993). 
[136] Thakur, M., et al. Review of evidence for genetic testing for CYP450 polymorphisms in 
management of patients with nonpsychotic depression with selective serotonin 
reuptake inhibitors. Genet Med 9, 826-835 (2007). 
[137] Khoury, M.J., et al. The continuum of translation research in genomic medicine: how 
can we accelerate the appropriate integration of human genome discoveries into 
health care and disease prevention? Genet Med 9, 665-674 (2007). 
[138] Pirmohamed, M. Acceptance of biomarker-based tests for application in clinical 
practice: criteria and obstacles. Clin Pharmacol Ther 88, 862-866 (2010). 
[139] Zimmern, R.L. Testing challenges: evaluation of novel diagnostics and molecular 
biomarkers. Clin Med 9, 68-73 (2009). 
[140] Lenfant, C. Shattuck lecture--clinical research to clinical practice--lost in translation? N 
Engl J Med 349, 868-874 (2003). 
[141] Collins, F.S. Reengineering translational science: the time is right. Sci Transl Med 3, 
(2011). 
[142] Jurgens, G., et al. Utility and adoption of CYP2D6 and CYP2C19 genotyping and its 
translation into psychiatric clinical practice. Acta Psychiatr Scand (2011). 
Public Health – Methodology, Environmental and Systems Issues 106 
[143] Rawlins, M. A new era for UK clinical research? Lancet 377, 190-192. 
[144] Perks, B. New regulations urged for UK health research. Nat Med 17, 142 (2011). 
[145] Rawlins, M., Barnett, D. & Stevens, A. Pharmacoeconomics: NICE's approach to 
decision-making. Br J Clin Pharmacol 70, 346-349 (2010). 
[146] Domenici, E., et al. Plasma protein biomarkers for depression and schizophrenia by 
multi analyte profiling of case-control collections. PLoS One 5, e9166 (2010). 
[147] Levin, Y., et al. Global proteomic profiling reveals altered proteomic signature in 
schizophrenia serum. Mol Psychiatry 15, 1088-1100 (2009). 
[148] Melas, P.A., et al. Epigenetic aberrations in leukocytes of patients with schizophrenia: 
association of global DNA methylation with antipsychotic drug treatment and 
disease onset. FASEB J (2012). 
[149] Kurian, S.M., et al. Identification of blood biomarkers for psychosis using convergent 
functional genomics. Mol Psychiatry 16, 37-58 (2011). 
[150] Kuzman, M.R., Medved, V., Terzic, J. & Krainc, D. Genome-wide expression analysis 
of peripheral blood identifies candidate biomarkers for schizophrenia. J Psychiatr 
Res 43, 1073-1077 (2009). 
[151] Dempster, E.L., et al. Disease-associated epigenetic changes in monozygotic twins 
discordant for schizophrenia and bipolar disorder. Hum Mol Genet 20, 4786-4796 
(2011). 
[152] Rutten, B.P. & Mill, J. Epigenetic mediation of environmental influences in major 
psychotic disorders. Schizophr Bull 35, 1045-1056 (2009). 
[153] Heijmans, B.T. & Mill, J. Commentary: The seven plagues of epigenetic epidemiology. 
Int J Epidemiol 41, 74-78 (2012). 
[154] Kumarasinghe, N., Tooney, P. & Schall, U. Finding the needle in the haystack: A 
review of microarray gene expression research into schizophrenia. Aust N Z J 
Psychiatry (2012). 
[155] de Jong, S., et al. Expression QTL analysis of top loci from GWAS meta-analysis 
highlights additional schizophrenia candidate genes. Eur J Hum Genet (2012). 
[156] Gibbs, J.R., et al. Abundant quantitative trait loci exist for DNA methylation and gene 
expression in human brain. PLoS Genet 6, e1000952 (2010). 
[157] Richards, A.L., et al. Schizophrenia susceptibility alleles are enriched for alleles that 
affect gene expression in adult human brain. Mol Psychiatry 17, 193-201(2011). 
Section 2 
Environmental and Nutritional Issues 
Public Health – Methodology, Environmental and Systems Issues 106 
[143] Rawlins, M. A new era for UK clinical research? Lancet 377, 190-192. 
[144] Perks, B. New regulations urged for UK health research. Nat Med 17, 142 (2011). 
[145] Rawlins, M., Barnett, D. & Stevens, A. Pharmacoeconomics: NICE's approach to 
decision-making. Br J Clin Pharmacol 70, 346-349 (2010). 
[146] Domenici, E., et al. Plasma protein biomarkers for depression and schizophrenia by 
multi analyte profiling of case-control collections. PLoS One 5, e9166 (2010). 
[147] Levin, Y., et al. Global proteomic profiling reveals altered proteomic signature in 
schizophrenia serum. Mol Psychiatry 15, 1088-1100 (2009). 
[148] Melas, P.A., et al. Epigenetic aberrations in leukocytes of patients with schizophrenia: 
association of global DNA methylation with antipsychotic drug treatment and 
disease onset. FASEB J (2012). 
[149] Kurian, S.M., et al. Identification of blood biomarkers for psychosis using convergent 
functional genomics. Mol Psychiatry 16, 37-58 (2011). 
[150] Kuzman, M.R., Medved, V., Terzic, J. & Krainc, D. Genome-wide expression analysis 
of peripheral blood identifies candidate biomarkers for schizophrenia. J Psychiatr 
Res 43, 1073-1077 (2009). 
[151] Dempster, E.L., et al. Disease-associated epigenetic changes in monozygotic twins 
discordant for schizophrenia and bipolar disorder. Hum Mol Genet 20, 4786-4796 
(2011). 
[152] Rutten, B.P. & Mill, J. Epigenetic mediation of environmental influences in major 
psychotic disorders. Schizophr Bull 35, 1045-1056 (2009). 
[153] Heijmans, B.T. & Mill, J. Commentary: The seven plagues of epigenetic epidemiology. 
Int J Epidemiol 41, 74-78 (2012). 
[154] Kumarasinghe, N., Tooney, P. & Schall, U. Finding the needle in the haystack: A 
review of microarray gene expression research into schizophrenia. Aust N Z J 
Psychiatry (2012). 
[155] de Jong, S., et al. Expression QTL analysis of top loci from GWAS meta-analysis 
highlights additional schizophrenia candidate genes. Eur J Hum Genet (2012). 
[156] Gibbs, J.R., et al. Abundant quantitative trait loci exist for DNA methylation and gene 
expression in human brain. PLoS Genet 6, e1000952 (2010). 
[157] Richards, A.L., et al. Schizophrenia susceptibility alleles are enriched for alleles that 
affect gene expression in adult human brain. Mol Psychiatry 17, 193-201(2011). 
Section 2 
Environmental and Nutritional Issues 
 6 
Iron Deficiency Anemia:  
A Public Health Problem of Global Proportions 
Christopher V. Charles 
University of Guelph,  
Canada 
1. Introduction 
Iron deficiency anemia (IDA) is the most common micronutrient disorder in the world, 
negatively affecting the health and socio-economic wellbeing of millions of men, women, 
and children (Baltussen et al., 2004). According to the World Health Organization (WHO), 
IDA constitutes a significant public health problem requiring immediate attention from 
governments, researchers and healthcare practitioners (McLean et al., 2008). Iron deficiency 
(ID) is inherently associated with poverty, and is thus particularly prevalent in the 
developing world where the problem is often exacerbated by limited access to appropriate 
healthcare and treatment (DeMaeyer & Adiels-Tegman, 1985). 
Iron deficiency and IDA result from a long term negative iron balance, culminating in 
decreased or exhausted iron stores (Allen, 2000; Clark 2008; Ramakrishnan & Yip, 2002). 
Iron, a component of every living cell, is intrinsically involved in numerous biochemical 
reactions in the body and is associated with oxygen transport and storage, energy 
production, DNA synthesis, and electron transport (Crichton et al., 2002; Theil, 2004).  
Although the etiology of IDA is multifaceted, it generally results when iron demands are 
not met by iron absorption for any number of reasons. Individuals with IDA may have 
inadequate intake of iron due to poor quantity and/or quality of diet, impaired 
absorption or transport of iron, or chronic blood loss due to secondary disease (McLean et 
al., 2008).  
Consequences of IDA are devastating: inhibited growth, impaired cognitive development, 
poor mental and motor performance, reduced work capacity, and an overall decreased 
quality of life (Macdougall et al., 1975; Newhouse et al., 1989; Preziosi et al., 1997; Soewondo 
et al., 1989; Walter et al., 1989; Zhu & Haas, 1997).  
Prevention and control is typically achieved through iron fortification of food staples 
like flour, rice, and pasta, and/or through administration of iron supplements most often in 
iron pill or, more recently sprinkle form (Baltussen et al., 2004; Faqih et al., 2006; Mumtaz 
et al. 2000; Ramakrishnan & Yip, 2002). Although iron supplements are widely available 
and fortified foods constitute a major component of the diet in the developed world, access 
is limited in the developing world and cost if often prohibitive. 
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National, regional and global efforts to combat the problem of iron deficiency and IDA have 
garnered momentum in recent years, but the prevalence does not appear to be decreasing 
and the disorder remains a severe global public health problem. The current review will 
provide a general summary of the problem, touching upon the physiological aspects related 
to iron and hemoglobin, the etiology and epidemiology of IDA, and current prevention and 
control measures.  
2. Defining iron nutritional status  
Iron deficiency is defined as a condition in which there are no mobilizable iron stores, 
resulting from a long-term negative iron balance and leading to a compromised supply of 
iron to the tissues (Beutler et al., 2003). Iron status can be considered as a continuum: the 
ideal stage is normal iron status with varying amounts of stored iron within defined ranges; 
this is followed by iron deficiency, characterized by the absence of measurable iron stores; 
next, iron-deficient erythropoiesis shows evidence of a restricted iron supply in the absence 
of anemia; finally, the most significant negative consequence of ID is anemia, usually 
microcytic, hypochromic in nature (McLaren et al., 1983).  
Anemia in general is characterized by a decrease in number of red blood cells or less  
than the normal quantity of hemoglobin. The condition is determined by the expected 
normal range of hemoglobin in a population, and is defined as existing in an individual 
whose hemoglobin concentration (Hb) has fallen below a threshold lying at two standard 
deviations below the median for a healthy population of the same demographic 
characteristics, including age, sex and pregnancy status (McLean et al., 2008). Anemic 
conditions can result from a myriad of causes that can be isolated, but more often than  
not co-exist. These causes include hemolysis with malaria and other infectious diseases, 
enzyme deficiencies, a variety of hemoglobinopathies, and other micronutrient 
deficiencies (McLean et al., 2008). That said, the most significant contributor to the  
onset of anemia worldwide is iron deficiency, and thus the terms ID, IDA, and anemia are 
often falsely used interchangeably. IDA represents the most severe form of iron 
deficiency, and has corresponding alterations in hematological laboratory values and 
observable signs and symptoms. Currently, the World Health Organization accepts that 
generally a little less than 50% of all anemias can be attributed to iron deficiency (McLean 
et al., 2008). 
3. Biochemical and physiological importance of iron in the blood  
3.1 Human iron metabolism: 
Iron is important in the formation of a number of essential compounds in the body, 
including but not limited to hemoglobin, myoglobin, and other metalloproteins (Lynch, 
1997). Most well-nourished adults in industrialized countries contain approximately 3 to 5 
grams of iron, of which about 65% is in the form of hemoglobin (Bothwell, 1995). The 
remaining iron in the body is in the form of myoglobin, other heme compounds that 
promote intracellular oxidization, or is stored as ferritin in the reticuloendothelial system 
and cells of liver hepatocytes, bone marrow, and spleen (Frazer & Anderson 2005). 
Typically men have more stored iron than women, as women are often required to use 
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iron stores to compensate for iron loss through menstruation, pregnancy, and lactation 
(Bothwell, 1995). 
3.2 Dietary iron sources 
In food, two basic forms of iron exist: non-heme (inorganic) and heme (organic) (Bothwell, 
1995; Charlton & Bothwell 1983). In an average diet, non-heme iron accounts for 
approximately 90% of total dietary iron content, while heme iron constitutes the remaining 
10% (Bothwell et al., 1979).  
Heme iron is highly bioavailable, and present in meat, fish, and poultry. In contrast, non-
heme iron is not as readily bioavailable absorption is greatly influenced by diet composition 
(Harvey et al., 2000). Enhancers, such as ascorbic acid, and inhibitors, such as phytates and 
polyphenols, significantly affect inorganic iron absorption (Baynes & Bothwell, 1990, Tseng 
et al., 1997). Although total iron content in a meal is an important consideration, it is crucial 
to appreciate that the overall composition of the meal is of far greater significance for iron 
nutrition than the amount of total iron provided (McLean et al., 2008). 
3.3 Dietary iron absorption 
Dietary iron digested from food and/or supplements is absorbed by the mature villus 
enterocytes of the duodenum and proximal jejunum (McKie et al., 2001). Non-heme and 
heme iron are absorbed via different pathways, though the understanding of heme iron 
absorption is somewhat more limited.  
Non-heme iron in ferrous form is transported across the apical membrane of enterocytes by 
a non-specific divalent metal transporter (DMT1) (Aisen et al., 1999, Hentze et al., 2004). 
Because much of the iron that enters the gastrointestinal tract is in the oxidized or ferric 
form, a duodenal ferric reductase (Dcytb) in the apical membrane of enterocytes reduces 
dietary iron prior to uptake (Latunde-Dada et al., 2002).  
In contrast, heme iron molecules bind to an apical membrane protein and are absorbed 
intact. With the discovery of heme carrier protein 1 (HCP1), understanding has improved 
(Shayeghi et al., 2005). HCP1 is a polypeptide belonging to a superfamily of transporter 
proteins, and is predicted to have nine transmembrane domains by which heme iron is 
taken up. Though the mechanism is unclear, research has shown that by altering gene 
expression in animal models, heme absorption can be enhanced or limited by 
overexpressing or silencing HCP1 genes, respectively (Shayeghi et al., 2005). 
Duodenal basolateral iron export into blood is mediated by the transmembrane protein 
ferroportin 1 (FPN1) (Zoller et al., 2001). The exact mechanism by which FPN1 functions is 
unclear, though it is thought to be facilitated by the ferroxidase activity of a membrane 
bound oxidase called hephaestin (Fleming & Bacon, 2005; Han & Kim 2007).  
After moving into the plasma, iron binds to transferrin and is transported by the blood to 
sites of use and storage (Bailey et al., 1988). Cellular iron uptake is mediated by transferrin 
receptor 1 (TfR)-mediated endocytosis (Fleming & Bacon, 2005). Once inside the cell, iron 
has two possible fates: incorporation into iron proteins (usually as heme) or storage as 
ferritin for later use during times of iron deficiency (Bleackley et al., 2009).   
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3.4 Regulation of iron homeostasis 
Since the discovery of the hormone hepcidin in 2000, the understanding of how  
iron homeostasis is achieved has shifted (Krause et al., 2000; Park et al. 2001). Hepcidin,  
a peptide hormone that is produced and predominately expressed in the liver, appears  
to be the master regulator of iron homeostasis in humans and other mammals (Ganz, 
2003).  
When iron levels are high, several regulatory molecules including hemochromatosis gene 
product, hemojuvelin and transferrin receptor 2, increase hepatic hepcidin expression, 
stimulating downstream molecular pathways. With up-regulation of hepcidin expression, 
iron levels are effectively regulated by binding to FPN1 which is found on the surface of 
iron storage cells. When iron levels are high, hepcidin causes internalization and 
degradation of FPN1, leading to decreased iron release from iron storage cells and a 
reduction in intestinal iron uptake (Dunn et al., 2007). In addition, hepcidin may also play a 
role in negatively regulating divalent metal transporter-1 (DMT1) and duodenal 
cytochrome-b (Dcytb) which are involved in intestinal iron absorption; currently, the 
mechanism and extent of control is unknown (Viatte et al., 2005). 
In situations where iron requirements are increased, during periods of increased 
erythropoietic activity, anemia and hypoxia, the down-regulation of hepcidin expression is 
observed, though again the mechanism is not clear (Dunn et al., 2007; Pak et al., 2006; 
Vokurka et al., 2006)  
4. Hemoglobin  
4.1 Formation of hemoglobin 
Hemoglobin is an allosteric protein with primary function of binding and transporting of 
oxygen in the blood to tissues in order to meet metabolic demands (Baldwin & Chothia, 
1979). Synthesis of Hb involves a series of complex steps occurring in the erythrocytes, 
with production continuing through the early phases of the development and maturation 
of red blood cells (London et al., 1964). The coordinated production of heme, the  
group that mediates reversible oxygenation, and globin, which is responsible for 
protection of the heme group during transport, is required during synthesis (Schwartz et 
al., 1961).  
Fully functional hemoglobin molecules consist of four globular protein subunits, each 
made of a protein chain that is tightly associated with a non-protein heme group (Perutz 
1969, 1976; Perutz et al., 1960). The first step in the synthesis of Hb is the binding of 
succinyl-CoA (formed during the Krebs cycle) with glycine to form a pyrrole molecule. 
Next, four pyrroles combine to form protoporphyrin IX, which subsequently binds with 
iron to form the heme molecule. Each heme molecule then combines with a ribosomal-
derived long polypeptide chain called a globin, forming a globular subunit of hemoglobin 
called a hemoglobin chain. Lastly, four Hb chains are loosely bound to produce a whole 
hemoglobin molecule. The most common form of Hb in adult humans, hemoglobin A, is a 
combination of two alpha and two beta chains arranged as a set of alpha-helix structural 
segments connected in a globin fold arrangement (Forget, 1979).  
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4.2 Reversible oxygenation of hemoglobin: 
Aerobic metabolism is critically dependent on maintaining normal concentrations of Hb, 
and the protein’s ability to combine with oxygen in a reversible manner is essential for 
normal physiological functioning (White & Beaven, 1954). Oxygen binds with Hb in the 
lungs during respiration and is later released in peripheral tissue capillaries in the form of 
molecular oxygen where the gaseous tension of the molecule is much lower than in the 
lungs (Campbell, 1927). This is a cooperative process as the binding affinity of hemoglobin 
for oxygen is increased by the oxygen saturation of the molecule (Perutz, 1980). 
In addition to hemoglobin’s ability to bind oxygen, the protein can also bind with carbon 
dioxide and carbon monoxide, though not in a cooperative manner (Christiansen et al., 1914; 
Hill, 1913). In the presence of carbon monoxide, hemoglobin’s ability to bind with oxygen is 
hampered as both gases compete for the same binding site with a much greater binding 
affinity for carbon monoxide than oxygen (Douglas et al., 1912). As a result, small amounts 
of carbon monoxide can dramatically reduce the oxygen transport in the body and carbon 
monoxide poisoning can ensue (Hill, 1913). On the other hand, hemoglobin’s ability to bind 
carbon dioxide is a necessary process to allow for removal of carbon dioxide and by-
products from the system. Because carbon dioxide occupies a different binding site on the 
hemoglobin molecule, this type of ligand binding is allosteric in nature (Christiansen et al., 
1914; Roughton, 1970). 
4.3 Physiological control of hemoglobin levels: 
The primary factor regulating the production of hemoglobin is tissue oxygenation. The 
peptide hormone erythropoietin (EPO), responding to a feed-back mechanism measuring 
blood oxygenation, is synthesized in times of decreased tissue oxygenation within 24 hours 
of the stimulus (Faura et al., 1969). EPO release triggers erythrocyte production in the bone 
marrow in an effort to achieve homeostasis of tissue oxygenation (Fandrey, 2004). As 
erythrocyte production increases, transferrin from plasma directly from diet and/or from 
iron stores enters the erythroblasts of bone marrow and is delivered to the mitochondria 
where heme synthesis occurs, thus inducing the formation of hemoglobin.  
5. Functional consequences of iron deficiency and anemia 
5.1 Cognitive development 
Over the past three decades a large number of studies on the relationship between iron 
status and cognitive development have been conducted, often with varying results (Lozoff 
& Georgieff 2006). Iron and other micronutrient deficiencies often occur in the context of 
poverty and among individuals and families who are influenced by multiple stressors that 
may interfere with health and well-being, further confounding the issue. While an 
association between IDA and impaired cognitive development has been reported, research 
that takes into consideration the multi-diseased state common among individuals with IDA 
is needed (Lozoff & Georgieff, 2006).  
Experiments employing animal models have demonstrated a key role for iron in brain 
development and function (Beard et al., 2006; Dallman et al., 1975; Felt & Lozoff, 1996; 
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3.4 Regulation of iron homeostasis 
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to be the master regulator of iron homeostasis in humans and other mammals (Ganz, 
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When iron levels are high, several regulatory molecules including hemochromatosis gene 
product, hemojuvelin and transferrin receptor 2, increase hepatic hepcidin expression, 
stimulating downstream molecular pathways. With up-regulation of hepcidin expression, 
iron levels are effectively regulated by binding to FPN1 which is found on the surface of 
iron storage cells. When iron levels are high, hepcidin causes internalization and 
degradation of FPN1, leading to decreased iron release from iron storage cells and a 
reduction in intestinal iron uptake (Dunn et al., 2007). In addition, hepcidin may also play a 
role in negatively regulating divalent metal transporter-1 (DMT1) and duodenal 
cytochrome-b (Dcytb) which are involved in intestinal iron absorption; currently, the 
mechanism and extent of control is unknown (Viatte et al., 2005). 
In situations where iron requirements are increased, during periods of increased 
erythropoietic activity, anemia and hypoxia, the down-regulation of hepcidin expression is 
observed, though again the mechanism is not clear (Dunn et al., 2007; Pak et al., 2006; 
Vokurka et al., 2006)  
4. Hemoglobin  
4.1 Formation of hemoglobin 
Hemoglobin is an allosteric protein with primary function of binding and transporting of 
oxygen in the blood to tissues in order to meet metabolic demands (Baldwin & Chothia, 
1979). Synthesis of Hb involves a series of complex steps occurring in the erythrocytes, 
with production continuing through the early phases of the development and maturation 
of red blood cells (London et al., 1964). The coordinated production of heme, the  
group that mediates reversible oxygenation, and globin, which is responsible for 
protection of the heme group during transport, is required during synthesis (Schwartz et 
al., 1961).  
Fully functional hemoglobin molecules consist of four globular protein subunits, each 
made of a protein chain that is tightly associated with a non-protein heme group (Perutz 
1969, 1976; Perutz et al., 1960). The first step in the synthesis of Hb is the binding of 
succinyl-CoA (formed during the Krebs cycle) with glycine to form a pyrrole molecule. 
Next, four pyrroles combine to form protoporphyrin IX, which subsequently binds with 
iron to form the heme molecule. Each heme molecule then combines with a ribosomal-
derived long polypeptide chain called a globin, forming a globular subunit of hemoglobin 
called a hemoglobin chain. Lastly, four Hb chains are loosely bound to produce a whole 
hemoglobin molecule. The most common form of Hb in adult humans, hemoglobin A, is a 
combination of two alpha and two beta chains arranged as a set of alpha-helix structural 
segments connected in a globin fold arrangement (Forget, 1979).  
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4.2 Reversible oxygenation of hemoglobin: 
Aerobic metabolism is critically dependent on maintaining normal concentrations of Hb, 
and the protein’s ability to combine with oxygen in a reversible manner is essential for 
normal physiological functioning (White & Beaven, 1954). Oxygen binds with Hb in the 
lungs during respiration and is later released in peripheral tissue capillaries in the form of 
molecular oxygen where the gaseous tension of the molecule is much lower than in the 
lungs (Campbell, 1927). This is a cooperative process as the binding affinity of hemoglobin 
for oxygen is increased by the oxygen saturation of the molecule (Perutz, 1980). 
In addition to hemoglobin’s ability to bind oxygen, the protein can also bind with carbon 
dioxide and carbon monoxide, though not in a cooperative manner (Christiansen et al., 1914; 
Hill, 1913). In the presence of carbon monoxide, hemoglobin’s ability to bind with oxygen is 
hampered as both gases compete for the same binding site with a much greater binding 
affinity for carbon monoxide than oxygen (Douglas et al., 1912). As a result, small amounts 
of carbon monoxide can dramatically reduce the oxygen transport in the body and carbon 
monoxide poisoning can ensue (Hill, 1913). On the other hand, hemoglobin’s ability to bind 
carbon dioxide is a necessary process to allow for removal of carbon dioxide and by-
products from the system. Because carbon dioxide occupies a different binding site on the 
hemoglobin molecule, this type of ligand binding is allosteric in nature (Christiansen et al., 
1914; Roughton, 1970). 
4.3 Physiological control of hemoglobin levels: 
The primary factor regulating the production of hemoglobin is tissue oxygenation. The 
peptide hormone erythropoietin (EPO), responding to a feed-back mechanism measuring 
blood oxygenation, is synthesized in times of decreased tissue oxygenation within 24 hours 
of the stimulus (Faura et al., 1969). EPO release triggers erythrocyte production in the bone 
marrow in an effort to achieve homeostasis of tissue oxygenation (Fandrey, 2004). As 
erythrocyte production increases, transferrin from plasma directly from diet and/or from 
iron stores enters the erythroblasts of bone marrow and is delivered to the mitochondria 
where heme synthesis occurs, thus inducing the formation of hemoglobin.  
5. Functional consequences of iron deficiency and anemia 
5.1 Cognitive development 
Over the past three decades a large number of studies on the relationship between iron 
status and cognitive development have been conducted, often with varying results (Lozoff 
& Georgieff 2006). Iron and other micronutrient deficiencies often occur in the context of 
poverty and among individuals and families who are influenced by multiple stressors that 
may interfere with health and well-being, further confounding the issue. While an 
association between IDA and impaired cognitive development has been reported, research 
that takes into consideration the multi-diseased state common among individuals with IDA 
is needed (Lozoff & Georgieff, 2006).  
Experiments employing animal models have demonstrated a key role for iron in brain 
development and function (Beard et al., 2006; Dallman et al., 1975; Felt & Lozoff, 1996; 
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Jorgenson et al., 2005; Nelson et al., 2002). Iron-containing enzymes and hemoproteins are 
necessary in many important development processes such as myelination, dendritogenesis, 
synaptogenesis, and neurotransmission. Iron deficiency disrupts these processes in a 
regionally specific manner depending on brain development at the time of deficiency. This 
disruption may lead to a variety of neurodevelopmental effects that usually do not respond 
to iron replenishment (Lozoff & Georgieff, 2006).  
In humans, the majority of research has focused on developmental and behavioural effects 
of ID on infancy during 6-24 months of age. Delayed psychomotor development, cognitive 
performance, and social/emotional functioning have been observed in numerous studies 
(Grantham-McGregor & Ani, 2001; Lozoff& Georgieff, 2006).  
A number of observational studies have found that children who suffered from IDA early in 
life continued to demonstrate lower academic performance during their school-age years. In 
Costa Rican children born at term and free of health problems other than moderate iron 
deficiency, persistence of motor differences, more grade repetition, anxiety, depression, and 
other social problems have been observed (Lozoff et al., 2000). When compared with 
children that were not anemic during infancy, these children achieved lower scores on 
intelligence and other cognitive performance tests upon entry into school, despite 
controlling for socioeconomic factors that may have acted as confounders (Lozoff et al., 
1991). A recent meta-analysis estimated the long term effects on IQ to be 1.73 points lower 
for each 10 g/L decrease in hemoglobin during infancy (Stoltzfus et al., 2005).  
The detrimental effects of iron deficiency have been ameliorated with iron supplementation. 
Randomized controlled trials of iron supplementation consistently show improvement in 
motor (Moffatt et al., 1994), social-emotional (Williams et al., 1999), and language outcomes 
(Stoltzfus et al. 2001).  
5.2 Resistance to infection 
The role that iron deficiency plays in decreased immune response has been reported in both 
animal and human studies (Dallman, 1987). Leukocytes (neutrophils, in particular) appear 
to have a reduced capacity to ingest and neutralize microorganisms (Chandra, 1973; 
Macdougall et al. 1975; Srikantia et al. 1976), while mitogen-stimulated lymphocytes exhibit 
a decreased ability to replicate (Neckers & Cossman, 1983). Additionally, depressed T-cell 
responses have been widely documented, with the depression proportional to the  severity 
of iron deficiency (Chandra, 1973; Srikantia et al., 1976, Bagchi et al., 1980; Prema et al., 
1982). Treatment regimens such as iron supplementation and food fortification programs 
have been reported to reduce morbidity from infectious disease, further implicating a role 
for iron in immune response (Walter et al., 1997).   
5.3 Working capacity  
Anemia has long been known to impair work performance, endurance, and productivity 
(Walker 1998). Studies in developing countries in South America (Walker, 1998; Desai et al., 
1984), East Africa (Davies, 1973; Davies &Haaren, 1973), and Sri Lanka (Gardner et al., 1977) 
report a linear relationship between ID and work capacity. Iron supplementation studies 
carried out on Indonesian rubber tappers (Basta et al., 1979), and Sri Lankan (Gardner et al., 
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1977) and Indonesian tea pickers (Basta et al., 1979) note significant gains in productivity 
following treatment of those individuals with significant IDA. One investigation conducted 
in China revealed that a rise of 10 g/L in Hb level was associated with an improvement in 
production efficiency of 14% in response to iron supplementation to treat IDA (Li et al., 
1994). 
A meta-analysis of 29 studies demonstrated a strong causal effect of severe and moderate 
IDA on aerobic work capacity in animals and humans (Haas & Brownlie, 2001). The 
presumed mechanism for this effect is reduced oxygen transport and reduced cellular 
oxidative capacity due to tissue iron deficiency (Haas & Brownlie, 2001; Davies et al., 1984). 
In laboratory and field trials, iron deficiency and IDA at all levels of severity also appears to 
affect energetic efficiency (Zhu & Haas 1997; Li et al., 1994) and endurance capacity 
(Edgerton et al., 1972; Rowland et al., 1988). Conversely, iron supplementation has been 
shown to improve endurance and aerobic work capacity in iron-depleted humans (Hinton et 
al., 2000; Brownlie et al., 2004; Brownlie et al., 2002). 
5.4 Maternal mortality 
Two meta-analyses drawing upon the same published studies reported on an association 
between ID and maternal mortality. In a 2001 paper, Brabin et al. suggested that there is 
an association between a higher risk of maternal mortality with severe anemia (Brabin et 
al., 2001). Stoltzfus and colleagues, using a methodologically-different analysis, 
corroborated these findings, suggesting that the risk of maternal mortality increased with 
decreasing hemoglobin levels, though not in a linear manner. Causal evidence for the role 
that mild or moderate anemia may play in maternal mortality is lacking (Stoltzfus et al., 
2005).   
In spite of these findings, a causal link between iron deficiency and mortality related to 
pregnancy and childbirth (ie. maternal mortality) remains unclear due to methodological 
concerns. To date there have been no large scale, placebo-controlled, prospective 
interventions to test the effect of iron supplementation on maternal mortality as large 
sample sizes would be required and it is considered unethical to withhold treatment from 
pregnant, anemic women. In addition, research in this field often does not take into 
consideration other possible causes of anemia and maternal mortality, such as concurrent 
micronutrient deficiencies, infectious disease, and other related conditions (Allen, 2000; 
Rush, 2000). For this reason, better observational data that controls for confounders are 
required (Stoltzfus et al., 2005). 
5.5 Preterm delivery and growth  
A negative correlation between maternal IDA with length of gestation is well established 
(Allen, 2001). There are currently two widely accepted biological mechanisms that explain 
this phenomenon (Allen, 2001). One theory suggests that anemia (leading to hypoxia)  
and iron deficiency (which increases serum nor-epinephrine concentrations) induces 
maternal and fetal stress, ultimately leading to stimulation of the production of 
corticotropin-releasing hormone (CRH) (Allen, 2001; Dallman, 1987; Emanuel et al., 1994). 
Elevated CRH is a major risk factor for preterm labour, pregnancy-induced hypertension, 
eclampsia, premature rupture of the membranes, maternal infection (leading to yet more 
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Jorgenson et al., 2005; Nelson et al., 2002). Iron-containing enzymes and hemoproteins are 
necessary in many important development processes such as myelination, dendritogenesis, 
synaptogenesis, and neurotransmission. Iron deficiency disrupts these processes in a 
regionally specific manner depending on brain development at the time of deficiency. This 
disruption may lead to a variety of neurodevelopmental effects that usually do not respond 
to iron replenishment (Lozoff & Georgieff, 2006).  
In humans, the majority of research has focused on developmental and behavioural effects 
of ID on infancy during 6-24 months of age. Delayed psychomotor development, cognitive 
performance, and social/emotional functioning have been observed in numerous studies 
(Grantham-McGregor & Ani, 2001; Lozoff& Georgieff, 2006).  
A number of observational studies have found that children who suffered from IDA early in 
life continued to demonstrate lower academic performance during their school-age years. In 
Costa Rican children born at term and free of health problems other than moderate iron 
deficiency, persistence of motor differences, more grade repetition, anxiety, depression, and 
other social problems have been observed (Lozoff et al., 2000). When compared with 
children that were not anemic during infancy, these children achieved lower scores on 
intelligence and other cognitive performance tests upon entry into school, despite 
controlling for socioeconomic factors that may have acted as confounders (Lozoff et al., 
1991). A recent meta-analysis estimated the long term effects on IQ to be 1.73 points lower 
for each 10 g/L decrease in hemoglobin during infancy (Stoltzfus et al., 2005).  
The detrimental effects of iron deficiency have been ameliorated with iron supplementation. 
Randomized controlled trials of iron supplementation consistently show improvement in 
motor (Moffatt et al., 1994), social-emotional (Williams et al., 1999), and language outcomes 
(Stoltzfus et al. 2001).  
5.2 Resistance to infection 
The role that iron deficiency plays in decreased immune response has been reported in both 
animal and human studies (Dallman, 1987). Leukocytes (neutrophils, in particular) appear 
to have a reduced capacity to ingest and neutralize microorganisms (Chandra, 1973; 
Macdougall et al. 1975; Srikantia et al. 1976), while mitogen-stimulated lymphocytes exhibit 
a decreased ability to replicate (Neckers & Cossman, 1983). Additionally, depressed T-cell 
responses have been widely documented, with the depression proportional to the  severity 
of iron deficiency (Chandra, 1973; Srikantia et al., 1976, Bagchi et al., 1980; Prema et al., 
1982). Treatment regimens such as iron supplementation and food fortification programs 
have been reported to reduce morbidity from infectious disease, further implicating a role 
for iron in immune response (Walter et al., 1997).   
5.3 Working capacity  
Anemia has long been known to impair work performance, endurance, and productivity 
(Walker 1998). Studies in developing countries in South America (Walker, 1998; Desai et al., 
1984), East Africa (Davies, 1973; Davies &Haaren, 1973), and Sri Lanka (Gardner et al., 1977) 
report a linear relationship between ID and work capacity. Iron supplementation studies 
carried out on Indonesian rubber tappers (Basta et al., 1979), and Sri Lankan (Gardner et al., 
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1977) and Indonesian tea pickers (Basta et al., 1979) note significant gains in productivity 
following treatment of those individuals with significant IDA. One investigation conducted 
in China revealed that a rise of 10 g/L in Hb level was associated with an improvement in 
production efficiency of 14% in response to iron supplementation to treat IDA (Li et al., 
1994). 
A meta-analysis of 29 studies demonstrated a strong causal effect of severe and moderate 
IDA on aerobic work capacity in animals and humans (Haas & Brownlie, 2001). The 
presumed mechanism for this effect is reduced oxygen transport and reduced cellular 
oxidative capacity due to tissue iron deficiency (Haas & Brownlie, 2001; Davies et al., 1984). 
In laboratory and field trials, iron deficiency and IDA at all levels of severity also appears to 
affect energetic efficiency (Zhu & Haas 1997; Li et al., 1994) and endurance capacity 
(Edgerton et al., 1972; Rowland et al., 1988). Conversely, iron supplementation has been 
shown to improve endurance and aerobic work capacity in iron-depleted humans (Hinton et 
al., 2000; Brownlie et al., 2004; Brownlie et al., 2002). 
5.4 Maternal mortality 
Two meta-analyses drawing upon the same published studies reported on an association 
between ID and maternal mortality. In a 2001 paper, Brabin et al. suggested that there is 
an association between a higher risk of maternal mortality with severe anemia (Brabin et 
al., 2001). Stoltzfus and colleagues, using a methodologically-different analysis, 
corroborated these findings, suggesting that the risk of maternal mortality increased with 
decreasing hemoglobin levels, though not in a linear manner. Causal evidence for the role 
that mild or moderate anemia may play in maternal mortality is lacking (Stoltzfus et al., 
2005).   
In spite of these findings, a causal link between iron deficiency and mortality related to 
pregnancy and childbirth (ie. maternal mortality) remains unclear due to methodological 
concerns. To date there have been no large scale, placebo-controlled, prospective 
interventions to test the effect of iron supplementation on maternal mortality as large 
sample sizes would be required and it is considered unethical to withhold treatment from 
pregnant, anemic women. In addition, research in this field often does not take into 
consideration other possible causes of anemia and maternal mortality, such as concurrent 
micronutrient deficiencies, infectious disease, and other related conditions (Allen, 2000; 
Rush, 2000). For this reason, better observational data that controls for confounders are 
required (Stoltzfus et al., 2005). 
5.5 Preterm delivery and growth  
A negative correlation between maternal IDA with length of gestation is well established 
(Allen, 2001). There are currently two widely accepted biological mechanisms that explain 
this phenomenon (Allen, 2001). One theory suggests that anemia (leading to hypoxia)  
and iron deficiency (which increases serum nor-epinephrine concentrations) induces 
maternal and fetal stress, ultimately leading to stimulation of the production of 
corticotropin-releasing hormone (CRH) (Allen, 2001; Dallman, 1987; Emanuel et al., 1994). 
Elevated CRH is a major risk factor for preterm labour, pregnancy-induced hypertension, 
eclampsia, premature rupture of the membranes, maternal infection (leading to yet more 
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CRH synthesis), and increased fetal cortisol production (inhibiting longitudinal growth  
of the fetus) (Allen, 2001; Falkenberg et al., 1999; Lin et al., 1998; Linton et al., 1990, 
McLean et al., 1995). A second theory suggests that iron deficiency may increase oxidative 
damage to erythrocytes and the fetal-placental unit (Cester et al., 1994; Poranen et al., 
1996).  
Maternal iron deficiency with and without anemia is also strongly associated with low birth 
weight and impeded growth (Stoltzfus et al., 2005). While full-term infants are normally 
born with sufficient iron stores, infants have high iron requirements and the diets offered to 
infants in the developing world are frequently inadequate in terms of satisfying the iron 
requirements for growth. Although iron in breast milk is highly bioavailable, maternal iron 
reserves are depleted after 4-6 months of feeding, thus infants commonly develop iron 
deficiency and IDA if the diet is not altered to include a readily absorbable source of iron 
(Friel et al., 1990).  
Iron supplementation of infants appears to ameliorate the problem of impaired growth. A 
number of studies conducted in Indonesia (Soewondo et al., 1989), Kenya (Latham et al. 
1990), Bangladesh (Briend et al., 1990), and the United Kingdom (Aukett et al., 1986) provide 
evidence that iron supplementation of iron deficient children leads to improved growth. 
5.6 Heavy-metal absorption 
An important consequence of iron deficiency is an enhanced ability for heavy-metal uptake, 
leading to heavy-metal poisoning. Iron deficiency is strongly associated with an increased 
absorption capacity that is not specific to iron, resulting in the uptake of divalent heavy-
metals like lead, cadmium, mercury and arsenic from the environment (Peraza et al., 1998). 
Heavy metal poisoning is a particular concern in children, as impaired cognitive 
development and irreversible physical and mental disability can result (Byers, 1959; Cebrian 
et al., 1983). For this reason, prevention of iron deficiency is important, predominantly in 
areas where exposure to heavy metals is common.  
6. Prevalence and epidemiology  
6.1 Prevalence of iron deficiency and iron deficiency anemia  
Globally, nearly two billion people are affected by anemia (McLean et al., 2008). The 
majority of those affected live in developing countries where the problem is exacerbated by 
limited access to inadequate resources and appropriate treatment (Baltussen et al., 2004). 
IDA is unique in that it is the only nutrient deficiency which is significantly prevalent in 
virtually all industrialized nations as well. Currently there are no figures specifically for 
IDA, but it is widely accepted that approximately 50% of all cases of anemia are caused by 
iron deficiency (McLean et al., 2008; DeMaeyer & Adiels-Tegman, 1985). While the extent to 
which anemia is a problem in women and children has been widely documented, data on 
the prevalence of anemia in adolescents, men, and the elderly are scarce. 
The level of hemoglobin concentration in the blood is used as an indicator to estimate the 
prevalence of anemia. Hemoglobin values that indicate the threshold for anemia have been 
published by the WHO and are widely accepted (Table 1) (McLean et al., 2008). 
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Age or gender group Hemoglobin (g/L) 
6 – 59 months 110 
5 – 11 years 115 
12 – 14 years 120 
Non-pregnant women (>15 years) 120 
Pregnant women  110 
Males (>15 years) 130 
Table 1. Hemoglobin levels below which anemia is present in a population.  
Source: McLean et al., 2008. 
Worldwide, the prevalence of anemia is highest in non-industrialized nations where 
prevalence is three to four times higher than developed countries (Table 2). Africa, Eastern 
Europe and the Western Pacific have a large burden of disease, with over 1 billion people in 
these three regions estimated to be anemic (McLean et al., 2008). That said, anemia in South-
East Asia is more prevalent than any other region in the world, with nearly 800 million 
affected. While the prevalence of IDA among women and children in the developed world is 
lower when compared to the developing world, a high prevalence is still reported in high-risk 
groups, including preschool-aged children and pregnant women.  
 

















































































































Table 2. Anemia prevalence and number of individuals affected in pre-school aged children, 
pregnant women, and non-pregnant women by WHO region.  
Source: (McLean et al., 2008). 
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CRH synthesis), and increased fetal cortisol production (inhibiting longitudinal growth  
of the fetus) (Allen, 2001; Falkenberg et al., 1999; Lin et al., 1998; Linton et al., 1990, 
McLean et al., 1995). A second theory suggests that iron deficiency may increase oxidative 
damage to erythrocytes and the fetal-placental unit (Cester et al., 1994; Poranen et al., 
1996).  
Maternal iron deficiency with and without anemia is also strongly associated with low birth 
weight and impeded growth (Stoltzfus et al., 2005). While full-term infants are normally 
born with sufficient iron stores, infants have high iron requirements and the diets offered to 
infants in the developing world are frequently inadequate in terms of satisfying the iron 
requirements for growth. Although iron in breast milk is highly bioavailable, maternal iron 
reserves are depleted after 4-6 months of feeding, thus infants commonly develop iron 
deficiency and IDA if the diet is not altered to include a readily absorbable source of iron 
(Friel et al., 1990).  
Iron supplementation of infants appears to ameliorate the problem of impaired growth. A 
number of studies conducted in Indonesia (Soewondo et al., 1989), Kenya (Latham et al. 
1990), Bangladesh (Briend et al., 1990), and the United Kingdom (Aukett et al., 1986) provide 
evidence that iron supplementation of iron deficient children leads to improved growth. 
5.6 Heavy-metal absorption 
An important consequence of iron deficiency is an enhanced ability for heavy-metal uptake, 
leading to heavy-metal poisoning. Iron deficiency is strongly associated with an increased 
absorption capacity that is not specific to iron, resulting in the uptake of divalent heavy-
metals like lead, cadmium, mercury and arsenic from the environment (Peraza et al., 1998). 
Heavy metal poisoning is a particular concern in children, as impaired cognitive 
development and irreversible physical and mental disability can result (Byers, 1959; Cebrian 
et al., 1983). For this reason, prevention of iron deficiency is important, predominantly in 
areas where exposure to heavy metals is common.  
6. Prevalence and epidemiology  
6.1 Prevalence of iron deficiency and iron deficiency anemia  
Globally, nearly two billion people are affected by anemia (McLean et al., 2008). The 
majority of those affected live in developing countries where the problem is exacerbated by 
limited access to inadequate resources and appropriate treatment (Baltussen et al., 2004). 
IDA is unique in that it is the only nutrient deficiency which is significantly prevalent in 
virtually all industrialized nations as well. Currently there are no figures specifically for 
IDA, but it is widely accepted that approximately 50% of all cases of anemia are caused by 
iron deficiency (McLean et al., 2008; DeMaeyer & Adiels-Tegman, 1985). While the extent to 
which anemia is a problem in women and children has been widely documented, data on 
the prevalence of anemia in adolescents, men, and the elderly are scarce. 
The level of hemoglobin concentration in the blood is used as an indicator to estimate the 
prevalence of anemia. Hemoglobin values that indicate the threshold for anemia have been 
published by the WHO and are widely accepted (Table 1) (McLean et al., 2008). 
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Age or gender group Hemoglobin (g/L) 
6 – 59 months 110 
5 – 11 years 115 
12 – 14 years 120 
Non-pregnant women (>15 years) 120 
Pregnant women  110 
Males (>15 years) 130 
Table 1. Hemoglobin levels below which anemia is present in a population.  
Source: McLean et al., 2008. 
Worldwide, the prevalence of anemia is highest in non-industrialized nations where 
prevalence is three to four times higher than developed countries (Table 2). Africa, Eastern 
Europe and the Western Pacific have a large burden of disease, with over 1 billion people in 
these three regions estimated to be anemic (McLean et al., 2008). That said, anemia in South-
East Asia is more prevalent than any other region in the world, with nearly 800 million 
affected. While the prevalence of IDA among women and children in the developed world is 
lower when compared to the developing world, a high prevalence is still reported in high-risk 
groups, including preschool-aged children and pregnant women.  
 

















































































































Table 2. Anemia prevalence and number of individuals affected in pre-school aged children, 
pregnant women, and non-pregnant women by WHO region.  
Source: (McLean et al., 2008). 
 
Public Health – Methodology, Environmental and Systems Issues 118 
Women and children are hardest hit by this nutritional disorder due to increased iron 
requirements during periods of growth as well as during menstruation and pregnancy. 
Nearly 40% of preschool children and women (aged 15-59 years) and more than 50% of all 
pregnant women in developing countries estimated to be anemic (McLean et al., 2008). 
6.2 Etiology of iron deficiency and iron deficiency anemia 
The prevalence of ID and IDA varies greatly from population to population according to a 
variety of host and environmental factors. The etiology of anemia is multifaceted and often 
several factors are at play in an anemic individual. Nutritional anemia as a result of iron 
deficiency is the most common cause of anemia worldwide, with approximately 50% of all 
cases attributed to a lack of iron in the diet. A number of host and environmental factors are 
associated with iron deficiency, and in more severe forms contribute to IDA as well. These 
include:  
1. Inadequate dietary iron intake: Diets low in iron or diets low in adequate amounts of 
bioavailable iron are a major cause of IDA, particularly in non-industrialized countries. 
Typically, high levels of IDA are also observed in old age when dietary quality and quantity 
deteriorates (Clark, 2008; Fiatarone-Singh et al., 2000). 
2. Menstruation and pregnancy: Blood losses associated with menstruation and pregnancy 
are common causes of ID and IDA. Typically non-menstruating women lose about 1 mg 
of iron per day, while menstruating women lose an additional 10 mg of iron per day 
during menses. Pregnancy is associated with an iron loss of approximately 1000 mg in a 
55kg woman (Bothwell, 1995). 
3. Infectious disease: In the developing world common infections which may be both 
chronic and recurrent are associated with blood loss leading to iron deficiency, and 
ultimately to IDA. Hemolytic malaria and parasitic infections such as hookworm, 
trichuriasis, amoebiasis, and schistosomiasis are particularly common diseases that 
contribute to the depletion of iron stores and often result in IDA (Oppenheimer, 2001). 
4. Interactions with medication: Several pharmacological agents can interfere with iron 
uptake and/or transport leading to iron loss or defective absorption. These include H2 
blockers, proton pump inhibitors, aspirin or non-steroidal anti-inflammatory drug use 
(Rockey & Cello, 1993). 
5. Gastrointestinal conditions: Both acute and chronic gastrointestinal illness is associated 
with IDA and is an important consideration in clinical diagnosis of the condition. 
Duodenal or gastric ulcers, carcinoma, polyps, irritable bowel disease, erosive gastritis, 
celiac disease, altered hepatic function for any number of reasons, and/or compromised 
protein status may lead to IDA (Clark, 2008). 
6. Periods of growth: Iron deficiency and IDA are particularly prevalent during peak 
periods of growth. Though full-term infants are normally born with adequate iron 
stores, if complementary foods containing iron are not introduced to the diet after six 
months of age then an infant is at risk of developing ID, and ultimately IDA. Iron 
requirements on a body weight basis are proportional to growth velocity, thus iron 
deficiency and IDA are common in preschool years and during puberty (McLean et al., 
2008; Tolentino & Friedman 2007; Turner et al., 2003). 
7. Socioeconomic status: Iron deficiency and IDA are most common among groups of low 
socioeconomic status for a number of reasons, including but not limited to: 
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malnutrition, poor education regarding health and hygiene, and greater presence of 
concomitant disease when compared to populations of higher socioeconomic status 
(Bhargava et al., 2001; Thankachan et al., 2007).  
7. Prevention and control 
Interventions to control iron deficiency and associated anemia are available, affordable, and 
sustainable (McLean et al., 2008, ACC/SCN, 2000). Food-based approaches are the most 
desirable and sustainable method of preventing IDA, with dietary improvement representing 
the most cost-effective and sustainable option. Advancements in the fortification of food 
staples and compliment have also shown promise. In addition, supplementation using 
multivitamins and vitamin complexes containing high levels of iron are accessible, though 
often at a higher cost than other preventive and treatment methods.  
7.1 Dietary improvement 
Efforts towards promoting the availability of, and access to iron-rich foods are a key 
prevention technique. Foods containing high levels of iron include: meat and organs from 
cattle, fish, and poultry, as well as non-animal foods such as legumes and green leafy 
vegetables (WHO, 2001).  
As overall meal composition is as important as total iron content of a meal, it is important 
to promote the consumption of foods that enhances iron absorption and while limiting the 
consumption of foods that act as inhibitors (Layrisse et al. 1969; Layrisse & Martinez-
Torres, 1968; Hallberg et al., 1986; Hallberg et al. 1991; Hallberg et al., 1989). Foods that 
enhance absorption of iron typically contain high levels of vitamins A, vitamin C, and 
folic acid; this includes various fruits, vegetables, and tubers. Conversely, phytates, found 
in cereal grains, tannins and other polyphenols found primarily in tea and coffee, and 
calcium from milk and milk products should be avoided where possible to limit the 
inhibition of iron absorption. 
Typically, diets of individuals in the developing world do not provide adequate iron. In a 
typical South-East Asian diet consisting of rice, vegetables and spices, iron absorption was 
reported to be inadequate (Hallberg et al. 1974; Hallberg et al. 1977). Even with the 
addition of fruit, meat and fish to these simple meals, iron absorption remained lower 
than the estimated requirement. These findings would suggest that individuals 
consuming such a diet could only maintain their iron balance in a state of iron deficiency, 
and would therefore greatly benefit from ID and IDA treatment and prevention programs 
(Hallberg et al., 1974). 
7.2 Iron fortification  
Iron fortification involves the addition of iron to an appropriate food vehicle that is 
distributed widely to the general population. Fortified flour and other cereals have 
historically been the most commonly used (Baltussen et al., 2004; Ramakrishnan & Yip 
2002). Research into self-fortification through plant breeding is also gaining momentum 
and in the future may have a great impact on improving nutritional status (Lucca et al., 
2001).  
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Women and children are hardest hit by this nutritional disorder due to increased iron 
requirements during periods of growth as well as during menstruation and pregnancy. 
Nearly 40% of preschool children and women (aged 15-59 years) and more than 50% of all 
pregnant women in developing countries estimated to be anemic (McLean et al., 2008). 
6.2 Etiology of iron deficiency and iron deficiency anemia 
The prevalence of ID and IDA varies greatly from population to population according to a 
variety of host and environmental factors. The etiology of anemia is multifaceted and often 
several factors are at play in an anemic individual. Nutritional anemia as a result of iron 
deficiency is the most common cause of anemia worldwide, with approximately 50% of all 
cases attributed to a lack of iron in the diet. A number of host and environmental factors are 
associated with iron deficiency, and in more severe forms contribute to IDA as well. These 
include:  
1. Inadequate dietary iron intake: Diets low in iron or diets low in adequate amounts of 
bioavailable iron are a major cause of IDA, particularly in non-industrialized countries. 
Typically, high levels of IDA are also observed in old age when dietary quality and quantity 
deteriorates (Clark, 2008; Fiatarone-Singh et al., 2000). 
2. Menstruation and pregnancy: Blood losses associated with menstruation and pregnancy 
are common causes of ID and IDA. Typically non-menstruating women lose about 1 mg 
of iron per day, while menstruating women lose an additional 10 mg of iron per day 
during menses. Pregnancy is associated with an iron loss of approximately 1000 mg in a 
55kg woman (Bothwell, 1995). 
3. Infectious disease: In the developing world common infections which may be both 
chronic and recurrent are associated with blood loss leading to iron deficiency, and 
ultimately to IDA. Hemolytic malaria and parasitic infections such as hookworm, 
trichuriasis, amoebiasis, and schistosomiasis are particularly common diseases that 
contribute to the depletion of iron stores and often result in IDA (Oppenheimer, 2001). 
4. Interactions with medication: Several pharmacological agents can interfere with iron 
uptake and/or transport leading to iron loss or defective absorption. These include H2 
blockers, proton pump inhibitors, aspirin or non-steroidal anti-inflammatory drug use 
(Rockey & Cello, 1993). 
5. Gastrointestinal conditions: Both acute and chronic gastrointestinal illness is associated 
with IDA and is an important consideration in clinical diagnosis of the condition. 
Duodenal or gastric ulcers, carcinoma, polyps, irritable bowel disease, erosive gastritis, 
celiac disease, altered hepatic function for any number of reasons, and/or compromised 
protein status may lead to IDA (Clark, 2008). 
6. Periods of growth: Iron deficiency and IDA are particularly prevalent during peak 
periods of growth. Though full-term infants are normally born with adequate iron 
stores, if complementary foods containing iron are not introduced to the diet after six 
months of age then an infant is at risk of developing ID, and ultimately IDA. Iron 
requirements on a body weight basis are proportional to growth velocity, thus iron 
deficiency and IDA are common in preschool years and during puberty (McLean et al., 
2008; Tolentino & Friedman 2007; Turner et al., 2003). 
7. Socioeconomic status: Iron deficiency and IDA are most common among groups of low 
socioeconomic status for a number of reasons, including but not limited to: 
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malnutrition, poor education regarding health and hygiene, and greater presence of 
concomitant disease when compared to populations of higher socioeconomic status 
(Bhargava et al., 2001; Thankachan et al., 2007).  
7. Prevention and control 
Interventions to control iron deficiency and associated anemia are available, affordable, and 
sustainable (McLean et al., 2008, ACC/SCN, 2000). Food-based approaches are the most 
desirable and sustainable method of preventing IDA, with dietary improvement representing 
the most cost-effective and sustainable option. Advancements in the fortification of food 
staples and compliment have also shown promise. In addition, supplementation using 
multivitamins and vitamin complexes containing high levels of iron are accessible, though 
often at a higher cost than other preventive and treatment methods.  
7.1 Dietary improvement 
Efforts towards promoting the availability of, and access to iron-rich foods are a key 
prevention technique. Foods containing high levels of iron include: meat and organs from 
cattle, fish, and poultry, as well as non-animal foods such as legumes and green leafy 
vegetables (WHO, 2001).  
As overall meal composition is as important as total iron content of a meal, it is important 
to promote the consumption of foods that enhances iron absorption and while limiting the 
consumption of foods that act as inhibitors (Layrisse et al. 1969; Layrisse & Martinez-
Torres, 1968; Hallberg et al., 1986; Hallberg et al. 1991; Hallberg et al., 1989). Foods that 
enhance absorption of iron typically contain high levels of vitamins A, vitamin C, and 
folic acid; this includes various fruits, vegetables, and tubers. Conversely, phytates, found 
in cereal grains, tannins and other polyphenols found primarily in tea and coffee, and 
calcium from milk and milk products should be avoided where possible to limit the 
inhibition of iron absorption. 
Typically, diets of individuals in the developing world do not provide adequate iron. In a 
typical South-East Asian diet consisting of rice, vegetables and spices, iron absorption was 
reported to be inadequate (Hallberg et al. 1974; Hallberg et al. 1977). Even with the 
addition of fruit, meat and fish to these simple meals, iron absorption remained lower 
than the estimated requirement. These findings would suggest that individuals 
consuming such a diet could only maintain their iron balance in a state of iron deficiency, 
and would therefore greatly benefit from ID and IDA treatment and prevention programs 
(Hallberg et al., 1974). 
7.2 Iron fortification  
Iron fortification involves the addition of iron to an appropriate food vehicle that is 
distributed widely to the general population. Fortified flour and other cereals have 
historically been the most commonly used (Baltussen et al., 2004; Ramakrishnan & Yip 
2002). Research into self-fortification through plant breeding is also gaining momentum 
and in the future may have a great impact on improving nutritional status (Lucca et al., 
2001).  
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7.2.1 Fortification in the developed world 
Fortification has played an important role in the reduction of ID in the developed world 
since the latter half of the 20th century (Ramakrishnan & Yip 2002; Rees et al., 1985). The 
addition of elemental iron powder to flour and other cereals has since been commonplace, 
with levels of enrichment ranging from approximately 30 to 60 μg/g (Baltussen et al., 2004). 
In Canada, for example, it has been mandatory to enrich all white flours, enriched pastas, 
enriched precooked rice and certain substitute foods since 1976 (Guggenheim, 1995). 
As the demand for processed foods has increased over the past 50 years, vitamins and 
minerals have slowly been added to an increasing array of foods. Ready-to-eat cereals in 
particular play an important role in daily iron intake in the Western world. Research in the 
last decade suggests that approximately 40% of total iron intake in women of reproductive 
age from the U.S. (Ramakrishnan& Yip, 2002), and approximately 78% of total iron intake in 
German children aged 2 to 13 years (Guggenheim, 1995) can be attributed to ready-to-eat 
cereals.  
The fortification of infant formulas and foods provides particularly convincing evidence for 
the benefits of food fortification (Walter et al., 1993). Following the introduction of 
fortification guidelines in the U.S. in the late 1960’s a clear reduction in IDA among infants 
and young children was noted (Yip et al., 1987).  
7.2.2 Fortification in the developing world 
In developing countries a much lower consumption of food from animal sources is observed 
and typically the overall nutritional value of the diet is lower when compared to developed 
nations (Yip & Ramakrishnan, 2002). In addition, both a high relative cost and a decreased 
availability of fortified products like cereal flours, ready-to-eat cereals, and infant formula 
leads to an overall decreased use of industry-prepared food that would otherwise benefit 
the population (Yip & Ramakrishnan, 2002). Thus, the relative absence of fortified food 
products from diets in developing nations could at least partly explain the high prevalence 
of iron deficiency and IDA and why current fortification practices have not ameliorated the 
situation. Research into fortifiable products that are culturally acceptable and desirable in 
developing nations should be conducted.  
7.3 Iron supplementation 
Iron supplementation is the most common and cost-effective strategy used to control ID and 
IDA in the developing world and is used as both a preventive measure and a treatment 
option (Baltussen et al., 2004). World Health Organization guidelines suggest that iron 
supplementation should include administration of 60 mg of iron daily with a dose of 400 μg 
of folic acid for women of reproductive age, 30 mg of iron and 250 μg of folic acid for school-
aged children, and approximately 2 mg/kg body weight per day for preschool-aged 
children (McLean et al., 2008). Weekly iron supplementation also exists, though is 
considered to be a less effective treatment option and requires additional research and 
evaluation (ACC/SCN, 2001).  
The majority of supplementation studies to date have examined a variety of treatments in 
women of reproductive age, as infants, preschool and school-aged children (Preziosi et al., 
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1997; Faqih et al., 2006, Mumtaz et al. 2000; Menendez et al. 1997; Suharno et al. 1993; 
Schultink et al. 1995; Berger et al. 1997; Viteri, 1997). It is becoming increasingly clear that 
a main target group for iron supplementation in the developing world should be all 
women of reproductive age, regardless of pregnancy status at the time, thereby ensuring 
adequate iron reserves for both the mother and fetus during pregnancy and lactation  
(Yip & Ramakrishnan, 2002). Of concern is the relative cost of iron supplements in 
developing nations, coupled with issues surrounding delivery to infants and children. 
Other problems with iron supplementation include: undesirable side effects (including 
gastrointestinal irritation, black stools, and constipation); poor adherence to treatment 
guidelines; awareness and motivation of the target group to take supplements, often due 
to inadequate health and nutrition education; quality and packaging of iron supplements; 
and risk of iron overload if supplementation guidelines are not followed correctly (WHO, 
2001).  
7.4 The use of adventitious iron sources 
Research conducted in the latter half of the 20th century has reported on the use of iron pots 
for cooking as an innovative way to reduce IDA, with the first study conducted in 1986 
(Martinez & Vannucchi, 1986). Wistar rats fed a basal diet low in iron though cooked in an 
iron pot demonstrated comparable hemoglobin, hematocrit, protoporphyrin, serum iron, 
and transferrin saturation levels to those rats fed a complete diet, thus implicating the iron 
pot as an adventitious source of iron.  
Since this time several studies have examined this supplementation technique in humans 
with similar findings. Experiments conducted on Ethiopian children aged 2-5 years and 
pre-term infants (between months 4 and 12) from Brazil reported that cooking food in iron 
pots led to lower rates of anemia than children whose food was cooked in non-iron pots 
(Adish et al. 1999; Borigato, Martinez 1998). Significantly improved hematologic values 
between iron pot and non-iron pot groups were noted, including increased hemoglobin, 
hematocrit, mean corpuscular volume, free erythrocyte protoporphyrin, and serum 
ferritin. In addition, the Ethiopian study indicated moderate height and weight gains in 
children assigned to treatment groups (Adish et al. 1999). A more recent study conducted 
in Malawi verifies this research, noting a reduction in iron deficiency among children and 
increased hemoglobin levels in adults living under malarial endemic conditions (Geerligs 
et al. 2003a, 2003b). 
Research into the beneficial aspects of contaminant iron and adventitious iron sources, 
should be conducted. This supplementation technique has the possibility of providing a 
low-cost and sustainable way of improving dietary iron content, and may be particularly 
effective in the developing world where resources are limited.  
8. Conclusion 
Anemia is a global public health problem with serious consequences for human and 
socioeconomic health and development. Despite a concerted effort to improve treatment 
and prevention of iron deficiency and anemia in recent years, the problem does not appear 
to be going away. 
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7.2.1 Fortification in the developed world 
Fortification has played an important role in the reduction of ID in the developed world 
since the latter half of the 20th century (Ramakrishnan & Yip 2002; Rees et al., 1985). The 
addition of elemental iron powder to flour and other cereals has since been commonplace, 
with levels of enrichment ranging from approximately 30 to 60 μg/g (Baltussen et al., 2004). 
In Canada, for example, it has been mandatory to enrich all white flours, enriched pastas, 
enriched precooked rice and certain substitute foods since 1976 (Guggenheim, 1995). 
As the demand for processed foods has increased over the past 50 years, vitamins and 
minerals have slowly been added to an increasing array of foods. Ready-to-eat cereals in 
particular play an important role in daily iron intake in the Western world. Research in the 
last decade suggests that approximately 40% of total iron intake in women of reproductive 
age from the U.S. (Ramakrishnan& Yip, 2002), and approximately 78% of total iron intake in 
German children aged 2 to 13 years (Guggenheim, 1995) can be attributed to ready-to-eat 
cereals.  
The fortification of infant formulas and foods provides particularly convincing evidence for 
the benefits of food fortification (Walter et al., 1993). Following the introduction of 
fortification guidelines in the U.S. in the late 1960’s a clear reduction in IDA among infants 
and young children was noted (Yip et al., 1987).  
7.2.2 Fortification in the developing world 
In developing countries a much lower consumption of food from animal sources is observed 
and typically the overall nutritional value of the diet is lower when compared to developed 
nations (Yip & Ramakrishnan, 2002). In addition, both a high relative cost and a decreased 
availability of fortified products like cereal flours, ready-to-eat cereals, and infant formula 
leads to an overall decreased use of industry-prepared food that would otherwise benefit 
the population (Yip & Ramakrishnan, 2002). Thus, the relative absence of fortified food 
products from diets in developing nations could at least partly explain the high prevalence 
of iron deficiency and IDA and why current fortification practices have not ameliorated the 
situation. Research into fortifiable products that are culturally acceptable and desirable in 
developing nations should be conducted.  
7.3 Iron supplementation 
Iron supplementation is the most common and cost-effective strategy used to control ID and 
IDA in the developing world and is used as both a preventive measure and a treatment 
option (Baltussen et al., 2004). World Health Organization guidelines suggest that iron 
supplementation should include administration of 60 mg of iron daily with a dose of 400 μg 
of folic acid for women of reproductive age, 30 mg of iron and 250 μg of folic acid for school-
aged children, and approximately 2 mg/kg body weight per day for preschool-aged 
children (McLean et al., 2008). Weekly iron supplementation also exists, though is 
considered to be a less effective treatment option and requires additional research and 
evaluation (ACC/SCN, 2001).  
The majority of supplementation studies to date have examined a variety of treatments in 
women of reproductive age, as infants, preschool and school-aged children (Preziosi et al., 
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1997; Faqih et al., 2006, Mumtaz et al. 2000; Menendez et al. 1997; Suharno et al. 1993; 
Schultink et al. 1995; Berger et al. 1997; Viteri, 1997). It is becoming increasingly clear that 
a main target group for iron supplementation in the developing world should be all 
women of reproductive age, regardless of pregnancy status at the time, thereby ensuring 
adequate iron reserves for both the mother and fetus during pregnancy and lactation  
(Yip & Ramakrishnan, 2002). Of concern is the relative cost of iron supplements in 
developing nations, coupled with issues surrounding delivery to infants and children. 
Other problems with iron supplementation include: undesirable side effects (including 
gastrointestinal irritation, black stools, and constipation); poor adherence to treatment 
guidelines; awareness and motivation of the target group to take supplements, often due 
to inadequate health and nutrition education; quality and packaging of iron supplements; 
and risk of iron overload if supplementation guidelines are not followed correctly (WHO, 
2001).  
7.4 The use of adventitious iron sources 
Research conducted in the latter half of the 20th century has reported on the use of iron pots 
for cooking as an innovative way to reduce IDA, with the first study conducted in 1986 
(Martinez & Vannucchi, 1986). Wistar rats fed a basal diet low in iron though cooked in an 
iron pot demonstrated comparable hemoglobin, hematocrit, protoporphyrin, serum iron, 
and transferrin saturation levels to those rats fed a complete diet, thus implicating the iron 
pot as an adventitious source of iron.  
Since this time several studies have examined this supplementation technique in humans 
with similar findings. Experiments conducted on Ethiopian children aged 2-5 years and 
pre-term infants (between months 4 and 12) from Brazil reported that cooking food in iron 
pots led to lower rates of anemia than children whose food was cooked in non-iron pots 
(Adish et al. 1999; Borigato, Martinez 1998). Significantly improved hematologic values 
between iron pot and non-iron pot groups were noted, including increased hemoglobin, 
hematocrit, mean corpuscular volume, free erythrocyte protoporphyrin, and serum 
ferritin. In addition, the Ethiopian study indicated moderate height and weight gains in 
children assigned to treatment groups (Adish et al. 1999). A more recent study conducted 
in Malawi verifies this research, noting a reduction in iron deficiency among children and 
increased hemoglobin levels in adults living under malarial endemic conditions (Geerligs 
et al. 2003a, 2003b). 
Research into the beneficial aspects of contaminant iron and adventitious iron sources, 
should be conducted. This supplementation technique has the possibility of providing a 
low-cost and sustainable way of improving dietary iron content, and may be particularly 
effective in the developing world where resources are limited.  
8. Conclusion 
Anemia is a global public health problem with serious consequences for human and 
socioeconomic health and development. Despite a concerted effort to improve treatment 
and prevention of iron deficiency and anemia in recent years, the problem does not appear 
to be going away. 
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In 2004, the Copenhagen Consensus brought together a panel of world-renowned 
development economists to consider and confront the ten most pressing challenges to 
“global welfare” that we face today (Copenhagen Consensus, 2004). Micronutrient 
interventions, including iron fortification, ranked at the top of the list and offered the 
highest benefit: cost ratio of any development intervention. These findings were confirmed 
in 2008, at the most recent Consensus meeting, where iron and zinc fortification were placed 
within the top three global challenges (Copenhagan Consensus, 2008). This prioritization of 
iron and other micronutrient interventions emphasizes the need for well-designed, 
sustainable and effective programming efforts to combat iron deficiency anemia.  
The adverse effects of anemia on mortality, morbidity and development are abundantly 
clear. Anemia affects how individuals participate in all areas of life, including work, school 
and social activities, and this limits the ability to generate income and afford iron-rich 
sources of food, medical treatment, and school fees. In turn, this leads to constrained social 
and economic development, ultimately contributing to a viscous cycle of poverty that is 
difficult to overcome.  
The widespread prevalence of anemia, both in the developed and developing worlds, is 
great cause for concern. The current review highlights some of the most promising research 
on the etiology, prevention and control of the disorder. From this, it should be clear that 
although we have made strides, there is still much that we do not understand about iron 
deficiency and anemia, especially in relation to treatment and prevention. A renewed effort 
to find effective ways to combat this problem is needed, as anemia is unique and complex 
public health crisis that is of global proportions. 
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In 2004, the Copenhagen Consensus brought together a panel of world-renowned 
development economists to consider and confront the ten most pressing challenges to 
“global welfare” that we face today (Copenhagen Consensus, 2004). Micronutrient 
interventions, including iron fortification, ranked at the top of the list and offered the 
highest benefit: cost ratio of any development intervention. These findings were confirmed 
in 2008, at the most recent Consensus meeting, where iron and zinc fortification were placed 
within the top three global challenges (Copenhagan Consensus, 2008). This prioritization of 
iron and other micronutrient interventions emphasizes the need for well-designed, 
sustainable and effective programming efforts to combat iron deficiency anemia.  
The adverse effects of anemia on mortality, morbidity and development are abundantly 
clear. Anemia affects how individuals participate in all areas of life, including work, school 
and social activities, and this limits the ability to generate income and afford iron-rich 
sources of food, medical treatment, and school fees. In turn, this leads to constrained social 
and economic development, ultimately contributing to a viscous cycle of poverty that is 
difficult to overcome.  
The widespread prevalence of anemia, both in the developed and developing worlds, is 
great cause for concern. The current review highlights some of the most promising research 
on the etiology, prevention and control of the disorder. From this, it should be clear that 
although we have made strides, there is still much that we do not understand about iron 
deficiency and anemia, especially in relation to treatment and prevention. A renewed effort 
to find effective ways to combat this problem is needed, as anemia is unique and complex 
public health crisis that is of global proportions. 
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1. Introduction 
Envenomings by snakebites constitute a highly relevant public health problem on a world 
wide basis, particularly in tropical regions of Africa, Asia and Latin America (Gutiérrez et 
al., 2006; WHO, 2007a). It affects mostly agricultural workers and their children living in 
rural settings. Thus, its highest impact occurs in poor and politically underpowered people, 
thus representing a ‘disease of poverty’ (Harrison et al., 2009) which fulfils the 
characteristics of a truly neglected tropical disease. Accordingly, the World Health 
Organization (WHO) incorporated, in 2009, snakebite envenoming in its list of neglected 
tropical diseases (www.who.int/neglected_disease/diseases/en). Despite the high impact 
of this pathology in terms of morbidity and mortality in vast regions of the world, it has 
received little attention from international health agencies and foundations, research 
agendas, and pharmaceutical companies, even when compared with other neglected 
diseases which have received a well deserved growing attention over the last decade 
(Williams et al., 2010). Such low concern for an important disease is due in part to the lack of 
political voice of the groups affected by snakebites, to the weakening of public health 
systems in many developing countries, and to the poor documentation of the actual global 
impact of this problem, which makes the advocacy to confront this neglected disease a 
difficult task. The present chapter reviews the main features associated with snakebite 
envenoming and its treatment, and highlights some of the most pressing tasks that need to 
be undertaken to confront this public health problem.   
2. Assessing the actual impact of snakebite envenoming 
The actual incidence and mortality associated with snakebite envenoming is poorly known, 
in part due to the lack of reliable information on this disease in many regions of the world. 
Although health statistics, based on the reports of hospital cases to health authorities, are 
satisfactory in some countries (for example in Brazil, de Oliveira et al., 2009), for many 
countries and regions this information is largely deficitary (Gutiérrez et al., 2010b; WHO, 
2007a). This is in part due to the fact that health statistics are poor in many countries, and 
also that many people affected by snakebites do not seek medical attention and instead rely 
on local traditional healers, thus remaining invisible to health authorities (Habib et al., 2001; 
Michael et al., 2010; Otero et al., 2000; Sharma et al., 2004). Despite these limitations, a 
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number of studies have generated valuable information on the real impact of snakebite 
envenoming. Snakebites affect mainly agricultural workers and their relatives, living in poor 
rural settings of Africa, Asia and Latin America (Alirol et al., 2010; Chippaux, 2010; Fan & 
Cardoso, 1995; Warrell, 2010). Thus, it is clearly an occupational hazard. Incidence is usually 
higher in men than women, and children are also affected mostly due to their involvement 
in agricultural duties. Most bites occur in lower limbs, although bites in hands are also 
frequent (Alirol et al., 2010; Warrell, 2010). Incidence varies along the year, associated with 
the rainy season and with the timing of agricultural activities (Chippaux, 2010). Natural 
disasters have been associated with increments in the number of snakebites, as shown in 
Bangladesh during the 2007 monsoon flood (Alirol et al., 2010). Some social and ethnic 
groups are affected to a higher extent by snakebites, as compared with other groups. In 
Latin America, for instance, indigenous groups present a high incidence of snakebites 
(Larrick et al., 1978; Pierini et al., 1996). In addition, these groups are generally more 
vulnerable owing to their limited access to health services, evidencing a pattern of inequity 
that has implications in terms of mortality and morbidity secondary to snakebite 
envenomings (Gutiérrez, 2011). Moreover, these accidents fuel a vicious circle of poverty, 
since they have a negative impact on the working performance of agricultural workers, thus 
affecting the already precarious source of income for their families. Thus, in addition of 
being a disease of the poor (Harrison et al., 2009), snakebites worsens the economic situation 
of victims and their families. 
A pioneer study on mortality due to this pathology was conducted by Swaroop & Grab 
(1954) on the basis of hospital statistics. Chippaux (1998) estimated an annual total of 
5,400,000 bites, over 2,500,000 envenomings and 125,000 deaths due to snakebites. A more 
recent study by Kasturiratne et al. (2008) estimated a global total of envenomings ranging 
from 421,000 to 1,841,000, with fatalities ranging from 20,000 to 94,000. These studies 
presented estimations of envenomings and fatalities by regions as well. South and Southeast 
Asia present the highest incidence of snakebites, followed by sub-Saharan Africa 
(Kasturiratne et al., 2008). Likewise, these three regions have the highest numbers of 
fatalities. However, these estimates were based on the extrapolation of data from some 
regions and countries and, therefore, have limitations. When community-based surveys 
have been performed, the picture that emerges is one of a much higher dimension, both in 
terms of incidence and mortality (Snow et al., 1994; Sharma et al., 2004; Trape et al., 2001). 
The incidence of snakebites in specific areas can be very high. Examples are the Benue valley 
of Nigeria (497 per 100,000 population per year, Pugh & Theakston, 1980) and in 
southeastern Nepal (1,162 per 100,000 population per year, Sharma et al., 2004). A meta-
analysis of snakebites in Africa suggested that the actual incidence might be 3-5 times higher 
than that derived from hospital statistics (Chippaux, 2011). Two recent studies further 
illustrate this concept. A community-based survey performed in rural Bangladesh revealed 
an incidence of 623.4 cases per 100,000 population per year (Rahman et al., 2010), which is 
much higher than the incidence derived from hospital-based statistics. Moreover, a recent 
study on mortality in India, which was part of a large national representative mortality 
survey, indicates that there are 45,900 deaths due to snakebite envenoming per year in this 
country (Mohapatra et al., 2011). The issue of underreporting needs to be addressed by 
different approaches, such as by identifying regions where underreport is more likely to 
occur (Hansson et al., 2010), and by performing community-based surveys in countries of 
high incidence of snakebites.  
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2.1 Beyond mortality: The impact of sequelae from snakebite envenomings 
Case fatality rate in snakebite envenomings, if not properly treated, can be very high, 
especially in bites inflicted by highly venomous species (Sharma et al., 2004; Warrell, 
2010). In addition, a percentage of people that survive develop sequelae as a consequence 
of envenoming. In the case of bites by viperid snakes, and by some elapids (genus Naja) 
that induce local tissue necrosis, sequelae include tissue loss and dysfunction, which may 
lead to amputation (S.B. Abubakar et al., 2010a; Gutiérrez & Lomonte, 2009; Otero et al., 
2002; Warrell, 2010). Despite the scarcity of statistics on the incidence of sequelae 
following snakebite, observations in sub-Saharan Africa indicate that up to 20% of the 
patients, perhaps more, develop permanent physical sequelae (Pugh et al., 1980; Snow et 
al., 1994). Bites in the hands by viperid species are more prone to leave permanent tissue 
damage than bites in the lower limbs (Dart et al., 1992). Moreover, people suffering 
snakebites also present psychological sequelae, as clearly revealed by a recent study in Sri 
Lanka (S.S. Williams et al., 2011). The combination of physical and psychological 
consequences of snakebites has a dramatic impact on the quality of life of both patients 
and dependants. These are mostly poor agricultural workers whose survival depends 
very much on their physical and emotional stability to confront everyday hardships. In 
many cases, a large group of people depend on them as the only source of income. 
Therefore, when snakebite envenomings are analyzed using the parameter of DALYs 
(‘disability adjusted life years’) lost, the actual impact of this disease becomes more 
evident. It is necessary to investigate the effects of this pathology from such broader 
perspective, through interdisciplinary research projects involving international 
partnerships and networks.  
In order to have a more rigorous and realistic assessment of the actual dimension of 
snakebite envenoming worldwide, the following tasks should be implemented: (a) 
Introducing compulsory notification of these envenomings. (b) Implementing the use in 
death certification of the specific classifier T 63.0 snake venom listed in the International 
Statistical Classification of Diseases and Related Health Problems (WHO, 2007b). (c) 
Performing well-designed epidemiological research based on health statistics and 
community-based surveys. (d) Supporting the training of health staff for proper record 
keeping on snakebite envenoming in many countries. These and related efforts will 
contribute to the generation of a solid body of information which will help to raise 
awareness on the seriousness of this problem and, at the same time, will provide decision-
makers with more accurate data for the design of interventions of various sorts (Gutiérrez 
et al., 2010b).   
3. Snake species responsible for the highest toll of envenomings 
Snakes capable of inducing serious envenoming in humans are classified in the families 
Colubridae (sensu lato), Atractaspididae, Elapidae and Viperidae. These families include 
more than 2,600 species, although a relatively reduced number of them, mostly belonging to 
the families Elapidae and Viperidae, are responsible for the vast majority of snakebite 
envenomings worldwide (Warrell, 2010). In Asia, the most relevant species belong to the 
elapid genera Bungarus (kraits) and Naja (cobras) (Figure 1A), and to various species of the 
viperid genera Echis, Daboia, Trimeresurus and Hypnale (Warrell, 1995a).  In Africa, species of 
Naja and few viperids are important in the northern countries, whereas the saw-scale viper 
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(Echis ocellatus) (Figure 1B) inflicts a heavy toll in the sub-Saharan region, together with 
other viperids classified in the genera Echis and Bitis, and some cobras (Naja sp) (WHO, 
2010b). In the Americas, species of rattlesnakes (Crotalus) are important in North America, 
whereas lance-head vipers of the genus Bothrops, such as B. asper (Figure 1C) and B. atrox, are 
responsible for most snakebites in Central and South America, in addition to a number of 
Bothrops species in South America (Fan & Cardoso, 1995; Gómez & Dart, 1995; Gutiérrez, 2010).  
 
 
Fig. 1A. Naja naja from Sri Lanka. Photo: Mark O’Shea. Reprinted from Journal of Proteomics 
74, 1735-1767, Williams et al., copyright 2011, with permission from Elsevier. 
 
 
Fig. 1B. Echis ocellatus from Togo. Photo: David Williams. Reprinted from Journal of 
Proteomics 74, 1735-1767, Williams et al., copyright 2011, with permission from Elsevier. 
 




Fig. 1C. Bothrops asper from Costa Rica. Photo: Mahmood Sasa. From Gutiérrez et al. (2006) 
PLoS Medicine 3: e150. 
In addition, some species, albeit not causing high numbers of bites, are capable of inflicting 
severe envenomings, such as Lachesis sp (bushmaster) and Micrurus sp (coral snakes) in the 
Americas (Warrell, 2004), Atractaspis sp (borrowing snakes) and Dendroaspis sp (mambas) in 
Africa/Middle East (WHO, 2010b), and a variety of elapid species in Australia and Papua 
New Guinea (White, 2010). Envenomings by colubrid species are usually not severe 
although fatal cases by species of the African genera Dispholidus and Thelotornis have been 
described (Warrell, 1995b). The taxonomy of venomous snakes is a highly dynamic field  
and recent modifications have been introduced in medically-relevant snake taxa (Quijada-
Mascareñas & Wüster, 2010). Toxinologists, clinicians and antivenom manufacturers  
should be aware of these changes in taxonomy. Detailed information on the country 
distribution of the most important poisonous snakes is available at the WHO website 
http://apps.who.int/bloodproducts/snakeantivenoms/database/ 
4. Snake venom biochemistry and toxicology 
These groups of ‘advanced’ snakes have acquired, through a long and complex evolutionary 
history (Fry et al., 2006, 2009), the ability to synthesize a toxic secretion, i.e. venom, by an 
exocrine gland located in the maxillary region, together with a venom delivery system based 
on the presence of ducts and fangs (Meier & Stocker, 1995; Vonk et al., 2008). The molecular 
evolution of venom toxins has involved an accelerated Darwinian process, by which genes 
have been duplicated and recruited in venom glands, with a concomitant process of 
acquisition of toxic functions based on a trend to generate mutations in sequences coding 
predominantly for amino acid residues located in the surface of these proteins, as well as 
other molecular mechanisms such as domain loss and neofunctionalization, thus generating 
a wide versatility in their ability to interact with diverse tissue targets (Casewell et al., 2011; 
Fry et al., 2006; Kini & Chan, 1999; Ohno et al., 2003). In the last decade, the use of proteomic 
 
Public Health – Methodology, Environmental and Systems Issues 
 
134 
(Echis ocellatus) (Figure 1B) inflicts a heavy toll in the sub-Saharan region, together with 
other viperids classified in the genera Echis and Bitis, and some cobras (Naja sp) (WHO, 
2010b). In the Americas, species of rattlesnakes (Crotalus) are important in North America, 
whereas lance-head vipers of the genus Bothrops, such as B. asper (Figure 1C) and B. atrox, are 
responsible for most snakebites in Central and South America, in addition to a number of 
Bothrops species in South America (Fan & Cardoso, 1995; Gómez & Dart, 1995; Gutiérrez, 2010).  
 
 
Fig. 1A. Naja naja from Sri Lanka. Photo: Mark O’Shea. Reprinted from Journal of Proteomics 
74, 1735-1767, Williams et al., copyright 2011, with permission from Elsevier. 
 
 
Fig. 1B. Echis ocellatus from Togo. Photo: David Williams. Reprinted from Journal of 
Proteomics 74, 1735-1767, Williams et al., copyright 2011, with permission from Elsevier. 
 




Fig. 1C. Bothrops asper from Costa Rica. Photo: Mahmood Sasa. From Gutiérrez et al. (2006) 
PLoS Medicine 3: e150. 
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http://apps.who.int/bloodproducts/snakeantivenoms/database/ 
4. Snake venom biochemistry and toxicology 
These groups of ‘advanced’ snakes have acquired, through a long and complex evolutionary 
history (Fry et al., 2006, 2009), the ability to synthesize a toxic secretion, i.e. venom, by an 
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have been duplicated and recruited in venom glands, with a concomitant process of 
acquisition of toxic functions based on a trend to generate mutations in sequences coding 
predominantly for amino acid residues located in the surface of these proteins, as well as 
other molecular mechanisms such as domain loss and neofunctionalization, thus generating 
a wide versatility in their ability to interact with diverse tissue targets (Casewell et al., 2011; 
Fry et al., 2006; Kini & Chan, 1999; Ohno et al., 2003). In the last decade, the use of proteomic 
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tools based on mass spectrometric analysis and sequence determination has allowed a 
detailed knowledge on the composition of venoms from many species (Calvete et al., 2007; 
Calvete, 2010; Fox & Serrano, 2008). Understanding the snake venom proteomes (‘venomes’) 
provides valuable information for the search of novel toxins and for the design of the most 
appropriate mixtures of venoms for animal immunization for antivenom production, among 
other applications (Calvete, 2010; Gutiérrez et al., 2009a). 
Venoms from snakes of the family Elapidae comprise a high percentage of proteins of the 
so-called ‘three finger toxin’ family, which are low molecular mass (6-9 kDa) polypeptides 
that exert a number of actions, such as the ability to block neuromuscular junctions at the 
post-synaptic level by binding with very high affinity to the nicotinic cholinergic receptor of 
the motor end-plate in skeletal muscle fibers (Hegde et al., 2010). Some three-finger toxins 
are membrane-disorganizing proteins, named ‘cardiotoxins’ or ‘cytotoxins’, which disrupt 
the integrity of cell membranes and are likely to play a role in the tissue damage associated 
with envenoming by some cobras (Dufton & Hider, 1988). The venoms of Dendroaspis sp 
(mambas) contain other types of neurotoxins, i.e. dendrotoxins and fasciculins, which 
interfere with neuromuscular junctions by various mechanisms (Harvey, 2001, 2010). Elapid 
venoms are also characterized by the high abundance of phospholipases A2 (PLA2s), some of 
which are potent neurotoxins whose mechanism of action relies in the specific binding to 
receptors in the presynaptic nerve terminal, followed by degradation of phospholipids at 
the plasma membrane of these terminals, thus affecting the normal process of 
neurotransmitter release (Rossetto et al., 2006). Other PLA2s induce acute muscle damage 
which, in the case of some sea snakes and other elapids, results in systemic myotoxicity, i.e. 
rhabdomyolisis, associated with myoglobinuria, hyperkalemia and acute renal failure 
(Gutiérrez & Ownby, 2003). Besides the predominant three-finger toxins and PLA2s, elapid 
venoms also contain other proteins in low concentrations, such as cysteine-rich secretory 
proteins (CRISPs), cobra venom factor and other hydrolases (serine proteinases, 
metalloproteinases, nucleotidases) (Correa-Neto et al., 2011; Kulkeaw et al., 2007; Petras et 
al., 2011). The clotting disturbances induced by some Australian elapid venoms are caused 
by procoagulant serine proteinases which are prothrombin activators (St Pierre et al., 2005) 
Venoms of snakes of the family Viperidae present large variations in their composition, but 
nevertheless the components showing the highest concentrations correspond to zinc-
dependent metalloproteinases, PLA2s and serine proteinases (Calvete, 2010; Fox & Serrano, 
2005). In addition, these venoms contain bradykinin-potentiating peptides (BPPs), 
disintegrins, C-type lectin-like proteins, L-amino acid oxidase and various other enzymes 
(Calvete et al., 2009). Metalloproteinases are largely responsible for degradation of the 
basement membrane of microvessels, with the consequent hemorrhage (Escalante et al., 
2011), activation of prothrombin and factor X (Kini, 2005; Tans & Rosing, 2001), thus 
generating the formation of microthrombi and fibrinogen depletion, i.e. defibrinogenation 
(Gutiérrez et al., 2010a), and degradation of the extracellular matrix (Moura-da-Silva et al., 
2009), among other effects. In turn, some viperid PLA2s induce acute muscle damage at the 
site of venom injection (Gutiérrez & Ownby, 2003; Lomonte et al., 2003). Some viperid PLA2s 
also exert presynaptic neurotoxicity, such as the complex ‘crotoxin’, abundant in the venom 
of South American rattlesnakes (Bon, 1997). Serine proteinases are responsible for clotting 
disturbances, i.e. defibrinogenation, and hypotension (Serrano & Maroun, 2005). Venoms 
from species of the family Atractaspididae (burrowing asps) contain sarafotoxins, which are 
low molecular mass components that induce vasospasm leading to cardiac toxicity (Bdolah, 
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2010). Finally, the venoms of snakes of the polyphyletic family Colubridae have been 
studied to a lesser extent, but they also contain metalloproteinases, serine proteinases, 
PLA2s, CRISPs and neurotoxins (Mackessy, 2002). Snake venoms present a high variability, 
not only between species, but also between different populations of the same species (Alape-
Girón et al., 2008; Chippaux et al., 1991; Jayanthi and Gowda, 1988). Moreover, some species 
present a conspicuous ontogenetic variability in the composition of their venoms, such as 
the Central American rattlesnake Crotalus simus (Calvete et al., 2010a) and the lance-head 
viper Bothrops asper (Alape-Girón et al., 2008). This high variability in venom composition 
has evident implications for the clinical manifestations of envenoming (Warrell, 1997) and 
for the preparation of antivenoms (Gutiérrez et al., 2009a).  
5. Clinical manifestations of envenoming 
The large variation occurring in venom composition urges caution when classifying the 
clinical manifestations of snakebite envenoming, since important differences have been 
described in the clinical features in envenomings by closely-related species or even within a 
single species. However, there are general trends in the clinical picture of envenoming by 
the various groups of poisonous snakes. Envenomings by elapid species (sea snakes, tiger 
snakes and taipans in Australia, cobras and kraits in Asia, cobras and mambas in Africa, and 
coral snakes in the Americas) are usually characterized by progressive descending 
neurotoxic paralysis secondary to the action of pre- or post-synaptic neurotoxins at the 
neuromuscular junctions (Warrell, 1996, 2010; White, 2010). The most serious consequence 
of this effect is respiratory paralysis, which may lead to death if not properly and timely 
attended. In addition, envenomings by a number of elapid species are also characterized by 
rhabdomyolysis, which may lead to acute renal failure (Warrell, 1996). Patients envenomed 
by elapids in Australia and Papua New Guinea develop coagulation disturbances which 
may provoke bleeding (White, 2010). On the other hand, human envenomings by some 
cobras in Asia and Africa are not characterized by neurotoxic manifestations, but instead by 
local tissue necrosis (Warrell, 1995a, 1995b).  
Viperid snake venoms provoke complex and often drastic local pathological effects, i.e. 
hemorrhage, dermonecrosis, blistering, myonecrosis and edema, always associated with pain 
(Gutiérrez & Lomonte, 2009; Warrell, 2004). These local manifestations may lead to permanent 
sequelae, such as tissue loss and dysfunction (Dart et al., 1992; Otero et al., 2002). After 
systemic venom distribution, and depending on the severity of the case, viperid snakebite 
envenomings are characterized by coagulopathies, bleeding, renal alterations and 
hemodynamic manifestations which may lead to cardiovascular shock and multisystem organ 
failure (Gutiérrez et al., 2009b; Warrell, 2004). Intravascular hemolysis might also occur, in 
some cases associated with microthrombi formation (Warrell, 1996). Exceptions to this general 
trend are envenomings by the South American and some populations of North American 
rattlesnakes, as well as some viperids in the Old World, which induce neurotoxicity (Azevedo-
Marques et al., 2009; Ferquel et al., 2007). Despite the existence of these general trends, clinical 
studies highlight the complexity of snakebite envenoming, as demonstrated by the description 
of ‘unusual’ manifestations in cases by some elapids in Asia and South America (Faiz et al., 
2010; Manock et al., 2008; Trinh et al., 2010). In addition, some venoms induce unique clinical 
features, such as the thrombotic effect described for the Caribbean viperid species Bothrops 
lanceolatus and B. caribbaeus (Thomas et al., 1996), and the acute hemorrhagic infarction of the 
pituitary in envenoming by Daboia russelli (Tun-Pe et al., 1987).  
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tools based on mass spectrometric analysis and sequence determination has allowed a 
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the various groups of poisonous snakes. Envenomings by elapid species (sea snakes, tiger 
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The severity of snakebite envenoming depends on a number of factors, such as the volume 
of venom injected, the size and physiological condition of the victim, and the region of the 
body where venom is delivered. A percentage of snakebites are not associated with venom 
injection (‘dry bites’) and, therefore, no clinical manifestations develop (Warrell, 2004). In 
general, bites in the head tend to be more severe than bites in the extremities, and 
envenoming in children are more prone to become severe. In the case of envenoming by pit 
vipers, bites in the hands are more likely to generate sequelae than bites in the lower limbs 
(Dart et al., 1992). Thus, a proper assessment of the clinical manifestations and severity of 
snakebites is a key element for the correct diagnosis and clinical management of these 
accidents. 
6. Diagnosis and treatment of snakebite envenomings 
6.1 Diagnosis 
Identification of the offending snake is often difficult because in many settings there are 
various similar species and the bitten person is usually unable to differentiate between 
them. Even when the snake is killed and brought to the health facility, identification is not 
always correct. In Australia, kits have been developed for the immunodetection of venom in 
the bite site or in urine, thus allowing the identification of the offending snake (White, 2010). 
However, this is not the case in the vast majority of regions in the rest of the world. A 
‘syndromic approach’ has been promoted for the diagnosis of the type of envenoming in 
various parts of the world (Ariaratnam et al., 2009; WHO, 2010b). For instance, in Central 
America, there are two predominant syndromes in snakebite envenomings: one presenting 
local pathological effects (swelling, pain, local tissue damage), clotting disturbances and 
bleeding, and another characterized by descending neuromuscular paralysis. The first 
syndrome is associated with envenomings inflicted by viperid species, whereas the second 
is due to envenomings by elapid species (Micrurus sp). This clinically-based diagnosis 
allows for the selection of the correct antivenom, i.e. polyvalent antivenom or anti-coral 
antivenom, respectively (Gutiérrez, 2010). Such syndromic approach has been advocated in 
other regions of the world as well, such as in sub-Saharan Africa (WHO, 2010b) and Sri 
Lanka (Ariaratnam et al., 2009). In large regions of the savannahs in sub-Saharan Africa, 
cases presenting clotting disturbances are associated with envenomings inflicted by the saw-
scale viper, Echis ocellatus (Warrell, 1995b). In this context, a simple laboratory test known as 
the ‘20 minute whole blood clotting test’ represents a useful diagnostic tool (Warrell et al., 
1974). In contrast, envenomings associated with a predominantly neurotoxic picture are 
caused by species of neurotoxic cobras (Naja sp) or mambas (Dendroaspis sp), and 
envenomings characterized by local tissue damage without coagulant disturbances are 
induced by species of Bitis or by cytotoxic cobras (WHO, 2010b).  
6.2 First aid in snakebite envenoming 
Snakebite cases in many regions of the world are initially attended by local healers who use 
a wide variety of interventions, most of which are ineffective and often exert harmful effects. 
Examples are the use of ligatures, incisions and suction, cryotherapy, electroshock, and the 
administration of synthetic or natural substances (Hardy, 2009; Warrell, 2010). Other 
interventions, such as application of ‘black stone’ or suction devices are largely ineffective 
for the removal of venom. In addition to their harmful effects, these actions delay the 
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transport of patients to health centers and, therefore, jeopardize the adequate management 
of these cases. First aid interventions should be focused on the immobilization of the bitten 
extremity and the rapid transportation to clinics or other health facilities. Communities 
should have strategies for rapid deployment of snakebitten people to medical treatment; an 
example is the use of motorcycle transportation in Nepal (Alirol et al., 2010). The interaction 
and communication of health staff with local healers is very important, in order to promote 
partnerships aimed at reducing harmful interventions and guaranteeing rapid mobilization 
for antivenom administration. The application of pressure-immobilization, by applying a 
bandage and a splint to the entire bitten limb, has been used in Australia for delaying the 
systemic absorption of neurotoxic venoms (Sutherland et al., 1979; White, 2010). Recently, a 
pharmacological intervention, based on the application of an ointment containing a nitric 
oxide donor, aimed at reducing the lymphatic absorption of venom, has been proposed 
(Saul et al., 2011), and its testing in the clinical setting is pending.  
6.3 Antivenoms: The key therapy of snakebite envenoming  
The parenteral administration of animal-derived antivenoms constitutes the mainstay in the 
therapy of snakebite envenoming (WHO, 2007a, 2010a), since the development of the first 
antivenoms, the serum anti-venimeux, during the last decade of the XIXth century (Bon, 1996). 
Antivenoms are preparations of immunoglobulins, or immunoglobulin fragments F(ab’)2 or 
Fab, obtained by fractionating the plasma of animals immunized with snake venoms 
(Gutiérrez et al., 2011a; Lalloo & Theakston, 2003; WHO, 2010a). Antivenoms can be 
monospecific, when animals receive the venom of a single species, or polyspecific, when 
venoms from two or more species are injected. The majority of manufacturers use horses for 
immunization, although few use sheep and donkeys (Gutiérrez et al., 2011a, 2011b). In most 
cases, plasma fractionation involves the digestion of proteins with pepsin or, by few 
producers, with papain, followed by the purification of antibody fragments by salting-out with 
ammonium salts or caprylic acid fractionation and, in some cases, with chromatographic 
procedures (dos Santos et al., 1989; Grandgeorge et al., 1996; Raw et al., 1991; WHO, 2010a). 
Some producers fractionate plasma with caprylic acid to obtain whole IgG preparations 
(Gutiérrez et al., 2005; Rojas et al., 1994). A detailed description of the methods used in animal 
immunization and plasma fractionation for antivenom production can be found in the WHO 
Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins (WHO, 
2010a). There are antivenom-manufacturing laboratories in every continent (a complete list can 
be found in http://apps.who.int/bloodproducts/snakeantivenoms/database/). Following 
manufacture, antivenoms are subjected to a quality control protocol which involves physical, 
chemical and biological tests aimed at ensuring the efficacy and safety of these products 
(Gutiérrez & León, 2009; WHO, 2010a).  
The ability of antivenoms to neutralize venom toxins is based on the capacity of antivenom 
antibodies, or antibody fragments, to bind and neutralize the most relevant toxins in a 
venom. It has been proposed that such neutralization is based on, at least, four mechanisms: 
(a) Binding of antibody paratopes to epitopes located at the pharmacologically-relevant 
molecular region, i.e. the catalytic active site in toxic enzymes such as phospholipases A2 
and metalloproteinases. (b) Binding of antibodies to epitopes located close to the toxin active 
site, thus exerting inhibition by steric hindrance. (c) Binding of antibodies to molecular 
regions distant from the active/toxic site of venom components, neutralization being 
achieved by allosteric changes induced in the toxins, with the consequent reduction in their 
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The parenteral administration of animal-derived antivenoms constitutes the mainstay in the 
therapy of snakebite envenoming (WHO, 2007a, 2010a), since the development of the first 
antivenoms, the serum anti-venimeux, during the last decade of the XIXth century (Bon, 1996). 
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The ability of antivenoms to neutralize venom toxins is based on the capacity of antivenom 
antibodies, or antibody fragments, to bind and neutralize the most relevant toxins in a 
venom. It has been proposed that such neutralization is based on, at least, four mechanisms: 
(a) Binding of antibody paratopes to epitopes located at the pharmacologically-relevant 
molecular region, i.e. the catalytic active site in toxic enzymes such as phospholipases A2 
and metalloproteinases. (b) Binding of antibodies to epitopes located close to the toxin active 
site, thus exerting inhibition by steric hindrance. (c) Binding of antibodies to molecular 
regions distant from the active/toxic site of venom components, neutralization being 
achieved by allosteric changes induced in the toxins, with the consequent reduction in their 
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ability to bind to tissue or cellular targets and to cause damage. (d) Formation of 
immunocomplexes between antibodies and toxins, with the subsequent removal by 
phagocytic cells; this last mechanism does not operate in the case of antivenoms made of 
monovalent Fab fragments, since they do not form complexes (Gutiérrez & León, 2009; 
Gutiérrez et al., 2011b). 
6.3.1 Clinical performance of antivenoms: Efficacy 
Antivenoms are administered parenterally, mostly by the intravenous route, and preferably 
diluted in physiological solution. Intradermal hypersentivity tests are not recommended 
since they have a very poor predictive value (Cupo et al., 1991; Malasit et al., 1986). The 
clinical performance of antivenoms depends on several factors associated with the 
immunological and physico-chemical characteristics of these products, as well as with the 
circumstances of their use in the clinical setting. At the preclinical level, antivenoms should 
be effective in the neutralization of the most relevant toxic activities of the venoms of 
medically-relevant snakes in a particular country or region. In some cases, this is achieved 
by using antivenoms raised against the venoms of the species that provoke the bite. In other 
cases, antivenoms are able to neutralize the venoms of species not used in the immunization 
of animals, but being phylogenetically related (WHO, 2010a). This phenomenon of 
immunological cross-reactivity has been clearly demonstrated, for instance, in the case of 
antivenoms raised against Bothrops sp venoms in Latin America (Otero et al., 1995; Segura et 
al., 2010a). In other cases, however, the cross-reactivity of antivenoms is low and, therefore, 
the efficacy of some products to neutralize venoms of medically-relevant species not 
included in immunization mixtures is limited, as occurs with venoms of some rattlesnakes 
and coral snakes in the Americas (Saravia et al., 2002; Tanaka et al., 2010). This issue of low 
cross-reactivity of some antivenoms may have potentially serious implications, when some 
products are used in the treatment of envenomings by species whose venoms are 
immunologically different from the ones used in immunization. One example has been the 
use of antivenoms manufactured in India for the treatment of envenomings in sub-Saharan 
Africa (Visser et al., 2008). This problem is complicated by the frequent lack of regulation 
and quality control of imported antivenoms in many countries, thus precluding the proper 
assessment of their neutralizing ability. This issue urges upgrading the regulatory capacities 
of countries in Asia, Africa and Latin America, as to ensure that antivenoms being 
introduced in these regions are evaluated with standard preclinical tests, such as those 
recommended by the WHO (2010a).  
Antivenoms have demonstrated to be highly effective, when administered timely, at halting 
the most relevant systemic manifestations of snakebite envenoming (Gutiérrez & León, 2009; 
Lalloo & Theakston, 2003; Warrell, 1992). In the case of bites by viperids, systemic bleeding, 
hemodynamic manifestations and coagulation disturbances are controlled within hours 
after antivenom infusion. In contrast, toxins responsible for local pathological effects 
(edema, dermonecrosis, local hemorrhage and myonecrosis) are more difficult to neutralize 
by antivenoms, basically because the early onset of these effects upon venom injection, thus 
precluding an effective blockade by antivenom antibodies (Gutiérrez et al., 1998), a problem 
that is worsened by the occurrence of venom-induced vascular alterations, which affect the 
distribution of antivenom to the affected tissue (Battellino et al., 2003). In the case of 
neurotoxic venoms, characteristic of most elapid and some viperid species, the development 
of neurotoxic manifestations is prevented by the timely administration of antivenoms, with 
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the consequent neutralization of neurotoxins in the circulation before reaching 
neuromuscular junctions. However, neutralization is more difficult when neurotoxins are 
bound to receptors at the synapse. In the case of post-synaptic neurotoxins, their binding 
can be reverted (Alape-Girón et al., 1996; Boulain & Ménez, 1982), but presynaptically-acting 
toxins are known to destroy the nerve terminal, thus precluding neutralization and 
generating a more prolonged pattern of nerve damage (Prasarnpun et al., 2005). Thus, the 
clinical efficacy of antivenoms is intimately related to the ability of these products to bind 
with high affinity and neutralize relevant venom toxins located in tissues or in the 
bloodstream, as well as to the toxicokinetics of toxins and the pharmacokinetics of 
antivenom antibodies or antibody fragments (Gutiérrez et al., 2003; Scherrmann, 1994; 
WHO, 2010a). For instance, low molecular mass neurotoxins characteristic of elapid snake 
venoms are rapidly distributed and readily reach their targets in the neuromuscular 
junctions; in these cases, there is a mismatch between the toxicokinetics of these neurotoxins 
and the pharmacokinetics of antivenom antibodies (Gutiérrez et al., 2003; Ismail et al., 1998). 
On the other hand, low molecular mass Fab fragments have a relatively short half-life, thus 
resulting in the phenomenon of recurrence of envenoming, i.e. the reappearance of signs 
and symptoms of envenoming several hours after antivenom therapy (Ariaratnam et al., 
1999; Boyer et al., 2001; Meyer et al., 1997). Careful clinical following up of patients is 
necessary to determine the need of an additional dose of antivenom.  
The rapid access to effective antivenoms constitutes a key issue in the proper management 
of snakebite envenoming. If the envenoming is potentially severe, and if the access to 
antivenom is delayed, due to reasons that range from hesitation to use antivenoms to 
prolonged transportation times to health facilities and lack of antivenoms in health posts, 
the efficacy of antivenoms is jeopardized and various pathophysiological complications 
might ensue. Another factor that determines the efficacy of antivenom treatment has to do 
with the use of a correct dose of this immunobiological, and to the assessment of whether 
the patient needs an additional dose of antivenom, based on the evolution of clinical and 
laboratory parameters. These considerations demand that the health staff in charge of 
treating these envenomings have an adequate knowledge of the basic elements of 
antivenom usage. 
6.3.2 Antivenom safety 
Administration of antivenom is associated, in a variable percentage of cases, with early and 
late adverse reactions. Early adverse reactions (EARs) can be, in few cases, truly 
anaphylactic reactions, i.e. IgE-mediated, or, alternatively, anaphylactoid reactions, which 
occur more frequently, and are de novo reactions not mediated by previous exposure to 
horse proteins (Warrell, 1995a). The mechanisms of these reactions are not well understood, 
but are likely to depend on (a) complement activation by antibody aggregates present in 
antivenom (Sutherland, 1977); (b) formation of complexes between human heterophylic 
antibodies against antivenom antibodies, with consequent complement activation (León et 
al., 2008); or (c) presence of antibodies in antivenoms that react with cells, such as 
erythrocytes (León et al., 2007), leukocytes or endothelial cells, thus provoking adverse 
reactions. Such EARs can be mild, characterized by urticaria and itching only, or severe, 
involving angioedema, bronchospasm and hypotension (Warrell, 1995a). The incidence of 
EARs varies significantly among different antivenoms, from as low as 5% to higher than 
70% of the cases with some products (Chippaux et al., 1998; Gawarammana et al., 2004; 
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of countries in Asia, Africa and Latin America, as to ensure that antivenoms being 
introduced in these regions are evaluated with standard preclinical tests, such as those 
recommended by the WHO (2010a).  
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after antivenom infusion. In contrast, toxins responsible for local pathological effects 
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by antivenoms, basically because the early onset of these effects upon venom injection, thus 
precluding an effective blockade by antivenom antibodies (Gutiérrez et al., 1998), a problem 
that is worsened by the occurrence of venom-induced vascular alterations, which affect the 
distribution of antivenom to the affected tissue (Battellino et al., 2003). In the case of 
neurotoxic venoms, characteristic of most elapid and some viperid species, the development 
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the consequent neutralization of neurotoxins in the circulation before reaching 
neuromuscular junctions. However, neutralization is more difficult when neurotoxins are 
bound to receptors at the synapse. In the case of post-synaptic neurotoxins, their binding 
can be reverted (Alape-Girón et al., 1996; Boulain & Ménez, 1982), but presynaptically-acting 
toxins are known to destroy the nerve terminal, thus precluding neutralization and 
generating a more prolonged pattern of nerve damage (Prasarnpun et al., 2005). Thus, the 
clinical efficacy of antivenoms is intimately related to the ability of these products to bind 
with high affinity and neutralize relevant venom toxins located in tissues or in the 
bloodstream, as well as to the toxicokinetics of toxins and the pharmacokinetics of 
antivenom antibodies or antibody fragments (Gutiérrez et al., 2003; Scherrmann, 1994; 
WHO, 2010a). For instance, low molecular mass neurotoxins characteristic of elapid snake 
venoms are rapidly distributed and readily reach their targets in the neuromuscular 
junctions; in these cases, there is a mismatch between the toxicokinetics of these neurotoxins 
and the pharmacokinetics of antivenom antibodies (Gutiérrez et al., 2003; Ismail et al., 1998). 
On the other hand, low molecular mass Fab fragments have a relatively short half-life, thus 
resulting in the phenomenon of recurrence of envenoming, i.e. the reappearance of signs 
and symptoms of envenoming several hours after antivenom therapy (Ariaratnam et al., 
1999; Boyer et al., 2001; Meyer et al., 1997). Careful clinical following up of patients is 
necessary to determine the need of an additional dose of antivenom.  
The rapid access to effective antivenoms constitutes a key issue in the proper management 
of snakebite envenoming. If the envenoming is potentially severe, and if the access to 
antivenom is delayed, due to reasons that range from hesitation to use antivenoms to 
prolonged transportation times to health facilities and lack of antivenoms in health posts, 
the efficacy of antivenoms is jeopardized and various pathophysiological complications 
might ensue. Another factor that determines the efficacy of antivenom treatment has to do 
with the use of a correct dose of this immunobiological, and to the assessment of whether 
the patient needs an additional dose of antivenom, based on the evolution of clinical and 
laboratory parameters. These considerations demand that the health staff in charge of 
treating these envenomings have an adequate knowledge of the basic elements of 
antivenom usage. 
6.3.2 Antivenom safety 
Administration of antivenom is associated, in a variable percentage of cases, with early and 
late adverse reactions. Early adverse reactions (EARs) can be, in few cases, truly 
anaphylactic reactions, i.e. IgE-mediated, or, alternatively, anaphylactoid reactions, which 
occur more frequently, and are de novo reactions not mediated by previous exposure to 
horse proteins (Warrell, 1995a). The mechanisms of these reactions are not well understood, 
but are likely to depend on (a) complement activation by antibody aggregates present in 
antivenom (Sutherland, 1977); (b) formation of complexes between human heterophylic 
antibodies against antivenom antibodies, with consequent complement activation (León et 
al., 2008); or (c) presence of antibodies in antivenoms that react with cells, such as 
erythrocytes (León et al., 2007), leukocytes or endothelial cells, thus provoking adverse 
reactions. Such EARs can be mild, characterized by urticaria and itching only, or severe, 
involving angioedema, bronchospasm and hypotension (Warrell, 1995a). The incidence of 
EARs varies significantly among different antivenoms, from as low as 5% to higher than 
70% of the cases with some products (Chippaux et al., 1998; Gawarammana et al., 2004; 
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Otero-Patiño et al., 1998). Such high variability is due to the different physicochemical 
quality of antivenoms, since some products have high protein concentration and high 
amounts of protein aggregates. Therefore, the physicochemical features of antivenoms 
greatly determine their safety profile, an issue that demands renewed efforts at the 
technological and regulatory levels. Another type of reaction observed in some antivenoms 
are pyrogenic reactions, associated with chills and fever (WHO, 2010b), but these should be 
avoided by a proper quality control, i.e. pyrogenicity testing, of these products. In the event 
of EARs, antivenom infusion should be stopped, and the reaction treated with adrenaline, 
anti-histamines and steroids (Warrell, 1995a). Once the reaction is controlled, antivenom 
infusion should be continued. Pretreatment with adrenaline has been advocated for 
reducing the incidence of EARs (de Silva et al., 2011). Late adverse reactions (LARs) to 
antivenoms occur 5-24 days after treatment, and are characterized by itching, fever, 
urticaria, arthralgia and proteinuria (Warrell, 1995a). This corresponds to a typical type III 
hypersensitivity reaction, i.e. serum sickness, due to the formation of immune complexes 
between antivenom antibodies and antibodies generated in the patient against antivenom 
proteins. The incidence of serum sickness after antivenom administration correlates with the 
amount of foreign protein, i.e. antivenom, administered (LoVecchio et al., 2003). LARs are 
treated with anti-histamines and steroids.  Another aspect of antivenom safety that has to be 
considered is microbial safety, which is guaranteed by sterile filtration of the final product 
and the use of viral inactivation/removal steps (Burnouf et al., 2004; WHO, 2010a). Some of 
the manufacturing steps currently used in antivenom production inactivate or remove 
viruses, thus contributing to the microbial safety of these products (Burnouf et al., 2004; 
WHO, 2010a).  
Such high heterogeneity in the safety of antivenoms, in terms of incidence of adverse 
reactions, calls for international cooperative efforts aimed at improving the technological 
platform of many antivenom producers, in order to increase the physicochemical quality of 
antivenoms on a world wide basis (Gutiérrez et al., 2011a). A number of antivenom 
producers in Asia, Africa and Latin America need to upgrade their facilities and protocols. 
The experience gained by well-developed antivenom manufacturing laboratories in various 
parts of the world should contribute to the improvement of less developed antivenom 
producers, through a variety of activities such as technology transfer programs, workshops, 
training and exchanges of various sorts. Such networking scenario should be promoted by 
the WHO and its regional offices, and by organizations such as the Global Snake Bite 
Initiative (www.snakebiteinitiative.org/).  
6.4 Ancillary treatments 
The therapy of snakebite envenoming includes a series of interventions in addition to 
antivenom administration. In the case of viperid venoms, hemodynamic and renal 
disturbances demand careful control of fluid therapy, monitoring of central venous 
pressure, and use of diuretics (Warrell, 1995a; WHO, 2010b). Infection often develops in 
viperid snakebites and requires the use of antibiotics. Moreover, local tissue damage by 
viperid and some elapid snakebites calls for debridement of necrotic tissue and care of the 
bitten limb. In some cases, when muscle intracompartmental pressures increase beyond 45 
mm Hg, compartment syndrome ensues and fasciotomy is indicated (WHO, 2010b). In the 
case of neurotoxic envenomings caused by elapid and some viperid species, mechanical 
ventilation should be provided in the event of respiratory paralysis (Warrell, 1995a; WHO, 
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2010b). The complexity of snake venoms and the corresponding variability in the clinical 
presentation of these envenomings complicates the management of the cases and demands 
an adequate training of the health staff in charge of treating these emergencies, in order to 
guarantee the implementation of effective therapeutic interventions.  
The poor efficacy of antivenoms to neutralize local tissue damage induced by viperid and 
some elapid venoms brings the need to find alternative therapies. A very promising avenue 
is the possibility of using natural or synthetic inhibitors of venom toxins, such as inhibitors 
of phospholipases A2, metalloproteinases and hyaluronidases, for blocking the action of 
tissue-damaging toxins by rapidly administering these inhibitors directly on the site of 
venom injection (Gutiérrez et al., 2007; Lomonte et al., 2009; Perales et al., 2005). Such 
possibility has been tested, with excellent results, at the preclinical level in mouse models 
(Borkow et al., 1997; Lomonte et al., 2009; Rucavado et al., 2000; Yingprasertchai et al., 2003). 
It is necessary to identify and develop inhibitors, some of which may be already in use for 
other pathologies, and to test them at the preclinical and clinical levels. The therapy of 
snakebite envenoming in the future will likely involve, in addition to intravenous 
antivenom administration, the local injection of toxin inhibitors, as well as other ancillary 
interventions aimed at controlling the systemic aspects of envenoming and to modulate the 
deleterious aspects of the inflammatory response of the organism to snake venoms 
(Gutiérrez et al., 2007).  
7. Preclinical and clinical testing of antivenoms 
The large intra- and interspecies variability in the composition of snake venoms poses a 
problem for antivenom efficacy, since cross-neutralization of antivenoms against venoms 
not used in the immunizing mixture might not occur. Therefore, the distribution of 
antivenoms to countries or regions where medically-relevant snakes are different from those 
used in immunization schemes needs to be carefully evaluated in order to ensure that these 
antivenoms are indeed effective. This issue gets complicated by the fact that, quite often, 
regulatory agencies in developing countries do not have the facilities and expertise to 
perform adequate preclinical testing of the antivenoms being imported (D. Williams et al., 
2011). A proper assessment of antivenom efficacy should be based on preclinical and clinical 
testing. At the preclinical level, it is necessary to assess the capacity of antivenoms to 
neutralize the lethal, as well as other relevant toxic activities, of the most important venoms 
in a country or region. This demands, in the first place, the establishment of local facilities to 
collect and keep medically-relevant snakes. These snake colonies should provide pools of 
venoms, which could then be used in preclinical testing of antivenoms. Precise indications 
on how to built and run these facilities are included in the WHO Guidelines for Antivenom 
Production, Control and Regulation of Antivenoms (WHO, 2010a). In the case of viperid 
venoms, a battery of preclinical tests usually includes the evaluation of the neutralization of 
lethal, hemorrhagic, coagulant, defibrinogenating and myotoxic activities (Gutiérrez et al., 
2011b; Theakston, 1986; WHO, 2010a). In the case of elapid snakes, antivenom preclinical 
efficacy should be assessed by the neutralization of lethality and, in the case of elapid 
venoms that induce necrosis or coagulopathy, by the neutralization of dermonecrosis and 
coagulant activities, respectively (Gutiérrez et al., 2011b; WHO, 2010a). These methods 
involve simple laboratory procedures that need to be implemented in countries where 
antivenoms are being produced or imported. In addition, international collaborative 
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presentation of these envenomings complicates the management of the cases and demands 
an adequate training of the health staff in charge of treating these emergencies, in order to 
guarantee the implementation of effective therapeutic interventions.  
The poor efficacy of antivenoms to neutralize local tissue damage induced by viperid and 
some elapid venoms brings the need to find alternative therapies. A very promising avenue 
is the possibility of using natural or synthetic inhibitors of venom toxins, such as inhibitors 
of phospholipases A2, metalloproteinases and hyaluronidases, for blocking the action of 
tissue-damaging toxins by rapidly administering these inhibitors directly on the site of 
venom injection (Gutiérrez et al., 2007; Lomonte et al., 2009; Perales et al., 2005). Such 
possibility has been tested, with excellent results, at the preclinical level in mouse models 
(Borkow et al., 1997; Lomonte et al., 2009; Rucavado et al., 2000; Yingprasertchai et al., 2003). 
It is necessary to identify and develop inhibitors, some of which may be already in use for 
other pathologies, and to test them at the preclinical and clinical levels. The therapy of 
snakebite envenoming in the future will likely involve, in addition to intravenous 
antivenom administration, the local injection of toxin inhibitors, as well as other ancillary 
interventions aimed at controlling the systemic aspects of envenoming and to modulate the 
deleterious aspects of the inflammatory response of the organism to snake venoms 
(Gutiérrez et al., 2007).  
7. Preclinical and clinical testing of antivenoms 
The large intra- and interspecies variability in the composition of snake venoms poses a 
problem for antivenom efficacy, since cross-neutralization of antivenoms against venoms 
not used in the immunizing mixture might not occur. Therefore, the distribution of 
antivenoms to countries or regions where medically-relevant snakes are different from those 
used in immunization schemes needs to be carefully evaluated in order to ensure that these 
antivenoms are indeed effective. This issue gets complicated by the fact that, quite often, 
regulatory agencies in developing countries do not have the facilities and expertise to 
perform adequate preclinical testing of the antivenoms being imported (D. Williams et al., 
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2011b; Theakston, 1986; WHO, 2010a). In the case of elapid snakes, antivenom preclinical 
efficacy should be assessed by the neutralization of lethality and, in the case of elapid 
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projects, involving well-developed laboratories, could be implemented in order to test 
antivenoms (D. Williams et al., 2011). More recently, a proteomic approach, named 
‘antivenomics’, has been adapted for the evaluation of immune reactivity of antivenoms 
against particular toxins in venoms (Calvete, 2010; Gutiérrez et al., 2009a; Lomonte et al., 
2008). This methodology allows for the identification of the toxins recognized by antivenom 
antibodies. 
The preclinical assessment of antivenoms should be followed by clinical evaluation of 
antivenom safety and efficacy (WHO, 2010a). Since phase I clinical trials in healthy 
volunteers are ethically unacceptable in the case of antivenoms, because they might induce 
adverse reactions, a substitution of phase I clinical trial, by a protocol known as ‘3 + 3 dose 
escalation design’, has been proposed for antivenoms (S.B. Abubakar et al., 2010b). This is 
then followed by phase III clinical trials in which a new antivenom is compared with an 
existing antivenom of known efficacy and safety (see for example the studies of I.S. 
Abubakar et al., 2010; Cardoso et al., 1993; Otero et al., 1999; Otero-Patiño et al., 1998; 
Smalligan et al., 2004; Warrell et al., 1974). Clinical trials should use robust clinical and 
laboratory end points for the assessment of therapeutic success. Furthermore, post-
marketing surveillance (pharmacovigilance) is required to detect possible adverse reactions 
not reported in the clinical trials and to follow up efficacy (WHO, 2010a).  
8. Technological aspects for antivenom improvement 
The need to have antivenoms of wide cross-reactivity, able to neutralize venoms from as 
many snake species as possible, demands a careful revision of the design of venom 
mixtures used for immunization of animals. There is a large body of knowledge in the 
biochemistry, toxicology and immunology of snake venoms, especially of venoms from 
species having a heavy medical impact, which should be used for the re-evaluation of the 
immunizing mixtures and for the design of novel mixtures for new antivenoms (Gutiérrez 
et al., 2009a; D. Williams et al., 2011). Proteomics technologies, together with 
neutralization tests, constitute valuable tools to analyze venom composition and effects, 
and to assess the neutralizing profile of current and new antivenoms. The Global Snake 
Bite Initiative has proposed a strategy to structure an international collaborative effort to 
evaluate current antivenoms and to design improved antivenoms (D. Williams et al., 
2011). One aspect of this strategy is based on the development of regional polyspecific 
antivenoms for use in sub-Saharan Africa and Asia using clinical, phylogenetic, proteomic 
and antivenomic analyses for the selection of the best venom mixtures for immunization. 
These antivenoms, manufactured by several laboratories, will then be evaluated by 
independent preclinical assessment, followed by clinical trials in various countries, 
performed by local medical personnel. In parallel, international expert committees will 
validate production facilities for prequalification, in a process aimed at ensuring the 
manufacture of the volume of antivenom needed in those regions (D. Williams et al., 
2011).   
One example of the potential usefulness of such an approach has to do with the design of 
immunizing mixtures for antivenoms to be used in sub-Saharan Africa. Several antivenoms 
use a mixture of venoms from many species; however, a recently developed antivenom was 
produced by using a mixture of venoms from only three species (Gutiérrez et al., 2005). 
Neutralization and antivenomic studies have shown that this new antivenom is able to 
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neutralize the venoms of several species of viperids and spitting cobras from sub-Saharan 
Africa (Calvete et al., 2010b; Segura et al., 2010b; Petras et al., 2011). Similarly, the ideal 
venom mixtures for antivenoms to be used in some parts of Asia need to be re-assessed on 
the basis of recent clinical evidence of the existence of medically-relevant species whose 
venoms are not routinely used in antivenom manufacture, such as that of the viperid 
Hypnale hypnale (Ariaratnam et al., 2008). Likewise, the decision on whether to prepare 
monospecific or polyspecific antivenoms has to be based on sound epidemiological, clinical, 
biochemical and immunological evidence. Consequently, the design and re-design of venom 
mixtures for immunization requires a multidisciplinary approach. On the other hand, there 
are other aspects of antivenom technological development that should be considered, such 
as stability and improved immunization schemes. Liquid antivenoms have to be stored at  
2-8 ºC (WHO, 2010a). However, the quality of the cold chain in many regions of the world is 
poor, thus complicating the distribution of antivenoms, especially to rural settings where 
most snakebites occur. This problem can be overcome by producing freeze-dried 
antivenoms, but this increases the production cost and, therefore, the price. Alternatives are 
being explored aimed at formulating liquid antivenoms stable at room temperature 
(Rodrigues-Silva et al., 1999; Segura et al., 2009). Likewise, the design of immunization 
protocols based on multi-site injection of small volumes containing low amounts of venom 
has resulted in higher neutralizing titers with very little damage to the immunized animals 
(Chotwiwatthanakun et al., 2001). Furthermore, the search for novel adjuvants is a relevant 
task in the efforts to improve antivenom antibody titers (Gutiérrez et al., 2011a). 
9. The accessibility and correct use of antivenoms 
Despite the widespread demonstration of antivenom efficacy for the treatment of snakebite 
envenoming, and the fact that many aspects of the know-how required to produce 
antivenoms are freely available (WHO, 2010a), there is a current deficit in antivenom 
accessibility in various regions of the world, most notably in sub-Saharan Africa and some 
countries of south-east Asia (Chippaux, 2010; Theakston et al., 2003; D. Williams et al., 2011; 
WHO, 2007a). This phenomenon has multiple causes, such as: (a) Withdrawal of some 
manufacturers from these markets due to profit considerations. (b) Privatization of former 
public laboratories, with the consequent increments in the prices of antivenoms. (c) The 
impact of international policies designed to reduce the size of the public sector, including a 
reduction in the provision of public health services and their privatization. (d) Weakening of 
antivenom manufacturing laboratories of the public sector in many developing countries, 
associated with lack of investment in facilities and technology, and reduction in training 
programs for the staff. (e) Lack of financial support for antivenom purchase by ministries of 
health, due to economic constraints and to prioritization on other health issues perceived as 
more pressing needs. (f) Loss of confidence in antivenom treatment in some regions due to 
the use of antivenoms of poor efficacy or safety. (g) Poor advocacy for promoting greater 
attention to snakebite envenoming as a neglected tropical disease. (h) Low profile of 
snakebite envenoming in the international public health agenda. As a result, antivenom 
accessibility is deficient in vast regions of Asia and Africa (WHO, 2007a; D. Williams et al., 
2011). The solution to this complex problem demands concerted actions at various levels, 
from the technological and manufacturing realm to the public health arena (Chippaux, 2010; 
Gutiérrez et al., 2010b; D. Williams et al., 2010, 2011). 
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9.1 How to enhance the accessibility of antivenoms 
Economic and political constraints constitute one of the main causes of poor accessibility of 
antivenoms in many countries. It is evident that the sole drive of the market forces will not 
solve this problem and, instead, well-designed strategies with a strong participation of 
governments and non-governmental organizations have to be implemented. This is a critical 
aspect that needs to be addressed by a variety of interventions such as: (a) Increasing the 
technological capacity of manufacturing laboratories in developing countries, both in the 
public and private realms, and introduction of cost-effective methodologies for antivenom 
production. One example is the manufacture of whole IgG antivenoms by caprylic acid 
fractionation of plasma (Gutiérrez et al., 2005; Rojas et al., 1994). This procedure generates 
antivenoms of high quality and high yield, at reduced production costs, thus constituting an 
excellent alternative for low-income countries (Brown & Landon, 2010). (b) Increased 
recognition of governments of low-income countries on the impact of snakebite envenoming 
as a public health problem, with the consequent political and financial decisions for the 
acquisition of adequate volumes of antivenom. (c) Using the capacity of large antivenom 
producers in order to manufacture antivenoms for other regions of the world at reasonable 
prices. This could be accomplished by promoting international partnerships between 
manufacturers, public health authorities, organizations of the civil society, and donors, 
similarly to what has been done for other neglected tropical diseases (Hotez et al., 2006). (d) 
Promoting strategies for price reduction, such as differential pricing arrangements or large 
scale ‘pooled’ purchases for various countries (Gutiérrez et al., 2010b).  
9.2 Distribution of antivenoms: guaranteeing access to regions where snakebites 
occur 
Even if governments purchase adequate volumes of antivenom, this does not guarantee that 
these drugs will reach the rural health posts where most snakebite envenomings occur. This 
problem has diverse roots, such as: (a) Incomplete information on the epidemiology of 
snakebites. In countries where official statistics of snakebite incidence are lacking or 
incomplete, the decision on where to distribute antivenoms cannot be taken on a rigorous 
base. This is another reason for underscoring the relevance of proper epidemiological 
register of this pathology. (b) Antivenom acquisition procedures by the ministries of health 
in many countries are slow and cumbersome; moreover, due to budgetary constraints, the 
volumes of antivenom purchased are often insufficient; both of these factors preclude the 
distribution of adequate volumes of this drug to rural settings. (c) Antivenoms are often 
distributed only to hospitals and clinics in large cities, distant from the regions where the 
majority of snakebites occur, thus affecting the timely treatment of patients. (d) As discussed 
previously, the lack of an adequate cold chain system in many rural settings of the world 
precludes the effective distribution of antivenoms. (e) Many rural regions are devoid of 
healthcare facilities, thus affecting the access to antivenom and other medical interventions 
and forcing people to travel large distances to receive medical attention.  
This complex scenario demands the design of well-structured and effective strategies of 
antivenom distribution, on the basis of sound epidemiological information on snakebite 
incidence. An intersectorial and interprogrammatic approach should be promoted, in 
conjunction with other efforts being performed in the public health realm, in order to favour 
a synergy with other actors and projects, with the consequent impact in the cost-
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effectiveness of interventions (WHO, 2007c). The compulsory report of snakebite 
envenoming (WHO, 2010a) and the use of geographical information systems to identify high 
risk areas (Hansson et al., 2010; Leynaud & Reati, 2009) would greatly contribute to generate 
a solid basis of information on the actual magnitude of the problem. Furthermore, the 
awareness of national and regional health authorities on the impact of snakebite 
envenoming should be promoted by academic, public health and civil society organizations, 
in order to ensure the acquisition and distribution of the required volumes of antivenom. 
Likewise, antivenom distribution strategies should benefit from the use of the cold chain 
system already developed for vaccine distribution. Also, the provision of antivenom access 
to rural settings and the training of rural health staff in the correct administration of 
antivenoms should be prioritized. Interventions tailored to the conditions of each country 
and region should be promoted, in order to optimize the available resources and guarantee 
a rapid access to treatment (see for example Otero et al., 1992).  
9.3 Promoting the correct use of antivenoms 
The distribution of antivenoms to regions where snakebites occur should be complemented 
by a proper training of health staff in the correct usage of this product and in the proper 
treatment of snakebite envenomings. There is evidence of poor knowledge of medical and 
nursing staff in various regions of the world on how to diagnose and treat snakebite 
envenomings, how to use antivenoms, and how to treat possible adverse reactions to their 
administration (Gutiérrez et al., 2009c; Simpson, 2008). This requires concerted efforts at 
medical and nursing schools in the universities, as well as the implementation of permanent 
educational programs on this subject, particularly aimed at rural health facilities. Likewise, 
the implementation of teaching material and the development of guidelines for the 
diagnosis and treatment of snakebite envenomings should be actively promoted, both at 
regional (WHO, 2010b) and national levels. These tasks should involve not only teaching 
institutions, but also public health authorities, local organizations of the civil society, and 
antivenom manufacturers. The critical revision of antivenom prospects, on the basis of 
current knowledge on the taxonomy of snakes and on the clinics of snakebite envenomings, 
are of great relevance, in the light of evident misconceptions included in the prospects of 
some antivenoms (Simpson & Norris, 2007).  
10. Prevention of snakebites 
Prevention programs aimed at reducing the impact and incidence of snakebite envenomings 
should be a priority in the international efforts required to confront this problem. The 
design of these programs should be tailored to the cultural, social, economic and 
institutional characteristics of the populations, and should involve the active participation of 
the communities in their design and implementation. Impoverished and excluded groups, 
such as indigenous communities in many parts of the world, should receive particular 
attention. The design of these programs should be also based on sound social science 
research aimed at understanding the particularities and needs of each region and context, 
with the participation of the communities. It is highly relevant, for instance, to understand 
how the problem is perceived in the community and what types of preventive interventions 
are suited for each particular context. Likewise, specific strategies should be designed for 
situations involving natural disasters, as snakebites have been reported to increase in such 
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circumstances. In addition, the natural history of envenomings should be considered, 
including the distribution of snakes in various types of crops and the behaviour of snakes. In 
some regions of Asia, bites by kraits (genus Bungarus) often occur at nights inside human 
dwellings while people are asleep on the ground (Sharma et al., 2004). The use of mosquito 
nets has reduced the incidence of envenoming by kraits in Nepal (Chapuis et al., 2007). The 
majority of viperid snakebites occur in the feet; thus, a preventive measure should be the 
use of footware (Alirol et al., 2010; Gutiérrez, 2010; Warrell, 2010).  
11. Final remarks: The need for an integrated approach and for the promotion of 
partnerships 
The world wide efforts required to reduce the impact of snakebite envenoming should be 
conceptualized within the frame of the Millennium Development Goals (MDGs) 
(http://www.un.org/millenniumgoals/global.shtml), particularly regarding the provision 
of access to essential drugs (WHO, 2011), in this case antivenoms, to developing countries. 
The access to adequate health services is a human right, and states and other international 
instances have the obligation to ensure the access to health facilities, goods and services on a 
non-discriminatory basis, especially to vulnerable and marginalized groups, and to provide 
education and access to information to the communities on relevant health issues, such as 
snakebite envenoming. Therefore, interventions aimed at ameliorating the impact of this 
pathology should be viewed within a frame of human rights and social responsibility of 
states, international organizations and non-governmental groups. 
Snakebite envenoming is a ‘tool-ready’ disease, in the sense that the basic technological 
therapeutic tools to treat this pathology, i.e. antivenoms, are available. However, there is a 
need to implement renewed efforts to improve the quality of some antivenoms, to design 
new antivenoms for various regions in the world, and to increase the volume of production 
as to fulfil the world wide needs to these immunobiologicals. Scientific, technological and 
public health tasks include acquisition of more rigorous data on the incidence of snakebite 
incidence and mortality, assessment of preclinical and clinical performance of currently 
available antivenoms, and development of novel antivenoms on the basis of 
epidemiological, biochemical, toxicological and immunological knowledge on venoms. 
Moreover, the strengthening of antivenom manufacture on a global basis should involve an 
active process of technology transfer and training aimed at improving the current 
technological platform of many antivenom producers, especially those located in developing 
countries. Finally, renewed efforts should be undertaken to guarantee the deployment and 
effective distribution and use of antivenoms to the regions of the world where this 
pathology has its highest impact. Table 1 summarizes some of the most pressing tasks that 
need to be promoted as part of a global strategy to reduce the impact of snakebite 
envenomings. 
The design of effective strategies to confront this problem should be also integrated with the 
more general efforts in the arena of neglected tropical diseases (WHO, 2007c). Such strategies 
should be conceived from an intersectorial and interprogrammatic perspective (see WHO, 
2007c), with a synergistic approach involving the control of other neglected tropical diseases; 
such an approach will significantly increase the cost-effectiveness of interventions. Areas of 
possible interprogrammatic cooperation include: (a) The collaborative delivery of antivenoms 
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within distribution channels already developed for other immunobiologicals, such as vaccines. 
(b) Incorporating antivenoms in integrated drug purchasing schemes in developing countries 
on a regional basis. (c) Strengthening the development of public health systems in remote rural 
areas where snakebite envenomings are frequent. (d) Promoting partnerships of diverse sorts 
with groups involved in the combat of neglected tropical diseases, such as foundations, non-
governmental organizations and other advocacy groups. (e) Including snakebite envenoming 
in the agenda of organizations that provide financial support for research and intervention 
programs for neglected tropical diseases in developing countries. (f) Incorporating the subject 
of snakebite prevention, diagnosis and treatment within the context of educational packages 
on neglected tropical diseases in teaching institutions, public health facilities and communities. 
(g) Promoting the inclusion of the subject of snakebite envenoming within the agenda of 
community organizations for the promotion of health in rural areas of countries in Africa, Asia 
and Latin America.  
 
1. Acquisition of reliable information on snakebite incidence and mortality 
2. Innovation in the technology for the production of antivenoms 
3. Strengthening the capacity of laboratories in low-income countries to manufacture 
and control antivenoms  
4. Commitment of manufacturers to produce antivenoms for regions devoid of local 
production 
5. Implementation of economic strategies to ensure the sustainable production of 
antivenoms 
6. Improvement of the national regulatory expertise and quality control of 
antivenoms in low-income countries 
7. Accessibility of antivenoms at affordable prices in low-income countries 
8. Preclinical and clinical assessment of antivenom efficacy and safety 
9. Development of effective antivenom distribution programs to regions of high 
incidence of snakebites 
10. Permanent training programs for health staff on snakebite envenomings and their 
treatment 
11. Development of programs to support people suffering from sequelae of snakebite 
envenomings 
12. Preventive and educational programs at the community level with involvement of 
local organizations 
Table 1. Summary of some of the most important tasks for an integrated strategy to confront 
the problem of snakebite envenoming from a global perspective. Adapted from Gutiérrez et 
al. (2010b) 
In the long term, the reduction of the impact of snakebite morbidity and mortality, with its 
drastic effects on the quality of human life, should involve a global partnership 
incorporating many different actors at various levels in our societies, such as: (a) The 
scientific (‘epistemic’) community of toxinologists, represented by the International Society 
on Toxinology (IST) and researchers in every continent. (b) Groups working on 
technological development and technology transfer activities, both in the pharmaceutical 
industry and in university departments. (c) Antivenom manufacturers. (d) International 
health organizations, especially the WHO and its regional offices. (e) National public health 
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authorities, i.e. Ministries of Health and other organizations of the public health sector. (f) 
National regulatory bodies, responsible for ensuring the safety and efficacy of antivenoms 
being distributed. (g) Non-governmental organizations (NGOs) and advocacy groups that 
promote a public health agenda and the access of essential drugs to developing countries. 
(h) Organizations of the civil society of countries having a high burden of snakebite 
envenoming (Figure 2). The current tasks of generating a growing international awareness 
on the magnitude of this problem, establishing partnerships to ensure the development, 
availability and accessibility to antivenoms, and promoting prevention and an effective 
clinical management of this pathology, are being promoted by the Global Snake Bite 
Initiative (GSI), the WHO, and a number of national and regional projects in various parts of 
the world.  
 
Fig. 2. Some of the participants that should be involved in a global partnership aimed at the 
reduction of the impact of snakebite envenoming in the world. 
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1. Introduction  
Human beings consume protein-rich foods to supply their nutritional requirements, mainly 
of animal origin, such origin lying in meat from different species (cattle, sheep, caprines, 
birds, pigs, fish and seafood/shellfish), milk and eggs. With the exception of some products 
derived from fishing, these foods are obtained from financial exploitations in which the 
animals’ health must be guaranteed, thereby ensuring that food is harmless. In several 
countries the safety of such food has mainly been focused on avoiding the transmission of 
zoonotic diseases, less attention thus being paid to potentially present chemical residues, 
perhaps due to the course of the resulting disease. Whilst infectious processes are frequently 
of the acute type, toxicosis caused by contaminants in foods (more than acute) may be 
chronic, silent and often lacking a known aetiological agent.  
The primary production of such food involves the animals’ interaction with their setting 
from which they may become exposed to undesirable chemical substances which may 
generate residuality. The chemical substances to which animals may become exposed 
during their production cycle which have been identified to date could come from drugs 
and growth promoters aimed at treating diseases and improving production parameters, 
biologically-derived toxins (mycotoxins, phycotoxins, phytotoxins) and/or environmental 
contaminants linked to atmospheric pollution, from the soil and/or water. This chapter will 
be orientated towards dealing with residues from chemicals substances in foodstuffs of 
animal origin caused by drugs and growth promoters, as well as by toxins having a 
biological origin. It will also deal with general concepts such as toxic agent’s target in an 
organism, the regulation of residues in food and the analytical methods used for detecting 
them. The contamination of food by chemical risks is a worldwide public health matter 
which may also hamper international trade.  
2. The destination for toxic agents in an organism 
Living beings continuously are being exposed to external substances, generically called 
xenobiotics, which can have adverse effects according to their chemical characteristics. Oral, 
dermal and inhalation routes represent the commonest means of exposure to these 
substances, the first being of interest as it deals with risks to human health due to the 
consumption of foodstuffs contaminated by potentially toxic substances. On the other hand, 
animals (representing a readily available source of food for humans) are exposed to 
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xenobiotics, which can have adverse effects according to their chemical characteristics. Oral, 
dermal and inhalation routes represent the commonest means of exposure to these 
substances, the first being of interest as it deals with risks to human health due to the 
consumption of foodstuffs contaminated by potentially toxic substances. On the other hand, 
animals (representing a readily available source of food for humans) are exposed to 
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xenobiotics in multiple ways which could be present in their products. If one is dealing with 
veterinary drugs then the route of exposure could be oral (for example, coccidiostatics in 
poultry), dermal (e.g. external antiparasitic agents in ruminants), parenteral (e.g. antibiotic 
treatment in large animals) and even inhalation (if the animals are given anaesthesia before 
surgical procedures). Biologically-derived toxins mainly enter food-producing animals by 
the oral route (e.g. forage contaminated with mycotoxins or fish consuming toxic algae). 
Xenobiotics in an organism go through a series of stages including absorption, distribution, 
metabolism and excretion, forming part of the pharmacokinetics or toxicokinetics according 
to the effects produced by a particular substance (pharmacological or toxicological). 
Xenobiotics enter a food-producing animals’ organism and, according to its kinetics, reach 
the tissues which will become food for human beings (Figure 1). These concepts will be dealt 
with below, approaching them from the perspective of potential residuality which different 
substances can cause in an animal’s organism. 
 
Fig. 1. Destination of toxicants in foodstuffs animal organism and risk for humans 
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2.1 Absorption 
During absorption, the xenobiotics cross cell membranes and reach the systemic circulation. 
Many toxic agents enter with foodstuff and are absorbed by the same routes as the other 
substances present in them. The chemicals cross the cell membrane’s lipid bilayer through 
two basic processes: diffusion (favouring their concentration gradients) and active transport 
(against their concentration gradients). Most liposoluble xenobiotics are transported by 
simple diffusion through the cell membranes. Organic acids and/or bases thus tend to 
become absorbed when they are in their most liposoluble form (non-ionised), which is 
determined by surrounding pH. Weak acids will become more easily absorbed in the 
stomach whilst this will happen to bases in the intestines. Hydrophilic substances having a 
small molecular weight become diffused through aqueous pores formed by proteins 
(facilitated diffusion). Active transport, against concentration gradients requiring an 
expenditure of energy, occurs through proteins present on the membrane mobilising a 
substance from one side to another (Lehman-McKeeman, 2008). 
It should be born in mind that certain factors may sometimes alter xenobiotics’ absorption; 
for example, the flora present in the gastrointestinal tract may transform them and leave 
them less available for being absorbed. This is why ruminants are resistant to some 
mycotoxins. Pre-systemic elimination of a toxic agent may occur with enterohepatic 
circulation, thereby minimising its potential adverse effect. 
2.2 Distribution 
Once it has been absorbed, a toxic agent becomes distributed throughout the whole body; 
during its initial phase this distribution is dominated by the blood flow. The penetration of 
toxic agent into the cells depends on passive diffusion or specialised transport; however, 
certain toxicants do not cross the membranes and become distributed via the blood flow. 
Some become accumulated in determined parts of the organism as a result of their binding 
to proteins or their high solubility in fat. When a toxicant becomes stored, then equilibrium 
is reached with the free fraction which is in the plasma. Thus, when the chemical becomes 
metabolised or is excreted, then substance is released from the storage site, thereby meaning 
that the xenobiotic half-life could become very long.  
Albumin is the main plasmatic protein transporting xenobiotics. This protein may also be a 
toxicant reservoir since it impedes transport through the membranes due to its high 
molecular weight. The presence of toxic agents in the blood could be exploited for 
recognising exposure, whether in humans or animals. 
Many organic compounds are very stable and lipophilic, becoming accumulated in the 
environment, becoming rapidly absorbed and concentrated in body fat. The toxicants 
become accumulated in fat because they are dissolved in it. A substance stored in fat is not 
toxic for the carrier, but there is rapid lipid mobilisation, for example poisoning may occur 
during long periods of fasting. Animal fat, a potential reserve of liposoluble toxicants, could 
be consumed by human beings.  
The liver and the kidneys have a large capacity for proteins to bind a broad range of 
chemicals. These organs important function lying in the metabolism and elimination of 
xenobiotics makes them concentrate more toxic agents than all the rest combined. Thus 
consuming such viscera may represent a risk for the end consumer. There is a lower 
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presence of residues in animals’ musculature (meat) compared to the viscera (kidneys, liver) 
and fat. Their accumulation at an injection site is feasible in cases where there has been 
exposure to the intramuscular drug route, this being important in animals which are to be 
consumed by humans.  
The distribution of some chemicals in eggs, as well as reducing palatability, could represent 
a risk for the end consumer. 
2.3 Metabolism  
The object of xenobiotics’ metabolism is to increase characteristics regarding an increase in 
substances’ hydrosolubility so that they can be more easily excreted. This process occurs in 
two phases; hydrolysis, reduction and oxidation reactions are presented during phase 1, 
most of them being enzyme-mediated. Cytochrome P450 (CYP450) oxidation enzymes being 
of particular importance during this phase due to their catalytic versatility and the great 
number of xenobiotics constituted in their substrate. Conjugation reactions occur during 
phase 2, mainly with glucuronic acid, glutathione conjugates and sulphates; such reactions 
are enzymatically mediated by protein superfamilies called, respectively, uridine 
diphosphate glucuronosyltransferase, glutathione S-transferases and sulphotransferases. In 
spite of the initial purpose of xenobiotics’ metabolism (or biotransformation) being 
detoxification, substances can occasionally acquire their true toxic power on being 
biotransformed; such reaction is called bioactivation or metabolic activation. Aflatoxins and 
pyrrolizidine alkaloids are bioactivated substances of interest regarding the residuality 
which they represent in food of animal origin.  
2.4 Excretion 
Toxicants are eliminated from the body by various routes, the kidneys being the most 
important organ for excreting xenobiotics since it is the main elimination route. The biliary 
route involving the faeces is the other elimination route for toxic substances which have 
been consumed. 
Milk is an important elimination route due to the risk of contamination which it represents; 
this liquid is a lipid emulsion in an aqueous protein solution and may thus contain whatever 
toxicant which is in solution in an animal’s body water. Simple chemicals arrive at the 
mammary glands by diffusion in their free form, bound to proteins or dissolved in lipids. 
The percentage of the total amount of compounds eliminated in milk is very low because 
the other elimination routes are more efficient. However, the main problem lies in chronic 
exposure and/or liposoluble compounds (Panter & James, 1990). 
The concept of withdrawal time has been established to avoid the accumulation of drug 
residues in animals; it is defined as being the time required after a drug has been 
administered to an animal to ensure that drug residues in marketable products (meat, eggs, 
viscera or other edible products) are below a determined maximum residue limit (MRL).  
3. Regulating and evaluating risk  
There can never be an absolute guarantee that our food is safe; it is simply impossible to test 
every contaminant. Every country has an agency which oversees food safety; this is defined 
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as being the, “reasonable certainty of no harm,” and the aforementioned agencies regulate 
which additives are allowed in food and what levels of unavoidable contaminants are 
acceptable. The US Department of Agriculture’s (USDA) Food Safety Inspection Service 
(FSIS) is responsible for the safety of meat, poultry, and egg products in the USA (Lodovico 
et al., 2008). The European Food Safety Authority (EFSA) is the keystone of the European 
Union’s (EU) risk assessment regarding food and animal feed safety. The Codex 
Alimentarius Commission (created by the FAO and WHO) develops food standards, 
guidelines and related texts such as codes of practice under the Joint FAO/WHO Food 
Standards Programme (JECFA). The main purposes of this programme are protecting 
consumers’ health, ensuring fair trade practices in the food trade and promoting the 
coordination of all food standards’ work undertaken by international governmental and 
non-governmental organisations. 
Health authorities recommend maximum acceptable or tolerable levels for chemicals which 
are neither genotoxic nor carcinogenic, such as acceptable daily intake (ADI), reference dose 
(RfD), especially for pesticides, tolerable daily intake (TDI) and provisional tolerable weekly 
intake (PTWI) for contaminants which may accumulate in the body. The responsible 
agencies conduct risk assessment to determine such levels; this consists of hazard 
identification and characterisation, exposure assessment and subsequent risk 
characterisation. 
Hazards are identified and characterised from human epidemiological observations and 
animal-based toxicity testing supported by in vitro mechanistic studies which can make 
extrapolation from animals to humans become more realistic. Structure–activity 
relationships-based indications and the increased use of novel molecular biology techniques 
are also very valuable.  
Dose–response information is essential for quantifying an adverse health effect. This may be 
graphically presented as being the relationship between the increase of a dose and the 
increase of a pertinent biological response. Such dose–response curve is essential for 
identifying a non-active dose taken as being the no observed adverse effect level (NOAEL), 
the highest dose of a substance which causes no detectable adverse alteration in line with 
defined treatment conditions. Interspecies differences should be taken into account as well 
as the fact that humans may exhibit substantial differences in their sensitivity to certain 
toxins due to differences regarding metabolic pathways and other factors. Uncertainty 
factors are thus applied when extrapolating from the toxicity observed in laboratory animals 
to health risks in humans, this usually being a factor of 10 for interspecies difference and a 
factor of up to 10 for human variability (depending on the extent and quality of available 
human data).  
The resulting value (equation 1) provides an estimate of the amount of a substance in 
food, expressed on a body weight basis, that can be ingested daily over a lifetime without 
appreciable risk (standard human= 60 kg). The ADI is then used for determining the 
maximum allowable levels of a particular chemical in a specific food, depending on the 
extent to which this food contributes towards the overall intake of such chemical 
(Lodovico et al., 2008). These are called maximum limits for some chemicals and 
maximum residue limits (MRLs) for substances such as veterinary drugs and hormone 
residues.  
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presence of residues in animals’ musculature (meat) compared to the viscera (kidneys, liver) 
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Equation 1. Acceptable daily intake calculation  
The regulatory approach (not strictly scientific) for genotoxic and carcinogenic compounds 
is based on the assumption that there is no threshold dose (it is assumed that one genotoxic 
molecule is sufficient to hit a single DNA base, thereby inducing damage). The aim in this 
case is to keep the exposure level as low as technologically achievable (Lodovico et al., 2008). 
4. Analytical methodologies 
Analytical data quality is a key factor in the success of a control programme dealing with 
residues in foodstuffs. The analytical results of methods regarding official standards offer 
the necessary information for developing and managing programmes responding to a 
population’s public health needs. It is very important that sanitary authorities have readily 
available practical analysis methods which will reliably detect and quantify (without 
ambiguity) a drug’s residues which could be present in meat, milk, or eggs at a suitable 
concentration level. Unfortunately, methods having these attributes are not available for all 
residues, partly due to the large amount of possible substances which may be found in 
animals’ food chains.  
Chemical residues in food of animal origin, such as meat, milk or eggs, are frequently 
present in very low concentrations or trace levels, thereby representing an important 
challenge for a chemical analyst, given that the analytical methods developed must be 
highly sensitive and selective. 
The prior treatment which a sample has received is very important for ensuring that methods 
reach desired detection levels as well as an acceptable level of exactitude and precision, 
thereby enabling the factors responsible for analyte loss to be controlled during such 
procedure (The Spanish Industrial Pharmaceutics Association – Asociación Española de 
Farmacéuticos de la Industria [AEFI], 2001); this would include  the presence of functional 
reactive  groups which can interfere with such determination (LoBrutto & Patel, 2007).  
Analytical methods will always have to be tested/proved on material from each animal 
species since differences in composition (fat, specifics proteins, eg: myoglobin) can influence 
both analyte extraction and separation. Another important consideration concerns the 
treatment which biotransformation enzyme-rich tissues such as the liver should receive as 
this may induce post-mortem metabolism thereby altering real results. Special management 
musts also be used for determining analytes in eggs because eggs consist of two 
distinct compartments (the white and the yolk) whose chemical composition is different, as 
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NOAEL  : Not Observed Adverse Effect Level 
UF         : Uncertainty Factor (10, 100, n) 
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The scientific community focuses on developing reliable, economic and rapid methods (and 
whenever possible automated) which could be applied to evaluating the safety of foodstuffs 
bearing in mind the broad range of existing chemicals and matrices (Botsoglou & Fletouris, 
2000). A unified procedure would eliminate the need for using separate methods for 
detecting multiple residues in the same product; however, such methods are rarely found in 
real life. There is an immense variety of methods for identifying, confirming and 
quantifying analytes which could be used individually or coupled to each other in a suitable 
way. These methods can be grouped into bioassays, microbiology assays, immunochemical 
assays and physical-chemical assays. 
4.1 Bioassays 
Biological methods for determining toxic residues in foodstuffs can be used both in vivo and 
in vitro (FAO, 2004) and have been particularly developed for detecting and quantifying the 
phycotoxins present in shellfish. The mouse bioassay is the most used one and is even 
accepted by regulating entities.  
A toxin extract is intraperitoneally injected into mice having around 20 g body weight in the 
mouse bioassay and their survival is monitored from 24 to 48 hours. One mouse unit (MU) 
is defined as being the minimum quantity of toxin needed to kill a mouse within 24 hours. 
Sample toxicity (MU/g whole tissue) is determined from the smallest dose at which two 
mice or more in a group of three die within 24 hours. The regulatory level is set at 0.05 
MU/g whole tissues in many countries; this assay’s major disadvantages are therefore a lack 
of specificity (no differentiation between various toxin components), subjectivity regarding 
the animals’ time of death as well as maintaining and killing laboratory animals. This assay 
may also give false positives because of interference which can be very toxic for mice. The 
EU has issued directions on how to perform this assay in an attempt to standardise the 
mouse bioassay methodology.  
Other bioassays which are also used would include the suckling mouse assay for detecting 
marine toxins which determin the weight of the intestine regarding body weight, the rat 
bioassay which is based on inducing diarrhoea in rats, the Daphnia magna assay which is 
used for detecting okadaic acid, the intestinal loop assay which determines the 
accumulation of fluids in rabbit intestine and mice and cytotoxicity assays which are based 
on observing morphological changes in cells. 
4.2 Microbiological assays 
The microbiological methods used for detecting antimicrobial residues in foodstuffs are 
based on inhibiting microbial growth, microbial receptor activity and enzymatic reactions 
and could be applied to all types of matrices, usually milk, meat, eggs and honey. Microbial 
inhibition assays involve culturing a microorganism from a standard strain, usually Bacillus 
stearothermophilus, Bacillus subtilis, Bacillus cereus, Micrococcus luteus, Escherichia coli, Bacillus 
megatherium, Sarcina lutea and/or Streptococcus thermophilus (AEFI, 2001). 
4.3 Immunochemical assays  
Immunochemical methods represent an important tool for determining drug residues, given 
their high specificity, they lead to analytes being determined in samples having had very 
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mouse bioassay methodology.  
Other bioassays which are also used would include the suckling mouse assay for detecting 
marine toxins which determin the weight of the intestine regarding body weight, the rat 
bioassay which is based on inducing diarrhoea in rats, the Daphnia magna assay which is 
used for detecting okadaic acid, the intestinal loop assay which determines the 
accumulation of fluids in rabbit intestine and mice and cytotoxicity assays which are based 
on observing morphological changes in cells. 
4.2 Microbiological assays 
The microbiological methods used for detecting antimicrobial residues in foodstuffs are 
based on inhibiting microbial growth, microbial receptor activity and enzymatic reactions 
and could be applied to all types of matrices, usually milk, meat, eggs and honey. Microbial 
inhibition assays involve culturing a microorganism from a standard strain, usually Bacillus 
stearothermophilus, Bacillus subtilis, Bacillus cereus, Micrococcus luteus, Escherichia coli, Bacillus 
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4.3 Immunochemical assays  
Immunochemical methods represent an important tool for determining drug residues, given 
their high specificity, they lead to analytes being determined in samples having had very 
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reduced prior cleaning treatment. These assays are based on the reaction of an antigen 
binding to a specific primary antibody or for each antigen, analogously to an enzyme-
substrate reaction. The most common immunochemical methods would include the 
enzyme-linked immunosorbent assay (ELISA), direct and indirect competitive enzyme-
linked immunosorbent assays, immunoaffinity chromatography (IAC), radioimmunoassay 
(RIA), the enzyme-monitored immunotest (EMIT), the fluorescent immunoassay (FIA) and 
the chemiluminescence immunoassay. 
4.4 Physical-chemical assays 
Physical-chemical methods are mainly used for isolating, separating, quantifying and 
confirming the presence of dangerous residues in samples; this requires that the sensitivity 
of a particular selection method and the determinative or confirmation method are similar. 
Numerous procedures based on the analytes’different physicochemical properties have 
been developed for achieving this objective. Even though a drug’s chemical structure greatly 
determines the most suitable method for its determination, different methods are usually 
available for the same analyte due to the large amount of possibilities and by coupling 
different methods to obtain optimum analyte separation and detection.  
Separation methods are based on the principles of chromatography and are generally 
coupled to high sensitivity and selectivity detection techniques leading to quantifying an 
analyte with a high level of precision and exactitude and also its unequivocal identification 
at very low concentration levels. The chromatographic methods used for determining 
analytes in complex matrices would be gas chromatography (GC), high performance liquid 
chromatography (HPLC), ionic chromatography (IC), size exclusion chromatography (SEC), 
supercritical fluid chromatography (SFC), affinity chromatography (AC). 
Spectrometric methods are also used either alone or coupled to chromatographic or 
immunochemical methods such as ultraviolet-visible absorption spectrometry, absorption 
spectrometry in the near and middle infrared sections, fluorescence and chemiluminescence 
spectrometry, X-ray fluorescence spectrometry, atomic absorption spectrometry, atomic 
emission spectrometry (AES), inductively-coupled plasma atomic emission spectrometry 
(ICP-AES), nuclear magnetic resonance (NMR), mass spectrometry (MS) and mass 
spectrometry in tandem (MS/MS) (Mastovska, 2011).  
Other separations methods are used in determined analysis such as capillary electrophoresis 
(CE), electro capillary chromatography (ECC) and polarimetry (Rouessac & Rouessac, 2003). 
5. Veterinary drugs and growth promoters in food of animal origin 
Currently, rearing animals aimed at feeding the human population mainly depends on 
using pharmacologically-active compounds. Using drugs in the animals is fundamental for 
animal health and wellbeing and for the economy of agribusiness. The reported benefits are 
mainly derived from keeping animals in good health, thereby reducing the possibility of a 
disease becoming transmitted from animals to humans. However, residues from drugs used 
in producing food of animal origin could increase the risk of disease in the people who 
consume products from treated animals. 
In principle, all pharmaceutical preparations administered to animals producing foodstuffs 
can give rise to residues in edible tissue, milk or eggs. In addition to drug dose, residue 
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levels depend on withdrawal time. In spite of most drugs representing a relatively low risk 
for the general public, when used responsibly and in line with instructions approved by the 
laboratories making veterinary drugs, adverse reactions have been frequently reported for 
some compounds; these would include antibacterial, antihelminthic, anticoccidial and 
antiprotozoal drugs and growth promoters.  
5.1 Antibacterial drugs 
Residues from antibacterial drugs in food products of animal origin can represent a danger 
for consumers. The poisonous effects are not very probable since the residues are present in 
very low concentrations. Some substances must receive particular attention due allergic 
reactions. The main hazardous effect is likely to be the development of resistant bacterial 
strains following sub-therapeutic doses of antimicrobials being ingested; such resistance 
could be transferred to other bacteria. This could include resistance being transferred from 
non-pathogenic organisms to pathogenic ones which would then no longer respond to 
standard drug treatment (the Institute of Food Technologists [IFT], 2006). However, the 
generally used antibacterial drugs are presented in Table 1. 
Differences in substitutions in the basic ring structures between the various aminoglycosides 
account for the relatively minor differences in antimicrobial spectra and resistance and 
toxicity patterns. Aminoglycosides given in therapeutic dosages mainly cause ototoxicosis, 
but may also cause nephrotoxicosis, allergy and neuromuscular disturbances. 
Chloramphenicol (an antibacterial belonging to the amphenicol group) has been used in 
treatment and prophylactically in food-producing animals for several years now (i.e. 
poultry, calves, pigs, sheep and fish). Chloramphenicol’s most serious toxic effect is bone 
marrow depression which is generally dose-related and reversible but can sometimes be 
fatal in patients who are probably genetically predisposed. A toxic syndrome has been 
reported in newborn infants receiving large doses of chloramphenicol which is characterised 
by vomiting, hypothermia, cyanosis and circulatory collapse followed by death; this 
syndrome rarely occurs in adults. Chloramphenicol may also cause neuritis, encephalopathy 
with dementia and ototoxicity; its use is restricted in many countries, while it is totally 
banned for use in food-producing animals within the European Union and the USA. 
Chloramphenicol and its metabolites could be genotoxic (Lozano & Arias, 2008). 
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5. Veterinary drugs and growth promoters in food of animal origin 
Currently, rearing animals aimed at feeding the human population mainly depends on 
using pharmacologically-active compounds. Using drugs in the animals is fundamental for 
animal health and wellbeing and for the economy of agribusiness. The reported benefits are 
mainly derived from keeping animals in good health, thereby reducing the possibility of a 
disease becoming transmitted from animals to humans. However, residues from drugs used 
in producing food of animal origin could increase the risk of disease in the people who 
consume products from treated animals. 
In principle, all pharmaceutical preparations administered to animals producing foodstuffs 
can give rise to residues in edible tissue, milk or eggs. In addition to drug dose, residue 
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levels depend on withdrawal time. In spite of most drugs representing a relatively low risk 
for the general public, when used responsibly and in line with instructions approved by the 
laboratories making veterinary drugs, adverse reactions have been frequently reported for 
some compounds; these would include antibacterial, antihelminthic, anticoccidial and 
antiprotozoal drugs and growth promoters.  
5.1 Antibacterial drugs 
Residues from antibacterial drugs in food products of animal origin can represent a danger 
for consumers. The poisonous effects are not very probable since the residues are present in 
very low concentrations. Some substances must receive particular attention due allergic 
reactions. The main hazardous effect is likely to be the development of resistant bacterial 
strains following sub-therapeutic doses of antimicrobials being ingested; such resistance 
could be transferred to other bacteria. This could include resistance being transferred from 
non-pathogenic organisms to pathogenic ones which would then no longer respond to 
standard drug treatment (the Institute of Food Technologists [IFT], 2006). However, the 
generally used antibacterial drugs are presented in Table 1. 
Differences in substitutions in the basic ring structures between the various aminoglycosides 
account for the relatively minor differences in antimicrobial spectra and resistance and 
toxicity patterns. Aminoglycosides given in therapeutic dosages mainly cause ototoxicosis, 
but may also cause nephrotoxicosis, allergy and neuromuscular disturbances. 
Chloramphenicol (an antibacterial belonging to the amphenicol group) has been used in 
treatment and prophylactically in food-producing animals for several years now (i.e. 
poultry, calves, pigs, sheep and fish). Chloramphenicol’s most serious toxic effect is bone 
marrow depression which is generally dose-related and reversible but can sometimes be 
fatal in patients who are probably genetically predisposed. A toxic syndrome has been 
reported in newborn infants receiving large doses of chloramphenicol which is characterised 
by vomiting, hypothermia, cyanosis and circulatory collapse followed by death; this 
syndrome rarely occurs in adults. Chloramphenicol may also cause neuritis, encephalopathy 
with dementia and ototoxicity; its use is restricted in many countries, while it is totally 
banned for use in food-producing animals within the European Union and the USA. 
Chloramphenicol and its metabolites could be genotoxic (Lozano & Arias, 2008). 
Differences in substitutions in the basic ring structures between the various aminoglycosides 
account for the relatively minor differences in antimicrobial spectra and resistance and 
toxicity patterns. Aminoglycosides given in therapeutic dosages mainly cause ototoxicosis, 
but may also cause nephrotoxicosis, allergy and neuromuscular disturbances. 
Chloramphenicol (an antibacterial belonging to the amphenicol group) has been used in 
treatment and prophylactically in food-producing animals for several years now (i.e. 
poultry, calves, pigs, sheep and fish). Chloramphenicol’s most serious toxic effect is bone 
marrow depression which is generally dose-related and reversible but can sometimes be 
fatal in patients who are probably genetically predisposed. A toxic syndrome has been 
reported in newborn infants receiving large doses of chloramphenicol which is characterised 
by vomiting, hypothermia, cyanosis and circulatory collapse followed by death; this 
syndrome rarely occurs in adults. Chloramphenicol may also cause neuritis, encephalopathy 
with dementia and ototoxicity; its use is restricted in many countries, while it is totally 
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banned for use in food-producing animals within the European Union and the USA. 
Chloramphenicol and its metabolites could be genotoxic (Lozano & Arias, 2008). 
 
Antibacterials 
Aminoglicosides Streptomycin, kanamycin, amikacin, neomycin, apramycin 
Amphenicols Chloramphenicol, thiamphenicol, florfenicol 
Beta-lactams Penicilins, cephalosporins 
Macrolides Erythromycin, spiramycin, kitasamycin, josamycin, desmycosin, mirosamycin, tilmicosin, leucomycin, tylosin  
Nitrofurans Furazolidone, nitrofurazone, furaltadone, nitrofurantoin 
Quinolones Ciprofloxacin, danofloxacin, difloxacin, enrofloxacin, flumequine, marbofloxacin, norfloxacin, ofloxacin   
Sulphonamides 
Sulfadiazine, sulfadimethoxine, sulfamethazine, 
sulfadoxine, sulfaethoxypyridazine, sulfaguanidine, 
sulfamerazine, sulfamethoxazole, sulfapyridine, 
sulfamethoxydiazine, sulfamethoxypyridazine, 
sulfamonomethoxine, sulfathiazole,  sulfaquinoxaline  
Tetracyclines Chlortetracycline, oxytetracycline, demeclocycline, doxycycline, methacycline, minocycline 
Antihelmintics 
Benzamidazoles Thiabendazol, flubendazol, fenbendazol, mebendazol, albendazol,  oxfendazol, febantel 
Imidazotiazoles Levamisole 
Organophosphates Haxolon, coumaphos, dichlorvos 
Tetrahydropyrimidines Morantel, pyrantel 
Salicylanilides Closantel, niclosamide, oxyclozanide, rafoxanide 
Sustituted phenols Dichlorophen, hexachlorophen 
Macrocycliclactones Abamectin, ivermectin, moxidectin 
Piperazinederivates Piperazine, diethylcarbamazine 
Antiprotozoals 
Benzamides Aklomide, nitromide, dinitolmide 
Carbanilides Nicarbazin, imidocarb 
Nitroimidazoles Ronidazole, dimetridazole, metronidazole,  ipronidazole 
Polyether ionophore Monensin, narasin, lasalocid, salinomycin, maduramicin  
Quinolonederivates Buquinolate, decoquinate, methylbenzoquate 
Triazines Clazuril, diclazuril, toltrazuril 
Growth 
promoters 
Antibiotics Monensin, salinomycin, bambermycin, avilamycin 
Anabolic hormones Estradiol-17,  progesterone, testosterone 
Synthetic steroidal 
Boldenone, chlormadinone acetate, ethylenestrol, 
fluoxymesterone, medroxyprogesterone acetate, megestrol 
acetate, methandienone, methylboldenone, 
methyltestosterone, drostanolone, norethandrolone, 
norgestomet, norgestrel, nortestosterone  oxymetholone  
Organic arsenicals Arsanilic acid 
Peptide antibiotics Avoparcin, bacitracin, efrotomycin, enramycin, thiopeptin  
Quinoxaline-1,4-dioxides Carbadox, olaquindox 
Beta-adrenergic agonists 
Bambuterol, bromobuterol, carbuterol, cimaterol, 
clenbuterol, dobutamine, fenoterol, isoproterenol, 
mabuterol, mapenterol, metaproterenol, pirbuterol, 
ractopamine, reproterol, rimiterol, ritodrine, salbutamol  
Table 1. Drugs administrated in treatment and prophylactically in food-producing animals 
Penicillins have low toxicity; hypersensitivity reactions, especially skin rashes, are by far 
their most common adverse effects. Gastrointestinal disturbances including diarrhoea, 
nausea and vomiting may also sometimes appear. No teratogenic effects have been 
reported. Some studies have indicated that sensitive people have experienced allergic 
reactions, such as genera pruritis (itching), difficulty in swallowing and talking, dyspnoea, 
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dermatitis caused by contact and urticaria (hives) caused by consuming residues present in 
meat and/or milk (Medina et al., 2008). The allergic reactions caused by penicillin and its 
derivatives have been considered by the JECFA committee as being determinant factors for 
evaluating and establishing safe residue levels in foodstuffs. The adverse effects associated 
with cephalosporins are similar to those described for penicillins. 
Lincomycine-macrolide is used for the initial treatment of mild to moderate staphylococcal 
infections in calves, sheep, goats and pigs and it is also added in feed for growth-promoting 
purposes. Lincomycine is reported to cause gastrointestinal disturbances including 
diarrhoea, vomiting and nausea which that may prove fatal. Other adverse effects include 
skin rashes, urticaria, polyarthritis, hepatic damage and haematological disturbances (WHO, 
1989). 
All nitrofurans have been widely used in the prophylactic and therapeutic treatment of 
infections caused by bacteria and protozoa in pigs, cattle, poultry, rabbits and fish. The use 
of nitrofurans in food-producing animals has been controversial because residues from 
these drugs may be mutagenic and tumorigenic. Toxicological studies have shown that 
nitrofurazone is a carcinogenic but not genotoxic agent, whereas furazolidone has exhibited 
both carcinogenic and genotoxic properties (WHO, 1993). The metabolites from nitrofurans 
can remain stored for weeks or m animal proteins, including eggs from farmyard birds, 
species in which this compound has been used as an anticoccidial. The systemic use of 
nitrofurans in food producing animals has thus been prohibited in the USA and Europe, 
(EMEA, 1997).  
Quinolones are synthetic antibiotics which are very effective in combating various diseases 
in animal husbandry and aquaculture. The most frequent adverse affects of quinolone 
antibiotics most frequently occurring adverse affects are gastrointestinal disturbances 
including nausea, vomiting, diarrhoea, headache, visual disturbances and insomnia. Rashes, 
pruritus and epidermal necrolysis have sometimes also occurred (Jimenez et al., 2011). 
The residuality of sulphonamides used in treating coccidial and bacterial infections and also 
as growth-promoting agents may cause hypersensitivity reactions, mainly cutaneous rash; 
however, no anaphylactic manifestations caused by this type of residues is known.  
There is sufficient evidence indicating that ingesting the  antibiotics in sub-therapeutic doses 
makes a significant contribution towards the appearance of resistant microorganisms in 
animals which can become transmitted to humans, thereby provoking difficult to treat 
infections. Some sample studies have found antibiotic-resistant coliform microorganisms in 
raw and cooked meat. Likewise, antibiotics consumed by human beings from residues 
present in food of animal origin lead to an alteration of intestinal flora and consequently a 
reduction of bacteria competing with pathogenous microorganisms, thereby increasing the 
risk of disease. 
Tetracyclines can generate bacterial resistance; oxytetracycline particularly induces 
antibiotic resistance in coliform microorganisms present in the human intestine. Recognition 
of this effect has been used by the JECFA committee as the point of reference for defining 
acceptable consumption levels for different antibiotics. 
The problem of resistance is not the only motive for the medical community’s 
preoccupation. Farmers and veterinarians are worried because bacterial resistance in farm 
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banned for use in food-producing animals within the European Union and the USA. 
Chloramphenicol and its metabolites could be genotoxic (Lozano & Arias, 2008). 
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Beta-lactams Penicilins, cephalosporins 
Macrolides Erythromycin, spiramycin, kitasamycin, josamycin, desmycosin, mirosamycin, tilmicosin, leucomycin, tylosin  
Nitrofurans Furazolidone, nitrofurazone, furaltadone, nitrofurantoin 
Quinolones Ciprofloxacin, danofloxacin, difloxacin, enrofloxacin, flumequine, marbofloxacin, norfloxacin, ofloxacin   
Sulphonamides 
Sulfadiazine, sulfadimethoxine, sulfamethazine, 
sulfadoxine, sulfaethoxypyridazine, sulfaguanidine, 
sulfamerazine, sulfamethoxazole, sulfapyridine, 
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Imidazotiazoles Levamisole 
Organophosphates Haxolon, coumaphos, dichlorvos 
Tetrahydropyrimidines Morantel, pyrantel 
Salicylanilides Closantel, niclosamide, oxyclozanide, rafoxanide 
Sustituted phenols Dichlorophen, hexachlorophen 
Macrocycliclactones Abamectin, ivermectin, moxidectin 
Piperazinederivates Piperazine, diethylcarbamazine 
Antiprotozoals 
Benzamides Aklomide, nitromide, dinitolmide 
Carbanilides Nicarbazin, imidocarb 
Nitroimidazoles Ronidazole, dimetridazole, metronidazole,  ipronidazole 
Polyether ionophore Monensin, narasin, lasalocid, salinomycin, maduramicin  
Quinolonederivates Buquinolate, decoquinate, methylbenzoquate 
Triazines Clazuril, diclazuril, toltrazuril 
Growth 
promoters 
Antibiotics Monensin, salinomycin, bambermycin, avilamycin 
Anabolic hormones Estradiol-17,  progesterone, testosterone 
Synthetic steroidal 
Boldenone, chlormadinone acetate, ethylenestrol, 
fluoxymesterone, medroxyprogesterone acetate, megestrol 
acetate, methandienone, methylboldenone, 
methyltestosterone, drostanolone, norethandrolone, 
norgestomet, norgestrel, nortestosterone  oxymetholone  
Organic arsenicals Arsanilic acid 
Peptide antibiotics Avoparcin, bacitracin, efrotomycin, enramycin, thiopeptin  
Quinoxaline-1,4-dioxides Carbadox, olaquindox 
Beta-adrenergic agonists 
Bambuterol, bromobuterol, carbuterol, cimaterol, 
clenbuterol, dobutamine, fenoterol, isoproterenol, 
mabuterol, mapenterol, metaproterenol, pirbuterol, 
ractopamine, reproterol, rimiterol, ritodrine, salbutamol  
Table 1. Drugs administrated in treatment and prophylactically in food-producing animals 
Penicillins have low toxicity; hypersensitivity reactions, especially skin rashes, are by far 
their most common adverse effects. Gastrointestinal disturbances including diarrhoea, 
nausea and vomiting may also sometimes appear. No teratogenic effects have been 
reported. Some studies have indicated that sensitive people have experienced allergic 
reactions, such as genera pruritis (itching), difficulty in swallowing and talking, dyspnoea, 
 
Chemical Residues in Animal Food Products: An Issue of Public Health 173 
dermatitis caused by contact and urticaria (hives) caused by consuming residues present in 
meat and/or milk (Medina et al., 2008). The allergic reactions caused by penicillin and its 
derivatives have been considered by the JECFA committee as being determinant factors for 
evaluating and establishing safe residue levels in foodstuffs. The adverse effects associated 
with cephalosporins are similar to those described for penicillins. 
Lincomycine-macrolide is used for the initial treatment of mild to moderate staphylococcal 
infections in calves, sheep, goats and pigs and it is also added in feed for growth-promoting 
purposes. Lincomycine is reported to cause gastrointestinal disturbances including 
diarrhoea, vomiting and nausea which that may prove fatal. Other adverse effects include 
skin rashes, urticaria, polyarthritis, hepatic damage and haematological disturbances (WHO, 
1989). 
All nitrofurans have been widely used in the prophylactic and therapeutic treatment of 
infections caused by bacteria and protozoa in pigs, cattle, poultry, rabbits and fish. The use 
of nitrofurans in food-producing animals has been controversial because residues from 
these drugs may be mutagenic and tumorigenic. Toxicological studies have shown that 
nitrofurazone is a carcinogenic but not genotoxic agent, whereas furazolidone has exhibited 
both carcinogenic and genotoxic properties (WHO, 1993). The metabolites from nitrofurans 
can remain stored for weeks or m animal proteins, including eggs from farmyard birds, 
species in which this compound has been used as an anticoccidial. The systemic use of 
nitrofurans in food producing animals has thus been prohibited in the USA and Europe, 
(EMEA, 1997).  
Quinolones are synthetic antibiotics which are very effective in combating various diseases 
in animal husbandry and aquaculture. The most frequent adverse affects of quinolone 
antibiotics most frequently occurring adverse affects are gastrointestinal disturbances 
including nausea, vomiting, diarrhoea, headache, visual disturbances and insomnia. Rashes, 
pruritus and epidermal necrolysis have sometimes also occurred (Jimenez et al., 2011). 
The residuality of sulphonamides used in treating coccidial and bacterial infections and also 
as growth-promoting agents may cause hypersensitivity reactions, mainly cutaneous rash; 
however, no anaphylactic manifestations caused by this type of residues is known.  
There is sufficient evidence indicating that ingesting the  antibiotics in sub-therapeutic doses 
makes a significant contribution towards the appearance of resistant microorganisms in 
animals which can become transmitted to humans, thereby provoking difficult to treat 
infections. Some sample studies have found antibiotic-resistant coliform microorganisms in 
raw and cooked meat. Likewise, antibiotics consumed by human beings from residues 
present in food of animal origin lead to an alteration of intestinal flora and consequently a 
reduction of bacteria competing with pathogenous microorganisms, thereby increasing the 
risk of disease. 
Tetracyclines can generate bacterial resistance; oxytetracycline particularly induces 
antibiotic resistance in coliform microorganisms present in the human intestine. Recognition 
of this effect has been used by the JECFA committee as the point of reference for defining 
acceptable consumption levels for different antibiotics. 
The problem of resistance is not the only motive for the medical community’s 
preoccupation. Farmers and veterinarians are worried because bacterial resistance in farm 
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animals is interfering with drug efficacy thereby leading to the use of greater 
concentrations than those initially established as being therapeutic. However, in spite of 
antibiotics being the type of veterinary drugs most used in the agribusiness industry, 
there are few options to choose from due to the limited offer of drugs which have been 
approved for use in animals producing foodstuffs compared to those regarding 
therapeutic use in humans. 
5.2 Antihelminthic, anticoccidial and antiprotozoal drugs 
Parasitic diseases constitute an ever present threat in rearing birds and livestock, but they 
may be controlled by adding low levels of drugs to daily rations. The drugs generally 
against internal parasites affecting animals collectively called helminths are shown in Table 
1. Such drugs are used at levels which do not allow resistant strains to develop and also 
become rapidly metabolised in an animal’s organism so that the residues in edible tissues 
are minimal. 
Benzimidazoles, like thiabendazole, are used in sheep, cattle, horses, pigs and poultry. They 
become rapidly eliminated from the organism due to their high solubility; however, some 
studies has shown that these compounds are teratogenic and nephrotoxic in mice and ewes 
(Danaher et al., 2007). Mebendazole metabolits (hydroxylmebendazole and amino-
mebendazole) belonging to the  benzimidazole group and which are widely used as an 
antinematode in horses, sheep, pigs and poultry,  have also been shown to have teratogenic 
effects (Buchmann et al., 1992). 
Levamisol is the most well-known drug from the imidazothiazole group, which has a broad 
spectrum of activity against nematodes; however, it has been found that it induces 
idiosyncratic organulocytosis in some individuals. Levamisol’s toxic effects have caused 
preoccupation in the regulatory bodies and, given that these effects the original compound 
than in its metabolites, this is the analyte of interest in tissue samples. 
Organophosphates represent one of the alternatives for treating benzimidazole-resistant 
nematodes; haloxon (being one of them) is the safest and has been approved by the US Food 
and Drug Administration (FDA) for use in sheep, cattle and goats. By contrast, dichlorvos 
has an acceptable antihelminthic spectrum in cattle and sheep, but it does not have FDA 
approval for use in ruminants due to its suspected carcinogenic effects and narrow safety 
margin (Botsoglou & Fletouris, 2000).  
Ivermectin, a macrocyclic lactone, is exceptionally effective in very low dosages against 
nematodes and arthropod parasites in cattle and has been widely used for treating endo- 
and ecto-parasites in cattle, sheep, goats and pigs; however, ivermectin has had a 
teratogenic effect in rats, rabbits and mice (Moreno et al., 2008). 
Anticoccidial and antiprotozoal drugs are generally used in the poultry industry against 
protozoan infections caused by pathogenic species of Eimeria. Some compounds used as 
antibacterial drugs are also used as coccidiostats, including sulphaquinoxaline, 
sulphadimethoxine, sulphamethoxypyridazine, sulphachlorpyrazine, sulphamethazine, 
sulphaguanidine, furazolidone, nitrofurazone, tetracycline and chlortetracycline. Table 1 
shows compounds whose primary function and use are related to antiprotozoal drugs.  
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A number of nitroimidazoles have already been banned within the European Union, even 
for therapeutic purposes, since they are mutagens and suspected carcinogens. The use of 
ronidazole has been banned by Council Regulation 3426/93/EEC (Official Journal of the 
European Communities, 1993) whereas dimetridazole use is banned by Council Regulation 
1798/95/EEC (Official Journal of the European Communities, 1995). Their antibacterial and 
mutagenic activity is closely related to the reduction of the 5-nitro group, which is common 
to all nitroimidazole drugs. Metronidazole is used for treating bovine trichomoniasis by 
topical application or intravenous injection but it is a genotoxic carcinogen in animals. 
Polyether antibiotics are produced by various actinomyces, mostly Streptomyces species, and 
constitute the agents most widely used by the poultry industry over the last two decades. 
They provide excellent disease control and are refractory for the development of resistance. 
They have a low therapeutic index but may be very toxic in certain species; salinomycin and 
narasin can be fatally toxic in turkeys, for example (Weissinger, 1994). 
The problem of residues from antihelminthic, anticoccidial and antiprotozoal drugs may be 
easily controlled by imposing obligatory withdrawal times, generally 7-10 days, but this is 
unfortunately not always respected. On the other hand, given the large number of drugs 
which may be easily obtained on the market, many producers change one compound for 
another to avoid resistance becoming developed to drugs; however, this increases the 
degree of exposure to thema the misms, which may lead to yet another problem if it is taken 
into account that these drugs are also used as growth promoters. 
5.3 Growth promoters 
Growth promoters are substances which produce improvements in growth rate when added 
to animal feed in sub-therapeutic dosages over an extended period of time. Table 1 shows 
the compounds most commonly used for this purpose. The anabolic hormonal-type growth 
promoters can be classified according to their chemical structure or origin into endogenous 
sex steroids, steroidal compounds, not naturally occurring non-steroidal compounds and 
polypeptide hormones.  
Anabolic hormones (estradiol-17 and progesterone - two female sex hormones, and 
testosterone - one male sex hormone) are used for increasing body mass in livestock rearing. 
Synthetic steroidal compounds have only been approved for therapy regarding 
reproductive behaviour and disorders in non-food-producing animals; however, they are 
used illegally around the world. Boldenone, chlormadinone acetate, ethylenestrol, 
fluoxymesterone, medroxyprogesterone acetate, megestrol acetate, methandienone, 
methylboldenone, methylthisterone, drostanolone, norethandrolone, norgestomet, 
norgestrel, norethisterone (nandrolone), norethisterone decanoate, oxymetholone, and 
stanozolol would be examples of synthetic steroidal compounds which have only been 
approved for therapy regarding reproductive behaviour and disorders in non-food-
producing animals. 
Zeranol and stilbene estrogens, including diethylstilbestrol, hexestrol and dienestrol, are the 
major non-steroidal not naturally occurring compounds included in the class of anabolic 
drugs and somatropin is the most common polypeptide compound affecting growth. 
Diethylstilbestrol, hexestrol and dienestrol are all stilbene estrogens which are currently 
banned worldwide for use in food-producing animals. They are genotoxic, not easily 
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animals is interfering with drug efficacy thereby leading to the use of greater 
concentrations than those initially established as being therapeutic. However, in spite of 
antibiotics being the type of veterinary drugs most used in the agribusiness industry, 
there are few options to choose from due to the limited offer of drugs which have been 
approved for use in animals producing foodstuffs compared to those regarding 
therapeutic use in humans. 
5.2 Antihelminthic, anticoccidial and antiprotozoal drugs 
Parasitic diseases constitute an ever present threat in rearing birds and livestock, but they 
may be controlled by adding low levels of drugs to daily rations. The drugs generally 
against internal parasites affecting animals collectively called helminths are shown in Table 
1. Such drugs are used at levels which do not allow resistant strains to develop and also 
become rapidly metabolised in an animal’s organism so that the residues in edible tissues 
are minimal. 
Benzimidazoles, like thiabendazole, are used in sheep, cattle, horses, pigs and poultry. They 
become rapidly eliminated from the organism due to their high solubility; however, some 
studies has shown that these compounds are teratogenic and nephrotoxic in mice and ewes 
(Danaher et al., 2007). Mebendazole metabolits (hydroxylmebendazole and amino-
mebendazole) belonging to the  benzimidazole group and which are widely used as an 
antinematode in horses, sheep, pigs and poultry,  have also been shown to have teratogenic 
effects (Buchmann et al., 1992). 
Levamisol is the most well-known drug from the imidazothiazole group, which has a broad 
spectrum of activity against nematodes; however, it has been found that it induces 
idiosyncratic organulocytosis in some individuals. Levamisol’s toxic effects have caused 
preoccupation in the regulatory bodies and, given that these effects the original compound 
than in its metabolites, this is the analyte of interest in tissue samples. 
Organophosphates represent one of the alternatives for treating benzimidazole-resistant 
nematodes; haloxon (being one of them) is the safest and has been approved by the US Food 
and Drug Administration (FDA) for use in sheep, cattle and goats. By contrast, dichlorvos 
has an acceptable antihelminthic spectrum in cattle and sheep, but it does not have FDA 
approval for use in ruminants due to its suspected carcinogenic effects and narrow safety 
margin (Botsoglou & Fletouris, 2000).  
Ivermectin, a macrocyclic lactone, is exceptionally effective in very low dosages against 
nematodes and arthropod parasites in cattle and has been widely used for treating endo- 
and ecto-parasites in cattle, sheep, goats and pigs; however, ivermectin has had a 
teratogenic effect in rats, rabbits and mice (Moreno et al., 2008). 
Anticoccidial and antiprotozoal drugs are generally used in the poultry industry against 
protozoan infections caused by pathogenic species of Eimeria. Some compounds used as 
antibacterial drugs are also used as coccidiostats, including sulphaquinoxaline, 
sulphadimethoxine, sulphamethoxypyridazine, sulphachlorpyrazine, sulphamethazine, 
sulphaguanidine, furazolidone, nitrofurazone, tetracycline and chlortetracycline. Table 1 
shows compounds whose primary function and use are related to antiprotozoal drugs.  
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A number of nitroimidazoles have already been banned within the European Union, even 
for therapeutic purposes, since they are mutagens and suspected carcinogens. The use of 
ronidazole has been banned by Council Regulation 3426/93/EEC (Official Journal of the 
European Communities, 1993) whereas dimetridazole use is banned by Council Regulation 
1798/95/EEC (Official Journal of the European Communities, 1995). Their antibacterial and 
mutagenic activity is closely related to the reduction of the 5-nitro group, which is common 
to all nitroimidazole drugs. Metronidazole is used for treating bovine trichomoniasis by 
topical application or intravenous injection but it is a genotoxic carcinogen in animals. 
Polyether antibiotics are produced by various actinomyces, mostly Streptomyces species, and 
constitute the agents most widely used by the poultry industry over the last two decades. 
They provide excellent disease control and are refractory for the development of resistance. 
They have a low therapeutic index but may be very toxic in certain species; salinomycin and 
narasin can be fatally toxic in turkeys, for example (Weissinger, 1994). 
The problem of residues from antihelminthic, anticoccidial and antiprotozoal drugs may be 
easily controlled by imposing obligatory withdrawal times, generally 7-10 days, but this is 
unfortunately not always respected. On the other hand, given the large number of drugs 
which may be easily obtained on the market, many producers change one compound for 
another to avoid resistance becoming developed to drugs; however, this increases the 
degree of exposure to thema the misms, which may lead to yet another problem if it is taken 
into account that these drugs are also used as growth promoters. 
5.3 Growth promoters 
Growth promoters are substances which produce improvements in growth rate when added 
to animal feed in sub-therapeutic dosages over an extended period of time. Table 1 shows 
the compounds most commonly used for this purpose. The anabolic hormonal-type growth 
promoters can be classified according to their chemical structure or origin into endogenous 
sex steroids, steroidal compounds, not naturally occurring non-steroidal compounds and 
polypeptide hormones.  
Anabolic hormones (estradiol-17 and progesterone - two female sex hormones, and 
testosterone - one male sex hormone) are used for increasing body mass in livestock rearing. 
Synthetic steroidal compounds have only been approved for therapy regarding 
reproductive behaviour and disorders in non-food-producing animals; however, they are 
used illegally around the world. Boldenone, chlormadinone acetate, ethylenestrol, 
fluoxymesterone, medroxyprogesterone acetate, megestrol acetate, methandienone, 
methylboldenone, methylthisterone, drostanolone, norethandrolone, norgestomet, 
norgestrel, norethisterone (nandrolone), norethisterone decanoate, oxymetholone, and 
stanozolol would be examples of synthetic steroidal compounds which have only been 
approved for therapy regarding reproductive behaviour and disorders in non-food-
producing animals. 
Zeranol and stilbene estrogens, including diethylstilbestrol, hexestrol and dienestrol, are the 
major non-steroidal not naturally occurring compounds included in the class of anabolic 
drugs and somatropin is the most common polypeptide compound affecting growth. 
Diethylstilbestrol, hexestrol and dienestrol are all stilbene estrogens which are currently 
banned worldwide for use in food-producing animals. They are genotoxic, not easily 
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metabolised compounds, which are considered capable of irreversibly initiating the 
carcinogenic process even in small residue concentrations. Diethylstilbestrol and hexestrol 
have been legally permitted for use as anabolics for quite some time in many countries, 
whilst the use of dienestrol, which is a diethylstilbestrol metabolite, has been restricted to 
illegal practice (Dickson, 2003).  
Using these compounds, either natural or synthetic, as growth promoters in meat-producing 
animals has not been allowed in the European Union since 1988, due to potential adverse 
effects to human health, unlike in the United States where some anabolic hormonal-type 
growth promoters are permitted.  
In vivo studies have demonstrated DNA strand breaks and oxidative damage being 
triggered by desencadenados por the 17-β estradiol, thereby leading to this hormone being 
considered as triggering a genotoxic effect (for example, the proliferation of carcinogenic 
mammary cells); however, the dosage at which these alterations occur is greater than that at 
which endocrine effects are produced in animals (Mikus et al., 2001). 
Testosterone’s adverse effects are due to its hormonal activity, particularly in the prostate 
gland. Testosterone is also considered to be potentially embryotoxic and its consumption in 
therapeutic doses has led to the induction of hepatic cystitis (Durlinger et al., 2002).  
Following the ban of stilbene and other hormonal-type growth promoters, interest has 
focused on alternative compounds for promoting live weight gain in food-producing 
animals. The beta-adrenergic agonists constitute such group of compounds, clembuterol 
being the main one. It has been reported that consuming calf liver in Spain and France 
containing clenbuterol residues has induced muscular tremors, tachycardia, muscular pain, 
nervousness, headache, vertigo, nausea, vomiting and fever. It has also been used as an 
anabolizant steroid; clenbuterol is used as a tocolytic in cows, thereby supposing an 
additional risk.  
A controversy has arisen around these events regarding whether to accept or prohibit using 
clenbuterol in animal production. This drug increases channel performance, it is not 
potentially oncogenic or mutagenic and is only embryotoxic in large doses whilst its adverse 
effects on consumers becomes evident when recommended withdrawal times are not 
respected and when excessive doses are used, whether through inadequate management or 
aimed at increasing animals’ weight gain even more (Brambilla et al., 2007).  
The foregoing has led to clenbuterol being a highly controlled drug today in many countries 
which have developed programmes and mechanisms for monitoring it and its follow-up. 
However, in spite of these controls and warning signs, unfortunate events involving adverse 
reactions continue to be presented, as happened in November 2005 in Jalisco, México, when 
about 225 people experienced trembling, headaches and discomfort after having consumed 
beef containing residues of this type (Gojmerac, 2002). 
Arsanylic acid, peptide antibiotics and quinoxaline-1,4-dioxides are non-steroidal 
compounds used as growth promoters in different animal species. Arsanylic acid and its 
sodium salt are most commonly used, particularly in pigs. They are also efficacious in the 
egg-producing industry and were previously approved for use in egg-laying hens. 
However, their use in animals is generally rather limited and the risk–benefit ratio is 
questionable because these drugs can produce toxicosis, known as peripheral nerve 
demyelination.  
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In spite of the aforementioned effects, the Codex Alimentarius considers it unnecessary to 
establish an LMR for anabolic hormones as it is improbable that residues arising from the 
correct used of these substances as growth stimulators represent a danger for human 
health. It has also been demonstrated that the endogenous concentration of these 
hormones is greater when they are administered exogenously. Another reason negating 
the potential risk of this type of substance is the availability of metabolic routes which 
become rapidly degraded, meaning that the residues which the meat of treated animals 
may contain do not affect a consumer’s endocrine system. However, dispositions in 
Europe regarding these substances are stricter and do not allow any residual level of 
anabolizant drugs in meats.  
Peptide antibiotics are compounds usually containing D-amino acids. They are usually 
added to animal feeds in low concentrations and produce residues in tissues at very low or 
undetectable levels. Unfortunately, most peptide antibiotics’ metabolic pathways have not 
yet been elucidated. These antibiotics are regulated under separate legislation within the 
European Union (Brogden et al., 2003). 
Quinoxaline-1,4-dioxides and their possible residues in edible animal products have caused 
much debate regarding their mutagenic and carcinogenic potency. Carbadox was initially 
the main drug in use, but suspicion as to its safety arose because this compound exhibited 
both genotoxic and mutagenic activity. Olaquindox is also a strongly mutagenic agent but 
seemingly devoid of carcinogenic activity. 
6. Toxins in food of animal origin 
Toxins have a biological origin, mycotoxins, phycotoxins and phytotoxins having attracted 
most attention due to their potential residuality in foodstuffs, including animal subproducts. 
6.1 Mycotoxins  
Mycotoxins are secondary metabolites from fungi, mainly from the species Aspergillus, 
Fusarium and Penicillium, aflatoxins, ochratoxins, zearalenone, trichothecenes and 
fumonisins having been the most studied to date. The foodstuffs fundamentally 
contaminated by these toxins are grains and cereals constituting the main source of 
contamination for human beings. However, farm animals consuming contaminated 
foodstuffs may generate residues in meat, viscera, milk and eggs. Residuality is determined 
by contamination by high concentrations in foodstuffs ingested by animals, this being very 
uncommon, and also by theway in which the xenobiotic becomes metabolised in the 
organism. Mycotoxins do not become totally destroyed during cooking or industrialisation 
of foodstuffs due to their heat-stability. 
The types of mycotoxicosis (disease resulting from consuming mycotoxins) in human beings 
are mainly chronic. These would include Balkan endemic neuropathy in Russia caused by 
the consumption of ochratoxin A which generates nephrotoxicosis, alimentary toxic aleukia 
in the former Soviet Union associated with dermatitis, vomiting and hematopoietic 
alterations caused by trichothecenes (diacetoxiscirpenol and T-2 toxin), possible endocrinal 
alterations related to reduced masculine fertility caused by consuming zearalenone (such 
toxin acting as an xenoestrogen), hepatic cancer caused by aflatoxin B1 and possible 
esophagic and renal cancer caused by fumonisin and ochratoxin A, respectively. The IARC 
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metabolised compounds, which are considered capable of irreversibly initiating the 
carcinogenic process even in small residue concentrations. Diethylstilbestrol and hexestrol 
have been legally permitted for use as anabolics for quite some time in many countries, 
whilst the use of dienestrol, which is a diethylstilbestrol metabolite, has been restricted to 
illegal practice (Dickson, 2003).  
Using these compounds, either natural or synthetic, as growth promoters in meat-producing 
animals has not been allowed in the European Union since 1988, due to potential adverse 
effects to human health, unlike in the United States where some anabolic hormonal-type 
growth promoters are permitted.  
In vivo studies have demonstrated DNA strand breaks and oxidative damage being 
triggered by desencadenados por the 17-β estradiol, thereby leading to this hormone being 
considered as triggering a genotoxic effect (for example, the proliferation of carcinogenic 
mammary cells); however, the dosage at which these alterations occur is greater than that at 
which endocrine effects are produced in animals (Mikus et al., 2001). 
Testosterone’s adverse effects are due to its hormonal activity, particularly in the prostate 
gland. Testosterone is also considered to be potentially embryotoxic and its consumption in 
therapeutic doses has led to the induction of hepatic cystitis (Durlinger et al., 2002).  
Following the ban of stilbene and other hormonal-type growth promoters, interest has 
focused on alternative compounds for promoting live weight gain in food-producing 
animals. The beta-adrenergic agonists constitute such group of compounds, clembuterol 
being the main one. It has been reported that consuming calf liver in Spain and France 
containing clenbuterol residues has induced muscular tremors, tachycardia, muscular pain, 
nervousness, headache, vertigo, nausea, vomiting and fever. It has also been used as an 
anabolizant steroid; clenbuterol is used as a tocolytic in cows, thereby supposing an 
additional risk.  
A controversy has arisen around these events regarding whether to accept or prohibit using 
clenbuterol in animal production. This drug increases channel performance, it is not 
potentially oncogenic or mutagenic and is only embryotoxic in large doses whilst its adverse 
effects on consumers becomes evident when recommended withdrawal times are not 
respected and when excessive doses are used, whether through inadequate management or 
aimed at increasing animals’ weight gain even more (Brambilla et al., 2007).  
The foregoing has led to clenbuterol being a highly controlled drug today in many countries 
which have developed programmes and mechanisms for monitoring it and its follow-up. 
However, in spite of these controls and warning signs, unfortunate events involving adverse 
reactions continue to be presented, as happened in November 2005 in Jalisco, México, when 
about 225 people experienced trembling, headaches and discomfort after having consumed 
beef containing residues of this type (Gojmerac, 2002). 
Arsanylic acid, peptide antibiotics and quinoxaline-1,4-dioxides are non-steroidal 
compounds used as growth promoters in different animal species. Arsanylic acid and its 
sodium salt are most commonly used, particularly in pigs. They are also efficacious in the 
egg-producing industry and were previously approved for use in egg-laying hens. 
However, their use in animals is generally rather limited and the risk–benefit ratio is 
questionable because these drugs can produce toxicosis, known as peripheral nerve 
demyelination.  
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In spite of the aforementioned effects, the Codex Alimentarius considers it unnecessary to 
establish an LMR for anabolic hormones as it is improbable that residues arising from the 
correct used of these substances as growth stimulators represent a danger for human 
health. It has also been demonstrated that the endogenous concentration of these 
hormones is greater when they are administered exogenously. Another reason negating 
the potential risk of this type of substance is the availability of metabolic routes which 
become rapidly degraded, meaning that the residues which the meat of treated animals 
may contain do not affect a consumer’s endocrine system. However, dispositions in 
Europe regarding these substances are stricter and do not allow any residual level of 
anabolizant drugs in meats.  
Peptide antibiotics are compounds usually containing D-amino acids. They are usually 
added to animal feeds in low concentrations and produce residues in tissues at very low or 
undetectable levels. Unfortunately, most peptide antibiotics’ metabolic pathways have not 
yet been elucidated. These antibiotics are regulated under separate legislation within the 
European Union (Brogden et al., 2003). 
Quinoxaline-1,4-dioxides and their possible residues in edible animal products have caused 
much debate regarding their mutagenic and carcinogenic potency. Carbadox was initially 
the main drug in use, but suspicion as to its safety arose because this compound exhibited 
both genotoxic and mutagenic activity. Olaquindox is also a strongly mutagenic agent but 
seemingly devoid of carcinogenic activity. 
6. Toxins in food of animal origin 
Toxins have a biological origin, mycotoxins, phycotoxins and phytotoxins having attracted 
most attention due to their potential residuality in foodstuffs, including animal subproducts. 
6.1 Mycotoxins  
Mycotoxins are secondary metabolites from fungi, mainly from the species Aspergillus, 
Fusarium and Penicillium, aflatoxins, ochratoxins, zearalenone, trichothecenes and 
fumonisins having been the most studied to date. The foodstuffs fundamentally 
contaminated by these toxins are grains and cereals constituting the main source of 
contamination for human beings. However, farm animals consuming contaminated 
foodstuffs may generate residues in meat, viscera, milk and eggs. Residuality is determined 
by contamination by high concentrations in foodstuffs ingested by animals, this being very 
uncommon, and also by theway in which the xenobiotic becomes metabolised in the 
organism. Mycotoxins do not become totally destroyed during cooking or industrialisation 
of foodstuffs due to their heat-stability. 
The types of mycotoxicosis (disease resulting from consuming mycotoxins) in human beings 
are mainly chronic. These would include Balkan endemic neuropathy in Russia caused by 
the consumption of ochratoxin A which generates nephrotoxicosis, alimentary toxic aleukia 
in the former Soviet Union associated with dermatitis, vomiting and hematopoietic 
alterations caused by trichothecenes (diacetoxiscirpenol and T-2 toxin), possible endocrinal 
alterations related to reduced masculine fertility caused by consuming zearalenone (such 
toxin acting as an xenoestrogen), hepatic cancer caused by aflatoxin B1 and possible 
esophagic and renal cancer caused by fumonisin and ochratoxin A, respectively. The IARC 
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has classified aflatoxin B1 within group 1 (proven carcinogenic effect on humans) and 
fumonisin B1 and ochratoxin A within group 2B (possibly carcinogenic to humans) (IARC, 
1993). The evidence from in vitro studies has shown that zearalenone is a probably 
implicated in cancer of the reproductive system (Khosrokhavar et al., 2009).  
Aflatoxins and ochratoxin A are the main mycotoxins which can generate residuality and 
attention concerning them as being animal subproduct contaminants has mainly been 
focused on their presence in milk; however, it has been demonstrated that they can also 
generate residuality in meat and eggs.  
6.1.1 Aflatoxins  
Aflatoxins (AF) B1 B2 G1 and G2 are produced by fungi from the genera Aspergillus. AFB1 
may be bioactivated through CYP450 enzymes to become an epoxide which is able to form 
adducts with DNA, meaning that it has been considered that AFB1 undergoes bioactivation 
in the organism. AFB1 may also become hydroxylised to AFM1 and be excreted in milk. It 
has been estimated that  1% to 6% of AFB1 ingested by a milk-producing cow could be 
excreted as AFM1 in milk, depending on bovine productivity. AFM1, like AFB1, may form 
an epoxide and alter DNA sequences. IARC is considered to be an AFM1 in group 2B 
(IARC, 1993). MRL regulated in different countries ranges from 0.05 to 0.5 µg/L; MRL has 
also been established for AF consumed by ruminants (FAO, 2003). Experimental studies 
have shown that when animals consume foodstuffs contaminated by high levels of AF, that 
it is difficult to find naturally, the liver and kidneys are the organs where most toxins 
become accumulated, and their presence in muscle is scarce (Bailly & Guerre, 2009). These 
types of studies have also demonstrated the presence of AF in eggs from different avian 
species.  
6.1.2 Ochratoxin A  
Ochratoxin A (OA) is produced by fungi from the genera Aspergillus and Pencillium,  
the former being from tropical regions and the latter from temperate regions. OA may 
thus be widely distributed throughout the world. OA may become biotransformed 
through hydrolysis reactions in which metabolites become less toxic by the opening of the 
lactone ring which occurs during bioactivation. Detoxification may occur in ruminants 
through digestive flora action before absorption, thereby limiting the possibility that OA 
might be found in milk and/or beef (Bailly & Guerre, 2009). However, a recent study 
evaluating the presence of OA in cows’ milk formulas for infants found contamination in 
72% of the samples analysed, levels around 690 ng/L being found (Meucci et al., 2010). It 
has been shown that OA may become accumulated in pigs’ kidneys. In countries such as 
Denmark, OA levels in these organs are regulated since porcine ochratoxicosis is 
common. 
6.1.3 Fusariotoxins  
The fusariotoxins are mycotoxins which are produced by fungi from the genera Fusarium, 
zearalenone (ZEA), the fumonisins (FUM) and the trichothecenes (TCT) being the most 
important for public health.  
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ZEA is frequently implicated in reproductive disorders in animals and occasionally in 
hyperestrogenism syndromes in humans. ZEA becomes biotransformed in the intestine by 
the mucosa or bacterial flora and involves the formation of α- and β-zearalenol and α- and 
β-zearalanol. Alpha-zearalanol and β-zearalenol have greater estrogenic power than ZEA 
since they bind with greater force to their corresponding receptors (Zinedine et al., 2007).  
Alpha-zearalanol has been employed as growth promoter in cattle. Studies orientated 
towards determining residuality through experimentation have suggested that residues are 
not present in meat or eggs, even at high doses. However, a recent study has show that the 
presence of α-zearalenol in meat-based foodstuffs for infants reached levels of 30.5 µg/kg; 
the same study demonstrated the presence of mycoestrogens (ZEA, α-zearalenole and β-
zearalenole) in infants’ cow milk formulas  (Meucci et al., 2011).  
FUM properties suggest that their presence in animal meat does not represent an important 
source of contamination, since they are poorly absorbed. FUM produce liquefaction of the 
brain in horse and pulmonary oedema in pigs; ruminants and birds are more resistant. They 
have been correlated with oesophageal cancer in humans in some parts of the world and it 
has also been presumed that they may cause neural tube alterations. Their presence has 
been demonstrated and in the liver and kidneys of turkeys fed  with the maximum levels 
permitted in Europe (Tardieu et al., 2008).  
The main TCT of interest in producing animals are T-2 toxin, HT-2 toxin, diacetoxiscirpenol 
and deoxinivalenol. The TCT do not usually represent a risk of contamination in food of 
animal origin due to their rapid metabolism (Bailly & Guerre, 2009).  
6.2 Phycotoxins  
Around 75 species of marine micro-algae, belonging to the dinoflagellate group, produce 
secondary metabolites which represent potent toxins, generically called phycotoxins. These 
organisms form part of the marine plankton and therefore the aquatic food chain leading to 
filtrator mollusks, gastropods, crustaceans and fish which can accumulate toxins being 
consumed (FAO, 2004).  
The microalgae population may increase suddenly and generate an algal bloom which has 
increased in frequency, intensity and geographical distribution during recent years. 
Amongst the explanations put forward to explain for this phenomena has been the 
increased use of coastal waters for aquaculture, eutrophication caused by domestic, 
industrial and agricultural residues, the mobility of trace metals and humic substances due 
to deforestation and/or acid rain and changes in climatic conditions (Erdner et al., 2008). 
Reports of phycotoxins poisoning have increased during the last few years, perhaps due to 
the scientific community’s greater knowledge and interest in the matter or due to the 
increase in algal bloom. Such poisoning is mainly acute course; however, there is interest in 
evaluating the effects being triggered by chronic consumption. The lack of studies on 
animals which are continuously exposed to phycotoxins and the scarce availability of 
certified reference materials have led to difficulties in evaluating risk, developing analytical 
methodologies and regulating these substances.  
Studying toxins produced by algae has classically been approached according to the type 
of poisoning which they have caused. Four groups of toxins can thus be distinguished, 
causing paralytic shellfish poisoning, diarrhoeic shellfish poisoning, amnesic shellfish 
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has classified aflatoxin B1 within group 1 (proven carcinogenic effect on humans) and 
fumonisin B1 and ochratoxin A within group 2B (possibly carcinogenic to humans) (IARC, 
1993). The evidence from in vitro studies has shown that zearalenone is a probably 
implicated in cancer of the reproductive system (Khosrokhavar et al., 2009).  
Aflatoxins and ochratoxin A are the main mycotoxins which can generate residuality and 
attention concerning them as being animal subproduct contaminants has mainly been 
focused on their presence in milk; however, it has been demonstrated that they can also 
generate residuality in meat and eggs.  
6.1.1 Aflatoxins  
Aflatoxins (AF) B1 B2 G1 and G2 are produced by fungi from the genera Aspergillus. AFB1 
may be bioactivated through CYP450 enzymes to become an epoxide which is able to form 
adducts with DNA, meaning that it has been considered that AFB1 undergoes bioactivation 
in the organism. AFB1 may also become hydroxylised to AFM1 and be excreted in milk. It 
has been estimated that  1% to 6% of AFB1 ingested by a milk-producing cow could be 
excreted as AFM1 in milk, depending on bovine productivity. AFM1, like AFB1, may form 
an epoxide and alter DNA sequences. IARC is considered to be an AFM1 in group 2B 
(IARC, 1993). MRL regulated in different countries ranges from 0.05 to 0.5 µg/L; MRL has 
also been established for AF consumed by ruminants (FAO, 2003). Experimental studies 
have shown that when animals consume foodstuffs contaminated by high levels of AF, that 
it is difficult to find naturally, the liver and kidneys are the organs where most toxins 
become accumulated, and their presence in muscle is scarce (Bailly & Guerre, 2009). These 
types of studies have also demonstrated the presence of AF in eggs from different avian 
species.  
6.1.2 Ochratoxin A  
Ochratoxin A (OA) is produced by fungi from the genera Aspergillus and Pencillium,  
the former being from tropical regions and the latter from temperate regions. OA may 
thus be widely distributed throughout the world. OA may become biotransformed 
through hydrolysis reactions in which metabolites become less toxic by the opening of the 
lactone ring which occurs during bioactivation. Detoxification may occur in ruminants 
through digestive flora action before absorption, thereby limiting the possibility that OA 
might be found in milk and/or beef (Bailly & Guerre, 2009). However, a recent study 
evaluating the presence of OA in cows’ milk formulas for infants found contamination in 
72% of the samples analysed, levels around 690 ng/L being found (Meucci et al., 2010). It 
has been shown that OA may become accumulated in pigs’ kidneys. In countries such as 
Denmark, OA levels in these organs are regulated since porcine ochratoxicosis is 
common. 
6.1.3 Fusariotoxins  
The fusariotoxins are mycotoxins which are produced by fungi from the genera Fusarium, 
zearalenone (ZEA), the fumonisins (FUM) and the trichothecenes (TCT) being the most 
important for public health.  
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ZEA is frequently implicated in reproductive disorders in animals and occasionally in 
hyperestrogenism syndromes in humans. ZEA becomes biotransformed in the intestine by 
the mucosa or bacterial flora and involves the formation of α- and β-zearalenol and α- and 
β-zearalanol. Alpha-zearalanol and β-zearalenol have greater estrogenic power than ZEA 
since they bind with greater force to their corresponding receptors (Zinedine et al., 2007).  
Alpha-zearalanol has been employed as growth promoter in cattle. Studies orientated 
towards determining residuality through experimentation have suggested that residues are 
not present in meat or eggs, even at high doses. However, a recent study has show that the 
presence of α-zearalenol in meat-based foodstuffs for infants reached levels of 30.5 µg/kg; 
the same study demonstrated the presence of mycoestrogens (ZEA, α-zearalenole and β-
zearalenole) in infants’ cow milk formulas  (Meucci et al., 2011).  
FUM properties suggest that their presence in animal meat does not represent an important 
source of contamination, since they are poorly absorbed. FUM produce liquefaction of the 
brain in horse and pulmonary oedema in pigs; ruminants and birds are more resistant. They 
have been correlated with oesophageal cancer in humans in some parts of the world and it 
has also been presumed that they may cause neural tube alterations. Their presence has 
been demonstrated and in the liver and kidneys of turkeys fed  with the maximum levels 
permitted in Europe (Tardieu et al., 2008).  
The main TCT of interest in producing animals are T-2 toxin, HT-2 toxin, diacetoxiscirpenol 
and deoxinivalenol. The TCT do not usually represent a risk of contamination in food of 
animal origin due to their rapid metabolism (Bailly & Guerre, 2009).  
6.2 Phycotoxins  
Around 75 species of marine micro-algae, belonging to the dinoflagellate group, produce 
secondary metabolites which represent potent toxins, generically called phycotoxins. These 
organisms form part of the marine plankton and therefore the aquatic food chain leading to 
filtrator mollusks, gastropods, crustaceans and fish which can accumulate toxins being 
consumed (FAO, 2004).  
The microalgae population may increase suddenly and generate an algal bloom which has 
increased in frequency, intensity and geographical distribution during recent years. 
Amongst the explanations put forward to explain for this phenomena has been the 
increased use of coastal waters for aquaculture, eutrophication caused by domestic, 
industrial and agricultural residues, the mobility of trace metals and humic substances due 
to deforestation and/or acid rain and changes in climatic conditions (Erdner et al., 2008). 
Reports of phycotoxins poisoning have increased during the last few years, perhaps due to 
the scientific community’s greater knowledge and interest in the matter or due to the 
increase in algal bloom. Such poisoning is mainly acute course; however, there is interest in 
evaluating the effects being triggered by chronic consumption. The lack of studies on 
animals which are continuously exposed to phycotoxins and the scarce availability of 
certified reference materials have led to difficulties in evaluating risk, developing analytical 
methodologies and regulating these substances.  
Studying toxins produced by algae has classically been approached according to the type 
of poisoning which they have caused. Four groups of toxins can thus be distinguished, 
causing paralytic shellfish poisoning, diarrhoeic shellfish poisoning, amnesic shellfish 
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poisoning and neurotoxic shellfish poisoning (FAO, 2004). Another group of phycotoxins 
of interest due to their accumulation in sea fish are the ciguatoxins causing ciguatera fish 
poisoning.  
6.2.1 Paralytic shellfish poisoning  
The toxins responsible for this poisoning are mainly produced by algae from the genera 
Alexandrium, Gymnodinium and Pyrodinium. Chemically, they correspond to tetrahydropurin 
molecules, saxitoxin (STX) having the most importance. PSP incidence and geographical 
distribution has increased since the 1970s; this poisoning was initially confined to temperate 
waters in Europe, North America and Japan, but is now considered to be worldwide 
problem (FAO, 2004). 
STX becomes rapidly absorbed through the gastrointestinal tract and equally has rapid 
distribution, metabolism and excretion. STX selectively blocks (and with high affinity) 
sodium-dependent channels present in nerves, skeletal muscular fibres and most  cardiac 
muscular fibres, thereby reducing or eliminating the action of propagation potential 
(Etheridge, 2010). 
Paralytic shellfish poisoning symptoms begin in human beings within the first 30 minutes 
following consumption of  contaminated foodstuff and the onset of numbness and/or pins 
and needles around the lips, gradually extending to the face, neck, arms and legs. 
Headaches, nausea, lack of muscular coordination and, occasionally, temporary blindness 
occur. There may be paraesthesia in the arms and legs, motor inability and difficulty in 
talking in moderate cases and paralysis of respiratory muscles leading to death may occur in 
severe cases. 
6.2.2 Diarrhoeic shellfish poisoning  
Diarrhoeic shellfish poisoning toxins are produced by dinoflagellates from the genera 
Dinophysis and Protoceratium, having worldwide distribution. Okadaic acid (OA) and its 
analogues (dinophysis toxins , pectenotoxin  and yessotoxin are included within this 
group. However, yessotoxin and pectenotoxin produce different toxicological effects in 
experimental animals. Yessotoxin is related to lesions in the cardiac muscle, liver, 
pancreas and cerebral neurons and pectenotoxin is clearly hepatotoxic. The effect which 
yessotoxin and pectenotoxin may have on human beings remains unknown (Dominguez 
et al., 2010). 
OA was initially reported in Japan and Europe, areas in which diarrhoeic shellfish poisoning 
has had greater importance. OA and its analogues are potent protein phosphatase inhibitors 
(serine/threonine phosphatases PP1 and PP2A) which dephosphorylate molecules closely 
related to metabolic processes. It has been postulated that OA induces diarrhoea due to an 
alteration in hydric balance in the intestines via one of the two following mechanisms: 
stimulating the phosphorylation of proteins controlling sodium secretion in enterocytes or 
promoting the phosphorylation of intercell binding proteins regulating solute permeability. 
Diarrhoeic shellfish poisoning is characterised by diarrhoea, nausea, vomiting and, in some 
cases,  abdominal pain which can begin within the first 3 or 12 hours after having consumed 
contaminated organisms. No lethal effects have been reported concerning human as having 
been caused by OA or its analogues. 
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6.2.3 Amnesic shellfish poisoning  
This poisoning is also known as domoic acid (DA) poisoning since memory loss is not 
always present. It was described for the first time in Canada (Prince Edward Island) in 1987 
when 105 people became poisoned after consuming blue mussels. There have also been 
several reports of poisoning involving effects on wild life, demonstrating that the toxin 
forms part of the food chain; the toxin responsible for this has been DA which is produced 
by diatoms from the genera Pseudo-nitzschia. 
The DA mechanism of action acts on excitatory amino acid receptors (L-glutamate, L-
aspartate) and/or synaptic transmission. DA activates specific excitatory amino acid L - 
glutamate receptors producing an excessive accumulation of calcium resulting in cell death. 
The kainate receptor is DA’s primary target. Recent interest in DA has been centred on 
recognising that effects can result following chronic exposure to it at low concentrations, 
given the discovery that chemical route alteration leads to neurological disturbances. 
Intestinal absorption is limited (5%-10% of  the dose administered to experimental animals). 
It has high distribution in the blood compartment and scarcely penetrates the 
hematoencephalic barrier. There is no evidence that DA may become metabolised. 
Elimination occurs via the kidneys. Poisoning in humans produces gastroenteritis which 
may be accompanied by headache, confusion and permanent loss of short-term memory 
(FAO, 2004). 
6.2.4 Neurotoxic shellfish poisoning  
Neurotoxic shellfish poisoning, which is endemic on the Gulf of México and the eastern 
coast of Florida, is caused by brevetoxin (BTX) produced by the dinoflagellate Gymnodinium 
breve (synonyms: Ptychodiscus breve, Karenia brevis) present in red-tides. This alga has the 
special feature of being able to form aerosols due to wave action thereby constituting a risk 
of aerial exposure. 
BTX are liposolube toxins consisting of around 14 different substances, leading to 
depolarisation opening sodium channels in cell membranes and increasing the inflow of 
sodium causing persistent and repetitive activation. Symptoms caused by oral exposure to 
BTX occur within the first 30 minutes to 3 hours after consuming contaminated organisms 
and include vomiting, diarrhoea, shivering, sweating, conflicting perception of temperature, 
hypotension, arrhythmias, numbness, paraesthesia of the lips, face and extremities, cramps, 
bronchoconstriction, paralysis, convulsions and coma. There have been no reports of 
lethality. Respiratory difficulty and irritation of the mucosa are the most common symptoms 
when inhalatory exposure occurs. 
6.2.5 Ciguatera fish poisoning  
Ciguatera fish poisoning is caused by ciguatoxin (CTX) which is produced by dinoflagellates 
from the genera Gambierdiscus. CTX becomes accumulated through the food chain, from 
small herbivorous fish up to large carnivorous fish. This poisoning has passed from being a 
problem limited to insular regions which affected local communities to being a global 
matter, given the worldwide consumption of seafood and international tourism. This is the  
most common poisoning caused by seafood and may affect up to 50,000 people annually 
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poisoning and neurotoxic shellfish poisoning (FAO, 2004). Another group of phycotoxins 
of interest due to their accumulation in sea fish are the ciguatoxins causing ciguatera fish 
poisoning.  
6.2.1 Paralytic shellfish poisoning  
The toxins responsible for this poisoning are mainly produced by algae from the genera 
Alexandrium, Gymnodinium and Pyrodinium. Chemically, they correspond to tetrahydropurin 
molecules, saxitoxin (STX) having the most importance. PSP incidence and geographical 
distribution has increased since the 1970s; this poisoning was initially confined to temperate 
waters in Europe, North America and Japan, but is now considered to be worldwide 
problem (FAO, 2004). 
STX becomes rapidly absorbed through the gastrointestinal tract and equally has rapid 
distribution, metabolism and excretion. STX selectively blocks (and with high affinity) 
sodium-dependent channels present in nerves, skeletal muscular fibres and most  cardiac 
muscular fibres, thereby reducing or eliminating the action of propagation potential 
(Etheridge, 2010). 
Paralytic shellfish poisoning symptoms begin in human beings within the first 30 minutes 
following consumption of  contaminated foodstuff and the onset of numbness and/or pins 
and needles around the lips, gradually extending to the face, neck, arms and legs. 
Headaches, nausea, lack of muscular coordination and, occasionally, temporary blindness 
occur. There may be paraesthesia in the arms and legs, motor inability and difficulty in 
talking in moderate cases and paralysis of respiratory muscles leading to death may occur in 
severe cases. 
6.2.2 Diarrhoeic shellfish poisoning  
Diarrhoeic shellfish poisoning toxins are produced by dinoflagellates from the genera 
Dinophysis and Protoceratium, having worldwide distribution. Okadaic acid (OA) and its 
analogues (dinophysis toxins , pectenotoxin  and yessotoxin are included within this 
group. However, yessotoxin and pectenotoxin produce different toxicological effects in 
experimental animals. Yessotoxin is related to lesions in the cardiac muscle, liver, 
pancreas and cerebral neurons and pectenotoxin is clearly hepatotoxic. The effect which 
yessotoxin and pectenotoxin may have on human beings remains unknown (Dominguez 
et al., 2010). 
OA was initially reported in Japan and Europe, areas in which diarrhoeic shellfish poisoning 
has had greater importance. OA and its analogues are potent protein phosphatase inhibitors 
(serine/threonine phosphatases PP1 and PP2A) which dephosphorylate molecules closely 
related to metabolic processes. It has been postulated that OA induces diarrhoea due to an 
alteration in hydric balance in the intestines via one of the two following mechanisms: 
stimulating the phosphorylation of proteins controlling sodium secretion in enterocytes or 
promoting the phosphorylation of intercell binding proteins regulating solute permeability. 
Diarrhoeic shellfish poisoning is characterised by diarrhoea, nausea, vomiting and, in some 
cases,  abdominal pain which can begin within the first 3 or 12 hours after having consumed 
contaminated organisms. No lethal effects have been reported concerning human as having 
been caused by OA or its analogues. 
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6.2.3 Amnesic shellfish poisoning  
This poisoning is also known as domoic acid (DA) poisoning since memory loss is not 
always present. It was described for the first time in Canada (Prince Edward Island) in 1987 
when 105 people became poisoned after consuming blue mussels. There have also been 
several reports of poisoning involving effects on wild life, demonstrating that the toxin 
forms part of the food chain; the toxin responsible for this has been DA which is produced 
by diatoms from the genera Pseudo-nitzschia. 
The DA mechanism of action acts on excitatory amino acid receptors (L-glutamate, L-
aspartate) and/or synaptic transmission. DA activates specific excitatory amino acid L - 
glutamate receptors producing an excessive accumulation of calcium resulting in cell death. 
The kainate receptor is DA’s primary target. Recent interest in DA has been centred on 
recognising that effects can result following chronic exposure to it at low concentrations, 
given the discovery that chemical route alteration leads to neurological disturbances. 
Intestinal absorption is limited (5%-10% of  the dose administered to experimental animals). 
It has high distribution in the blood compartment and scarcely penetrates the 
hematoencephalic barrier. There is no evidence that DA may become metabolised. 
Elimination occurs via the kidneys. Poisoning in humans produces gastroenteritis which 
may be accompanied by headache, confusion and permanent loss of short-term memory 
(FAO, 2004). 
6.2.4 Neurotoxic shellfish poisoning  
Neurotoxic shellfish poisoning, which is endemic on the Gulf of México and the eastern 
coast of Florida, is caused by brevetoxin (BTX) produced by the dinoflagellate Gymnodinium 
breve (synonyms: Ptychodiscus breve, Karenia brevis) present in red-tides. This alga has the 
special feature of being able to form aerosols due to wave action thereby constituting a risk 
of aerial exposure. 
BTX are liposolube toxins consisting of around 14 different substances, leading to 
depolarisation opening sodium channels in cell membranes and increasing the inflow of 
sodium causing persistent and repetitive activation. Symptoms caused by oral exposure to 
BTX occur within the first 30 minutes to 3 hours after consuming contaminated organisms 
and include vomiting, diarrhoea, shivering, sweating, conflicting perception of temperature, 
hypotension, arrhythmias, numbness, paraesthesia of the lips, face and extremities, cramps, 
bronchoconstriction, paralysis, convulsions and coma. There have been no reports of 
lethality. Respiratory difficulty and irritation of the mucosa are the most common symptoms 
when inhalatory exposure occurs. 
6.2.5 Ciguatera fish poisoning  
Ciguatera fish poisoning is caused by ciguatoxin (CTX) which is produced by dinoflagellates 
from the genera Gambierdiscus. CTX becomes accumulated through the food chain, from 
small herbivorous fish up to large carnivorous fish. This poisoning has passed from being a 
problem limited to insular regions which affected local communities to being a global 
matter, given the worldwide consumption of seafood and international tourism. This is the  
most common poisoning caused by seafood and may affect up to 50,000 people annually 
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(FAO, 2004). CTX are liposoluble toxins having 13 to 14 rings fused in a rigid structure. CTX 
bind to sodium channels causing them to open during cell membranes’ potential repose 
altering bioenergetic mechanisms. CTX acts on the same receptor as BTX does but with 
greater affinity (Lehane & Lewis, 2000).  
Gambierdiscus toxicus, the alga specie most commonly related to CTX production, is 
distributed throughout the tropical region of the Pacific Ocean, western Indian Ocean and 
the Caribbean where CFP is endemic. Many coral fish species are involved, including 
herbivores and carnivores. The latter constitute the main vector for poisoning in humans, 
particularly Muraenidae (moray eels), Lutjanidae (snappers), Carrangidae (carrangs), 
Scombridae (mackerels) and Sphyraenidae (barracuda) (FAO, 2004).  
CTX become rapidly absorbed through the intestine and are mainly excreted in the faeces 
via the bile. The symptoms are gastrointestinal or neurological in nature, the former include 
vomiting, diarrhoea, nausea and abdominal pain. The neurological symptoms which can 
begin later include pins and needles in the lips, hand and feet, disturbances in perception of 
temperature, severe pruritus and fatigue. Some patients can experience pain (muscular, 
articular and dental) and anxiety. There may be hypotension and bradycardia in severe 
cases and death may occur, though this is not very common. The neurological symptoms 
can persist for years in some cases; it seems that the toxin may become accumulated in fat 
and be released in certain circumstances or also produce an immunological response 
(Shoemaker et al., 2010). 
Other phycotoxins of interest due to their residuality are the azaspiracida, discovered in 
1998, and whose symptoms resemble those of diarrhoeic shellfish poisoning; the cyclic imins 
(gymnodimine, spirolids, pinnatoxins, prorocentrolide, spirocentrimine and pteriatoxin), 
still have no associated effects in humans, but their residuality does interfere with the 
analytical methodologies used for determining the presence of marine toxins and 
cianotoxins (nodularin and cylindrospermin) by producing hepatoxicity and inhibiting 
protein synthesis.  
6.3 Phytotoxins  
Plants have secondary metabolites with which they defend themselves from the aggression 
of herbivorous animals. Many of these are toxic for humans and animals, causing numerous 
pathologies. Given that the diverse compounds present in plants are degraded during 
digestion and/or the metabolism of xenobiotics in animals of livestock interest, only some 
manage to contaminate products of animal origin. Milk is the main subproduct which has 
been studied in which toxins from plants may be present; however, their presence has also 
been demonstrated in muscle, viscera and eggs. Regulations regarding these toxins are 
scarce and are mainly orientated towards their presence in botanical products having 
pharmacological uses; however, there is growing interest in making advances in this field. 
The regulating entities have shown the greatest interest in pyrrolizidine alkaloids amongst 
the plant toxins due to their abundance and proven toxic effects. 
6.3.1 Pyrrolizidine alkaloids  
Pyrrolizidine alkaloids (AP) are present in a large variety of  plants and are perhaps the 
most widely distributed toxins. Foodstuffs or botanically-based remedies represent the most 
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probable risk of exposure for humans; however, food of animal origin can also contain 
pyrrolizidine alkaloids. It has been presumed that more than 6,000 plant species contain AP, 
mainly those belonging to the families Asteraceae or Compositae (genera Senecio and 
Eupatorium), Boraginaceae (genera Heliotropium and Echium) and Fabaceae or Leguminosae 
(genera Crotalaria).  
APs are heterocyclic compounds which are mainly derived from four necine bases: 
retronecine, heliotridine, otonecine and platynecine. AP can become enzimatically 
hydrolised or oxidised; the resulting N-oxide is slightly toxic and may also be found in 
plants. AP becomes bioactivated to a toxin pyrrole through CYP450 which is electrophilic 
and unstable and reacts rapidly with endogenous macromolecules (particularly with DNA 
forming adducts). DNA adducts could be a continuous source of carbon ions originating 
new adducts, meaning that the total elimination of AP derivates may take months (Edgar et 
al., 2011).  
AP levels in foodstuffs are rarely so significant that they can cause acute diseases; however, 
low levels and continuous exposure could lead to the presentation of chronic diseases which 
could hardly be attributable to the toxin in foodstuffs. Pyrroles cause thickening and 
occlusion of the hepatic vessels resulting in veno-occlusive disease and cirrhosis. They can 
also alter the pulmonary vessels, causing pulmonary hypertension and congestive cardiac 
failure. The IARC has classified lasiocarpine, monocrotaline and riddelliine AP within group 
2B (probably carcinogenic for humans, given the pertinent evidence regarding how they are 
cancerigens in animals) (Edgar et al., 2011).  
It has been demonstrated that 0.1% to 4% of AP in foodstuffs for lactating cows and sheep 
could be excreted in milk (Hoogenboom, 2011). The meat and viscera of cattle fed on AP-
rich plants may contain the toxin and its derivates at levels reaching 250 mg/kg in muscle 
and 2,500 mg/kg in liver (Fletcher et al., 2011). AP can potentially be present in eggs when 
fowl are fed on AP-rich diets, thereby constituting a risk for human health (Eröksüz et al., 
2008). In spite of potential contamination in milk, meat, viscera and eggs, honey is the only 
foodstuff of animal origin which has been shown to be naturally contaminated with AP; a 
large number of plants habitually used in apiaries could be a source of significant levels of 
the toxins.  
Other alkaloids of interest due to their potential residual effect on animal subproducts are 
the indolizidinics (especially swainsonine) producing lysosomal storage disease and 
piperidine (coniin and gamma-conicein) which in acute form can produce muscular 
paralysis and (chronically) teratogenesis (Panter & James, 1990). These last named alkaloids 
seem to be responsible for coturnism, a human disease which occurs following the 
consumption of migrating wild European quail; it is characterised by weakness, muscular 
pain, paralysis of the legs, vomiting and myoglobinuria. It has been postulated that these 
symptoms occur due to the accumulation of coniin in birds’ tissues following the 
consumption of Conium maculatum (López & Bianchini, 1999).  
6.3.2 Glucosinolates 
Glucosinolates, known as mustard oil glucosides as they confer the characteristic flavour on 
black mustard (Brassica nigra), are secondary metabolites produced by plants belonging to 
the  order Brassicales, mainly in the family Brassicaceae (or Cruciferae). Many plants which are 
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(FAO, 2004). CTX are liposoluble toxins having 13 to 14 rings fused in a rigid structure. CTX 
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Scombridae (mackerels) and Sphyraenidae (barracuda) (FAO, 2004).  
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begin later include pins and needles in the lips, hand and feet, disturbances in perception of 
temperature, severe pruritus and fatigue. Some patients can experience pain (muscular, 
articular and dental) and anxiety. There may be hypotension and bradycardia in severe 
cases and death may occur, though this is not very common. The neurological symptoms 
can persist for years in some cases; it seems that the toxin may become accumulated in fat 
and be released in certain circumstances or also produce an immunological response 
(Shoemaker et al., 2010). 
Other phycotoxins of interest due to their residuality are the azaspiracida, discovered in 
1998, and whose symptoms resemble those of diarrhoeic shellfish poisoning; the cyclic imins 
(gymnodimine, spirolids, pinnatoxins, prorocentrolide, spirocentrimine and pteriatoxin), 
still have no associated effects in humans, but their residuality does interfere with the 
analytical methodologies used for determining the presence of marine toxins and 
cianotoxins (nodularin and cylindrospermin) by producing hepatoxicity and inhibiting 
protein synthesis.  
6.3 Phytotoxins  
Plants have secondary metabolites with which they defend themselves from the aggression 
of herbivorous animals. Many of these are toxic for humans and animals, causing numerous 
pathologies. Given that the diverse compounds present in plants are degraded during 
digestion and/or the metabolism of xenobiotics in animals of livestock interest, only some 
manage to contaminate products of animal origin. Milk is the main subproduct which has 
been studied in which toxins from plants may be present; however, their presence has also 
been demonstrated in muscle, viscera and eggs. Regulations regarding these toxins are 
scarce and are mainly orientated towards their presence in botanical products having 
pharmacological uses; however, there is growing interest in making advances in this field. 
The regulating entities have shown the greatest interest in pyrrolizidine alkaloids amongst 
the plant toxins due to their abundance and proven toxic effects. 
6.3.1 Pyrrolizidine alkaloids  
Pyrrolizidine alkaloids (AP) are present in a large variety of  plants and are perhaps the 
most widely distributed toxins. Foodstuffs or botanically-based remedies represent the most 
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probable risk of exposure for humans; however, food of animal origin can also contain 
pyrrolizidine alkaloids. It has been presumed that more than 6,000 plant species contain AP, 
mainly those belonging to the families Asteraceae or Compositae (genera Senecio and 
Eupatorium), Boraginaceae (genera Heliotropium and Echium) and Fabaceae or Leguminosae 
(genera Crotalaria).  
APs are heterocyclic compounds which are mainly derived from four necine bases: 
retronecine, heliotridine, otonecine and platynecine. AP can become enzimatically 
hydrolised or oxidised; the resulting N-oxide is slightly toxic and may also be found in 
plants. AP becomes bioactivated to a toxin pyrrole through CYP450 which is electrophilic 
and unstable and reacts rapidly with endogenous macromolecules (particularly with DNA 
forming adducts). DNA adducts could be a continuous source of carbon ions originating 
new adducts, meaning that the total elimination of AP derivates may take months (Edgar et 
al., 2011).  
AP levels in foodstuffs are rarely so significant that they can cause acute diseases; however, 
low levels and continuous exposure could lead to the presentation of chronic diseases which 
could hardly be attributable to the toxin in foodstuffs. Pyrroles cause thickening and 
occlusion of the hepatic vessels resulting in veno-occlusive disease and cirrhosis. They can 
also alter the pulmonary vessels, causing pulmonary hypertension and congestive cardiac 
failure. The IARC has classified lasiocarpine, monocrotaline and riddelliine AP within group 
2B (probably carcinogenic for humans, given the pertinent evidence regarding how they are 
cancerigens in animals) (Edgar et al., 2011).  
It has been demonstrated that 0.1% to 4% of AP in foodstuffs for lactating cows and sheep 
could be excreted in milk (Hoogenboom, 2011). The meat and viscera of cattle fed on AP-
rich plants may contain the toxin and its derivates at levels reaching 250 mg/kg in muscle 
and 2,500 mg/kg in liver (Fletcher et al., 2011). AP can potentially be present in eggs when 
fowl are fed on AP-rich diets, thereby constituting a risk for human health (Eröksüz et al., 
2008). In spite of potential contamination in milk, meat, viscera and eggs, honey is the only 
foodstuff of animal origin which has been shown to be naturally contaminated with AP; a 
large number of plants habitually used in apiaries could be a source of significant levels of 
the toxins.  
Other alkaloids of interest due to their potential residual effect on animal subproducts are 
the indolizidinics (especially swainsonine) producing lysosomal storage disease and 
piperidine (coniin and gamma-conicein) which in acute form can produce muscular 
paralysis and (chronically) teratogenesis (Panter & James, 1990). These last named alkaloids 
seem to be responsible for coturnism, a human disease which occurs following the 
consumption of migrating wild European quail; it is characterised by weakness, muscular 
pain, paralysis of the legs, vomiting and myoglobinuria. It has been postulated that these 
symptoms occur due to the accumulation of coniin in birds’ tissues following the 
consumption of Conium maculatum (López & Bianchini, 1999).  
6.3.2 Glucosinolates 
Glucosinolates, known as mustard oil glucosides as they confer the characteristic flavour on 
black mustard (Brassica nigra), are secondary metabolites produced by plants belonging to 
the  order Brassicales, mainly in the family Brassicaceae (or Cruciferae). Many plants which are 
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common in the human diet belong to this family (broccoli, Brussels sprouts, cabbage and 
cauliflower) and several genera (Brassica, Crambe, Sinapis and Raphanus) including crops 
used for producing vegetal oils. The plant Camelina sativa (false flax) has recently aroused 
interest due to biofuel production. When the oils are extracted, the glucosinolates remain in 
the seed; the resulting press cake is used in animals diet (EFSA, 2008).  
The glucosinolates become hydrolysed by enzymatic action giving place to isothiocyanates, 
thiocyanates, oxazolidinethiones and nitriles. The thiocyanates interfere with iodine capture 
and the oxazolidinethiones with thyroid (T3 and T4) hormone synthesis, leading to 
hypothyroidism and thyroid gland enlargement. Consequently, metabolism in all tissues, 
including the reproductive organs, may become affected.  
It has been shown that high glucosinolate consumption in lactating cows reduces iodine 
levels and increases thiocyanates in milk, the liver and the kidneys. The residues in milk 
account for around 0.1% of the dose received by animals; the residues in muscles and 
viscera are even lower. Residuality has also been found in eggs after rapeseed has been 
administered to egg-laying birds; these also acquire a disagreeable flavour (EFSA, 2008). 
6.3.3 Ptaquiloside 
Bracken fern (genus Pteridium), considered one of the five most abundant plants in the world, 
contains a norsesquiterpene glucoside called ptaquiloside. It has been proved that ptaquiloside 
may cause tumours in the urinary bladder, mammary glands, intestine and other organs in 
laboratory rodents. It causes degeneration of the retina in sheep and causes urinary bladder 
cancer known as bovine enzootic haematuria in cattle. There is epidemiological evidence 
relating the consumption of bracken fern in humans (Japanese population) suffering from 
esophagic and gastric cancer, possibly caused by ptaquiloside. Around 8.6% of the 
ptaquiloside present in P. aquilinum, consumed by lactating cows, is excreted in milk, thereby 
making contaminated raw milk a risk for human health (Alonso-Amelot et al., 1996).  
6.3.4 Tremetol  
This is a liposoluble compound mixture of terpene, sterols, tremetone, hydroxytremetone 
and dehydrotremetone; the last three are present in a ketonic fraction. It is present in the 
perennial plants white snakeroot (Ageratina altissima, previously called Eupatorium rugosum) 
and rayless goldenrod (Haploppapus heterophyllus). This poisoning reached an epidemic 
proportion during the 18th and 19th centuries in the USA (Indiana, Illinois and Ohio), 
producing high mortality, and its aetiological agent was only discovered in 1910. Cows 
accumulate the toxin in fat and excrete it in milk. The toxin becomes diluted in milk 
reception tanks, making such poisoning not very common in modern milk production 
systems. Tremetol produces acidosis, hyperglycaemia and ketonaemia, as a consequence in 
the Krebs cycle inhibitor. The symptoms of poisoning are anorexia, listlessness, weakness, 
stiffness of muscles, vomiting, constipation and coma. Marked acidosis and ketosis may lead 
to death (Lewis & Elvin-Lewis, 2003).  
7. Conclusions 
Interest in diseases caused by food has mainly been orientated towards the acute 
presentation principally produced by microbiological agents; however, consuming food 
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contaminated by chemical substances could lead to chronic exposure leading to the 
presentation of diseases lacking an apparent cause and being difficult to diagnose. Foods of 
animal origin presuppose the risk of contamination, whether from drugs and growth 
promoters used for optimising livestock production systems, or with biological toxins 
present in food ingested by animals. It is thus necessary to control these substances in foods, 
thereby supposing technological and institutional efforts.  
Sanitary authorities must thus promulgate and ensure compliance with standards and 
guidelines concerning the production of harmless foodstuffs. Achieving such objective 
represents a great challenge for underdeveloped and developing countries due to 
institutional difficulties and the limited availability of equipment and qualified personnel. 
All nations must make it a priority to try to ensure the safe consumption of foodstuffs by 
their populations, exercising strict sanitary control aimed to avoid problems of health in the 
population and preventing the appearance of new problems affecting the development of 
the agro-food industry and global trade in foodstuffs. 
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contaminated by chemical substances could lead to chronic exposure leading to the 
presentation of diseases lacking an apparent cause and being difficult to diagnose. Foods of 
animal origin presuppose the risk of contamination, whether from drugs and growth 
promoters used for optimising livestock production systems, or with biological toxins 
present in food ingested by animals. It is thus necessary to control these substances in foods, 
thereby supposing technological and institutional efforts.  
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represents a great challenge for underdeveloped and developing countries due to 
institutional difficulties and the limited availability of equipment and qualified personnel. 
All nations must make it a priority to try to ensure the safe consumption of foodstuffs by 
their populations, exercising strict sanitary control aimed to avoid problems of health in the 
population and preventing the appearance of new problems affecting the development of 
the agro-food industry and global trade in foodstuffs. 
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1. Introduction 
"Dis-moi ce que tu manges, je te dirai ce que tu es." (Tell me what you eat and I will tell 
you what you are - Anthelme Brillat-Savarin, Physiologie du Goût, ou Méditations de 
Gastronomie Transcendante, 1826) 
"Ninety per cent of the diseases known to man are caused by cheap foodstuffs. You are 
what you eat." (Victor Lindlahr, 1923) 
In every time, availability of food has been a struggle for human survival. In particular, food 
storage techniques and maintaining have represented one of the most important milestones 
in the evolution and development of human society. In that sense, the use of fire for cooking 
and salt and spices for conservation have been important discoveries in food processing, 
with immediate consequences on human habits and life. 
Nowadays, food resources remain a primary objective for human society, specifically in 
terms of safety and control. 
In fact, up to date more than 250 foodborne diseases have been described. 
Infectious foodborne diseases are caused by the consumption of food contaminated by 
pathogen bacteria, viruses,  parasites and prions. 
Contamination may occur as consequence of incorrect practices at different steps of food 
processing, such as handling of feedstock, decontamination, packaging and storage. 
The rapid globalization and trade among countries with different hygienic standards have 
increased the possibility of food contamination. Hence, outbreaks of foodborne diseases that 
were once contained within a small community may now take place on global dimensions. 
The fundamental strategy for outbreaks monitoring is the traceability, that is the possibility 
to identify the pathogen(s), the ways of food contamination and the spreading. 
One of the most critical problems in traceability of bacterial pathogens is represented by a 
state of latency of most foodborne bacterial species, called “viable but nonculturable (VBNC) 
state”, induced by environmental stresses, such as low temperature, high osmolarity, and 
nutrient starvation. 
In such a state, bacteria show a discrete metabolic activity, but are not able to replicate. 
Following environmental stimuli, as temperature shift or replenishment of nutrients, VBNC 
bacteria can “resuscitate”, so restoring their ability to grow on common culture media. 
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Still open is the debate about the possibility, for pathogen bacteria in VBNC state, to 
maintain pathogenicity and trigger disease in their hosts. 
The evidence of contrasting results, in fact, indicates the need for a better understanding of 
such complex phenomenon, particularly about the underlying molecular network. 
Several studies have shown that the most of human pathogens, especially foodborne 
bacteria, may enter VBNC state as survival strategy against environmental stress. 
Many chemo-physical characteristics in food (as acidic pH, low content in carbohydrates, 
etc.), as well as processing, decontamination and storage, may induce VBNC state.  
The observation of VBNC forms of foodborne bacteria and the lack of a ultimate information 
about the possibility for VBNC bacteria to retain their virulence has raised the problem 
about the necessity of new procedures for VBNC detection in food. 
Many systems have been proposed for VBNC detection in water, but their application on 
food seems to be quite difficult. In fact, factors as food texture and pH, as well as presence of 
free lytic enzymes and other compounds, may interfere with the chemical reaction(s) 
required for the assay. 
Then, traceability of foodborne VBNC pathogens strongly requires the design of new 
detecting systems. 
2. The causes of infectious foodborne disease outbreaks 
Infectious foodborne diseases are caused by the consumption of food or beverages 
contaminated by many pathogenic bacteria, viruses,  parasites and prions. In addition, 
contamination can also be due to molecules produced by bacteria, called toxins.  Toxins can 
be derived from cell structure, such as lipopolysaccharide (LPS) of Gram negative bacteria 
(endotoxins), as well as they are synthesized inside the cell and secreted in the surrounding 
environment (exotoxins), as botulinum, cholera and Shiga toxins. 
After food contamination, the microbe or its toxin enters the organism via the digestive 
tract, triggering the illness.  
In general, an outbreak of foodborne disease occurs when a group of people eats the same 
contaminated food and two or more of them develop the same illness.  
Many outbreaks consist of sporadic cases and are self-limiting, in that they are related to a 
small quantity of contaminated food which, usually, is totally eaten by few people and 
involve a specific geographic area. A sporadic outbreak may follow a catered meal or eating 
a meal at a restaurant on a particularly busy day.  
The number of people affected and the extension of geographic areas in which a foodborne 
outbreak occurs have considerably increased as consequence of the variations in social 
habits. Commonly, workers and students may have meals at large-scale retail trade 
structures as canteens, highway stops, fast food chains and refectories. Such structures, 
usually, look to suppliers which, from the place where food is produced, distribute their 
products on national scale. Then, contaminated food may be transported in different places, 
causing many distinct outbreaks at the same time within a country. 
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For example, in 2005, in South Wales an outbreak of Escherichia coli O157 occurred, with 
identification of 157 cases, 31 people hospitalized, and one 5-year old child died, as well as 
in 2008, an outbreak of listeriosis in Canada (57 clinical cases) killed 23 people. 
Recently, in October 2010 an outbreak of cholera occurred in Haiti. On 18 August 2011, the 
total number of reported cholera cases was 419,511, with 222,359 hospitalized. Overall, data 
from health facilities indicate that 5,968 people have died (case fatality rate 1.4%). 
Moreover, actually it has been recognized that outbreaks may spread on wider geographic 
areas. In fact, the rapid globalization and trade among countries with different hygienic 
standards has increased the risk and entity of food contamination. As consequence, many 
outbreaks that were once contained within a small community may now take place on wider 
geographic areas and several examples can be considered. 
The Bovine spongiform encephalopathy (BSE), commonly known as mad-cow disease, was 
firstly detected in United Kingdom and represented a world-wide crisis. The cause of global 
infection was attributed to the use of contaminated bone meal, used in livestock feeding. 
Only in the United Kingdom, 4.4 millions of cattle were slaughtered in the attempt to 
eradicate the pathology and limit its spreading; moreover, the European Union banned 
exports of British beef from March 1996 to May 2006.  
In 2011, an outbreak of gastroenteritis caused by E. coli O104:H4 in Germany had several 
social, political and economic implications throughout whole Europe. 
Often, such kind of outbreaks are very difficult to identify while occurring. An example is 
represented by an outbreak of Salmonella which simultaneously happened in Europe, North 
America and Israel, following the importation of contaminated snack food. The outbreak 
identification was accidental, because it was caused by a rare strain of Salmonella and the 
number of cases in each geographical entity was not high.  
Therefore, there is a strong probability that contaminated foodstuffs distributed in different 
countries could origin outbreaks which are not readily pointed out by national health 
authorities if the spreading in each single country is limited. Many sporadic cases 
happening in single countries may be, then, part of a common global outbreak. 
3. The causes of food contamination 
Contamination may occur as consequence of incorrect practices at different steps of food 
processing, such as feedstock production and handling, food preparation, packaging and 
storage. Each stage of food processing shows critical points. 
3.1 Feedstock production 
Use of raw manure or sewage for fertilization and lack of hygiene and health controls in fish 
and cattle breeding are the first cause of contamination. Spinach and lettuce have been 
linked to E. coli O157:H7 outbreaks (Erickson et al., 2010). Untreated food, such as fresh fruit 
juice and milk, carry risks because they are not subjected to any decontaminating procedure.  
Similarly, incorrect slaughterhouse practices can lead to contamination, especially when 
faecal or intestinal matter from cattle mixes with the meat.  
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3.2 Feedstock handling 
Handling and washing of feedstock before processing are very important sources of 
contamination. Handling by ill people which have cuts, open sores or skin infections 
causes spreading of Staphylococcus aureus, which is often found on skin with boils and 
blisters. That is why food handling should be performed by personnel wearing gloves. 
However, touching contaminated surfaces, coughing into a gloved hand or handling 
money before food preparation can still spread germs, which is why gloves should be 
changed often.   
3.3 Food preparation 
Beyond the causes of contamination above discussed, in this step cross contamination is a 
crucial factor. This can happen during food preparation and storage. For example, juices 
from raw beef and poultry could mix with ready-to-eat food or when kitchen tools are used 
without distinction for both raw beef and fresh vegetables. Cleaning tools with soap and hot 
water strongly reduces contamination. 
Also undercooking can be cause of food contamination, because heat drastically reduces the 
presence of bacteria in food. 
3.4 Food packaging 
In food packaging, hygiene of handlers and materials employed are critical parameters.  
Historically, canned food, if prepared under unsafe conditions, can be susceptible to 
contamination by toxinogenic microbes, such as Clostridium botulinum. 
Nowadays, food packaging is mostly based on plastics, employed for vegetables, cheese, 
fruit. However, even if a correct packaging assures food safety from microbe 
contamination and remarkably prolongs shelf-life, much attention has to be paid about 
hygienic requirements. Bacteria can colonize and adhere on plastics, producing biofilms 
which may reduce shelf life or, for pathogenic bacteria, they may secrete toxins or 
proliferate on food.  
3.5 Food storage 
This is a critical step for perishable food which requires refrigeration or freezing, because 
low temperature slows down bacterial reproduction, even if some species, called 
psycrophiles, such as Listeria monocytogenes, Yersinia enterocolitica and Pseudomonas sp., are 
able to develop also at refrigerator temperature. 
Food storage has become increasingly important in the perspective of globalization, in 
that different food tipologies may be transported together. Physical contact and dripping 
of juices to other foodstuffs are causes of crosscontamination. In this way, one kind of 
food can be contaminated by unusual bacteria, that become difficult to be identified. Also 
changes in livestock farming and industrialization of slaughtering of pigs have played an 
important role. Transportation of live animals for slaughtering has in some studies been 
proved to be an important factor in dissemination of Y. enterocolitica from farm to farm 
(Nesbakken, 2007).  
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4. Foodborne bacteria  
Bacteria are single-cell microrganisms colonizing any environment. From an ecological point 
of view, they play a pivotal role in the biogeochemical cycles, by which chemical elements 
move from living to non-living matter and vice versa. Some of them produce molecules 
which improve the quality of human life, such as antibiotics, vitamins, probiotics and other 
nutritional factors.  
In food industry, several Lactobacillus species are very important for production of cheese, 
yogurt, beer, cider, wine, bread and chocolate, as well as in functional food. 
Several bacteria inhabit the skin and the intestine of animals and humans, protecting them 
from contamination by hazardous microbes and playing a role in metabolism.  
Pathogen bacteria are responsible for infectious diseases, by colonization of tissues and 
organs, whose physiology is altered by bacterial metabolism and reproduction. 
Foodborne pathogen bacteria are a group of microrganisms which can contaminate food 
and, after swallowing, cause illness. 
Common symptoms of foodborne illness are diarrhoea and/or vomiting, abdominal 
cramps, nausea, fever, joint/back aches, and fatigue. 
A description of the most common known foodborne pathogen bacteria and related 
illness(es) follows. Intriguingly, for the most of them, the VBNC state has been described. 
Bacillus cereus 
Gram positive rod-shaped bacterium, able to form endospores under negative conditions, 
commonly found in soil and vegetation. After pasteurisation or heating, endospores survive, 
whereas competing microflora is eliminated. During food cooling, endospores germinate 
and vegetative cells proliferate, producing several toxins, one of which is highly resistant to 
heat and to pH between 2 and 11. The infection may be almost diarrhoeal, but some cases 
described nausea and vomiting. The illness is self-limiting. 
Brucella spp. 
Genus of gram negative, aerobic, rod-spherical shaped bacteria which infect animals  and 
humans. Four species are recognised as harmful, that is B. abortus (from cattle), B. melitensis 
(from goats, sheep, and camels), B. suis (from pigs), and B. canis (from dogs). 
It can contaminate raw milk and cheese, but may be acquired also by inhalation, causing 
brucellosis, also known as Malta fever, undulant fever, Rock of Gibraltar fever, and Bang’s 
disease.  
The symptoms are non-specific and systemic, with fever, sweats, headache, anorexia, back 
pain. The chronic form causes suppurative lesions in the liver, spleen, and bone, with a 
mortality of 5% in untreated individuals. 
Campylobacter jejuni  
Gram negative, microaerophilic, spirally curved bacterium, commonly living in the bowel of 
animals, especially in poultry, and spread by faeces and milk.  
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It can also contaminate incorrectly prepared meat and poultry. 
It is one of the first cause of foodborne illness (campylobacteriosis) in United States and in 
United Kingdom. Symptoms of campylobacteriosis are fever, cramping abdominal pain and 
diarrhoea. Remission follows within a week. 
Clostridium botulinum 
Gram positive rod-shaped bacterium, obligate anaerobe, which forms endospores in 
presence of oxygen or other environmental stresses. Food contamination can occur due to 
improperly preserved or home-canned, low-acid food, which allows endospore 
germination and subsequent toxin secretion. Among the toxins, seven are neurotoxins, 
that cause the flaccid muscular paralysis by inhibition of neuromuscular transmission 
through decreased acetylcholine release. Death occurs when respiratory mechanics is 
compromised. 
Clostridium perfringens 
Gram positive rod-shaped bacterium, obligate anaerobe, which forms endospores in 
presence of oxygen or other environmental stresses. Preferentially, it contaminates meat-
based food, because aminoacid content satisfies its nutritional requirements. After cooking, 
oxygen concentration is lowered and endospores germinate during cooling. Storage time 
and refrigeration are critical, in that the vegetative cell can duplicate in 20 minutes. After 
ingestion, in the bowel the bacterium produces an exotoxin which causes abdominal pain 
and diarrhoea. In the most of cases, the illness is self-limiting.  
Corynebacterium ulcerans 
Gram-positive, nonmotile, straight to slightly curved rod-shaped bacterium that causes 
subacute bovine mastitis, but C. ulcerans has increasingly been isolated from domestic 
animals such as dogs and cats. 
Consumption of raw milk and dairy products or contact with cattle may cause infection of 
humans, causing a disease very similar to diphtheria by secretion of a toxin which inhibits 
protein synthesis of epithelial cells, leading them to death. 
Symptoms are sore throat, low fever, and a pseudomembrane on the upper respiratory tract.  
Toxin may spread through the bloodstream and can lead to life-threatening complications in 
heart and kidneys. It can also cause nerve damage, eventually leading to paralysis. 40% to 
50% of those left untreated can die. 
Coxiella burnetii  
C. burnetii is an obligate intracellular, small Gram-negative bacterium highly resistant to 
high temperature, osmotic pressure, ultraviolet light.  
It can contaminate people after ingestion of raw milk or contact with infected animals.  
C. burnetii is highly infectious via the respiratory route, but the infectivity via the oral 
route is poorly understood. It has been proposed that C. burnetii can escape the 
gastrointestinal tract and produce infection sufficient to stimulate systemic immunity 
(Loftis et al., 2010). 
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C. burnetii secretes a toxin inside the phagolysosome which inhibits its fusion with the cell 
degradation endosomes. 
In humans it causes the Q fever, with fever, severe headache, muscle and joint pains, upper 
respiratory problems and gastro-intestinal symptoms such as nausea, vomiting and 
diarrhoea. Life threatening complications are acute respiratory distress syndrome (ARDS), 
granulomatous hepatitis and retinal vasculitis. 
The chronic form of Q fever is virtually identical to endocarditis. It is usually fatal if 
untreated; however, with appropriate treatment the mortality falls to around 10%. 
Escherichia coli  
Gram negative, rod-shaped bacterium, inhabitant of mammal bowel. Among the pathogenic 
strains, distinct groups can be identified. 
• Enterotoxigenic (ETEC) E. coli produces and releases two exotoxins, LT (heat-labile) 
enterotoxin, similar to cholera toxin, and ST enterotoxin, which causes cGMP accumulation 
in the target cells and a subsequent secretion of fluid and electrolytes into the intestinal 
lumen. Both toxins induce watery diarrhoea, similarly to cholera. It is responsible of the 
majority of “traveller’s diarrhoea” and infant diarrhoea in developing countries. 
• Enteroinvasive (EIEC) E. coli can invade the intestinal wall, giving inflammation, fever 
and diarrhoea similar to Shigella-like dysentery. 
• Among the enterohaemorrhagic (EHEC) E. coli strains, the most important is the well 
known serotype O157:H7. EHEC strains produce Shiga-like toxins, which induce 
haemorrhagic colitis, resulting in bloody diarrhoea. Sometimes the toxin may spread in 
kidney, causing a very dangerous complication called haemolytic uraemic syndrome. 
The first symptom is the presence of blood in urine leading to kidney failure. 
• Enteropathogenic (EPEC) strains use an adhesin known as intimin to bind host 
intestinal cells. Adherence to the intestinal mucosa causes a rearrangement of actin in 
the host cell, causing significant deformation. EPEC cells are moderately invasive and 
elicit an inflammatory response. Changes in intestinal cell ultrastructure are likely the 
prime cause of diarrhoea in those afflicted with EPEC. 
• Enteroaggregative (EAEC) strains have fimbriae which aggregate tissue culture cells. 
EAEC strains bind to the intestinal mucosa to cause watery diarrhoea without fever and 
are not invasive. They produce a haemolysin and a ST enterotoxin similar to that of ETEC 
strains. 
Helicobacter pylori 
Gram negative, spiral-shaped microaerophilic bacterium, normally colonising the stomach 
of 30-50% of the human population in developed countries.  
The ways of transmission are likely to be oral and oro-faecal routes, even if it has been quite 
difficult its isolation by the faeces (Thomas et al., 1992; Kelly et al., 1994). 
In the stomach, the bacterium secretes the enzyme urease, which degrades urea to ammonia. 
Ammonia lowers the pH locally, so permitting the development of the infection. 
It is responsible of chronic gastritis, peptic ulcer disease and stomach cancer. Actually, it is 
also associated with the gastric MALT lymphoma and its role on other several illnesses, as 
Sjögren, Prader-Willy and  Raynaud syndromes, is matter of discussion. 
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Gram positive, facultative anaerobe, rod-shaped intracellular bacterium, commonly spread 
in soil and water. Vegetables are contaminated by the soil or by manure used as fertilizer. 
Animals can carry the bacterium asymptomatically and can contaminate food, such as 
uncooked meat, raw milk and soft cheeses, that are usually prohibited to pregnant women. 
It is the causative agent of listeriosis. After having entered immune system cells, it becomes 
septicemic and can grow. The intracellular state in phagocytic cells may permit access to the 
brain and probably  to reach the fetus in pregnant women by crossing the placenta. 
Listeriosis may arise as septicaemia, meningoencephalitis, corneal ulcer, pneumonia and 
during pregnancy (causing abortion within 6-9 months or stillbirth).  
When no internalization in cells occurs, the disease is presented as a febrile gastroenteritis.  
L. monocytogenes is the leading cause of death among foodborne bacterial pathogens, with 20 
to 30 percent of clinical infections resulting in death.  
Plesiomonas shigelloides 
Gram-negative, rod-shaped bacterium, which has been isolated from freshwater, freshwater 
fish, and shellfish and from many types of animals including cattle in tropical and sub-
tropical areas. 
Common symptoms are fever, shivers, abdominal pain, nausea, diarrhoea (which, in severe 
cases, may be greenish-yellow, foamy, and bloody) or vomiting and appear 20-24 hours 
after consumption of contaminated food or water. 
P. shigelloides gastroenteritis is usually a mild self-limiting disease with remission in healthy 
people within 1-7 days, described in African countries, but sporadic cases have been 
reported also in Europe and North America. Severe forms may include sepsis and 
meningoencephalitis in newborns, arthritis, cholecystitis and osteomyelitis (Terpeluk, 1992). 
Salmonella spp.  
The genus Salmonella consists of Gram negative, rod-shaped facultatively anaerobe bacteria, 
which live in the bowel of humans and animals.  
Meat, poultry and eggs are the most common food contaminated by Salmonella. However, 
food is contaminated by low loads of Salmonella, which are quite difficult to be appreciated 
by standard detection methods. 
All species are considered pathogenic and responsible for a gastroenteritis known as 
salmonellosis. Bacteria reach the bowel and duplicate. Sometimes, they may cross the 
mucosa, entering lymphatic and cardiovascular systems; from there, they may infect other 
organs, causing septicaemia. 
Symptoms are moderate fever, nausea, abdominal pain and cramps, diarrhoea. Average 
mortality rate is below 1%, but increases in children and old people, occurring as 
septicaemia. 
Among the species, S. typhi is the most virulent. It is the aetiological agent of typhoid fever 
and is spread only by human faeces. Symptoms are high fever (40°C) and continued 
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headache, then diarrhoea appears and fever declines. Differently from salmonellosis, 
bacteria multiply into phagocytic cells and disseminate in the body. In severe cases, 
perforation of bowel mucosa may occur. 
Today, the mortality rate of typhoid fever is about 1-2%; in the past it exceeded also 10%. 
Shigella spp. 
The genus Shigella is composed of Gram negative, rod-shaped bacteria, which are normally 
present in the bowel of humans, apes and monkeys. 
Food contamination occurs via handling by unhealthy operators. Four species are 
pathogenic: S. sonnei, S. dysenteriae, S. flexneri and S. boydii. Many cases of “traveller’s 
diarrhoea” are supported by Shigella spp. 
S. dysenteriae causes severe dysentery and prostration by secreting the “Shiga toxin”, which 
inhibits protein synthesis in epithelial cells of intestinal wall, killing them. Bacteria multiply 
in the small intestine and spread in the large intestin, entering the epithelial cells. Infection 
proceeds towards neighbouring cells, via a “cell-to-cell” mechanism, thus avoiding immune 
system response. As consequence, intestinal mucosa is damaged, causing severe diarrhoea 
with blood and mucus in the faeces. Additional symptoms may be abdominal cramps and 
fever.  
Only S. dysenteriae may reach the bloodstream, causing septicaemia. Its mortality rate is 
quite significant and may reach 20% in tropical areas, where it is prevalent. 
Staphylococcus aureus 
Gram positive, spherical-shaped bacterium, it is a frequent inhabitant of respiratory tract 
from which it can contaminate hands and skin. Typically, S. aureus and others 
staphylococcal species are resistant to various stresses. They can survive 60°C for 30 
minutes, drying and high osmotic pressures. Such characteristics allow their survival under 
conditions that, generally, eliminate the most of bacteria. In absence of competitors, then, it 
can rapidly proliferate. 
It is able to produce several toxins that improve the virulence or damage tissues, but the 
toxin produced by serogroup A is responsible for most of the cases. The toxin is heat-stable, 
in that maintains its virulence up to 30 minutes of boiling.  
Symptoms of intoxication are vomiting and abdominal cramps followed by diarrhoea. 
Remission is reached within 24 hours. 
Streptococcus spp. 
Genus of gram positive, microaerophilic, spherical-shaped bacteria which occur in chains or 
pairs. The genus is defined by a combination of antigenic, haemolytic, and physiological 
characteristics into Groups A, B, C, D, F, and G.  
Groups A and D can be transmitted to humans via food.  
Group A is formed by a single species,  S. pyogenes, with 40 antigenic types, while Group D 
is represented by the new genus Enterococcus.  
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Many types of food may be contaminated by Group A Streptococcus, including raw milk, ice 
cream, ham, potato salad, shrimps salad, steamed lobster via manipulation by ill handlers. 
Moreover, they may contaminate food with low content of free water, rich in salt or with 
very acidic pH, which is generally difficult to be contaminated by other bacterial species. 
Group A Streptococcus may cause several diseases, as bacteraemia, impetigo, erysipelas, 
pneumonia, osteomyelitis, septic arthritis, meningitis and toxic shock syndrome. 
Among complications, acute rheumatic fever may follow respiratory infections as an 
autoimmune disease, in which antibodies raised against the streptococcal M-protein cross-
react with autoantigens of pericardium and synovium.  
Enterococci can cause food intoxication through production of biogenic amines, such as 
histamine and tyramine, mainly by the decarboxylation of amino acids in fish, meat and 
dairy products, wine, beer, vegetables, fruits, and nuts.  
The genus Enterococcus is responsible for severe diseases, such as urinary tract infections, 
bacteraemia, bacterial endocarditis, diverticulitis, and meningitis.  
Vibrio cholerae 
Gram negative, slightly curved rod-shaped bacterium, which lives naturally in brackish 
waters, but can easily spread also in freshwater. 
It can contaminate fish and seafood. 
It is the aetiological agent of cholera, a serious illness that stroke Europe and North America 
during the XIX century with different outbreaks. Symptoms are nausea, vomiting, abdominal 
pain, watery diarrhoea which may induce severe dehydratation, that can be fatal if untreated. 
Nowadays, cholera is endemic in India and rarely it causes outbreaks in Western countries. 
In 1991-1994, Latin America had an epidemic, in consequence of importation of 
contaminated seafood from Asia, with more than one million cases and 9600 deaths. In 2010, 
a new outbreak in Haiti has occurred. 
Vibrio parahaemolyticus 
Gram negative, slightly curved rod-shaped bacterium, which lives naturally in salt waters.  
The related gastroenteritis follows the consumption of contaminated seafood. Symptoms 
include abdominal pain, vomiting, a burning sensation in the stomach and cholera-like 
watery faeces. Remission occurs within few days. 
Vibrio vulnificus 
As V. parahemolyticus, it is found in estuarine waters and contaminates seafood. It represents 
a serious threat for people with compromised immune system. In people with liver disease, 
it may cause septicaemia, with mortality rates often exceeding 50%. 
Yersinia enterocolitica and Y. pseudotuberculosis 
Psycrofile Gram-negative bacteria which usually colonise the bowel of domestic animals 
and are transmitted by milk and meat. Outside their natural habitat, they are able to grow at 
refrigeration temperature (4°C). The symptoms are diarrhoea, fever, headache and 
abdominal pain.  
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For the most of the above described foodborne bacteria, the VBNC state has been proven by 
several studies. Therefore, the meaning of VBNC state as well as inducing and resuscitating 
factors have to be well understood, in order to plan how to face the difficulties of detection 
and make traceability feasible. 
5. The bacterial stress response 
In their natural environments, bacteria undergo fluctuating chemo-physical conditions, such 
as nutrient availability, temperature, osmolarity, and pH, which may interfere with their 
growth and survival. In such a situation, they modulate their gene expression, in order to  
survive, by activating the bacterial stress response, which consists in variations of cell 
morphology, dimensions, energetic levels, directly related to cell survival. The final effect is 
an increased global resistance of surviving cells against further stresses, such as exposure to 
antibiotics, hydrogen peroxide and high osmolarity (Matin, 1991; Nyström et al., 1992). 
In such a situation, some genera of Gram positive bacteria, as Bacillus, Clostridium and few 
others, differentiate into endospore.  
Endospore is a differentiated bacterial cell in which new structures, required for mechanical 
and physical resistance, are synthesised. In the endospore, metabolism has been abolished 
by a controlled process of dehydration. The lack of metabolism confers a global resistance 
extended for prolonged periods of time. When environmental conditions become 
favourable, endospore undergoes germination, a process by which the metabolic activity is 
restored and cell turns to vegetative life. 
The most of Gram positive and all Gram negative bacteria are not able to generate 
endospores. However, they can trigger a stress response with a highly-complex network of 
molecular mechanisms. 
Studies carried on bacterial stress response have started from bacterial physiology in natural 
oligotrophic environments (Kurath & Morita, 1983; Morita, 1982). 
Subsequent studies have focused on the underlying molecular mechanisms, especially 
regarding a specific chemophysical stress and single-nutrients starvation (Eberl et al, 1996; 
Matin, 1991; Nakashima et al., 1996; Rockabrand et al., 1995).  
One aspect on which little is known is that, in natural environments, nutritional and chemo-
physical factors inducing bacterial stress response may change simultaneously, with one 
specific factor influencing another and being, in turn, influenced by a third one.  
Therefore, several mechanisms of bacterial stress responses should be activated. Unfortunately, 
few data are available about bacterial response to simultaneously-acting multiple stresses.  
5.1 The bacterial stress response to chemophysical stress 
Bacterial responses to chemophysical stresses, such as cold- and heat-shock, 
hyperosmolarity and acid pH, have been investigated. 
5.1.1 The cold shock response 
It has been observed that E. coli, when subjected to a temperature decrease, triggers the cold 
shock response, in which sets of proteins are synthesised, globally indicated as CIPs (Cold 
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Induced Proteins), as transcription regulators, ribosomal proteins, elongation factors and β 
subunit of RNA-polymerase (Berger et al., 1996; Jones & Inouye, 1996; Nakashima et al., 
1996), in order to allow mRNAs transcription and protein synthesis. 
5.1.2 The heat shock response 
When subjected to heat shock, bacteria have to counteract macromolecules denaturation, so 
the overexpression of chaperones is induced to stabilize cell macromolecules and to degrade 
denaturised polypeptides (Gage & Neidhardt, 1993; Spence, 1990). 
5.1.3 The osmotic shock response 
Osmotic shock causes considerable shrinkage of the cytoplasmic volume. In this process, 
known as plasmolysis, intracellular water tends to migrate towards the external 
environment. As a consequence, the concentrations of all the intracellular metabolites 
increase and thus reduce the intracellular water activity (wa). Bacteria may react by 
increasing the concentrations of solutes that have no effects on cell processes. Such solutes, 
called compatible solutes, are potassium ions, some amino acids (such as glutamate, 
glutamine, proline, γ-aminobutyrate, alanine), the quaternary amines glycinebetaine and 
some sugars (sucrose, threalose). Their accumulation inside the cells allows the cytoplasmic 
wa to be restored, with maintaining of metabolism (Csonka, 1989).  
5.1.4 The acid shock response 
When a sudden drop in pH occurs, bacteria generally use proton pumps, which literally 
pump protons out of the cell to keep the cytoplasmic pH. Another approach is to increase 
the concentration of alkaline compounds within the cell to counteract the acidification of the 
cytoplasm (Bore et al., 2007). 
5.2 The bacterial stress response to nutrient starvation 
Under nutrient starvation, variations at structural, metabolic and physiological levels are 
observed.  
During carbon starvation, heterotrophic bacteria enter a quiescent state, with a decrease in 
ATP content and a general reduction in metabolic activity. Moreover, gram negative rod 
bacteria undergo a characteristic morphology transition to spherical shape. When an 
energetic source becomes newly available, carbon-starved bacteria rapidly resume their 
metabolic activities, simultaneously restoring the rod shape (Givskov et al., 1994). 
On the other hand, under nitrogen or phosphate starvation, anabolism is strongly reduced 
and the cell undergoes an energetic surplus, which is dissipated by futile cycles reactions or 
accumulation of high-energy storage compounds, such as PHAs (Eberl et al., 1996). 
6. The viable but nonculturable (VBNC) state 
One of the most intriguing findings on stressed bacteria in natural environments was the so-
called viable but nonculturable (VBNC) state (Xu et al., 1982). 
The VBNC state is defined as a state of dormancy triggered by environmental harsh 
conditions, such as nutrient starvation (Cook & Bolster, 2007), temperature (Besnard et al., 
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2002), osmotic stress (Asakura et al., 2008), oxygen availability (Kana et al., 2008), several 
food preservatives (Quirós et al., 2009), heavy metals (Ghezzi & Steck, 1999), exposure to 
white light (Gourmelon et al., 1994) and decontaminating processes, as pasteurization of 
milk (Gunasekera et al., 2002) and chlorination of wastewater (Oliver et al., 2005).  
In such a state, bacteria lose the ability to grow on solid media and undergo reduction in 
size; moreover, several metabolic variations occur, such as reductions in nutrient transport 
across cytoplasmic membrane, respiration rates, and macromolecular synthesis (Oliver, 
2000; Porter et al., 1995). Biosynthesis does not cease, in that starvation and cold shock 
proteins are synthesized (McGovern & Oliver, 1995; Morton & Oliver, 1994). ATP levels 
remain high in VBNC cells (Beumer et al., 1992; Federighi et al., 1998). Further, recent 
studies have demonstrated continued gene expression by cells in the VBNC state (Lleò et al., 
2000, 2001; Yaron and Matthews, 2002). Other cellular characteristics, such as cell wall 
(Signoretto et al., 2000; Signoretto et al., 2002) and membrane composition (Day and Oliver, 
2004), differ remarkably from culturable cells.  
When environmental conditions become permissive, resuscitation of VBNC bacteria occurs. 
Resuscitated bacteria are culturable on solid media and display the vegetative lifecycle.  
Also resuscitation is a very complex phenomenon. A group of extracellular proteins, 
indicated as resuscitation promoting factors (Rpfs), play a key role in several other bacterial 
species (Hett et al., 2007; Mukamolova et al., 1998a, 1998b; Shleeva et al., 2004). 
Another class of resuscitation factors is  a heat-stable autoinducer of growth (Reissbrodt et 
al., 2002), which has been identified as a novel quorum-sensing system, termed AI-3 
(Sperandio et al., 2003) and secreted after incubation in media containing norepinephrine 
(Freestone et al., 1999). Norepinephrine is produced in large amounts in humans following 
severe tissue injury, and is thus considered to be a stress-related hormone. Both epinephrine 
and norepinephrine could replace AI-3 in activating enterohaemorrhagic E. coli virulence 
gene expression (Sperandio et al., 2003). 
These findings would support the hypothesis of resuscitation of VBNC enteropathogens in 
the human intestinal tract, at a time (e.g. tissue damage) when the host may be under 
significant physiological stress, with consequent secretion of norepinephrine. 
Interestingly, even several higher organisms may induce  resuscitation from the VBNC state. 
Many conditions have been found to allow resuscitation of pathogens, as inoculation into 
yolk sacs of embryonated eggs (Cappelier et al., 1999b, 2007), into mice (Cappelier et al., 
1999a) and into human volunteers (Colwell et al., 1996).  
The observations of the VBNC state for the most of foodborne pathogens have raised several 
questions about the retention of virulence in such a state as well as recovery of virulence 
together with resuscitation in the host. The matter is highly debated because contrasting 
results have been presented. In some cases, virulence of L. monocytogenes in the VBNC state 
has been shown to depend on the experimental conditions adopted for resuscitation 
(Cappelier et al., 2005, 2007). It seems that VBNC pathogens are not generally able to initiate 
disease, but virulence is retained and infection can be initiated following their resuscitation. 
In fact, VBNC cells of Vibrio harveyi were avirulent, but resuscitated cells were lethal, 
indicating that VBNC V. harveyi cells retained pathogenic potential (Sun et al., 2008). 
Similarly, Oliver & Bockian (1995) reported V. vulnificus to lose virulence for mice in 
 
Public Health – Methodology, Environmental and Systems Issues 
 
200 
Induced Proteins), as transcription regulators, ribosomal proteins, elongation factors and β 
subunit of RNA-polymerase (Berger et al., 1996; Jones & Inouye, 1996; Nakashima et al., 
1996), in order to allow mRNAs transcription and protein synthesis. 
5.1.2 The heat shock response 
When subjected to heat shock, bacteria have to counteract macromolecules denaturation, so 
the overexpression of chaperones is induced to stabilize cell macromolecules and to degrade 
denaturised polypeptides (Gage & Neidhardt, 1993; Spence, 1990). 
5.1.3 The osmotic shock response 
Osmotic shock causes considerable shrinkage of the cytoplasmic volume. In this process, 
known as plasmolysis, intracellular water tends to migrate towards the external 
environment. As a consequence, the concentrations of all the intracellular metabolites 
increase and thus reduce the intracellular water activity (wa). Bacteria may react by 
increasing the concentrations of solutes that have no effects on cell processes. Such solutes, 
called compatible solutes, are potassium ions, some amino acids (such as glutamate, 
glutamine, proline, γ-aminobutyrate, alanine), the quaternary amines glycinebetaine and 
some sugars (sucrose, threalose). Their accumulation inside the cells allows the cytoplasmic 
wa to be restored, with maintaining of metabolism (Csonka, 1989).  
5.1.4 The acid shock response 
When a sudden drop in pH occurs, bacteria generally use proton pumps, which literally 
pump protons out of the cell to keep the cytoplasmic pH. Another approach is to increase 
the concentration of alkaline compounds within the cell to counteract the acidification of the 
cytoplasm (Bore et al., 2007). 
5.2 The bacterial stress response to nutrient starvation 
Under nutrient starvation, variations at structural, metabolic and physiological levels are 
observed.  
During carbon starvation, heterotrophic bacteria enter a quiescent state, with a decrease in 
ATP content and a general reduction in metabolic activity. Moreover, gram negative rod 
bacteria undergo a characteristic morphology transition to spherical shape. When an 
energetic source becomes newly available, carbon-starved bacteria rapidly resume their 
metabolic activities, simultaneously restoring the rod shape (Givskov et al., 1994). 
On the other hand, under nitrogen or phosphate starvation, anabolism is strongly reduced 
and the cell undergoes an energetic surplus, which is dissipated by futile cycles reactions or 
accumulation of high-energy storage compounds, such as PHAs (Eberl et al., 1996). 
6. The viable but nonculturable (VBNC) state 
One of the most intriguing findings on stressed bacteria in natural environments was the so-
called viable but nonculturable (VBNC) state (Xu et al., 1982). 
The VBNC state is defined as a state of dormancy triggered by environmental harsh 
conditions, such as nutrient starvation (Cook & Bolster, 2007), temperature (Besnard et al., 
 
Viable but Nonculturable Bacteria in Food 
 
201 
2002), osmotic stress (Asakura et al., 2008), oxygen availability (Kana et al., 2008), several 
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Similarly, Oliver & Bockian (1995) reported V. vulnificus to lose virulence for mice in 
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proportion to the length of time that the cells were in the VBNC state. The cells retained 
virulence, however, and even when fully nonculturable, were able to cause fatal infections, 
with resuscitation occurring within the mouse. Continued virulence for a variety of 
pathogenic vibrios has also been demonstrated (Baffone et al., 2003).  
Then, it can be concluded that VBNC forms of foodborne pathogen bacteria into a human or 
animal host may be a realistic threat for public health, because it has been demonstrated that 
virulence can be maintained or recovered after resuscitation. 
7. Role of food in induction of VBNC state 
Chemophysical characteristics of food select the bacteria able to colonize and survive. 
Such characteristics, defined as intrinsic factors, are pH, redox potential (or oxygen 
concentration) and aw. However, other factors, that have to be considered, will be also 
discussed. 
7.1 pH 
Although optimal bacterial growth requires a pH near neutrality, it has been demonstrated 
that foodborne pathogens can trigger the acid shock response for survival in acidic 
environments.  
Then, acidic food may be an environment inducing the VBNC state and risk becomes higher 
for food, as fresh juices and salads, not subjected to antimicrobial treatments.  
7.2 Redox potential (or oxygen concentration) 
Food redox potential is a factor which influences the development of bacteria. Vegetable 
food has a redox potential ranging from  +300 and -400 mV, which favours aerobes and 
eukaryotic microrganisms (yeasts and moulds). Meat has a value of -200 mV, which allows 
persistence of microaerobes and anaerobes bacteria. 
Oxygen influences food redox potential, so its concentration is critical for bacterial growth. 
Aerobe bacteria need oxygen for growth, whereas anaerobes use compounds other than 
oxygen, such as nitrate, nitrite, sulphate, sulphite, etc. Some anaerobes, defined obligate, 
have been considered as totally inhibited by presence of oxygen for a long time, in that were 
believed to be unable to face the oxidative damage caused by Reactive Oxygen Species 
(ROS). Nowadays, it has been demonstrated that Clostridium may withstand oxidative 
stress, in that genome sequencing revealed the presence of genes related to oxygen 
metabolism (Kawasaki et al., 2005). 
Also oxidative stress may induce VBNC state, as demonstrated in Vibrio sp. (McDougald  & 
Kjelleberg, 2006). 
7.3 Water activity (aw) 
The aw is a measure of free water available for microbial growth and its value ranges from 
1.00 of mineral water to 0.60 of  bakery products, candies and dried fruit. A range of aw 
around 0.995 to 0.998 allows the growth of most of bacteria. The use of salting as ancient 
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conservation technique for meat and vegetables consists, ultimately, in bringing down aw to 
reduce microbial development. 
As already stated, bacteria may face osmotic shock; moreover, high osmolarity may induce 
VBNC state (Asakura et al., 2008). 
7.4 Chemical composition 
Biological macromolecules are used as substrates for growth, but bacteria may use only a 
limited part of the macromolecular content. Moreover, several compounds, such as 
polyphenols of fruit and vegetables and organic acids, display bacteriostatic and bactericide 
activities, which are further stress-inducing factors. 
7.5 Feedstock treatment 
Decontamination procedures, such as pasteurisation, salting and acidification, can induce 
VBNC state (Gunasekera et al., 2002; Makino et al., 2000; Quirós et al., 2009). Moreover, 
untreated food is more susceptible to microbial contamination (Erickson et al., 2010). 
7.6 Food storage 
Before consumption, food is stored during packaging, distribution and commercialization. 
Time and temperature are critical factors which are related to bacterial stress response and 
induction of VBNC state (Besnard et al., 2002). 
7.7 Presence of endogenous microflora 
Feedstock and untreated food possess a resident microflora, not necessarily hazardous for 
human health. Such microflora may interact with contaminating bacterial pathogens by 
intercellular exchange of signalling molecules, as the autoinducers, which may activate 
secretion of virulence factors or resuscitation in VBNC bacteria (Reissbrodt et al., 2002). 
8. VBNC state of foodborne bacteria – The new challenge in food safety 
Despite the few studies, strong evidences of VBNC bacteria in food have been reported. In 
stored wine, for example, acetic acid and lactic acid bacteria entered VBNC state as 
consequence of lack of oxygen and presence of sulphites, respectively (Millet and Lonvaud-
Funel, 2000).  
The role played by chemo-physical characteristics of food in triggering VBNC state in 
foodborne pathogen bacteria is poorly undestood. The most of the studies consists in 
analysing the effects provoked by a single stress on a homogeneous population of 
bacteria. 
However, it has to be considered that, in their habitat, bacteria are continuously subjected to 
the simultaneous action of factors, as nutrient availability, pH, osmolarity, temperature, 
presence of toxic compounds, ecological competition with other organisms, which are 
continuously changing. The time and the entity of the change of a single factor influences, 
and in turn is influenced by, changes and entities of other factors, according to chaos 
dynamics observed in nature, in an unpredictable way.  
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conservation technique for meat and vegetables consists, ultimately, in bringing down aw to 
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human health. Such microflora may interact with contaminating bacterial pathogens by 
intercellular exchange of signalling molecules, as the autoinducers, which may activate 
secretion of virulence factors or resuscitation in VBNC bacteria (Reissbrodt et al., 2002). 
8. VBNC state of foodborne bacteria – The new challenge in food safety 
Despite the few studies, strong evidences of VBNC bacteria in food have been reported. In 
stored wine, for example, acetic acid and lactic acid bacteria entered VBNC state as 
consequence of lack of oxygen and presence of sulphites, respectively (Millet and Lonvaud-
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dynamics observed in nature, in an unpredictable way.  
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In the same way,  food and its surrounding environment have to be considered as a complex 
system, in which the chemo-physical characteristics (pH, aw, chemical composition) and 
environmental factors (storage temperature and time, decontamination treatments, 
packaging under modified atmosphere) act simultaneously on contaminating bacteria. 
It has been demonstrated (Nicolò et al., 2011) that refrigerated pasteurised grapefruit juice 
induces VBNC state in E. coli O157:H7 and S. Typhimurium within 24 hours of incubation.  
Grapefruit has a very acidic pH, low content in carbohydrates and several antimicrobial 
compounds. Such characteristics, generally described as factors inducing VBNC state in 
laboratory, together with the refrigeration used for storage, suggested the hypothesis that 
grapefruit juice could induce VBNC state in foodborne pathogens.  
On the contrary, grape juice, which differs from grapefruit juice for the higher content in 
carbohydrates, did not induce VBNC state (Nicolò et al., unpublished data), despite the 
acidic pH and refrigeration temperature. 
Therefore, the role of food in induction of VBNC state has to be elucidated. Predictive 
models offered by biomathematics and bioinformatics would be very helpful tools, in order 
to evaluate the possibility that, under certain conditions, pathogen bacteria contaminating a 
tipology of food may enter the VBNC state.   
In pasteurised milk, de novo expression of a gfp reporter gene has been demonstrated to be 
higher than culturable cells for both E. coli and Pseudomonas putida, so showing that, after 
thermal treatment, contaminant bacteria had lost the ability to form colonies, but retained 
transcription and translation machineries (Gunasekera et al., 2002). 
A study on dried salted squid contaminated by Salmonella enterica subsp. enterica Oranienburg, 
responsible for an outbreak in Japan in 1999, has showed the inefficacy of cultural methods for 
detection of VBNC bacteria. In such a study, less than 20 culturable cells were recovered by 
plating a sample of salted squid, a value that cannot support the septicaemia observed in 
patients, but BacLight assay showed that more than 90% of the population was viable. In such 
a way, the hypothesis that an outbreak of foodborne bacteria in VBNC state could be 
underestimated on the basis of culturable cells has been demonstrated (Asakura et al., 2002). 
In another outbreak in Japan, due to contamination of salted salmon roe by E. coli O157 in 
VBNC state, the authors demonstrated the resuscitation in vivo of VBNC bacteria and the 
maintaining of virulence in mice (Makino et al., 2000). 
Such studies demonstrate that also treatments for food preservation have to be considered 
as a possible factor inducing pathogen bacteria into VBNC state. On the basis of such 
observations, the role of preservation treatments has to be investigated, in order to identify 
the critical points of a given procedure and make the adequate corrections.  
9. Detection of VBNC bacteria  
Actually, several systems for VBNC detection in water environments have been set up. Such 
systems are based on fluorescent staining, DNA hybridization and mRNA quantization. 
Many fluorescent stains are used as indicators of metabolic activity (or viability), because 
they can accept the electrons flowing through cell respiratory chains. The most common are 
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known as tetrazolium salts, as 5-cyano-2,3-ditolyl tetrazolium chloride (CTC) and 2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-phenyl tetrazolium chloride (INT). 
In recent years, a new differential staining assay, the BacLight® Live/Dead assay, has been 
developed. The assay allows to simultaneously count total and viable (metabolically active) 
cells, by using two nucleic acid stains, that is green-fluorescent SYTO® 9 stain and red-
fluorescent propidium iodide stain. These stains differ in their ability to penetrate intact cell 
membranes. When used alone, SYTO® 9 stain labels both live and dead bacteria. In contrast, 
propidium iodide penetrates only bacteria with damaged membranes, reducing SYTO® 9 
fluorescence when both dyes are present. Thus, live bacteria with intact membranes 
fluoresce green, while dead bacteria with damaged membranes fluoresce red.  
CTC, INT and BacLight® Live/Dead assay are commonly used for the Direct Viable Count 
(DVC), by visualization of VBNC bacteria under fluorescence microscopy, one of the most 
widespread techniques for assessing bacterial viability (Rowan, 2011).  
When DVC values are higher than culturable cells, obtained by CFU assay (that is when cell 
viability is higher than culturability), then it is assumed that bacteria have entered VBNC 
state. 
Fluorescent antibodies have also been employed in DVC for VBNC detection of E. coli in 
recreational water (Zimmerman et al., 2009). In such technique, the sample is incubated in 
presence of yeast extract and nalidixic acid, which inhibits bacterial replication.  Then, living 
cells increase their biomass, but cannot duplicate, so they elongate or enlarge. After addition 
of fluorescent antibody, fluorescing cells with altered morphology can be counted with 
epifluorescence microscopy. The difference between fluorescing cells, obtained by DVC, and 
culturable cells, obtained by CFU assay, indicates the presence of VBNC bacteria. 
DNA hybridization is based on the identification of nucleic acid sequences that are specific 
for a given species, such as those present in ribosomes (16S and 23S rRNAs), by using a 
fluorescent known DNA sequence, called probe.  
In fluorescence in situ hybridization (FISH), the hybridization between probe and nucleic 
acid sequence can be visualized in epifluorescence microscopy and used for DVC after 
incubation of the sample in a medium containing an antibiotic which prevents bacterial 
division. Comparison between DVC and culture count by miniaturized most-probable 
number (MPN) gives information about the presence of VBNC cells (Garcia-Armisen, 2004; 
Servais et al., 2009). 
Flow cytometry has been successfully employed to gather information about cell viability, 
antigenic surface components, and the quantification of morphological variations of V. 
parahaemolyticus during entry into the VBNC state (Falcioni et al., 2008).  
mRNA quantization is performed by quantitative reverse transcription polymerase chain 
reaction (qRT-PCR). Such technique is derived from the classic polymerase chain reaction 
(PCR), which allows the synthesis of huge quantities of a DNA sequence.  
Dunaev et al. (2008) recently reported on the rapid and accurate quantification of VBNC 
pathogens in biosolids via monitoring and quantifying stress-related genes in Salmonella 
spp. using cDNA microarrays combined with qRT-PCR. Quantification of mRNA was 
correlated to cell viability and their ability to grow. 
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Other techniques, such as microradiography, have been proposed for VBNC identification, 
but they resulted to be time-consuming and quite expensive. 
The above described detection methods, used in water environment, are not part of 
routinary food safety procedures, in that they are not simple enough, the equipment is too 
expensive and specialised technical personnel is necessary.  
Moreover, it has to be considered that food could be quite difficult to investigate, because of 
the presence of heterogeneous compounds that could interfere with the molecular reaction 
required by a single detection technique.  
However, new methods for VBNC detection should be designed, in terms of rapidity, 
sensitivity and ease of use. 
10. Social and economical consequences of an outbreak 
In any outbreak, beyond the health aspect, several social and economic implications are 
strictly associated to the emergence of a foodborne disease. 
20% of illnesses are referable to known pathogens, but the remaining 80% is due to 
unspecified agents, intended as known agents not yet identified as cause of foodborne 
illness, agents known to be in food whose pathogenicity is not proven and unidentified 
agents. 
As consequence, their traceability by traditional food safety methods is difficult. 
In this regard, VBNC role in foodborne outbreaks has still to be defined. 
In fact, the appearance of an outbreak has a critical effect on public opinion, generating fears 
that often become panic. The difficulty of a correct communication among health 
authorities, politics and people has been matter of study by World Health Organization, 
which published a manual containing the guidelines to overcome such problem. 
Moreover, the difficulty to identify in a timely fashion the primary causes of the outbreak 
has a negative impact at economic level, because any foodstuff suspected to be infected is 
removed from the market and destroyed, with consequent economic losses. 
The management of the recent outbreak of E. coli O104:H4 in Germany can be considered as 
a good source for several considerations. 
At the onset of the outbreak, the identification of the aetiological agent was erroneous and 
only later it was demonstrated that the true cause was an enteroaggregative E. coli strain, 
able to synthesize Shiga toxins. 
The source of infection was sprouted food produced by an organic farm in Bienenbüttel, 
Lower Saxony, Germany; local laboratories failed in finding the pathogen and correct 
identification was achieved later by a laboratory in North Rine-Westphalia. 
Before the test results, German health authorities erroneously declared that the pathogen 
was present in cucumbers imported from Spain. Later, they admitted that the E. coli strain 
responsible of the outbreak was not found in cucumber samples they had analysed.  
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As consequence of the false information, Spanish exporters lost more than 200 millions of 
Euro per week. Political tension between Spain and Germany exploded on behalf of the 
European summit in Debrecen, Hungary, where the Spanish Minister of Agriculture 
publicly accused the German government of irresponsible behaviour. Spain, in fact, is the 
first world producer of cucumbers and more than 90% of its agricultural produce is 
exported in Europe. The destruction of vegetables and fruit had dramatic economic losses, 
because at that time Spain was already heavily hit by international financial crisis. 
Moreover, Russia banned the import of fresh vegetable from Europe, with economic 
consequences which impacted on all the countries of European Union. 
Another cause of diplomatic tension was a joint risk-assessment by European Food Safety 
Agency (EFSA)/European Centre for Disease Prevention and Control (ECDC), which 
identified a link between the German outbreak and a simultaneous haemolytic urea 
syndrome outbreak in France, caused by the same E. coli strain. The assessment indicated 
fenugreek seeds imported in Europe from Egypt as a possible source of contamination, even 
if in the same document it was stated that such hypothesis had to be truly demonstrated. 
Such behaviour induced the Egyptian Minister of Agriculture to comment such opinions as 
“sheer lies”. 
Several critical points about the German outbreak management emerge. First of all, 
standard procedures for the fast and unambiguous pathogen(s) identification are 
required, in order to alert health care points and allow them to plan the best response for 
people assistance.  
Then, a real-time communication between health care points and national health authorities 
is needed, for continuous monitoring of the outbreak. 
Health authorities have to communicate with politics, to plan the best way to inform people 
about the situation, giving appropriate information and warnings.  
Further, communication among health authorities of the countries involved in the outbreak 
has to be promoted, to efficiently identify the causes of the outbreak and track it. 
Communication, then, is the keystone for the best management of an outbreak. Appropriate 
procedures have to be established, with the creation of multilevel joint committees, formed 
by health and political authorities, which have to control quality and completeness of 
available information and manage subsequent communication to public opinion. 
The importance of communication has been matter of the WHO Expert Consultation on 
Outbreak Communications held in Singapore on 2004. As result, a manual containing the 
guidelines to be followed has been published and is freely available (WHO, 2005).  
11. International programs devoted to monitoring and tracking of foodborne 
pathogens 
Surveillance of foodborne disease is a fundamental component of food safety systems and 
data are used for planning, implementing and evaluating public health policies. There is 
therefore a strong need to strengthen such systems, particularly for establishing whether 
VBNC foodborne pathogens may be responsible for an outbreak.  
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In this regard, the New Zealand Food Safety Authority has charged the Institute of 
Environmental Science and Research Limited to investigate the resuscitation of putative 
VBNC foodborne bacteria of significance to New Zealand. The final report concluded that 
some foodborne pathogen bacteria may become VBNC under certain conditions, that there 
may be no universal system for resuscitation of VBNC cells and that the phenomenon may 
be highly variable and bacterial species specific. 
The difficulty in investigating the VBNC state and the related potential risk did not allow 
health authorities to establish guidelines for their detection.  
Anyway, several efforts are carried out for surveillance of emerging foodborne diseases, 
creating new and interdisciplinary teams of research for data generation, collection and 
analysis.  
In 2000, the Food and Agriculture Organization (FAO) of the United Nations and World 
Health Organization (WHO) started to expand their activities in the area of microbiological 
risk assessment to meet the increasing need for risk-based scientific advice and information 
and tools to undertake microbiological risk assessment. FAO and WHO coordinate their 
work in this area through the implementation of joint FAO/WHO meetings on 
microbiological risk assessment (JEMRA). 
The activities of JEMRA can be categorised as follows: 
• Generation of scientific information - risk assessments 
• Elaboration of guideline documents 
• Data collection and generation 
• Use of risk assessment within a risk management framework 
• Information and technology transfer  
Moreover, WHO is promoting many programs and projects, by the creation of several 
worldwide collaborations involving technical existing structures, to give support, 
information and instructions on how to face an incoming outbreak. 
The Global Alert and Response (GAR) is an integrated system for epidemics and other 
public health emergencies based on strong national public health systems and capacity and 
an effective international system for coordinated response. 
The Global Outbreak Alert and Response Network (GOARN) is a technical collaboration 
of existing institutions and networks that pool human and technical resources for the 
rapid identification, confirmation and response to outbreaks of international importance. 
The Network provides an operational framework to link this expertise and skill to keep 
the international community constantly alert to the threat of outbreaks and ready to 
respond. 
In 2011, United States President Obama signed into law the FDA Food Safety Modernization 
Act (FSMA). It aims to ensure the U.S. food supply is safe by shifting the focus of federal 
regulators from responding to contamination to preventing it. As a mandate, the FDA will 
launch a test of two different programs that they hope will help with locating the source of 
food contamination more quickly. 
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One program will track processed foods, and the other will trace raw fruits and vegetables. 
The program will focus on keeping more detailed records of food and the path it makes as it 
travels across the country. 
A new project has been established at Centers for Disease Control and Prevention (CDC), in 
collaboration with  the Food and Drug Administration (FDA), which is called the Food-
borne Disease Active Surveillance Network or FoodNet.  
The project consists of active surveillance for foodborne diseases and related epidemiologic 
studies designed to help public health officials better understand the epidemiology of 
foodborne diseases in the United States. 
In the United States, using FoodNet data from 2000–2007, the Centers for Disease Control 
and Prevention estimated that 48 million people get sick, 127,839 were hospitalized and 
3,037 people died. 
Similarly, the European Food Safety Authority (EFSA) is the keystone of European Union 
(EU) risk assessment regarding food and feed safety and emerging risks, in close 
collaboration with national authorities. 
Particularly, European food safety policy is to ensure a high level of protection of human 
health and consumers' interests in relation to food, taking into account diversity, including 
traditional products, whilst ensuring the effective functioning of the internal market. 
Since 2000, the European Commission's guiding principle, primarily set out in its White 
Paper on Food Safety, is to apply an integrated approach from farm to table covering all 
sectors of the food chain, from feed production to transport and retail sale. 
Moreover, the regional office for Europe of WHO supports countries in building capacity to 
manage food safety challenges in accordance with the WHO European Action Plan for Food 
and Nutrition Policy 2007–2012 and the WHO global strategy for food safety. The Action 
Plan is an important guide for policy-makers and health professionals that includes a wide 
range of actions in the area of food safety. 
Despite the care by public health entities to track efficiently many known foodborne 
pathogens and identify the possibility of outbreaks, it is known that a consistent number of 
outbreaks is due to unknown pathogens. Such data may be due to microbes that are not 
proven to cause diseases as well as to VBNC state of known foodborne pathogen bacteria 
that, up to date, are undetectable. 
12. Conclusions  
Foodborne pathogens are the greatest threat to food safety. Despite the several efforts, much 
remains to be done to reach the national health objectives.  
The first action to be taken is the enhancement of measures to reduce or prevent 
contamination in the food and to educate stakeholders more effectively about risks and 
prevention measures. 
Whereas in developed countries food safety procedures and surveillance network monitor 
continuously the insurgence of possible emergencies, the situation is drastically different in 
developing countries, where many difficulties have to be considered. 
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In general, the lack of people education is the first problem, in that social habits as well as 
cultural factors may favour the spread of a foodborne infection. 
Then, people education is the keystone needed to strongly limit the raise and diffusion of an 
outbreak within a community. 
Moreover, a continuous support, in terms of updating of political authorities and retraining 
of health personnel, could contribute to an efficient action by the local governments. 
Another step for developing countries is the creation of a permanent educational system 
that allows people, since infancy to adult age, to be informed about foodborne infections, 
their causes and ways of spreading. In this way, such information will become part of the 
community culture and will be transmitted to the future generations. 
Overall, it is important to encourage the local formation of specialised personnel in 
healthcare sector for medical care, research, monitoring and communication. 
Furthermore, it would be also desirable that international health authorities could take into 
account the focusing of VBNC state of foodborne bacteria. In fact, despite the studies 
performed up to date, several topics have to be clarified, that is i) the risk that food may 
induce VBNC state in contaminating foodborne pathogens; ii) wheter VBNC state can be 
considered as a resistance strategy against stress or a transitory condition which precedes 
cell death; iii) the factors triggering the VBNC state; iv) the factors triggering the 
resuscitation and v) the maintaining of the virulence. 
In fact, in food field it is very important to fit into a global frame the effects of the various 
food parameters, as chemophysical characteristics, decontamination procedures and storage 
conditions and time. All these factors, in fact, may be source of multiple and subsequent 
stresses for contaminating pathogen bacteria and evaluating the possibility of onset of 
VBNC state is a primary need. In such sense, bioinformatics and predictive mathematical 
models could be a powerful tool to identify whether a specific association of different 
stresses acting on a bacterial population may induce the entry into VBNC state. 
Unfortunately, up to date detection of VBNC foodborne pathogen bacteria in food is 
problematic.  
New methods have been proposed for VBNC detection, but they are not satisfying in that 
difficult to use as routinary procedures.  
Therefore, innovative detection procedures, in terms of ease of use and rapidity of analysis, 
are urgently needed to allow an efficient monitoring and tracking of foodborne VBNC to 
prevent outbreaks in today’s and future global market. 
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1. Introduction 
Winslow (1920) has defined the meaning of public health as "the science and art of 
preventing disease, prolonging life and promoting health through the organized efforts and 
informed choices of society, organizations, public and private, communities and 
individuals". Thus, the focus of public health intervention is the improvement of health and 
quality of life through the prevention and treatment of disease, and promotion of healthy 
behaviors. Promotion of hand washing is a typical common public health practice to prevent 
the spread of “unwanted” diseases (Samuel et al., 2005).  
With the rapid increase on applications for nanoparticle silver, its potential impact on public 
health has become a critical issue. Nanosized silver can be made with different shapes such 
as particles, wires, and rods. Silver nanoparticles (AgNPs; many other names such as 
nanosilver (nAg) and colloidal silver) have already been used in everyday consumer 
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products requiring broad spectrum antibiotic performance because of their enormous 
surface area and reactivity. Faunce & Watal (2010) recently analyzed international 
regulatory issues for medical and domestic use in the United States, European Union, 
United Kingdom, and Australia. They found that despite the numerous studies reported in 
recent decades, many scientists are still uncertain of its safety. Very recently, Powers (2010) 
showed positive that Ag+ and AgNPs are developmental neurotoxicants in vitro and in 
vivo. Therefore, there is a need to conduct a study to identify a global landscape of AgNPs, 
their products, and their manufacturers. A market-based intellectual property (IP) study has 
been conducted to examine the current global patent landscape of companies using AgNPs 
in their consumer product development and production from 1980 to 2010 (Lem et al., 2012). 
Information on materials, compositions, formulation, manufacturing processes, and ultimate 
application were extracted using a “two-stage” stage-gate process using the IP activity in the 
use of nanosilver in consumer products. The two stages studied were commercial and 
consumer products. In the first stage for AgNPs and AgNPs-based commercial products, 
Lem et al. (2012) reported that there were 7,422 patent families from January 1, 1980 to 
December 31, 2010. In the second stage for AgNPs-based consumer products, 932 patent 
families from January 1, 1980 for to December 31, 2010 were found.  
Korea, China and the USA were found to be the major players in AgNPs and AgNPs-based 
commercial and consumer products. Korea has been the leader and consumer products 
containing nanosilver are even sold on the streets. Due to its enormous surface reactivity, 
nanosilver has already found utility in everyday products that require antibiotic 
performance, such as materials that contact food, textiles and fabrics, appliances, consumer 
products, children’s toys, infant products, ‘health’ supplements, cosmetics and 
pharmaceuticals (Chaloupka et al., 2010). Thus, safety has become a potentially critical issue 
for companies that make products containing nanosilver. For product stewardship to their 
customers, suppliers must address environmental health and safety issues in terms of real 
risks, perceptual risks, and government regulation.  
In this chapter, we evaluate consumer products containing nanosilver especially in Korea 
using an IP landscaping study. We examine the recent literature regarding the effect of 
silver and nanosilver on public health from a clinical medicine perspective. We then 
evaluate the concept of waste generation and waste minimization in the material life cycle. 
We examine the flow of silver and nanosilver in the life cycle of food metabolism to identify 
ways to minimize potential adverse effects of nanosilver and to provide concepts of eco-
products to minimize exposure to nanosilver for public health. Coupling the recent 
literature and the IP landscaping study, together with Design for Lean Six Sigma – Green 
(DFLSS-G) and TRIZ, we demonstrate the concept of waste minimization by controlling the 
release of nanosilver (Lem et al., 2011; Liu JG et al., 2010) in eco-product design.  
2. Manufacturing commercial AgNPs products 
Nanoproducts can be produced in two ways: top-down or bottom-up. A top-down 
approach is essentially tearing down of a device to gain insight into its components, 
materials and compositions (e.g., ball milling). A bottom-up approach is the piecing together 
of materials to give rise to components and finally to build a device (e.g., chemical 
precipitation). 
Waste Minimization for the Safe Use of Nanosilver  
in Consumer Products – Its Impact on the Eco-Product Design for Public Health 219 
Figure 1 gives a roadmap of top-down and bottom-up development of nanoproducts under 
a value chain of “material – properties – processing – structure – performance – 
applications”. This roadmap helps to identify the unmet needs from materials to/from 
applications in nanoproduct development and manufacture. 
 
Fig. 1. Top-Down and Bottom-Up Development [Lem et al., 2009; Brauer et al., 2009)] 
Commercial AgNPs products are typically produced via a bottom-up process, while analysis 
of environmental impact by AgNPs products is a top-down process (Tolaymat et al., 2010). 
In order to use nanosilver for different applications, various chemical and physical methods 
are used to synthesize the nanosilver. One of the best recent overviews is the U.S. EPA’s 
report by EI-Badawy et al. (2010). Chemical methods usually require a silver salt precursor, 
a reducing agent (formaldehyde, glucose or hydrogen peroxide.), a solvent, a stabilizer and 
a capping agent. Silver nitrate is a commonly used precursor to produce silver nanoparticles 
(Mousa & Linhart, 2010). Alternatively, the wet/dry electroplating method (Yang et al, 
2006), electric spark bombardment (Koecher et al., 2009), and other mechanical techniques 
(polishing and grinding) are used as physical methods to produce nanoparticles.  
Fabrication of nanosilver in the nanofiber form is usually done by electro spinning 
techniques. Other methods are being explored in applications to wound dressing and textile 
or personal care products.  
Coatings have been used to employ the antibacterial property of nanosilver in biomedical 
devices or electronic devices. The nanosilver coating techniques include technologies such 
as spraying , chemical vapor deposition, dipping, printing knife-coating, transfer coating, 
and spin coating (Koecher et al., 2009).  
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Furthermore it is known that functionalizing the nanosilver with different functional 
groups/moieties can make nanosilver suitable for specific applications like biomedical 
devices, dye-doped particles, biomedical imaging, etc. One interesting example uses 
glycosaminoglycan conjugated nanosilver particles for biomedical devices (Mousa & 
Linhart, 2010). Anti-coagulation is another active area for research where a core of metal 
silver is coated with a surface layer of silver oxide (Zhu et al., 2002; Zhu & Zhu, 2004). One 
method of increasing sterilizing power and antibacterial property of nanosilver is by mixing 
it with nanosulfur compounds (Oh, 2002). Coated nanoparticles are produced by 
precipitating nanoparticle cores from two aqueous reactant solutions in a microemulsion, 
and adding a coating agent to coat the cores (Tan, 2003). 
3. The landscaping of consumer products containing nanosilver 
To have a better global picture of nanosilver in commercial and consumer products, Lem et 
al. (2012) have conducted an exhaustive intellectual property (IP) search study using a “two 
stages” stage-gate process. This search is divided into three parts based on timelines.  
Part A. Before 1980 “pre nano”: In this the search is done to identify patent documents 
which have a mention of nano sized silver material before nanotechnology became an 
establish field of science and technology. 
Part B: Jan 1980 to Jul 2008: Time prior to EPA expressing their concern about toxicological 
uncertainty as a consequence of using nano scale silver. 
Part C: Aug 2008 to Dec 2010: This is the time after the EPA has started showing concern 
towards toxicological uncertainties as a consequence of using nano scale silver. The 
search is terminated 2010 to avoid complications of handling data for the incomplete 
year 2011. 
 
Fig. 2. AgNPs Patent Filing Countries (Adopted from Lem et al., 2012) 
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The details of the search methodology and results are not the subjects of this article. They 
have been reported recently by Lem et al. (2012). Figure 2 shows the countries researching 
AgNPs. Figure 2 shows that out of all the major patenting authorities, South Korea is 
leading with 2087 publications. The U.S. is second and China is third. These three countries 
have about 80% of the total patent publications. It is important to note that Chinese patent 
numbers are over-weighted by their Chinese Utility Model Patents that only protect the 
shape and/or structure of a product for 10 years and are not subject to substantive 
examination. The International Bureau or WIPO’s Patent Cooperation Treaty (PCT) is a 
parallel patenting route that covers most of the world’s patenting countries.  
Due to its antiseptic and biocidal nature, more than 50% patenting activity of AgNPs is seen 
in the area of pharmaceuticals, healthcare, consumer goods, preservatives, sterilization, and 
water treatment.  Using the patent landscape analysis, we identified relevant patents for 
pharmaceutical, healthcare, and consumer goods patents. Intensive IP analysis, such as 
broadness of claims, details of office actions can help in identifying the share of the market 
that can be attributed to current and future technology. Active companies in the technology 
space were identified as they can influence the market. For example, LG Household and 
Health Care Ltd (health care) and L’Oreal (cosmetics) are amongst the major assignees in the 
space of pharma and consumer goods patents.  
Several observations were found in the 932 patent families from January 1, 1980 to 
December 31st, 2010 that was related to AgNP in consumer products. These 932 patent 
publications were reviewed to distil information with respect to:  
1. Nanosilver size or percentage loading,  
2. Nanosilver form or geometry,  
3. Material composition, and  
4. Application area and products.  
Among these 932 publications, cosmetics, personal care, medical, and health care occupy 
more than 70% of the application areas as shown in Figure 3. 
In order to analyze the data in more detail, we defined four different classes of formulation 
to examine the role of the concentration of nanosilver (e.g., dose) used in the formulations 
on these applications:  
1. Trace dose, less than 0.01 wt. %.  
2. Low dose, 0.01 to 1.0 wt. %.  
3. Medium dose, 1.0 to 10 wt. %.  
4. High dose, greater than 10 wt. %.  
Clearly trace dose formulation found applications in foods, drinking water, drugs, facial 
mask, cream, wound care, gel, and textiles (Lem et al., 2012). At low and medium doses, the 
formulations found applications in household products materials, medical, personal care 
and cosmetics. Typical medical applications include catheter, endotracheal tube, and 
subcutaneous central venous port; pacemakers, prosthetic heart valves, prosthetic joints, 
voice prostheses, contact lenses, stents, heart valves, penile implants, small or temporary 
joint replacement, urinary dilators, cannulae, and intrauterine devices; catheter lock, needle, 
luer-lok (medical device) connectors, needleless connectors, clamps, forceps, scissors, skin 
hooks, tubing, needles, retractors, sealer, drills, chisel, rasps, surgical instruments, dental 
instruments, intravenous tubes, breathing tubes, dental water line, dental drain tubes, 
feeding tubes, bandages, wound dressings, orthopedic implants, and saws (Lem et al., 2012).  
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The details of the search methodology and results are not the subjects of this article. They 
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High dose formulation applications were in antimicrobial pharmaceuticals, hair mousse, 
biocides, disinfectants, electronic chemicals, silver conductive ink, medical applications, 
solar panels, smart glass, and suppository (Lem et al., 2012).  
4. The landscaping of consumer products containing nanosilver in Korea  
As indicated earlier, Korea is a leader in patent publications for use of nanosilver in consumer 
products. Cosmetics and personal care, medical, and health care occupy 65% of the Korean 
applications shown in Figure 4. This is a similar percentage as the global consumer products 
shown in Figure 3. Comparing Figure 3 and Figure 4 illustrates some of the Asian cultural and 
societal differences. While the world is spending more (40%) on medical/ health care and little 
less (32%) on cosmetics/ personal care, Korea invested more than twice in cosmetic/personal 
care (47%) than in medical /health care (18%) (Lem et al., 2012). 
Koreans spent about $130 per person in 2008 on makeup and skin care products and use in 
plastic surgery clinics doubled to about 1,000 facilities between 2004 and 2007 (Shin, 2008; 
Barry, 2002; U.S. Commercial Service, 2011; Consumer Demand Beneficiaries in Korea, 
2008). Several reasons accounted for the strong growth of cosmetics in the Korean market.  
1. Life expectancy of Koreans has increased from 62 in 1970 to 79 years in 2006 (Shin, 
2008).  
2. Korea’s rapidly aging population and increasing female workforce are now driving 
the demand for beauty and personal cares products in the domestic market. Also the 
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life expectancy of female Korean has increased from 66 in 1970 to 82 in 1986 (Shin, 
2008).  
3. A notable trend is the rising demand of the male consumer. Male Korean life 
expectancy has increased from 59 in 1970 to 79 in 2006 (Shin, 2008).  
4. The younger populace is looking for general skin care and hair care products while the 
older generation has more specific needs for their cosmetics products.  
5. There is a clear trend of the market heading towards premium cosmetic products that 
need new technology, especially nanotechnology.  
 
 
Fig. 4. Nanosilver in Different Application Areas in Korea (Adopted from Lem et al., 2012) 
(January 1, 1980 to December 31, 2010) 
Recently, nanosilver has also found use in everyday products such as antimicrobial 
products, consumer products, and electronic products. Consumer products containing 
nanosilver have been selling everywhere in South Korea, especially on the streets of her 
capital – Seoul as illustrated in Figure 5. 
At this juncture, it should be pointed out that not all the consumer products claimed to 
contain AgNPs indeed have AgNPs. Using energy dispersive X-ray spectroscopy (EDS) 
analysis (Yang et al., 2011), we have found that not all the commercial products sold in 
Korea claimed to have AgNPs indeed contain AgNPs (Kim et al., 2011; Yang et al., 2011). 
These experimental results are not unusual, though negative results can also be due to 
washing away over time. However, it appears that marketing (especially by street vendors) 
of AgNPs is not always directly tied to science. Even with a sophisticate Cloud Point 
Extraction-Based Separation together with EDS, SEM, TEM, and UV analyses, Chao et al., 
(2011) reported that only three out of six tested antibacterial AgNPs containing commercial 
products actually contained AgNPs.  
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Fig. 5. Selling AgNPs Consumer Products on the Street in Seoul, Korea 
5. Silver/nanosilver and public health 
Today, about 320 tons/year of AgNPs are produced and used worldwide in industrial 
products (Nowack et al., 2011). Stensberg et al. (2011) reported that an estimate of 1,120 tons 
of AgNPs will be used in 2015. They also reported that the number of products that contain 
AgNPs has increased from 30 in 2006 to over 300 at the beginning of 2011.  In any event, the 
assumption that silver is benign to humans or that health effects are relatively mild cannot 
be made without further research to confirm these views. The existence of previous studies 
show, if anything, that there are potentially very real and severe side-effects which must be 
addressed prior to increasing the use of silver and especially nanosilver in health, consumer, 
and professional settings. Therefore, whether it is an old or new problem, we must deal with 
it seriously.  
The growth in investment in nanoscience and nanotechnology has been astounding. Among 
the $12.4B spent in 2006 worldwide nanotechnology research funding (Mamikunian, 2007), 
at least 50 %, that is >$6B, was spent on the effect of size on the development of 
nanomaterials and devices.  
Nanotechnology application focuses on exploitation of the size effects to create structures, 
devices and systems with novel properties and functions. The focus of nanoscience research 
is the understanding of the effect of size and its influence on the properties of nano-material. 
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With this rapid growth of nanotechnology, it is only natural that the next major wave of 
applications for silver would include nanoscale particles. However, the safety of nanosilver 
(AgNPs) in public health is a potential “Nano-Titanic” possibly preventing a sustainable 
nanosilver industry. As with macroscale silver, nanosilver effectively kills bacteria and is 
therefore biocidal, but many scientists are still uncertain of its safety.  
At the nanoscale, materials have different properties as a function of size compared with the 
same materials at a larger size. The size range of greatest interest is typically from 100 nm 
down to approximately 0.2 nm, because in this size range properties of the materials become 
tunable (Sun, 2007; Lem et al., 2010). This tuneability requires a better understanding of 
effect of size of particles on public health. 
Given the explosive growth in applications of nanosilver, certain authors have expressed 
misgivings about potential public health effects. Senjen and Illuminato (2007; 2009) of 
Friends of the Earth claimed that nanosilver was an extreme germ killer which presents a 
growing threat to public health. Chaloupka et al. (2010) discussed a number of medical uses 
of Ag and AgNPs in human prophylactic antibacterial effects such as bone cement, 
implants, and coating for neurosurgical shunts and catheters. In their literature citation, 
Wijnhoven et al. (2010) and Chao et al. (2010) found that AgNPs were toxic to rat and 
human cells. They further noted that these silver nanoparticles could enter the human skin 
via textile and dressing contact, via release from medical devices ingressing into the female 
gentile tract, forming protein-silver complexes that can deposit in human vital organs such 
as the liver, lungs, and kidneys. Recently, silver has found use in everyday products such as 
antimicrobial products, consumer products, and electronic products.  
Even with the urgent need to specify the nanotechnology that could be the most assist the 
developing world, Faunce & Watal (2010) reported that the role of AgNPs was not 
specifically mentioned in water purification due to their potential environmental toxicity. 
Very recently, Powers (2010) mentioned in her dissertation that her results showed positive 
that Ag+ and AgNPs are developmental neurotoxicants in vitro and in vivo.  Furthermore, 
the discharge, emission, and disposal of AgNPs and their products to the environment 
during their entire products life cycle are also a major concern (Rebitzera et al., 2004; Ross et 
al., 2002; Panyala et al., 2008; Hansen, 2009; Danscher & Locht, 2010; Nowack, 2010). In 
recent years, the uncertainty of safety has increasingly made nanosilver a concern of 
potential threats to public health. Despite the fact that silver and nanosilver has been used 
for many centuries in applications pertinent to our daily life because silver has an antiseptic 
effect. In ancient times, many Greeks used silver vessels for drinking water storage.  
In contrast, Volpe (2010) and Height (2009) of The Silver Nanotechnology Working Group 
(SNWG) argued that AgNPs used in antimicrobial applications are identical to all the EPA-
registered silver products that were used for decades. Very recently, Nowack et al. (2011) 
urged the policy regulators should not hastily declare nanosilver materials as new chemicals 
in their study on the 120+ years of nanosilver history. However, Schäfer et al. (2011) rebuked 
Nowack et al. (2011) by questioning the difference between the scientific definition of 
“colloid silver” and nanosilver. They further raised five pertinent questions regarding the 
safety of nanosilver in consumer products that need to be clarified:  
1. Is the toxic potential of nanosilver identical to “classical” silver? 
2. Since when has it been possible to analyze silver at the nanoscale? 
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3. Does nanosilver enter the body in the same way as “classical” silver? 
4. Do we know enough about the environmental spread of silver resistance? 
5. Is our current knowledge on nanosilver in consumer products sufficient to account for 
safe use? 
In her exhaustive study, Powell (2011) clearly concluded that, “I propose that enough is 
known already about the toxicity of silver as a metal to begin taking strong steps to prevent 
human exposures and environmental releases now, rather than waiting till silver becomes 
the next mercury.”  
Recently, the German Federal Institute for Risk Assessment (BfR) has conducted the Delphi 
study (Bartels, 2010) regarding nanoscale silver compounds in food products, cosmetics and 
every day products. To ensure that products are safe for consumer health, BfR recently 
recommended that German manufacturers not use nanoscale silver or nanoscale silver 
compounds in foods and everyday products until the data are available and comprehensive 
enough to allow a conclusive risk assessment (Bartels, 2010). Faunce & Watal (2010) noted 
further the uncertainty of the safety may be compounded by lack of toxicological data and 
lifecycle studies of acceptable environmental exposure limits. 
6. A clinical medicine perspective of silver and nanosilver 
In view of the many applications in Asian countries like Korea, the importance of a clinical 
medicine perspective of silver and nanosilver needs to be emphasized. Silver has long been 
used as an antimicrobial agent in medicine to keep wounds clean since the days of ancient 
Greece, Egypt, and Rome (Chen & Schluesener, 2008; Lansdown, 2010). This is because of 
the efficacy of thiol group reactions which inactivate bacterial enzymatic activity (Faunce & 
Watal, 2010).  Colloidal silver was introduced as long ago as 1884 by German physician Dr. 
C.S.F. Crede, to prevent transmission of maternal gonorrhea to newborns and thus 
preventing blindness. This is still a practice used in nurseries today (Feder, 2005).  Silver was 
used as a wound dressing and disinfectant during World War I until the advent of 
penicillin, but the combination of silver with the antibiotic sulfonamide into silver 
sulfadiazine cream is still the first-line treatment for burns (Atiyeh et al., 2007; Ahamed et 
al., 2008; Faunce & Watal, 2010).  
Nanosilver, or nano-particle sized silver provide a greater surface area of silver and 
theoretically a more efficacious product. It has also been used extensively in medical 
applications, from the impregnation and coating of surgical mesh, indwelling catheters, 
ports, stents, tubes, scopes, and cuffs to other devices to prevent the growth of bacterial 
biofilms which can precipitate infection. (Faunce & Watal, 2010)  Additionally, the use of 
nanosilver has extended into the public health arena, where it is being used to coat food and 
agricultural facilities in an effort to prevent bacterial outbreaks in the general population 
(Powell, 2011).  
Despite the wide ranging applications of silver and nanosilver in medicine, it is not clear 
that enough regulation exists or that there is sufficient research on the potential toxicity of 
silver to the human body and environment at large. Not only is there evidence for the 
potential toxicity of nanosilver, there is evidence to suggest that nanosilver is uniquely 
harmful to the human body when compared to silver compounds because of its ability to 
generate reactive oxygen species (ROS). ROS, also known as free radicals, cause a 
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biochemical chain reaction which eventually leads to the destruction of cellular metabolism, 
structures, and DNA (Faunce & Watal, 2010).  Oxidative stress can disrupt cell membranes 
or cell walls, leading to cell destruction (Powell, 2011).  In vitro studies have shown that 
silver can increase the rate of cell death, inhibit cell growth, decrease DNA and protein 
synthesis, disrupt DNA replication, affect cell membrane ion transport and integrity, cause 
cell swelling and toxicity, cause cell death, inhibit neutrophil and lymphocyte activity, and 
decrease the body’s cell count (Powell, 2011).   
Environmental concerns surrounding nanosilver have also entered the public health arena 
(Yu, 2008). Nanosilver production can lead to bulk form release of silver and nanosilver into 
waste streams, which have previously led to major environmental toxicities (Faunce & 
Watal, 2010).  Such pollution can lead to not only deleterious effects to the ecosystem as a 
whole, but also cause direct poisoning of humans and animals. In fact, ionic silver is 
considered to be the second most toxic metal after mercury, in part because of its efficacy in 
binding prokaryotic and non-mammalian organisms (Power, 2011).  
One common condition linked to increased silver deposits in the skin is argyria, a 
permanent blue-gray discoloration of the skin, and the related argyrosis, a similar 
discoloration in the eye (Atiyeh et al., 2007; Powell, 2011).  The presence of silver is thought 
to increase melanin production, therefore leading to the color change, particularly in the 
presence of sun exposure (Powell, 2011).  Though long thought to be a harmless cosmetic 
change, the finding of argyria is a proxy for increased systemic contamination with silver 
and suggests deeper pathophysiological effects in the body.  
Medically, well-documented effects have suggested that silver harms the renal and 
hepatological systems (Powell, 2011).  Deposits of silver in the glomerular subunits of the 
kidney have led to its classification as a nephrotoxin (Powell, 2011).  In the cardiovascular 
system, case reports have noted an association with arteriosclerosis, a precursor of coronary 
artery disease (Powell, 2011).  The inhalation of silver in the respiratory system has also been 
linked to inflammation, emphysema, reduction of lung volume, and straining of the tissues 
in the lung (Powell, 2011).  As a result, patients have complained of sometimes daily upper 
respiratory tract irritation, cough, wheezing, and chest tightness (Powell, 2011).  Silver has 
also been used as an abortifacient and sterilizing agent, suggesting its intrinsic damage to 
the reproductive tract (Powell, 2011).  In pregnant women, silver has also been show to cross 
the placental barrier, allowing it to enter the fetus as well (Powell, 2011).  One case-control 
study also suggested an association between the presence of silver in drinking water and 
developmental abnormalities (Powell, 2011).  
Delayed wound healing and decreased white cell count has been found to be a result of 
silver-enhanced wound dressings (Powell, 2011).  In patients with argyrosis, discoloration of 
the eyes with decreased night visual acuity has also been reported (Powell, 2011).  
Neurological effects include deposits in the central nervous system, glial changes, and 
cellular gliosis (Powell, 2011).  Clinical manifestations may include seizures, vertigo, 
weakness, gait disturbance, and decreased sensation (Powell, 2011).  Finally, studies in 
mouse embryonic stem cells have shown a rise in levels of p53, one of the main tumor 
suppressor proteins which help prevent cancer in the body, which inevitably leads to the 
question of whether nanosilver use can potentially contribute to greater likelihoods of 
cancer (Faunce & Watal, 2010). On the other hand, enhanced efficiency of wound healing 
has also been reported by application of AgNPs on skin wounds in mice (Liu X et al., 2010). 
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biochemical chain reaction which eventually leads to the destruction of cellular metabolism, 
structures, and DNA (Faunce & Watal, 2010).  Oxidative stress can disrupt cell membranes 
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Novel research done recently by Powers (2010) has shown that monovalent silver impairs 
mechanisms of neuronal development in vitro, but also causes disruption of 
neurodevelopmental mechanisms in vivo, which persists as lasting changes in adult 
neurochemistry and behavior (Powers, 2010).  Working with the model organism, zebrafish 
(Danio rerio), Powers was the first to show that while lower levels of silver ion did not affect 
morphology or embryonic viability, they do nevertheless negatively impact swimming 
performance and thus long-term mortality. Higher concentrations of ionic silver resulted in 
clear embryonic problems such as delayed hatching, decreased survival, and 
dysmorphology, suggesting a concentration-dependent effect (Powers, 2010).  Powers also 
provides evidence for the teratogenic effect of silver nanoparticles and of note, shows that 
the toxicity of nanoparticles was through a distinct mechanism from ionic silver. Some of 
these biological effects can be explained through differing toxicokinetic and toxicodynamic 
effects, which elicited unique developmental and neurobehavioral pathologies (Powers, 
2010).  
Another study conducted by Seoul National University showed that nanosilver enhances 
platelet activation and procoagulant activity (Jun et al., 2009).  Nanosilver worked 
synergistically with thrombin, a native blood protein which precipitates platelet activation 
and aggregation, to amplify thrombotic effects. Jun et al. (2009) found that nanosilver works 
in separate ways to enhance both the activation of platelets as well as facilitate platelet 
aggregation, or clumping. Intracellular calcium levels were increased by more than two fold 
in the presence of nanosilver, which is directly related to the activation of GPIIb/IIIa, a 
protein found on platelet surfaces which aids in platelet activation and binding to 
fibrinogen.  By potentiating these platelet activation and aggregation pathways, nanosilver 
exposure can theoretically lead to increased thrombotic events. Thrombosis can lead to 
decreased blood flow or infarction in the circulatory system, particularly in individuals 
already predisposed to blood clots. Potential complications include venous 
thromboembolism, deep vein thrombosis, pulmonary embolism, stroke, and myocardial 
infarction, underscoring the importance of understanding the thrombotic effects of 
nanosilver (Jun et al., 2009)..  
Despite the plethora of studies which suggest certain harmful effects of silver, the data are 
incomplete. The links between in vitro and animals studies to humans are in dispute, and 
the existing data on humans are largely through case reports, case-control studies, or 
retrospective analyses. There is a lack of high-quality, randomized controlled trials (RCTs) 
which can increase statistical power while minimizing biases. Obvious ethical concerns limit 
the amount and type research that can be done on human subjects, though longer-term, 
broader retrospective studies of patients exposed to silver may prove to be more helpful 
(Powell, 2011).  In any event, the assumption that silver is benign to human begins or that 
health effects are relatively mild cannot be made without further research to confirm these 
views. The existence of previous studies show, if anything, that there are potentially very 
real and severe side-effects which must be addressed prior to increasing the use of silver 
and especially nanosilver in the health, consumer, and professional settings. 
7. Concept of waste generation 
Waste generation is a critical limitation for any sustainable industrial system (Evens et al., 
2009). Waste is an important part of our life. Humans are not perfect and thus create wastes. 
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The actual performance is often lower than the theoretical because the efficiency is always 
less than 100% (Berglund and Snyder, 1990).  
Elimination and minimization of waste have been making great progress in industries and 
businesses using advanced methodologies such as Lean Six Sigma (Curran et al., 2006; EPA, 
2009). For instance, in polymer composite manufacturing, the total waste generated from 
these processes could be as high as 25% based on the theoretical yield of raw materials (Lem 
et al., 2006). Figure 6 gives a typical schematic of a materials processing value chain. The 
steps of the process include component selection, processing, structure, product, and 
performance. Each step can generate waste only if the waste cannot be recycle back to the 
start or inputs. Gutowski (2002) has examined the product induced material flows through 
the product manufacturing system, and has suggested several research strategies to reduce 
material related environmental loads. This can be accomplished by focusing on three key 
aspects of the manufacturing process: (a) resource productivity, (b) cleaning products, and 
(c) re-manufacturing, recycle, and compositing.  
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Where a, b, c, d are constants. In term of a continuous flow process, we can rewrite Eqns 1 
and 2 into Eqn 3  
 λ ω= − ( ) ( ) ( )j j j j jP x V x dx W x dx  (3) 
Where, P(x) is a value performance function, V(xj) is the value generating function at component 
xj stage or phase j, and W(xj) is the waste generating function at component xj, and λj , and ωj are 
constants. ). The variation of V (xj), W(xj), λj , and ωj greatly affects the value of P(x).  
 
Fig. 6. Relationship of Component Selection–Processing-Structure-Product-Performance 
(Adopted from Lem et al., 2006) 
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The expression in Eqn 3 has found uses in many applications in science and engineering. An 
example of such is the tensile modulus of several ordered polymers (Lem et al., 2006) in 
Table 1, in which the actual value [P(x)] is substantially lower than the theoretical value 
[V(x)]. V (xj) is not restricted with any limitations in Eqn 3 and it is valid to include the 
feedback loops (as in a recycling process) in Figure 6 except with different forms of V (xj) 
and W (xj), and different values of λj and ωj.  
 
 
Table 1. Tensile Modulus of Several Ordered Polymers (Adapted from Lem et al., 2006) 
8. Waste minimization in flow of materials as a food metabolism process in a 
material life cycle 
The quality of our life is improved by our industrial system, but the current system is 
creating unintended and serious consequences for the environment and public health at a 
global scale. For nanotechnology, to minimize these consequences, one must be able to 
transform all sources of waste and toxicity into “technical” or “biological nutrients”. We can 
then reuse them indefinitely without harm to living systems.  
Senge and Carstedt (2001) offered a view of why industry produces waste and suggested 
that a synthetic process can emulate nature to reduce the waste using a cyclic industrial 
system. One example of this approach is recycling of nylon 6 carpets (Sifniades et al., 1999; 
Lem et al., 2001, 2002). This type of cyclic process has addressed and overcome the 
economic, technical, and logistical barriers to commercialize a closed loop recycling process 
and recover caprolactam from waste nylon 6 materials (Lem et al., 2010). Based on the 
exergy analysis by Dewulf et al. (2002-2007), in Figure 7, Lem et al. (2010; 2011) have shown 
that waste generation in a real process is more than just exergy loss (destroyed) in industrial 
metabolism. Waste generation is unavoidable so waste minimization becomes a 
fundamental requirement for economic feasibility. The energy and exergy concepts can be 
formulated in the laws of thermodynamics. Energy is motion or ability to produce motion. It 
is always conserved in a process (1st law). Exergy is work or ability to produce work. It is 
always conserved in a reversible process, but is always consumed in an irreversible process 
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Fig. 7. Waste Generation and Exergy Loss (Dewulf et al., 2008, Lem et al., 2009, 2010)  
9. Flow of Ag and AgNPs as a food metabolism process in material life cycle 
Using a material flow analysis (MFA), Johnson et al. (2006) in their “anthropogenic 
cycling of silver in 1997” study have found that North America and Europe have  
the biggest share of use of silver products on a per capita basis. They found that global 
silver discards are approximately 57% of the silver mined and only 57% of the silver 
entering waste management globally is recycled. The amount of silver entering landfills 
globally is comparable to the amount found in silver mining tailings. Eckelman and 
Graedel (2007) reported that more than 13 Gg of silver are emitted annually to the 
environment globally. The tailings and landfills make up almost three-fourths of the total 
emission.  
Figure 8 gives an overview of a silver/nanosilver product’s life cycle as food and waste in 
industrial metabolism. The metabolization of resources should be optimized with respect 
to exergy. Dewulfn and Van Langenhove (2002, 2004) have previously applied exergy 
analysis as a quantitative tool in the thermodynamic optimization of the life cycle of 
plastics.  
Exergyin =  Exergyout + Exergy Loss
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Fig. 8. A Silver/Nanosilver Product’s Life Cycle as Food and Waste in Industrial 
Metabolism (Adopted from Lem et al., 2010) 
Once again as in Figure 6, a mass balance of each step in the life cycle in Figure 8 is equal to 
the food resource (in blue color arrows) available in each step minus the wastes (in red color 
arrows) at each step. Therefore, a summation of all the steps gives rise to the total value 
generated. Eqn 4 can be found 
 ( ) ( )= −             all sourcesTotal Value Performance Food Resource in Each Step wastes  (4)  
For the continuous process we have the generalized Eqn. 3 (above)  
 λ ω= − ( ) ( ) ( )j j j j jP x V x dx W x dx  (5) 
Therefore, the main thrust in the waste minimization is to minimize the waste generation 
function W (xj) at any step j. 
10. Effect of size on functional materials (silver) 
It is well established that the size of nanomaterials affects its properties (Sun, 2007). There is 
no exception in AgNPs, particularly as an antibacterial and anti-biofouling agent 
(Chaloupka et al., 2010; Liu H-L et al., 2010; Liu JG et al., 2010; Sotiriou & Pratsinis, 2010). 
Fundamental morphology, surface area, and property changes with smaller size have led to 
Waste Minimization for the Safe Use of Nanosilver  
in Consumer Products – Its Impact on the Eco-Product Design for Public Health 233 
size dependent material properties which are substantially different from their counterparts 
in bulk. The extent of valence electron delocalization can vary with the size of the particle or 
domain. Quantum effects become relevant for sizes less than 10 nm. Material properties 
become tunable by size (Sun, 2007); notably, coordination number imperfection, surface 
relaxation behavior, nanosolidification in physical properties, superplasticity in mechanical 
properties, melting and thermal diffusivity in thermal properties, acoustic phonon 
hardening and optical phonon softening behavior, quantum confinement effects in optical 
properties, work function and dielectric suppression in electrical properties, and magnetic 
modulation in magnetic properties. For example, the bandgap of semiconductors such as 
ZnO, CdS, and Si, changes with size. Magnetic materials such as Fe, Co, Ni, Fe3O4, etc., 
exhibit size dependent magnetic memory properties (Sun, 2007). 
In spite of the significance in the size of nanosilver, patenting directly addressing size effects 
only started in 2006 as seen in Figure 9. It is growing every year and 19 patent publications 
mentioned the size of nanosilver in 2010.  
 
Fig. 9. Patents Describing Size of Nanosilver (Adopted from Lem et al., 2012) 
As seen in Table 2, much effort has been employed to refine the type of stabilizers 
depending on the size of the nanosilver. For the larger diameters up to 400 nm, polyethylene 
glycol, poly (styrenesulfonate), cetyltrimethylammonium bromide have been used. For the 
medium diameters up to 100 nm, proteins, peptides, polyvinylpyrrolidone, human serum 
albumin and transferring have been reported in the IP publication to stabilize the 
nanosilver. For the very small diameter up to 15 nm, polyvinylpyrrolidone, (1-vinyl 
pyrrolidone)-acrylic acid copolymer, polyoxyethylene stearate, and 1-vinylpyrrolidone-
vinyl acetic acid copolymer were used. Since most AgNPs require to be capped by 
stabilizers for dispersion, the cytotoxic effect from NP size may be mixed with that from 
stabilizers. A study employed physically produced AgNPs for examination of the size effect 
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(Liu H-L et al., 2010). Results revealed that AgNPs of smaller average size (among 3 nm,  
6 nm or > 10 nm) had greater antibacterial activity as well as cytotoxicity. This study pointed 
out the critical role of NP size in their effect on human health and environment. 
11. Waste minimization in eco-product design for public health 
We have recommended earlier to use Design for Lean Six Sigma - Green (DFLSS-G) and 
TRIZ to design eco-products (Lem et al., 2009). Kobayashi (2005) has used a product life 
planning methodology based on a quality function deployment (QFD) and a software tool to 
establish an eco-design concept of a product and its life cycle in multigenerational eco-
products development. Serban et al., (2004) have used a TRIZ approach to design for 
environment for over a product life cycle. We need to answer the following three hard 
questions in this design: 
1. Do we have a complete understanding of AgNPs product life cycle? 
2. Do we have a clear understanding on the unmet needs? 
3. What can we do to minimize use of AgNPs with optimal effects? 
 
Table 2. Type of Stabilizers Used (Adopted from Lem et al., 2012) 
 
Publication Number Stabilizers/Important Components
Application Area/ End 
Product Nanosilver Size 
WO2010091529A1
Stabilizers: Proteins And/Or Peptides And/Or 
Polyvinylpyrrolidone: Human Serum Albumin And 
Transferrin;
Cosmetics And Personal 
Care / Hair Care
 1-100 nm in 
diameter
US20100172997A1
Stabilizer : Agarose, Hydrogel, Paa (Poly Acrylic Acid), Pva 
(Poly Vinyl Alcohol), Chitosan, Pnipam (Poly-N-Isopropyl 
Acrylamide), Substituted Pnipam (Including Pnipam-Aa (Poly-
N-Isopropyl Acrylamide-Acrylic Acid), Pnipam-Allylamine 
(Poly-N-Isopropyl Acrylamide-Allylamine), And Pnipam-Sh), 
Pamam (Polyamidoamine), Peg (Polyethylene Glycol), Alginic 
Acid and/or Hpc (Hydroxyl Propyl Cellulose)
US20090326614A1
Stabilizer :  Polyethylene Glycol (Peg), 
Poly(Styrenesulfonate), Cetyltrimethylammonium Bromide; 1-400 nm
CN101402757A Stabilizer: Amine Light Stabilizer. Packaging




Stabilizer : Hydroquinone, Hydroquinone Monomethyl Ether, 
T-Butyl Paracresol And Hydroxy Methoxybenzophenone, A 
Pigment, Or A Beneficial Agent.
Medical - Implant
KR2008083499A
Stabilizer:  Polyvinylpyrrolidone, (1-Vinyl Pyrrolidone)-Acrylic 
Acid Copolymer, Polyoxyethylene Stearate, And 1-
Vinylpyrrolidone-Vinyl Acetic Acid Copolymer.
1-15 nm
US20080181931A1 Stabilizer: Acrylic Acid, Polyacrylic Acid, Poly(Ethyleneimine), 
Polyvinylpyrrolidone
KR2006026362A
Stabilizer: Glycerin, Polyethylene Glycol, Ethanol, Ethylene 
Glycol, Propylene Glycol, Sorbitan Fatty Acid Alkylester And 
Its Ethylene Oxide, Hydrogenated Caster Oil
US20050013842A1
Stabilizer: Polyacrylic Acid (PAA), A Poly(Ethyleneimine) (PEI), 
A Poly(Vinylpyrrolidone) (PVP), A Copolymer of Acrylic Acid 
(AA) with a Vinylic Monomer, Acrylic Acid
Biomedical Device - 
Lense
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We have started to answer the first question by examining each step of the material flow in a 
metabolism during the life cycle as discuss earlier. The value generated is equal to the food 
resource available in each step minus the wastes at each step (Lem et al., 2009). In the 
material flow model, we need to include probabilistic method as suggested by Gottschalk et 
al. (2010) that is commonly being used in Design for Six Sigma (DFSS, Curran et al., 2006). 
To answer the second and third question, we need to understand how the use of nanosilver 
can be minimized based on specific needs in release and apply the DFLSS and TRIZ to 
generate innovative ideas for the eco-products design. As an exercise, we will use a shoe 
pad as an example as illustrated as in Figure 10. 
 
Fig. 10. Shoe Pads (Adopted from Lem et al., 2012) 
The amount of AgNPs release depends on the mechanics of the release. To prevent and 
control these occurrences, it is necessary to use “right amount” of suitable biocides to 
control fowl and kill microbes. Using a TRIZ approach (Terninko et al., 1998; Rantanen & 
Dom., 2002) in Figure.11, such a concept is proposed to use water activity as a means to 
control the water content of AgNO3 in the nanofibers where these nanofibers have a shell 
and core structure. In addition to the controlled release of AgNPs, the use of the nanofibers 
is to produce a very high contact angle surface to prevent water absorption on the surface 
(i.e., the Lotus Leaf Effect).  
AgNPs can be controlled release at least seven in ways:  
1. Particle size,  
2. Particle surface modification,  
3. Oxidant availability,  
4. Media composition,  
5. Structured release materials (such as multilayer shell and core structured nanofibers),  
6. Release device structure,  
7. Locality.  
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5. Structured release materials (such as multilayer shell and core structured nanofibers),  
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The release can be by one, combination of several, or a combination of all. The first four have 
been demonstrated by Liu JG et al. (2010) experimentally that the release of AgNPs can be 
tuned. To understand better the mechanic of the release, we will extend the work by Schiesser 
(1992, 2011) to describe the release control (desorption and diffusion) in our model.  
Using Water Activity to Control the Water Content of 
AgNO3 in Nanofibers with a Core and Shell Structure
Ag+
NO3-
Water Activity Affected 
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Fig. 11. The Proposed TRIZ Concept (Adopted from Lem et al., 2011) 
11.1 DFLSS and TRIZ 
A flow chart of the procedure to be used in our study is given in Figure 12 and a TRIZ 
approach in Design for Lean Six Sigma – Green for AgNPs products life cycle is given in 
Table 3. We are using the following four steps iterative approach: 
First: determine the Voice of the Environment regarding the safety of the AgNPs products 
using two extreme sides of the debate between Friends of Earth/USEPA and Silver 
Nanotechnology Work Group (SNWG) to obtain a resolution regarding “Conflict”. We try to 
answer the question - could improving one technical characteristic to solve a problem cause 
other technical characteristics to worsen? Once the problem is defined, we need to define the 
system boundaries, quantify mass flows of AgNPs, and define several emission scenarios.  
Second: search for previously well-solved problems by looking at the 39 engineering 
parameters/40 principles (Terninko et al., 1998; Rantanen & Dom., 2002). Antimicrobial 
nanoscale silver is typically embedded within substrates, mainly a a matrix such as a 
polymer, where any antimicrobial functionality is achieved via release of silver ions (Ag+).  
The behavior of silver in environment will be reviewed, and a mass balance model applied 
to calculate predicted environmental concentrations. The uncertainty of the results is 
assessed and predicted concentrations are compared to experimental and empirical data 
(examine an example such as “Nanoparticle Silver Released into Water from Commercially 
Available Sock Fabrics” by Benn and Westerhoff, 2008). 
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Fig. 12. Flow Chart for DFLSS-G with TRIZ (Adopted from Lem et al., 2010) 
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Third: compile and predict the toxicity data for environmentally relevant silver compounds 
for no effect concentrations. This material flow will be optimized based on a review of our 
earlier search for previously well-solved problems. 
Fourth: evaluate and determine the potential for risk caused by the release of silver into 
environment using all available experimental data and literature data.  
11.2 Release mechanics of AgNPs 
As discussed earlier, the release of AgNPs can be controlled seven ways: (1) particle size, (2) 
particle surface modification, (3) oxidant availability, (4) media composition, (5) structured 
release materials, (6) structure of release device, and (7) locality. The release can be by one, 
combination of several, or a combination of all. The first four have been demonstrated by Liu JG 
et al. (2010) that the release of AgNPs can be tuned. The readers are referred to their excellent 
paper for details. In this section, we will focus our discussion on the last three methods.  
11.2.1 Structured release material  
One way to control the release of AgNPs is the control of the presence of water. Water 
activity (aw) is defined as aw=p/po (where p and po are the partial pressures of water above a 
medium such as a food and a pure solution under identical conditions It is a measure of 
how efficiently the “free” water vs. the “bound” water present can take part in a chemical 
and/or physical reaction. Water content as a function of water activity has played a critical 
role in the understanding of food processing science and technology (Cassini et al., 2009). 
Nadia et al. (2011) have suggested further use of the glass transition temperature (Tg) of the 
material together with water activity in the material. This combination is a powerful tool for 
understanding the quantification of water mobility in foods and controlling the shelf-life of 
products. They reported that Tg, moisture content, and aw are useful tools to quantify the 
water migration pattern in food precisely (Nadia et al., 2011).  
The design of the structured release material must have an appropriate Tg, and the desired 
concentration of total water content present in a medium strongly bound to specific sites. 
These sites can be the hydroxyl groups of polysaccharides, the carbonyl, amino groups of 
proteins or synthetic polymers like nylon, polyurethanes, and other polar polymers 
containing hydrogen bonds and ion-dipole bonds. The preferred structure of the release 
material can be either bilayer such as shell/core or multilayered where the availability of 
free water in the material containing AgNO3 can be controlled as needed (see Figure 13).  
11.2.2 Structure of the release device 
It has been known for many centuries that water forms spherical droplets on a leaf as seen 
in Figure 14, and it is more pronounced in the lotus leaf (Luzinov et al., 2006; Ramaratnam et 
al., 2008; Schilthuizen, 2009; Eichhoff, 2011). Lotus leaves are unusually water-repellent and 
keep themselves spotless, because on their surface there are countless miniature protrusions, 
coated with a water-repellant hydrophobic substance. Water cannot spread out on the 
leaves; so it acts as droplets, removing grime and soil as it moves. The rough surface inhibits 
wettability and reduces the contact area for dirt particles. Lotus effect has found many 
interesting applications in consumer products, surface coatings, electronic materials, and 
smart textile (Luzinov et al., 2006; Ramaratnam et al., 2008; Schilthuizen, 2009). 
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Our goal is to control the wetting of water on the release device by using the concept 
advanced by Nano-Tex, LLC. Nano-Tex improves the water-repellent property of fabric 
using the so-called “Lotus Effect” by creating hydrocarbon nano-whiskers that are of 1/1000 
of the size of a typical cotton fiber. The distance between the whiskers on the fabric is 
smaller than a typical drop of water and water thus remains on the top of the whiskers and 
above the surface of the fabric. (Eichhoff, 2011; Schneider, 2008; Wong et al., 2006; Lo, 2006).  
A pictorial diagram of our proposed structure of the release device is shown in Figure 15. 
The materials used to make the release device have been suggested by KnollTextile (2010) 
and Wong et al. (2006). 
 
Fig. 15. Proposed Structure of Release Device (Adopted from Lem et al., 2011) 
11.2.3 Locality 
Bacterial fouling by humans has become a serious environmental and health issue. The 
existence of bacteria and its fouling in shoes and socks used/worn by human can lead to 
problems such as biofouling accumulation which leads to health problems. However, as 
seen in Figure 16, only certain areas in a shoe pad may require suitable biocides such as 
AgNPs for antifouling. Most sweat and frictional force occur in these areas indicated by the 
changing of the color of the pad. 
 
Fig. 16. Locality of Required Biocides for a Foot and a Shoe (Adopted from Yang et al., 2010) 
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12. Future study 
In our Design for Lean Six Sigma based Waste Minimization research program, we have 
begun our journey to study the life cycle assessment of nanosilver starting with the use of 
product life cycle process mapping and Design for Lean Six Sigma with TRIZ. We are 
planning to have a more multidisciplinary and international interaction to the 
characterization of AgNPs products and their transformations in relevant biological and 
environmental media. A rigorous material flow analysis is needed to quantitatively assess 
the environmental impact of AgNPs emission. We have continued our study on waste 
minimization for the safe use of nanosilver in consumer products with particular attention 
paid to the eco-product design for public health. The data that have been generated from an 
IP search study help us design eco-products using Design for Lean Six Sigma - Green 
(DFLSS - G) and TRIZ (Curran et al., 2006; Lem et al., 2006; Terninko et al., 1998) as seen in 
Figure 17. In addition we need to verify the concept illustrated in Figure 17 experimentally. 
We will use Monte Carlo (Curran et al., 2006), artificial neural network modeling (Chayjan 
et al., 2011), and generic programming (Langdon, 2008) approach in the front-end of the 
innovative concept generation process to search for the best new generation design. To have 
a better understanding the mechanic of the release control, we will extend the work by 
Schiesser and his coworkers (Silebi & Schiesser, 1992; 2011) to describe the desorption and 
diffusion in a pore with Monte Carlo simulations (Gottschalk et al., 2010). 
 
Fig. 17. Proposed Structure of an Eco-Product Required Biocides for a Shoe Pad (Adopted 
from Lem et al., 2011) 
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seen in Figure 16, only certain areas in a shoe pad may require suitable biocides such as 
AgNPs for antifouling. Most sweat and frictional force occur in these areas indicated by the 
changing of the color of the pad. 
 
Fig. 16. Locality of Required Biocides for a Foot and a Shoe (Adopted from Yang et al., 2010) 
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12. Future study 
In our Design for Lean Six Sigma based Waste Minimization research program, we have 
begun our journey to study the life cycle assessment of nanosilver starting with the use of 
product life cycle process mapping and Design for Lean Six Sigma with TRIZ. We are 
planning to have a more multidisciplinary and international interaction to the 
characterization of AgNPs products and their transformations in relevant biological and 
environmental media. A rigorous material flow analysis is needed to quantitatively assess 
the environmental impact of AgNPs emission. We have continued our study on waste 
minimization for the safe use of nanosilver in consumer products with particular attention 
paid to the eco-product design for public health. The data that have been generated from an 
IP search study help us design eco-products using Design for Lean Six Sigma - Green 
(DFLSS - G) and TRIZ (Curran et al., 2006; Lem et al., 2006; Terninko et al., 1998) as seen in 
Figure 17. In addition we need to verify the concept illustrated in Figure 17 experimentally. 
We will use Monte Carlo (Curran et al., 2006), artificial neural network modeling (Chayjan 
et al., 2011), and generic programming (Langdon, 2008) approach in the front-end of the 
innovative concept generation process to search for the best new generation design. To have 
a better understanding the mechanic of the release control, we will extend the work by 
Schiesser and his coworkers (Silebi & Schiesser, 1992; 2011) to describe the desorption and 
diffusion in a pore with Monte Carlo simulations (Gottschalk et al., 2010). 
 
Fig. 17. Proposed Structure of an Eco-Product Required Biocides for a Shoe Pad (Adopted 
from Lem et al., 2011) 
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1. Introduction  
In an increasingly market driven society, characterised by neoliberal economic policies and 
promotion of free trade, powerful multinationals have become significant actors, for good and 
bad, in global public health. These powerful multinational companies are using increasingly 
sophisticated marketing strategies not only to promote products - some of which are 
deleterious to health – but also to lobby against public health initiatives that threaten their 
profit. Should public health practitioners cooperate with, or even attempt to coopt, these 
powerful organisations in an endeavour to promote health? Although this seems to be an 
increasing trend one must remain cogniscent that these companies will promote profit at the 
expense of health and often they are more effective at coopting health causes for their profit 
driven purposes than health causes are at coopting them for public health ends (Wright 2010).  
In particular, this chapter explores how sponsorship of charities by corporates is actually a 
form of advertising that, when unhealthy products are promoted, can damage public health. 
The favoured approach by industry to minimise negative impacts of such advertising is via 
self regulatory codes. However, in Australia and elsewhere, these have by and large failed 
(Handsley E, Nehmy C et al. 2007; Ofcom 2008; National Preventative Health Taskforce 2009, 
p151; World Advertising Research Centre 2009). For example, in Australia the voluntary self 
regulatory policy to limit advertising of unhealthy products to children, called the Quick 
Service Restaurant Industry (QSRI), has resulted in no meaningful change since being 
introduced in 2009. The New South Wales Cancer Council concluded that “Children’s 
exposure to unhealthy fast-food advertising has not changed following the introduction of 
self-regulation” (Chapman, Hebden et al. 2011). Is it time for policy makers to impose limits on 
the promotion of unhealthy products in order to protect the health of the public.  
It is not so surprising that self regulation initiatives fail as it is counter intuitive, and against 
shareholder interests, for a profit seeking industry to minimise profit through self 
regulation. For example, arround 50% of profit from gambling  comes from those who are 
being harmed by the product: “problem gamblers” (The Public Health Association of 
Australia 2008). Therefore limiting advertising of unhealthy products in order to remove 
damage to health would threaten the viability of such industries and that outcome is 
definitely not in the interests of the shareholders!  
 11 
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In relation to corporate funding of health charities this seems to be entirely unchecked by 
either government or industry self regulation. At the very best this approach involves 
fundraising for a good cause that would otherwise be underfunded, and no doubt the 
charities themselves have no other motivation than to see their important cause supported. 
However, cynics of Corporate Social Responsibility (CSR) would argue that the ultimate 
goal for industry is profit, or at the very least trying to mitigate criticism of the organisation 
(Wright 2010). At its most sinister, might CSR involve an ethically questionable model 
whereby the charity is exploited to promote a company whose product is deleterious to 
health? This chapter describes how unethical behaviour increases along a spectrum when 
using charities to advertise by: 
1. Funding a charitable cause in order to advertise a product  
2. Funding a children’s charity to advertise a product 
3. Funding a children’s charity to promote a product that causes harm 
4. Funding a children’s charity to promote a product that causes the very illness that the 
charity seeks to respond to 
5. Funding a children’s charity to promote a product that causes the very illness that the 
charity seeks to respond to, and use this sponsorship to attain the high moral ground 
and lobby against public health approaches to address the public health problem 
Although there are various international case studies one could cite (see 
www.cmaj.ca/cgi/content/full/cmaj.110085/DCI for a list) this chapter unpacks four 
examples demonstrating potentially unhealthy alliances where industry has seemingly 
coopted children’s charities and public causes in order to sell a product that damages health. 
This discussion attempts to raise awareness about such subtle marketing and intends to help 
readers discern what might be appropriate and inappropriate use of charitable causes.  
Ultimately, we would hope that reading this chapter leads the reader towards taking action 
to protect our most vulnerable consumers from powerful industry interests. The chapter 
finishes by exploring how those in public health can creatively engage with this issue and 
respond by even using many of the same tactics utilised by companies whose products 
damage health.  
2. What is an acceptable form of company sponsorship of health charities? 
Advertising and marketing is very effective at selling ‘goods’, but these goods are not 
necessarily good. In the area of marketing Energy Dense and Nutrient Poor Food and 
Beverages (EDMPFB) various international reviews have concluded that heavy marketing is 
likely to have deleterious effects on children by encouraging products high in salt, sugar and 
fat (World Health Organization 2003; Livingstone 2006; National Preventative Health 
Taskforce 2009). Accordingly, in many countries, various codes exist to regulate marketing. 
However, Australian restrictions have been largely voluntary self-regulated codes which 
have failed to prevent ethically questionable advertising, such as advertising to children 
(Hebden, King et al. 2011) (Chapman, Hebden et al. 2011). 
On the surface it seems acceptable, or even desirable, that a company whose product causes 
damage should contribute to alleviation of the same damage. Such is the basis for carbon 
credits and taxes whereby companies contributing to carbon production may choose, or be 
required, to contribute towards mitigation of the problem to which they contribute. An 
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example from the health field is DrinkWise, a charity funded by the alcohol industry, 
aiming to shape “a healthier and safer drinking culture in Australia where drinking to 
excess, or drinking too young, is considered undesirable”. Such recompense is desirable if 
the aim and the effect is mitigation. 
However, sponsorship is ethically tenuous when a company whose product potentially 
causes illhealth, assists victims, and in doing so advertises the very product that caused the 
illhealth. Libertarians would argue that companies should be entitled to pursue such 
strategies, as informed adults are capable of discernment and can decide accordingly.  
However, there is a flaw in the assumption of consumers being fully informed or having the 
necessary agency to make such distinctions. For example, are people aware that DrinkWise is 
industry sponsored and have been accused of promoting the very products that caused the 
harm they are seeking to mitigate? The consumer may be unable to make a fully informed 
choice if the true identity of the organisation is unclear. If company X sponsors a charity Y 
which addresses the ill-health caused by the same company X, then consumers should surely 
be informed that charity Y is supported by Company X whose product causes the ill health.  
However, it seems more ethically objectionable when a company whose product could harm 
children, then assists the children who might be harmed, to make these children consume 
more of their potentially harmful product. Not only is a potentially harmful product being 
advertised to children, but the immature target audience, unaware of the danger of the 
product being marketed, could be influenced to view it as harmless or even good. 
Acknowledging the effect of advertising unhealthy products to children, Australia’s 
National Public Health Task Force (NPHTF) recommended phasing out of “premium offers, 
toys, competitions and the use of promotional characters, including celebrities and cartoon 
characters, to market EDNP food and drink to children across all media sources”. Similar 
moves have been initiated in other countries (Handsley E, Nehmy C et al. 2007; Ofcom 2008; 
National preventative health taskforce 2009, p151; World Advertising Research Centre 2009) 
(World Health Organization 2003; Livingstone 2006): Sweden and Norway prohibit 
commercial advertising directed at children via television, and Quebec prohibits the use of 
any media (Handsley E, Nehmy C et al. 2007, p153).  
Perhaps even more insidious is where the funding of worthy charities creates an unhealthy 
alliance which allows a company to attain the moral high ground, and so limit their 
vulnerability to challenges regarding their unhealthy products and questionable practices. 
For example, if a policy-maker decided to limit a company’s ability to inappropriately 
market their product to children, the company might then generate popular opinion against 
the politician with arguments like “this will undermine our ability to support children’s 
charities such as the Ronald McDonald kids health truck!” (Prisk 2011). This supports a 
concept described in the literature where Corporate Social Responsibility, such as 
sponsoring a charity, is really about company credibility and positioning in order to benefit 
their bottom line (Wright 2010), or as Wright describes, limited to where it is profitable and 
often as a reaction to criticism of their product and practices. An example of ethically 
questionable practices might involve sponsoring a children’s organisation to divert attention 
away from a product that potentially harms children.  
I will outline four case studies which demonstrate that this practice might be more common 
than we perceive. Each case study may represent the intentional use of CSR to gain moral 
 
Public Health – Methodology, Environmental and Systems Issues 
 
252 
In relation to corporate funding of health charities this seems to be entirely unchecked by 
either government or industry self regulation. At the very best this approach involves 
fundraising for a good cause that would otherwise be underfunded, and no doubt the 
charities themselves have no other motivation than to see their important cause supported. 
However, cynics of Corporate Social Responsibility (CSR) would argue that the ultimate 
goal for industry is profit, or at the very least trying to mitigate criticism of the organisation 
(Wright 2010). At its most sinister, might CSR involve an ethically questionable model 
whereby the charity is exploited to promote a company whose product is deleterious to 
health? This chapter describes how unethical behaviour increases along a spectrum when 
using charities to advertise by: 
1. Funding a charitable cause in order to advertise a product  
2. Funding a children’s charity to advertise a product 
3. Funding a children’s charity to promote a product that causes harm 
4. Funding a children’s charity to promote a product that causes the very illness that the 
charity seeks to respond to 
5. Funding a children’s charity to promote a product that causes the very illness that the 
charity seeks to respond to, and use this sponsorship to attain the high moral ground 
and lobby against public health approaches to address the public health problem 
Although there are various international case studies one could cite (see 
www.cmaj.ca/cgi/content/full/cmaj.110085/DCI for a list) this chapter unpacks four 
examples demonstrating potentially unhealthy alliances where industry has seemingly 
coopted children’s charities and public causes in order to sell a product that damages health. 
This discussion attempts to raise awareness about such subtle marketing and intends to help 
readers discern what might be appropriate and inappropriate use of charitable causes.  
Ultimately, we would hope that reading this chapter leads the reader towards taking action 
to protect our most vulnerable consumers from powerful industry interests. The chapter 
finishes by exploring how those in public health can creatively engage with this issue and 
respond by even using many of the same tactics utilised by companies whose products 
damage health.  
2. What is an acceptable form of company sponsorship of health charities? 
Advertising and marketing is very effective at selling ‘goods’, but these goods are not 
necessarily good. In the area of marketing Energy Dense and Nutrient Poor Food and 
Beverages (EDMPFB) various international reviews have concluded that heavy marketing is 
likely to have deleterious effects on children by encouraging products high in salt, sugar and 
fat (World Health Organization 2003; Livingstone 2006; National Preventative Health 
Taskforce 2009). Accordingly, in many countries, various codes exist to regulate marketing. 
However, Australian restrictions have been largely voluntary self-regulated codes which 
have failed to prevent ethically questionable advertising, such as advertising to children 
(Hebden, King et al. 2011) (Chapman, Hebden et al. 2011). 
On the surface it seems acceptable, or even desirable, that a company whose product causes 
damage should contribute to alleviation of the same damage. Such is the basis for carbon 
credits and taxes whereby companies contributing to carbon production may choose, or be 
required, to contribute towards mitigation of the problem to which they contribute. An 
New Challenges in Public Health Practice:  
The Ethics of Industry Alliance with Health Promoting Charities 
 
253 
example from the health field is DrinkWise, a charity funded by the alcohol industry, 
aiming to shape “a healthier and safer drinking culture in Australia where drinking to 
excess, or drinking too young, is considered undesirable”. Such recompense is desirable if 
the aim and the effect is mitigation. 
However, sponsorship is ethically tenuous when a company whose product potentially 
causes illhealth, assists victims, and in doing so advertises the very product that caused the 
illhealth. Libertarians would argue that companies should be entitled to pursue such 
strategies, as informed adults are capable of discernment and can decide accordingly.  
However, there is a flaw in the assumption of consumers being fully informed or having the 
necessary agency to make such distinctions. For example, are people aware that DrinkWise is 
industry sponsored and have been accused of promoting the very products that caused the 
harm they are seeking to mitigate? The consumer may be unable to make a fully informed 
choice if the true identity of the organisation is unclear. If company X sponsors a charity Y 
which addresses the ill-health caused by the same company X, then consumers should surely 
be informed that charity Y is supported by Company X whose product causes the ill health.  
However, it seems more ethically objectionable when a company whose product could harm 
children, then assists the children who might be harmed, to make these children consume 
more of their potentially harmful product. Not only is a potentially harmful product being 
advertised to children, but the immature target audience, unaware of the danger of the 
product being marketed, could be influenced to view it as harmless or even good. 
Acknowledging the effect of advertising unhealthy products to children, Australia’s 
National Public Health Task Force (NPHTF) recommended phasing out of “premium offers, 
toys, competitions and the use of promotional characters, including celebrities and cartoon 
characters, to market EDNP food and drink to children across all media sources”. Similar 
moves have been initiated in other countries (Handsley E, Nehmy C et al. 2007; Ofcom 2008; 
National preventative health taskforce 2009, p151; World Advertising Research Centre 2009) 
(World Health Organization 2003; Livingstone 2006): Sweden and Norway prohibit 
commercial advertising directed at children via television, and Quebec prohibits the use of 
any media (Handsley E, Nehmy C et al. 2007, p153).  
Perhaps even more insidious is where the funding of worthy charities creates an unhealthy 
alliance which allows a company to attain the moral high ground, and so limit their 
vulnerability to challenges regarding their unhealthy products and questionable practices. 
For example, if a policy-maker decided to limit a company’s ability to inappropriately 
market their product to children, the company might then generate popular opinion against 
the politician with arguments like “this will undermine our ability to support children’s 
charities such as the Ronald McDonald kids health truck!” (Prisk 2011). This supports a 
concept described in the literature where Corporate Social Responsibility, such as 
sponsoring a charity, is really about company credibility and positioning in order to benefit 
their bottom line (Wright 2010), or as Wright describes, limited to where it is profitable and 
often as a reaction to criticism of their product and practices. An example of ethically 
questionable practices might involve sponsoring a children’s organisation to divert attention 
away from a product that potentially harms children.  
I will outline four case studies which demonstrate that this practice might be more common 
than we perceive. Each case study may represent the intentional use of CSR to gain moral 
 
Public Health – Methodology, Environmental and Systems Issues 
 
254 
high ground and sell potentially harmful products, or may be merely coincidental. Either 
way these practises need to be challenged.  
2.1 Case study 1: The Donut King alliance HeartKids 
The Donut King has become a regular supporter of HeartKids which is a foundation to 
support children with heart diseases and their families. On a single day in 2011 they kindly 
offered to give 50 cents of every purchase of a coffee from their fast food chain to the 
HeartKids charity. Of course this was promoted widely through adverts and in store 
promotion that cobranded Donut King products with the HeartKids logo (HeartKids 2011). 
Many readers would not initially discern any problem with Donut King supporting such a 
worthy charity, but the partnership warrants closer scrutiny. 
 
 
Doughnuts are Energy Dense and Nutrient Poor Food and Beverage (EDNPFB) foods and 
such foods are linked with childhood obesity and cardiovascular disease later in life 
(National preventative health taskforce 2009). Whilst adults might be aware that doughnuts 
are potentially damaging EDNPFB and that sponsorship of a charity might actually be 
advertising, children may not be (HeartKids 2011). Additionally, children may be incapable 
of disentangling the apparent contradiction of an advertisement that links a fast food chain 
selling unhealthy food that can ultimately damage hearts, with a charity promoting healthy 
hearts in children! Is such advertising ethical if it exploits our most vulnerable community 
members: children and their health?  
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Indeed, such sponsorship can divert attention away from the potential harms of this 
company’s EDNPFB whilst also attaining a moral high ground. That is, any challenge to the 
Donut King’s charitable sponsorship - probably including this challenge - will immediately 
draw a response such as “Get a heart! Are you saying we shouldn’t support HeartKids”! 
Interestingly, a medical colleague originally forwarded me this advertisement and 
encouraged us to visit Donut King to support HeartKids. I couldn’t easily express my 
disapproval to her given that her child suffered congenital heart disease and would 
potentially benefit financially by the sponsorship.  
The objection was not that children with congenital heart disease are harmed by Donut 
King’s product and, indeed, most children with congenital heart disease need a high calorie 
intake. However, looking beyond the individual level, is there a population effect of 
normalising such unhealthy products? Through such sponsorship the Donut King is 
promoted as a good citizen who cares about health, and its products might be widely 
associated with a health cause, both of which may potentially increase sales of unhealthy 
products population wide. Secondly, even if the population effect is small, is it ethically 
appropriate to promote unhealthy products using vulnerable children to convey a message 
that this company cares about the very hearts that their product may damage?  
2.2 Case study 2: McDonalds’ alliances with the Royal Children’s Hospital (RCH) 
McDonald’s relationship with the RCH Melbourne permits them to have a fast-food 
franchise on the hospital’s grounds (Royal Children's Hospital 2010). The EDNPFBs that 
McDonalds promote are linked with childhood obesity and ill-health. In the famous UK 
libel case McDonalds sued two individuals for disseminating brochures claiming that 
McDonalds, amongst other things, was bad for health. The UK court of appeal found that 
“there is a respectable (not cranky) body of medical opinion which links a junk food diet 
with a risk of cancer and heart disease' and 'this link was accepted both in the literature 
published by McDonalds themselves and by one or more of McDonald's own experts and in 
medical publications of high repute'” (Judgement, p169). 
Granted, McDonalds at RCH is much appreciated by parents and children alike, making the 
perfect sweetener for a child facing the trauma of visiting hospital. I also confess that as a 
father of a chronically unwell child, after leaving the ward at 10pm I have visited 
McDonalds to wind down in a friendly environment. However, I could have just as easily 
wound down in whatever cafe or restaurant was still open and accessible. Additionally, the 
government has stepped in to require the McDonalds at the new RCH to provide 80% 
healthy foods choices (green and amber) whilst restricting unhealthy food choices to 20% 
(Royal Children's Hospital 2010). 
Yet the concern around McDonalds in the RCH is more complex than the negligible health 
impact on individual parents or children visiting McDonalds on a few random occasions 
whilst receiving care. There are ethical concerns about this alliance. Firstly, McDonalds can 
use their sponsorship to promote their brand name and unhealthy products to children and 
the wider community. This normalisation of EDNPFB consumption in the wider community 
is hazardous given that childhood obesity is approaching 30% in Australia. Secondly, is it 
ethically acceptable to allow our most vulnerable children to be exploited for the marketing 
of potentially unhealthy and harmful products? We allow these companies to promote an 
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image of a company which cares about the very children that their product may harm. 
Finally, is it acceptable to allow McDonalds or Donut King to attain the moral high ground 
by affiliating themselves with children’s healthcare institutions and causes? It is very 
difficult to oppose unhealthy practices and products when these ‘good corporate citizens’ 
are seen to be promoting children’s health.  
So why do we allow an organisation whose product may damage children’s health to 
sponsor our children’s hospital? Are there other ‘healthier’ organisations which could 
support the RCH? I would like to reiterate Margaret Chan’s challenge to such companies: “I 
would like to ask the food and beverage industries. Does it really serve your interests to 
produce, market, globally distribute, and aggressively advertise, especially to children, 
products that damage the health of your customers?”(Chan 2011). Again, such a case is 
difficult to sustain given outrage generated by threatening funds for children’s healthcare 
(Prisk 2011). McDonalds are very safely on the moral high ground.  
 
 
How can one argue against “supporting families” and “helping seriously ill children”? 
2.3 Case study 3: Tattersall’s alliance with the RCH  
Would you allow the following company to speak to your kids when the company has a 
majority stake in an industry which: 
• Makes more than 50% of their profit by trapping powerless addicts (Hancock, 
Schellinck et al. 2008) 
• Profits from the most vulnerable and poorest  
• Increases crime rates in the area (study reported in the Age, July, 2010)  
• Impoverishes and breaks up thousands of families in Australia each year 
• Is associated with one in five suicide attempts in patients presenting to the Alfred 
Hospital in Melbourne 
Most responsible parents would not allow such companies to promote their product to their 
children, so why does RCH allow Tattersall’s to do so in the Children’s Hospital? A RCH 
Foundation report provides an answer:  
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“The ongoing contribution of Tattersall’s, one of the hospital’s longest standing 
corporate partners, has reached a total of $8 million. Each and every dollar that  
comes into the Foundation represents both personal sacrifice and the affectionate regard 
that Victorians have for the Royal Children’s Hospital.” (Royal Children's Hospital 
2010).  
This outlines both the reasons for the link ($8 million) and also demonstrates the moral high 
ground obtained in that every dollar from Tattersall’s “represents both a personal sacrifice 
and affectionate regard”. How can one question a donor who has an affectionate regard for 
an important institution like the RCH? Such organisations can use their moral high ground 
to influence policy as was shown in the recent senate committee investigation into gaming 
where Woolworths, the biggest owner of electronic gaming machines, threatened that they 
would have to decrease their investment in the community if profits from electronic gaming 
machines were limited by legislation (Needham 2011 (Feb 11)). Perhaps the new RCH, 
“completed in 2011”, might reconsider this unhealthy association? 
The community needs to recognise that the products that Tattersall’s promotes actually 
cause significant harm to the very society that it claims to be helping through its support of 
charities. One expert researcher in the field, Professor Charles Livingstone argues: 
“The problems of pokie gambling are not trivial. They include financial distress and 
ruin, bankruptcy, fraud, embezzlement, and theft and misappropriation of the funds, 
property and income of family, friends, employers and others. Gambling problems are 
also strongly associated with crime generally, family breakdown, divorce, the neglect 
and abuse of children, mental and physical illness, depression and anxiety, and not 
infrequently include suicide. The children of regular and problem gamblers are 
themselves significantly more likely to have a gambling problem than those of non-
gamblers, and poker machine venues are most strongly concentrated in poorer 
suburbs”(The Public Health Association of Australia 2008). 
However, despite Tattersall’s association with such damage, it has represented itself  
by sponsoring the very society that it harms. Tattersall’s do not only sponsor children’s 
hospitals and hospital emergency departments in Australia but various sporting clubs  
in which our children participate. Many sporting clubs have become dependent on  
the revenue from sponsorship of Gambling agencies or from revenue from owning 
gaming machines. There is little doubt that allowing the gambling industry to operate in 
sports clubs exposes children to advertising and normalisation of such products. Do we 
need better protection? However, once again the gambling agencies have attained  
the moral high ground where clubs and supporters may well contest that the club 
depends on that revenue. If we ban the “Tattersals’ sponsorship” then we risk accusations 
of compromising institutions that actually promote health. In Australia McDonalds has 
similarly inserted itself into the health DNA of our schools and youth clubs through 
sponsoring Auskick, kids sporting events and, at a higher level, sponsoring Australian 
international sporting teams such as the Australian Olympic Team. The Australian 
Olympic Team website allows McDonalds to boast “In Australia, we are very proud to be 
helping kids be active by supporting Little Athletics, Soccer, and Basketball in various 
states” (http://corporate.olympics.com.au/sponsor/mcdonalds) 
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2.4 Case study 4: Alcohol industry alliance with children’s fundraising  
There is good evidence that exposure to alcohol advertising shapes young adolescents’ 
attitudes toward alcohol, their intentions to drink, and underage drinking behaviour 
(Martin 2002). Additionally, studies show that alcohol advertisements are often shown 
during the shows that target teens such as sporting events (Martin 2002). In Australia, 
thankfully, alcohol advertisements are no longer shown during children’s programs. 
However, alcohol advertisements do still target youngsters during shows watched by large 
numbers of children such as sporting events. In 2002, in the US, over a billion dollars was 
spent to advertise alcohol on TV and around 22% of these advertisements were seen more 
by youth than adults (Center on Alcohol Marketing and Youth 2004). 
Similarly to Tattersall’s and McDonalds, alcohol companies do not only advertise through 
traditional media platforms. The alcohol industry has been a regular sponsor of sporting 
and charity events held through our schools. This can achieve a similar end to more 
traditional forms of advertising. A recent report by the Australian National Council on 
Drugs found that alcohol was often the focus of various fundraisers which include 
supporting wine "drives" conducted via newsletters, liquor "tasting events" on school 
premises, and alcoholic bottles featuring school logos. Dr Herron from the Australian 
National Council on Drugs states:  
“I think we all know subliminal messages have a huge impact on young people. 
Through attaching (fundraisers) to a school newsletter, we're legitimising them and 
saying it's all right for students to be transporting information about alcohol between 
the home and school." (Barry 2011) 
Again it must be questioned if such charitable sponsorship is benevolent or little more than 
blatant advertising to adults and children by profit driven alcohol companies.  
However, the involvement of charitable causes makes rational debates on this issue difficult 
to have. Few critics of advertising to children would doubt that well meaning parents and 
friends have the best intentions in raising funds for worthy causes. Indeed, the alcohol 
companies take advantage of this very fact to, once again, attain the moral high ground and 
an immunity to being challenged. Parents and friends become a powerful ally for the 
alcohol companies and might well defend the company by passing off the ‘sponsorship’ as 
harmless and merely for philanthropic purposes. 
Similarly to the first three case studies, we again question if it is ethical to allow an alcohol 
company to link itself to a school when damage from youth alcohol usage is so prevalent 
and damaging throughout Australian society (Chikritzhs, Pascal et al. 2004). The list of 
damage caused to youth by alcohol is long and well established but can be best summarised 
by the fact that Alcohol accounts for 13 % of all deaths among people 14-17 years of age and 
in Australia, each week, one teenager dies and around 60 are hospitalized from alcohol-
related causes (Jones, Chikritzhs et al. 2004; Clark, Thatcher et al. 2008). Teenagers without 
the benefit of good judgement from experience, are particularly vulnerable to alcohol related 
harm in a way that older drinkers may not be (Australian Medical Association 2009). 
Among young Australians, the most common causes of death and injury due to risky or 
high-risk drinking are road injury, suicide, and violent assault (Chikritzhs, Pascal et al. 
2004). The Australian School Students' Alcohol and Drug Survey (hereinafter ASSAD) 
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highlights the extent of the alcohol problem amongst youth with 13% of children aged 16 
year olds having drunk at dangerous levels in the past week (Centre for Behavioural 
Research in Cancer 2008). 
As these statistics suggest, allowing companies to insert themselves into schools is self 
evidently unacceptable but the alcohol industry inserts itself more insidiously into 
children’s health causes outside the school environment. The AMA documents how the 
increasingly sophisticated marketing of alcohol is aimed at attracting, influencing, and 
recruiting new generations of potential drinkers (Australian Medical Association 2009). 
One example is the targeting and supporting of not-for-profit Australian sporting clubs by 
alcohol companies. Children involved in these clubs grow up viewing alcohol 
advertisements and conceivably accepting the industry as an important part of their 
society and a promoter of good health. Nothing could be further from the truth given that 
alcohol is one of the greatest dangers faced by the young people of Australia! 
Furthermore, alcohol, from whatever perspective you look at it, is damaging to sporting 
performance so it is ironic, or maybe intentional, to link a health damaging product to 
health promoting activities. Instead such support of charities by the alcohol industry 
would seem to be another example of an industry injurious to children’s health allying 
itself with children’s charities in order to promote its product and image.  
3. Why is it unethical? 
To help determine if a sponsorship is ethical it is also worth referring to the stewardship 
model outlined in the report by the Nuffield Council on Ethics (2007). They concluded that 
in regards to the role of industry, the media and other parties, “businesses have obligations 
towards society. Many businesses already have social responsibility policies. Where 
industries fail to meet reasonable standards it is acceptable for the state to intervene through 
regulations (Paragraphs 2.47-2.50 and 3.41)”. If the above case studies represent failure to 
meet acceptable standards, then should the state government intervene to limit this 
sponsorship?  
Secondly, when promotion of unhealthy products involves children, through the use of 
children’s health institutions and charities, the mandate for action is clearer. The 
stewardship model outlines “protecting and promoting the health of children and other 
vulnerable groups” as a high order principle that can justify limiting freedoms (Nuffield 
Council on Bioethics 2007). It would seem that allowing companies to exploit children’s 
charities to promote harmful products would go against the stewardship model. In effect 
children represent a market failure due to imperfect information and information 
asymmetry as they are incapable of being fully informed consumers. We therefore have 
an ethical mandate to steward our most vulnerable by protecting them against 
exploitation. 
Permitting companies to exploit children’s charities and children’s health services to 
promote harmful products might qualify as “behaviour harming others”. According to J.S. 
Mill, in his famous volume ‘On liberty’, intervention by the state is only justified when 
behaviour harms others, as such sponsorship might do if it causes more consumption of the 
harmful products (Mills 1909). Similarly a recent article in the Lancet argues “Liberty should 
be restricted, in a liberal society, only when there is a clear and direct threat of harm to 
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highlights the extent of the alcohol problem amongst youth with 13% of children aged 16 
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would seem to be another example of an industry injurious to children’s health allying 
itself with children’s charities in order to promote its product and image.  
3. Why is it unethical? 
To help determine if a sponsorship is ethical it is also worth referring to the stewardship 
model outlined in the report by the Nuffield Council on Ethics (2007). They concluded that 
in regards to the role of industry, the media and other parties, “businesses have obligations 
towards society. Many businesses already have social responsibility policies. Where 
industries fail to meet reasonable standards it is acceptable for the state to intervene through 
regulations (Paragraphs 2.47-2.50 and 3.41)”. If the above case studies represent failure to 
meet acceptable standards, then should the state government intervene to limit this 
sponsorship?  
Secondly, when promotion of unhealthy products involves children, through the use of 
children’s health institutions and charities, the mandate for action is clearer. The 
stewardship model outlines “protecting and promoting the health of children and other 
vulnerable groups” as a high order principle that can justify limiting freedoms (Nuffield 
Council on Bioethics 2007). It would seem that allowing companies to exploit children’s 
charities to promote harmful products would go against the stewardship model. In effect 
children represent a market failure due to imperfect information and information 
asymmetry as they are incapable of being fully informed consumers. We therefore have 
an ethical mandate to steward our most vulnerable by protecting them against 
exploitation. 
Permitting companies to exploit children’s charities and children’s health services to 
promote harmful products might qualify as “behaviour harming others”. According to J.S. 
Mill, in his famous volume ‘On liberty’, intervention by the state is only justified when 
behaviour harms others, as such sponsorship might do if it causes more consumption of the 
harmful products (Mills 1909). Similarly a recent article in the Lancet argues “Liberty should 
be restricted, in a liberal society, only when there is a clear and direct threat of harm to 
 
Public Health – Methodology, Environmental and Systems Issues 
 
260 
innocent parties who cannot respond for themselves” (Finn and Savulescu 2011). There 
seems adequate evidence now that advertising of unhealthy products to children does cause 
harm to children who are incapable of responding.  
The intervention ladder developed under the Nuffield Bioethics report holds that more 
intrusive interventions require stronger justification. Although the ethics of advertising to 
children is still being contested, we conclude that allowing companies promoting unhealthy 
products to link their product to health institutions or causes, is a justification for action.  
Regulating advertising to children is gathering widespread support in Australia where 
consumers (or more accurately the parents of consumers) are tired of having to fight against 
blanket advertising to maintain healthy diets for their children. Key findings from a recent 
phone survey is South Australia were:  
• 85% of consumers believe children should be protected from unhealthy food 
advertising. 
• 93% of people were in favour of the government introducing stronger restrictions to 
reduce the amount of unhealthy food and drink advertising seen by children, with 79% 
strongly in favour. 
• 86% of grocery buyers are in favour of a ban on advertising of unhealthy foods at times 
when children watch TV, with 70% strongly in favour. 
• When asked what most commonly negatively impacted their children's food purchase 
requests, grocery buyers reported television commercials (36%) or toys and giveaways 
(24%). 
(Cancer Council SA 2011) 
Along these lines of protecting minors, the Gambling Regulation Act 2003 (Vic) would 
seemingly be justified in seeking “to ensure that minors are neither encouraged to gamble 
nor allowed to do so” (section 1.1.iib) (Victorian Government 2003). This act therefore 
challenges Tattersall’s promotion of their brand at the RCH. 
4. What action should be taken? 
If such behaviour is proceeding with little regulation in many countries then what can be 
done? I suggest a similar approach to what has worked in previous campaigns such as the 
one to limit tobacco companies’ right to advertise their harmful product. It has taken a 
concerted, multipronged and sustained campaign to undermine the supposed right to 
advertise this dangerous product. This included advertising, mobilising physicians around 
the cause, raising public awareness, undertaking research and advocating to the policy 
makers and key stakeholders. 
Firstly we believe that public health practitioners and doctors should raise awareness of 
potentially unethical approaches. Doctors and the health profession more generally are 
still widely respected by the community. As professionals concerned for the health of 
those in our community we must be making efforts to protect the health of our most 
vulnerable. At the very least, awareness can be raised in the public health arena by 
writing to media outlets, journals and other fora in order to expose, or at least question, 
apparent unhealthy alliances. Such lobbying has been shown to be an important part of a 
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concerted campaign, and effective when it is part of a multipronged approach. The use of 
the new media is also important. A website called unhealthyalliances is under 
development. A campaign in Canada drew on a Facebook group to undermine the Burger 
King’s placement of its product in a children’s hospital. 
In particular, health professionals should advocate for the banning of advertising of 
damaging products in children’s hospitals and institutions where they work. After all, the 
problem is not primarily related to the companies, which are by nature profit driven. 
Instead the onus falls largely on the health organizations themselves where many of us 
work. We should be continually challenging our employers towards more ethical behaviour 
by dissuading them from accepting money from, and partnering with, companies whose 
products damage children’s health. We should not accept ethical standards being 
compromised merely in order to finance health programs, buildings and services. In 
Toronto staff contributed to preventing the Burger King from continuing to operate at the 
Sick Kids Hospital. The group drew comments from physicians and health professionals to 
add pressure not to renew the Burger King’s lease despite the $2.5million the Burger King 
had raised for the hospital (Farquharson 2011, March 20). 
Physicians who sit on boards and advise on hospital governance issues need to avoid being 
complicit by not taking action. They can advocate for regulations and clauses to limit the 
food industry exploiting children. An article in the CMJ advises that at the very least 
“partnerships should comprise unconditional arm’s-length grants with clauses limiting how 
corporations use health organization brands” (Freedhoff Y and PC. 2011). They warn that if 
we do not act we risk compromising health promotion goals by helping to promote 
unhealthy brands.  
Awareness could be raised through counter advertising campaigns aimed at unravelling the 
unhealthy alliance between health charities and a company which promotes unhealthy 
products.  
https://www.getup.org.au/campaigns/pokies-reform/grandfinal-ad/get-this-ad-on-the-air  
The Get Up advocacy group has produced various counter advertising campaigns such as 
the one challenging the positioning of pokies in sporting clubs frequented by children. Such 
campaigns can be particularly effective but are often prohibitively expensive and risk 
defamation cases being brought against the group. 
Given the significant power of the companies and their ability to scare journals, publishers 
and media formats, is it reasonable to revert to the type of tactics used in the Billboard 
Utilising Graffitists Against Unhealthy Promotions (BUGAUP) campaign? BUGAUP 
successfully countered tobacco advertising by adding counter slogans on the advertising by 
tobacco companies. 
A similar idea was utilised in a recent campaign to expose Tattersall’s unhealthy alliance 
with RCH. Members of the public used the Tattersall’s advertising sign to educate the public 
about the hazards of gambling. Over a three month period eight messages were written, 
before the message was successfully conveyed and the RCH finally removed the sign. 
Whilst not advocating illegal graffiti, other legal forms of public health advocacy and protest 
on such important issues are important. 
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5. The bigger picture 
This chapter has focussed on relevant examples from Australia where youth alcohol, 
childhood obesity and social problems from gambling are some of our most significant 
public health problems. However, this is a global problem and there are numerous 
examples from different countries where companies, whose product is harmful,  
link themselves to health organisations and health causes in order to mitigate their  
poor image or even to leverage support policies from these health organisations. The 
Canadian Medical Journal published a list of health organizations whose messages and 
reputations have been tarnished by partnerships with food companies (available at 
www.cmaj.ca/cgi/content/full/cmaj.110085/DCI ).  
The common message from all these examples is that we need to be cogniscent of this 
tendency whereby charities are utilised, or subverted, to ultimately sell unhealthy products 
to our children and community. We need to question if corporate sponsorship of charities is 
altruistic philanthropy or merely exploitation of charities to sell what can be dangerous 
products? Companies may not always act so insidiously but it should be remembered that 
they are ultimately accountable not to public health but to their shareholders who are 
concerned about the bottom line. 
Beyond just attaining the moral high ground there is very real danger that such 
companies can use their support to pressure health institutions and policy making bodies 
to avoid implementing healthy policies that might damage the image, and profit, of the 
sponsoring company. Such unhealthy alliances also help the company to lobby against 
important health initiatives. An editorial in the CMJ describes how the CEO of Coca-Cola, 
Sandy Douglas, leveraged the company’s relationship with the American Academy of 
Family Physicians to help make the case that soda taxes were unnecessary (Freedhoff Y 
and PC. 2011).  
More recently there has been concern about corporate lobby power being brought to bear 
on multilateral UN agencies. An example of an unhealthy alliance with a multilateral is 
where UNICEF Canada, which amongst other things undertakes nutritional programs in 
developing countries, allowed its name to be used to promote Cadbury chocolate bars 
(Lancet 2010). Such partnerships are of growing concern given that changes to WHO 
funding mechanisms could see it receive more funding from, and work more closely with, 
the private sector. One commentator on the recent WHO reforms being discussed stated: 
“fears about WHO's independence remain as a result of the repeated calls for an increase 
in the role of the private sector and the possibility of funding from them”. In effect the 
WHO would be opening itself up to a conflict of interest where the world’s largest 
independent health watchdog and peak advisory and normative body in health, could 
receive funds from vested interests. If the food and beverage industry is allowed to 
become involved in sponsoring the WHO would it compromise the WHO’s power to 
promote normative guidelines on obesity prevention which may involve setting limits on 
advertising to kids, and advising limits on salt/sugar/fat in certain foods? There is 
already such a precedent where food and beverage industry applied lobby pressure on 
powerful member states to oppose an evidence based guidelines around limits on sugar 
consumption.  
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We believe that there is an ominous, and largely unquestioned, trend for unhealthy 
products to be co-advertised with children’s health services and charities. Whilst not 
accusing companies of inappropriate behaviour, this viewpoint challenges regulators and 
health institutions themselves to reconsider unhealthy alliances. These alliances 
potentially advertise unhealthy products to children, give companies that produce 
harmful products a moral high ground of supporting children’s health, and ultimately 
undermine important health promotion messages. We argue that such activities are 
ethically questionable, and using a public health framework for ethics, warrant more 
intrusive regulations on advertising through our children’s health institutions and 
charities.  
In the new era of public health this issue must be dealt with effectively if we are to maintain 
our health levels and challenge the increasing double burden of infectious and non 
infectious diseases in the developing world. This is the new frontline in public health and 
we are currently lagging behind in this conflict. This chapter, it is hoped, has helped expose 
potential opposition to public health and this might serve as a call to action for public health 
practitioners and advocates. 
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12 
Primary and Hospital Healthcare in Poland – 
Organization, Availability and Space 




Spatial distribution and location of healthcare facilities have been long acknowledged as 
main interests of Polish medical geography, although most research done dates back to the 
late 1980s and early 1990s (Mazurkiewicz, 1994; Michalski, 1999). These include e.g. some 
renowned studies of health services in Warsaw (Grochowski, 1988; Malczewski, 1989). 
Unfortunately, healthcare accessibility and availability have not been widely explored by 
geographers in the 2000s; thus marginalized in spatial sciences, has been detained by other 
disciplines such as public health (see Chawla et. al, 2004).  
In 1952 geography of health was officially recognized and incorporated into geographical 
sciences by Medical Geography Committee operating within the structures of International 
Geographical Union. At the time, geography of health endeavored to investigate geographical 
factors of causes and consequences related to changes in population health status and 
morbidity. Presently, this subdiscipline consists of two distinctive strands: the spatial 
distribution of disease and death, and the geographical complexities surrounding the 
provision, access to and inequality of health care (Kearns & Gesler, 2002; Parr, 2003). Hence, 
most researchers clearly distinguish geography of healthcare as a domain that focuses on 
spatial accessibility of health services through the lenses of their distribution, demand, supply, 
utilization and planning (Mayer, 1982; Moon et. al., 1998). Moreover, geography of health care 
has evolved to investigate how medical resources meet population needs in space (Rosenberg, 
1998; Kearns & Moon, 2002). Irrespective of such collaborative approaches some spatially-
aware researchers frequently explore spatial and non-spatial factors underlying healthcare 
accessibility (Haynes, 2003; Wang & Luo 2005; Unal et. al, 2007). 
The most important regulation of Polish healthcare system guarantees equal access for 
everyone, which is directly declared in the Polish Constitution, Article 68, Paragraph 2:  
„Equal access to health care services, financed from public funds, shall be ensured by public 
authorities to citizens, irrespective of their material situation. The conditions for, and scope of, the 
provision of services shall be established by statute”. As suggested here, equal access refers to 
free utilization of health services. Although provided and financed by the state, health 
services should be congruent with other dimensions of accessibility. These are: affordability, 
accommodation, acceptability, availability and spatial accessibility (Penchansky & Thomas, 
1981). First three dimensions can be viewed as non-spatial, however planning and fund 
distribution on healthcare in particular regions and counties should be based on potential 
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and actual/expected population needs (Guagliardo, 2004). The notions of availability and 
accessibility describe the relationship between location of healthcare facilities and patient 
residence. Availability reflects an assessment of how the volume and type of existing 
services (and resources) reflect the clients (patients) volume and types of needs (Joseph & 
Phillips, 1984). Spatial accessibility refers to distance, travel time, cost and modes of 
transportation. 
The most important barrier to egalitarian conditions of healthcare utilization includes much 
higher demand of medical services as compared to the supply. This demand increases along 
with economic growth and development of new technologies. The existing medical 
resources (especially in secondary – specialized care and tertiary – hospital care) can no 
longer meet the needs of all patients simultaneously, nor do the financial resources can be 
distributed across all in need. As a consequence, long lines to the specialist offices 
discourage the sick and make them shift from public to non-public healthcare facilities. 
Worse still, heath services offered in non-public facilities are not always refunded by the 
National Health Fund (Narodowy Fundusz Zdrowia – NFZ – the institution responsible for 
redistribution of insurance contributions); thus patients have to pay for services. 
Furthermore, annual budgetary limits to health services also constrain access to healthcare 
and contribute to long wait times. These restrictions result from new technologies in 
medicine and pharmacy, which provide more efficient, but expensive medical equipment, 
treatments and medicines. In 2009 only 5% of patients generated no fewer than 60% of the 
total expenditures on services guaranteed by the NFZ (Ruszkowski, 2010). 
Commercialization in Polish healthcare system has progressed dynamically since the early 
1990s. Presently, about 75% of general practitioner offices and 82% of specialist offices in 
Poland operate as non-public facilities. In case of hospitals this proportion in 2010 amounts 
to 35% with a total number of hospital beds in non-public facilities reaching 32.8 thousands 
(16% of all hospital beds in Poland). This indicates that the majority of commercialized 
hospitals comprise relatively small facilities whereas the largest ones remain either state or 
province-owned. 
2. Data sources and setting 
According to Kaczmarek (2007) the availability of medical services depends on the volume 
and structure of current resources (e.g. number of medical doctors, nurses, hospital beds, 
medical equipment). Unfortunately, under the socialist rule before 1989 access to data 
concerning material and personal resources in healthcare was very limited. Neither existing 
registers nor Central Statistical Office was capturing data for all of the medical specialties. 
Besides, official figures were often aggregated and presented as simple classifications 
(Dziubińska-Michalewicz, 1994). Presently, Central Statistical Office (Local Databank, 
www.stat.gov.pl) provides scarce information concerning healthcare facilities (total 
number), although most is available on a municipal level. This data is divided by the 
ownership (public and non-public), type of care (primary and hospital) and utilization 
(crude number of consultations with physicians). County-level data includes the number of 
public and non-public hospital beds and the number of hospitalized patients (until 2003). In 
order to assess the distribution, organization, ownership and medical staff in healthcare 
facilities across the country the best databases offer the Register of Health Care Units 
(Rejestr Zakładów Opieki Zdrowotnej, www.rejestrzoz.gov.pl) and Central Register of 
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Health Professionals (Centralny Rejestr Lekarzy, www.nil.org.pl). These sources are 
extremely useful in geographical analyses of such subjects as: 
a. location and organization of healthcare facilities 
b. location of new facilities, changes of ownership (since 2004) 
c. spatial accessibility and availability of health professionals by specialty 
d. number and structure of hospital beds with respect to potential health needs 
Center of Health Information Systems operating within the Ministry of Health is the main 
body responsible for data capture and storage. Annual Survey Programs of Official Statistics 
include public health data, which obligates every healthcare institution to send the required 
information to the Center monthly or annually. The records collected facilitate accurate 
analyses of medical resources and their utilization (data available on a municipal level). For 
example, MZ-88 and MZ-89 forms are used to collect data about medical staff employed in 
each health care unit in the whole country. Similarly, forms MZ-11 to MZ-15 include the 
data about number of patients and consultations with physicians by date, patients’ age and 
sex, type of ailment etc. Analogous information about hospital care can be derived from 
MZ-11Szp forms provided by every facility in the country (by both facility location and 
patient residence). Unfortunately, not all hospitals follow this regulation what would result 
in strong underestimations (no data for one hospital in an area) if any geographical analysis 
was conducted. All of the data sheets are also sent to Centers of Public Health located in 16 
provincial seats. Until recently, these institutions operated as separate entities, but they have 
now been incorporated into Health Departments of Province Offices. Administrative 
division of Poland authors wish to refer to in this study is presented below (Figure 1). 
Poland is divided into 16 provinces (49 until 1999), 314 land and 65 urban counties, 2478 
self-governed municipalities. 
 
Source: authors’ own work 
Fig. 1. Administrative division of Poland since 1999.  
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Health Professionals (Centralny Rejestr Lekarzy, www.nil.org.pl). These sources are 
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Source: authors’ own work 
Fig. 1. Administrative division of Poland since 1999.  
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This study employs the data extracted from both Register of Health Care Units and Central 
Statistical Office. According to The Act of 30th September 1991 on Health Care Units (Ustawa z 
dnia 30 września 1991 o zakladach opieki zdrowotnej; Dz.U. 1991, Nr 220, Poz. 1600.) register 
entry is tantamount to official permission to run a medical office or health center (fines are 
levied upon those unregistered). Register of Health Care Units includes detailed information 
about facility address, location of its branches, legal foundations, organizational structure, 
type of medical specialty, number of beds in each ward (for hospitals and other inpatient 
clinics). Unfortunately, some information found in the Register turns out to be unreliable as 
not all specialist offices are included into the computer database (regardless of declared 
trustworthiness by the Center of Health Information Systems). For this reason, authors 
decide to take into consideration only primary and hospital healthcare. In spite of clear 
attempts to enhance data availability, a lack of necessary information provided by Polish 
statistical institutions is considered as a major limitation for health-related research and 
medical geography in particular. The main indicator of primary healthcare availability 
utilized this study includes practitioner’s office to population ratio. In case of hospital care 
this measure comprises the number of hospital beds to population ratio.  
3. Organization of healthcare system in Poland after World War II  
Contemporary spatial organization of healthcare system in Poland has been shaped by 
historical determinants, healthcare model employed by the politicians as well as recent 
socio-economic processes. Under socialist rule, as in many other sectors of the national 
economy, management and planning in healthcare fell under central authorities. The Act of 
28th October 1948 on Collective Health Care Centers and Planned Economy in Healthcare (Ustawa z 
dnia 28 października 1948 r. o zakładach społecznych służby zdrowia i planowej gospodarce w 
służbie zdrowia, Dz.U. 1948 Nr 55, Poz. 434.) virtually barred local governments and 
territorial health care centers from making consecutive decisions in healthcare organization 
and planning. Every resolution must have been first discussed and then approved by the 
district departments of national administration. Former healthcare system was organized in 
conjunction with the administrative division of the country. The provincial hospitals (so-
called integrated provincial hospitals – Wojewódzki Szpital Zespolony) were most 
privileged as they offered the widest variety and highest quality of medical services. As a 
result, inequalities in spatial distribution of tertiary care increased significantly and favored 
these provinces with the largest district/regional facilities. Moreover, this gap widened after 
locations of some institutions in accordance with the political and military will of the 
Warsaw Pact (Ruszkowski 2008). Such locations were justified ideologically as communistic 
authorities were determined to arrange sufficient hospital infrastructure for the army in case 
of war (anticipated World War III). Hence, oversized and strategically-located institutions 
were being constructed across the entire country, but chiefly in the west of Poland. 
Consequently, large hospital facilities usually exceeded the needs of local population. A 
good example of such location could be Stanislaw Staszic’s county hospital in Piła 
(Wielkopolskie Province), of which construction began in 1977 (Photo. 1.) 
The number of beds in Stanislaw Staszic’s Hospital in Piła peaked in 1992 when comprised 
as many as 726 beds.  This number greatly exceeded local demand and was gradually 
reduced down to 601 beds in 2010; thus maladjustment of hospital size to the population 
needs was evident. The same problem concerned the spatial distribution of expenditures on 
healthcare financed both by the national (institutions of a nationwide range) and the 
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provincial budgets (institutions of a regional range). These expenditures were allocated 
without any regard to spatial distribution of population demand and healthcare utilization. 
All in all, fund distribution was organized by extrapolation of expenditures incurred in the 
previous year, providing their maximization with no rights to transfer any expenses for the 
next year (Curtis & Malczewski, 1990). Such management was ineffective, inadequate to the 
current social expectations and put numerous health care units in financial hardship. After 
the political transformation of 1989, this extensive policy led to shortages of personnel, 




Photo 1. Stanislaw Staszic’s county hospital in Piła. 
The aforementioned system of healthcare managed and financed by the state budget and 
based on the lack of private health care institutions is called the Semashko model. This model, 
criticized for the extensive allocation of funds, dominated Poland and other socialist countries 
in the second half of the 20th century. Healthcare institutions were utilized only by patients 
who resided in the preventive-therapeutic districts (embracing from 30 000 to 150 000 
inhabitants). Nonetheless, the basic units were called micro-district and embraced from 3 000 
to 6 000 inhabitants. These units had to possess at least one physician in service and cover at 
least one village or district (borough) (Kaser, 1976). Moreover, health services for certain social 
groups were organized by completely different public bodies e.g. enterprise health services, 
railroad health services, Ministry of the Interior Affairs and Ministry of Defense health services 
(Grochowski, 1988). In 1972, the integrated health care management units - ZOZ (Zespół 
Opieki Zdrowotnej) were established. These entities were responsible for management of 
hospitals, outpatient clinics, specialist and primary health care as well as some social services. 
In 1991 health care units replaced integrated health care managements units, but retained the 
same acronym (ZOZ – Zakład Opieki Zdrowotnej). The Semashko model operated until 1999, 
when, in the aftermath of reforms in the Polish healthcare, insurance contributions were 
introduced. By this means, a transition from budgetary to insurance model put healthcare 
system in Poland on different tracks leading to the Bismarck model (social insurance model). 
This model introduces mandatory insurances, free choice of service and insurance provider as 
well as contract-based organization of healthcare system. New model alters spatial patterns of 
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healthcare utilization by the patients, who are now allowed to choose health professional and 
health care institution wherever they wish including locations outside their area of residence. 
Irrespectively, the system present in Poland is now criticized as the individual contributions 
remain involuntary, do not depend on individual decisions and the insured have no influence 
on the quality of service received (Siwińska et. al., 2008). 
Presently, changes in Polish healthcare system to some extent follow principals of the 
Bismarck’s model as gradual decentralization of management and financing have been 
implemented since the early 1990s. From economic and administrative viewpoints this 
decentralization is reflected by the liberalization of healthcare market, which results in 
gradual replacements of state health care units by municipal and non-public entities. Local 
governments (provinces, counties and municipalities) are now allowed to found and 
manage health care units what is permitted by the Act of 30th September 1991 on Health Care 
Units. Four forms of health care units are mentioned in this act with respect to their 
ownership and financial system: independent public health care centers (SPZOZ), budget 
entity, self-governmental budgetary establishment, and non-public health care unit (NZOZ). 
Decentralization of financial system and transformation of health care units into 
independent public health care centers began in 1998 and 1999 after sickness funds were 
established. This decentralization was reversed in 2003 as National Health Fund was 
founded, something that led to concentration of financial resources on a national level. The 
return to central healthcare financier and insurer was fiercely criticized by the politicians 
and scientific community; thus regional branches of NFZ were established, each responsible 
for healthcare financing and insurances in one province (but still operating under the 
Ministry of Health). Consequently, a lack of state-independent insurer and provider of 
healthcare limits patients’ choice, which plainly contradicts the Bismarck’s model principals. 
Contrarily to the healthcare financing and insuring, the responsibilities of management and 
planning in healthcare were imposed on local governments. Unfortunately, local 
communities were not able to cover increasing expenses and debts which health care units 
amassed over the years. These debts resulted from operation in accordance with 
constitutional principle of equal and free access to health services as well as life saving 
obligations. Moreover, the financial burdens are excavating prompted by the inability to 
declare bankruptcy by these health care units which are crucial for local population in order 
to retain overall health security intact.  
4. Spatial inequalities in the availability of primary and hospital care 
Legal and administrative characteristics concerning the organization of Polish healthcare 
system have a direct impact on spatial issues of the essence for researchers in medical 
geography. From an economic perspective, geographical sciences may lie beneath the 
premises for allocation of funds in particular regions (in accordance with spatially diverse 
needs) as well as the distribution of decisive and executive competences in health policy 
(spatial scale problem – consistency between administrative level and responsibility for 
health policy goals). From a social perspective, a key issue is to increase accessibility to and 
availability of medical services for all citizens, particularly the poorer friction of population 
who reside in peripheral areas. 
Both spatial accessibility and availability of healthcare was radically improved by the 
enforcement of legal acts that gave non-public entities rights to run healthcare practices as 
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well as make contracts with the National Health Fund. These novelties triggered a 
continuous increase in the number of health care units and health care centers across the 
country since 1991, but most intense spread was observed at the beginning of the 21th 
century. The data currently available allow for investigating these phenomena in a spatial 
dimension since 2004 (when a computer database – Register of Health Care Units was 
created). The number of health care units in 2004, 2007 and 2010 per 10 thousand inhabitants 
is presented in the Figure 2 irrespective of medical specialty and organizational forms. 
Higher number of health care units contributes to better availability and diversity of medical 
services. The changes in the number of health care units are inarguably connected with an 
increase of non-public entities. Because the range of influence for certain units often exceeds 
the municipal or regional borders (patients choose health professionals located nearby their 
places of residence) an average measure was calculated. This measure combines each 
municipality and all adjacent to them according to queen contiguity spatial weights 
frequently used in spatial statistics. 
Most health care centers are located in the largest metropolitan areas both in cities and their 
vicinity as the suburban inhabitants often utilize health services provided by the institutions 
located in the inner city. More favorable healthcare availability in metropolitan areas results 
from large demographic potential, extensive financial resources, and excellent access to 
specialized medical services, the latter caused by high-rank education provided by medical 
universities that educate most qualified personnel. Thus, health professionals who obtained 
rare specializations usually practice in the largest cities. Furthermore, hospital wards with a 
catchment area encompassing several provinces (e.g. due to the uncommon specialization 
and rare disease treatment) are located in the largest cities too. Nevertheless, certain areas 
such as medium-sized towns, especially former province capitals (between 1975 and 1999 
Poland was divided into 49 provinces; this period gave an economic boost to provincial 
capitals), are distinguished by a high-level and numerous medical services. The 
infrastructure inherited from the period of the People’s Republic of Poland contributed to 
the concentration of health care units in these towns presently. Regional approach 
demonstrates Śląskie, Łódzkie, Zachodniopomorskie and Podlaskie Provinces as those of 
the best healthcare availability. Fast pace of changes can be observed in 
Zachodniopomorskie and Podlaskie Provinces whereas fewer health care units per 10 
thousands inhabitants can be found in Kujawsko-Pomorskie, Pomorskie, and Warmińsko-
Mazurskie Provinces. 
4.1 Primary heathcare 
General practitioner is considered as a key element of primary healthcare in Poland. 
Individual GP practices were established quite recently – in 1991. These doctors are 
supposed to perform gatekeeper’s role that is to provide entrance to the whole healthcare 
system as a first institution patients refer to. As follows, this role assumes that initial 
patient-doctor contact begins at general practitioner office (in Poland, these physicians are 
called family doctors). Theoretically, family doctors ought to possess enough knowledge 
and experience to cure (or at least assist) the majority of diseases; however they are 
granted a wide range of administrative competences. Aside from prescriptions, they can 
issue referrals to other specialists or hospitals and for numerous medical examinations.  
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Source: Authors’ own work based on Central Statistical Office (www.stat.gov.pl). 
Fig. 2. The number of medical facilities per 10 thousands inhabitants in Poland in 2004, 2007 
and 2010. 
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By this means, their medical functions are limited to distribution of prescriptions (most 
common and easy-to-cure diseases) or a set of referrals when the case is difficult to 
diagnose. Moreover, appointments aimed at receiving sick leaves are also very common. 
Therefore, the contemporary general practitioner office can be dubbed as a generator of 
referrals/hospitalizations and in this way whole sets of these documents can free family 
doctors from the responsibility to assist in more difficult and atypical cases. The original 
idea of family doctor assumes long-term and permanent contact between patients and 
health professional. The family doctor should be acquainted with patients’ medical record 
and earn his trust through the years. However, frequent rotation of health professionals 
working in health care centers (mainly these located in cities) abides these goals from 
being obtainable. In sparsely populated rural areas, health services are usually provided 
by one general practitioner and a nurse. Moreover, in certain localities only branches of 
public health care centers are located and services are provided only during a few hours 
per day.  
The foundation of healthcare model based on family doctor in Poland makes treatment 
more accessible and receivable everywhere, though the free-of-charge care can be obtained 
in both public and non-public health care unit, provided that the latter made a contract with 
the National Health Fund. The free choice of family doctor does not change the fact that the 
majority of patients are registered at general practitioner offices located in the vicinity of 
their places of residence. This solution is convenient for patients, especially when the change 
of residence in Poland does not require obligatory registration. Nevertheless, more changes 
of family doctor than twice a year requires from patient 80 PLN fee, unless this change is 
caused by a permanent migration to another place of residence, involuntary obligation, or 
results from other circumstantial conditions beyond patient’s control. Patients who wish to 
change their primary care provider have to declare this will on a proper form. According to 
the National Health Fund a maximum number of patients registered to one general 
practitioner should not exceed 2750 (in other words: there should be at least 3.64 family 
doctors per 10 thousand inhabitants). However, the number of family doctors in Poland 
amounted to 10 206 in 2010, that is 2.67 family doctors per 10 thousand inhabitants (The 
Polish Chamber of Physicians and Dentists, www.nil.org.pl). This implies that there is rather 
a shortfall than excess of general practitioners in the country.  
The distribution of primary health care units in Poland shows significant spatial diversity 
among provinces and counties (Figure 3). As for geographical factors of healthcare in 
different regions, this pattern does not directly refer to the level of socio-economic 
development, population distribution or historical background. Conversely, a noticeable 
diversity within certain regions can be observed. Among five provinces with the highest 
number of health care institutions per 10 thousand inhabitants there are regions of 
completely different background and socio-economic characteristics. Some diverse as far as 
primary healthcare availability is concerned counties are adjacent to each other. For 
example, they include counties located to the west of Poland (territories that used to be a 
part of Germany before World War II) in Zachodniopomorskie Province as well as less 
developed regions located to the east (so-called Eastern Wall) represented by Lubelskie 
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GP offices, e.g.  Wielkopolskie and Podlaskie. Whereas the former can be considered as an 
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Fig. 2. The number of medical facilities per 10 thousands inhabitants in Poland in 2004, 2007 
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depopulation processes. Such diversity results from different models of healthcare 
organization and strategies implemented by local governments, but also spatial inequalities 
inherited after the Communistic times. In the areas of worse availability of primary care, 
family practices are probably larger as measured by the number of physicians in service. For 
this reason, significant differences can be observed between cities with county status (the 
largest towns and cities) and land counties. The majority of land counties are characterized 
by favorable accessibility of GP offices, what stems from higher population density and 
concentration medical facilities as a part of larger health care centers. As for land counties 
more GP offices per 10 thousand inhabitants are present in those with the lowest population 
number and density. Despite theoretically lower demand for medical services in these areas 
the network of GP offices is left uninterrupted what minimizes the distance between patient 




Source: Authors’ own work based on Register of Health Care Units (www.rejestrzoz.gov.pl) and 
Central Statistical Office data (www.stat.gov.pl). 
Fig. 3. The number of general practitioner offices per 10 thousand inhabitants in Polish 
counties and provinces in 2010. 
Analyses of primary healthcare on a regional level hide local disparities in health care 
accessibility reflected by the distribution of population. In order to detect conditions that 
underlie the availability of primary healthcare four types of areas (counties) in the whole 
country are singled out. The prerequisite for this selection is a simple spatial typology 
created according to the number of GP offices per 10 thousand inhabitants and population 
density (Figure 4). 
 





Source: Authors’ own work based on Register of Health Care Units (www.rejestrzoz.gov.pl) and 
Central Statistical Office data (www.stat.gov.pl). 
Fig. 4. The rural counties in I (low) and V (high) quintile in general practitioner availability 
as measured by offices per 10 thousand inhabitants or I (low) and V (high) quintile in 
population density in 2010 (encircled counties were selected for further local analyses). 
The selected areas include: 
a. Tucholski County (Kujawsko-Pomorskie Province – orange color) placed in the I 
quintile in GP offices availability and population density 
b. Górowski County (Dolnośląskie Province – green color) placed in the V quintile in GP 
offices availability and I quintile of population density 
c. Olkuski County (Małopolskie province – red color)placed in I quintile of GP offices 
availability and V quintile of population density 
d. Ropczycko-Sędziszowski County (Podkarpackie Province – blue color) placed in V 
quintile of GP offices availability and V quintile of population density (Figure 5). 
The example of Tucholski County shows that spatial accessibility to family doctors is 
constrained only in sparsely populated areas of the low GP offices availability. Within 
Tucholski County there are numerous small villages located further than 10 km from the 
nearest GP office, although most are located within the range of 3 km. Such areas are 
rather rare in Poland and can be found only in the northern part of the country and in 
some municipalities located in the Carpathians. Among the counties with high population 
density spatial accessibility is comparable for both the areas of low and high GP offices 
availability. Nonetheless, the high concentration of GP offices in towns elevates the 
indicator for the whole county (Ropczycko-Sędziszowski County). The areas 
characterized by high density of population and considerable number of GP offices are 
located only in southern Poland.  
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Source: Authors’ own work. 
Fig. 5. Primary healthcare in four counties of different population density and GP offices 
availability in 2010. 
On the other hand, many sparsely populated counties have a high GP offices availability, 
what is particularly prominent in Zachodniopomorskie Province. The example of Górowski 
County demonstrates that, unless there are villages without family doctor offices in 
operation, the majority of such villages are located within 5 km distance from the nearest GP 
office. The opposite situation exists in Olkuski County, where larger villages are located 
relatively far from GP offices and some concentration of health care institutions is observed 
only in towns and adjoining villages. Interestingly, within the counties of low availability of 
GP offices and high population density fall some suburban areas of the biggest cities in 
Poland such as: Poznań, Warszawa, Gdańsk and Kraków. This proves that inhabitants of 
metropolitan areas utilize the healthcare services in the central city, what decreases the 
demand for GP offices in suburban areas. 
4.2 Hospital healthcare 
Inappropriate spatial and organizational structure of Independent Public Health Care 
Centers (SPZOZ) is believed to underpin the inequalities in Polish inpatient healthcare 
(Ruszkowski, 2008). Undoubtedly, higher actual net needs (in this case the number of 
hospitalized patients) concern large urban centers, what directly results from their 
demographic potential. However, healthcare needs are considered to be the best satisfied 
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not in urban centers with a high concentration of healthcare resources, but in sparsely 
populated areas, where there is one large hospital (Ruszkowski, 2010).  
These inequalities in access to hospitals could have been mitigated alongside with the 
implementation of legislative Act on Network of Hospitals. The project of this legislation 
propounded a set of criteria to decide which institutions should be incorporated into Polish 
hospital network (hospitals that do not fulfill the criteria were either to be shut down or 
privatized). Among other things, these conditions included the optimal number of hospital 
beds with a regard to geographical distribution of medical resources. So-called regional 
adjustment plans were supposed to take into account “the directions of hospital infrastructure 
development, demographic and epidemiologic determinants and their changes in time, the structure 
and length of hospitalizations”. Besides, these plans had to include the provision of sufficient 
accessibility to high-quality health services. As follows, according to the guidelines 
provided by the Ministry of Health  a hospital must have at least 150 beds and the minimal 
number of beds per 10 thousand inhabitants should not be less than 40 (The projected Act on 
Network of Hospitals, 2007). Aforementioned project was vetoed in January 2009 due to 
political reasons and strong criticism from local governments (particularly controversial was 
the issue of closing down small hospitals). Though turned down, this project showed a great 
importance of geographic aspects concerning hospital network and its organization. No 
sooner than 15 years after transformation did the decision makers notice a need to fix the 
unfavorable distribution of tertiary healthcare in Poland. 
 
 
Source: Authors’ own work based on Healthcare Register (www.rejestrzoz.gov.pl) and Central 
Statistical Office data (www.stat.gov.pl). 
Fig. 6. The number of hospital beds per 10 thousands inhabitants in 2000 and 2010 (without 
psychiatric hospitals and facilities located in health resorts). 
Currently, an increase in the number of hospital beds Poland is observed, what was not the 
issue shortly after socio-economic transformation in the 1990s. Figure 6 shows some mosaic-
like disparities across Polish counties as measured by hospital beds per 10 thousand 
inhabitants. In many counties this indicator falls below the recommended 40 beds per 10 
thousand inhabitants. The regions “abundant” with hospital beds include Dolnośląskie and 
Śląskie Provinces. Urban areas, especially these of the largest Polish cities, possess relatively 
high number of hospital beds, which rarely fall below 60 beds per 10 thousand patients. This 
 





Source: Authors’ own work. 
Fig. 5. Primary healthcare in four counties of different population density and GP offices 
availability in 2010. 
On the other hand, many sparsely populated counties have a high GP offices availability, 
what is particularly prominent in Zachodniopomorskie Province. The example of Górowski 
County demonstrates that, unless there are villages without family doctor offices in 
operation, the majority of such villages are located within 5 km distance from the nearest GP 
office. The opposite situation exists in Olkuski County, where larger villages are located 
relatively far from GP offices and some concentration of health care institutions is observed 
only in towns and adjoining villages. Interestingly, within the counties of low availability of 
GP offices and high population density fall some suburban areas of the biggest cities in 
Poland such as: Poznań, Warszawa, Gdańsk and Kraków. This proves that inhabitants of 
metropolitan areas utilize the healthcare services in the central city, what decreases the 
demand for GP offices in suburban areas. 
4.2 Hospital healthcare 
Inappropriate spatial and organizational structure of Independent Public Health Care 
Centers (SPZOZ) is believed to underpin the inequalities in Polish inpatient healthcare 
(Ruszkowski, 2008). Undoubtedly, higher actual net needs (in this case the number of 
hospitalized patients) concern large urban centers, what directly results from their 
demographic potential. However, healthcare needs are considered to be the best satisfied 
 
Primary and Hospital Healthcare in Poland – Organization, Availability and Space 
 
279 
not in urban centers with a high concentration of healthcare resources, but in sparsely 
populated areas, where there is one large hospital (Ruszkowski, 2010).  
These inequalities in access to hospitals could have been mitigated alongside with the 
implementation of legislative Act on Network of Hospitals. The project of this legislation 
propounded a set of criteria to decide which institutions should be incorporated into Polish 
hospital network (hospitals that do not fulfill the criteria were either to be shut down or 
privatized). Among other things, these conditions included the optimal number of hospital 
beds with a regard to geographical distribution of medical resources. So-called regional 
adjustment plans were supposed to take into account “the directions of hospital infrastructure 
development, demographic and epidemiologic determinants and their changes in time, the structure 
and length of hospitalizations”. Besides, these plans had to include the provision of sufficient 
accessibility to high-quality health services. As follows, according to the guidelines 
provided by the Ministry of Health  a hospital must have at least 150 beds and the minimal 
number of beds per 10 thousand inhabitants should not be less than 40 (The projected Act on 
Network of Hospitals, 2007). Aforementioned project was vetoed in January 2009 due to 
political reasons and strong criticism from local governments (particularly controversial was 
the issue of closing down small hospitals). Though turned down, this project showed a great 
importance of geographic aspects concerning hospital network and its organization. No 
sooner than 15 years after transformation did the decision makers notice a need to fix the 
unfavorable distribution of tertiary healthcare in Poland. 
 
 
Source: Authors’ own work based on Healthcare Register (www.rejestrzoz.gov.pl) and Central 
Statistical Office data (www.stat.gov.pl). 
Fig. 6. The number of hospital beds per 10 thousands inhabitants in 2000 and 2010 (without 
psychiatric hospitals and facilities located in health resorts). 
Currently, an increase in the number of hospital beds Poland is observed, what was not the 
issue shortly after socio-economic transformation in the 1990s. Figure 6 shows some mosaic-
like disparities across Polish counties as measured by hospital beds per 10 thousand 
inhabitants. In many counties this indicator falls below the recommended 40 beds per 10 
thousand inhabitants. The regions “abundant” with hospital beds include Dolnośląskie and 
Śląskie Provinces. Urban areas, especially these of the largest Polish cities, possess relatively 
high number of hospital beds, which rarely fall below 60 beds per 10 thousand patients. This 
 
Public Health – Methodology, Environmental and Systems Issues 
 
280 
surplus is utilized by the population of counties located in suburban zones where there are 
either no hospitals or some small unspecialized institutions. Counties located along the 
province boundaries have considerably lower number of hospital beds. Importantly, one 
large hospital, even though located in a small county, may have a broad catchment area. As 
a consequence, adjoining counties have fewer hospital beds per 10 thousand inhabitants. 
This attests to the inequality in spatial distribution of tertiary care in Poland. This problem 
particularly concerns large institutions, sizes of which often exceed local demand. 
Simultaneously, such hospital catchment areas become large and attract patients residing in 
more distant areas with no at all or only small general hospitals. The concentration of 
hospital resources in one place is perceived as profitable and socially approvable when these 
institutions offer a wide variety of specialized health services and operate as centers of 
scientific research and new technologies (Ferguson et al., 1997). The selective concentration 
of specialized hospital infrastructure in 1960s and 1970s in Poland resulted in too many 
hospital beds which cannot be explained neither by local demand nor accessibility of 
qualified personnel. 
In 2000, there were 49.9 hospital beds per 10 thousand inhabitants in Poland. During next 
ten years this proportion increased to 55.2. However, the observed number did not always 
increase in accordance with in the improvements in accessibility of stationary health care 
and across particular medical specializations. The research conducted by the Centre of 
Health Care Organization and Economics by the end of 1990s showed significant 
inequalities in spatial distribution of long-term care beds and the necessity to increase their 
number significantly (Kozierkiewicz, 2008). Results of the study conducted by the National 
Institute of Hygiene indicated that the greatest excess of hospital beds concerns such wards 
as: ophthalmology, otolaryngology, pediatric surgery, obstetrics and gynecology, and 
especially in the west of Poland. On the other hand, shortages of hospital beds can be found 
on rehabilitation, hematological and oncological wards (Goryński et al., 2006). 
Aforementioned study was questioned by Murkowski (2007), who argues that the largest 
surplus of hospital beds is observed  in Śląskie, Łódzkie, Lubelskie and Podlaskie Provinces, 
so in the central and eastern Poland. This finding is more or less congruent with the results 
presented in the Figure 6. On the other hand, reflections presented by Krzanowski (2007) are 
somewhat controversial and reveal alleged influence of healthcare system on hospital 
morbidity. As pointed out by this author, regional differences in hospitalization rates for 
certain diseases are well explained by the available number of hospital beds. Medical 
geographers with a sufficient experience and skills in finding spatial relations between the 
needs and supplies in many socio-economic domains should be included into researchers 
exploring this phenomenon. The application of causative and consecutive analyzes would 
help find solutions for Krzanowski’s concern that is to tell whether  and in which regions the 
statement “if there are spare beds, there will also be patients” can be true.  
5. Commercialization and privatization in Polish healthcare 
Commercialization and privatization in Polish healthcare are considered as key 
determinants of spatial and non-spatial availability to primary and hospital care in the 
recent years. From a spatial perspective these processes lead to an increase in the number of 
medical facilities, however commercialized healthcare limit affordability for both insured 
and uninsured citizens as some services are paid. Commercialization does not occur 
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uniformly throughout the country and across medical specialties. In 2009, about 75% general 
practitioner offices (max. Wielkopolskie 94%, min. Świętokrzyskie 48%), 82% specialist 
offices (Wielkopolskie 91%, Świętokrzyskie 70%) and 45% of general and specialized 
hospital facilities (Dolnośląskie 68%, Świętokrzyskie 24%) belonged to commercial entities. 
Changes in ownership structure are clearly reflected by inverse care law – a concept 
developed by Hart in 1971 (Hart, 1971). This law assumes that the availability of good 
medical care tends to vary inversely with the need of the population served. In other words, 
financial resources are not allocated in conjunction with the distribution of needs, but rather 
along with the distribution of resources. Location and quality of health services offered by 
non-public health care units become market-oriented and favor more affluent regions and 
social groups. The poorer patients are not as attractive customers as other inhabitants 
despite of higher needs reported by the former. Such situation is most characteristic for the 
USA – a country with a dominance of private healthcare financed by non-public insurance 
companies (except for the elderly and low-income groups). This organization of healthcare 
Whiteis (1997) calls „corporate-sponsored medicine”. 
Spatial aspects concerning privatization and directions of ownership changes are presented 
on the example of all medical facilities, general practitioner offices and hospitals. Figure 7 
depicts transformations of public health care units into non-public entities for 2004, 2007 and 
2010. According to the Act of 30th September 1991 on Health Care Units non-public health care 
units can be founded by: churches and religious groups, employers, foundations, trade 
unions, professional or other associations, other national or foreign legal or natural persons 
or non-legal partnerships.  
Changes in health care unit ownership structure evidenced by an increase of non-public 
facilities progresses rapidly in the whole country. In small rural communities private entities 
get complete or partial hold of municipal health centers followed by a contract drew with 
the National Health Fund. As for primary care, almost all services remain refunded by the 
NFZ, but in case of specialist offices some services are paid. Thus, in many areas the spatial 
accessibility of healthcare increases as branch offices are more likely to be opened by 
commercialized health care units, but this happens selectively (usually in the largest 
villages). Private medical offices in large cities remain market-oriented and operate under 
great competition. Therefore, firms locate their offices is strategic locations usually in the 
vicinity of potential clients e.g. in large shopping centers. A good example of this is Enel-
Med healthcare provider which possesses offices in the biggest shopping malls across the 
country: Arkadia and Blue City (Warsaw), Galeria Krakowska (Cracow), Arkady 
Wrocławskie (Wrocław), Manufaktura (Łódź) and Kupiec Poznański (Poznań). Some of the 
services offered by private healthcare firms are not refunded by the NFZ, so, in spite of 
improved spatial accessibility, their affordability is limited. In less populous urban areas 
and towns medical offices are often located in private houses what is rare in the bigger cities 
(except for dental offices). Unfortunately, in spite of rising market-oriented availability the 
possibilities to utilize health services are constrained by too high demand and annual 
limitations for certain services and their refund by the NFZ. As a consequence, long lines 
and wait times to the physicians are observed what discourages the patients and attracts 
them to utilize paid services (frequent in specialist offices). Free healthcare can be utilized 
without a need to wait after private (and paid) consultation – such practices are not 
uncommon. 
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In 2004, public healthcare units prevailed only in Świętokrzyskie and Kujawsko-Pomorskie 
Provinces, but in 2010 the majority of healthcare facilities in the whole country were non-
public. Commercialization in the Polish healthcare first dominated Wielkopolskie Province, 
where liberal and entrepreneurial attitudes prevail among the local population. Conversely, 
in Świętokrzyskie and Mazowieckie Provinces left-wing political parties traditionally gain 
great popularity among traditionally pretentious communities. These parties strive to delay 
the privatization of healthcare in fear of paid services and undermined health security. Such 
social attitudes are clearly reflected in election results; therefore more conservative 
municipal authorities are not likely to foster quick changes in health care unit ownership. 
This selective commercialization depends on leading political fraction in local governments. 
Perhaps, low availability and quality of services in some areas make their residents press on 
local authorities for non-public care irrespective off political affiliations. This factor may be 
of the essence in the eastern part of the country 
In primary healthcare commercialization processes occur very fast (Figure 8). In 2004 most 
counties had more than a half of their general practitioner offices commercialized. In 2010 
about 75% of all GP practices belonged to non-public entities. Three separate areas of 
sizeable prevalence in the proportion of non-public facilities can be demarcated: prosperous 
and liberal west (Lubuskie and Wielkopolskie Provinces), most industrialized south of 
population traditionally emigrating to the west, Germany in particular (Śląskie and 
Opolskie) as well as poor eastern borderland (Lubelskie). On the other hand, Świętokrzyskie 
Province, the south of Mazowieckie and Łódzkie Provinces are represented by a dominance 
of people’s and left-wing political affiliations; thus comprise a majority of areas with public 
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According to some scientific views the most financial problems experienced by hospitals can 
be easily solved by changing their ownership to join stock or commercial companies 
(Masiakowski, 2005; Milczarek, 2005; Rój, 2006). This does not mean that the majority of 
independent public health care centers (mainly hospitals) need to be converted into private 
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properties because they operate with no regard to economic rationality (Jończyk, 2008). 
Unfortunately, considerable service overproduction and capital intensity (rising needs, new 
technologies in medicine and pharmacy) combined with simultaneous financial scarcities in 
municipal budgets led to large indebtedness. This is the main reason why 
commercialization processes are at issue and worry local and regional authorities as well as 
politicians. However, ownership changes do not result in a complete lack of control over 
hospitals as most shares are often hold by public bodies; thus, instead of privatization, the 
term commercialization better illustrates current transformation in the Polish healthcare 
(Misińska & Nawara, 2008). These processes are selective and connected with restructuring 
and reforms in healthcare system, but particularly with vigorous attempts to clear hospitals 
of liability for debts. The germ of these endeavors was to be the Act of Regulations of 
Healthcare Legislations (so-called healthcare legislation package), which proposed mandatory 
choice: to convert all public hospitals into commercial companies or pay their debts by 
public owners (local and regional governments). In 2009, this legislation was vetoed by 
President Lech Kaczyński, who refused to allow for paid services and put population health 
security in jeopardy as some unprofitable hospitals could have been shut down in the 
aftermath of the new code.  
Nevertheless, commercialization of healthcare facilities continues, partially fueled by 
financial aid of so-called Governmental B Plan. This plan promises a donation for these 
governments which commercialize hospital, make over all assets, property and other 
resources (unless a new owner already possess the resources necessary to run a hospital), 
and designate the entity that would take over all of the debts amassed. Most frequently, 
commercialized independent health care centers are converted to limited liability companies 
with shares held by local or regional governments. In 2004, 6.4% of all hospital beds were 
owned by non-public entities. In 2010, this indicator increased to 15.5%, so 32.8 thousand 
hospital beds per 210.8 thousand in the whole Poland belonged to non-public bodies. The 
spatial depiction of these transformations is presented in the Figure 9.  
 
 
Source: Authors’ own work based on Register of Health Care Units (www.rejestrzoz.gov.pl).  
Fig. 9. The share of hospital beds in non-public facilities in 2004 and 2010 (without 
psychiatric and facilities located in health resorts, urban counties are combined with rural 
except the largest cities). 
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The largest proportion of commercialized hospitals between 2004 and 2010 concerned 
Kujawsko-Pomorskie, Pomorskie and Dolnośląskie Provinces. Usually, one or largest facility 
was commercialized in one county, thus small disparities within counties contrast with large 
disparities between them. The latter, though, show a mosaic spatial configuration as a direct 
consequence of selective processes dependent on either undisputed and quick decisions or 
social protests and political unwillingness among the decision makers. Nevertheless, faster 
changed can be observed in western Poland what is comparable to the level of socio-
economic development. 
6. Conclusions 
In this study Polish healthcare system is characterized from spatial and organizational 
viewpoints. The analyses conducted show considerable regional and local disparities in 
access to health services across the country. While existing inequalities are evident and 
allow for delineation of excess/shortage areas as far as health resources are concerned, the 
evolution of geographical studies should aim at seeking spatial relationships between 
healthcare resources and population needs. Such approach has been put into practice in the 
USA health policy. The main purpose of Health Professional Shortage Areas (HPSA) is to 
identify areas of greater need for health care services and redirect limited healthcare 
professional resources to people in those areas. This objective is congruent with the 
geography of healthcare principal that is matching healthcare resources to population needs 
in time and space. Consequently, some apparent scientific goals also come to the fore. These 
include more complex cross comparisons between volume and structure of health resources 
and volume and structure of population needs. Such multivariate analyses ought to be able 
to provide answers to simple questions i.e.  how many hospital beds do we need?;  What 
hospital wards need to be expanded or downsized?; What is the optimal number of general 
practitioners/ practitioner offices per 10 thousand inhabitants in an area including current 
health, demographic and economic situation?.  
Limited geographic access to primary care in Poland concerns only areas of very low 
population density, which are not as common as in other European counties. For that reason 
non-spatial limitations (including financial and legal) should forge ahead when analyzing 
utilization of healthcare facilities (Jones & Moon, 1987; Powell, 1995).   
This study introduces to the complexities of Polish healthcare legal and administrative 
foundations and spatial availability with a special regard to difficulties adversely affecting 
patients’ access to healthcare facilities. To conclude, spatial and organizational availability of 
healthcare in Poland are shaped by the following phenomena and processes:  
a. ineffective and extensive management of healthcare resources during the communistic 
times, lack of regional and local health policies, system centralization (state 
organization, management, planning and financing) 
b. hospital locations in 1945-1989 unrelated to population needs  
c. transition from budgetary to insurance healthcare model (similar to Bismarck model), 
contract-based financing of healthcare 
d. increasing number of health care units  higher accessibility and availability (much 
better in metropolitan areas) 
e. mosaic spatial distribution of hospital care (better availability explained by the 
proximity to large general hospital) 
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f. increasing needs along with advancements in medicine and pharmacy as well as better 
availability of healthcare facilities 
g. various quality of hospital services linked to the following dilemma: does 
contemporary hospital heal or perform contracts? A quest for balance between money 
saving, debt reduction and patient needs 
h. the role of the general practitioner: limited in treatment, but major in administration 
(sick leaves, prescriptions, referrals); organizational and spatial access impeded in case 
of secondary healthcare 
i. threats of hospital privatization and healthcare security of citizens, declining role of 
small hospitals, even though some may be important for peripheral areas 
j. faster ownership change in the west of Poland parallel to rising socio-economic 
development and liberal attitudes among the locals 
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1. Introduction 
The incorporation process of Health Technology (HT), particularly, Medical Equipment(s) 
(ME) encompasses all activities ranging from purchasing, renting, leasing or exchanging, 
technology assessment, planning and identification of needs, installation, technical 
rehearsals, calibration, users’ training etc. The incorporation process also includes prediction 
of technology use for ascertaining if what has been planned can be realized, and for aiding 
future incorporations (World Health Organization [WHO], 2011a). 
According to Wang (2009), the incorporation process of ME can be divided into two phases: 
planning and acquisition. The planning phase includes assessment of needs and impacts, 
and costs and benefits of ME after auditing the existing resources. The data collected during 
auditing and assessment should be established and converted into a technology 
incorporation plan, which might guide future investments. The second phase relies on the 
selection and acquisition of products that are appropriate to a certain application and 
environment. Purchasing options, such as leasing, lending and the revenue sharing models, 
should always be considered. 
Health systems must be built in blocks in order to inform the financing policies, human 
resources, information, service aid, management and health technology. The inter-
relations and interactions among these blocks constitute a system. If any of these is 
lacking, the health system cannot work on the level needed to improve public health. Each 
block has its own organizational and political challenges. This chapter will discuss the 
health technology block, considering ME as the essential tool to public health (WHO, 
2007; WHO, 2009). 
Technology in health service aid is indispensable, even in the most remote and low-resource 
areas. Drugs, implants, disposable products and medical equipment are the main items that 
contributed to the progress of health care in the last century, as compared with that during 
the preceding thousands years. Unfortunately, technology also adds significantly to the fast 
and ever-growing health costs. Within this context the ME stand for relevant costs to the 
health system and sometimes under low and limited resources, besides of many medical 
procedures being totally dependable of technological resources. 
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Management and administration of this health system technology, which aims at improving 
the cost-benefit ratio, safety, and reliability, falls within the domain of Biomedical 
Engineering. Clinical Engineering, which forms part of this domain, incorporates the quality 
parameters in all phases of the technology life cycle (Raymond, 2004; Moraes & Garcia, 
2007). 
Therefore, the Clinical Engineer, through ME management and administration, must 
identify the needs, limitations and factors required to evolve a methodology that leads to 
appropriate planning of ME incorporation through a systematized and rational structure. 
Thus, the health system can recommend incorporating just safe and effective ME that has 
infrastructure, human resources and financial viability. Moreover, it has to observe the legal, 
social and ethical aspects of the context in which the ME is to be inserted (Centers for 
Medicare and Medicaid Services, 2000; Cutler & Mcclellan, 2001; Sônego, 2007; Santos & 
Garcia, 2010). 
Inadequate planning of ME incorporation practices can lower the quality of service aid or of 
ME’s performance. On the other hand, adequate planning can lead to safe, equitable and 
quality health care. Besides, it also helps in identifying the technology that is appropriate to 
the Health Care Center (HCC)— not just the cheapest one taken from proposal selection 
(public bidding)—in terms of well defined and satisfactory parameters, such as deliverance, 
installation, performance test , training, payment and guarantee. Also, the technology must 
be so chosen as to encourage the distributors and manufacturers come back with future 
offerings (Calil, 2007; WHO, 2011a). 
These guidelines are to be followed not only in case of purchases, but also in case of the 
equipments received through donation, renting or borrowing, including the ones replacing 
the existing ones. Moreover, should be applied to the individual institutions and/or 
network systems composed of several hospitals in various levels, health centers and 
community clinics, although the complexity and deadlines are very different from one case 
to another (Wang, 2009). 
This chapter deals with identifying and recommending the main factors that must be 
considered for ME incorporation. The Clinical Engineer can help the actors involved, as a 
process facilitator, in identifying these factors and in deciding if incorporation is a real 
necessity. Thus, the performance of the Clinical Engineer strengthens not just the ME 
incorporation, but the whole health system and thus the public health. 
2. Incorporation process of medical equipment 
The main target of ME incorporation process is to maximize the benefits–clinical or 
financial—and minimize the costs—investment or recurrent ones-- especially of the local 
low resource communities, thus helping them in controlling the health problems effectively. 
The objectives may vary from one HCC to the other, but they usually include some of the 
following (Kaur, 2005a; Wang, 2009; WHO, 2011a; Santos & Garcia, 2010): 
• Improve clinical results and patient satisfaction. 
• Guarantee better access, quality and use of ME. 
• Increase patients’ life expectancy. 
• Decrease the time spent in investigation, treatment and rehabilitation. 
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• Increase the access of patients to health care in equitable manner. 
• Enlarge the coverage of patients’ population and geographic areas. 
• Reduce risks to patients, clinicians and environment. 
• When suitable, keep or improve the ME market. 
• Obtain balance between clinical needs, personal desire and available financial 
resources. 
• Introduce pro-active planning to meet long-term needs, and thereby reduce emergency 
acquisitions. 
• Reduce the Total Cost of Ownership (TCO). 
• Offer more learning opportunities to clinicians and students when they are 
academically affiliated. 
• Maintain or increase standardization to improve efficiency and reduce risks. 
• Increase transparency of the public lender process. 
• Encourage the actors involved in the incorporation process to create conditions 
conducive to establishment of monitoring actions towards the long life cycle of ME, and 
thus contribute to future planning. 
• Observe the valid legal aspects in national and regional contexts. 
• Identify the cultural and social barriers and facilitators. 
It is important to note that other objectives can be added to the foregoing list depending on 
the need of each ME or health care. The Clinical Engineer must help in identifying the key 
factors for achieving the objectives defined. These factors must consider aspects inherent to 
technology, infrastructure, human resources and costs. They thus have a wide scope for 
choosing the parameters that meet the challenge of ME incorporation by using Clinical 
Engineering methodology. 
After identifying the parameters, it will be possible to develop a systematized 
methodology that is based on the decision making domain, health technology assessment 
(HTA) and health technology incorporation. The Clinical Engineer can, therefore, act as a 
facilitator and as an actor of a team or interdisciplinary commission that formulates 
recommendations and supports decision making for ME incorporation, based on the 
evidence available in literature, in such a way as to minimize or even eliminate 
subjectivity in decision making. 
2.1 Conceptual approach 
A conceptual approach is needed to understand health technology, especially ME, its role 
and life cycle, and the actors involved in its incorporation process. 
2.1.1 Medical equipment function 
Health care is a human right, according to the Universal Declaration of Human Rights. 
However, it does not give access to universal health care. The World Health Report 
commented on this issue, in the context of primary health care, thus: “Primary care and social 
protection reforms depend on choosing health-systems policies, such as those related to essential 
drugs, technology, human resources and financing, which are supportive of the reforms and promote 
equity and people-centred care” (WHO, 2008; United Nations, 2011). 
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In this regard, it can be observed that health systems depend on health technology for the 
desired health results. It is important to plan ME programs according to the protocols and 
policies that can result in equitable, safe, appropriate and high technology access. ME 
requires adjustment, maintenance, repairing, user training and deactivation, which are 
usually performed by Clinical Engineers. ME is used for diagnostic purposes, treatment of 
certain diseases and rehabilitation with some kind of accessory input or other equipment. 
ME does not include implants and disposables (WHO, 2011b). 
Technology1 by itself has low intrinsic value and its value depends on how it is used.  
It is through the ME that health-predicted needs and benefits are realized, considering its 
impact on the patients, users, infrastructure, maintenance, costs and valid legislation.  
If the incorporation is planned and properly guided, then the ME can help policy 
formulators, decision makers, Clinical Engineers and health professionals in fulfilling 
their objectives of treating the patients under a better cost-benefit relation. However, if  
the technology is inappropriately incorporated or used, it can harm people, and cause  
loss of value and resources (Wang, 2009; National Institute for Health Research [NHS], 
2010). 
In this context, efforts must be made to manage the ME in a rational way, so that some 
balance can be found between the desired needs and benefits on the one hand, and the 
positive or negative impacts on the other. The importance of Clinical Engineering structures 
is thus evident in offering mechanisms that enable efficient and transparent ME 
incorporation planning. Nonetheless, the actors involved in the process must be aware that 
the incorporation is directly linked to the necessity of treating or diagnosing some clinical 
condition. Consequently, the eligibility of the applicant ME for incorporation must be 
assessed. 
The eligibility refers to justification in realizing the ME assessment in the incorporation. To 
help this, some issues must be addressed, considering different aspects of demographic 
density, complexity of the health problem, and the nonexistence of unused ME in the HCC. 
This could enable the manufacturer and the distributor to guarantee the supply of spare 
parts during servicing of the equipment. 
2.1.2 The medical equipment life cycle 
ME is vital to health care service in that it improves the public health system. From the 
innovation phase to the replacement one, the tools used in the system must have four 
essential characteristics: availability; accessibility; adjustment; and financial capacity2. These 
would help to enhance the life cycle of the ME in such a way that not all the efforts may not 
have to be centered on the innovation phase alone, but on the incorporation one too in an 
adequate and rational manner; this ensures their use in an efficient and equitable way 
(WHO, 2011b). 
                                                 
1The majority of dictionaries define technology as the application of knowledge to practical  
means. 
2Relationship between prices of services according to the maintainer, the deposit required for the entry 
of customers and the ability to pay, or the existence of health insurance by the customer. 
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In general, ME life cycle presents four phases (WHO, 2011b): 
• Research and Development (R & D). 
• Regulation. 
• Health Technology Assessment (HTA). 
• Health Technology Management (HTM). 
These phases are efficient as long as they are supported by the health policies which are 
supervised by trained personnel. While interdependence of these phases is important to 
achieve the desired results, the operation within each phase must also be planned and 
executed with protocols that correspond to the administrative level (national, regional and 
local) (WHO, 2011b).  
In the R&D phase, the entry parameters depend on the national policy of health technology 
R & D and on the health needs of the population. Besides meeting these requirements, the 
national policy must concentrate on encouraging the industry, so that the industry can 
generate innovative health products and make them available to whoever needs them 
(WHO, 2011b). 
The regulation phase consists in protecting the society by publishing rules, rehearsing 
protocols, pre-authorizing purchases, registering, post-sale vigilance and reporting on 
contra-indications. The focus in this phase is on guaranteeing the safety of patients and 
technology users (WHO, 2011b). 
In the HTA phase, it is possible to systematically evaluate the proprieties, effects and/or 
impacts of ME on the deliverance of health care by a well-designed and defined 
methodology. The main target of this phase is to educate the health policy formulators on 
related technology. Thus, it is possible to properly plan from incorporation of the ME to the 
removal of ME. Depending on the issues involved, time frame for decision making and 
availability of resources, the HTA can be tackled in different ways, such as by more detailed 
HTA reports, availing of reports produced elsewhere, fast review, and monitoring 
technological reports (Velasco-Garrido & Busse, 2005; HTA GLOSSARY, 2010). 
The HTM phase encompasses a variety of attributions, which include, inter alia, the 
following: identification of needs, collection of reliable data about ME, incorporation 
process, a complete inventory of ME, maintenance program based on risk reduction and 
safe operation, aiming for safe tools and high quality health service, allotting sufficient 
resources to maintain the technology under use, monitoring the clinical effectiveness of ME, 
updating and deactivation or replacement of unsafe and obsolete equipment (Kaur, 2005b; 
Santos & Garcia, 2010; WHO, 2011b). 
From the foregoing discussion, it follows that each phase has specific attributions. However, 
it is important to highlight that technology life cycle phases are not independent; that is, 
action taken in one phase may impact other phases. This underlines the need for adequate 
planning of ME incorporation, and thus for strengthening technology life cycle, the actors 
involved and the health system. 
The technology life cycle phases can operate at local, regional and national levels. The 
characteristics, perspectives and impacts of each phase are described in Table 1. 
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1The majority of dictionaries define technology as the application of knowledge to practical  
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action taken in one phase may impact other phases. This underlines the need for adequate 
planning of ME incorporation, and thus for strengthening technology life cycle, the actors 
involved and the health system. 
The technology life cycle phases can operate at local, regional and national levels. The 
characteristics, perspectives and impacts of each phase are described in Table 1. 
 




Table 1. Characteristics of ME life cycle phases (Source: WHO, 2011b). 
2.1.3 Actors involved in the incorporation process 
Past experience shows that ME incorporation process has not been well coordinated in 
most countries. In many cases, it led to undesirable results, such as increase in cost, 
abusive use of the facilities and frustrating managers, users and patients. However, by 
learning from these experiences, the application of knowledge has been so conditioned as 
to derive maximum advantage from each of the ME life cycle phases (David & Judd, 1993; 
Sprague, 1988). 
The incorporation process, which involves clinical, technical, financial, infrastructural and 
human resource impacts, is a challenging task. Therefore, a multidisciplinary team is 
required to plan and execute the ME incorporation process effectively. The team can prevent 
recurrence of past errors, and identify the potential factors that may lead to dissatisfactory 
results. The team must be formed by including representatives from clinical, administrative, 
financial, clinical engineering, installations, information technology and material 
management areas. Besides, it needs to be strengthened with specialized knowledge and 
services of consultants and distributors (Coe & Banta, 1992; Wang, 2009). 
The Clinical Engineers can be strong members of the team in that they ensure that the real 
clinical needs of the user are identified, treated and, when possible, attended to. They can 
serve as a communication link between professionals of different disciplines involved in the 
incorporation process, inside or outside the HCC. Besides, their experience and skills can be 
used to help the HCC in its systematic and safe incorporation of the technology process. It is 
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fundamental that those Engineers never forget that they are just members of a team and not 
the only ones responsible for ME incorporation (Harding & Epstein, 2004). 
User’s integration in the development and assessment of ME is explicitly recommended in 
literature. This perspective turns out to be beneficial to technology producers, besides 
highlighting the importance of users inside the incorporation process (Woodside et al, 1998; 
Kittel et al, 2002; Sarwar & Robinson, 2007). In addition, other approaches directly reflect on 
the potential impact of the user’s integration into the assessment process. (Mcgregor & 
Brophy, 2005). 
Just as Clinical Engineers and users, all other actors in the incorporation process—interns, 
like patient groups, or externs like manufacturers, distributors or regulators—need to be 
considered equally important, and treated accordingly(Gibson et al., 2004). 
Regarding decision making in ME incorporation, the representation of multiple perspectives 
of the actors is a key element of justice (Singer et al., 2000). Similar approaches can be found 
in Drummond et al. (2008), which presents the key principles to guide the HTA.  
2.2 Identification of resources for incorporation 
It is important to stress that, without necessary resources, adequate planning of ME is not 
possible, and consequently the incorporation process too. The progress of health technology 
with assured benefits to the patients and increased efficacy is rather slower within the health 
systems than in other health service economies. This can be ascribed to several barriers in 
this process, such as the following (Robert et al., 2009): 
• Lack of formal mechanisms to disseminate recommendations and information about 
ME assessment. 
• Availability of adequate data on the cost and price of new health technology. 
• Insufficient sharing of information between buyers and sellers that can result in bad 
purchasing decisions. 
• The culture within the health systems is not sufficiently entrepreneurial. 
• Lack of financial and technical support to the companies in turning innovative ideas 
into marketable products. 
• Bureaucracy around purchasing procedures. 
• Need for training the health system teams in using the new ME. 
Fortunately, notwithstanding these barriers, the new ventures introduced by World Health 
Organization, along with recommendations towards ME, have been well accepted by the 
country members. These can be turned into better and more efficient health systems. 
Nowadays, in developing countries like Brazil, some attention is being given to preparation 
and dissemination of methodology guidelines for assessment and incorporation of ME. This 
contributes to the development of recommendations to deal with the challenge of ME 
incorporation process. 
Even so, many barriers still remain to be broken down to achieve complete success in ME 
incorporation and usage. In this context, it is important to identify clearly the needs for 
adequate planning. One of the most critical necessities is undeniably the human resources. 
In general, the two common mistakes are excessive centralization of decision-making and 
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reposing too much confidence in the specialists concerned. Centralizing decisions brings 
political problems related to favoritism, subjectivity, and lack of transparency. And, too 
much confidence in specialists needs credibility and general support, which sometimes get 
worse because of lack of a wider view (Wang, 2009). 
Therefore, it is necessary to establish a transparent and efficient process that can identify 
and plan the actions pertinent to ME incorporation process. As has already been said, the 
engagement of many actors in this challenge can bring more transparency and a generalized 
approach, as well as all the relevant factors. So, it is recommended that a multidisciplinary 
team be formed and supported by representatives of every group of actors involved, where 
the Clinical Engineer can act as a task facilitator.  
However, it is necessary to get information and evidence of internal and external sources of 
ME, which can enable the planning of ME incorporation. Following are some internal 
sources of information and evidence and the main factors to be considered for each source 
(Wang, 2009): 
• Current users: efficacy, effectiveness, safety, easy training and usage. 
• Clinical Engineering: reliability, safety, maintenance and availability. 
• Installation management: requirements of usefulness and environment impact. 
• Information Technology: network problems and software support. 
• Material management: input, accessories and alternative distributors. 
Following are the external sources of information and evidence, and the main factors to be 
considered (Wang, 2009): 
• Health Information Centers: epidemiological data, possible refund, rules and 
regulations, marketing rivalry, financial problems and HTA reports. 
• Manufacturers: product specifications, financial conditions, requisites to installation 
and functioning, post-purchasing guarantee and support. 
• Regulating mediums, Civil Engineers and Architects: infrastructure requisites and 
impacts, regulations and codes. 
• Other distributors: aiding equipment and furniture, alternative supply and service 
sources. 
The multidisciplinary teams at the local level can be considered as determined people to ME 
incorporation management in the health system as a whole. However, their attributions and 
actions must be tailored to the needs of the situation. The actions of the multidisciplinary 
team at local level need administrative and technical support. Systematic research of 
scientific literature and HTA reports by specialized technicians would be helpful for 
simultaneous execution of the planning tasks within the timeframe given for ME 
incorporation process (Kaur, 2005a; WHO, 2011a). 
2.3 Evaluation of the necessity for medical equipment incorporation 
Prior to ME incorporation, one must clearly understand the difference between desire and 
need. This is because many acquisitions were made more under the impulse of desire and 
for subjective reasons, than in the common interest of the majority of the actors, which must 
be the case. The need for ME incorporation must be assessed rationally by discussions with 
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the clinical team on the diseases that need to be addressed and the health policies they 
recommend, and not the technology they want (Wang, 2009). 
Besides, a survey must be undertaken to check if the HCC that is going to receive the 
technology has already some ME that meets the clinical needs under consideration, or if it 
has any unused equipment. Following are the other questions that must be taken into 
account in this regard (Kaur, 2005a; WHO, 2011a; Robert et al., 2009; Wang, 2009): 
• Does the demographic density of the HCC region that is going to use the ME justify the 
incorporation? 
• Does the ME have an entry in the register of competent regulating establishment? 
• Is there any demand in the health service offered by the ME? 
• Is there any personal preference from the clinical or administrative team of the HCC? 
• Will the ME incorporation and its results impact significantly on the 
treatment/diagnosis of patients by any other specialist? 
• Does the complexity of the identified health problem justify ME incorporation? 
• Is there any guarantee that the manufacturer will offer spare parts during the projected 
life cycle of the ME? 
All these issues justify a detailed ME assessment, which needs time, human resources and 
financial investments. If the majority of the factors justify the need for ME incorporation, 
one can pass on to the next planning phase, which involves assessment of the impacts upon 
users, patients, infrastructure and immanent traits of technology. In case the need is not 
justified, immediate disengagement of the incorporation process must be considered. 
Answers to the proposed questions can be found in international and national literature. 
Yet, the technological park of HCC may have to be covered to check if any unused ME 
exists. Data in respect of demographic density and demand can be taken from the Health 
Ministry sites. Interviews with clinical and administrative team, as well as with some 
manufacturers, are recommended to identify personal preferences and ascertain the capacity 
to supply the spares, respectively. 
When applicable, it might be necessary to assess the amount of ME needed, on the basis of 
epidemiological data, population to be assisted, geographic distances to be covered, status 
of the HCC that is recently in need of technology, including its capacity to utilize the 
equipment or the usage time per case. However, sometimes, it may not be possible to go 
beyond just the figures, because many variables are subjective or difficult to estimate. 
Besides, the available data might not be reliable enough to lead to correct indications. 
Nonetheless, some attempts can be made, assuming potential risks and making adjustments, 
so that they provide some basis for future assessments (Wang, 2009). 
2.4 Impact of medical equipment incorporation 
The impact of technology incorporation into health services, particularly of ME, can be 
viewed in both positive and negative ways. The determining point of the impact will be the 
way in which the planning is conducted. Therefore, before incorporating ME into the health 
systems, one must study the likely impact of this equipment on the service, both direct and 
indirect. One of the main reasons cited for the disuse of ME is sometimes the failure to 
predict ME’s impact (World Health Assembly Health Technologies [WHA], 2007). These 
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the clinical team on the diseases that need to be addressed and the health policies they 
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impacts can be portrayed as three pillars: Human Resources, Technology and Infrastructure. 
Figure 1 shows the impact on health technology from Clinical Engineering view, 
particularly ME: 
 
Fig. 1. Impact on health technology, particularly ME, from clinical engineering view must be 
considered to obtain safety, reliability and efficiency deliverance of health service by ME 
usage (Source: Santos, Souza & Garcia, 2010). 
2.4.1 Impact on human resources 
Health professionals are individually responsible for the transparency of their practices in 
certain aspects of health care offers. Therefore, they have the responsibility, as part of their 
continuous professional development, to acquire, maintain and disseminate knowledge and 
abilities in availing of ME. Before inducting health technology into HCC, the managers must 
ensure that the health professionals are adequately educated to guarantee safe usage of 
technology (NHS, 2005).  
The users’ training needs can cover educational services, as well as clinical users’ training. 
Safety training aspects, such as those with laser equipment, must also be considered for 
inclusion in user training needs (Harding & Epstein, 2004). 
Additionally, a training plan is necessary, considering the training material, manuals, 
trainers and other resources pertinent to the training, as also the need of the establishment 
of a schedule of personal training activities in order to regard the personal turnover and 
gradual loss of competence. This plan must take into account some fundamental aspects 
(NHS, 2005) listed below: 
• Degree of ME risk and, therefore, priority level. 
• The need for flexible approaches to learning. 
• Accessibility to all ME users. 
• Constant information about the changes made in the legislation pertinent to ME. 
However, for conducting any program one incurs cost, which can be directly related to the 
learning curve of the user in relation to the ME which will be used.  
The learning curve is a tool which can monitor the performance of workers assigned with 
certain tasks. Through the curves, it is possible to evaluate and plan for more productive 
tasks, and thereby, to reduce the loss arising out of the inability, which is checked, above all, 
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in the first periods of implementation (Dar-El, 2000). The tool also allows adequate 
allocation of tasks to the members of the workgroups so as to enable them complete their 
performance characteristics, besides the monitoring of costs related to the process 
(Anzanello & Fogliatto, 2007). 
Figure 2 shows the relation of cost versus ME complexity, divided into two categories (A & 
B). The line 0b represents the cost or time spent to train a technician (beginner) in operating 
the equipment of category B and the line ba in operating the equipment of category A. From 
their comparison, it can be seen that the more complex the ME is, the more would be the 
time (or cost) required to train the professional (Souza et al, 2010; Cheng, 2006). 
 
Fig. 2. Training curve based on ME complexity (Source: Cheng, 2004). 
In terms of the magnitude of complexity, one can consider classifying the ME based on the 
following definitions (Calil & Teixeira, 1998): 
• Low complexity equipment: The ME of this category has complex electronic or 
mechanical circuits, but they pose no maintenance problem (e.g., thermal double boiler, 
sterilizer, sphygmomanometer, mechanical scales, etc.) Those who operate this 
equipment need not be specialists, and the training they need is quite simple.  
• Medical equipment of medium complexity: The ME of this category requires personnel 
with basic education and training that can meet the repairing needs. Examples of the 
ME of this category are incubator, centrifuge, cardiac monitor, electrocardiograph, 
hemodialysis equipment, etc.  
• High complexity equipment: The ME of this category demands qualified technicians 
with specialized training. In many cases, these technicians have higher education and 
some of them had foreign training. Following are some examples of this equipment: 
nuclear magnetic resonance, scanner, chemical analyzers (some types), gamma 
chamber, linear accelerator, ultrasound machine (image diagnosis system), etc. 
Therefore, the degree of complexity of ME can help in estimating the costs and the training 
time required for each ME, because the more complex the ME is, the higher would be the 
cost and time needed. In other words, from the degree of complexity of the equipment, one 
can draw a qualitative estimate of the cost and time required to train a person in operating 
that equipment. For instance, the cost and time required to manage an ultrasound machine, 
which belongs to the high complexity category, would be much higher than the cost and 
time required to operate a cardiac monitor that belongs to the medium complexity category. 
With that information in mind, it is possible to properly hire specialized training services or 
even sign maintenance contracts for users’ training. However, final cost estimates can be 
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in the first periods of implementation (Dar-El, 2000). The tool also allows adequate 
allocation of tasks to the members of the workgroups so as to enable them complete their 
performance characteristics, besides the monitoring of costs related to the process 
(Anzanello & Fogliatto, 2007). 
Figure 2 shows the relation of cost versus ME complexity, divided into two categories (A & 
B). The line 0b represents the cost or time spent to train a technician (beginner) in operating 
the equipment of category B and the line ba in operating the equipment of category A. From 
their comparison, it can be seen that the more complex the ME is, the more would be the 
time (or cost) required to train the professional (Souza et al, 2010; Cheng, 2006). 
 
Fig. 2. Training curve based on ME complexity (Source: Cheng, 2004). 
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time required to operate a cardiac monitor that belongs to the medium complexity category. 
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made only after a market survey and discussions with manufacturers, distributors, and 
companies specialized in ME training. 
2.4.2 Impact on technology 
The ME needs to be operated in an efficient and safe way. To achieve this, various factors 
that may interfere with each other will have to be considered. So, one must prepare a 
maintenance plan that covers not only preventive or remedial maintenance, but also detects 
potential and hidden errors that are not usually identified by users, but can cause injury or 
death to the patients (Kaur, 2005a; Wang, 2009). 
For preparing a maintenance plan, one must consider the following actions (Kaur, 2005a): 
• Check the guarantee date and enquire if the distributor offers, during the guarantee 
period, the spares required, and if the guarantee period can be extended for an 
acceptable cost. 
• Check, in case of any breakage of ME, whether the manufacturer will replace or repair 
the broken part or even offer refund if the equipment has manufacturing or material 
defects. Will the offer cover all parts of the equipment? Does the manufacturer pay for 
the shipping expenses? 
• Ensure availability of consumables, accessories, spare parts and maintenance materials. 
• Check if the maintenance requires the service of a qualified engineer, and if the answer 
is ‘yes’, identify the local distributor or representative who can help in case of 
breakdown or glitch. 
• If no distributor or representative is available locally, check if somebody is available at 
regional or national level.  
• To increase the bargaining power for entering into a maintenance contract, check if 
there are companies, other than the authorized agent, who can offer maintenance 
service. 
• Identify, from the options available, the maintenance contract that has the best cost-
benefit ratio for each ME. In most cases, purchasing ME by lending or leasing is 
advantageous, but it needs to be checked if the input and maintenance costs do not 
exceed the purchasing costs in a short time. 
It is important to note that the ME, which does not have adequate support of maintenance 
services, consumable goods, and replacement parts, it is probable that the ME may remain 
unused for long periods and might ultimately be replaced prematurely. Therefore, it is 
essential to any health establishment, no matter its size, to implement a ME maintenance 
program. The complexity of this program depends on the size and type of installation, its 
locale, and necessary resources. The need for a good maintenance program will be the same 
regardless of whether the ME is in a high income, urban environment or in a low or medium 
income, rural environment (Kaur, 2005a; WHO, 2011c). 
The ME maintenance can be divided into two categories: Inspection and Preventive 
Maintenance (IPM), and Corrective Maintenance (CM) (see Figure 3). IPM includes all 
programmed activities that guarantee equipment functionality and prevention of failure3. 
                                                 
3The condition of not meeting intended performance or safety requirements, and/or a breach of 
physical integrity. A failure is corrected by repair and/or calibration (WHO, 2011b). 
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Inspections of performance and safety verify the functionality and safe usage of a tool. 
Preventive Maintenance (PM) refers to the programmed activities to ensure that the ME 
endures its useful life through actions like calibrating, replacing dysfunctional parts, 
greasing, cleaning, etc. Under PM, the inspection can be done as an individual or group 
activity to guarantee ME’s functionality. CM refers to activities carried out to restore the 
physical integrity, safety and/or performance of a failure ME (WHO, 2011c). 
 
 
Fig. 3. Categories and types of ME maintenance: Inspection and Preventive Maintenance; 
and Corrective Maintenance (Source: WHO, 2011c). 
2.4.3 Impact on infrastructure 
Once the ME is incorporated into HCC, it is important to understand different aspects of the 
resulting impact on the infrastructure. Following are some of the advance actions to be 
carried out before acquiring the technology (Calil, 2007; Wang, 2009; WHO, 2011d): 
• The space needed to install the ME. 
• The type of floor, and equipment weight and disposition in relation with other 
technology equipment in adjacent rooms. 
• Type, size, and position of the place and building. 
• Check if the HCC has more than one floor, and if ‘yes’, identify the floor for installing 
the ME. 
• Ascertain the availability of gas and water supply and their supply conditions, like 
type, quality and quantity, and pressure. 
• Check the availability of power supply for electric connections; also, check if the HCC 
has an emergency generator. 
• Check the need for weatherproofing such as air-conditioning, and quality control (air 
quality and humidity). 
• Other factors that may be specified as installation prerequisites. 
These actions are particularly important to HCCs in rural areas and developing countries 
where stable sources of energy, adequate water supply and controlled environment in terms 
of temperature and humidity are not always available. 
 
Public Health – Methodology, Environmental and Systems Issues 
 
300 
made only after a market survey and discussions with manufacturers, distributors, and 
companies specialized in ME training. 
2.4.2 Impact on technology 
The ME needs to be operated in an efficient and safe way. To achieve this, various factors 
that may interfere with each other will have to be considered. So, one must prepare a 
maintenance plan that covers not only preventive or remedial maintenance, but also detects 
potential and hidden errors that are not usually identified by users, but can cause injury or 
death to the patients (Kaur, 2005a; Wang, 2009). 
For preparing a maintenance plan, one must consider the following actions (Kaur, 2005a): 
• Check the guarantee date and enquire if the distributor offers, during the guarantee 
period, the spares required, and if the guarantee period can be extended for an 
acceptable cost. 
• Check, in case of any breakage of ME, whether the manufacturer will replace or repair 
the broken part or even offer refund if the equipment has manufacturing or material 
defects. Will the offer cover all parts of the equipment? Does the manufacturer pay for 
the shipping expenses? 
• Ensure availability of consumables, accessories, spare parts and maintenance materials. 
• Check if the maintenance requires the service of a qualified engineer, and if the answer 
is ‘yes’, identify the local distributor or representative who can help in case of 
breakdown or glitch. 
• If no distributor or representative is available locally, check if somebody is available at 
regional or national level.  
• To increase the bargaining power for entering into a maintenance contract, check if 
there are companies, other than the authorized agent, who can offer maintenance 
service. 
• Identify, from the options available, the maintenance contract that has the best cost-
benefit ratio for each ME. In most cases, purchasing ME by lending or leasing is 
advantageous, but it needs to be checked if the input and maintenance costs do not 
exceed the purchasing costs in a short time. 
It is important to note that the ME, which does not have adequate support of maintenance 
services, consumable goods, and replacement parts, it is probable that the ME may remain 
unused for long periods and might ultimately be replaced prematurely. Therefore, it is 
essential to any health establishment, no matter its size, to implement a ME maintenance 
program. The complexity of this program depends on the size and type of installation, its 
locale, and necessary resources. The need for a good maintenance program will be the same 
regardless of whether the ME is in a high income, urban environment or in a low or medium 
income, rural environment (Kaur, 2005a; WHO, 2011c). 
The ME maintenance can be divided into two categories: Inspection and Preventive 
Maintenance (IPM), and Corrective Maintenance (CM) (see Figure 3). IPM includes all 
programmed activities that guarantee equipment functionality and prevention of failure3. 
                                                 
3The condition of not meeting intended performance or safety requirements, and/or a breach of 
physical integrity. A failure is corrected by repair and/or calibration (WHO, 2011b). 
 
Planning Incorporation of Health Technology into Public Health Center 
 
301 
Inspections of performance and safety verify the functionality and safe usage of a tool. 
Preventive Maintenance (PM) refers to the programmed activities to ensure that the ME 
endures its useful life through actions like calibrating, replacing dysfunctional parts, 
greasing, cleaning, etc. Under PM, the inspection can be done as an individual or group 
activity to guarantee ME’s functionality. CM refers to activities carried out to restore the 
physical integrity, safety and/or performance of a failure ME (WHO, 2011c). 
 
 
Fig. 3. Categories and types of ME maintenance: Inspection and Preventive Maintenance; 
and Corrective Maintenance (Source: WHO, 2011c). 
2.4.3 Impact on infrastructure 
Once the ME is incorporated into HCC, it is important to understand different aspects of the 
resulting impact on the infrastructure. Following are some of the advance actions to be 
carried out before acquiring the technology (Calil, 2007; Wang, 2009; WHO, 2011d): 
• The space needed to install the ME. 
• The type of floor, and equipment weight and disposition in relation with other 
technology equipment in adjacent rooms. 
• Type, size, and position of the place and building. 
• Check if the HCC has more than one floor, and if ‘yes’, identify the floor for installing 
the ME. 
• Ascertain the availability of gas and water supply and their supply conditions, like 
type, quality and quantity, and pressure. 
• Check the availability of power supply for electric connections; also, check if the HCC 
has an emergency generator. 
• Check the need for weatherproofing such as air-conditioning, and quality control (air 
quality and humidity). 
• Other factors that may be specified as installation prerequisites. 
These actions are particularly important to HCCs in rural areas and developing countries 
where stable sources of energy, adequate water supply and controlled environment in terms 
of temperature and humidity are not always available. 
 
Public Health – Methodology, Environmental and Systems Issues 
 
302 
Information about the likely impact on the infrastructure can be obtained from the 
manufacturers. They usually offer architectonic projects and support structuring layouts for 
installing robust ME, such as robotic surgery system and magnetic resonance instrument 
(Wang, 2009). 
2.5 Proposed model for medical equipment incorporation 
Clinical Engineering plays an important role, through Health Technology Management 
(HTM), in innovation, incorporation, usage/utilization and ME re-processing. Thus, the 
proposed model comes from HTM incorporation phase. It is important to highlight here 
that, in the last few years, the profile has been undergoing some changes in the 
incorporation process, which are not being released just in the HCC, but also in the entire 
health system. Therefore, the methodology aimed at helping this process must contemplate 
taking such actions that can be applied to the benefit of public health (Sônego, 2007; Santos 
& Garcia, 2010). Figure 4 depicts the conceptualization of the proposed model, with focus on 
ME incorporation phase. 
 
 
Fig. 4. Conceptualization of the proposed model with focus on ME incorporation phase. 
It is important to note that the phases of ME life cycle are not independent, i. e., the actions 
in any one phase can impact the other phases. Besides, each phase has specific stages, which 
must be appropriately planned and guided to obtain satisfactory results in respect of the 
patients. Thus, by monitoring the actions carried out in one phase of technology, and 
observing the consequent impact on other phases, one can plan in a better way the actions in 
other phases of the ME life cycle. 
Against this background, a model was developed to support the ME incorporation process, 
as shown in Figure 5. 
 




Fig. 5. Model depicting the process of health technology incorporation process, particularly 
ME. The proposal is based on decision making domains, technology assessment and HT 
incorporation. The domains establish interconnections, and there are multiple parameters 
and actors to be considered. 
In the decision making domain, interconnections are made among the mind functions, 
decision making types and actions. The mind functions are made by analysis, synthesis and 
imagination, and evaluation. The analysis consists in separating a whole into its constituent 
parts, the synthesis and imagination is the reverse of analysis, that is, it presents or puts the 
things in groups to make a whole. Evaluation comes into action in mental activities, such as 
success criteria establishment, performance evaluation and judging people (Adair, 2007). 
These functions can relate with those decision making types that can assume a reflective or 
deliberated form. The reflective one comes from the necessity of reflecting on how people 
make decisions based on their experiences, where they use the knowledge acquired by 
experience to identify and evaluate the situations and later make decisions (Fadok, Boyd & 
Warden, 1995; Zsambock, 1997). The deliberated form is based on reason, which supports 
the decision process, wherein the decision maker within his/her context will analyze, 
synthesize and evaluate to achieve the desired result (Klein, 1997; Joseph, 2007). So, from the 
interconnections between the mind functions and the decision making form, actions and 
post results can be created with the decision maker as the actor. 
The decision analysis, which sets relevant technological alternatives, together with 
systematic review of studies about the effects of technology on health management, and the 
economic analysis that relates costs and effects, forms the main methodology used in HTA 
(Krauss-Silva, 2004).  
Within the technology assessment domain, it is possible to choose and apply multi-criteria 
methodology to support decision making, and assessment methods of clinical evidences and 
 
Public Health – Methodology, Environmental and Systems Issues 
 
302 
Information about the likely impact on the infrastructure can be obtained from the 
manufacturers. They usually offer architectonic projects and support structuring layouts for 
installing robust ME, such as robotic surgery system and magnetic resonance instrument 
(Wang, 2009). 
2.5 Proposed model for medical equipment incorporation 
Clinical Engineering plays an important role, through Health Technology Management 
(HTM), in innovation, incorporation, usage/utilization and ME re-processing. Thus, the 
proposed model comes from HTM incorporation phase. It is important to highlight here 
that, in the last few years, the profile has been undergoing some changes in the 
incorporation process, which are not being released just in the HCC, but also in the entire 
health system. Therefore, the methodology aimed at helping this process must contemplate 
taking such actions that can be applied to the benefit of public health (Sônego, 2007; Santos 
& Garcia, 2010). Figure 4 depicts the conceptualization of the proposed model, with focus on 
ME incorporation phase. 
 
 
Fig. 4. Conceptualization of the proposed model with focus on ME incorporation phase. 
It is important to note that the phases of ME life cycle are not independent, i. e., the actions 
in any one phase can impact the other phases. Besides, each phase has specific stages, which 
must be appropriately planned and guided to obtain satisfactory results in respect of the 
patients. Thus, by monitoring the actions carried out in one phase of technology, and 
observing the consequent impact on other phases, one can plan in a better way the actions in 
other phases of the ME life cycle. 
Against this background, a model was developed to support the ME incorporation process, 
as shown in Figure 5. 
 




Fig. 5. Model depicting the process of health technology incorporation process, particularly 
ME. The proposal is based on decision making domains, technology assessment and HT 
incorporation. The domains establish interconnections, and there are multiple parameters 
and actors to be considered. 
In the decision making domain, interconnections are made among the mind functions, 
decision making types and actions. The mind functions are made by analysis, synthesis and 
imagination, and evaluation. The analysis consists in separating a whole into its constituent 
parts, the synthesis and imagination is the reverse of analysis, that is, it presents or puts the 
things in groups to make a whole. Evaluation comes into action in mental activities, such as 
success criteria establishment, performance evaluation and judging people (Adair, 2007). 
These functions can relate with those decision making types that can assume a reflective or 
deliberated form. The reflective one comes from the necessity of reflecting on how people 
make decisions based on their experiences, where they use the knowledge acquired by 
experience to identify and evaluate the situations and later make decisions (Fadok, Boyd & 
Warden, 1995; Zsambock, 1997). The deliberated form is based on reason, which supports 
the decision process, wherein the decision maker within his/her context will analyze, 
synthesize and evaluate to achieve the desired result (Klein, 1997; Joseph, 2007). So, from the 
interconnections between the mind functions and the decision making form, actions and 
post results can be created with the decision maker as the actor. 
The decision analysis, which sets relevant technological alternatives, together with 
systematic review of studies about the effects of technology on health management, and the 
economic analysis that relates costs and effects, forms the main methodology used in HTA 
(Krauss-Silva, 2004).  
Within the technology assessment domain, it is possible to choose and apply multi-criteria 
methodology to support decision making, and assessment methods of clinical evidences and 
 
Public Health – Methodology, Environmental and Systems Issues 
 
304 
costs. The methodology that can be employed in the ME assessment includes, inter alia, the 
following approaches: calculation of Maintenance Expended Limits (MEL) value; economic 
analysis; Elimination and Choice Translation Reality (ELECTRE); Analytic Hierarchy 
Process (AHP); Multi-Attribute Failure Mode Analysis (MAFMA); Measuring Attractiveness 
by a Category Based Evaluation Technique (MACBETH); fuzzy logic; systematic review; 
Grading of Recommendations Assessment, Development and Evaluation (GRADE). 
Lastly, the HT incorporation domain includes three stages: planning; proposal production; 
receiving and installation. These stages show multiple parameters to be evaluated. In the 
planning stage, four classes of parameters must be considered. These are Class I: Safety; 
Class II: Efficacy/Effectiveness; Class III: Infrastructure Impacts, Human Resources, 
Maintenance and Regulatory Aspects; and Class IV: TCO and Economic Analysis. The 
proposed production stage must enable technical specification of the technology to meet the 
clinical and technical needs. At the time of receiving the technology, one must check if the 
technology satisfies the technical specifications, and if it has all the essential accessories. 
Only after that, the equipment can be installed as planned and commissioned after 
performance and safety tests. 
Thus, the architecture of the model depends on the inter-relations the domains, where the 
HT incorporation domain relates to the decision making one and the technology assessment 
one has multiple parameters and actors involved in the process (decision maker, health 
system and HCC). 
2.5.1 Surveying parameters to be evaluated 
Initially, the researcher must verify whether the foundation available for ME incorporation 
is strong enough to justify detailed assessment of health technology. This is because a 
thorough assessment of ME needs time, specialist professionals and consequently 
investments. If the foundation is found unfavorable, the assessment can be aborted with 
justifications based on the same questions raised for eligibility assessment, following the 
issues against item 2.3. However, depending on the context and technology under 
assessment, the incorporation team might ask additional questions during eligibility 
assessment for an initial map of the technology and thereby avoid wastage of time and 
investment over unjustified assessment or even unnecessary ME incorporation. 
If the eligibility is found to be favorable to technology, one must identify the phase in which 
the ME is. This is important, because the ME in the adoption or incorporation phase will 
possibly have higher variation in clinical effect in comparison with that of the ME in usage 
phase. The ME in the obsolescence phase must be avoided, because of non-availability of 
spares and high maintenance costs. 
It is important that this survey considers the life cycle phases of technology right from the 
acquisition phase. The ME identified as belonging to previous phases, such as ‘under 
development’ and ‘pre-market’, which are relevant to the health system, must be evaluated 
by the Early awareness and alert systems of EuroScan (Simpson et al., 2009). This is because the 
technology under the previous phases of incorporation has specific characteristics, mainly in 
relation to scientific safety evidence and efficacy/effectiveness, as the ME effect has not been 
observed in large scale. 
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After assessing the eligibility and identifying the life cycle phase of the ME under 
consideration for incorporation, one must undertake a more detailed assessment of the 
technology. This assessment must satisfy all aspects of Classes I, II, III, IV considered in the 
planning phase of incorporation, as shown in the model presented in Figure 5. 
Classes I and II are essential in the evaluation process, because there must be evidences of 
safety and efficacy/effectiveness that satisfy at least the minimum conditions for using the 
technology without causing any harm to the patients and users. These parameters must be 
evaluated from the clinical data available in literature, systematic reviews or HTA 
approaches, such as the following: “Methodological Guidelines: Health Technology Assessment 
Appraisals” “(BRASIL, 2009a), “Clinical Evidence for Medical Devices: Regulatory Processes 
Focusing on Europe and the United States of America “(WHO, 2010) or “Health Technology 
Assessment Handbook”(Jørgensen, 2007; Stenbæk &Jensen, 2007). 
In a rational sense, the ME incorporation team must satisfy itself about the quality of the 
available evidence and assess whether the criteria of safety and efficacy/effectiveness meet 
the minimum acceptable conditions required to proceed with the assessment of the ME 
applicant for incorporation. Failing this, it makes no sense to evaluate other aspects. 
However, if the results obtained in Classes I and II are favorable, one must try evaluating 
Classes III and IV. Class III covers different aspects of infrastructure, human resources, 
maintenance and regulatory procedures. The investigators are encouraged to consider four 
essential factors in this regard: 
• Learning curve: This criterion refers to the time and effort required to train a user in 
effective use of the ME. For estimating these, the complexity of the ME must first be 
assessed, because the more complex the ME is, the more would be the time and effort 
required to train operators and technical team. For information relevant to this criterion, 
one must check with the distributors, manufacturers, similar ME inventories, and 
establishments that publish technical manuals about ME, such as ECRI.  
• Installation ease: Installation ease is linked to infrastructure conditions, which may 
include alteration of physical space, adaptors, accessories, compatibility with other 
technologies, energy, water and gas supply nets, humidity and temperature controls, 
and input storage needs. Information relevant to these aspects can be obtained from 
regulatory establishments and sometimes manufacturer’s manuals. 
• Maintenance ease: This criterion covers all the conditions necessary for executing  
the maintenance plan. Foremost among them is the availability of professionals in  
the region, state or country, who can train the technicians and technology users  
in operating and maintaining the ME to be installed. Besides, one must also ensure  
a suitably worded guarantee, availability of spares, facilities for software updating, 
indigenous availability of authorized distributors, and possibility of finding a  
third party for maintenance through a contract that is linked to the purchasing of 
goods or even the renting of ME. The most important thing in meeting these 
requirements is to identify the best cost-benefit ratio that calls for no compromise in 
meeting the clinical needs, and the one that ensures optimum utilization of the useful 
life time of the ME. 
• Usability: As far as this criterion is concerned, no single technique can answer all the 
questions. Therefore, what is needed is a combination of techniques, considering the 
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medical environment limitations, and the human costs in terms of fatigue, stress, 
frustration, discomfort and satisfaction, learning talent, ME use tax, adaptability to the 
task and the user’s needs, and user’s characteristics. To achieve global usability, one 
must address the following measures: 
• Efficacy: Percentage of aims realized, and of users who completed the task 
successfully, and the average of completed tasks. 
• Efficiency: Time to complete a task, tasks completed per unit of time and monetary 
cost of task realization. 
• Satisfaction: Satisfaction scale and frequency of use and complaints. 
The usage measures cited above (or their estimates) can be obtained by interviewing the 
clinical team or from similar ME inventories, and pre-market study reports submitted to the 
departments concerned by the registrar of commerce, for example, ANVISA4 and FDA5. 
As regards Class IV costs, the criteria that must be considered are those, which might be 
covered by the TCO and economic analysis. The TCO corresponds to the sum of the costs of 
acquisition, operation, maintenance, training and replacement. Calculating these costs is 
sometimes challenging. Therefore, they might be estimated on the basis of information 
gathered from the distributors, manufacturers and HTA reports. The idea behind estimating 
the total property cost is to ensure that one does not go just by the acquisition cost, which 
can be attractive, but also other costs that might go against technology usage. 
Through economic analysis, one can investigate the cost-benefit relation to ascertain if the 
results obtained from the technology under assessment justify the costs, and whether they 
compare favorably with other technological options that show good cost-benefit relations. 
Instructions on economic analysis with focus on health technologies can be obtained from 
the guide “Methodological Guidelines: Economic Evaluation of Health Technologies” (BRASIL, 
2009b).  
These guidelines would be helpful in undertaking the team activities of ME incorporation. 
However, with the help of the Clinical Engineer, one can add another criterion. The 
incorporation process will be a challenging one in the context of variations related to 
geographical regions, health policies, demand, human and financial resources, and cultural 
aspects, among other pertinent factors. 
3. Conclusions 
One of the factors that reaffirms the importance of ME incorporation is the improvement in 
people’s health during the last decade, an achievement that could not reach the poor and 
other socially marginalized or excluded groups earlier. Increasing inequalities in health 
status are more evident in rural areas. This situation was created by the uneven distribution 
of money, power and other resources at global, national and local levels, which were in turn 
influenced by political equations. The health social determinant is mainly responsible for the 
inequalities in health. The available evidence points to a two-way relationship between 
poverty and health. Within this vicious circle, poverty creates poor health, and poor health 
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creates poverty. Within the vicious circle of higher income is good health and good health is 
related with higher income and welfare (WHO, 2011b). 
The Clinical Engineering can contribute, through administration and management of ME, to 
the preparation, guidance and observation of the impact of methodologies aimed at ME 
incorporation planning in the HCC in the context of health systems. Additionally, adequate 
incorporation planning requires multidisciplinary knowledge; so, the Clinical Engineer, 
who has multidisciplinary education, can act as a facilitator by establishing an interface 
among the actors involved in ME incorporation and by promoting the culture of constant 
monitoring of the impact of technology on health, after its incorporation in the health 
system. The observation of the impacts and the lessons learnt from past and recent needs 
can contribute to planning future incorporation, (Moraes, 2007; Santos & Garcia, 2010; 
Signori & Garcia, 2010). 
Many times, technology management in health is seen as an independent task, but for a few 
links with other parts of the health service. In other words, in the past, the technical 
personnel were hardly ever involved in crucial activities such as investment plans, service 
quality evaluation or organizational issues. However, this scenario has been undergoing 
some change in the last few years. So, ME management can now be clearly defined as an 
integral part of the health system and its activity felt at all levels of the public health service 
(KAUR, 2005a).  
The ME cannot be managed in isolation, but only with other components of the health care, 
including the aims, procedures, finances, level of personnel and support systems at each 
health service level. To accomplish this, the creation of a multidisciplinary group of 
management of technology is recommended for each level (local, estate, and national). This 
group must have representatives of different disciplines: medical, clinical, clinical 
engineering, support service, purchasing sector, financial and maintenance team of ME 
(KAUR, 2005a). 
Within this context, the incorporated ME is fundamental to health care service, particularly 
to diagnosis and disease treatment. The available and accessible ME in health care 
environment is related to the equity and health service offer that is more relevant to the 
patients’ needs. Any national health plan needs policies, strategies and plans of action to 
health technologies, especially the ME. A robust health system must guarantee access to 
safe, efficient and high quality ME, in order to prevent, diagnose and treat diseases and 
injuries, and help the patients in their rehabilitation, and to promote public health (WHO, 
2011b). 
ME incorporation is an important element of the HTM. This is a complex and 
multidisciplinary process for developing the activities to support decision making, though 
some members of the health team and distributors believe that it is just the action of 
purchasing. For example, costs outside the budget for additional accessories may become 
necessary after the supply order for ME has already been placed. Or, some unexpected 
changes may become necessary in installation plans, because the dimensions and other 
specifications of the ME have not been properly worked out. This entails considerable costs 
and delays, besides impairing the quality of the public health system. Yet, the technology 
may remain completely unused, consequently its use can harm the patient or personnel, 
thus impacting the public health in a negative way (Harding & Epstein, 2006). It underlines 
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the need to systematize the ME incorporation process and thereby mitigate or eliminate 
some negative factors of the process that can affect the technology life cycle. 
The model proposed here is based on constructing three domains: Decision Making; 
Technology Assessment and ME incorporation. It can help the incorporation team in 
identifying, predicting and guiding the realization of measures to minimize possible 
unfavorable impacts, as also to maximize the benefits obtained through ME incorporation. 
This is possible because the model has been built on scientific evidence and reliable 
information available in literature. Besides, the proposed model would be helpful to future 
researches in that it represents a consolidated methodology that deals with the multiple 
parameters involved in the ME incorporation process in a systematic and rational way. The 
Clinical Engineer, as a multidisciplinary education professional, can be a fundamental actor 
in methodology development and a facilitator of ME incorporation, which can ensure health 
service deliverance in a safe, effective, and equitable way, besides rational utilization of the 
resources in the developing countries. 
One can observe that health technology, particularly ME, suffers from lack of clinical 
evidences in the innovation and incorporation phases of the life cycle. Besides, a higher 
variation is expected on the clinical effect as compared with the technology under wide 
usage. This is because the technology that belongs to the initial phases has not been 
monitored on a large enough scale. Therefore, at the time of incorporation, one must 
prioritize the ME that is in the usage phase. The Clinical Engineering can be helpful to the 
incorporation team in the identification phase of the life cycle, as well as in the search, 
selection and assessment of available evidences in literature so as to ensure that the 
technology to be incorporated is safe and effective. So, the deliverance of health system with 
quality and equality contributes to the promotion of public health (Sônego, 2007). 
Additionally, it is important to highlight that the phases of technology life cycle are not 
independent, i. e., actions in any one phase can impact other phases. For example, an 
inadequate incorporation plan can lead to high costs of maintenance, unavailability of 
technology, risks to patients and users, and spilling of unsatisfactory clinical results into 
other phases of the ME life cycle (Moraes, 2007). 
Lastly, one must note that, after ME incorporation, the Clinical Engineer retains the 
management of other phases of technology life cycle with him for future ME updating, 
improvement and replacement. The services of Clinical Engineering are more necessary at 
this stage to deal with the responsibility of ME management program within the framework 
of guidelines that range from the strategic phase to the replacement phase. 
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1. Introduction 
Health technology, according to WHO is the application of organized knowledge and skills 
in the form of devices, medicine, vaccines, procedures and systems development to solve a 
health problem and improve quality of lives4. When used in this paper, the term healthcare 
technology means the different types of devices or equipment used in health facilities. Its 
encompasses: medical equipment for clinical use; hospital furniture; vehicles; service 
Supplies; plant; communication equipment; fire fighting equipment; fixtures built into the 
building; office equipment; office furniture; training equipment, walking aids and workshop 
equipment.  
Healthcare technologies offer many benefits and have greatly enhanced the ability of health 
professionals to prevent, diagnose and treat diseases11. They are one of the essential 
elements for the delivery of health services. The use of technology in health care systems in 
developing and transition countries faces a great number of difficulties. Since about 95% of 
the healthcare technology used in these countries is imported30; mismatches occur because 
the technology development process has not usually considered the needs and realities of 
the target environments. These mismatches in the technology transfer process to countries 
with financial and technical constraints are often of great significance. Thus, in Benin, 
medical devices and equipment represent a significant proportion of national health care 
expenditure. Each year, more than 10,600,000 US$, (about 20%)20 of the national health 
budget, are spent on procurement of medical devices and equipment for healthcare 
facilities. Despite this great amount of money spent each year on an ever-increasing array of 
medical devices and equipment, not enough attention is paid to the equipment use and 
maintenance. Management of medical devices is not yet recognised as an integral part of 
public health policy. Planning, follow up and maintenance of the equipment are inefficient 
and ineffective 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21. 
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This study, supported by the Netherlands Organisation for International Cooperation in Higher 
Education (NUFFIC) from 2007 was conducted in Benin Ministry of Health (MoH) and at the 
University of Abomey-Calavi in collaboration with the Athena Institute, Vrije Universiteit 
Amsterdam from 2006-2008 aimed to identify factors appearing between 1998 and 2008 that 
adversely affected the healthcare technology management cycle i.e., planning, budgeting, 
selection, procurement, distribution, installation, training, operation, maintenance and 
disposal of medical devices. The results will allow to identify the key factors of 
mismanagement and critical maintenance system of medical devices in Benin and to 
formulate recommendations to improve the system. The first part of this paper gives 
background information on the country, its health system and an overview of its healthcare 
technology management state. The second part describes the methods and materials used 
and the third part presents the results, followed by discussion, comments and 
recommendations in the final section. 
2. Background information 
2.1 Benin: The country 
Located on the West coast of Africa, the Republic of Benin is small (114,763 square 
kilometers), with a coastline on the Gulf of Guinea nestled between Nigeria, Niger, Burkina 
Faso, and Togo (Figure 1). The population, estimated at 7,839,914 in 2006, includes a 
multitude of ethnic and linguistic groups. Benin remains one of the world’s least developed 
countries and has been ranked 163 of 177 on the United Nations Human Development Index 






Fig. 1. Map of Benin (Source: USAID, 2006) 
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Indicators 
 Population in 2006      7,839,914 
 Human Development Index      0.437 
 Country rank      163/177  
 GPD per capita (Purchasing Power Parity US$)   1,141 
 Life expectancy at birth (years)     55.4 
 Public expenditure on health (% of GPD) in 2004   4.5 
 Health expenditure per capita (PPP US$) in 2004   40 
 Infant mortality rate per 1,000 live births     67 
 Maternal mortality ratio per 100,000 live births   474 
 HIV/AIDS prevalence (%)     2.0 
 Adult literacy rate (% ages 15 and older)    34.7 
Sources: 1. Human Development Reports: 2007/2008;  
2. Benin Demographic and Health Survey 2006;  
3. Benin Health Statistics Directory 2006. 
Table 1. Selected demographic and health indicators of Benin 
2.2 The health system 
The public healthcare system of the country has been reorganized according to the 
decentralization policy and consists of three levels: central with the National Referral 
Hospital (> 600 beds), intermediate with five Province or Departmental Hospitals (>100 
beds) and peripheral with thirty four Health Zones, twenty seven fairly functional Zone 
Hospitals (> 46 beds), seventy seven Communal Health Centers, four hundred eighty seven 
Arrondissement Health Centers and many Village Health Units and other private health 
facilities. Apart from that, the health system also has the following public hospitals: the 
Mother and Child Hospital, many detection and treatment centers for tuberculosis and 
leprosy, the National Hospital for Psychiatry, the National Hospital for Gerontology, two 
Buruli Ulceration Treatment Centers12 etc…  
2.3 Healthcare technology management and maintenance 
Healthcare technology management and maintenance remains one of the main challenges of 
the developing countries healthcare systems in general and, of Benin particularly. Thus, 
although many financial resources are used for procurement of devices, not enough 
attention is paid to their future. While some of the equipment were donated, a significant 
portion was purchased with loans provided by bilateral and multilateral agencies and will 
have to be paid back with great sacrifice26. One of the root causes of the equipment idleness 
is the lack of effective management. It is important to point out that despite the several 
initiatives undertaken by the ministry of health to improve the healthcare technology 
management cycle no significant changes have been noticed13, 14, 15, 16 and 17.  
Many facilities, especially Zone Hospitals, continue to lack the basic technologies they need 
to provide quality care to the patients, because equipment is unavailable, inoperative, 
misused or inappropriate. The situation is most severe in the Communal and 
Arrondissement health facilities far from the first referral hospitals. This has far-reaching 
implications for the prevention and treatment of disease and disability and often leads to a 
waste of scarce resources. 
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3. Materials and methods  
The study was carried out in the MoH, 321 healthcare facilities of the southern part of the 
country, the Ministry of Economy and Finance, some representatives of external support 
agencies in Benin and ten accredited suppliers of medical device companies. It consisted of 
surveys undertaken in 2006 and 2007 and of desk research (content analysis) based on 1998 
to 2008 procurement collected data. It aimed to determine the factors that adversely affect 
the healthcare technology management cycle (planning, budgeting, selection, procurement, 
distribution, installation, training, operation, maintenance and disposal of medical devices) 
in Benin. 
3.1 Desk research and short survey 
This study focused on the procurement management of medical devices in the Republic of 
Benin and aimed to identify the main weak points in the procurement management 
system of medical devices from 1998 to 2008. It was based on data collected from 
documents (such as national procurement magazines and health equipment public 
procurement and bidding contracts from the Ministries of Health and Economy and 
Finances), and on interviews and informal discussions with ten local accredited suppliers 
of medical devices in Benin.  
A comparative study was done concerning the selling prices of ten medical devices 
procured by Benin MoH further to international tenders. The steps were i) Ten medical 
devices were selected from the available essential medical device list. ii) Their  
mean reference selling prices (based on their specifications) were determined from 10 
local medical device accredited suppliers based on the prices the devices were sold to  
the private health facilities. iii) The mean prices at which the same devices were sold to 
the Ministry of Health following open tenders public procurement were identified, in 
three periods: 1998 to 1999; 2001 to 2004 and 2005 to 2008 when the procurement 
evaluation process has been changed and improved. iv) The mean prices at which they 
were sold to the MoH were compared to the ad hoc mean reference selling prices 
provided by the private healthcare facilities and/or from the local suppliers’ price list for 
private facilities.  
3.2 Surveys 
Two surveys were carried out in 321 healthcare facilities of the six southern departments 
(provinces). The first, entitled “management and maintenance of healthcare technology”, 
was conducted in 2006 in 11 health centers and hospitals. It aimed to identify the 
weaknesses in the healthcare technology management and maintenance system in order 
to make recommendations for its improvement. Data were collected through 
observational visits, interviews and questionnaires. The second, entitled “healthcare 
technology assessment in the southern Benin public healthcare facilities” was carried out 
in 310 health centers and hospitals in 2006 and 2007. The first objective was to determine 
the extent of disparity between what medical devices/equipment were planned and what 
was actually available in each selected health facility to facilitate procurement for the 
poorly equipped health facilities of the essential medical devices. The second objective 
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was to identify weaknesses in the whole Benin healthcare technology management cycle. 
Data were collected through observational visits and reading reports, interviews, and 
questionnaires (inventory sheets). The steps were i) Equipment inventory was done at all 
the public healthcare facilities in southern Benin; ii) Healthcare equipment in these 
facilities were compared to the MoH available Essential Medical Device List of each health 
facility level iii) The needs assessment of each healthcare facility was done using a pilot 
asset assessment software. Finally, interviews were held with a range of stakeholders 
including policy makers of the MoH, healthcare facility managers, equipment users 
(physicians, nurses, midwives, lab technicians, X-ray machine technician ….) and, 
maintenance technicians.  
4. Results 
The results of the study are summarised in tables 2 to 6 and figure2. Tables 2, 3 and 4 show 
the mean ad hoc reference selling prices of selected medical devices in comparison with the 
prices the same devices were sold to the Ministry of Health from 1998 to 1999, 2001 to 2004 
and 2005 to 2008. Table 5 and figure 2 show the trends of [MoH device acquisition 
prices/Ad hoc device reference selling prices] ratio during the three periods of years. The 
ten equipment studied were: 1) blood pressure device 2) spectrophotometer 3) electric 
suction unit 4-) Electrocardio-graph 5) X-ray apparatus 6) hot air sterilizer 7) autoclave 8) 
ventilator 9) anaesthesia system and 10) blood bank refrigerator.  
The letter X that may be a, b, c, d, e, f, g, h, i or j represents respectively the “ad hoc 
reference prices” (the private healthcare facilities device acquisition prices) of each device 
in local currency. The letter Y that may be A, B, C, D, E, F, G, H, I or J are respectively the 
MoH same device acquisition prices through public procurement. Table 6 presents the 
findings of the two surveys and shows the factors affecting the healthcare technology 
management cycle in 321 health centers and hospitals in southern Benin. The factors were 
grouped (but not ranked) in sixth categories which were respectively maintenance and 
repair; distribution; use; technology assessment; policy, planning and budgeting; and 
procurement. 
The key factors that have been identified so far include the high acquisition costs; the lack 
of insight of the government on medical device market prices, the lack of capacity to 
monitor reasonable prices from suppliers, the lack of insight into the cost/performance 
ratio of various brands of medical devices, an unequal distribution of devices among 
health care facilities, an unbalanced allocation of resources to acquisition of devices 
compared to infrastructure, and maintenance. Other key factors identified included the 
insufficiency of human resources with appropriate capacity to manage equipment, the 
unavailability of spare parts, and the lack of an annual maintenance budget. In a nutshell, 
the lack of policy and management tools like “the up to date essential medical devices list 
and “the reference prices list for essential medical devices” to support the implementation 
of the existing policy. The latter allows health sector authorities to monitor financial 
diversions occurring in public procurement contract awards, while the former serves as a 
reference tool to assess availability of fully operational devices at different hierarchical 
levels of healthcare facilities.  
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4.1 Findings of the desk research and short survey 
 
 
Table 2. Comparison of the mean ad hoc reference prices of medical devices to the Ministry 
of Health same device acquisition prices, 1998 to 1999. 
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Table 5. Trend of the [MoH device acquisition price/Ad hoc device reference prices] ratio 






Fig. 2. Comparative graphs of the MoH selected medical device acquisition prices  
during the three periods of years:1998-1999; 2001-2004 and 2005-2008. 
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Table 6. Factors affecting the healthcare technology management cycle in 321 health  
centers and hospitals in southern Benin. 
5. Discussion and recommendations 
Goods acquisition, especially healthcare technology, represents an important part of any 
health budget and need to be looked with close attention. Through the results shown in 
Tables 2, 3, 4, 5 and, figure 2, it is clearly seen that, independently of the procurement years, 
the device acquisition prices by the MoH remain higher than the private healthcare facilities 
same device acquisition prices. Although the Benin first Goods and Services Procurement 
Code was implemented during the years 2001 to 2004 and has also been amended in 2004 
and be implemented from 2005 to 2008, no significant improvements were found regarding 
the higher prices of medical equipment paid by the MoH. One can notice that the MoH pays 
too much for medical devices acquisition through public procurement and this was at its 
worst in 2001-2004. When analysing year by year available data of this period it was found 
that the highest acquisition prices were critical in 2003 and 2004. It is important to deeply 
understand the real reasons that underlie this phenomenon. Many hypotheses could be 
drawn to explain this fact but, it will be more interesting to increase the sample size (>10 
medical devices) of the study for more reliability. The internal and external validities of the 
findings could be improved if a quasi-experimental study was designed. Thus, widely 
surveys will be conducted in the next papers with more representative sample size and 
strong method as controlled interrupted time series based on segmented regression analysis 
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to infirm or to confirm the present findings and also to understand the true reasons of the 
ineffective management of healthcare equipment in Benin.  
The Ministry of Health still needs a national public procurement policy and management tool 
like a reference prices list of the most widely used devices to overcome and to master the 
increasing and unreasonable medical device prices. It is normal to have the device acquisition 
costs paid by the government a bit higher than the reference set prices because of financial and 
administrative fees involved when the suppliers submit tenders. It is acceptable and 
reasonable to have the average device selling prices comprised between 1.1 to 1.2 times higher 
than the ad hoc reference prices. But, when the device selling prices offers by a supplier are 
more than that, they could be considered as outbidding. It is thus urgent for the Benin 
government especially the MoH to have an insight on that fact, to encourage the development 
of policies and laws regarding a reference price lists document of medical devices. The 
availability of the reference prices of the essential medical devices will allow the health sector 
authorities to monitor the usual financial diversion occurring during the procurement 
management activities. It is expected that once this document becomes available, the MoH 
could buy value-based pricing equipment each year and save a lot of money that can be used 
to improve the health of Benin population through other investments.  
The results of the two surveys: i) “management and maintenance of healthcare technology” 
and ii) “healthcare technology assessment in the southern Benin public healthcare facilities” 
have revealed many weaknesses in the Benin health system through its healthcare 
technology management cycle. The results show failures in each link of the cycle (planning, 
budgeting, selection, procurement, distribution, installation, training, operation, 
maintenance and disposal of medical devices) resulting in low overall community health 
effectiveness. It is necessary to point out that the findings of the two surveys, i.e. the factors 
affecting healthcare technology management were only grouped (but not ranked) in sixth 
categories. The ranking of the factor categories (I, II, III, IV, V and VI) in order to set up 
priority actions will be discussed in the next paper.  
As recommendations, twenty actions need to be taken by the government to overcome this 
situation in order to achieve its goal to improve the quality of/and access to health services 
that taking into account the poor and indigent. It is thus urgent to develop and implement a 
good medical device national policy which can include the following: i)An improved 
national list of essential medical devices and equipment based on evidence from the studies; 
ii) A national policy and plan for medical devices; iii) A national functional regulation 
authority in medical device empowered with legislation; iv) A document on assessment of 
medical device needs; v) National regulations based on ISO standards or WHO 
specifications; vi) National procurement procedure; vii) National policy for acceptance of 
donations; viii) Negotiated pricing list of each item of equipment; ix) National guide for 
management and use of medical devices; x) An inventory of suppliers and medical in use; 
xi) The cost of all the equipment of each level of Benin health facility related to the cost of 
infrastructure; xii) The service life span of each medical device or equipment in use in Benin 
health care facility or hospital in order to plan the replacement at a systematic time; xiii) The 
list of medical devices which have the highest risk; xiv) The spare parts which have the 
highest failure rate in order to plan their procurement; xv) The list of critical equipment and 
instrument affected by the electrical power outages and power anomalies in Benin hospitals; 
xvi) Good software based planning and management tools for management and 
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maintenance of medical devices; xvii) A post-market surveillance/vigilance system for 
alerts, notifications and recalls; xviii) A national budget for devices, using costing, 
budgeting and financing; xix) Standard operating procedures and best practices that cover 
every stage in the life span of medical devices; xx) Creation of an independent Direction of 
Healthcare Technology Management and maintenance within the Ministry of Health. 
The following Healthcare Technology Management Cycle (Figure 3) could be used as a 
framework for health equipment management in developing country, providing a guideline 
for the necessary regulations and systems.  
The Healthcare Technology Management Cycle11:An example of a framework for health 













































Fig. 3. The Healthcare Technology Management Cycle 
6. Conclusion 
Management and maintenance of healthcare technology in developing countries especially 
in the poor sub-Saharan Africa countries, remain a challenge. From the planning to the 
disposal of the devices many actions need to be undertaken to improve the Healthcare 
Technology Management Cycle. The achievements in the public healthcare sector depend on 
the full involvement of each stakeholder, but the main responsibility is still that of the 
governments. They need the political willingness and commitment to recognize 
management and maintenance of devices as an integral part of public health policy in order 
improve the quality and access to healthcare in each country. 
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For a long time non-communicable diseases (NCDs) have been a major cause of death and 
disability worldwide. However, the profile of this health challenge is changing: Having 
dominated the epidemiologic contour of high-income countries in the 20th century, it is now 
increasingly affecting the developing regions of our planet. Unless we start implementing 
measures to reduce the burden of NCDs in low- and middle-income countries, the pressure on 
their health systems will be unbearable and will limit the prospects for economic development.1 
In this chapter we discuss the need to confront this emerging challenge through a change in the 
orientation of global health. The central message is that it is necessary to incorporate NCDs into 
the global agenda and deploy comprehensive strategies in developing countries to address 
them. Such strategies should include both prevention services and cost-effective treatments. 
In the first part of the chapter we discuss the present situation of NCDs in low- and middle-
income countries, with emphasis on cardiovascular diseases, cancer, chronic respiratory 
diseases, and diabetes, along with a major risk related to most of them, obesity. Part two is 
devoted to the discussion of four myths that have hindered the incorporation of NCDs to 
the global health agenda and a set of proposals to strengthen the battle against them, using 
as an example several initiatives implemented in Mexico as part of a comprehensive health 
reform. The chapter concludes with a call to mobilize international collective action in the 
pursuit of shared goals around NCDs. 
2. The global burden of NCDs 
During the past half-century the world witnessed a fundamental transformation in the field 
of health: a shift in the dominant patterns of disease and death towards higher age groups 
and towards chronic conditions. 
Improvements in nutrition, access to water and sanitation, and expanded coverage of public 
health interventions such as immunizations and oral rehydration therapy reduced the 
burden of disease attributed to under-nutrition, common infections and reproductive 
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problems, and produced major gains in child survival beyond age 5. Recently, the expansion 
of the global coverage of immunizations, for example, produced a 74% drop of measles 
deaths between 2000 and 2007.2 The number of global deaths due to malaria declined from 
almost one million in 2000 to 780 thousand in 2009.3 Annual maternal deaths also fell from 
more than a half a million in 1980 to less than 350 thousand in 2008.4 
The gains made against infectious diseases and advances in child survival rendered huge 
improvements in life expectancy. In fact, during the 20th century the world as a whole 
experienced a larger gain in life expectancy than in all the previously accumulated history of 
humankind. Life expectancy was only 30 years in 1900. By 1985 it had more than doubled to 
62 years. In 2010 the average estimate for the world reached 70 years, but with huge regional 
differences, ranging from 83 years in Japan to scarcely 47 years in Zimbabwe.5 
Today growing proportions of the world population are living long enough to experience 
the effects of the exposure to health risks related to modern living such as lack of physical 
activity, consumption of unhealthy diets and products (tobacco, alcohol and illicit drugs), 
stress and social isolation, all of which increased the prevalence of NCDs to the point of 
turning them into the leading cause of death worldwide. According to a recent World 
Health Organization (WHO) report, two thirds (36 million) of the total annual deaths are 
attributed to these diseases and 80% of them occur in low- and middle-income countries.6  
The most common NCDs are cardiovascular diseases, cancer, chronic respiratory diseases, 
and diabetes. Heart diseases are the main cause of death worldwide. They produce 17 
million deaths annually, 80% of which occur in low- and middle-income countries.6 In fact, 
deaths due to heart diseases today are more numerous in China and India than in all the 
developed world.  
Cancer is another major challenge. According to WHO, there are 7.6 million cancer deaths 
annually worldwide, which represent around 21 percent of all NCD deaths.6 Two thirds of 
them occur in low- and middle income countries.  
The most common cancers among women in developing nations are breast, cervical, 
stomach, lung, and colorectal cancer.7 Every year more than half a million new cases of 
breast cancer occur in this part of the world.8 In Latin America, Uruguay (83 per 100,000 
women) and Argentina (75 per 100,000 million) have already reached breast cancer 
incidence rates similar to that of Canada (96 per 100,000 women), which is one of the highest 
in the world.9 Cervical cancer, which has become a rare disease in rich nations, produces 
more than 200,000 deaths annually in developing countries.10 
Among men, the most common neoplasms in developing nations are lung, stomach, liver, 
esophageal, and colorectal cancer.7 While rich countries are witnessing a decline in new 
cases of lung cancer as a result of broad anti-smoking campaigns, many low- and middle-
income nations are experiencing the opposite trend. Liver cancer is also increasing among 
men in poor countries. More than 80% of the new cases of this disease occur in developing 
nations, with Sub-Saharan Africa and Southeast Asia showing the highest rates worldwide. 
It comes as no surprise to find out that in these same regions hepatitis B virus infection is 
endemic. 
The third major group of NCDs is formed by chronic respiratory diseases, including asthma 
and chronic obstructive pulmonary disease, which produce 4.2 million deaths annually.6 
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Diabetes is the fourth major non-communicable challenge. The number of adults with this 
disease has doubled in the past three decades, from 153 million in 1980 to 347 million in 
2008.11 This disease produces 1.3 million deaths annually, more than 80% of them in 
developing regions.6 To this we should add its morbidity impacts, since diabetes is the 
leading cause of renal failure, limb amputation, and visual impairment and blindness. This 
imposes huge economic burdens on individuals, households, health care systems, and 
national economies. According to a report of the International Diabetes Federation, total 
expenditure on diabetes reached 376 billion dollars in 2010 and is projected to exceed 490 
billion dollars by 2030.12 
Obesity is closely related to the increasing prevalence of cardiovascular diseases, several 
forms of cancer, and diabetes. According to a paper recently published in The Lancet, there 
are 1.46 billion overweight adults globally; 495 million of them obese.13 Among other 
factors, this is the result of recent changes in the global food system which is producing 
increasing amounts of affordable processed food.14 Obesity levels range from 3% in Japan to 
around 80% in some of the islands of the South Pacific. Children are being increasingly 
affected. A report of the US Institute of Medicine indicates that 20% of American children 
between the ages of 2 years and 5 years are overweight or obese.15 Figures of the latest 
National Health and Nutrition Survey in Mexico indicate that the prevalence of obesity 
among children 5 to 12 years old increased from 6% to 10% between 1999 and 2006.16  In the 
developing world this epidemic first affected the affluent middle-aged adults in urban 
settings, but it is now spreading to rural areas and indigenous populations, affecting 
younger age groups, and rapidly turning obesity into a disease of the poor. 
If the present trends continue, by 2050 more than 50% of the world population could be 
clinically obese and national health systems would be overburdened by the demands 
associated to this health risk.17 Withrow and colleagues estimated that obese individuals 
have medical costs 30% higher than those with normal weight.13 
The shift of the burden of disease in developing countries towards chronic conditions is 
demanding the design and implementation of new local health strategies, but it is also calling 
for changes in the contents and orientation of the global health agenda. In the following 
section we will discuss four myths that have delayed the incorporation of NCDs to the global 
agenda and a set of proposals to successfully address these emerging challenges. 
3. Overcoming the barriers to incorporate NCDs to the global agenda   
During the 20th century international health was mostly involved in the control of 
communicable diseases, which were supposed to be characteristic of developing countries 
and mostly controlled in the developed world. NCDs, in contrast, had a low profile in the 
global health agenda, under the belief that they would be limited for quite a long time to 
high-income countries. In those days there was also a general consensus around the idea 
that infections and NCDs were biologically un-related. 
Reality proved to be more complex. Infections never disappeared from the developed 
world. AIDS and antibiotic resistance have been strong remainders of the danger of 
lowering the guard against communicable diseases. As shown in the previous section, 
NCDs are increasingly dominating the health profile of the developing world. Finally, many 
ailments originally classified as non-communicable have now been found to have an 
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infectious cause. According to WHO, one fifth of all cancers worldwide are caused by 
chronic infections produced by agents such as HIV, HPV, and hepatitis B virus.18 Bacterial, 
viral, and parasitic infections also underlie other NCDs, such as rheumatic heart disease, 
Chagas cardiomyopathy, and peptic ulcer.  
To make matters more complex, many NCDs can literally be transmitted through genetic, 
epigenetic, and social networking mechanisms. The former Director General of WHO, Gro 
Harlem Brundtland, used to talk about “communicated diseases,” which may be non-
communicable in the epidemiologic sense of the word, but are transmitted through advertising 
and sponsorship of unhealthy products such as tobacco, junk food, and soft drinks.19 
If we are to successfully meet the NCD challenge, we must overcome the four following 
myths, which have been identified in the work of the Global Task Force on Expanding 
Access to Cancer Care. 
Myth #1: NCDs are not a major problem in developing countries. As shown above, a solid body 
of evidence has documented the rising importance of NCDs. According to the WHO Global 
Status Report on NCDs, nearly 80% of NCD deaths occur in low- and middle-income 
countries, and even in African countries they will exceed communicable, maternal, 
perinatal, and nutritional diseases as the most common causes of death by 2030.6 
Myth #2: Even if the NCDs are important, there is very little that developing nations can do to 
address them. Actually, we have at our disposal cost-effective interventions for the majority 
of NCDs common in developing regions, and we should deploy them alongside preventive 
strategies in what has been called the full cycle of care.20 
Myth #3: Even if there are effective interventions, developing countries cannot afford them. Several 
experiences show that it is feasible to mobilize both global and national resources in a 
fiscally responsible way to greatly expand access to comprehensive services for NCDs. 
Myth #4: Responding to the challenge of NCDs would distract attention from other more urgent 
priorities, mainly the health-related Millennium Development Goals (MDGs). This myth is 
especially pernicious because it tends to polarize the global health community in a zero-
sum, competitive mentality. Instead, we should look for synergies among disease-specific 
programs and strengthen health systems so that they can address the multiple, diverse, 
and complex needs of real people. A solid health system will be able to meet the needs 
related both to the unfinished agenda of common infections and to the emerging burden of 
NCDs. 
These four myths sound very familiar because they were applied to AIDS over a decade 
ago. Back then, these same four misconceptions were put forward as justifications for 
inaction. Fortunately they were successfully eradicated and expanded access to prevention 
and care for HIV/AIDS is now considered one of the greatest achievements in the history of 
global health. The same success can now apply to NCDs if we develop the right evidence-
based policies and if we continue to involve all relevant actors. 
NCDs are the driving force behind a health picture that can be characterized by two words: 
change and complexity. Our common challenge is that most health systems simply have not 
kept up with the pressures derived from the epidemiologic transition. In particular, 
ministers of health throughout the world are facing unprecedented demands as they seek to 
become effective stewards to develop health systems that respond to the needs and 
expectations of the population with equity, quality, and financial protection for all. 
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This complexity can only be addressed through a comprehensive response to NCDs built on 
three major pillars: 
• First, the design and application of a new generation of health promotion and disease 
prevention strategies; 
• Second, the achievement of universal social protection guaranteeing access to high-
quality care without fear of financial catastrophe; 
• Third, the adoption of innovations in the delivery of health services that make use of 
the technological and managerial revolutions of our times.  
Many countries have made progress along these pillars. Mexico is a relevant example. In the 
following paragraphs, some of the most important lessons in the use of each of the pillars in 
a reform recently implemented in this country are discussed. 
The first pillar was predicated on the notion that health systems will not be able to handle 
the growing burden of NCDs without a renewed emphasis on public health. Aware of this 
reality, a crucial component of the Mexican reform was the establishment of a new public 
health agency charged with protection of the population against health risks through food 
safety, definition of environmental and occupational standards, regulation of the 
pharmaceutical industry, and control of hazardous substances like alcohol and tobacco.  
Along with other developments, this new agency has greatly strengthened the stewardship 
role of the Ministry of Health, which has become empowered to mobilize all instruments of 
public policy in the pursuit of health as a social objective. 
In addition, the financial re-engineering of the health system included a protected fund for 
community health services targeting health promotion and disease prevention 
interventions, including, of course, those targeted at NCDs.  
Important as promotion and prevention are, control efforts must also include access to health 
care. Indeed, even if we invest increasing amounts of resources in the prevention of NCDs, 
we will still need to deal with the consequences of exposures to risks that have already 
occurred. Those consequences include episodes of disease that require treatment, which all 
too often exposes families to the associated risk of financial catastrophe. For this reason, a 
comprehensive strategy must also include the second pillar: universal social protection. 
Based on sound evidence about the extent of pernicious out-of-pocket payments, in 2003 the 
Mexican Congress approved a major legislative reform establishing a system of social 
protection in health. This system has substantially increased public funding for health in 
order to provide universal health insurance, including the half of the population, 50 million 
persons, most of them poor, who had lacked protection until then. 
The vast majority of these persons are now enrolled in a new public insurance scheme called 
Seguro Popular, which guarantees access to a comprehensive package of cost-effective 
services covering the prevention, early detection, diagnosis, treatment, and palliation of the 
major causes of ill health, including, of course, NCDs. The law stipulates that the package 
must be progressively expanded and updated annually on the basis of changes in the 
epidemiologic profile, technological developments and resource availability.  
The key to expand such resources has been to start with an explicit set of guaranteed 
benefits. This ties the reform to concrete deliverables, which is a main ingredient to gain 
public support. This approach tackles health system strengthening starting with the desired 
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prevention strategies; 
• Second, the achievement of universal social protection guaranteeing access to high-
quality care without fear of financial catastrophe; 
• Third, the adoption of innovations in the delivery of health services that make use of 
the technological and managerial revolutions of our times.  
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occurred. Those consequences include episodes of disease that require treatment, which all 
too often exposes families to the associated risk of financial catastrophe. For this reason, a 
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protection in health. This system has substantially increased public funding for health in 
order to provide universal health insurance, including the half of the population, 50 million 
persons, most of them poor, who had lacked protection until then. 
The vast majority of these persons are now enrolled in a new public insurance scheme called 
Seguro Popular, which guarantees access to a comprehensive package of cost-effective 
services covering the prevention, early detection, diagnosis, treatment, and palliation of the 
major causes of ill health, including, of course, NCDs. The law stipulates that the package 
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The key to expand such resources has been to start with an explicit set of guaranteed 
benefits. This ties the reform to concrete deliverables, which is a main ingredient to gain 
public support. This approach tackles health system strengthening starting with the desired 
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outcomes, rather than with the existing inputs, as is the usual practice. Once the package of 
guaranteed interventions has been defined, it is possible to work our way backwards to 
estimate the requirements for inputs, including financial resources, workforce development, 
facilities, drugs, and other technologies. 
Thanks to this approach, there was ample support for increasing public investments in health, 
despite general economic difficulties. The recipe for success was very simple: the Ministry of 
Health didn’t ask for money; rather it offered explicit benefits for all, including the health 
benefits but also the large economic benefits of reducing the burden of chronic diseases. 
An explicit package of interventions is the key to develop a “diagonal” strategy, whereby 
specific disease priorities are used to strengthen the overall structure and function of the 
health system.2121 
The true test of a reform, however, comes when benefits and resources make their way to 
the communities and facilities where actual delivery of services takes place. And this leads 
to the third and final pillar of health system strengthening: the deployment of innovations to 
assure that high-quality services reach all who need them. A particularly promising avenue 
is offered by the mobile phone revolution, with its enormous potential to expand access. 
Equally important are managerial innovations to improve efficiency, such as the delivery of 
NCD care in settings that require less intensity in the use of human resources and medical 
technology but still achieve good levels of quality. 
4. Conclusions 
In order to address the challenge of NCDs in the developing world we need to put in place a 
comprehensive strategy whose components have to be implemented both at the global and 
the local levels. 
First of all, we need to overcome the lack of attention to this development challenge and 
integrate NCDs with communicable diseases in the global health agenda. The main objective 
in this regard should be to expand the MDGs to include health targets related to NCDs 
common in low- and middle-income countries, such as hypertension, diabetes, and cancer. 
WHO, in fact, has already proposed a 25% reduction of deaths attributed to NCDs by 2025 
based on 2010 rates. 
Second, it is necessary to mobilize local and global resources to finance the sustainable 
implementation of comprehensive strategies to address NCDs. Additional global resources 
will be crucial to implement these strategies in low-income countries. 
Third, new health initiatives should consider the integration of prevention and treatment to 
control NCDs in a mutually reinforcing way.  There are lessons to be learned in this respect 
from AIDS, where treatment has enormous impacts in preventing dissemination. Early 
detection and treatment of diabetes is also crucial to avoid the complications of this ailment, 
which require complex and costly interventions that impose pressures both on households 
and health systems. In reality there is no choice but to strengthen health systems so that they 
can offer comprehensive responses to the double burden of disease confronted by low- and 
middle-income countries.  
The attention to the full cycle of care also implies the integration of all sectors whose 
activities are related to health in order to design and implement not only health policies but 
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also healthy policies. This integration is particular relevant to the control of NCDs since 
many of the risk factors related to them fall beyond the limits of the health sector.  
Finally, the health community should strive to create networks that guarantee the continuity 
of care, which is a crucial component of the treatment of most chronic diseases. A related 
transformation involves moving beyond health centers, which by definition concentrate 
human and technological resources, into health spaces, which extend the reach of 
comprehensive care into schools, workplaces, recreational areas, and the homes of those 
who live with a chronic condition. 
We should recognize that the driving force to face the NCD challenge will be located in 
countries. However, no individual nation can respond on its own to the global challenges 
that underlie the risk factors for NCDs. To address them we require international collective 
action in the pursuit of shared goals. A major vehicle in this respect is the development of 
global policy instruments, like the Framework Convention on Tobacco Control. Another 
crucial element comes in the form of global public goods, like the evidence base that must be 
built by rigorously evaluating national innovations. In this way, it will be possible to fuel a 
process of shared learning among countries about what works and in which context. 
International action also requires the mobilization of global solidarity, as the fight against 
HIV/AIDS has so successfully exemplified. NCDs once again offer the world the chance to 
demonstrate that we are all committed to the universal value of health. Everyone has a role in 
this common endeavor: national governments, bilateral agencies, international organizations, 
global partnerships, private business, and the rich diversity of civil society, from professional 
associations and advocacy groups to academic institutions and research centers. 
Giving NCDs their rightful place in the global health agenda will not be an easy task. Yet, if 
we act together to develop a prompt and comprehensive response, major improvements will 
be made in the health and wellbeing of the world population. 
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1. Introduction 
Diseases of poverty are those diseases identified as affecting the poorest and most 
disadvantaged populations in the world. Poverty is one of the main risk factors for the 
conditions, creating exposure to poor water and sanitation; poor nutrition, poor 
environmental conditions that favour the growth and spread of micro-organisms and vectors 
that cause and transmit disease; and lack of education and access to appropriate disease 
prevention, health promotion, treatment and rehabilitative services. Diseases of poverty 
include for instance, the neglected tropical (communicable) diseases (NTDs) which until 
relatively recently were considered low priority for both governments and pharmaceutical 
companies (1–4). Furthermore, diseases of poverty increasingly include the non-
communicable diseases (5–7); hypertension, cardiovascular diseases, diabetes and other 
metabolic diseases and cancers, previously considered diseases of affluence (8–11). While 
there is some variation in the specific drivers that cause and exacerbate the communicable 
and non-communicable diseases for the poor, invariably, the processes and context are 
similar, impeding choices for healthier lifestyles, access to and acceptability and affordability 
of regular and quality care for chronic conditions and strategies for prevention and health 
promotion. In turn, affliction with these diseases hinders economic opportunities and 
development and perpetuates poverty. The disease increases vulnerability and exposure to 
poverty by increasing household expenditure and decreasing household income. 
Through mechanisms provided by the Millennium Declaration and associated Millennium 
Development Goals, the World Economic Forum, the Global Fund, the Bill and Melinda Gates 
Foundation and the US President’s Emergency Fund for AIDS Relief, the global health 
community has highlighted the plight of the poor and vulnerable, and gained support to 
address the major diseases. There is more funding available in global health now than there 
has ever been before (12–14). Major drug companies have committed to free donation of 
particular pharmaceuticals in an effort to achieve elimination of a number of diseases (15). The 
more recent UN Summit on NCDs employed this global advocacy process to elicit support 
from the highest levels of government to address the growing burden of specific chronic 
diseases. Critically however, programmes that result from these global health campaigns have 
historically been characterised largely by disease focused, vertical interventions that treat 
communities as a collective, providing a large scale clinical intervention. Much less attention is 
 
Public Health – Methodology, Environmental and Systems Issues 334 
 
[6] World Health Organization. Global Status Report on Noncommunicable Diseases 2010. 
Geneva: WHO, 2011:1. 
[7] Economist Intelligence Unit. Breakaway: The global burden of cancer- challenges and 
opportunities. London: The Economist Intelligence Unit, 2009. 
[8] García M, Jemal A, Ward EM, et al. Global cancer facts and figures 2007. Atlanta, GA: 
American Cancer Society, 2007. 
[9] Lozano R, Gómez-Dantés H, Lewis S, Torres-Sánchez L, López-Carrillo L. Tendencias del 
cáncer de mama en América Latina y el Caribe. Salud Pública de México 
2009;51(supplement 2):S147-S156. 
[10] World Health Organization. Cancer. Available at:  
http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Accessed 
September 6, 2011. 
[11] Goodarz D, Finucane MM, Lu Y, Singh G, Cowan MJ, Pachiorek CJ et al. National, 
regional, and global trends in fasting plasma glucose and diabetes prevalence since 
1980: systematic analysis of health examination surveys and epidemiological 
studies with 370 country-years and 2.7 million participants. Lancet 
2011;378(9785):31-40. 
[12] International Diabetes Federation. The economic impacts of diabetes. Available at: 
http://www.idf.org/diabetesatlas/economic-impacts-diabetes. Accessed 
September 6, 2011. 
[13] Withrow and colleagues quoted in Wang YC, McPherson K, Marsh T, Gortmaker S, 
Brown M. Health and economic burden of the projected obesity trends in the USA 
and the UK. Lancet 2011;378:815-25. 
[14] Swinburn BA, Sacks, G, Hall KD, McPherson KI, Finegood DT, Moodie M, Gortmaker 
SL. The global obesity pandemic: shaped by global drivers and local environments. 
Lancet 2011;378:804-14. 
[15] Institute of Medicine. Early Childhood Obesity Prevention Policies. Washington, DC: 
IOM, 2011. 
[16] Instituto Nacional de Medicina. Encuesta Nacional de Salud y Nutrición 2006. 
Cuernavaca, Morelos: Instituto Nacional de Salud Pública, 2006. 
[17] King D. The future challenge of obesity. Lancet 2011;378:743-44. 
[18] World Health Organization. About two out of five cancers can be prevented. Available at: 
http://www.who.int/mediacentre/multimedia/podcasts/2010/cancer_day_20100
204/en/index.html. Accessed February 25, 2011. 
[19] Brundtland GH. International Policy Conference on Children and Tobacco. Available at: 
http://www.who.int/director-
general/speeches/1999/english/19990318_international_policy_conference.html. 
Accessed Febraury 27, 2011. 
[20] Porter M. A strategy for health care reform. Toward a value-based system. New 
England Journal of Medicine 2009; 361:109-112. 
[21] Sepúlveda J. Foreword. In: Jamison DT, Breman JG, Measham AR, et al, editors. Disease 
control priorities in developing countries [2nd edition]. New York: Oxford 
University Press for The World Bank, 2006: xiii-xv. 
16 
Diseases of Poverty:  
The Science of the Neglected 
Pascale Allotey, Daniel D. Reidpath and Shajahan Yasin 
Global Public Health, School of Medicine and Health Sciences,  
Monash University, Sunway Campus,  
Malaysia 
1. Introduction 
Diseases of poverty are those diseases identified as affecting the poorest and most 
disadvantaged populations in the world. Poverty is one of the main risk factors for the 
conditions, creating exposure to poor water and sanitation; poor nutrition, poor 
environmental conditions that favour the growth and spread of micro-organisms and vectors 
that cause and transmit disease; and lack of education and access to appropriate disease 
prevention, health promotion, treatment and rehabilitative services. Diseases of poverty 
include for instance, the neglected tropical (communicable) diseases (NTDs) which until 
relatively recently were considered low priority for both governments and pharmaceutical 
companies (1–4). Furthermore, diseases of poverty increasingly include the non-
communicable diseases (5–7); hypertension, cardiovascular diseases, diabetes and other 
metabolic diseases and cancers, previously considered diseases of affluence (8–11). While 
there is some variation in the specific drivers that cause and exacerbate the communicable 
and non-communicable diseases for the poor, invariably, the processes and context are 
similar, impeding choices for healthier lifestyles, access to and acceptability and affordability 
of regular and quality care for chronic conditions and strategies for prevention and health 
promotion. In turn, affliction with these diseases hinders economic opportunities and 
development and perpetuates poverty. The disease increases vulnerability and exposure to 
poverty by increasing household expenditure and decreasing household income. 
Through mechanisms provided by the Millennium Declaration and associated Millennium 
Development Goals, the World Economic Forum, the Global Fund, the Bill and Melinda Gates 
Foundation and the US President’s Emergency Fund for AIDS Relief, the global health 
community has highlighted the plight of the poor and vulnerable, and gained support to 
address the major diseases. There is more funding available in global health now than there 
has ever been before (12–14). Major drug companies have committed to free donation of 
particular pharmaceuticals in an effort to achieve elimination of a number of diseases (15). The 
more recent UN Summit on NCDs employed this global advocacy process to elicit support 
from the highest levels of government to address the growing burden of specific chronic 
diseases. Critically however, programmes that result from these global health campaigns have 
historically been characterised largely by disease focused, vertical interventions that treat 
communities as a collective, providing a large scale clinical intervention. Much less attention is 
 
Public Health – Methodology, Environmental and Systems Issues 
 
336 
focused on the more persistent underlying contributors to diseases of poverty – poverty and 
its other contextual drivers that are intimately interlinked with the diseases and outcomes. 
In this discussion paper, we argue that despite the importance of these contextual drivers, 
they are largely neglected in the science and evidence that contributes to solutions for 
addressing diseases of poverty. We begin with the premise that there are fundamental 
differences in the ways that different disciplines conceptualise health, illness and disease. 
From a biomedical and clinical sciences perspective, diseases of poverty represent ‘slugs, 
bugs and drugs’ and present an ideal opportunity for technical fixes. There is robust 
evidence on the efficacy of these fixes and a strategy based on this evidence presents good 
value for money(16–20). From the perspective of the social sciences however, there is less of 
a separation between the person, the human condition, the environment and the disease 
process. The interest, from a social science perspective is primarily in the social, cultural, 
environmental and economic drivers of poverty and disadvantage, societal norms that 
mitigate marginalisation and the ecological factors that determine who becomes ill, what 
they do about it, and the outcomes of the illness. This would therefore also encompass the 
contextual factors that would enhance or hinder the delivery of a given biomedical strategy 
that involves populations. While robust and theoretically grounded, evidence from social 
science research and solutions that arise from that research may not necessarily present the 
kinds of context free, quantifiable, linear solutions that are frequently desired under 
biomedical research models. Similarly, under social science models, a solution that removes 
proximal causes of suffering without addressing the more distal and complex contextual 
factors that continue to put populations at risk, may not appear to be a desirable end point 
for a strategy. In this paper therefore we explore: 
1. The contextual factors the define diseases of poverty; 
2. The challenges in conceptualising and operationalizing these factors for the purposes of 
generating evidence; 
3. The barriers to the translation of social science generated evidence in global public 
health; and  
4. Some solutions to rebalancing the scientific approaches to neglected.  
To address these questions, this report consists of a critical review of the diseases of poverty 
with a focus on the social, cultural, environmental and other contextual factors that affect 
risk, exposure, treatment and sequelae. In this context, diseases of poverty refer to the 
neglected diseases defined as those diseases which (i) have a disproportionate effect on the 
most disadvantaged sections of the community (the poor and marginalised); and (ii) lack 
investment in research and development for solutions that are explicitly accessible to the 
disadvantaged. We then provide a critical analysis of the sciences required to explore the 
complex nature of neglect in diseases of poverty and offer some suggestions for a broader 
approach to achieving long term solutions.  
2. The context of diseases of poverty 
Most of the conditions identified as diseases of poverty are treatable with currently available 
drugs. That notwithstanding, prevalence of these conditions remains high and the 
conditions persist (21). The neglected tropical diseases campaign for instance has 
relentlessly highlighted the plight of the populations affected by the range of target diseases. 
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A great deal has been made of stigmatization, disfigurement, persistent poverty, poor 
maternal and child health outcomes, poor health and education of children caused by 
infectious diseases (4,22–24). The choice of the word “neglect” is pointed and loaded, forcing 
us to reflect on our social obligations. Inherent in this campaign strategy is an appeal for the 
recognition of human suffering and the need for social justice (25).  
These issues have been raised time and again by researchers working across the areas of 
health and human rights, the social determinants of health (26) anthropology and sociology 
(27–31) to mention a few. At the very least increasing standards of living, provision of the 
basic human rights of food, shelter, and clothing are definitive interventions towards the 
elimination of diseases of poverty. The body of evidence that supports the need for 
structural intervention is significant (32) and is obvious in the lack of these diseases in 
communities with an even marginally higher socio-economic status than “the bottom 
billion” (33). Tackling structural problems is harder because the interventions required are 
more complex; some have suggested too complex to consider (34). However not intervening 
at these levels increases the futility of current efforts. The re-emergence of diseases that were 
supposed to have been eradicated 40 years ago (35) is a case in point.  
Other vulnerabilities highlighted in diseases of poverty include stigmatisation, social 
isolation, and disfigurement. These are vulnerabilities that result from social and cultural 
norms of what is considered normal and who is an acceptable member of the community 
(28,36,37). The effects of these on health relate to values that are less tangible than disease; 
equity, opportunity, access - and require intervention at different levels. 
The basic concern here is not new and to a significant degree, revisits the major, largely 
unresolved debates that raged almost 40 years ago between proponents and opponents of 
Primary Health Care (PHC) (38–40). The critical question is this: does one partition out 
individual, proximal, biological causes (i.e., the disease) and address them as independent 
context free problems, or is there a need for a different approach which attempts to address 
the multiple distal and proximal causes within the context in which they occur? The primary 
health care debates addressed this question in favour of a disease specific approach with the 
introduction of Selective Primary Health Care programmes (41), vertical programmes. This 
establishes the putative ‘pro-poor’ credentials of diseases of poverty, despite the focus on 
identifying unabashed medical and technological fixes – the “magical bullet” to combat 
disease (38).  
The contribution of the biomedical technologies cannot be underestimated. However, unless 
there are also significant interventions to address health and poverty, and the myriad 
marginalising factors in the social, cultural, economic, political and physical environments 
in which affected populations live, there will continue to be neglected people. Even in the 
research into the NTDs there is a distinct and patent disinterest in the social and contextual 
(42). Vaccines and drugs do not cure neglect or poverty and are not sufficient to rescue the 
neglected bottom billion from poverty (18). 
3. The Implementation gap1 
Even if it is decided that it would be safe to focus on the health side of the agenda rather 
than the poverty side, social and environmental (i.e., contextual) concerns cannot be 
                                                 
1 This section draw significantly on earlier work of the authors and re-presents a number of the ideas 
without repeated citation, but also extends on some of those ideas(43). 
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focused on the more persistent underlying contributors to diseases of poverty – poverty and 
its other contextual drivers that are intimately interlinked with the diseases and outcomes. 
In this discussion paper, we argue that despite the importance of these contextual drivers, 
they are largely neglected in the science and evidence that contributes to solutions for 
addressing diseases of poverty. We begin with the premise that there are fundamental 
differences in the ways that different disciplines conceptualise health, illness and disease. 
From a biomedical and clinical sciences perspective, diseases of poverty represent ‘slugs, 
bugs and drugs’ and present an ideal opportunity for technical fixes. There is robust 
evidence on the efficacy of these fixes and a strategy based on this evidence presents good 
value for money(16–20). From the perspective of the social sciences however, there is less of 
a separation between the person, the human condition, the environment and the disease 
process. The interest, from a social science perspective is primarily in the social, cultural, 
environmental and economic drivers of poverty and disadvantage, societal norms that 
mitigate marginalisation and the ecological factors that determine who becomes ill, what 
they do about it, and the outcomes of the illness. This would therefore also encompass the 
contextual factors that would enhance or hinder the delivery of a given biomedical strategy 
that involves populations. While robust and theoretically grounded, evidence from social 
science research and solutions that arise from that research may not necessarily present the 
kinds of context free, quantifiable, linear solutions that are frequently desired under 
biomedical research models. Similarly, under social science models, a solution that removes 
proximal causes of suffering without addressing the more distal and complex contextual 
factors that continue to put populations at risk, may not appear to be a desirable end point 
for a strategy. In this paper therefore we explore: 
1. The contextual factors the define diseases of poverty; 
2. The challenges in conceptualising and operationalizing these factors for the purposes of 
generating evidence; 
3. The barriers to the translation of social science generated evidence in global public 
health; and  
4. Some solutions to rebalancing the scientific approaches to neglected.  
To address these questions, this report consists of a critical review of the diseases of poverty 
with a focus on the social, cultural, environmental and other contextual factors that affect 
risk, exposure, treatment and sequelae. In this context, diseases of poverty refer to the 
neglected diseases defined as those diseases which (i) have a disproportionate effect on the 
most disadvantaged sections of the community (the poor and marginalised); and (ii) lack 
investment in research and development for solutions that are explicitly accessible to the 
disadvantaged. We then provide a critical analysis of the sciences required to explore the 
complex nature of neglect in diseases of poverty and offer some suggestions for a broader 
approach to achieving long term solutions.  
2. The context of diseases of poverty 
Most of the conditions identified as diseases of poverty are treatable with currently available 
drugs. That notwithstanding, prevalence of these conditions remains high and the 
conditions persist (21). The neglected tropical diseases campaign for instance has 
relentlessly highlighted the plight of the populations affected by the range of target diseases. 
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A great deal has been made of stigmatization, disfigurement, persistent poverty, poor 
maternal and child health outcomes, poor health and education of children caused by 
infectious diseases (4,22–24). The choice of the word “neglect” is pointed and loaded, forcing 
us to reflect on our social obligations. Inherent in this campaign strategy is an appeal for the 
recognition of human suffering and the need for social justice (25).  
These issues have been raised time and again by researchers working across the areas of 
health and human rights, the social determinants of health (26) anthropology and sociology 
(27–31) to mention a few. At the very least increasing standards of living, provision of the 
basic human rights of food, shelter, and clothing are definitive interventions towards the 
elimination of diseases of poverty. The body of evidence that supports the need for 
structural intervention is significant (32) and is obvious in the lack of these diseases in 
communities with an even marginally higher socio-economic status than “the bottom 
billion” (33). Tackling structural problems is harder because the interventions required are 
more complex; some have suggested too complex to consider (34). However not intervening 
at these levels increases the futility of current efforts. The re-emergence of diseases that were 
supposed to have been eradicated 40 years ago (35) is a case in point.  
Other vulnerabilities highlighted in diseases of poverty include stigmatisation, social 
isolation, and disfigurement. These are vulnerabilities that result from social and cultural 
norms of what is considered normal and who is an acceptable member of the community 
(28,36,37). The effects of these on health relate to values that are less tangible than disease; 
equity, opportunity, access - and require intervention at different levels. 
The basic concern here is not new and to a significant degree, revisits the major, largely 
unresolved debates that raged almost 40 years ago between proponents and opponents of 
Primary Health Care (PHC) (38–40). The critical question is this: does one partition out 
individual, proximal, biological causes (i.e., the disease) and address them as independent 
context free problems, or is there a need for a different approach which attempts to address 
the multiple distal and proximal causes within the context in which they occur? The primary 
health care debates addressed this question in favour of a disease specific approach with the 
introduction of Selective Primary Health Care programmes (41), vertical programmes. This 
establishes the putative ‘pro-poor’ credentials of diseases of poverty, despite the focus on 
identifying unabashed medical and technological fixes – the “magical bullet” to combat 
disease (38).  
The contribution of the biomedical technologies cannot be underestimated. However, unless 
there are also significant interventions to address health and poverty, and the myriad 
marginalising factors in the social, cultural, economic, political and physical environments 
in which affected populations live, there will continue to be neglected people. Even in the 
research into the NTDs there is a distinct and patent disinterest in the social and contextual 
(42). Vaccines and drugs do not cure neglect or poverty and are not sufficient to rescue the 
neglected bottom billion from poverty (18). 
3. The Implementation gap1 
Even if it is decided that it would be safe to focus on the health side of the agenda rather 
than the poverty side, social and environmental (i.e., contextual) concerns cannot be 
                                                 
1 This section draw significantly on earlier work of the authors and re-presents a number of the ideas 
without repeated citation, but also extends on some of those ideas(43). 
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avoided. An almost exclusive focus on the biomedical overestimates the value of the current 
science, leaving unresolved issues with implementation; that is, embedding a putatively 
effective intervention in a community. It is, after all, not enough to have the perfect cure if 
no one in need is able to receive it. Whether an intervention to be implemented in neglected 
populations has the same benefit in that population as it does in another population is an 
empirical question. 
The randomised control trial (RCT) is widely regarded as the “gold standard” form of 
scientific evidence for establishing the effectiveness of a treatment (i.e., the cause effect 
relationship between treatment and cure), with decreasing levels of evidence treated with 
increasing levels suspicion. The problem with the RCT (and the levels of evidence) is that, in 
a general sense, and contrary to the expectations of many researchers, an RCT does not 
show the effectiveness of a treatment. It shows the effectiveness of a treatment in a 
particular context. Conducting multi-site RCTs, or conducting meta-analyses of multiple 
RCTs supports the generality of the finding. However, the conclusions about effectiveness 
can never be made without acknowledging the very controlled nature of experimental 
studies on which the conclusions about effectiveness are based; and by extension, the 
limitations imposed on generalising the results into less controlled, more realistic, contexts. 
The intention to treat (ITT) analysis of RCTs is a partial acknowledgement of the problems of 
context. In the simplest kind of RCT, patients are randomly allocated to a treatment or a 
control (non-treatment / “usual treatment”) group. Imagine that some people who were 
allocated to the treatment group ended up receiving no treatment – just like the control group. 
Under the ITT analysis, one analyses the results of the intervention as if all the people allocated 
to the treatment group, even those who did not receive treatment, did end up receiving 
treatment. This can seem somewhat counter-intuitive. Why would one analyse data counter to 
the reality of what happened? The analysis, however, establishes the effectiveness of a policy, 
i.e., an intention to treat patients in a particular way. The biological efficacy of the treatment 
should have already been established in early stage trials, and not be in doubt. The ITT 
analysis established the effectiveness of a treatment policy in a particular clinical setting.2 
The use of community-based trials, and 'less rigorous' forms of effectiveness study try to 
capture the likely context in which an intervention might actually be employed; and to some 
degree they support the generalisation of the findings. A caveat, however, always remains, 
because study sites are inevitably different from sites that do not fall under the scrutiny of 
researchers. The context of the research study is not the context in which most lives are 
lived. The generalisation of the conclusions from the research study site to the populations 
that do not live under those conditions goes beyond the science. 
The philosopher of science Nancy Cartwright raised points relevant to this argument in other 
branches of science. The issue is about what one knows in a general sense from doing scientific 
research. One of her points was that what one knows, relates to the context in which the 
research was conducted. Two illustrative examples of hers relate to the electronic transistor and 
to a leaf blowing in an alley. Consider the first example of the electronic transistor; a device used 
to regulate the flow of electricity. The basis of the transistor is grounded in quantum physics – a 
                                                 
2 Interestingly, DDR recently read a description of statistical techniques to avoid the ITT analysis, so 
that the “true” effect of the intervention could be estimated. This presupposes that the idea of a true 
effect devoid of a context in which a treatment is applied makes any sense – which seems very doubtful.  
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theory that is free of contextual considerations. This means that a transistor works the same in 
New York, Bogotá, and Ouagadougou. When you start your laptop computer, which has 
millions of transistors, you do not first have to find out where to make contextual adjustments 
to the transistors. Superficially the science under-pinning the transistor looks to provide the 
very kinds of context-free insight that real science is all about.  
On reflection the context-free nature of the findings are superficial. It is not the case that the 
transistor works in all contexts; rather, industrial manufacturing processes have been 
developed which make sure that the context within the transistors' housings remain the same 
without regard to where the transistors are. In effect, manufacturers have learned to create 
miniature, identical, controlled environments, with a fixed context of operation that conforms 
to an idealised model. The quantum effects work reliably and consistently within the bounds 
of the miniature environment, but without the same certainty outside that environment. 
The second example is of a leaf. Science and engineering has provided significant insights 
into aerodynamics. We have instrumentally valuable theories that predict airflow and lift. 
Empirical work in wind tunnels, computer simulation efforts and theoretical advances allow 
for very precise predictions to be made about how aircraft will behave under a range of 
plausible environmental conditions. Predicting the path, however, that a leaf will follow 
when blown down an alley is beyond us. The idealised understanding that we have of 
aerodynamics allows us to frame and control the context of the science that is done. Aircraft 
wings are crafted so that they maximise our predictive capacity, and conform to our 
understandings of the laws of aerodynamics. When we cannot control the context of the 
science, however, what we actually know becomes far less impressive. 
These observations are not pedantry, and they do not belittle the science that allows us to fly 
aircraft and build computers. What they do suggest, however, is that our science works 
because we know and understand the context in which it is applied. With a change in 
context, the success of the science is less certain. When developing health interventions, we 
do not have the luxury of constructing the context to suit the kinds of interventions or 
designing the intervention to work in a single context. Rather, we need to engage in the type 
of science that embraces interventions that are contextually appropriate.  
At a recent scientific meeting on community directed ivermectin distribution program for 
the control of Onchocerciasis, a report was presented from Nigeria where the intervention 
was not achieving the results anticipated given known effectiveness and the reported high 
coverage of ivermectin. When the gap between coverage and results was investigated, the 
evaluation team found that the villagers were receiving the ivermectin; however, instead of 
taking the tablets themselves, they were distributing them among their cattle. The villagers 
had decided that the economic benefit of a healthy herd far out-weighted the health loss 
they faced by failing to treat their personal affliction with onchocerciasis. 
The science had shown that ivermectin was a clinically effective approach to onchocerciasis 
control in one context. Community-based trials confirmed the effectiveness after scaling up 
the intervention in another context (44); and the economic analysis showed that it was cost-
effective (45,46). This was the 'truth' as revealed by the science of fixed contexts. The reality, 
however, was that the effectiveness of the intervention depended on a range of contextual 
factors – such as competing economic incentives. Having located the research in fixed (or 
well regulated) contexts, the likely variability of outcome that occurs in the wilds of real life, 
did not enter into any decisions about effectiveness. 
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avoided. An almost exclusive focus on the biomedical overestimates the value of the current 
science, leaving unresolved issues with implementation; that is, embedding a putatively 
effective intervention in a community. It is, after all, not enough to have the perfect cure if 
no one in need is able to receive it. Whether an intervention to be implemented in neglected 
populations has the same benefit in that population as it does in another population is an 
empirical question. 
The randomised control trial (RCT) is widely regarded as the “gold standard” form of 
scientific evidence for establishing the effectiveness of a treatment (i.e., the cause effect 
relationship between treatment and cure), with decreasing levels of evidence treated with 
increasing levels suspicion. The problem with the RCT (and the levels of evidence) is that, in 
a general sense, and contrary to the expectations of many researchers, an RCT does not 
show the effectiveness of a treatment. It shows the effectiveness of a treatment in a 
particular context. Conducting multi-site RCTs, or conducting meta-analyses of multiple 
RCTs supports the generality of the finding. However, the conclusions about effectiveness 
can never be made without acknowledging the very controlled nature of experimental 
studies on which the conclusions about effectiveness are based; and by extension, the 
limitations imposed on generalising the results into less controlled, more realistic, contexts. 
The intention to treat (ITT) analysis of RCTs is a partial acknowledgement of the problems of 
context. In the simplest kind of RCT, patients are randomly allocated to a treatment or a 
control (non-treatment / “usual treatment”) group. Imagine that some people who were 
allocated to the treatment group ended up receiving no treatment – just like the control group. 
Under the ITT analysis, one analyses the results of the intervention as if all the people allocated 
to the treatment group, even those who did not receive treatment, did end up receiving 
treatment. This can seem somewhat counter-intuitive. Why would one analyse data counter to 
the reality of what happened? The analysis, however, establishes the effectiveness of a policy, 
i.e., an intention to treat patients in a particular way. The biological efficacy of the treatment 
should have already been established in early stage trials, and not be in doubt. The ITT 
analysis established the effectiveness of a treatment policy in a particular clinical setting.2 
The use of community-based trials, and 'less rigorous' forms of effectiveness study try to 
capture the likely context in which an intervention might actually be employed; and to some 
degree they support the generalisation of the findings. A caveat, however, always remains, 
because study sites are inevitably different from sites that do not fall under the scrutiny of 
researchers. The context of the research study is not the context in which most lives are 
lived. The generalisation of the conclusions from the research study site to the populations 
that do not live under those conditions goes beyond the science. 
The philosopher of science Nancy Cartwright raised points relevant to this argument in other 
branches of science. The issue is about what one knows in a general sense from doing scientific 
research. One of her points was that what one knows, relates to the context in which the 
research was conducted. Two illustrative examples of hers relate to the electronic transistor and 
to a leaf blowing in an alley. Consider the first example of the electronic transistor; a device used 
to regulate the flow of electricity. The basis of the transistor is grounded in quantum physics – a 
                                                 
2 Interestingly, DDR recently read a description of statistical techniques to avoid the ITT analysis, so 
that the “true” effect of the intervention could be estimated. This presupposes that the idea of a true 
effect devoid of a context in which a treatment is applied makes any sense – which seems very doubtful.  
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theory that is free of contextual considerations. This means that a transistor works the same in 
New York, Bogotá, and Ouagadougou. When you start your laptop computer, which has 
millions of transistors, you do not first have to find out where to make contextual adjustments 
to the transistors. Superficially the science under-pinning the transistor looks to provide the 
very kinds of context-free insight that real science is all about.  
On reflection the context-free nature of the findings are superficial. It is not the case that the 
transistor works in all contexts; rather, industrial manufacturing processes have been 
developed which make sure that the context within the transistors' housings remain the same 
without regard to where the transistors are. In effect, manufacturers have learned to create 
miniature, identical, controlled environments, with a fixed context of operation that conforms 
to an idealised model. The quantum effects work reliably and consistently within the bounds 
of the miniature environment, but without the same certainty outside that environment. 
The second example is of a leaf. Science and engineering has provided significant insights 
into aerodynamics. We have instrumentally valuable theories that predict airflow and lift. 
Empirical work in wind tunnels, computer simulation efforts and theoretical advances allow 
for very precise predictions to be made about how aircraft will behave under a range of 
plausible environmental conditions. Predicting the path, however, that a leaf will follow 
when blown down an alley is beyond us. The idealised understanding that we have of 
aerodynamics allows us to frame and control the context of the science that is done. Aircraft 
wings are crafted so that they maximise our predictive capacity, and conform to our 
understandings of the laws of aerodynamics. When we cannot control the context of the 
science, however, what we actually know becomes far less impressive. 
These observations are not pedantry, and they do not belittle the science that allows us to fly 
aircraft and build computers. What they do suggest, however, is that our science works 
because we know and understand the context in which it is applied. With a change in 
context, the success of the science is less certain. When developing health interventions, we 
do not have the luxury of constructing the context to suit the kinds of interventions or 
designing the intervention to work in a single context. Rather, we need to engage in the type 
of science that embraces interventions that are contextually appropriate.  
At a recent scientific meeting on community directed ivermectin distribution program for 
the control of Onchocerciasis, a report was presented from Nigeria where the intervention 
was not achieving the results anticipated given known effectiveness and the reported high 
coverage of ivermectin. When the gap between coverage and results was investigated, the 
evaluation team found that the villagers were receiving the ivermectin; however, instead of 
taking the tablets themselves, they were distributing them among their cattle. The villagers 
had decided that the economic benefit of a healthy herd far out-weighted the health loss 
they faced by failing to treat their personal affliction with onchocerciasis. 
The science had shown that ivermectin was a clinically effective approach to onchocerciasis 
control in one context. Community-based trials confirmed the effectiveness after scaling up 
the intervention in another context (44); and the economic analysis showed that it was cost-
effective (45,46). This was the 'truth' as revealed by the science of fixed contexts. The reality, 
however, was that the effectiveness of the intervention depended on a range of contextual 
factors – such as competing economic incentives. Having located the research in fixed (or 
well regulated) contexts, the likely variability of outcome that occurs in the wilds of real life, 
did not enter into any decisions about effectiveness. 
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There are two important corollaries to this. The first: imagine two interventions both of 
which are significantly more effective than no treatment. Furthermore, in clinical trials 
researchers have established that intervention A is significantly more effective than 
intervention B (i.e., 0A B> > ). When the context changes from the controlled research 
environment to point of implementation, the apparent magnitude of the effect of the 
interventions can reverse, with intervention B having a greater effect than intervention A 
(i.e., 0B A> >  or 0B A> = ). This will occur if, at the stage of implementation, the more 
effective A cannot be embedded in the community.  
The second corollary, which is an extension of the first, is that interventions that seem to be 
cost-ineffective in one context maybe the cost-effective interventions in another context, and 
the cost-effective intervention in another context will be the cost-ineffective intervention in 
this context. Continuing to use interventions A and B, following the effectiveness studies, 
the economic analysis established that A is more cost-effective than B. However, on 
implementation, when A fails to achieve any community up-take, B becomes the more cost-
effective of the interventions. The implications of this are hard to under-estimate.  
Decision making based on effectiveness and cost-effectiveness, which is a rational approach 
to the optimal allocation of scarce resources, may fail dramatically if the information on 
which the decision is based comes from the partial science of fixed contexts. 
As Allotey et al. observed (p.3), effectiveness is regarded as the appropriate end point for 
most intervention research. But knowing that a treatment is effective in routine clinical care 
is not enough, particularly in resource poor settings (i.e., the settings of the neglected). The 
goal must be the sustainable adoption of the intervention by the health systems and the 
target population, and not simply the establishment of effectiveness in a monitored clinical 
population. In other words, an intervention must become embedded; firmly integrated as 
part of the health system and the health culture of the disease endemic setting. It must be 
available, acceptable, accessible and affordable to those who need it; used appropriately, 
and become a part of the disease prevention, treatment seeking culture. 
Biomedical research is neither intended to address nor capable of addressing questions 
about implementation. Thus, not only is the value of the biomedical research limited by our 
lack of research on the contextual effects associated with implementation, it is also outside 
the expertise of those scientists to address the issues. 
4. The science of the neglected 
To this point we have argued that the approach to the neglected diseases has leveraged the 
idea of the vulnerable and neglected population to advance an argument for providing 
additional resources to the biomedical scientists so that they can develop cures for neglected 
diseases – “vaccines against poverty”. We then discuss the evidence about social 
vulnerability to disease, and the possibility of social interventions that address more distal 
causes of disease – intervening before the biomedical concerns arise. Finally we argued that 
the focus on proximal interventions is based on a flawed notion of the under-lying science 
and the generality of that science. In effect we argue for the development of contextually 
relevant science capable of accounting for social and environmental factors affecting the 
implementation of interventions. 
What is missing from our discussion is (i) the research that supports the implementation of 
proximal cures, and (ii) the research that supports distal interventions that change the social 
 
Diseases of Poverty: The Science of the Neglected 
 
341 
vulnerability of neglected populations to disease. The obvious place to look for this research 
is in the social sciences literature, or the intersection between the clinical, biomedical, and 
social sciences literature. 
In a bibliometric analysis of four diseases of poverty (chikungunya, dengue, leishmaniasis, 
and onchocerciasis) we found that social sciences contribute to less than 2% of the published 
research (42). That was a generous counting of the social sciences contribution. The research 
that was funded was generally insipid, because it was there to act as a hand-maiden for 
biomedical research, never intended to support a research agenda of implementation or 
distal intervention. And the lack of a social sciences research agenda has a negative impact 
on the value of the biomedical research that is conducted, and limits our options for 
intervention to proximal cures. 
To say that the social sciences have been totally overlooked in the global health efforts would 
however be inaccurate. The value of the social sciences up until now, however, is qualified. In 
the area of NTDs, evidence from anthropological studies on stigmatization, the lived 
experiences of patients disfigured by diseases such as leprosy, yaws, onchocerciasis and 
filariasis, and the effects of these on health seeking, access to and quality of care, have been used 
particularly to support advocacy (4,18,28,53,24,54,55). The research that explores the reasons for 
the failures of programmes for instance is not insubstantial. Anthropological research has 
provided data on the importance of cultural and social constructions of illness and disease. We 
have some understanding of the different levels of practitioners, how and why they might be 
consulted and their role (or lack thereof) within a formal health system. There is evidence from 
the social sciences of the complexities and pathways to health seeking, the economic and social 
drivers, the effects of gender and other social determinants. Health economics has shed light on 
willingness of patients or clients to pay for different types of health services, interventions and 
pharmaceuticals; and the local market forces that hinder or enable distribution of and access to 
health services and pharmaceuticals. Health services and health systems research provides 
rigorous data on the socio-economic and political context in which local, national and global 
health policy supports (or otherwise) disease control programs.  
In broad terms however, social science research in this area has to date focused largely on 
the evaluation of the implementation process and on factors that will enhance community 
participation in community based programs (56). Both the process and the outcome 
indicators therefore relate to the administration of treatment and where appropriate, a short 
term reduction in NCDs. In other words these approaches to ‘deploying’ the social sciences 
are rather utilitarian and often tokenistic (43). The consequences to this are the often 
questionable quality of the social science evidence generated. Implementation research for 
instance, if well designed and implemented has the potential to contribute significantly to 
disease control efforts – however it is an area of research that is poorly funded (43) The 
problem arises often because social scientists are invited onto teams to undertake specific 
research projects rather than being a conceptual part of the planning of the intervention (27) 
To obtain the higher objective of improving the health and reducing vulnerabilities, it is 
important for researchers, policy makers and funding agencies to broaden the perspective 
on the range of research that is needed to address neglected diseases of neglected 
populations, and to rethink the types of integrated interventions and the nature of evidence 
to show effectiveness. There is a need to refocus on the health of neglected populations - 
health as an enabling process (38) - and not merely removing disease.  
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There are two important corollaries to this. The first: imagine two interventions both of 
which are significantly more effective than no treatment. Furthermore, in clinical trials 
researchers have established that intervention A is significantly more effective than 
intervention B (i.e., 0A B> > ). When the context changes from the controlled research 
environment to point of implementation, the apparent magnitude of the effect of the 
interventions can reverse, with intervention B having a greater effect than intervention A 
(i.e., 0B A> >  or 0B A> = ). This will occur if, at the stage of implementation, the more 
effective A cannot be embedded in the community.  
The second corollary, which is an extension of the first, is that interventions that seem to be 
cost-ineffective in one context maybe the cost-effective interventions in another context, and 
the cost-effective intervention in another context will be the cost-ineffective intervention in 
this context. Continuing to use interventions A and B, following the effectiveness studies, 
the economic analysis established that A is more cost-effective than B. However, on 
implementation, when A fails to achieve any community up-take, B becomes the more cost-
effective of the interventions. The implications of this are hard to under-estimate.  
Decision making based on effectiveness and cost-effectiveness, which is a rational approach 
to the optimal allocation of scarce resources, may fail dramatically if the information on 
which the decision is based comes from the partial science of fixed contexts. 
As Allotey et al. observed (p.3), effectiveness is regarded as the appropriate end point for 
most intervention research. But knowing that a treatment is effective in routine clinical care 
is not enough, particularly in resource poor settings (i.e., the settings of the neglected). The 
goal must be the sustainable adoption of the intervention by the health systems and the 
target population, and not simply the establishment of effectiveness in a monitored clinical 
population. In other words, an intervention must become embedded; firmly integrated as 
part of the health system and the health culture of the disease endemic setting. It must be 
available, acceptable, accessible and affordable to those who need it; used appropriately, 
and become a part of the disease prevention, treatment seeking culture. 
Biomedical research is neither intended to address nor capable of addressing questions 
about implementation. Thus, not only is the value of the biomedical research limited by our 
lack of research on the contextual effects associated with implementation, it is also outside 
the expertise of those scientists to address the issues. 
4. The science of the neglected 
To this point we have argued that the approach to the neglected diseases has leveraged the 
idea of the vulnerable and neglected population to advance an argument for providing 
additional resources to the biomedical scientists so that they can develop cures for neglected 
diseases – “vaccines against poverty”. We then discuss the evidence about social 
vulnerability to disease, and the possibility of social interventions that address more distal 
causes of disease – intervening before the biomedical concerns arise. Finally we argued that 
the focus on proximal interventions is based on a flawed notion of the under-lying science 
and the generality of that science. In effect we argue for the development of contextually 
relevant science capable of accounting for social and environmental factors affecting the 
implementation of interventions. 
What is missing from our discussion is (i) the research that supports the implementation of 
proximal cures, and (ii) the research that supports distal interventions that change the social 
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vulnerability of neglected populations to disease. The obvious place to look for this research 
is in the social sciences literature, or the intersection between the clinical, biomedical, and 
social sciences literature. 
In a bibliometric analysis of four diseases of poverty (chikungunya, dengue, leishmaniasis, 
and onchocerciasis) we found that social sciences contribute to less than 2% of the published 
research (42). That was a generous counting of the social sciences contribution. The research 
that was funded was generally insipid, because it was there to act as a hand-maiden for 
biomedical research, never intended to support a research agenda of implementation or 
distal intervention. And the lack of a social sciences research agenda has a negative impact 
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health as an enabling process (38) - and not merely removing disease.  
 
Public Health – Methodology, Environmental and Systems Issues 
 
342 
Critical opportunities are missed through the lack of integration of data from the social 
science disciplines. Health and illness are social constructs and as such, the disciplines and 
theories that help us to make sense of these issues should be as much a part of the agenda as 
pharmaceutical developments. It is tragic, for instance that so much is made of the suffering 
of patients of neglected tropical diseases, but there is little if any evidence in the funded 
programmes that addresses how families and communities affected by these diseases could 
be supported to deal with the social and economic sequelae. Studies of outbreaks of 
infectious diseases in South East Asia also highlight the almost exclusive disease focus of 
public health interventions and the total neglect of the mental health and social and economic 
consequences of these interventions (described as social chaos) on the populations affected 
(57). To address these issues would require a more complex understanding of the community 
and its dynamics and the broader political context in which the affected populations live. 
Studies in gender for instance have produced frameworks that facilitate the integration of 
gender across programmes. Similar approaches have been suggested for use with the social 
sciences (27,43,57,58) 
5. Alternative models 
There are essentially two issues that are conflated in the advocacy and the current approach 
to diseases of poverty. The first is the focus on neglect and vulnerabilities – as highlighted 
above, a significantly complex issue which we, as global health professionals, have an 
obligation to address (47). These issues cannot however, be fully addressed by vertical 
programmes. The second is the specific issue of disease which forms an important part of 
the factors which may be the cause of, but also exacerbate and sustain poverty and 
vulnerability. This issue is the focus of vertical programmes (41). Interventions to address 
these two issues should clearly not be mutually exclusive, but often are.  
The question of which general approach is better does depend on the expected outcomes but 
may of course be empirical. Assuming that the expected goal, as most global health 
programs stipulate, is the improvement of the health of populations, how would a poverty 
reduction, empowerment, equity based development programme fare against a preventive 
chemotherapy programme for instance, or one that combined approaches. Studies that test 
this empirically are rarely designed, in part because the different interventions seek different 
outcomes. Vertical programmes measure success in terms of reductions in the occurrence of 
specific diseases. Contextually based, comprehensive programmes count some broader 
measure of well-being as the desirable outcome. However it is difficult to imagine that there 
would be no value added to ensuring that the pieces lock together seamlessly. Programmes 
that privilege longer term improvements in the living conditions over merely achieving 
significant coverage of mass drug administration have shown a greater impact in rescuing 
communities and tackling concerns about neglected diseases and neglected populations 
(48). These tend to be smaller programmes, with significant input from communities and do 
not operate under the pressures of reporting to funders. Furthermore, when the outcomes of 
such programmes are published, the robustness of the ‘evidence’ is often questioned 
because they were not designed as ‘empirical’ studies (4,49–51). 
There are data that could arguably have the potential to provide a proxy indication of how 
the different approaches measure up. We know for instance that significant funds have been 
invested into global public health most of which have gone into vertical programmes 
dealing with the big three and more recently, the neglected tropical diseases (13,52). Data 
 
Diseases of Poverty: The Science of the Neglected 
 
343 
are also available on investments into other programmes designed to meet the other 
millennium development goals, which also address the vulnerabilities highlighted by the 
neglected disease advocates. A cost effectiveness analysis of these investments could 
technically provide an indication of what a dollar could purchase per intervention type. 
However the success of programmes still tends to be measured often by their coverage 
rather than by longer term outcomes, and in global health, seldom by improvements in the 
levels of poverty and broader development. Reasons for this include the time limited nature 
of programmes; the discipline focus of people involved in programmes, that is health sector 
and therefore the disease focus – lack of capacity to design the relevant research, monitoring 
and evaluation tools that would allow a focus that were any broader.  
To focus on the addressing neglect and vulnerabilities from a health perspective would 
require a different way of conceptualising the link between poverty, health and disease, 
acknowledging the complexities and developing appropriate and realistic solutions. This 
would mean more than a simple combination of individual supplementary (vertical) 
programmes. It would also necessarily require a redefinition of outcomes and successes, 
working to a longer time frame than is currently adhered to in disease based vertical 
programmes. A detailed discussion is beyond the scope of this paper.  
6. Conclusion 
Diseases of poverty represent a rich and dynamic interplay between the context of people’s 
lives and the disease process. The interaction is complex and evolves within a social and 
cultural context as much as it does within a physical and biological context. Understanding 
this complex dynamic is crucial for the sustainable management of diseases of poverty. The 
evidence from the health literature, however, is that there is little investigator driven social 
science research to speak of in the diseases of poverty, and a similarly poor presence of 
interdisciplinary science. Without this, our understanding and management of diseases of 
poverty is inevitably reduced to a strategy that relies on a repetitive, reductionist flat-world 
science to overcome an acknowledged complex system. 
The research to address neglected diseases of poverty needs more sophisticated funders and 
priority setters. Pharmaceuticals (including vaccines) are critical, but they are not the only 
solutions, and their final application is not in flat worlds. Their application is in complex 
dynamic worlds in which pathologies evolve to exploits the social nature of humans. Our 
current understanding of the dynamic, and our understanding of how to develop 
sustainable approaches to disease management are poor. There are no research templates to 
overcome this, and the silos of current science into the diseases of poverty have discouraged 
the development of genuinely interdisciplinary research. 
As a major recommendation there is a need to reconceptualise the outcomes for addressing 
vulnerability and the addressing the health needs of the neglected, poor, disenfranchised 
and dispossessed. Recognising that the challenges cannot be reduced to simplistic 
biomedical solutions is a first step. Global public health is ideally placed to bring together 
the different disciplines to engage in these developments.  
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but will interest his patient in the care of the human frame,  
in diet and the cause and prevention of disease. 
Thomas Alva Edison (1847-1931),  
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1. Introduction 
1.1 Health in ontogenesis 
Health in the human life cycles produces healthy longevity. The construction of health-
longevity can be accomplished through primary prophylaxis, namely education, promotion, 
training, protection and prevention. 
As such, medicine seeks to achieve the prevention of disease; it aspires to treat all 
pathologies, as secondary prophylaxis and leads to recovery after illnesses, as tertiary 
prophylaxis. 
The common elements of longevity health sciences - LHS (Cutler et al., 2005a) and mental 
health - MH (Knapp et al., 2007) consist of personal sanogenesis at an individual level, and 
public health in relation to the societal dimension. 
1.2 Objectives for health-longevity medicine. Past, present and future 
Nowadays it is time to promote and apply the ancient wisdom concerning health and 
healing concepts alongside medical ones. 
Actual scientific data about health strategy (human biology and risk factors, behaviour and 
lifestyle, health care systems, the environment), technological medical progress, information 
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technology and information technology and communication (ITC), together with experience 
and the practice of developed countries should be integrated at a regional and global level. 
In addition, new concepts can be used and applied to the understanding of the complexity 
of healthy-longevity medicine at a global level: 
- regional and global programmes, strategies and actions (WHO, Regional Office for 
Europe, 1986; Knapp et al., 2007); 
- new paradigms for medical education: from health promotion and protection to 
longevity health sciences and life extension (S. Riga et al., 2010d); 
- the implementation of a healthy diet and a physically active lifestyle (Simopoulous, 
2005); 
- nutraceuticals and nutrigenomics (D. Riga and S. Riga, 2011b); 
- the palaestra paradigm (D. Riga and S. Riga, 2010a); 
- synergistic anti-stress, anti-impairment and anti-ageing drugs and strategies (D. Riga 
and S. Riga, 1995-2005); 
- regenerative and pro-longevity medicine (de Grey, 2004; D. Riga et al., 2004a; S. Riga et 
al., 2004b); 
- a new pyramid of health-longevity services (S. Riga et al., 2011a); 
- health, longevity and ecology - an integrated paradigm (D. Riga et al., 2010b); 
- the bio-psycho-socio-ecological dimension of human being (S. Riga et al., 2010c). 
2. Health and preventative medicine in ancient times 
2.1 Prophylaxis and physical activity in traditional Chinese medicine 
Dating back thousands of years, the practice of traditional Chinese medicine includes 
Yinyangism and Daoism as philosophical concepts, holistic and integrative medical 
concepts, phytotherapy (herbal medicine) and dietary therapy, acupuncture, Shiatsu and 
Tui na massage, movement therapy, Qigong, Taiji and other methods of maintaining health 
and vitality. 
A remarkable characteristic of the Chinese system of natural healthcare is its prophylactic 
side. A programmatic document in this direction is the first Chinese medical text (c2600 
B.C.). It stipulates: Superior doctors prevent the disease. Mediocre doctors treat the disease before 
evident. Inferior doctors treat the full-blown disease (Unschuld, 2003). In addition, this famous 
manuscript Huángdi Neijing Suwen (Inner Canon: Basic Questions), also known as The  Inner 
Canon of Huángdi or Yellow Emperor’s Inner Canon, book written between 2698 B.C. - 2596 B.C. 
presents a dialogue between the Yellow Emperor (Huángdi) and Qibo (Qi Bo,  Chi Bo), his 
minister and advisor, an excellent physician and the father of massage treatment. Another 
quote from this treatise shows the importance of prophylaxis: To treat an illness after it has 
already set in or to smother a riot already spread is liked digging for a fountain when you’re already 
thirsty or making weapons after the war has already begun. Isn’t it too late, I wonder? (Lin, 2000).  
A further defining feature of the traditional Chinese therapeutic system is the promotion of 
movement and physical activity in maintaining health and treating illness. The famous 
Chinese physician Huà Tuó (c145 A.D. - c208 A.D.), the first person in China to use 
anaesthesia in surgery, created a series of exercises called Wuqinxi or Frolics (Exercise) of the 
Five Animals, towards the end of the 2nd Century A.D. The exercises mimicked the 
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movements of the tiger, the deer, the bear, the monkey and the crane. In Huà Tuó’s medical 
system, the therapeutic use of movement was inspired from nature: Running water never 
grows stale, and the doorpost is never eaten away by wood decay. For the same reason, if we do 
physical activity on a regular basis, we can remain in good health and keep disease away. Regular 
exercises stimulate blood flow and the circulation of the qi (energy), thus maintaining the agility of 
the body (Lin, 2000). 
2.2 Preventative medicine in Greek and Roman antiquity 
The doctrines of Mediterranean ancient medicine are also based on dietary (rational 
nutrition) and physical exercises.  
Hippocrates of Cos (Kos), c460 B.C. - c370 B.C., one of the most outstanding figures in the 
history of medicine, emphasized the importance of diet: Let thy food be thy medicine and thy 
medicine be thy food (Hanson, 2006). Moreover, the veneration of the human body as well as 
daily and professional physical activity were extensively spread in Hellas. Palaestra (special 
arranged places and also a type of physical exercises) and the Ancient Olympic Games are 
only two examples.  
The Romans, who conquered, took over and enriched Greek civilization, also had great respect 
for a harmonious development of the human body. Besides this, they pointed out the necessity 
and simultaneity of the sanogenetic binomial psychic ↔ body. The old adage: Mens sana in 
corpore sano, Satyrae X (Book IV, Satyrae X, Line 356 - 10.356), Decimus Iunius Iuvenalis (c60 A.D. 
- c135 A.D.), Roman poet, in still famous and up-to-date even now (D. Riga et al., 2009c). 
The principles of preventative medicine and competitive health-vitality have been well-
documented in human history since ancient times. Unfortunately, current civilizations and 
human beings could not manage, up to the present, to transform these principles into their 
daily routine or integrate them into their lifestyles.     
3. From health to disease  
3.1 Stress bio-medicine 
From this perspective, the strategic key in public health is represented by stress medicine 
(stressology), adaptology and MH (S. Riga and D. Riga, 2008). 
Figure 1 shows the multi-factorial progress, which localizes stress bio-medicine at the 
boundary/interface between normality-health-longevity and ageing-disease. 
The integrative concept (from molecule to individual and society) groups together:  
- the diseases of lifestyle/adaptation/civilization (Selye, 1976);  
- stress-related disorders, burnout and chronic fatigue syndrome (Cooper, 1996; WHO. 
ICD-10, 1992);  
- the free radical theory of ageing and free radical diseases (Harman, 1984);  
- The oxidative stress theory of ageing and oxidative stress-associated diseases (Cutler et 
al., 2005c);  
- antioxidant deficit diseases (in food, blood and tissues) (Slater and Block, 1991; Muller 
et al., 1992). 
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Fig. 1. Oxidative stress in stress bio-medicine, health, ageing and disease 
In conclusion, the new concept of stress in bio-medicine represents the primary cause (the 
beginning) of various human illnesses: pathological manifestations of acute and chronic 
psychic stress, stress-related disorders, free radical diseases, oxidative stress-associated 
pathologies, accelerated impairment and ageing (premature senescence), diseases of lifestyle 
and civilization, nervous and body inflammatory-degenerative pathologies and senility. 
3.2 Antagonism of health construction versus human pathology 
Public health strategies and policies, as well as everyday preventative-prophylactic and 
medical-curative practice, are substantiated in dynamics by two opposite tetrads (cascades), 
(D. Riga and S. Riga, 2007; S. Riga et al., 2009a). These concepts also represent two 
antagonistic fundamental pathways: 
- stress ↔ ageing, entropic, aetio-pathogenic tetrad: distress/stress-dependent disorders  
wear and tear/impairment  premature/accelerated ageing  poly-pathology; 
- health ↔ longevity, anti-entropic, protective-therapeutic tetrad: anti-
stress/eustress/adaptation  anti-impairment/vitality/resistance  anti-
ageing/active, healthy longevity  anti-illnesses/anti-diseases.  
Therefore, health construction is in total opposition to the development of human 
pathology.  Health construction promotes and protects sanogenesis and impedes the 
appearance and evolution of disease.  
3.3 Dynamic structure of destructive cascade 
Stress ↔ ageing tetrad (distress ↔ impairment ↔ ageing ↔ disease) is a progressively 
destructive, entropic and time-dependent phenomenon: from primary processes and chronic 
manifestations (distress, impairment, ageing) to chronic illnesses. The dynamic pattern of 
this cascade is shown in Figure 2 (D. Riga and S. Riga, 2007).   
 




Fig. 2. Dynamic structure of destructive cascade:  
distress  impairment  ageing  disease.  
From human healthy life/longevity to old age/poly-pathologies 
Time acts in a very complex way: 
- as a harmful amplifier – the initial subclinical stages turn into final clinical phases, 
namely into manifest diseases; and 
- as a continuous initiator, by transforming causes into effects, which in their turn 
become secondary and multiple causes for new negative consequences; thus, the four 
components of the cascade successively represent both cause and effect.  
In addition, free radical attacks, oxidative stress and antioxidant deficits are amplifiable and 
worsen in accordance with a pattern of destructive synergism. Therefore, the accumulation 
of distress, impairment and ageing is aggravated in oxidative stress (chronic) diseases 
(Cutler, 1996; Miwa et al., 2008).    
3.4 Risk factors and preclinical stages of ageing and disease 
”Risk factor” (an epidemiological concept) is a variable (characteristic, condition or behaviour) 
associated with an increased risk of disease (or infection, or injury). Sometimes, “determinant” 
is also used, being a variable associated with either increased or decreased risk. Risks factors 
are co-relational and not necessarily causal, since correlation does not imply causation.  
They are categorized into intrinsic “within oneself” and extrinsic “outside” influences. 
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In another classification, risk factors are divided into four domains:  
- biological risk factors. Firstly, they are represented by age, gender and race (ethnicity), which 
are non-modifiable. In addition, heredity, genetic predisposition and inherited familial risks 
are all very important, as well as other diseases and conditions (among others, hypertension, 
high cholesterol levels, obesity and diabetes mellitus); 
- behavioural risk factors are associated with a person’s daily choices, emotions and 
actions. Mainly they are inappropriate habits: level of acute and/or chronic distress, dietary 
factors (eating customs, fat intake, alcohol consumption and excess), tobacco smoking, intake of 
multiple medications, level of physical activity (often a lack of physical exercises, sedentary 
behaviour);  
- environmental risk factors with regards to the interplay of individuals with their 
environment: geo-graphic location, home hazards, hazardous features in the public 
environment, industrial toxins and poisons; the chaotic technological development of 
civilization; 
- socio-economic risk factors connected with a person’s social conditions and the economic 
status of the individual which has a direct impact on access to healthcare: occupation, 
social status, other social determinants of health (poor housing, low education, low degree of 
social interaction, low income, limited access to social healthcare services). 
Some examples of risk factors connected to a specific disease in the second part of life and in 
the ageing period: 
- cardiovascular diseases: heredity (genetic factors); other diseases (obesity, 
hypertension, diabetes); stressful lifestyle; smoking; wrong and harmful diet habits 
(not drinking enough water, too much salt in the diet, increased fate and/or sugar 
intake, high LDL-cholesterol); lack of  physical activity and exercises; drug use, abuse 
and combinations;  
- stroke: advanced age; hypertension; previous stroke or transient ischemic attacks; 
diabetes; high LDL-cholesterol levels; smoking;  
- Alzheimer’s disease: advancing age; family history and heredity (risk and deterministic 
genes);  
- complex interactions among genes and other risk factors, resulting from defective 
lifestyle and the deficient management of health conditions (i.e. head trauma, heart-
brain connection and pathology, cardiovascular risk factors, interference with vascular 
dementia, low level of education); 
- breast cancer: age, gender and racial factors; heredity (BRCA 1 and BRCA 2 autosomal 
dominant genes), prior cancers, hormones and obesity; dietary factors; environmental 
chemical and physical agents; socioeconomic factors. 
Controlling health risk factor, in relation to type, number and intensity, is paramount to the 
development of a global health strategy. Risk factors: 
- are strong distressors;  
- disturb the good functioning of human socioeconomic organization; 
- increase the cost of healthcare services; and  
- are taken into account as anti-globalization factors. 
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The impact of risk factors on health is represented by preclinical (infra-, sub-clinical) phases 
of disease, which are the chronic-silent periods. The action of risk factors, diseases of 
lifestyle and silent pathologies (e.g. hypertension, hyperglycaemia etc.) cumulate their 
negative effects and thus they self-amplify into cascades of diseases. 
In the pre-senescence and pre-disease period of the individual, knowledge of the preclinical 
phase of disorders obliges one to perform sub-clinical diagnosis and evaluation, and as a 
consequence determines personalized prevention.   
The preclinical diagnosis of ageing and disease involves the investigation of oxidative stress 
-inflammatory disorders by establishing a pre-morbid individual profile: assays of 
biomarkers for the oxidative stress - inflammation status (Cutler et al., 2005c). 
The increase of oxidative damages (evaluated in blood/serum, urine and breath) and a 
decrease of protective/defence antioxidant capacity (in serum), together with the 
augmentation of inflammation markers (in serum) will lead over the course of time to 
changes in the proper state of differentiation (Cutler, 2005b): cancer, senescence and 
senility.  
4. Construction of human health-longevity 
4.1 Longevity health sciences and mental health. Common characteristics 
LHS and MH are in essence a form of health promotion associated with preventative 
medicine. For this reason (S. Riga et al., 2009a):  
- the complementarity of LHS  MH is evident as a binomial: the construction of one of 
them meaning the development of the other one and vice versa; 
- the superposition of LHS with MH is total during the last cycles of life: mature adult  
old adult  3rd age (65-85 years)  4th age (over 85 years); 
- The dependence of LHS  MH coupled to ecology (human, social and environmental) 
is manifested antagonistically: 
(–) in a negative register, stress ↔ ageing tetrad: aetio-pathogenic and morbigenerating 
factors, ways and processes; 
(+) in a positive register, health ↔ longevity tetrad: resources, strategies and therapies 
for longevity and mental health. 
Essentially, bio-medical gerontology is the global and interdisciplinary study of ageing 
phenomena in phylogeny, ontogeny and medicine, while clinical gerontology and geriatrics 
are the medicine of ill old people (consequences of senescence and senility). In opposition 
with geriatrics, anti-ageing medicine and positive ageing are causal and preventative (from 
childhood and adolescence). Therefore, anti-ageing medicine is focused on health and 
longevity development, in conformity with genetic programming, the theoretical estimate of 
the maximum human lifespan being around 125 years (Weon and Je, 2009). Longevity health 
sciences and SENS (Strategies for Engineered Negligible Senescence) involve the utilization of 
advanced studies and translational medicine in public policies, in health and longevity 
(causes, resources, means, evaluations, programs and strategies) (D. Riga, 2003; de Grey, 
2004; D. Riga and S. Riga, 2007).  
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4.2 From health to health-longevity 
Man is a bio-psycho-social being, in close interrelation with his environment. Therefore, the 
bio-psycho-socio-ecological dimension of contemporary humans is fundamental for health-
longevity (S. Riga et al., 2010c). 
On the other hand, the 1946 WHO definition of health (a state of complete physical, mental and 
social well-being, and not merely the absence of disease or infirmity) confirms the bio-psycho-
socio-ecological determinant of contemporary man. The definition of healthy ageing (Haber, 
2003) comprises the following three components:  
- health promotion, which includes strategies for reducing lifestyle risk factors as well as  
concepts for increasing  healthy lifestyle habits; 
- health protection, which contains strategies for modifying social and environmental 
structural health risks; 
- disease prevention, which includes strategies to maintain and to improve health through 
medical care systems. 
At present, the percentage of determining factors in ensuring health is as follows:  
- lifestyle - 51%;  
- biologic factor - 20%;  
- environment - 19%;  
- health care system - 10%.  
Their control at national, regional and global levels involves coherent and efficient measures 
and strategies. 
4.3 Palaestric civilization 
The concept of palaestric civilization is an integrative global health conception (D. Riga and 
S. Riga, 2010a). At present, it comprises the beliefs, customs and culture of the ancients, the 
Renaissance ideals of physical beauty attained through exercise, the 19th - 20th Century 
efforts to institutionalize, generalize and popularize physical education and sports, and 
contemporary strategies of complementary health nutrition-physical activity.  
The palaestric principles, characteristics which are clearly defined and highly positive, are: 
- applicable throughout ontogenesis: child, adolescent, adult, old person; 
- universal, efficient, long-term, easily put into practice, pleasant (entertaining) and low-
cost; 
- sanogenetic-prophylactic, therapeutic and recuperative (Bogdan and Bogdan, 2009); 
- entropic, reorganizing, physical and cerebral activator, motivating, volitive, re-
balancing (D. Riga and S. Riga, 2007). 
The palaestric remedies work quite efficiently owing to the strong, long-term, multiple, 
positive effects that daily physical activity displays. Thus, they are important factors in: 
- anti-stress, by lowering distress and raising eustress; 
- anti-impairment, against the negative effects of daily life: lack of utilization, socio-sensory 
deprivation and physical inactivity, which is a complex deprivation, namely socio-sensory-
effector deprivation (tactile, exercise and physical activity deprivation) and by overwork; 
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- anti-senescence, since they are somatic and psychic ageing decelerators;  
- anti-polypathology, resulting from sedentariness and dysmetabolic syndrome: 
muscular atrophy, joint stiffness, osteoporosis, obesity, high blood pressure, diabetes, 
cardiovascular diseases, chronic fatigue syndrome. 
There is a positive correlation between nourishment and exercise. Both rational nutrition 
and regular physical activity contribute to maintaining and improving good health 
(Simopoulos, 2005). Moreover, the palaestric solution also takes into account the bio-psycho-
socio-ecological human dimension (S. Riga et al., 2010c). Physical education is a contributing 
factor in biologically and socially harmonizing a human being, as well as in integrating 
humans in their natural surroundings. In palaestric education, healthy nutrition is the 1st 
strategy for health-longevity. An unhealthy diet represents a major risk factor in non-
communicable/chronic diseases, in the causation of global morbidity and for mortality. A 
lifestyle including physical activity is the 2nd principle and remedy. Physical inactivity 
represents a pathological habit, which increases the prevalence of 25 chronic diseases and 
produces more than 2 million deaths worldwide.  
At present, there is strong global concern in relation to educating individuals in view of 
leading a healthier lifestyle, irrespective of age. In this sense, the palaestric paradigm, 
scientifically backed up by a large number of studies and researches, is prefigured as a valid 
solution. The Declaration of Olympia, May 28-29, 1996, drawn out and published one hundred 
years after 1896, when the modern and contemporary Olympic games were resumed in 
Athens, and the WHO Documents and Recommendations and the European Union Legislation 
(White paper on a Strategy for Europe on Nutrition, Overweight and Obesity related Health Issue, 
2007; White paper on Sport, 2007) officially advocate the necessity of physical culture and 
education for each individual, as well as for the entire human society.  
4.4 Declaration of Olympia on nutrition and fitness 
4.4.1 Ancient Olympia, Greece, May 28-29, 1996 (Simopoulos, 2005) 
1. Nutrition and physical activity interact in harmony and are the two most important 
positive factors that contribute to metabolic fitness and health interacting with the 
genetic endowment of the individual. Genes define opportunities for health and 
susceptibility to disease, while environmental factors determine which susceptible 
individuals will develop illness. Therefore, individual variation may need to be 
considered to achieve optimal health and to correct disorders associated with 
micronutrient deficiency, dietary imbalance and a sedentary lifestyle. 
2. Every child and adult needs sufficient food and physical activity to express their genetic 
potential for growth, development, and health. Insufficient consumption of energy, 
protein, essential fatty acids, vitamins (particularly vitamins A, C, D, E and the B 
complex) and minerals (particularly calcium, iron, iodine, potassium and zinc), and 
inadequate opportunities for physical activity impair the attainment of overall health 
and musculoskeletal function. 
3. Balancing physical activity and good nutrition for fitness is best illustrated by the 
concept of energy intake and output. For sedentary populations, physical activity must 
be increased; for populations engaging in intense occupational and/or recreational 
physical activities, food consumption may need to be increased to meet their energy 
needs. 
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4. Nutrient intakes should match more closely human evolutionary heritage. The choice of 
foods should lead to a diverse diet high in fruits and vegetables and rich in essential 
nutrients, particularly protective antioxidants and essential fatty acids. 
5. The current level of physical activity should match more closely our genetic 
endowment. [The] reestablishment of regular physical activity into everyday life on a 
daily basis is essential for physical, mental and spiritual well-being. For all ages and 
both genders the physical activity should be appropriately vigorous and of sufficient 
duration, frequency, and intensity, using large muscle groups rhythmically and 
repetitively. Special attention to adequate nutrition should be given to competitive 
athletes. 
6. The attainment of metabolic fitness through energy balance, good nutrition and 
physical activity reduces the risk of and forms the treatment framework for many 
modern lifestyle diseases such as diabetes mellitus, hypertension, osteoporosis, some 
cancers, obesity, and cardiovascular disorders. Metabolic fitness maintains and 
improves musculoskeletal function, mobility, and the activities of daily living into old 
age. 
7. Education regarding healthy nutrition and physical activity must begin early and 
continue throughout life. Nutrition and physical activity must be interwoven into the 
curriculum of school age children and of educators, nutritionists and other health 
professionals. Positive role models must be developed and prompted by society and the 
media. 
8. Major personal behavioural changes supported by the family, the community, and 
societal resources are necessary to reject unhealthy lifestyles and to embrace an active 
lifestyle and good nutrition. 
9. National governments and the private sector must coordinate their efforts to encourage 
good nutrition and physical activity throughout the life cycle and thus increase the pool 
of physically fit individuals who emulate the Olympic ideal. 
10. The ancient Greeks (Hellenes) attained a high level of civilization based on good 
nutrition, regular physical activity, and intellectual development. They strove for 
excellence in mind and body. Modern men, women, and children can emulate this 
Olympic ideal and become swifter, stronger and fitter through regular physical activity 
and good nutrition”.   
4.5 New conception - strategy - therapeutics in pro-longevity medicine 
Anti-stress, anti-impairment, anti-ageing and anti-pathology therapy is a new specific, 
simultaneous and synergistic strategy and conception in preventative, curative and recovery 
medicine (Class of the Antagonic-Stress® drugs), (D. Riga and S. Riga, 1995-2005).  
The therapy acts aetio-pathogenically in antagonizing and attenuating the stress ↔ ageing 
tetrad (mental-biologic-oxidative-inflammatory distress ↔ impairment-wear and tear ↔ normal and 
accelerated ageing-inflammaging ↔ poly-pathologies as stress- and age-associated diseases), at 
metabolic, subcellular, cellular, tissual, organic and systemic levels. This way, the entropic 
cascade of stress ↔ ageing is replaced with the health ↔ longevity, anti-entropic, protective-
therapeutic tetrad: anti-stress/eustress/adaptation  anti-impairment/vitality/resistance 
 anti-ageing/active, healthy longevity  anti-illnesses/anti-diseases. In addition, this 
first-hand restorative therapy recovers the anti-oxidative capacity/reserve/defence, a 
feature of the human body which has a direct relation with health-longevity. 
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The drug-therapy was elaborated by association of the following active principles: 
- against oxidative and catabolic stress: methionine with aminoethanol phenoxyacetates 
and/or aminoethyl phenoxyacetamides; 
- against anabolic stress: hydrooxopyrimidine carboxylates and/or oxopyrrolidine 
acetamides with potassium, zinc and lithium; 
- vasodilative and normolipidemic: nicotinic alcohol and/or acid, or its derivatives, with 
magnesium and iodine; 
- energo-active and anti-toxic: aspartate, fructose, vitamin B1, vitamin B6, monoacid 
phosphate and sulphate. 
The process for manufacturing the drug stipulates: 
- pharmaceutical preparation in two complementary types of capsules or coated tablets, 
gastrosoluble and enterosoluble, the last being enteric coated; 
- prolonged-release of vasodilator from the enterosoluble unit. 
For competitive and long-term health-longevity, this original therapy must be associated 
and integrated with: 
- healthy diet, nutraceuticals, and regenerative bioactive factors; 
- caloric restriction with adequate nutrition; 
- cerebral activation therapy, other antioxidants, nootropics, neurovascular and 
neurometabolic activators; 
- cognitive stimulation, continuous learning-education, brain training and fitness; 
- regular exercise, daily physical activity, and resistance exercises; 
- hormesis, including adaptation to stimulation, and low-level stress (Rattan and 
Demirovic, 2009). 
5. Health-longevity strategy 
5.1 Quality of life for all. The WHO public health policy 
“Targets for Health for All - 2000” is a global strategy envisioned by the WHO and 
represents a programmatic document (WHO, Regional Office for Europe, 1986): “Primary 
health care is the most important single element in the reorientation of the health care 
system and will require very strong support” (p. 11). For this objective, “Lifestyles 
conductive to health” (Ch. 4) and a “Healthy environment” (Ch. 5) become fundamental.  
The six important subjects and the four dimensions of health promotion were very well 
emphasized: 
“Six major themes run throughout the whole book. 
 Health for all implies equity. This means that the present inequalities in health between 
countries and within countries should be reduced as far as possible. 
 The aim is to give a positive sense of health so that they can make full use of their 
physical, mental and emotional capacities. The main emphasis should therefore be on 
health promotion and the prevention of disease. 
 Health for all will be achieved by people themselves. A well-informed, well-motivated 
and actively participating community is a key element for the attainment of the common 
goal. 
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system and will require very strong support” (p. 11). For this objective, “Lifestyles 
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“Six major themes run throughout the whole book. 
 Health for all implies equity. This means that the present inequalities in health between 
countries and within countries should be reduced as far as possible. 
 The aim is to give a positive sense of health so that they can make full use of their 
physical, mental and emotional capacities. The main emphasis should therefore be on 
health promotion and the prevention of disease. 
 Health for all will be achieved by people themselves. A well-informed, well-motivated 
and actively participating community is a key element for the attainment of the common 
goal. 
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 Health for all requires the coordinated action of all sectors concerned. The health 
authorities can deal only with a part of the problems to be solved, and multisectoral 
cooperation is the only way of effectively ensuring the prerequisites for health, promoting 
healthy policies and reducing risks in the physical, economic and social environment. 
 The focus of the health care system should be on primary health care - meeting the basic 
health needs of each community through services provided as close as possible to 
where people live and work, readily accessible and acceptable to all, and based on full 
community participation. 
 Health problems transcend national frontiers. Pollution and trade in health-damaging 
products are obvious examples of problems whose solution requires international 
cooperation” (pp. 5-6).  
“Thus, health for all in Europe has four dimensions as regards health outcomes, involving 
action in order to: 
 ensure equity in health, by reducing the present gap in health status between countries 
and groups within countries; 
 add life to years, by ensuring the full development and use of people’s integral or 
residual physical and mental capacity to derive the full benefit from it and to cope with 
life in a healthy way; 
 add health to life, by reducing disease and disability; 
 add years to life, by reducing premature deaths, and thereby increasing life expectancy” 
(p. 23).  
The WHO (a specialized agency of the United Nations, primarily responsible for 
international public health) published, in 1987, an essential tool: “Measurement in health 
promotion and protection” (Abelin et al., 1987). This WHO manual represents a new health 
movement for a global strategy, promoting positive health, in the socio-ecological paradigm 
of health. Therefore, “the main goal of health promotion is to maintain or improve health 
potential” (p. 19). 
Also, on October 12, 1990, the WHO teleconference cautions against “diseases of lifestyle”, 
which are the cause of 70-80% of premature deaths in industrialized countries. Thus, health 
promotion signifies the prevention of stress-related diseases (Cooper, 1996). 
Therefore, the quality of life for all represents the promotion of positive health, a new socio-
ecological paradigm of health and preventative medicine (S. Riga and D. Riga, 2009b). 
5.2 Health ↔ longevity tetrad 
Mental (psychic, behavioural) and somatic (body, metabolic) health with the construction of 
the health-longevity couple represent the medicine of the future. The health ↔ longevity 
tetrad (anti-stress ↔ anti-impairment ↔ anti-ageing ↔ anti-diseases) is in total opposition with 
the stress ↔ ageing cascade.  
LHS and MH have common principles and strategies. Both:  
- will reform the previous paradigm of contemporary medicine (Figure 3), the modern 
pyramid of (mental) medical services (Funk et al., 2007), from treatments and illness 
recovery;  
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- to the medicine of the healthy individual (Figure 4), - New pyramid of (mental) health 
services (S. Riga et al., 2009a; S. Riga et al., 2011a). 
 
Fig. 3. Modern pyramid of (mental) medical services.  
Optimal mix recommended by WHO (2007)  
 
Fig. 4. New pyramid of (mental) health services.  
Advanced paradigm in (mental) health - longevity services (2009)  
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The societal cost/benefit ratio is decisively in favour of health-longevity promotion, in 
comparison with current medical care systems, represented by polyclinics, hospitals and 
sanatoriums. The cost/benefit ratio will always rank prevention and prophylaxis as 
higher place than therapeutics and recovery whenever savings and economic factors are 
involved.  
5.3 New health-longevity strategy. Structure of health as a pyramid 
This original paradigm is structured in a new pyramid of health-longevity services (S. Riga 
and D. Riga, 2009a; S. Riga et al., 2011a), with five levels:  
1. Ecology: “the health” of the environment, permanent human healthy conceptions and 
actions on the surroundings, normal human-environment interactions;   
2. The culture of sanogenesis, which involves education, learning, construction, 
development, training, maintenance, continuity and permanence;  
3. Rational life and use of health-longevity resources: balanced diet and often dietary 
restriction, regular physical activity, cerebral metabolic activation, cognitive and social 
stimulation, hormesis;  
4. Health protection (promotion) and preventative medicine;  
5. Sub-clinical (infra-clinical) medicine, with developmental origins of health and diseases, 
risk factors for health, biologic and psychic impairment, pre-senescence, pre-illness and 
silent pathologies. 
An optimal mix of ecological, bio-medical and care systems and services in the promotion of 
health-longevity integrates the costs (left side), the frequency of needs (right side) and the 
quantity of services needed (presented on a horizontal line). The most favourable and viable 
combination is structured as a new pyramid of health-longevity services (Figure 4), (S. Riga 
et al., 2010d; S. Riga et al., 2011a). 
From the base to the top, the hierarchy of services needed comprises five levels: 
1. Ecology: the “health” of the environment (natural, artificial, societal, regional and, 
finally, global - the earth), (WHO, Regional Office for Europe, 1986; Abelin et al., 1987); 
2. The continuous education, learning and training of sanogenesis (Abelin et al., 1987; S. 
Riga et al., 2009b): 1st stage (cognitive education  construction  development) and 
2nd stage (maintenance  training/coaching  improvement  continuity / 
permanence);   
3. The rational utilization of personal life and health-longevity resources (Klatz and 
Goldman, 2003; Le Bourg, 2003; Simopoulous, 2005; D. Riga et al., 2006b): diet, 
physical activity, cerebral activation (psychic, nutraceutical, metabolic, psychological 
and social); 
4. Health protection  promotion  development and preventative medicine (primary 
prophylaxis), (WHO, Regional Office for Europe, 1986; Abelin et al., 1987; Knapp et al., 
2007; S. Riga and D. Riga, 2008); 
5. Infra-clinical medicine in pre-senescence and pre-pathology (Cutler, 1996; Cutler et al., 
2005a; D. Riga and S. Riga, 2007): diagnosis - evaluation - intervention for risk factors, 
inductors of pre-senescence, pre-illness and silent pathology and, finally, for diseases 
(markers of oxidative stress and inflammation, cancer antigens etc.).  
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5.4 Health-longevity - A global progress  
The First Law (Law of use and disuse), in its extended form, enunciated by Jean-Baptiste 
Lamarck (1744-1828), the French naturalist, is very important for the health-longevity 
strategy: In every animal which has not passed the limit of its development, a more frequent and 
continuous use of any organ gradually strengthens, develops and enlarges that organ, and gives it a 
power proportional to the length of time it has been so used; while the permanent disuse of any organ 
imperceptibly weakens and deteriorates it, and progressively diminishes its functional capacity, until 
it finally disappears (Lamark, 1809, trans. 1914). 
As an actual concept, it becomes “use it or lose it” (engl.)/“utilisez-la ou perdez-la” (fr.), 
both for neurons (Swaab, 1991) as well as for mental activity (Roth, 1975; Giurgea, 1993), 
namely therapy for cerebral activation, utilized in sanogenesis, prophylaxis of neuro-
degenerative diseases and against pathological ageing. 
At an individual (personalized) level the continuous education of health is defining. 
At a national (societal) level, for an increased efficacy of health-longevity strategies, two 
directions must be covered: 
- the improvement of programmes for the assessment of risks of diseases and of the 
precocious discovery of illnesses, followed by: 
- the elaboration and implementation of programmes for health-longevity improvement 
and maintenance. 
Now, is the time to create global standards in the training of health promotion. For this 
reason, the International Institute for Health promotion was organized in 1996 at the 
American University in Washington, DC (Kirsten, 2010), as an interdisciplinary network of 
specialists from various fields, and also of academic, governmental and non- governmental 
organizations.  
In our new conception, the aim of health-longevity is health promotion together with illness 
prevention and the improvement of the quality of life. Moreover, the advantages of the 
proposed public health strategies and policies (pyramid of health) are low societal costs 
compared to the enduring treatments for chronic diseases. Therefore, a new millennium 
strategy for a healthy person’s medicine must entail qualified interventions:  
- in the early life of the origins of human health and disease (Newnham and Ross, 2009);  
- in stress-ageing aetio-pathogenic entropic cascade (distress-impairment-ageing-illness), 
(Fahy et al., 2010; D. Riga et al., 2006a; D. Riga et al., 2006b; S. Riga et al., 2010d);  
- in diseases of lifestyle, risk factors, silent pathologies (persistent mental - biologic - 
oxidative - inflammatory stress).  
Consequently, future medicine will be and must be the medicine of health, mainly the 
planning of personalized and public health, together with the strategies of longevity, 
somatic and mental health. 
The ageing of the population (implicitly chronic diseases) and also mental/behavioural 
disorders are in rapid expansion. Due to the high public costs, these phenomena will force 
society towards a new health policy: health protection/promotion and 
preventative/prophylactic medicine. Consequently, in the global world, the future medicine 
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will be the medicine of health: the planning of personalized/public health and strategies of 
longevity/mental health. 
In 2002, non-communicable diseases accounted for 60% of total mortality worldwide and 
46% of the global burden of disease (WHO, 2003). This disease burden is expected to 
increase from 46% in 2002 to 60% in 2020. The major causes of this are represented by five 
factors (high blood pressure, high cholesterol, low intake of vegetables and fruits, high body 
mass index and physical inactivity) from the top 10 global disease burden factors 
enumerated by the WHO. These current risk levels (a worldwide risk diagram) predict 
major increases in chronic diseases, as a poly-pathology of ageing. 
On May 2004, at the 56th World Health Assembly, the WHO substantiated an important 
global public health initiative (Waxman, 2005), the main targets of which were diet, physical 
activity and health. 
6. Conclusions 
The progress in science, medicine, technology and communication imposes global policies - 
strategies - standards in health promotion from the WHO regarding education, training, 
expertise, culture and research.  
Contemporary civilization should therefore substantiate key competences:  
- durable health development;  
- a knowledge-based society;  
- social, communication and civic abilities;  
- learning to learn competencies.  
Health-longevity medicine is a new concept for public health, health promotion and 
protection, in accordance with world demographic tendencies. This strategy for future 
health at a global level reunites preventative (prophylaxis and hygiene) medicine, LHS, MH 
and the human bio-psycho-socio-ecological dimension. 
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1. Introduction  
Life expectancy is the key aggregated indicator of a country’s well-being along with gross 
domestic product and living standards. While Russia approaches the group of developed 
countries in terms of per capita GDP, it is strikingly different in terms of the living standards 
and the dynamics of life expectancy. Thus, life expectancy among males in Russia has not 
only not increased since the 1970s, but has dropped to barely above 60 years (Fig.1). The low 
living standards and lack of improvement in life expectancy dynamics in Russia are in 
contrast with the experience of the majority of developed countries and countries with 
transitional economies. Thus, male life expectancy at birth in Finland has increased from 66 
years in 1970 to 76 years in 2007, in Norway from 71 to 77 years and in Sweden from 72 to 78 
years during the same period. In the Czech Republic male life expectancy has increased 
from 66 to 68 years. Female life expectancy in these countries reveals comparable dynamics. 
Russia has still to go into an upward trend (both for men and for women) characteristic of 
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Source: European Health for All Database, 2011. 
Fig. 1. Life expectancy at birth, 1970-2007, male (left) and female (right). Top down: France, 
Finland, the Czech Republic, and the Russian Federation. 
Numerous studies of the causes of high mortality among the Russian population all confirm 
the negative impact of excessive alcohol consumption (Leon et al, 1997; Shkolnikov et al, 
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Fig. 1. Life expectancy at birth, 1970-2007, male (left) and female (right). Top down: France, 
Finland, the Czech Republic, and the Russian Federation. 
Numerous studies of the causes of high mortality among the Russian population all confirm 
the negative impact of excessive alcohol consumption (Leon et al, 1997; Shkolnikov et al, 
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1998; Brainerd and Cutler, 2005; Leon, 2007; Nemtsov, 2002). The majority of studies use 
aggregated death certificate data, which limits a more detailed study of the impact of 
alcohol consumption patterns on health and ultimately on the risk of death1. The data of the 
Russian Longitudinal Monitoring Survey (RLMS-HSE) make it possible to identify types of 
alcohol consumption and analyze the impact of the main types on health and the risk of 
death. Section 2 analyzes aggregate alcohol consumption in Russia and Europe. Section 3 is 
devoted to the structure of alcohol consumption in Russia. Section 4 reports the results of 
the assessment of the impact of alcohol consumption on health and mortality in Russia. 
Section 5 is devoted to the experience of European countries in implementing active anti-
alcohol policies. Section 6 concludes.  
2. Alcohol consumption in Russia and Europe 
The total registered consumption of alcohol in Russia in 2008 reached 11.5 litres of pure 
alcohol per person above the age of 15 (Fig.2). The consumption of spirits increased by 233% 
between 1988 and 1998, the consumption of beer by 31%, while the consumption of wine 
dropped slightly by 6% (World Drink Trends, 1999, Global Status Report on Alcohol, 2004). 
The production of illicit (unregistered) products adds almost 5 litres, according to expert 
assessments2. That adds up to 16 litres of pure alcohol per citizen over 15 years of age (the 
Ministry of Healthcare and Social Development puts the figure at 18 litres). It has to be 
noted that unregistered alcohol consumption is not a peculiarly Russian phenomenon. In 
the majority of West European countries unregistered consumption is put by experts at 
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Source:
World Drink Trends (WDT) 1963-1999; Russia Federal State Statistical Service 2000-2008
 
Fig. 2. Total (registered) consumption of alcohol in Russia, consumption of beer, spirits and 
wine. Litres of pure alcohol per capita of 15 + per year.  
1 A small group of studies are based on micro-data collected either with the express purpose of 
identifying the impact of harmful habits on the risk of death (surveys of the relatives of the dead in 
Izhevsk), or for other purposes (lipids test program).  
2 European Addiction Research (2001), Gilinskiy Y. (2000). 
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Aggregate consumption in Russia is higher than in the countries of Europe, although not 
much higher than in the Czech Republic, France and Germany. At the same time, the 
general trend of consumption in Europe and the US is a gradual decline in alcohol 
consumption (in litres of pure alcohol) since the 1980s, with the trend more manifest in 
Europe than in the US. Strong drinks are being replaced with lighter ones. Thus, for 
example, in the period between 1988 and 1998 consumption of spirits in Italy dropped by 
50%, consumption of wine by 18% while consumption of beer increased by 15%. In Great 
Britain consumption of spirits and beer dropped by 28% and 17% respectively while wine 
consumption increased by a third (27%). During the same period in Europe as a whole 
consumption of spirits dropped by 23.2%, consumption of wine dropped by 3.6%, while 
consumption of beer increased by 3.6%3. Similar trends have been noted not only in 
developed countries. Thus in the majority of Latin American countries consumption of 
alcohol is going down and consumption of beer is going up. 
For Russia the experience of North European countries where consumption patterns are 
historically similar to Russia is of the greatest interest. Figs. 3 and 4 show the dynamics of 
aggregate registered consumption of alcohol, beer, spirits and wine in Iceland, Finland, 
Norway and Sweden. As seen from the charts, all these countries witnessed dramatic 
changes in the structure of alcohol consumption in the 1980s and 1990s. The consumption of 
spirits dropped significantly: by 1.5 litres of pure alcohol per person in Norway, by 2 litres 
in Iceland and Finland and by almost 3 litres in Sweden. At the same time the total 
consumption of alcohol has not diminished and has actually grown a little because the 
consumption of spirits has been replaced with the consumption of beer and wine. As a 
result these countries moved from the group of countries with predominant consumption of 
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Source: National Research and Development Centre for Welfare and Health (STAKES), Finland 1961-2008
 
Fig. 3. Aggregate (registered) consumption of alcohol in Iceland (left) and Finland (right), 
consumption of beer, strong spirits and wine. Litres of pure alcohol per capita of 15 + per 
year. 
3 The calculations use data not from all the European countries, but from countries with larger 
populations (Belgium, Great Britain, France, Germany, Spain, Italy, Poland, the Czech Republic, 
Portugal and Switzerland).    
Public Health – Methodology, Environmental and Systems Issues 368 
1998; Brainerd and Cutler, 2005; Leon, 2007; Nemtsov, 2002). The majority of studies use 
aggregated death certificate data, which limits a more detailed study of the impact of 
alcohol consumption patterns on health and ultimately on the risk of death1. The data of the 
Russian Longitudinal Monitoring Survey (RLMS-HSE) make it possible to identify types of 
alcohol consumption and analyze the impact of the main types on health and the risk of 
death. Section 2 analyzes aggregate alcohol consumption in Russia and Europe. Section 3 is 
devoted to the structure of alcohol consumption in Russia. Section 4 reports the results of 
the assessment of the impact of alcohol consumption on health and mortality in Russia. 
Section 5 is devoted to the experience of European countries in implementing active anti-
alcohol policies. Section 6 concludes.  
2. Alcohol consumption in Russia and Europe 
The total registered consumption of alcohol in Russia in 2008 reached 11.5 litres of pure 
alcohol per person above the age of 15 (Fig.2). The consumption of spirits increased by 233% 
between 1988 and 1998, the consumption of beer by 31%, while the consumption of wine 
dropped slightly by 6% (World Drink Trends, 1999, Global Status Report on Alcohol, 2004). 
The production of illicit (unregistered) products adds almost 5 litres, according to expert 
assessments2. That adds up to 16 litres of pure alcohol per citizen over 15 years of age (the 
Ministry of Healthcare and Social Development puts the figure at 18 litres). It has to be 
noted that unregistered alcohol consumption is not a peculiarly Russian phenomenon. In 
the majority of West European countries unregistered consumption is put by experts at 
















1960 1970 1980 1990 2000 2010
Year
Total Beer Wine Spirits
Source:
World Drink Trends (WDT) 1963-1999; Russia Federal State Statistical Service 2000-2008
 
Fig. 2. Total (registered) consumption of alcohol in Russia, consumption of beer, spirits and 
wine. Litres of pure alcohol per capita of 15 + per year.  
1 A small group of studies are based on micro-data collected either with the express purpose of 
identifying the impact of harmful habits on the risk of death (surveys of the relatives of the dead in 
Izhevsk), or for other purposes (lipids test program).  
2 European Addiction Research (2001), Gilinskiy Y. (2000). 
Alcoholism and the Russian Mortality Crisis 369 
Aggregate consumption in Russia is higher than in the countries of Europe, although not 
much higher than in the Czech Republic, France and Germany. At the same time, the 
general trend of consumption in Europe and the US is a gradual decline in alcohol 
consumption (in litres of pure alcohol) since the 1980s, with the trend more manifest in 
Europe than in the US. Strong drinks are being replaced with lighter ones. Thus, for 
example, in the period between 1988 and 1998 consumption of spirits in Italy dropped by 
50%, consumption of wine by 18% while consumption of beer increased by 15%. In Great 
Britain consumption of spirits and beer dropped by 28% and 17% respectively while wine 
consumption increased by a third (27%). During the same period in Europe as a whole 
consumption of spirits dropped by 23.2%, consumption of wine dropped by 3.6%, while 
consumption of beer increased by 3.6%3. Similar trends have been noted not only in 
developed countries. Thus in the majority of Latin American countries consumption of 
alcohol is going down and consumption of beer is going up. 
For Russia the experience of North European countries where consumption patterns are 
historically similar to Russia is of the greatest interest. Figs. 3 and 4 show the dynamics of 
aggregate registered consumption of alcohol, beer, spirits and wine in Iceland, Finland, 
Norway and Sweden. As seen from the charts, all these countries witnessed dramatic 
changes in the structure of alcohol consumption in the 1980s and 1990s. The consumption of 
spirits dropped significantly: by 1.5 litres of pure alcohol per person in Norway, by 2 litres 
in Iceland and Finland and by almost 3 litres in Sweden. At the same time the total 
consumption of alcohol has not diminished and has actually grown a little because the 
consumption of spirits has been replaced with the consumption of beer and wine. As a 
result these countries moved from the group of countries with predominant consumption of 
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Fig. 3. Aggregate (registered) consumption of alcohol in Iceland (left) and Finland (right), 
consumption of beer, strong spirits and wine. Litres of pure alcohol per capita of 15 + per 
year. 
3 The calculations use data not from all the European countries, but from countries with larger 
populations (Belgium, Great Britain, France, Germany, Spain, Italy, Poland, the Czech Republic, 
Portugal and Switzerland).    
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Fig. 4. Aggregate (registered) consumption of alcohol in Norway (left) and Sweden (right), 
consumption of beer, strong alcoholic beverages and wine. Litres of pure alcohol per capita 
of 15 + per year. 
Changes in the structure of consumption, while not the only cause of increased life 
expectancy in the North European countries, have undoubtedly had a positive impact on 
bringing down the death rate and increasing life expectancy in these countries (see Fig.1). 
The change in the structure of alcohol consumption in Northern Europe has been the result 
of a massive, large-scale and sustained anti-alcohol policy in these countries. These 
measures will be discussed in more detail in Section 5.  
It has to be noted that the switch from predominant consumption of spirits (hard liquor) to 
the consumption of beer or wine does not in itself guarantee lower risks of death. Another 
crucial factor is the frequency and volumes of alcohol consumption. Thus, France, which is 
traditionally a wine-drinking nation (Fig.5) has managed to reduce alcohol consumption 
almost by half between the 1960s and 2000 due to the reduction of wine consumption. The 
drop in consumption reduced the deaths from cardiovascular diseases (Fig.6). At the same 
time growing alcohol consumption, above all of spirits, in Russia has resulted in a growing 
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Fig. 5. Total (registered) alcohol consumption in France (left) and Russia (right), 
consumption of beer, strong alcoholic beverages and wine. Litres of pure alcohol per capita 
of 15 + per year. 
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Source: European health for all database, 2011 
Fig. 6. Standardized coefficients of death from ischemic heart disease chronic diseases per 
1000 persons in France and Russia.  
On the whole aggregate alcohol consumption in Russia, although higher than in 
developed countries, is not so much higher as to explain the differences in mortality rate 
and life expectancy. It is true that the rate of alcohol-related deaths per litre consumed in 
Russia is substantially higher than similar indicators in Western Europe. The main 
reasons for that, as noted by scholars (e.g., Nemtsov, 2009) are the specific structure of 
consumption (a larger share of strong drinks), the northern type of alcohol consumption 
(large doses within a short time), the low standard of healthcare (especially the treatment 
of drug and alcohol addiction) as well as the traditional neglect of Russian people of their 
state of health.  
3. Structure of alcohol consumption: frequency, volumes, beverages  
As noted above, the type of consumption is a key characteristic of alcohol consumption 
(no less important than the amounts). The pattern of consumption is determined by the 
type of drinks in terms of strength and quality and the time and places when and where 
alcohol is consumed. Epidemiological studies in various countries show that the risk of 
cardiovascular diseases among those who drink a glass of wine a day is on average 32% 
less than among those who do not drink at all. A similar indicator for beer is 22% (Di 
Castelnuovo et al, 2002).  Nemtsov (2009) notes that the impact of the pattern of 
consumption on the nation’s health has been poorly studied by Russian narcologists. At 
the same time studies in other countries note that the “ideal structure” of alcohol 
consumption – the ratio that minimizes negative consequences – is consumption in which 
beer accounts for 50%, wine for 35% and spirits for 15% (Edwards et al., 1994). In 2002, 
according to official alcohol sales figures (that do not take into account illicit alcohol) 
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(large doses within a short time), the low standard of healthcare (especially the treatment 
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3. Structure of alcohol consumption: frequency, volumes, beverages  
As noted above, the type of consumption is a key characteristic of alcohol consumption 
(no less important than the amounts). The pattern of consumption is determined by the 
type of drinks in terms of strength and quality and the time and places when and where 
alcohol is consumed. Epidemiological studies in various countries show that the risk of 
cardiovascular diseases among those who drink a glass of wine a day is on average 32% 
less than among those who do not drink at all. A similar indicator for beer is 22% (Di 
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consumption on the nation’s health has been poorly studied by Russian narcologists. At 
the same time studies in other countries note that the “ideal structure” of alcohol 
consumption – the ratio that minimizes negative consequences – is consumption in which 
beer accounts for 50%, wine for 35% and spirits for 15% (Edwards et al., 1994). In 2002, 
according to official alcohol sales figures (that do not take into account illicit alcohol) 
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strong beverages accounted for 35% of the total consumption. The figure is obviously 
grossly understated because it does not take into account illicit production (both 
industrial and domestic).  
The Russian Longitudinal Monitoring Survey (RLMS-HSE) makes it possible to analyze the 
structure of alcohol consumption by Russian households on the basis of respondents’ 
answers4. According to the RLMS-HSE, about three quarters of the adult Russian population 
consume some kind of alcohol (Fig.7). The figure of drinkers is higher among males in all 
the age groups. The share of alcohol consumption is higher in the main age groups and a 
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Fig. 7. Alcohol consumption in Russia5: total (left) and men and women by age groups 
(right). Percentage of total number of respondents.  
It has to be noted that the share of alcohol drinkers is higher in groups with higher incomes 
and among those who have finished vocational training schools (PTU) or have higher 
education, although the difference in consumption depending on education is not great 
(Fig.8).  
4 RLMS-HSE is a nationally representative longitudinal survey of Russian households conducted 
since 1992 by the Demoscope Centre, the RAS Sociology Institute and the University of North 
Carolina at Chapel Hill (USA) Population Center. The National Research University Higher School of 
Economics (Moscow) joined the group in 2008. Cooperation with the top world centers for the study 
of the behavior of households in forming the sample, developing the questionnaire, recruiting and 
training interviewers earned this study a high degree of trust among Russian and foreign scholars 
and decision-makers. The RLMS-HSE data are nationally representative and are based on a survey of 
more than 4,000 households per year which amounts to more than 10,000 adults per year. The sample 
is from a two-stage random draw of dwellings from the population from the micro census of 1989. 
The dwellings are surveyed each year with some additional dwellings added in the later periods of 
the survey to meet the national representation criteria (http://www.cpc.unc.edu/projects/rlms-hse). 
5 Respondents were asked whether they had consumed any alcohol (including beer) in the last  
30 days. 
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Fig. 8. Consumption of alcohol in Russia: by income group (left) and educational group 
(right). Percentage of total answers. 
The share of abstainers (those who do not drink any alcohol) in the 18-24 and 14-16 age 
groups is shown in Fig.9. Among teenagers aged 14-16 about 25% consume alcohol and 75% 
are abstainers. The share of those who do not consume alcohol has grown somewhat in 
recent years. A similar trend of growing abstinence is revealed in the 18-24 age group: 
among women that share increased from 23% in 2006 to almost 30% in 2008; among men the 
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Fig. 9. Share of abstainers (non-drinkers) in Russia: 18-24 age group (left) and 14-16 age 
group (right). Percentage of total number of respondents in age groups.  
The share of drinkers in different age groups is an important but not the only characteristic 
of a nation’s alcohol consumption. Thus, in France, which has managed to diminish total 
alcohol consumption in recent years, more than 90% of the adult population and nearly 80% 
of persons aged 17-19 consume alcohol (WHO Global Status Report on Alcohol, 2004). 
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Carolina at Chapel Hill (USA) Population Center. The National Research University Higher School of 
Economics (Moscow) joined the group in 2008. Cooperation with the top world centers for the study 
of the behavior of households in forming the sample, developing the questionnaire, recruiting and 
training interviewers earned this study a high degree of trust among Russian and foreign scholars 
and decision-makers. The RLMS-HSE data are nationally representative and are based on a survey of 
more than 4,000 households per year which amounts to more than 10,000 adults per year. The sample 
is from a two-stage random draw of dwellings from the population from the micro census of 1989. 
The dwellings are surveyed each year with some additional dwellings added in the later periods of 
the survey to meet the national representation criteria (http://www.cpc.unc.edu/projects/rlms-hse). 
5 Respondents were asked whether they had consumed any alcohol (including beer) in the last  
30 days. 
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Fig. 8. Consumption of alcohol in Russia: by income group (left) and educational group 
(right). Percentage of total answers. 
The share of abstainers (those who do not drink any alcohol) in the 18-24 and 14-16 age 
groups is shown in Fig.9. Among teenagers aged 14-16 about 25% consume alcohol and 75% 
are abstainers. The share of those who do not consume alcohol has grown somewhat in 
recent years. A similar trend of growing abstinence is revealed in the 18-24 age group: 
among women that share increased from 23% in 2006 to almost 30% in 2008; among men the 
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Fig. 9. Share of abstainers (non-drinkers) in Russia: 18-24 age group (left) and 14-16 age 
group (right). Percentage of total number of respondents in age groups.  
The share of drinkers in different age groups is an important but not the only characteristic 
of a nation’s alcohol consumption. Thus, in France, which has managed to diminish total 
alcohol consumption in recent years, more than 90% of the adult population and nearly 80% 
of persons aged 17-19 consume alcohol (WHO Global Status Report on Alcohol, 2004). 
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However, the fact that the overwhelming majority drink dry wine, and then in small or 
medium doses, puts France in an upward trend in terms of life expectancy. Russia is still 
characterized by the predominant consumption on strong alcoholic beverages.  
The structure of alcohol consumption in Russia as reflected in the share of those who 
consume this or that type of drink, is shown in Fig.10. As seen from the charts, in Russia 
about 70% of men and nearly 50% of women drink beer. The next most popular drink is 
vodka and other strong spirits, consumed by more than 60% of men and 37% of women. 
About 12% of men and 5% of women drink home-made alcohol. About 40% of women and 
11% of men drink dry wine or champagne. Thus, the most popular alcoholic beverages in 
Russia are vodka and home-produced alcohol, on the one hand, and beer on the other. At 
the same time, if one recalls Fig.2 which shows total consumption of beer and spirits in 
Russia in litres of pure alcohol, the absolute predominance of vodka cannot be disputed, 
whereas beer and wine account for only a small share of total alcohol consumption. This 
indicates the type of consumption: vodka is drunk more frequently and in larger quantities 
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Fig. 10. Structure of alcohol consumption in Russia: by gender (left) and by age groups 
(right). Percentage of total number of drinkers. 
It is notable that the consumption of beer, on the one hand, and of vodka and home brewed 
alcohol on the other reveals substantial differences by age group (Fig.10, right-hand side). 
Indeed, the distribution of beer consumers is tilted towards younger age groups whereas 
consumption of vodka is more characteristic of older age groups. This picture may attest to 
the beginnings of change in the pattern of consumption and a shift from predominantly 
strong alcoholic beverages towards beer. Whether the trend turns out to be sustained 
remains to be seen.  
The structures of alcohol consumption by income groups and education are shown in Fig.11. 
The share of vodka and beer in the structure of consumption in different income groups is 
approximately the same, with beer consumption slightly higher in the lower-income groups. 
At the same time there is a marked trend of increased share of those who drink wine and 
champagne in the higher-income groups. Thus in the first (lowest) quantile only 16% of 
alcohol consumers drink wine and in the fifth (top) quantile the percentage is 31%. Similarly 
the consumption of wine and champagne is more common among people with a higher 
level of education. The lower share of vodka and beer drinkers in the groups with a higher 
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Fig. 11. Structure of alcohol consumption in Russia: by income group (left) and by 
educational group (right). Percentage of total number of drinkers.  
A comparison of the frequency of alcohol consumption in Russia and some West European 
countries (Table 1) shows a similarity with Finland and Sweden. Indeed, the percentage of 
men who frequently consume alcohol (every day or 4-5 times a week) is 6.3% in Russia, 8% 
in Finland and 7% in Sweden. A further 35% of Russian men drink once or 2-3 times a week. 
Similar figures are reported in Sweden (40%) and Finland (50%). Russian women do not 
drink more frequently than women in the Nordic countries. This type of consumption 
contrasts with consumption in the southern countries: in Italy, for example, 45% of men and 
30% of women drink (usually wine) every day or 4-5 times a week. The figures for France 
are 26% for men and 11% for women.    
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Finland 4 4 20 32 19 7 8 6
France 21 5 19 23 7 5 6 13
Germany 12 6 24 18 11 11 7 12
Italy 42 3 17 14 4 4 6 11
Sweden 3 4 16 24 23 12 12 7
UK 9 16 31 18 8 4 4 11
Russia (RLMS) 2.8 3.5 15.4 19.6 20.3 8.4 n.a. 30
Females:
Finland 2 2 7 22 22 14 24 8
France 9 3 10 16 9 12 14 27
Germany 5 2 13 20 15 10 17 18
Italy 26 4 10 12 8 4 14 22
Sweden 1 1 5 17 2 17 23 13
UK 5 6 18 22 12 10 11 14
Russia (RLMS) 0.5 0.5 3.5 10 20.5 15 n.a. 50  
Source: Alcohol in post-war Europe (2001), Table 5.1, p. 107 for Western Europe and authors’ 
calculations for Russia  
Table 1. Frequency (%) of alcohol consumption, West Europe and Russia, men and women  
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Fig. 11. Structure of alcohol consumption in Russia: by income group (left) and by 
educational group (right). Percentage of total number of drinkers.  
A comparison of the frequency of alcohol consumption in Russia and some West European 
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men who frequently consume alcohol (every day or 4-5 times a week) is 6.3% in Russia, 8% 
in Finland and 7% in Sweden. A further 35% of Russian men drink once or 2-3 times a week. 
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The frequency of alcohol consumption hardly varies in different income groups and varies 
only slightly by education group (Fig.12). The better educated drink less frequently: the 
share of those who drink every day or 4-6 times a week among graduates of vocational 
training schools is 7% and among graduates of secondary professional schools and higher 
education institutions 4%. The number of those who drink 2-3 times a month is 5% higher 
among university graduates: 37% versus 32% among graduates of vocational secondary 
schools. These differences reflect more moderate alcohol consumption among women who 
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Fig. 12. Frequency of alcohol consumption in Russia: by income group (left) and by 
education group (right). Percentage of total number of drinkers. 
Differences in the structure of alcohol types and frequency of consumption manifest 
themselves in differences in the average quantity of ml of ethanol consumed. The 
differences in the average daily consumption of ethanol between different income groups 
are shown in Fig.13. As seen from the chart, consumption of ethanol is the highest in the 
first three income groups (the poorest) which is due to the prevalence of the consumption 
of vodka and home brewed alcohol in these groups. At the same time the high income 
groups in the 8th, 9th and 10th deciles show a high consumption of ethanol comparable to 
the 3rd and 4th income groups, which is a consequence of the high consumption of vodka 
in top deciles.    
The structure of alcoholic drinks consumption by frequency is shown in Fig. 14. As seen 
from the chart, the prevalent type of alcohol consumption in Russia is the drinking of vodka 
separately or in combination with other drinks. This type of consumption is more 
pronounced among frequent drinkers: almost 60% of those who drink every day or 4-6 
times a week drink vodka, separately or in combination with other drinks. Among those 
who drink less frequently vodka drinkers account for more than half. At the same time it is 
noticeable that the share of those who drink wine and beer, but do not drink vodka is higher 
among the groups of infrequent drinkers (once a year or 2-3 times a month) than among 
other groups.    
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Source: Authors calculations based on RLMS-HSE, 2005 using Andrienko and Nemtsov, 2005 approach. 
Fig. 13. Structure of alcohol consumption by income groups in Russia (1 – the poorest, 10 – 
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Fig. 14. Structure of alcohol consumption by frequency (% of those who drank alcohol).   
4. The impact of alcohol consumption on health and risk of death  
This section presents the results of the estimates of the impact of alcohol consumption on the 
health and risk of death in Russia based on the data of the Russian Longitudinal Monitoring 
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Differences in the structure of alcohol types and frequency of consumption manifest 
themselves in differences in the average quantity of ml of ethanol consumed. The 
differences in the average daily consumption of ethanol between different income groups 
are shown in Fig.13. As seen from the chart, consumption of ethanol is the highest in the 
first three income groups (the poorest) which is due to the prevalence of the consumption 
of vodka and home brewed alcohol in these groups. At the same time the high income 
groups in the 8th, 9th and 10th deciles show a high consumption of ethanol comparable to 
the 3rd and 4th income groups, which is a consequence of the high consumption of vodka 
in top deciles.    
The structure of alcoholic drinks consumption by frequency is shown in Fig. 14. As seen 
from the chart, the prevalent type of alcohol consumption in Russia is the drinking of vodka 
separately or in combination with other drinks. This type of consumption is more 
pronounced among frequent drinkers: almost 60% of those who drink every day or 4-6 
times a week drink vodka, separately or in combination with other drinks. Among those 
who drink less frequently vodka drinkers account for more than half. At the same time it is 
noticeable that the share of those who drink wine and beer, but do not drink vodka is higher 
among the groups of infrequent drinkers (once a year or 2-3 times a month) than among 
other groups.    
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Source: Authors calculations based on RLMS-HSE, 2005 using Andrienko and Nemtsov, 2005 approach. 
Fig. 13. Structure of alcohol consumption by income groups in Russia (1 – the poorest, 10 – 
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Fig. 14. Structure of alcohol consumption by frequency (% of those who drank alcohol).   
4. The impact of alcohol consumption on health and risk of death  
This section presents the results of the estimates of the impact of alcohol consumption on the 
health and risk of death in Russia based on the data of the Russian Longitudinal Monitoring 
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Survey. The RLMS-HSE questionnaire contains a wide range of questions characterizing 
various aspects of the behavior of individuals in the family and in the labor market and 
detailed information on harmful habits and health indicators. In addition, the longitudinal 
character of the study makes it possible to trace the behavior trajectories of respondents over 
many years and to study the causes of death.       
The regressions cited below test the impact of frequent alcohol consumption on health 
(Tables 2 and 3) and the risk of death (Table 4) and separates the overall effect of frequent 
consumption of alcohol from frequent consumption of vodka (straight or in combination) 
and divide frequent alcohol consumption into frequent consumption of vodka (straight or 
mixed) and frequent consumption of beer (separately or mixed with drinks other than 
vodka). RLMS makes it possible to determine how frequently and what beverages an 
individual drinks. We have identified a group of those who consume alcohol every day or 4-
6 times a week, calling it “frequent drinkers”. In addition we have identified two subgroups 
among the frequent drinkers: those who drink vodka, separately or in combination with 
other drinks (“frequent vodka drinkers”) and those who drink beer, but do not drink vodka 
(“frequent beer drinkers”).  
The health variable used is the person’s own assessment of his/ her state of health (very bad, 
bad, satisfactory, good and very good). We use all the categories as well as define the binary 
variable: bad and very bad health versus all the other variants. Death is registered in the 
sample on the basis of the information provided by the household head when the unit is 
surveyed at least two rounds in a row. A household head is asked to report whether any 
household member is missing during the survey round and the reason for that member being 
not in the household. One of the reasons reported is the death of the household member. More 
details on the measurement and methodology could be found in Denisova (2010). 
In all cases we control for gender, age, the respondent’s education, per capita household 
income, place of residence, body mass index and smoking (whether or not the respondent 
smokes). We also control for the individual’s assessment of his own social status on a nine-
point scale (“respected – not respected”). This makes it possible to take into account the 
impact of constant psychological stress on a person’s health and separate that impact from 
the impact from alcohol consumption. 
The impact of alcohol consumption on health is estimated based on pooled cross-section for 
1994-2007 (Table 2) and on a panel for the same years (Table 3). The impact of alcohol 
consumption on the risk of death is estimated with Gompertz proportional hazard model 
(Table 4).     
The results of the estimates of the impact of alcohol consumption on health in Table 2 show 
that frequent alcohol consumption harms health. Thus, frequent alcohol consumption 
increases the probability of having bad or very bad health by 7 percentage points. Moreover, 
frequent alcohol consumption that includes vodka leads to health deterioration (the risk of 
bad health increases by 9 percentage points) whereas frequent consumption of beer does not 
have a statistically significant effect on health. The negative impact of frequent alcohol 
consumption on health is stable regardless of the method of assessment and of control for 
individual specific recorded effects in particular (Table 3). Frequent alcohol consumption 
increases the probability of bad or very bad health by 17 percentage points, with the entire 
effect caused by frequent consumption of vodka.   
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Males and females Males Females
Age -0.02 -0.02 -0.021 -0.021 -0.018 -0.018 0.035 0.037 0.032
[0.000]*** [0.000]*** [0.000]*** [0.000]*** [0.000]***[0.000]*** [0.001]*** [0.001]*** [0.001]***
Gender: Males 0.209 0.209 -0.202
[0.006]*** [0.006]*** [0.017]***
Married 0.032 0.032 0.031 0.031 0.029 0.029 -0.14 -0.172 -0.12
[0.005]*** [0.005]*** [0.009]*** [0.009]*** [0.007]***[0.007]*** [0.015]*** [0.026]*** [0.019]***
Junior or secondary professional education -0.01 -0.01 -0.029 -0.029 0.004 0.004 -0.085 -0.063 -0.099
[0.006]* [0.006]* [0.009]*** [0.009]*** [0.007] [0.007] [0.016]*** [0.026]** [0.020]***
Higher education 0.063 0.063 0.056 0.056 0.057 0.056 -0.211 -0.219 -0.193
[0.008]*** [0.008]*** [0.012]*** [0.012]*** [0.009]***[0.009]*** [0.022]*** [0.038]*** [0.027]***
Log of real per capita income, 1992 prices 0.022 0.022 0.019 0.019 0.023 0.023 -0.075 -0.088 -0.066
[0.003]*** [0.003]*** [0.004]*** [0.004]*** [0.004]***[0.004]*** [0.008]*** [0.012]*** [0.010]***
Self-perceived status, respect rank on 9-step ladder 0.027 0.027 0.035 0.036 0.018 0.018 -0.035 -0.053 -0.02
[0.001]*** [0.001]*** [0.002]*** [0.002]*** [0.002]***[0.002]*** [0.004]*** [0.006]*** [0.005]***
Frequent alcohol drinker -0.025 -0.016 -0.021
[0.014]* [0.015] [0.033]
Frequent vodka drinker (pure and in mix) -0.029 -0.023 -0.025 0.092 0.084 0.066
[0.017]* [0.018] [0.043] [0.043]** [0.048]* [0.113]
Frequent beer drinker (no vodka) 0.002 0.012 0.021 -0.105 -0.122 -0.187
[0.031] [0.035] [0.066] [0.101] [0.115] [0.212]
Smokes -0.06 -0.06 -0.041 -0.041 -0.07 -0.071 0.038 -0.024 0.07
[0.006]*** [0.006]*** [0.007]*** [0.007]*** [0.008]***[0.008]*** [0.017]** [0.024] [0.026]***
Body mass index 0.029 0.029 0.111 0.111 0.007 0.007 -0.064 -0.184 -0.017
[0.017]* [0.017]* [0.025]*** [0.025]*** [0.011] [0.011] [0.003]*** [0.058]*** [0.028]
 Body mass index squared/1000 -0.538 -0.539 -1.891 -1.891 -0.241 -0.241 1.158 2.998 0.503
[0.304]* [0.304]* [0.468]*** [0.468]*** [0.195] [0.195] [0.047]*** [1.082]*** [0.452]
Unemployed -0.002 -0.002 0.004 0.004 -0.002 -0.002 0.082 0.031 0.1
[0.011] [0.011] [0.017] [0.017] [0.015] [0.015] [0.032]** [0.052] [0.042]**
Urban settlement -0.061 -0.061 -0.062 -0.062 -0.06 -0.06 0.034 0.046 0.026
[0.005]*** [0.005]*** [0.008]*** [0.008]*** [0.007]***[0.007]*** [0.015]** [0.023]** [0.019]
Constant 3.197 3.196 2.288 2.287 3.575 3.575 -0.87 0.737 -1.705
[0.230]*** [0.230]*** [0.321]*** [0.321]*** [0.155]***[0.155]*** [0.084]*** [0.756] [0.380]***
Year dummies Yes Yes Yes Yes Yes Yes Yes Yes Yes
Number of observations 75037 75037 34083 34083 40954 40954 75265 34204 41061
R squared 0.19 0.19 0.17 0.17 0.18 0.18 0.12 0.12 0.12
Standard errors in brackets;                     * significant at 10%; ** significant at 5%; *** significant at 1%
Bad and very bad health
p p
Self-accessed health
Males and females Males Females
 
Table 2. Influence of alcohol consumption on health, pooled cross-section, 1994-2007 
Males Females
Age -0.016 -0.016 -0.023 -0.023 -0.01 -0.01 0.004 0.004 0.006 0.003
[0.001]*** [0.001]*** [0.001]*** [0.001]*** [0.001]***[0.001]***[0.000]*** [0.000]*** [0.000]*** [0.000]***
Married 0.031 0.031 0.038 0.038 0.034 0.034 -0.002 -0.002 -0.006 -0.001
[0.007]*** [0.007]*** [0.011]*** [0.011]*** [0.008]***[0.008]*** [0.003] [0.003] [0.005] [0.005]
Log of real per capita income, 1992 prices 0.007 0.007 0.006 0.006 0.008 0.008 -0.005 -0.005 -0.005 -0.006
[0.003]** [0.003]** [0.004] [0.004] [0.004]** [0.004]** [0.001]*** [0.001]*** [0.002]** [0.002]***
Self-perceived status, respect rank on 9-step ladder 0.01 0.01 0.013 0.013 0.007 0.007 -0.002 -0.002 -0.003 -0.002
[0.001]*** [0.001]*** [0.002]*** [0.002]*** [0.002]***[0.002]***[0.001]*** [0.001]*** [0.001]*** [0.001]**
Frequent alcohol drinker -0.028 -0.008 -0.098 0.017
[0.013]** [0.015] [0.031]*** [0.006]***
Frequent vodka drinker (pure and in mix) -0.028 -0.008 -0.13 0.017 0.01 0.056
[0.015]* [0.017] [0.039]*** [0.007]** [0.007] [0.021]***
Frequent beer drinker (no vodka) 0.017 0.042 -0.037 -0.005 -0.004 -0.015
[0.029] [0.035] [0.059] [0.014] [0.015] [0.032]
Smokes -0.011 -0.012 0.01 0.01 -0.048 -0.048 -0.012 -0.012 -0.022 0.003
[0.010] [0.010] [0.013] [0.013] [0.014]***[0.014]***[0.005]*** [0.005]** [0.006]*** [0.008]
Body mass index 0.015 0.015 0.052 0.052 0.005 0.005 -0.008 -0.008 -0.021 -0.005
[0.003]*** [0.003]*** [0.008]*** [0.008]*** [0.003] [0.003] [0.001]*** [0.001]*** [0.003]*** [0.002]***
Body mass index squared/1000 -0.15 -0.15 -0.71 -0.711 -0.057 -0.057 0.073 0.073 0.277 0.045
[0.036]*** [0.036]*** [0.130]*** [0.130]*** [0.037] [0.037] [0.018]*** [0.018]*** [0.056]*** [0.020]**
Constant 3.451 3.451 3.252 3.254 3.338 3.338 0.15 0.149 0.262 0.163
[0.050]*** [0.050]*** [0.117]*** [0.117]*** [0.060]***[0.060]***[0.025]*** [0.025]*** [0.050]*** [0.033]***
Number of observations 75054 75054 34097 34097 40957 40957 75283 75283 34219 41064
Number of individuals (groups) 19026 19026 9025 9025 10002 10002 19056 19056 9043 10014
R squared 0.16 0.16 0.15 0.15 0.16 0.16 0.06 0.06 0.06 0.05
Standard errors in brackets;                     * significant at 10%; ** significant at 5%; *** significant at 1%
p , p ,
Self-accessed health Bad and very bad health
Males and females Males Females Males and females
 
Table 3. Influence of alcohol consumption on health, panel fixed effects, 1994-2007 
The results of the assessment of the impact of alcohol on risk of death are shown in Table 4. As 
seen from the table, frequent consumption of alcohol, above all of strong spirits, increases the 
risk of death. Simple consumption of vodka or beer does not yield a statistically significant 
effect. Frequent consumption of alcohol increases the risk of death by 60 percentage points. 
Frequent consumption of vodka increases the risk of death by 66 percentage points whereas 
frequent consumption of beer does not have a statistically significant effect.  
Public Health – Methodology, Environmental and Systems Issues 378 
Survey. The RLMS-HSE questionnaire contains a wide range of questions characterizing 
various aspects of the behavior of individuals in the family and in the labor market and 
detailed information on harmful habits and health indicators. In addition, the longitudinal 
character of the study makes it possible to trace the behavior trajectories of respondents over 
many years and to study the causes of death.       
The regressions cited below test the impact of frequent alcohol consumption on health 
(Tables 2 and 3) and the risk of death (Table 4) and separates the overall effect of frequent 
consumption of alcohol from frequent consumption of vodka (straight or in combination) 
and divide frequent alcohol consumption into frequent consumption of vodka (straight or 
mixed) and frequent consumption of beer (separately or mixed with drinks other than 
vodka). RLMS makes it possible to determine how frequently and what beverages an 
individual drinks. We have identified a group of those who consume alcohol every day or 4-
6 times a week, calling it “frequent drinkers”. In addition we have identified two subgroups 
among the frequent drinkers: those who drink vodka, separately or in combination with 
other drinks (“frequent vodka drinkers”) and those who drink beer, but do not drink vodka 
(“frequent beer drinkers”).  
The health variable used is the person’s own assessment of his/ her state of health (very bad, 
bad, satisfactory, good and very good). We use all the categories as well as define the binary 
variable: bad and very bad health versus all the other variants. Death is registered in the 
sample on the basis of the information provided by the household head when the unit is 
surveyed at least two rounds in a row. A household head is asked to report whether any 
household member is missing during the survey round and the reason for that member being 
not in the household. One of the reasons reported is the death of the household member. More 
details on the measurement and methodology could be found in Denisova (2010). 
In all cases we control for gender, age, the respondent’s education, per capita household 
income, place of residence, body mass index and smoking (whether or not the respondent 
smokes). We also control for the individual’s assessment of his own social status on a nine-
point scale (“respected – not respected”). This makes it possible to take into account the 
impact of constant psychological stress on a person’s health and separate that impact from 
the impact from alcohol consumption. 
The impact of alcohol consumption on health is estimated based on pooled cross-section for 
1994-2007 (Table 2) and on a panel for the same years (Table 3). The impact of alcohol 
consumption on the risk of death is estimated with Gompertz proportional hazard model 
(Table 4).     
The results of the estimates of the impact of alcohol consumption on health in Table 2 show 
that frequent alcohol consumption harms health. Thus, frequent alcohol consumption 
increases the probability of having bad or very bad health by 7 percentage points. Moreover, 
frequent alcohol consumption that includes vodka leads to health deterioration (the risk of 
bad health increases by 9 percentage points) whereas frequent consumption of beer does not 
have a statistically significant effect on health. The negative impact of frequent alcohol 
consumption on health is stable regardless of the method of assessment and of control for 
individual specific recorded effects in particular (Table 3). Frequent alcohol consumption 
increases the probability of bad or very bad health by 17 percentage points, with the entire 
effect caused by frequent consumption of vodka.   
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Males and females Males Females
Age -0.02 -0.02 -0.021 -0.021 -0.018 -0.018 0.035 0.037 0.032
[0.000]*** [0.000]*** [0.000]*** [0.000]*** [0.000]***[0.000]*** [0.001]*** [0.001]*** [0.001]***
Gender: Males 0.209 0.209 -0.202
[0.006]*** [0.006]*** [0.017]***
Married 0.032 0.032 0.031 0.031 0.029 0.029 -0.14 -0.172 -0.12
[0.005]*** [0.005]*** [0.009]*** [0.009]*** [0.007]***[0.007]*** [0.015]*** [0.026]*** [0.019]***
Junior or secondary professional education -0.01 -0.01 -0.029 -0.029 0.004 0.004 -0.085 -0.063 -0.099
[0.006]* [0.006]* [0.009]*** [0.009]*** [0.007] [0.007] [0.016]*** [0.026]** [0.020]***
Higher education 0.063 0.063 0.056 0.056 0.057 0.056 -0.211 -0.219 -0.193
[0.008]*** [0.008]*** [0.012]*** [0.012]*** [0.009]***[0.009]*** [0.022]*** [0.038]*** [0.027]***
Log of real per capita income, 1992 prices 0.022 0.022 0.019 0.019 0.023 0.023 -0.075 -0.088 -0.066
[0.003]*** [0.003]*** [0.004]*** [0.004]*** [0.004]***[0.004]*** [0.008]*** [0.012]*** [0.010]***
Self-perceived status, respect rank on 9-step ladder 0.027 0.027 0.035 0.036 0.018 0.018 -0.035 -0.053 -0.02
[0.001]*** [0.001]*** [0.002]*** [0.002]*** [0.002]***[0.002]*** [0.004]*** [0.006]*** [0.005]***
Frequent alcohol drinker -0.025 -0.016 -0.021
[0.014]* [0.015] [0.033]
Frequent vodka drinker (pure and in mix) -0.029 -0.023 -0.025 0.092 0.084 0.066
[0.017]* [0.018] [0.043] [0.043]** [0.048]* [0.113]
Frequent beer drinker (no vodka) 0.002 0.012 0.021 -0.105 -0.122 -0.187
[0.031] [0.035] [0.066] [0.101] [0.115] [0.212]
Smokes -0.06 -0.06 -0.041 -0.041 -0.07 -0.071 0.038 -0.024 0.07
[0.006]*** [0.006]*** [0.007]*** [0.007]*** [0.008]***[0.008]*** [0.017]** [0.024] [0.026]***
Body mass index 0.029 0.029 0.111 0.111 0.007 0.007 -0.064 -0.184 -0.017
[0.017]* [0.017]* [0.025]*** [0.025]*** [0.011] [0.011] [0.003]*** [0.058]*** [0.028]
 Body mass index squared/1000 -0.538 -0.539 -1.891 -1.891 -0.241 -0.241 1.158 2.998 0.503
[0.304]* [0.304]* [0.468]*** [0.468]*** [0.195] [0.195] [0.047]*** [1.082]*** [0.452]
Unemployed -0.002 -0.002 0.004 0.004 -0.002 -0.002 0.082 0.031 0.1
[0.011] [0.011] [0.017] [0.017] [0.015] [0.015] [0.032]** [0.052] [0.042]**
Urban settlement -0.061 -0.061 -0.062 -0.062 -0.06 -0.06 0.034 0.046 0.026
[0.005]*** [0.005]*** [0.008]*** [0.008]*** [0.007]***[0.007]*** [0.015]** [0.023]** [0.019]
Constant 3.197 3.196 2.288 2.287 3.575 3.575 -0.87 0.737 -1.705
[0.230]*** [0.230]*** [0.321]*** [0.321]*** [0.155]***[0.155]*** [0.084]*** [0.756] [0.380]***
Year dummies Yes Yes Yes Yes Yes Yes Yes Yes Yes
Number of observations 75037 75037 34083 34083 40954 40954 75265 34204 41061
R squared 0.19 0.19 0.17 0.17 0.18 0.18 0.12 0.12 0.12
Standard errors in brackets;                     * significant at 10%; ** significant at 5%; *** significant at 1%
Bad and very bad health
p p
Self-accessed health
Males and females Males Females
 
Table 2. Influence of alcohol consumption on health, pooled cross-section, 1994-2007 
Males Females
Age -0.016 -0.016 -0.023 -0.023 -0.01 -0.01 0.004 0.004 0.006 0.003
[0.001]*** [0.001]*** [0.001]*** [0.001]*** [0.001]***[0.001]***[0.000]*** [0.000]*** [0.000]*** [0.000]***
Married 0.031 0.031 0.038 0.038 0.034 0.034 -0.002 -0.002 -0.006 -0.001
[0.007]*** [0.007]*** [0.011]*** [0.011]*** [0.008]***[0.008]*** [0.003] [0.003] [0.005] [0.005]
Log of real per capita income, 1992 prices 0.007 0.007 0.006 0.006 0.008 0.008 -0.005 -0.005 -0.005 -0.006
[0.003]** [0.003]** [0.004] [0.004] [0.004]** [0.004]** [0.001]*** [0.001]*** [0.002]** [0.002]***
Self-perceived status, respect rank on 9-step ladder 0.01 0.01 0.013 0.013 0.007 0.007 -0.002 -0.002 -0.003 -0.002
[0.001]*** [0.001]*** [0.002]*** [0.002]*** [0.002]***[0.002]***[0.001]*** [0.001]*** [0.001]*** [0.001]**
Frequent alcohol drinker -0.028 -0.008 -0.098 0.017
[0.013]** [0.015] [0.031]*** [0.006]***
Frequent vodka drinker (pure and in mix) -0.028 -0.008 -0.13 0.017 0.01 0.056
[0.015]* [0.017] [0.039]*** [0.007]** [0.007] [0.021]***
Frequent beer drinker (no vodka) 0.017 0.042 -0.037 -0.005 -0.004 -0.015
[0.029] [0.035] [0.059] [0.014] [0.015] [0.032]
Smokes -0.011 -0.012 0.01 0.01 -0.048 -0.048 -0.012 -0.012 -0.022 0.003
[0.010] [0.010] [0.013] [0.013] [0.014]***[0.014]***[0.005]*** [0.005]** [0.006]*** [0.008]
Body mass index 0.015 0.015 0.052 0.052 0.005 0.005 -0.008 -0.008 -0.021 -0.005
[0.003]*** [0.003]*** [0.008]*** [0.008]*** [0.003] [0.003] [0.001]*** [0.001]*** [0.003]*** [0.002]***
Body mass index squared/1000 -0.15 -0.15 -0.71 -0.711 -0.057 -0.057 0.073 0.073 0.277 0.045
[0.036]*** [0.036]*** [0.130]*** [0.130]*** [0.037] [0.037] [0.018]*** [0.018]*** [0.056]*** [0.020]**
Constant 3.451 3.451 3.252 3.254 3.338 3.338 0.15 0.149 0.262 0.163
[0.050]*** [0.050]*** [0.117]*** [0.117]*** [0.060]***[0.060]***[0.025]*** [0.025]*** [0.050]*** [0.033]***
Number of observations 75054 75054 34097 34097 40957 40957 75283 75283 34219 41064
Number of individuals (groups) 19026 19026 9025 9025 10002 10002 19056 19056 9043 10014
R squared 0.16 0.16 0.15 0.15 0.16 0.16 0.06 0.06 0.06 0.05
Standard errors in brackets;                     * significant at 10%; ** significant at 5%; *** significant at 1%
p , p ,
Self-accessed health Bad and very bad health
Males and females Males Females Males and females
 
Table 3. Influence of alcohol consumption on health, panel fixed effects, 1994-2007 
The results of the assessment of the impact of alcohol on risk of death are shown in Table 4. As 
seen from the table, frequent consumption of alcohol, above all of strong spirits, increases the 
risk of death. Simple consumption of vodka or beer does not yield a statistically significant 
effect. Frequent consumption of alcohol increases the risk of death by 60 percentage points. 
Frequent consumption of vodka increases the risk of death by 66 percentage points whereas 
frequent consumption of beer does not have a statistically significant effect.  
Public Health – Methodology, Environmental and Systems Issues 380 
 
(1) (2) (3) (4)
Economic well-being
    Household in poverty: the 1st poverty episode 0.86 0.853 0.86 0.854
[0.045]*** [0.045]*** [0.045]*** [0.045]***
    Household in poverty: the 2nd, 3d, ... poverty episodes 1.373 1.338 1.369 1.343
[0.227]* [0.230]* [0.226]* [0.232]*
    Consumption decile (within year) 0.981 0.98 0.98 0.975
[0.154] [0.155] [0.155] [0.154]
Self-perceived status
    Economic rank on 9-step ladder 0.973 0.97 0.972 0.971
[0.035] [0.035] [0.035] [0.035]
    Respect rank on 9-step ladder 0.947 0.945 0.946 0.947
[0.023]** [0.023]** [0.023]** [0.023]**
Stress indicator
    Concern about getting necessities 1.088 1.065 1.083 1.077
[0.113] [0.112] [0.112] [0.113]
Habits
    Smokes 1.582 1.577 1.584 1.563
[0.193]*** [0.191]*** [0.193]*** [0.188]***
    Frequent alcohol drinker 1.594 1.514
[0.282]*** [0.273]**
   Vodka/hard liquids drinker 1.142 1.117
[0.123] [0.124]
   Beer drinker 1.021 0.999
[0.136] [0.132]
    Frequent vodka drinker 1.663
[0.324]***
   Frequent beer drinker 1.243
[0.726]
Alchohol availability
    Relative price of vodka to bread in locality 1.015 1.015 1.015 1.015
[0.011] [0.011] [0.011] [0.011]
(1) (2) (3) (4)
Labor market experience
     Unemployed 1.495 1.503 1.498 1.498
[0.363]* [0.361]* [0.365]* [0.363]*
    Experience as entrepreneur/self-employed 0.472 0.472 0.471 0.472
[0.182]* [0.182]* [0.181]* [0.182]*
    Mobile in labor market 0.488 0.493 0.489 0.492
[0.087]*** [0.087]*** [0.087]*** [0.087]***
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    Could not afford or find prescribed medicine 1.179 1.144 1.174 1.149
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[0.087] [0.087]* [0.089] [0.087]*
      University degree or higher 0.649 0.647 0.652 0.649
[0.123]** [0.124]** [0.124]** [0.124]**
     Urban settlement 0.758 0.744 0.755 0.743
[0.072]*** [0.076]*** [0.071]*** [0.076]***
Health undicators Yes*** Yes***
Gompertz function coefficients 0.053 0.053 0.053 0.053
[0.004]*** [0.004]*** [0.004]*** [0.004]***
Observations 70715 70513 70715 70513
No. of subjects              17606 17596 17606 17596
No. of failures 420 418 420 418
Log Pseudolikelihood -603.07 -602.64 -603.24 -600.36
Robust standard errors in brackets; * significant at 10%; ** significant at 5%; *** significant at 1%  
Table 4. Determinants of mortality, working age population, 18-65, parametric Gompertz 
regression 
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The results obtained can be represented as differences in survival functions for those who 
frequently drink strong alcoholic beverages and those who rarely or never consume strong 
liquor. Such functions are represented in Fig. 15. As seen from the ratio of the curves, 
frequent consumption of vodka shortens life by an average 9-10 years. At the same time, as 
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Fig. 15. Predicted survival curves: frequent drinkers of strong liquor (broken line) and 
infrequent drinkers and non-drinkers (solid line). The forecast is based on estimates 
presented in Table 3. 
Thus, the regression analysis based on longitudinal data makes it possible to isolate the 
impact of various types of alcohol consumption on the health and mortality controlled for 
the impact of other groups of factors. Our results attest to a strong negative impact of 
frequent alcohol consumption on health and the risk of death. Moderate alcohol 
consumption does not exert a statistically significant effect. In addition, the negative impact 
of frequent consumption of strong alcoholic beverages is greater than the effect of frequent 
consumption of wine and beer: frequent consumption of vodka shortens life by an average 
9-10 years, whereas no statistically significant impact of frequent beer drinking has been 
revealed. 
5. Anti-alcohol policy measures: The experience of European countries 
The experience of the countries of Northern Europe in encouraging people to switch from 
the consumption of mainly strong alcoholic beverages to lighter ones (beer and wine) shows 
active use of excise policy measures. Table 5 contains information on excise rates on alcohol, 
intermediate products, wine and beer in European countries in 2010. As seen from the table, 
the excise rates in the North  European countries are significantly higher than in other 
countries, and excise on alcohol is 2-4 times higher than excise on beer (in liters of pure 
alcohol). In some other European countries the gap between excise on spirits and beer is six-
fold, although excise is much lower than in the North European countries in absolute terms.  
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fold, although excise is much lower than in the North European countries in absolute terms.  
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Similar calculations of the ratio of excise on various types of alcoholic drinks in Russia could 
be found in the bottom line in Table 5. As seen from the table, excise on all alcoholic 
beverages in Russia is several times lower than in European countries. Moreover, the 
structure of excise tax in Russia differs drastically from the structure in excise in Europe. 
Russia has a very low excise on distilled spirits: 5.25 euros against 49.21 euros in Sweden 
(and even 85.36 euros in Norway) and 10 euros in Austria. The excise rate on wine in Russia 
is close to the rates of wine-consuming countries of southern Europe, a mere 80 eurocents. 
The rate of tax on beer increased significantly in 2010 but is much lower than the similar 
rates in North Europe, UK and Ireland in absolute terms. It is though comparable – and 
even higher if income differences are taken into account – with excise rates in beer-
consuming countries. Beer excise amounts to 26 euros in Finland, 19.87 euros in Ireland, 
18.08 euro in UK, 17.07 euros in Sweden, but is only 1.73 euros in Germany, 4.4 euros in 
Austria, 4.9 euros in Netherlands and 4.5 euros in Russia. In addition, strong beer (upward 
of 8.6%) is common in Russia, unlike in Europe.   
Country Distilled spirits Wine (11%) Beer (5%)
Austria 10.03 0 4.4
Belgium 17.52 4.28 3.76
Denmark 20.14 7.42 6.84
Finland 39.4 25.47 26
France 15.12 0.3 2.71
Germany 13.04 0 1.73
Greece 15.7 0 3.58
Ireland 31.13 23.81 19.87
Italy 8 0 5.17
Netherlands 15.04 6.23 4.9
Portugal 10 0 2.76
Spain 8.3 0 2
Sweden 49.21 19.25 17.07
UK 24.85 21.59 18.08
Russia 5.25 0.8 4.5  
Source: CEPS, Summary of EU Member States at 
http://www.europeanspirits.org/OurIndustry/TaxationIndustry.asp (Rates as of January 2010)  for 
Europe and Federal Law No. 171-FZ for Russia (converted according to 40 rubles per euro exchange rate). 
Table 5. Alcohol excise rates (euros per litre of pure alcohol), Russia and Europe, 2010  
On the whole excise rates on alcohol in Russia are rather low, especially for distilled spirits, 
even with due account of the differences in the purchasing power of the population in 
Europe and Russia. Excise rates on distilled spirits in Russia are strikingly low when 
compared to the rates in countries with unhealthy high alcohol consumption and high share 
of consumption of hard liquids. Moreover, the ratios of excise rates on distilled spirits and 
beer are in sharp contrast to those in all European countries. Wine excise rate is comparable 
to wine-consuming countries of Europe. The policy of reducing alcohol consumption 
dictates an increase of excise on all alcoholic products. If Russians are to be induced to 
consume less alcohol and strong alcoholic beverages in particular, excise on distilled spirits 
must grow faster than on other goods.  
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The effectiveness of the use of price mechanisms to limit alcohol consumption depends on 
how price-elastic demand for alcoholic beverages is. Assessments of the elasticity of demand 
for alcoholic beverages in the European countries and Russia will be found in Table 6. 
Country Price elasticity Income elasticity
Finland, Sweden, Norway -0.782 0.752
Austria, France, Greece, Italy, Portugal 
and Spain -0.216 0.752
Belgium, Denmark, Ireland, UK -0.495 0.752
Netherlands -1.466 0.752
Russia
      Vodka -1.774 0.524
      Beer -3.017 1.114
      Wine -1.045 1.304  
Source: Leppanen et al, 2001 for European countries, Andrienko and Nemtsov, 2005 for Russia 
Table 6. Elasticity of demand for alcoholic beverages in the countries of Europe and Russia 
As seen from the table the assessment of the elasticity of demand for vodka, beer and wine 
depending on price in Russia is much higher than the same indicators for the European 
countries and is comparable to the elasticity of demand in the Netherlands. This suggests 
that price measures of influencing alcohol consumption – increasing excise on strong 
beverages in order to encourage people to switch to types of alcohol consumption that cause 
less harm to health – can be effective. In Russia the experience of the past decades has 
revealed a relative cheapening of vodka. Thus in the late 1980s the ratio of vodka and beer 
prices was such that one could buy nine bottles of beer for the price of one bottle of vodka. 
At present it can buy on average 3-4 bottles of beer (and some vodkas are even cheaper).    
Along with price measures, an effective anti-alcohol policy must include other measures: the 
system of control of the production and sale of alcohol, restriction of the sale of alcohol outside 
restaurants, bars, etc., restrictions on the minimum age of the customer to whom alcohol can 
be sold, restrictions on alcohol advertising, on sponsorship of sporting and youth events, and 
on consumption of alcohol in public places. All the European countries, and not only the 
northern ones, have significantly strengthened their anti-alcohol policies in the last 50 years.  
6. Conclusions  
Mortality dynamics in Russia are due in large part to excessive alcohol consumption. In  
Russia consumption of strong alcoholic beverages exceeds the consumption of beer and 
wine both in terms of the aggregate volume and prevalence among the population. This 
“northern” type of consumption is characteristic of all the income and education groups.  
There is a trend for vodka consumption to shift towards the older age group while young 
people are switching to the consumption of beer. Whether this is a sustained trend is 
unclear. There is a trend for better educated and wealthier people to switch to the 
consumption of wine rather than hard liquor.  
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An analysis of the impact on health and mortality attests to a strong negative impact of 
frequent alcohol consumption. Moderate alcohol consumption does not produce a 
statistically significant negative effect.  
The negative impact of frequent consumption of hard liquor exceeds that of the 
consumption of wine and beer. Frequent consumption of vodka shortens the lifespan by an 
average 9-10 years while no statistically significant impact has been revealed of frequent 
consumption of beer. 
An active anti-alcohol policy must include both price and non-price measures. The policy 
aimed at reducing alcohol consumption calls for a rise of excise on all the alcoholic products.  
If Russians are to be encouraged to switch to lighter drinks, excise on hard liquor must grow 
faster than other excise rates.  
There is a large untapped potential for the use of non-price anti-alcohol measures aimed at 
reducing alcohol consumption in Russia. The experience of North European countries which 
have succeeded in switching from the consumption of predominantly hard liquor to the 
consumption of beer and wine and significantly cutting the consumption of hard liquor is of 
particular relevance.  
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Insomnia is a common sleep disorder. People suffering from insomnia generally report not 
only sleep-related symptoms such as difficulty initiating, maintaining, obtaining sufficient 
restorative sleep, but also experience various daytime impairment reflective of sleep deficits 
(Buysse, 2008; Riemann et al., 2011). The generic term “insomnia” as a diagnostic entity is 
defined as a complaint of sleep problems coupled with impairment of daytime functioning, 
including reduced alertness, fatigue, exhaustion, dysphoria and other symptoms. The 
complaints have to endure for at least 4 weeks to be diagnosed as insomnia, according to the 
current diagnostic classification manual (Abe & Mishima, 2008).  
 Chronic insomnia is a “24-hour disease”, meaning not only reduces the quality of sleep during 
the night, but also causes a variety of impairments in mental and physical functioning during 
the daytime (Bonnet & Arand, 1995, 2011). Although some patients who have this problem 
may not report it as such, inadequate sleep has been associated with reduced physical health 
and mental health (Morin & Espie, 2004; LeBlanc et al., 2007). Thus, many people are likely 
those who are in the “pre-insomnia” moment, and do not even consider themselves 
insomniacs (Bastien et al., 2004). Chronic insomnia is also associated with both human and 
socioeconomic costs, such as increased long-term absenteeism at work, reduced performance 
and productivity, and increased industrial accidents and health-care costs. This impact could 
be explained by three points: 1) comorbid mental (psychiatric) conditions, 2) comorbid medical 
conditions and 3) socioeconomic impact of insomnia (Mai & Buysse, 2008). 
In primary care, practitioners usually prescribe medication such as hypnotics without for 
such insomnia complaints. However, the use of these sedative agents is often problematic, 
especially when patients have kept a good QOL activity in daily life (Riemann et al., 2011). 
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The mere augmentation of medication runs a risk of exacerbating daytime impairment itself. 
The continued widespread use of sedative medication to treat insomnia raises concern about 
the potential for long term tolerance and addiction, particularly where insomnia is the 
presenting complaint of missed diagnoses such as comorbid depression and anxiety 
disorder, or when adverse effects might be a problem—for example, falls in older adults 
(Riemann et al., 2011).  
We will review about insomnia in terms of several aspects: its concept, epidemiology, 
pathophysiology, psychobehavioral correlates and possible psychiatric interventions.  
At the same time, we will show our own epidemiological study about Japanese people 
with insomnia based on the general population sample, and present some clinical case 
studies in order to describe several aspects of insomnia comorbid with mental disorders. 
We will also mention the correlates of nightmares, sleep disturbances related to 
suicidality and alcoholism as current important clinical and research topics. Finally, we 
will comment on future remarks based on the current society in Japan aftermath of 
Tsunami disaster in March 2011. In discussing mainly insomnia and nightmare, we used 
the terms “sleep disturbances” and “sleep problems” interchangeably in this paper, 
following the context.  
2. Current definition and prevalence of insomnia 
The reported prevalence of insomnia in the general population varies widely, ranging 
between 4.4% and 48%, depending on sample characteristics and the definition of insomnia 
(Ohayon, 2002). According to the American Sleep Disorders Association International 
Classification of Sleep Disorders (ICSD-2) published in 2005, its coding manual, insomnia 
refers to “a repeated difficulty with sleep initiation, duration, consolidation, or quality that 
occurs despite adequate time and opportunity for sleep and results in some form of daytime 
impairment and lasting for at least one month.” (AASM, 2005).  
2.1 DSM-5 proposed criteria of insomnia  
The major current diagnostic systems ICD-10 (International Classification of Disorders 10th 
edition) and DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, APA) includes 
sections on insomnia and several sleep disorders. Both ICD-10 and DSM-IV are currently 
under review (Riemann et al., 2011). Contemporary psychiatry has been greatly influenced 
by these nosographic changes. In 2010, the DSM-V proposed criteria were tentatively 
manifested, which might be espected to increase the significance of the notion of sleep 
disturbances, after the presumable publication of DSM-V in 2013. It is under discussion 
whether the category primary/secondary insomnia should be replaced by the term « 
insomnia disorder ». In any case, this would emphasize the independence of the category in 
favor of the insomnia comorbidity concept, as suggested by the State of the Science 
conference on insomnia (NIH, 2005).  
The concept and diagnostic criterion of insomnia are still fluctuating. In orde to become 
familiar with the current nosographic controversy, we show Table 1, which explains the 
general criteria for insomnia in ICSD-2, as well as the draft criteria for insomnia disorder in 
DSM-5 draft published in 2010 (Proposed DSM-5 Draft, 2010).  
Insomnia and Its Correlates:  




ICSD-2 General Criteria for insomnia (2005): 
 
A.  A complaint of difficulty initiating sleep, difficulty maintaining sleep, or waking up too 
early or sleep that is chronically unrestorative or poor in quality. In children, the sleep 
difficulty is often reported by the caretaker and may consist of observed bedtime 
resistance or inability to sleep independently.  
B.  The above sleep difficulty occurs despite adequate opportunity and circumstances for 
sleep.  
C.  At least one of the following forms of daytime impairment related to the nighttime 
sleep difficulty is reported by the patient: fatigue or malaise; attention, concentration, or 
memory impairment; social or vocational dysfunction or poor school performance; 
mood disturbance or irritability; daytime sleepiness; motivation, energy, or initiative 
reduction; proneness for errors or accidents at work or while driving; tension, 
headaches, or gastrointestinal symptoms in response to sleep loss; concerns or worries 
about sleep.  
 
DSM-5 proposed Insomnia Disorder (2010). 
 
A.  The predominant complaint is dissatisfaction with sleep quantity or quality made by 
the patient (or by a caregiver or family in the case of children or elderly).  
B.  Report of one or more of the following symptoms: 
- Difficulty initiating sleep; in children this may be manifested as difficulty initiating 
sleep without caregiver intervention  
- Difficulty maintaining sleep characterized by frequent awakenings or problems 
returning to sleep after awakenings (in children this may be manifested as 
difficulty returning to sleep without caregiver intervention)  
- Early morning awakening with inability to return to sleep  
- Non restorative sleep  
- Prolonged resistance to going to bed and/or bedtime struggles (children)  
C.  The sleep complaint is accompanied by significant distress or impairment in daytime 
functioning as indicated by the report of at least one of the following: fatigue or low 
energy; daytime sleepiness; cognitive impairements (e.g., attention, concentration, 
memory); Mood disturbances (e.g., irritability, dysphoria); behavioral problems (e.g., 
hyperactivity, impulsivity, aggression); impaired occupational or academic function; 
impaired interpersonal/social function; negative impact on caregiver or family 
functioning (e.g., fatigue, sleepiness).  
D.  The sleep difficulty occurs at least three nights per week.  
E.  The sleep difficulty is present for at least three months.  
F.  The sleep difficulty occurs despite adequate age-appropriate circumstances and 
opportunity for sleep. 
* Duration: i. Acute insomnia (< 1month); ii. Sub acute insomnia (1-3 months); iii. Persistant insomnia  
(> 3 months).  
* Clinically Comorbid Conditions: i. Psychiatric disorder; ii. Medical disorder; iii. Another disorder. 
Table 1. General criteria for insomnia in ICSD-2 (2005) and insomnia disorder in proposed 
DSM-5 (2010) 
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2.2 Japanese general population sample, re-analysed 
Following this current insomnia concepts, we reanalyzed our Japanese population 
representative sample of 24,551 adults performed in 2000 (Abe et al., 2011). The present 
study was conducted using partial data from the Active Survey of Health andWelfare 
performed in June 2000 by the Ministry of Health, Labour and Welfare. To provide a 
representative sample of the general population in Japan, the survey was conducted 
through public health centers in 300 target areas randomly selected from the 881, 851 
national census areas nationwide. The self-administered questionnaire consisted of 44 items 
covering the general health status, physical and psychological complaints and sleep habits 
and problems. We first selected cases reporting the presence of both insomnia symptoms 
and physical/psychological complaints during the past one month, identified based on the 
responses to the survey questionnaire about sleep problems and daytime functioning during 
the past one month. Then we excluded cases reporting a common comorbid sleep disorder 
(sleep-disordered breathing and restless leg syndrome).  
The result was that we found a fairly high prevalence of insomnia (43.4%) as defined in 
this study (see Table 2) compared to before in the general population sample in Japan. 
Although previous studies have pointed out that Japanese people tend to underreport 
their sleep problems, because of cultural reticence compared with those in Western 
cultures, our results did not necessarily align with these studies (Abe & Mishima, 2008; 
Abe et al., 2011).  
Possible reasons for the higher prevalence of insomnia obtained in our study include the 
following. First, following the ICSD-2 criteria, an item on “nonrestorative sleep” was added 
to our definition of insomnia. Secondly, our sample may have included cases with short-
term insomnia occurring in less than the past one month (e.g. adjustment insomnia) in the 
absence of specifications on the duration and frequency of insomnia symptoms. The case 
definition of insomnia based partially on the ICSD-2 and DSM-IV was more liberal than the 
original definitions of the disorder. Lastly, the greatest factor responsible for such a higher 
prevalence rate was the inadequate assessment of daytime impairments associated with 




Table 2. Presence of insomnia and insomnia comorbid with depression, by age, group and 
sex in a sample of the general Japanese adult population, conducted in 2000 (n=24, 551) .  
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It is possible that the complaints from participants were related to physical or psychological 
problems, which are separate issues from insomnia. However, as far as we know, there is no 
validated self-reporting tool about which researchers are in consensus for accurately 
measuring daytime impairments due to insomnia (Ohayon & Lemoine, 2004; Shekleton et 
al., 2010). One of the main reasons for this overdiagnosis of insomnia is that we used « 
daytime impairment » related to insomnia, including various items such as fatigue. This 
result implies one important subject, that is to say, “fatigue” itself can be regarded as a core 
symptom of insomnia (Choquet et al., 1993; Riemann et al., 2011). In recent literature, 
daytime sleepiness, hypersomnia and fatigue are common symptoms of depression 
(Franzen & Buysse, 2008). But, such symptoms can occur independently, or they may occur 
secondarily to insomnia comorbidity, as well as short- or long-term side effects of 
antidepressant medications themselves (Riemann et al., 2011).  
3. The current psychobiological model of insomnia: Hyperarousal model  
Although pathophysiology of insomnia remains to be explored, physiological hyperarousal 
evidenced by cognitive, endocrine, and neurophysiologic variables has been revealed to be 
involved in onset and development of insomnia (Bonnet, 1995, 2010; Riemann et al., 2010). 
Patients with insomnia suffer from cognitive deficit. Characteristically, they report their 
sleep and psychoperformance to be worse than are objectively measured (Endo, 1962; Orff et 
al., 2007). This “perceived” deficit is exactly what aggravates the QOL of insomniac patients 
and let them fall in a vicious cycle (Abe & Mishima, 2008). Also, insomnia is often induced 
by stressful events, and is assumed to develop by the 3P model (predisposing, precipitating 
and perpetuating factors), proposed by Spielman that is widely used to explain the onset 
mechanism of insomnia (Spielman et al., 1987; Ellis et al., 2011).  
There is a need for clarification of pathophysiology of insomnia for development of efficient 
treatment skills and critical prevention of chronic insomnia. Just recently, reductions in 
hippocampal volume size have been reported in patients suffering from primary insomnia 
in brain research (Riemann et al., 2009). In the light of neurobiological theories of sleep-wake 
regulation, insomnia may be conceptualised as the final common pathway of the interaction 
of a genetic vulnerability to an imbalance between arousing and sleep-inducing brain 
centres, which is triggered by psychosocial and/or medical stressors, with perpetuating 
mechanisms such as maladaptive behaviours, learned sleep-preventing associations and 
cognitive factors (Basta et al., 2007; Riemann et al., 2010).  
3.1 Development of chronic insomnia: 3P model 
According to Spielman, insomnia is often induced by stressful events, and assumed to 
develop by his 3P model (predisposing, precipitating and perpetuating factors), that is 
widely used to explain the onset mechanism of insomnia (Spielman et al., 1987). Factors 
leading to the onset and worsening of insomnia are multidimensional in nature, and many 
life events and life stresses can result in acute insomnia. Inadequate stress coping behavior 
also precipitates insomnia, and heightens uneasiness and tension around being unable to 
sleep, thereby perpetuating the sleeplessness (Abe & Mishima, 2008). Furthermore, 
insomniacs may often engage in poor sleep hygiene, such as having an inadequate sleep 
environment, lack of daytime activities, and excessive afternoon napping. It is reported that 
the majority of people with insomnia attempt to cope with sleep problems in various ways, 
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Abe et al., 2011).  
Possible reasons for the higher prevalence of insomnia obtained in our study include the 
following. First, following the ICSD-2 criteria, an item on “nonrestorative sleep” was added 
to our definition of insomnia. Secondly, our sample may have included cases with short-
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absence of specifications on the duration and frequency of insomnia symptoms. The case 
definition of insomnia based partially on the ICSD-2 and DSM-IV was more liberal than the 
original definitions of the disorder. Lastly, the greatest factor responsible for such a higher 
prevalence rate was the inadequate assessment of daytime impairments associated with 




Table 2. Presence of insomnia and insomnia comorbid with depression, by age, group and 
sex in a sample of the general Japanese adult population, conducted in 2000 (n=24, 551) .  
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It is possible that the complaints from participants were related to physical or psychological 
problems, which are separate issues from insomnia. However, as far as we know, there is no 
validated self-reporting tool about which researchers are in consensus for accurately 
measuring daytime impairments due to insomnia (Ohayon & Lemoine, 2004; Shekleton et 
al., 2010). One of the main reasons for this overdiagnosis of insomnia is that we used « 
daytime impairment » related to insomnia, including various items such as fatigue. This 
result implies one important subject, that is to say, “fatigue” itself can be regarded as a core 
symptom of insomnia (Choquet et al., 1993; Riemann et al., 2011). In recent literature, 
daytime sleepiness, hypersomnia and fatigue are common symptoms of depression 
(Franzen & Buysse, 2008). But, such symptoms can occur independently, or they may occur 
secondarily to insomnia comorbidity, as well as short- or long-term side effects of 
antidepressant medications themselves (Riemann et al., 2011).  
3. The current psychobiological model of insomnia: Hyperarousal model  
Although pathophysiology of insomnia remains to be explored, physiological hyperarousal 
evidenced by cognitive, endocrine, and neurophysiologic variables has been revealed to be 
involved in onset and development of insomnia (Bonnet, 1995, 2010; Riemann et al., 2010). 
Patients with insomnia suffer from cognitive deficit. Characteristically, they report their 
sleep and psychoperformance to be worse than are objectively measured (Endo, 1962; Orff et 
al., 2007). This “perceived” deficit is exactly what aggravates the QOL of insomniac patients 
and let them fall in a vicious cycle (Abe & Mishima, 2008). Also, insomnia is often induced 
by stressful events, and is assumed to develop by the 3P model (predisposing, precipitating 
and perpetuating factors), proposed by Spielman that is widely used to explain the onset 
mechanism of insomnia (Spielman et al., 1987; Ellis et al., 2011).  
There is a need for clarification of pathophysiology of insomnia for development of efficient 
treatment skills and critical prevention of chronic insomnia. Just recently, reductions in 
hippocampal volume size have been reported in patients suffering from primary insomnia 
in brain research (Riemann et al., 2009). In the light of neurobiological theories of sleep-wake 
regulation, insomnia may be conceptualised as the final common pathway of the interaction 
of a genetic vulnerability to an imbalance between arousing and sleep-inducing brain 
centres, which is triggered by psychosocial and/or medical stressors, with perpetuating 
mechanisms such as maladaptive behaviours, learned sleep-preventing associations and 
cognitive factors (Basta et al., 2007; Riemann et al., 2010).  
3.1 Development of chronic insomnia: 3P model 
According to Spielman, insomnia is often induced by stressful events, and assumed to 
develop by his 3P model (predisposing, precipitating and perpetuating factors), that is 
widely used to explain the onset mechanism of insomnia (Spielman et al., 1987). Factors 
leading to the onset and worsening of insomnia are multidimensional in nature, and many 
life events and life stresses can result in acute insomnia. Inadequate stress coping behavior 
also precipitates insomnia, and heightens uneasiness and tension around being unable to 
sleep, thereby perpetuating the sleeplessness (Abe & Mishima, 2008). Furthermore, 
insomniacs may often engage in poor sleep hygiene, such as having an inadequate sleep 
environment, lack of daytime activities, and excessive afternoon napping. It is reported that 
the majority of people with insomnia attempt to cope with sleep problems in various ways, 
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have fewer adaptive coping skills, rely more on emotion-focused coping strategies than on 
problem-solving strategies and report lower feelings of mastery (Vollath et al., 1989). 
Reduced quality of life associated with insomnia has already been reported in a general 
population sample (LeBlanc et al., 2007).  
3.2 Brief empirical evidence about insomnia 
Since the classical study of Monroe et al., the validity of the hyperarousal concepts in 
patients with insomnia has been tested by measuring autonomous variables, including 
ECG-derived heart rate and heart rate variability, body temperature, whole-body 
metabolism and galvanic skin response (Riemann et al., 2010). The majority of studies 
measuring such variables in insomnia documented an increased arousal tone in this patient 
group. However, it is still unclear whether increased autonomic activity is causing insomnia 
or whether vice versa, insomnia and its sleep loss triggers increased autonomic activity. 
Bastien et al. investigated a group of 285 patients evaluated for insomnia at a sleep medical 
clinic and found that 35% had a positive history for a sleep disturbances (Bastien & Morin, 
2000). Dauvilliers et al. described that of 77 patients with primary insomnia, 72.7% reported 
familial insomnia compared to 24.1% in a non-insomnia control group in a French 
population sample (Dauvilliers et al., 2005). Similar result was reported by Morin’s group 
from a Canadian polulation sample (Beaulieu-Bonneau et al., 2007). Drake et al. suggested 
that 37% of the variance in vulnerability to stress-related insomnia in siblings could be 
explained by familial aggregation (Drake et al., 2008). 
Neuroimaging studies in insomnia are now widely used in human basic sleep research.. A 
PET study, condulted by Nofzinger et al., acquired data from 7 chronic insomniacs and 20 
good sleeper controls during wakefulness and during consolidated Non-REM sleep. 
Patients with insomnia exhibited increased global glucose metabolism during wakefulness 
and Non-REM sleep. Patients with insomnia exhibited smaller declines in relative glucose 
metabolism from wakefulness to Non-REM sleep in wake promoting regions including the 
ascending reticular activation system. Reduced relative metabolism in the prefrontal cortex 
was found in insomniac while awake (Nofzinger et al., 2004). Another recent pilot study, 
using manual morphometry of structural magnetic resonance images showed that out of 
several regions of interest only one significant difference concerning a bilateral reduction of 
hippocampal volumes was found between 8 chronic insomniacs and 8 healthy control 
sleepers (Riemann et al., 2007). It remains to be determined whether these alterations of 
hippocampal structures are directly related to the insomnia. Nevertheless, these studies 
referred to above have taught us that the development of chronic insomnia is associated 
with measurable alterations of brain function pointing to Central Nervous System 
hyperarousal with a vulnerable familial aggregation. 
The study of daytime performance in patients with insomnia has been driven by the 
assumption that short-term or chronic sleep loss has a negative impact on daytime 
functioning. Thus, such a compensatory effot might play an important role in the opposing 
effects of sleep deficits and hyperarousal that influence daytime performance. 
The study of Orff et al. showed no impairments at all objective measures of cognitive 
performance in insomnia patients, with a discrepancy between subjective reports of deficits 
and objective neuropsychological tests (Orff et al., 2007). Despite the fact that there might be 
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only minor deficits in this population, investigating neuropsychological tests in large 
sample sizes might reveal stable deficits in the insomnia patients population (Edinger et al., 
2008).  
4. Symptomatic overlap: Insomnia-depression-anxiety connection 
4.1 Insomnia-depression 
In terms of descriptive symptomatology, insomnia symptoms often coexist with depressive 
and anxiety symptoms. As many as 90% of patients with depression will have sleep quality 
complaints (Tsuno et al., 2005). Alongside insomnia being the most common symptom of 
depression and anxiety disorder, persistent insomnia is a risk or exacerbating factor of 
depressive disorders (Riemann et al., 2003).  
In a Japanese general population sample, the presence of insomnia comorbid with 
depression was 5.5% with a rate of 12.7% among the sample of people with insomnia (Abe 
et al., 2011). In line with this, Ford & Kamerow reported 14.0% as a prevalence of insomnia 
co-occurring with depression in a study based on 7954 American households (Ford & 
Kamerow, 1989). These studies showed that the frequency of insomnia comorbid with 
depression observed in Western countries is stable among Japanese adults as well 
(approximately one seventh of the insomnia population). Vollarath et al. state that insomnia 
constitutes an independent syndrome (Vollath et al., 1989), and Buysse et al. suggest that 
insomnia and depression are commonly comorbid, and insomnia comorbid with depression 
is an important intermediate phenotype (Buysse et al., 2008). Following the current 
insomnia-depression literature, we can consider as follows: (1) Insomnia and depression are 
bidirectionally related; (2) Insomnia is a risk factor for developing depression and (3) 
Insomnia is a risk factor for poor depression outcomes. Taken together, treating insomnia 
may favorably impacts the trajectory of depression (Franzen & Buysse, 2008).  
4.2 Insomnia-anxiety 
In general, insomniacs manifest their multi-complaints and they often have a comorbidity 
with anxiety disorders. Harvey et al. proposed her cognitive model of insomnia, explaining 
that excessive worriness about insomnia itself exacerbates insomnia. Bader et al. suggested 
that adverse childhood experiences are associated with sleep in primary insomnia (Bader et 
al, 2007 ), and Gregory et al. reported that familial conflicts in childhood predicted later 
insomnia, a modest but robust longitudinal link between family conflict during childhood 
and insomnia experienced at 18 years of age. (Gregory et al., 2006).  
With regard to the comorbidity with anxiety disorder, the potential pathological link 
between insomnia and PTSD (posttraumatic stress disorder) and alcohol dependence should 
be more investigated. Especially, sleep disturbances have been considered the hallmark of 
PTSD for decades. Since insomnia has been observed in 90% of PTSD cases, both 
pharmacologic and psychosocial context of sleep of trauma should be needed to improve 
comorbid insomnia (Hendin et al., 2008 ). 
4.3 Case Study 1; PTSD coexist with sleep disturbances 
Clinically, sleep disturbances are common among individuals with posttraumatic stress 
disorder (PTSD), which are often resistant to first-line recommended treatments 
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have fewer adaptive coping skills, rely more on emotion-focused coping strategies than on 
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patients with insomnia has been tested by measuring autonomous variables, including 
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metabolism and galvanic skin response (Riemann et al., 2010). The majority of studies 
measuring such variables in insomnia documented an increased arousal tone in this patient 
group. However, it is still unclear whether increased autonomic activity is causing insomnia 
or whether vice versa, insomnia and its sleep loss triggers increased autonomic activity. 
Bastien et al. investigated a group of 285 patients evaluated for insomnia at a sleep medical 
clinic and found that 35% had a positive history for a sleep disturbances (Bastien & Morin, 
2000). Dauvilliers et al. described that of 77 patients with primary insomnia, 72.7% reported 
familial insomnia compared to 24.1% in a non-insomnia control group in a French 
population sample (Dauvilliers et al., 2005). Similar result was reported by Morin’s group 
from a Canadian polulation sample (Beaulieu-Bonneau et al., 2007). Drake et al. suggested 
that 37% of the variance in vulnerability to stress-related insomnia in siblings could be 
explained by familial aggregation (Drake et al., 2008). 
Neuroimaging studies in insomnia are now widely used in human basic sleep research.. A 
PET study, condulted by Nofzinger et al., acquired data from 7 chronic insomniacs and 20 
good sleeper controls during wakefulness and during consolidated Non-REM sleep. 
Patients with insomnia exhibited increased global glucose metabolism during wakefulness 
and Non-REM sleep. Patients with insomnia exhibited smaller declines in relative glucose 
metabolism from wakefulness to Non-REM sleep in wake promoting regions including the 
ascending reticular activation system. Reduced relative metabolism in the prefrontal cortex 
was found in insomniac while awake (Nofzinger et al., 2004). Another recent pilot study, 
using manual morphometry of structural magnetic resonance images showed that out of 
several regions of interest only one significant difference concerning a bilateral reduction of 
hippocampal volumes was found between 8 chronic insomniacs and 8 healthy control 
sleepers (Riemann et al., 2007). It remains to be determined whether these alterations of 
hippocampal structures are directly related to the insomnia. Nevertheless, these studies 
referred to above have taught us that the development of chronic insomnia is associated 
with measurable alterations of brain function pointing to Central Nervous System 
hyperarousal with a vulnerable familial aggregation. 
The study of daytime performance in patients with insomnia has been driven by the 
assumption that short-term or chronic sleep loss has a negative impact on daytime 
functioning. Thus, such a compensatory effot might play an important role in the opposing 
effects of sleep deficits and hyperarousal that influence daytime performance. 
The study of Orff et al. showed no impairments at all objective measures of cognitive 
performance in insomnia patients, with a discrepancy between subjective reports of deficits 
and objective neuropsychological tests (Orff et al., 2007). Despite the fact that there might be 
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only minor deficits in this population, investigating neuropsychological tests in large 
sample sizes might reveal stable deficits in the insomnia patients population (Edinger et al., 
2008).  
4. Symptomatic overlap: Insomnia-depression-anxiety connection 
4.1 Insomnia-depression 
In terms of descriptive symptomatology, insomnia symptoms often coexist with depressive 
and anxiety symptoms. As many as 90% of patients with depression will have sleep quality 
complaints (Tsuno et al., 2005). Alongside insomnia being the most common symptom of 
depression and anxiety disorder, persistent insomnia is a risk or exacerbating factor of 
depressive disorders (Riemann et al., 2003).  
In a Japanese general population sample, the presence of insomnia comorbid with 
depression was 5.5% with a rate of 12.7% among the sample of people with insomnia (Abe 
et al., 2011). In line with this, Ford & Kamerow reported 14.0% as a prevalence of insomnia 
co-occurring with depression in a study based on 7954 American households (Ford & 
Kamerow, 1989). These studies showed that the frequency of insomnia comorbid with 
depression observed in Western countries is stable among Japanese adults as well 
(approximately one seventh of the insomnia population). Vollarath et al. state that insomnia 
constitutes an independent syndrome (Vollath et al., 1989), and Buysse et al. suggest that 
insomnia and depression are commonly comorbid, and insomnia comorbid with depression 
is an important intermediate phenotype (Buysse et al., 2008). Following the current 
insomnia-depression literature, we can consider as follows: (1) Insomnia and depression are 
bidirectionally related; (2) Insomnia is a risk factor for developing depression and (3) 
Insomnia is a risk factor for poor depression outcomes. Taken together, treating insomnia 
may favorably impacts the trajectory of depression (Franzen & Buysse, 2008).  
4.2 Insomnia-anxiety 
In general, insomniacs manifest their multi-complaints and they often have a comorbidity 
with anxiety disorders. Harvey et al. proposed her cognitive model of insomnia, explaining 
that excessive worriness about insomnia itself exacerbates insomnia. Bader et al. suggested 
that adverse childhood experiences are associated with sleep in primary insomnia (Bader et 
al, 2007 ), and Gregory et al. reported that familial conflicts in childhood predicted later 
insomnia, a modest but robust longitudinal link between family conflict during childhood 
and insomnia experienced at 18 years of age. (Gregory et al., 2006).  
With regard to the comorbidity with anxiety disorder, the potential pathological link 
between insomnia and PTSD (posttraumatic stress disorder) and alcohol dependence should 
be more investigated. Especially, sleep disturbances have been considered the hallmark of 
PTSD for decades. Since insomnia has been observed in 90% of PTSD cases, both 
pharmacologic and psychosocial context of sleep of trauma should be needed to improve 
comorbid insomnia (Hendin et al., 2008 ). 
4.3 Case Study 1; PTSD coexist with sleep disturbances 
Clinically, sleep disturbances are common among individuals with posttraumatic stress 
disorder (PTSD), which are often resistant to first-line recommended treatments 
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(Singareddy & Balon, 2001). Recently, many studies and clinical experiences have suggested 
that sleep disturbances mainly representing insomnia and nightmare, have a distinct risk of 
suicide (Nadorff et al., 2011). If not, as some Holocaust survivors presented, impaired sleep 
and frequent nightmares had been considerable problems, even 45 years after the liberation 
(Rosen et al., 1991).  
This PTSD patient, a 40 year-old careered woman, still suffered from her residual sleep 
disturbance, even if she partially recovered from her PTSD symptoms and improved her 
quality of life again, resulting in returning to her work environment. She was firstly presented 
an anxiety related with insomnia in the context of the accidental loss of her husband in front of 
her, at the age of 36. This event led her to consult a psychiatrist for the first time, and she has 
continued to be treated with medication and an individual psychotherapy regularly once a 
month. Her insomnia, nightmare and occasional suicidal ideation made her continue to 
maintain her treatment. Of importance, this patient exacerbated suicide ideation every year the 
day of incident approached. Outside her stabilized period, every time the clinician tried to 
reduce her nocturnal treament, she exacerbated her sleep complaints and related somatic 
complaints, alluding to the clinician her suicidal ideations.  
For more than three decades, sleep disturbance had been considered the hallmark of PTSD 
(Hendin et al., 2008; Nadorff et al., 2011). Since insomnia has been observed in 90% of PTSD 
cases and nightmare related to the trauma in 70%, this is understandable (Hendin et al., 
2008). In this case, the clinician has mainly prescribed paroxetine (10-20 mg) and trazodone 
(25-50 mg) at night to improve subjective sleep disturbances. One of the paradoxical 
difficulties in psychopharmacology is that there has been increasing awareness of 
psychotropic-related sleep disruptions in PTSD patients. Especially, it is reported that 
selective serotonin reuptake inhibitors (SSRIs), usually prescribed as a first-line medication 
to PTSD, have conversely been associated with clusters of side effects, including insomnia 
and nightmare symptoms (Li et al., 2010). Trazodone, prescribed at low dose, may reverse 
the SSRI-induced insomnia; increases the antidepressant effects of SSRIs; promotes sleep 
through its sedative properties; and suppresses rapid eye movement sleep, thus reducing 
nightmares associated with PTSD (Sungareddy & Balon, 2001). This case showed that the 
residual symptoms related with sleep in PTSD resisted, even though the traumatic event 
had passed away and the patient recovered on a social function level. Probably, most 
experienced psychiatrists must have had the same treatment impressions before. It is true 
that sleep disturbance should be more than a marker of PTSD and hence may be important 
in the identification of suicidal ideation (Nadorff et al., 2011). Recently, Hendin et al. (2008) 
have insisted on the equal importance of the psychosocial context of trauma in treating sleep 
disturbance associated with PTSD. It is stressed again that sleep assessment should be 
considered in the evaluation of suicide risk in PTSD. Both pharmacological and 
psychotherapeutic approaches to the disorder have concentrated on improving sleep 
complaints. This case showed us the necessity of long-term sleep-focused approach in order 
to treat patients suffering from PTSD with suicidal ideation. That implies that incorporating 
individual psychotherapy, combined with sleep hygiene approach, can lead the patient to 
recovery from traumatic event in the long term setting. The emotional consequence of 
suicide will be devastating to the victim’s family, friends, community, and society. Studies 
of incidence, risk and protective factors related to sleep disturbances need to be high on the 
research agenda across many countries.  
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4.4 PSQI-A scale 
As this case description shows, PTSD patients report a wide variety of subjective 
complaints. These subjective sleep disturbances are non-specific and also observed in other 
sleep disorders and psychiatric clinical samples. For example, PTSD and depressed patients 
show similar global score on The Pittsburgh Sleep Quality Index, one of the most frequently 
used self-report instruments to assess sleep quality. Disruptive nocturnal behaviors  (DNB), 
such as trauma-related nightmares, may represent more specific sleep disturbances in PTSD. 
Recently, Germain et al. developed the PSQI Addendum for PTSD (PSQI-A), a brief sleep 
scale for PTSD, to evaluate DNB (Germain et al., 2005). This self-report instrument consists 
of 7 items that focus on the frequency of seven DNB, and includes three additional items 
regarding the frequency of anxiety and anger accompanying DNB and the timing of these 
events during tht night (Table 3). Such an assessment may support the clinical utility of 
assessing DNB to determine the need for further PTSD evaluation and intervention.  
 
PSQI Addendum for PTSD 
 
1. During the past month, how often have you had troubles sleeping because you… 
a. Feel hot flashes: 
b. Feel general nervousness: 
c. Had memories or nightmares of a traumatic experience: 
d. Had severe anxiety or panic, not related to traumatic memories: 
e. Had bad dreams, not related to traumatic memories: 
f. Had episodes of terror or screaming during sleep without fully awaking: 
g. Had episodes of “acting out” your dreams, such as kicking, punching, running , or 
screaming: 
2. If you had memories or nightmares of a traumatic experiences during sleep  
a. How much anxiety did you feel during the memories/nightmares? 
b. How much anger did you feel during the memories/ nightmares? 
c. What time of night did most memories/nightmares occur? 
. 
Table 3. Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A) (Germain et al., 2005) 
4.5 Stress coping and sleep hygiene among Japanese people with insomnia 
Factors leading to the onset and worsening of insomnia are multidimensional in nature, and 
many life events and life stresses can result in acute insomnia. Inadequate stress coping 
behavior also precipitates insomnia, and heightens uneasiness and tension around being 
unable to sleep, thereby perpetuating the sleeplessness. Furthermore, insomniacs may often 
engage in poor sleep hygiene, such as having an inadequate sleep environment, lack of 
daytime activities, and excessive afternoon napping (Abe et al., 2011). The majority of 
people with insomnia attempt to cope with sleep problems in various ways, have fewer 
adaptive coping skills, rely more on emotion-focused coping strategies than on problem-
solving strategies and report lower feelings of mastery (LeBlanc et al., 2007 ). Reduced 
quality of life associated with insomnia has already been reported in a general population 
sample. We have recently studied specific daily stress coping behaviors (SCBs) and sleep 
hygiene practices (SHPs) of people with insomnia in our Japanese population based sample. 
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(Singareddy & Balon, 2001). Recently, many studies and clinical experiences have suggested 
that sleep disturbances mainly representing insomnia and nightmare, have a distinct risk of 
suicide (Nadorff et al., 2011). If not, as some Holocaust survivors presented, impaired sleep 
and frequent nightmares had been considerable problems, even 45 years after the liberation 
(Rosen et al., 1991).  
This PTSD patient, a 40 year-old careered woman, still suffered from her residual sleep 
disturbance, even if she partially recovered from her PTSD symptoms and improved her 
quality of life again, resulting in returning to her work environment. She was firstly presented 
an anxiety related with insomnia in the context of the accidental loss of her husband in front of 
her, at the age of 36. This event led her to consult a psychiatrist for the first time, and she has 
continued to be treated with medication and an individual psychotherapy regularly once a 
month. Her insomnia, nightmare and occasional suicidal ideation made her continue to 
maintain her treatment. Of importance, this patient exacerbated suicide ideation every year the 
day of incident approached. Outside her stabilized period, every time the clinician tried to 
reduce her nocturnal treament, she exacerbated her sleep complaints and related somatic 
complaints, alluding to the clinician her suicidal ideations.  
For more than three decades, sleep disturbance had been considered the hallmark of PTSD 
(Hendin et al., 2008; Nadorff et al., 2011). Since insomnia has been observed in 90% of PTSD 
cases and nightmare related to the trauma in 70%, this is understandable (Hendin et al., 
2008). In this case, the clinician has mainly prescribed paroxetine (10-20 mg) and trazodone 
(25-50 mg) at night to improve subjective sleep disturbances. One of the paradoxical 
difficulties in psychopharmacology is that there has been increasing awareness of 
psychotropic-related sleep disruptions in PTSD patients. Especially, it is reported that 
selective serotonin reuptake inhibitors (SSRIs), usually prescribed as a first-line medication 
to PTSD, have conversely been associated with clusters of side effects, including insomnia 
and nightmare symptoms (Li et al., 2010). Trazodone, prescribed at low dose, may reverse 
the SSRI-induced insomnia; increases the antidepressant effects of SSRIs; promotes sleep 
through its sedative properties; and suppresses rapid eye movement sleep, thus reducing 
nightmares associated with PTSD (Sungareddy & Balon, 2001). This case showed that the 
residual symptoms related with sleep in PTSD resisted, even though the traumatic event 
had passed away and the patient recovered on a social function level. Probably, most 
experienced psychiatrists must have had the same treatment impressions before. It is true 
that sleep disturbance should be more than a marker of PTSD and hence may be important 
in the identification of suicidal ideation (Nadorff et al., 2011). Recently, Hendin et al. (2008) 
have insisted on the equal importance of the psychosocial context of trauma in treating sleep 
disturbance associated with PTSD. It is stressed again that sleep assessment should be 
considered in the evaluation of suicide risk in PTSD. Both pharmacological and 
psychotherapeutic approaches to the disorder have concentrated on improving sleep 
complaints. This case showed us the necessity of long-term sleep-focused approach in order 
to treat patients suffering from PTSD with suicidal ideation. That implies that incorporating 
individual psychotherapy, combined with sleep hygiene approach, can lead the patient to 
recovery from traumatic event in the long term setting. The emotional consequence of 
suicide will be devastating to the victim’s family, friends, community, and society. Studies 
of incidence, risk and protective factors related to sleep disturbances need to be high on the 
research agenda across many countries.  
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4.4 PSQI-A scale 
As this case description shows, PTSD patients report a wide variety of subjective 
complaints. These subjective sleep disturbances are non-specific and also observed in other 
sleep disorders and psychiatric clinical samples. For example, PTSD and depressed patients 
show similar global score on The Pittsburgh Sleep Quality Index, one of the most frequently 
used self-report instruments to assess sleep quality. Disruptive nocturnal behaviors  (DNB), 
such as trauma-related nightmares, may represent more specific sleep disturbances in PTSD. 
Recently, Germain et al. developed the PSQI Addendum for PTSD (PSQI-A), a brief sleep 
scale for PTSD, to evaluate DNB (Germain et al., 2005). This self-report instrument consists 
of 7 items that focus on the frequency of seven DNB, and includes three additional items 
regarding the frequency of anxiety and anger accompanying DNB and the timing of these 
events during tht night (Table 3). Such an assessment may support the clinical utility of 
assessing DNB to determine the need for further PTSD evaluation and intervention.  
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1. During the past month, how often have you had troubles sleeping because you… 
a. Feel hot flashes: 
b. Feel general nervousness: 
c. Had memories or nightmares of a traumatic experience: 
d. Had severe anxiety or panic, not related to traumatic memories: 
e. Had bad dreams, not related to traumatic memories: 
f. Had episodes of terror or screaming during sleep without fully awaking: 
g. Had episodes of “acting out” your dreams, such as kicking, punching, running , or 
screaming: 
2. If you had memories or nightmares of a traumatic experiences during sleep  
a. How much anxiety did you feel during the memories/nightmares? 
b. How much anger did you feel during the memories/ nightmares? 
c. What time of night did most memories/nightmares occur? 
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Table 3. Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A) (Germain et al., 2005) 
4.5 Stress coping and sleep hygiene among Japanese people with insomnia 
Factors leading to the onset and worsening of insomnia are multidimensional in nature, and 
many life events and life stresses can result in acute insomnia. Inadequate stress coping 
behavior also precipitates insomnia, and heightens uneasiness and tension around being 
unable to sleep, thereby perpetuating the sleeplessness. Furthermore, insomniacs may often 
engage in poor sleep hygiene, such as having an inadequate sleep environment, lack of 
daytime activities, and excessive afternoon napping (Abe et al., 2011). The majority of 
people with insomnia attempt to cope with sleep problems in various ways, have fewer 
adaptive coping skills, rely more on emotion-focused coping strategies than on problem-
solving strategies and report lower feelings of mastery (LeBlanc et al., 2007 ). Reduced 
quality of life associated with insomnia has already been reported in a general population 
sample. We have recently studied specific daily stress coping behaviors (SCBs) and sleep 
hygiene practices (SHPs) of people with insomnia in our Japanese population based sample. 
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As a result, we clarified that Japanese adults with insomnia might also engage in various 
maladaptive SCBs and SHPs (Table 4). Most importantly, we found that people with 
insomnia may not necessarily engage in the same SCB as insomniacs comorbid with 
depression (Abe & Mishima, 2008). It has often been considered that treatment with 
insomnia played a bunch of treatments of depression. But, our findings indicated that novel 
therapeutic strategies need to be developed, taking into account both characteristics of 
insomnia and depression. These kinds of concrete findings about daily behaviors related 
with insomnia may offer critical insights for developing effective sleep educational 
preventive programs in public health, as reported by Morin’s group in Canada (Morin et al, 
2006). For example, concerning substance dependence, the association between insomnia 
and its self-medication with alcoholism has been acknowledged (Brower et al., 2001). Our 
unpublished data in alcoholic groups in Japan also showed that the majority of middle-aged 
alcoholic patients entering treatment reported insomnia symptoms and recognized 
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Abe et al. have recently studied several specific daily stress coping behaviors and sleep 
hygiene practices of people with adult insomnia in the Japanese adult general population 
(Abe et al., 2011). As a result, they clarified that Japanese adults with insomnia might also 
engage in various maladaptive conducts. They also found that people with insomnia may 
not necessarily engage in the same behaviors and practices as insomniacs comorbid with 
depression. Although this study mainly targeted adults, future research needs to examine 
these aspects among minors in order to clarify the onset of insomnia and its temporal 
development into chronic adult insomnia. Such minors may be characterized by 
vulnerabilities in how they perceive and experience stressful life events negatively during 
adolescent periods. Most of them are not seeking help, thus possibly they will continue to 
engage in self-help maladaptive practices, such as substance abuse, until they are finally 
diagnosed with chronic insomnia or depression later (Vollath et al., 1989; Wong et al., 2009). 
4.5.1 Stress coping behaviors among people with insomnia 
As far as we know, our study is the first report that investigates stress-coping behaviors 
among people with insomnia in the general adult population. According to the classical 
formulation by Lazarus and Folkman (1984), coping behavior refers to cognitive and 
behavioral efforts to manage external and internal demands (Morin & Espie, 2004). There 
are two types of coping behaviors: problem-focused and emotion-focused behaviors. With 
regards to the coping behaviors among people with insomnia, Morin et al. indicate that, 
compared with good sleepers, people with insomnia are apt to perceive their lifestyle as 
more stressful and choose more emotion-focused coping behaviors (Morin et al., 2003). This 
does not contradict reports indicating that people with insomnia tend to internalize stress, 
affecting emotions (Basta et al., 2007). Similar trends were observed in the sample of people 
with insomnia in this study (Abe et al., 2011). Our multivariable logistic regression analysis 
revealed that, among the seven SCBs, insomnia was positively related to the emotion-
focused coping behaviors of bearing, smoking, eating, and TV/radio. Bearing had the 
strongest positive correlation with insomnia (OR = 1.69), and an even stronger correlation 
with insomnia comorbid with depression (OR = 3.44). Therefore, this study indicates that 
problem-focused behaviors represented by Problem-solving could be helpful in overcoming 
insomnia. While Ease was not significantly related to insomnia, it had a significant relation 
with insomnia comorbid with depression (OR = 0.74). This indicates that people with 
insomnia may not necessarily engage in the same stress-coping behavior as insomniacs 
comorbid with depression. The present findings indicate that novel therapeutic strategies 
need to be developed, taking into account both characteristics of insomnia and depression. 
This study further revealed a strong positive association between Smoking and insomnia 
(OR = 1.26). Previous research in Europe and in the United States indicates a relationship 
between nicotine consumption through smoking and poor sleep quality (Morin & Espie, 
2004). Furthermore, the strong association between Smoking and insomnia comorbid with 
depression (OR = 1.73) indicates that individuals with insomnia comorbid with depression 
tend to rely on more unhealthy coping strategies in their daily life. Our results might 
highlight the importance of strongly urging people complaining of insomnia to quit 
smoking. Eating was significantly related to insomnia. A previous epidemiological study 
reported that irregular eating habits and subjective sleep insufficiency were closely 
associated. TV/Radio is also significantly related to insomnia. Morin et al. indicated that 
many individuals initiate a variety of self-help strategies to alleviate insomnia, including 
listening to music and relaxation (Morin et al, 2006). In fact, these individuals may 
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As a result, we clarified that Japanese adults with insomnia might also engage in various 
maladaptive SCBs and SHPs (Table 4). Most importantly, we found that people with 
insomnia may not necessarily engage in the same SCB as insomniacs comorbid with 
depression (Abe & Mishima, 2008). It has often been considered that treatment with 
insomnia played a bunch of treatments of depression. But, our findings indicated that novel 
therapeutic strategies need to be developed, taking into account both characteristics of 
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with insomnia may offer critical insights for developing effective sleep educational 
preventive programs in public health, as reported by Morin’s group in Canada (Morin et al, 
2006). For example, concerning substance dependence, the association between insomnia 
and its self-medication with alcoholism has been acknowledged (Brower et al., 2001). Our 
unpublished data in alcoholic groups in Japan also showed that the majority of middle-aged 
alcoholic patients entering treatment reported insomnia symptoms and recognized 
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Abe et al. have recently studied several specific daily stress coping behaviors and sleep 
hygiene practices of people with adult insomnia in the Japanese adult general population 
(Abe et al., 2011). As a result, they clarified that Japanese adults with insomnia might also 
engage in various maladaptive conducts. They also found that people with insomnia may 
not necessarily engage in the same behaviors and practices as insomniacs comorbid with 
depression. Although this study mainly targeted adults, future research needs to examine 
these aspects among minors in order to clarify the onset of insomnia and its temporal 
development into chronic adult insomnia. Such minors may be characterized by 
vulnerabilities in how they perceive and experience stressful life events negatively during 
adolescent periods. Most of them are not seeking help, thus possibly they will continue to 
engage in self-help maladaptive practices, such as substance abuse, until they are finally 
diagnosed with chronic insomnia or depression later (Vollath et al., 1989; Wong et al., 2009). 
4.5.1 Stress coping behaviors among people with insomnia 
As far as we know, our study is the first report that investigates stress-coping behaviors 
among people with insomnia in the general adult population. According to the classical 
formulation by Lazarus and Folkman (1984), coping behavior refers to cognitive and 
behavioral efforts to manage external and internal demands (Morin & Espie, 2004). There 
are two types of coping behaviors: problem-focused and emotion-focused behaviors. With 
regards to the coping behaviors among people with insomnia, Morin et al. indicate that, 
compared with good sleepers, people with insomnia are apt to perceive their lifestyle as 
more stressful and choose more emotion-focused coping behaviors (Morin et al., 2003). This 
does not contradict reports indicating that people with insomnia tend to internalize stress, 
affecting emotions (Basta et al., 2007). Similar trends were observed in the sample of people 
with insomnia in this study (Abe et al., 2011). Our multivariable logistic regression analysis 
revealed that, among the seven SCBs, insomnia was positively related to the emotion-
focused coping behaviors of bearing, smoking, eating, and TV/radio. Bearing had the 
strongest positive correlation with insomnia (OR = 1.69), and an even stronger correlation 
with insomnia comorbid with depression (OR = 3.44). Therefore, this study indicates that 
problem-focused behaviors represented by Problem-solving could be helpful in overcoming 
insomnia. While Ease was not significantly related to insomnia, it had a significant relation 
with insomnia comorbid with depression (OR = 0.74). This indicates that people with 
insomnia may not necessarily engage in the same stress-coping behavior as insomniacs 
comorbid with depression. The present findings indicate that novel therapeutic strategies 
need to be developed, taking into account both characteristics of insomnia and depression. 
This study further revealed a strong positive association between Smoking and insomnia 
(OR = 1.26). Previous research in Europe and in the United States indicates a relationship 
between nicotine consumption through smoking and poor sleep quality (Morin & Espie, 
2004). Furthermore, the strong association between Smoking and insomnia comorbid with 
depression (OR = 1.73) indicates that individuals with insomnia comorbid with depression 
tend to rely on more unhealthy coping strategies in their daily life. Our results might 
highlight the importance of strongly urging people complaining of insomnia to quit 
smoking. Eating was significantly related to insomnia. A previous epidemiological study 
reported that irregular eating habits and subjective sleep insufficiency were closely 
associated. TV/Radio is also significantly related to insomnia. Morin et al. indicated that 
many individuals initiate a variety of self-help strategies to alleviate insomnia, including 
listening to music and relaxation (Morin et al, 2006). In fact, these individuals may 
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experiment with a variety of these passive emotional focused self-help remedies for a 
considerable period of time before seeking professional help (Morin & Espie, 2004).  
4.5.2 Sleep hygine pracitices among people with insomnia 
There have been several studies that have shown that individuals with insomnia often engage 
in some inappropriate sleep practices. In a population-based sample of 258 insomniacs, 
Jefferson et al. reported that, compared with healthy people, insomniacs more habitually drank 
alcohol before going to bed (Jefferson et al., 2005). Our study also demonstrated that alcohol 
consumption before going to bed is positively related to insomnia. Research in the United States 
suggests that drinking alcohol is an important risk factor for sleep problems. In their 
comparison of sleep habits among people in ten different countries, Soldatos et al. found that 
Japan ranked the highest in terms of the prevalence of alcohol use as a sleep aid (30.3%) 
(Soldatos et al., 2005). Thus, it is critical to provide sleep hygiene education about minimizing 
alcohol consumption before bedtime to people with insomnia. Our analysis further found that 
Books/Music was also positively related to insomnia. Some previous studies have reported that 
reading behavior is significantly more frequent among groups with insomnia than control 
groups. Morin et al. found in their epidemiological survey of a general population in Canada 
that insomnia syndrome sufferers use music (OR = 2.6) and reading (OR = 1.8) as self-help 
strategies to facilitate sleeping (Morin et al. 2006). In our study, combining Books and Music 
into one item in the questionnaire may have comparatively reduced the odds ratio (Table 4). 
One epidemiological study among Japanese indicates that poor exercise habits are associated 
with insomnia. Based on this finding, we hypothesized that physical activity would be an 
inhibiting factor for insomnia symptoms; however, there was no significant relationship 
between Exercise and insomnia. Previous research suggests that daytime physical activity 
improves sleep. The inconsistency in the findings might be attributable to the lack of 
information available regarding the type (level), duration, and frequency of physical activity in 
our study. While Bath was slightly related to insomnia, it had no significant association with 
insomnia comorbid with depression. Subjective sleep sufficiency is better for individuals when 
they take a bath before going to bed rather than when they do not. Taken together, these 
observations may indicate that taking a bath improves the subjective quality of comorbid 
depression. By contrast with previous studies, our analysis found no significant association 
between Regularity and insomnia. This may be attributable to the fact that we did not define the 
behaviors belonging to this SHP in a concrete manner. Regular exposure to photic and 
nonphotic time cues (Zeitgebers) for the circadian clock system supposedly stabilizes the 
acrophases of the sleep–wake rhythm as well as the physiological rhythm, allowing one to fall 
asleep and maintain sleep more easily (Wirz-Justice et al., 2009). The strong negative association 
between Regularity and insomnia comorbid with depression (OR = 0.64) found in the present 
study supports a treatment emphasis on regularity for mood disorders including bipolar 
disorder.  
4.6 Future remarks about insomnia 
The studies of the relationship between insomnia and suicidality started from investigating 
the relationship between depression and suicidality. It is still needed to clarify whether 
insomnia could be a distinct factor related to suicidality, even controlling for depression 
(Pigeon & Caine, 2010). Suicide prevention of depression often includes insomnia, but they 
are not always in line and insomnia has a distinct psychopathology, different from the one 
of depression. According to current etiological models of insomnia, a cognitive, emotional 
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and physiological hyperarousal may play an important role in the development and 
maintenance of the disorder. This hyperarousal concept has just recently been summarized 
in several review articles. Riemann et al. pointed out that it is important to note that two 
effects are, at least to some extent, opposing in chronic insomnia: on the one hand, sleep 
deficits or chronic minor sleep loss affects neurobiological processes and neuropsychological 
performance; on the other hand, there is the elevated arousal level which can be measured 
in several physiological systems (Riemann et al., 2011). These opposing processes might 
construct the rather paradoxal psychopathology of insomnia (Baglioni et al., 2010; Riemann 
et al., 2010, 2011). Needless to say, further studies will be needed to clarify the relationship 
between insomnia related hyperarousal and suicidality. Perhaps, subtyping insomnia 
patients according to signs of hyperarousal and the intensity of daytime impairment, such 
as the intensity of fatigue, might offer a way to disentangle the pathology of suicidality. In 
this sense, attachment theory may provide a useful framework for considering how the 
socio-emotional climate influences affect and arousal across the lifespan, and may be 
particularly important for understanding psychopathology of insomnia. For example, 
anxious attachment styles which are characterized by ‘hyper-activating’ strategies during 
times of threat or stress, may predispose an individual to insomnia by influencing stress-
arousal systems and cognitions related to the emotional and physical availability of the 
partner (Troxel & Germain, 2011).  
5. Adolescent insomnia 
Adolescents experience changes in their opposing societal demands, such as early school-
start times and an increase in the significance of social roles coincide with these physiologic 
changes (Brand & Kirov, 2011; Liu & Buysse, 2006). These incongruous demands may 
explain why adolescents are prone to sleep disturbances, such as delayed phase sleep 
syndrome and insomnia. The multiple changes that adolescents experience can be very 
stressful, and serve as precipitating factors that activate biological and/or psychological 
diathesis, and subsequently, to the development of other mental health problems.  
Studies in adults have already found that insomnia is associated with psychological 
problems (Singareddy & Balon, 2001). However, little research has explored the relationship 
between insomnia and mental health during adolescence and young adulthood. 
Substantially less research has evaluated insomnia and psychological disorders in 
adolescents. Safer D.J. suggested that adolescents differed from adults in suicidal behavior 
in their greater attempt rate, higher attempt/completion ratio, and lower rates of short and 
intermediate completion following psychiatric treatment. He claimed that the frequent 
practice of combining adult and adolescent suicide and suicide behavior findings can result 
in misleading conclusions (Safer, 1997).  
5.1 Epidemiology: Prevalence of adolescent insomnia  
Youth and adolescent suicidality constitutes a major public health problem, ranking among 
the leading causes of death for young people in many countries worldwide. Risk for 
completed suicide increases dramatically during adolescence, and research implicates an array 
of associated factors from genetic, biological, psychosocial, and cognitive domains (Bridge et 
al., 2006; Brand & Kirov, 2011). Sleep disturbances are prevalent not only among adults but 
also among 10–40% of adolescents (Liu et al., 2000; Johnson et al., 2006; Roane & Taylor, 2008). 
An estimated 10.7% of adolescents in the general population experience insomnia according to 
 
Public Health – Methodology, Environmental and Systems Issues 
 
398 
experiment with a variety of these passive emotional focused self-help remedies for a 
considerable period of time before seeking professional help (Morin & Espie, 2004).  
4.5.2 Sleep hygine pracitices among people with insomnia 
There have been several studies that have shown that individuals with insomnia often engage 
in some inappropriate sleep practices. In a population-based sample of 258 insomniacs, 
Jefferson et al. reported that, compared with healthy people, insomniacs more habitually drank 
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consumption before going to bed is positively related to insomnia. Research in the United States 
suggests that drinking alcohol is an important risk factor for sleep problems. In their 
comparison of sleep habits among people in ten different countries, Soldatos et al. found that 
Japan ranked the highest in terms of the prevalence of alcohol use as a sleep aid (30.3%) 
(Soldatos et al., 2005). Thus, it is critical to provide sleep hygiene education about minimizing 
alcohol consumption before bedtime to people with insomnia. Our analysis further found that 
Books/Music was also positively related to insomnia. Some previous studies have reported that 
reading behavior is significantly more frequent among groups with insomnia than control 
groups. Morin et al. found in their epidemiological survey of a general population in Canada 
that insomnia syndrome sufferers use music (OR = 2.6) and reading (OR = 1.8) as self-help 
strategies to facilitate sleeping (Morin et al. 2006). In our study, combining Books and Music 
into one item in the questionnaire may have comparatively reduced the odds ratio (Table 4). 
One epidemiological study among Japanese indicates that poor exercise habits are associated 
with insomnia. Based on this finding, we hypothesized that physical activity would be an 
inhibiting factor for insomnia symptoms; however, there was no significant relationship 
between Exercise and insomnia. Previous research suggests that daytime physical activity 
improves sleep. The inconsistency in the findings might be attributable to the lack of 
information available regarding the type (level), duration, and frequency of physical activity in 
our study. While Bath was slightly related to insomnia, it had no significant association with 
insomnia comorbid with depression. Subjective sleep sufficiency is better for individuals when 
they take a bath before going to bed rather than when they do not. Taken together, these 
observations may indicate that taking a bath improves the subjective quality of comorbid 
depression. By contrast with previous studies, our analysis found no significant association 
between Regularity and insomnia. This may be attributable to the fact that we did not define the 
behaviors belonging to this SHP in a concrete manner. Regular exposure to photic and 
nonphotic time cues (Zeitgebers) for the circadian clock system supposedly stabilizes the 
acrophases of the sleep–wake rhythm as well as the physiological rhythm, allowing one to fall 
asleep and maintain sleep more easily (Wirz-Justice et al., 2009). The strong negative association 
between Regularity and insomnia comorbid with depression (OR = 0.64) found in the present 
study supports a treatment emphasis on regularity for mood disorders including bipolar 
disorder.  
4.6 Future remarks about insomnia 
The studies of the relationship between insomnia and suicidality started from investigating 
the relationship between depression and suicidality. It is still needed to clarify whether 
insomnia could be a distinct factor related to suicidality, even controlling for depression 
(Pigeon & Caine, 2010). Suicide prevention of depression often includes insomnia, but they 
are not always in line and insomnia has a distinct psychopathology, different from the one 
of depression. According to current etiological models of insomnia, a cognitive, emotional 
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and physiological hyperarousal may play an important role in the development and 
maintenance of the disorder. This hyperarousal concept has just recently been summarized 
in several review articles. Riemann et al. pointed out that it is important to note that two 
effects are, at least to some extent, opposing in chronic insomnia: on the one hand, sleep 
deficits or chronic minor sleep loss affects neurobiological processes and neuropsychological 
performance; on the other hand, there is the elevated arousal level which can be measured 
in several physiological systems (Riemann et al., 2011). These opposing processes might 
construct the rather paradoxal psychopathology of insomnia (Baglioni et al., 2010; Riemann 
et al., 2010, 2011). Needless to say, further studies will be needed to clarify the relationship 
between insomnia related hyperarousal and suicidality. Perhaps, subtyping insomnia 
patients according to signs of hyperarousal and the intensity of daytime impairment, such 
as the intensity of fatigue, might offer a way to disentangle the pathology of suicidality. In 
this sense, attachment theory may provide a useful framework for considering how the 
socio-emotional climate influences affect and arousal across the lifespan, and may be 
particularly important for understanding psychopathology of insomnia. For example, 
anxious attachment styles which are characterized by ‘hyper-activating’ strategies during 
times of threat or stress, may predispose an individual to insomnia by influencing stress-
arousal systems and cognitions related to the emotional and physical availability of the 
partner (Troxel & Germain, 2011).  
5. Adolescent insomnia 
Adolescents experience changes in their opposing societal demands, such as early school-
start times and an increase in the significance of social roles coincide with these physiologic 
changes (Brand & Kirov, 2011; Liu & Buysse, 2006). These incongruous demands may 
explain why adolescents are prone to sleep disturbances, such as delayed phase sleep 
syndrome and insomnia. The multiple changes that adolescents experience can be very 
stressful, and serve as precipitating factors that activate biological and/or psychological 
diathesis, and subsequently, to the development of other mental health problems.  
Studies in adults have already found that insomnia is associated with psychological 
problems (Singareddy & Balon, 2001). However, little research has explored the relationship 
between insomnia and mental health during adolescence and young adulthood. 
Substantially less research has evaluated insomnia and psychological disorders in 
adolescents. Safer D.J. suggested that adolescents differed from adults in suicidal behavior 
in their greater attempt rate, higher attempt/completion ratio, and lower rates of short and 
intermediate completion following psychiatric treatment. He claimed that the frequent 
practice of combining adult and adolescent suicide and suicide behavior findings can result 
in misleading conclusions (Safer, 1997).  
5.1 Epidemiology: Prevalence of adolescent insomnia  
Youth and adolescent suicidality constitutes a major public health problem, ranking among 
the leading causes of death for young people in many countries worldwide. Risk for 
completed suicide increases dramatically during adolescence, and research implicates an array 
of associated factors from genetic, biological, psychosocial, and cognitive domains (Bridge et 
al., 2006; Brand & Kirov, 2011). Sleep disturbances are prevalent not only among adults but 
also among 10–40% of adolescents (Liu et al., 2000; Johnson et al., 2006; Roane & Taylor, 2008). 
An estimated 10.7% of adolescents in the general population experience insomnia according to 
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DSM-IV criteria (Johnson et al., 2006). Roane & Tayler also showed that insomnia symptoms 
were reported by 9.4% of the 4495 adolescents, 12 to 18 years old, suggesting that one out of 
ten adolescents met the criteria for insomnia (Roane & Taylor, 2008). The authors examined 
adolescent insomnia as a risk factor for mental health problems in a longitudinal study. They 
concluded that insomnia should be treated with specific interventions as an independent 
disorder in adolescents (Taylor & Roane, 2010). The Japanese research team of Ohida et al. has 
performed large-scale epidemiological studies on the sleep status of Japanese adolescents 
(Ohida et al., 2004; Kaneita et al., 2006). In a survey of approximately 106,300 Japanese junior 
and high school students, 30.6% reported an average sleep duration of less than 6h per night. 
Of these, 12.5% reported excessive daytime sleepiness, and 40% were not satisfied with their 
sleep quality (Ohida et al., 2004). Another survey reported that 23.5% of adolescents 
experienced symptoms of insomnia (Kaneita et al., 2006). Most studies of sleep disturbances 
among adolescents have focused on sleep deprivation and insomnia, and other types of sleep 
disturbances have not been adequately addressed.  
5.2 Adolescent insomnia and suicidality 
Sleep undergoes substantial changes during adolescence and suicide risk begins to increase 
during this period as well (Liu & Buysse, 2006; Wong et al., 2011). Adolescent sleep is 
characterized by widespread sleep restriction, irregular sleep schedules, daytime sleepiness, 
and elevated risk for sleep disturbances (Gangwisch et al., 2010). Sleep is indispensable in 
terms of brain maturation and learning for adolescents. Maladaptive sleep habits prevent 
them from growing, even run a risk of increasing suicide ideation. Sleep loss or disturbances 
are likely to signal an increased risk of future suicidal action in adolescents. Large-scale 
prospective studies and neurobiological studies are needed for a better understanding of the 
complex relationship between sleep, psychopathology, and youth suicidal behavior. 
Research with adolescents has demonstrated a clear relationship between suicidal 
ideation and sleep problems. Cross-sectional studies have found that adolescents with 
insomnia experience more depressive symptoms, and suicide ideations and attempts and 
are more likely to use alcohol, cigarettes, illicit drugs, or a combination of these 
substances. In a provident epidemiological study of French teenagers, Choquet et al. 
found that adolescents with suicidal ideation reported more insomnia as well as more 
nightmares than adolescents who denied suicidal ideation (Choquet & Menke, 1990). In 
their subsequent study, suicidal ideation was linked to more sleep difficulties and 
frequent feelings of daytime tiredness (Choquet et al., 1993). It follows that the findings 
linking sleep disturbance with suicidality may serve as a proxy for severity of insomnia 
comorbid with depression more generally.  
Better understanding the relationship between disturbed sleep and suicidality in 
adolescents may also serve for suicide prevention with this population (Goldstein et al., 
2008). There is evidence to suggest that some factors associated with adolescent suicide may 
be different from adult suicide (Safer, 1997). For example, although impulsive–aggressive 
behavior is a common risk factor for both adult and teenage suicide, aggression and 
impulsivity are traits highly related to suicidal behavior in adolescents (Apter et al., 1995). 
Higher levels of impulsive aggressiveness play a greater role in suicide among younger 
individuals with importance decreasing with age. Adolescents with aggression and conduct 
disorders may be suicidal even in the absence of depression. Psychosocial factors associated 
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with adolescent suicide, such as stress and contagion, bullying and peer victimization may 
also be different from adults. Alcohol and drug abuse contribute significantly to the risk of 
suicide in teenagers (Apter et al., 1995). Additional potential contributors to suicidal 
behavior in depressed adolescents are early defined traits such as temperament and 
emotional regulation. One recent study suggests that suicidal youth are characterized by 
highly maladaptive regulatory responses and low adaptive emotional regulation responses 
to dysphoria (Tamas et al., 2007).  
5.3 Sleep problems in highschoolers, students and youth sample 
College students will be an ideal population to examine sleep disturbances and mental 
health relationships (Yang et al., 2003; Taylor et al., 2010; Nardoff et al., 2011). Yang et al. 
investigated the 1,922 first year college students’ coping strategies for sleep disturbances 
and their effectiveness in Taiwan (Yang et al., 2003). They pointed out the relative lack of 
effective coping strategies for the management of such problems in this population. The 
results showed that taking naps and adjusting sleep schedules were coping strategies 
associated with better sleep quality. As mentioned throughout, the young adult age group is 
particularly susceptible to the onset of major psychiatric disorders. If so, the next logical step 
would be to develop primary and secondary sleep prevention programs for behavioral 
changes in this population (Liu & Buysse, 2006).  
Brand et al. evaluated the effect of early stage intense romantic love on sleep quality in 113 
adolescents (mean age: 17.8) (Brand et al., 2007, 2010). The research showed that adolescents 
reported significantly less daily sleepiness, higher daily concentration, more physical 
activity, and better mood compared to the other groups. Intense love in adolescents seems to 
be comparable with hypomanic state of bipolar mood spectrum. Intense positive emotions 
could disturb sleep quantity through the presence of heightened psychophysiological 
arousal, while improving perceived sleep quality and daytime activity. At least, combined 
PSG or actigraphic studies may be needed to understand the effects of such intense and 
positive emotions on sleep among adolescents and youth adults.  
6. Another symptomatic aspect: Insomnia and nightmare, distinct suicide risk? 
Clinical observations have showed that nocturnal sleep disturbances, including insomnia 
and recurrent nightmares, represent common distressing sleep complaints that might have 
important prognostic and therapeutic implications in psychiatric patients. Epidemiological 
studies have demonstrated that insomnia, nightmares, and sleep insufficiency are associated 
with elevated risk for suicide. Several studies have suggested an independent predictive 
role of nightmares in future suicidal behavior. It should be more noticed that nightmares 
may be more than a marker of PTSD and really important in the identification of suicidal 
ideation in primary care.  
6.1 Sleep disturbances in mental health epidemiology 
There is a consensus that one growing area of research in mental health includes the study 
of the relationship between sleep disturbances and suicidality in this decade (Ağargün & 
Beşiroğlu, 2005; Bernert et al., 2005; Bernert & Joiner, 2007; Pigeon & Caine, 2010). Increasing 
evidence in both clinical and epidemiological studies suggests that disturbances in sleep are 
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DSM-IV criteria (Johnson et al., 2006). Roane & Tayler also showed that insomnia symptoms 
were reported by 9.4% of the 4495 adolescents, 12 to 18 years old, suggesting that one out of 
ten adolescents met the criteria for insomnia (Roane & Taylor, 2008). The authors examined 
adolescent insomnia as a risk factor for mental health problems in a longitudinal study. They 
concluded that insomnia should be treated with specific interventions as an independent 
disorder in adolescents (Taylor & Roane, 2010). The Japanese research team of Ohida et al. has 
performed large-scale epidemiological studies on the sleep status of Japanese adolescents 
(Ohida et al., 2004; Kaneita et al., 2006). In a survey of approximately 106,300 Japanese junior 
and high school students, 30.6% reported an average sleep duration of less than 6h per night. 
Of these, 12.5% reported excessive daytime sleepiness, and 40% were not satisfied with their 
sleep quality (Ohida et al., 2004). Another survey reported that 23.5% of adolescents 
experienced symptoms of insomnia (Kaneita et al., 2006). Most studies of sleep disturbances 
among adolescents have focused on sleep deprivation and insomnia, and other types of sleep 
disturbances have not been adequately addressed.  
5.2 Adolescent insomnia and suicidality 
Sleep undergoes substantial changes during adolescence and suicide risk begins to increase 
during this period as well (Liu & Buysse, 2006; Wong et al., 2011). Adolescent sleep is 
characterized by widespread sleep restriction, irregular sleep schedules, daytime sleepiness, 
and elevated risk for sleep disturbances (Gangwisch et al., 2010). Sleep is indispensable in 
terms of brain maturation and learning for adolescents. Maladaptive sleep habits prevent 
them from growing, even run a risk of increasing suicide ideation. Sleep loss or disturbances 
are likely to signal an increased risk of future suicidal action in adolescents. Large-scale 
prospective studies and neurobiological studies are needed for a better understanding of the 
complex relationship between sleep, psychopathology, and youth suicidal behavior. 
Research with adolescents has demonstrated a clear relationship between suicidal 
ideation and sleep problems. Cross-sectional studies have found that adolescents with 
insomnia experience more depressive symptoms, and suicide ideations and attempts and 
are more likely to use alcohol, cigarettes, illicit drugs, or a combination of these 
substances. In a provident epidemiological study of French teenagers, Choquet et al. 
found that adolescents with suicidal ideation reported more insomnia as well as more 
nightmares than adolescents who denied suicidal ideation (Choquet & Menke, 1990). In 
their subsequent study, suicidal ideation was linked to more sleep difficulties and 
frequent feelings of daytime tiredness (Choquet et al., 1993). It follows that the findings 
linking sleep disturbance with suicidality may serve as a proxy for severity of insomnia 
comorbid with depression more generally.  
Better understanding the relationship between disturbed sleep and suicidality in 
adolescents may also serve for suicide prevention with this population (Goldstein et al., 
2008). There is evidence to suggest that some factors associated with adolescent suicide may 
be different from adult suicide (Safer, 1997). For example, although impulsive–aggressive 
behavior is a common risk factor for both adult and teenage suicide, aggression and 
impulsivity are traits highly related to suicidal behavior in adolescents (Apter et al., 1995). 
Higher levels of impulsive aggressiveness play a greater role in suicide among younger 
individuals with importance decreasing with age. Adolescents with aggression and conduct 
disorders may be suicidal even in the absence of depression. Psychosocial factors associated 
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with adolescent suicide, such as stress and contagion, bullying and peer victimization may 
also be different from adults. Alcohol and drug abuse contribute significantly to the risk of 
suicide in teenagers (Apter et al., 1995). Additional potential contributors to suicidal 
behavior in depressed adolescents are early defined traits such as temperament and 
emotional regulation. One recent study suggests that suicidal youth are characterized by 
highly maladaptive regulatory responses and low adaptive emotional regulation responses 
to dysphoria (Tamas et al., 2007).  
5.3 Sleep problems in highschoolers, students and youth sample 
College students will be an ideal population to examine sleep disturbances and mental 
health relationships (Yang et al., 2003; Taylor et al., 2010; Nardoff et al., 2011). Yang et al. 
investigated the 1,922 first year college students’ coping strategies for sleep disturbances 
and their effectiveness in Taiwan (Yang et al., 2003). They pointed out the relative lack of 
effective coping strategies for the management of such problems in this population. The 
results showed that taking naps and adjusting sleep schedules were coping strategies 
associated with better sleep quality. As mentioned throughout, the young adult age group is 
particularly susceptible to the onset of major psychiatric disorders. If so, the next logical step 
would be to develop primary and secondary sleep prevention programs for behavioral 
changes in this population (Liu & Buysse, 2006).  
Brand et al. evaluated the effect of early stage intense romantic love on sleep quality in 113 
adolescents (mean age: 17.8) (Brand et al., 2007, 2010). The research showed that adolescents 
reported significantly less daily sleepiness, higher daily concentration, more physical 
activity, and better mood compared to the other groups. Intense love in adolescents seems to 
be comparable with hypomanic state of bipolar mood spectrum. Intense positive emotions 
could disturb sleep quantity through the presence of heightened psychophysiological 
arousal, while improving perceived sleep quality and daytime activity. At least, combined 
PSG or actigraphic studies may be needed to understand the effects of such intense and 
positive emotions on sleep among adolescents and youth adults.  
6. Another symptomatic aspect: Insomnia and nightmare, distinct suicide risk? 
Clinical observations have showed that nocturnal sleep disturbances, including insomnia 
and recurrent nightmares, represent common distressing sleep complaints that might have 
important prognostic and therapeutic implications in psychiatric patients. Epidemiological 
studies have demonstrated that insomnia, nightmares, and sleep insufficiency are associated 
with elevated risk for suicide. Several studies have suggested an independent predictive 
role of nightmares in future suicidal behavior. It should be more noticed that nightmares 
may be more than a marker of PTSD and really important in the identification of suicidal 
ideation in primary care.  
6.1 Sleep disturbances in mental health epidemiology 
There is a consensus that one growing area of research in mental health includes the study 
of the relationship between sleep disturbances and suicidality in this decade (Ağargün & 
Beşiroğlu, 2005; Bernert et al., 2005; Bernert & Joiner, 2007; Pigeon & Caine, 2010). Increasing 
evidence in both clinical and epidemiological studies suggests that disturbances in sleep are 
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associated with an elevated risk for suicidal behaviors. Both sleep disorders and general 
sleep complaints appear to be linked to greater levels of suicidal ideation and depression, as 
well as both attempted and completed suicide (Fawcett et al., 1990; Ağargün et al., 1997; 
Krakow et al., 2000). As these provident studies have already stressed, one major expected 
suggestion is that sleep disturbances may have prognostic significance in predicting suicide 
among patients with depression. A recent study conducted in Japan, Fujino et al. showed 
that, among 13,259 middle-aged adults, only difficulty maintaining sleep (sleep maintenance 
insomnia), compared to other sleep disturbances (e.g., difficulty initiating sleep, 
nonrestorative sleep), significantly predicted death by suicide 14 years later (Fujino et al., 
2005). But, depression was not accounted for when examining the association between sleep 
and completed suicide. Such findings would often elucidate whether sleep disturbances 
stand alone as a risk factor for completed suicide or, conversely, whether such sleep 
complaints simply vary with increased depressive symptoms (Ağargün & Beşiroğlu, 2005; 
Fujino et al., 2005). Sleep problems and more specifically, significant changes in sleep, have 
been considered as warning signs of suicide in many mental health policies. Thus, 
improvement in the identification of risk factors for suicidal behaviors and possible early 
intervention and postvention thus ultimately enhance our competence to intervene and 
prevent death by suicide (Krakow et al., 2011).  
Fawcett et al. conducted the first study to prospectively examine sleep, depression and 
suicide in 1990 (Fawcett et al., 1990). They considered insomnia to be one of the ‘modifiable 
risks’ for suicide in patients with depression. Ağargün et al. demonstrated a significant 
association between poor sleep quality and suicidal behavior in depression (Ağargün et al., 
1997). Further studies will be needed to the posssible intervention with regard to suicidality. 
Again, does insomnia (sleep disturbances) still manifest distinct suicide risk, even 
controlling after several confounding factors? During several years, many studies and 
clinical experiences have tried to investigate this concern (Wojnar et al., 2009; Li et al., 2010; 
Pigeon & Caine, 2010). But, this question was already asked nearly one century ago by a 
British doctor. In 1914, in the medical journal Lancet, Pronger wrote an epoch-making 
article, entitled “Insomnia and Suicide” (Pronger, 1914). His clinical intuition still impresses 
us enormously, even about one century afterwards. A recent clinical case report stressed 
again that sleep assessment should be considered in the evaluation of suicide risk in 
depressed patients (Mahgoub, 2009).  
6.2 Chronobiogical factors and diurnal fluctuation of suicidality 
The study of chronobiological factors in the relationship between sleep and suicidal 
behaviors remains a largely unexplored, yet fruitful area of research (Ağargün & Beşiroğlu, 
2005; Bernert & Joiner, 2007). A diurnal variation in the tiling of self-injurious behaviors and 
completed suicide is supported by several reports. Blenkiron et al. prospectively assessed 
158 patients presenting at a hospital referred for psychiatric assessment due to deliberate 
self-harm (Blenkiron et al., 2000). The authors classified these deliberate self-harm incidents 
as suicide attempters, and concluded that the frequency of these acts were higher in the 
evening and lower in the early morning hours. They also showed a bimodal peak in 
frequency for deliberate self-harm among older and younger adults. And they concluded 
that the severity of deliberate self-harm appeared to vary according to the time of day 
(Blenkiron et al., 2000). In another study in Japan, ambulance report records were 
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retrospectively reviewed for a 7-year period in Tokyo to examine time-of-day and 
documented suicide attempts. Results indicated that suicide attempts showed a peak earlier 
in the evening (18h00) compared to the morning (Motohashi, 1990).  
Selvi et al. assessed 80 patients clinically diagnosed with major depression and 80 healthy 
subjects who were demographically matched with the patient group (Selvi et al., 2010). Results 
showed that morningness-type circadian rhythm may play as a significant relief factor after 
the onset of major depression, but sleep variables of chronotype and sleep quality did not 
significantly predict suicide ideation after controlling for depressive symptoms in the major 
depression group. They concluded that suicide ideation and poor sleep quality were 
antecedents of depression symptom severity in patients with major depression. They 
discussed these findings under the theoretical assumptions concerning possible relations 
between chronotype, sleep quality, depression, and suicidality (Selvi et al., 2010). 
In studying time-related risk factors, additional research is needed, particularly studies 
that better define the severity of suicidal behaviors. It will be important for such studies to 
carefully distinguish suicide attempts and deliberate self-harm with an intent to die from 
self harm behaviors without suicidal intent. Investigation of the timing of sleep and 
suicidal acts may inform risk assessment procedures, emergency responding and 
surveillance, as well as treatment (Bernert & Joiner, 2007). There is an association between 
circadian rhythms and suicidality. This topic has always been investigated in terms of 
diurnal fluctuation of symptoms related to depression or Seasonal Affective Disorder 
(Wirz-Justice et al., 2009). Future research will also be necessary to thoroughly evaluate 
chronobiological correlates of suicidality in non-clinical samples for preventative 
purposes.  
6.3 Sleep homeostasis hypothesis and suicidality 
Sleep abnormalities are common in patients with suicidal behavior. Sleep complaints such 
as insomnia, hypersomnia, nightmare, and sleep panic attacks are frequent in suicidal 
adolescents and adults. Results from school-based survey in the USA indicate that whereas 
insomnia and hypersomnia independently increase risk for suicidal ideation in adolescents, 
the presence of both insomnia and hypersomnia incurs further increased suicidal risk in this 
population (Roberts et al., 2001). In another study, a significant and temporal relationship 
between sleep problems and completed suicide has been observed (Goldstein et al., 2008). 
Considerable evidence supports a strong link between sleep disturbances and suicidality 
but the pathway remains to be established (Sher, 2008). 
In 2003, an innovative theoretical model, called “sleep synaptic hypothesis”, reflecting on 
the significance of slow-wave activity and its homeostatic regulation was proposed (Tononi 
& Cirelli, 2003). According to this hypothesis, neuroplastic processes occurring during 
wakefulness result in a net increase in synaptic strength in many brain circuits. The role of 
sleep is to downscale synaptic strength to a baseline level that is energetically sustainable, 
makes efficient use of gray matter space, and is beneficial for learning and memory. Thus, 
sleep is the price we have to pay for plasticity, and its goal is the homeostatic regulation of 
the total synaptic weight impinging on neuron (Tononi & Cirelli, 2003, 2006). It has been 
suggested that wakefulness is associated with synaptic potentiation in several cortical 
circuits; synaptic potentiation is tied to the homeostatic regulation of slow-wave activity; 
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associated with an elevated risk for suicidal behaviors. Both sleep disorders and general 
sleep complaints appear to be linked to greater levels of suicidal ideation and depression, as 
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Krakow et al., 2000). As these provident studies have already stressed, one major expected 
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that, among 13,259 middle-aged adults, only difficulty maintaining sleep (sleep maintenance 
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nonrestorative sleep), significantly predicted death by suicide 14 years later (Fujino et al., 
2005). But, depression was not accounted for when examining the association between sleep 
and completed suicide. Such findings would often elucidate whether sleep disturbances 
stand alone as a risk factor for completed suicide or, conversely, whether such sleep 
complaints simply vary with increased depressive symptoms (Ağargün & Beşiroğlu, 2005; 
Fujino et al., 2005). Sleep problems and more specifically, significant changes in sleep, have 
been considered as warning signs of suicide in many mental health policies. Thus, 
improvement in the identification of risk factors for suicidal behaviors and possible early 
intervention and postvention thus ultimately enhance our competence to intervene and 
prevent death by suicide (Krakow et al., 2011).  
Fawcett et al. conducted the first study to prospectively examine sleep, depression and 
suicide in 1990 (Fawcett et al., 1990). They considered insomnia to be one of the ‘modifiable 
risks’ for suicide in patients with depression. Ağargün et al. demonstrated a significant 
association between poor sleep quality and suicidal behavior in depression (Ağargün et al., 
1997). Further studies will be needed to the posssible intervention with regard to suicidality. 
Again, does insomnia (sleep disturbances) still manifest distinct suicide risk, even 
controlling after several confounding factors? During several years, many studies and 
clinical experiences have tried to investigate this concern (Wojnar et al., 2009; Li et al., 2010; 
Pigeon & Caine, 2010). But, this question was already asked nearly one century ago by a 
British doctor. In 1914, in the medical journal Lancet, Pronger wrote an epoch-making 
article, entitled “Insomnia and Suicide” (Pronger, 1914). His clinical intuition still impresses 
us enormously, even about one century afterwards. A recent clinical case report stressed 
again that sleep assessment should be considered in the evaluation of suicide risk in 
depressed patients (Mahgoub, 2009).  
6.2 Chronobiogical factors and diurnal fluctuation of suicidality 
The study of chronobiological factors in the relationship between sleep and suicidal 
behaviors remains a largely unexplored, yet fruitful area of research (Ağargün & Beşiroğlu, 
2005; Bernert & Joiner, 2007). A diurnal variation in the tiling of self-injurious behaviors and 
completed suicide is supported by several reports. Blenkiron et al. prospectively assessed 
158 patients presenting at a hospital referred for psychiatric assessment due to deliberate 
self-harm (Blenkiron et al., 2000). The authors classified these deliberate self-harm incidents 
as suicide attempters, and concluded that the frequency of these acts were higher in the 
evening and lower in the early morning hours. They also showed a bimodal peak in 
frequency for deliberate self-harm among older and younger adults. And they concluded 
that the severity of deliberate self-harm appeared to vary according to the time of day 
(Blenkiron et al., 2000). In another study in Japan, ambulance report records were 
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retrospectively reviewed for a 7-year period in Tokyo to examine time-of-day and 
documented suicide attempts. Results indicated that suicide attempts showed a peak earlier 
in the evening (18h00) compared to the morning (Motohashi, 1990).  
Selvi et al. assessed 80 patients clinically diagnosed with major depression and 80 healthy 
subjects who were demographically matched with the patient group (Selvi et al., 2010). Results 
showed that morningness-type circadian rhythm may play as a significant relief factor after 
the onset of major depression, but sleep variables of chronotype and sleep quality did not 
significantly predict suicide ideation after controlling for depressive symptoms in the major 
depression group. They concluded that suicide ideation and poor sleep quality were 
antecedents of depression symptom severity in patients with major depression. They 
discussed these findings under the theoretical assumptions concerning possible relations 
between chronotype, sleep quality, depression, and suicidality (Selvi et al., 2010). 
In studying time-related risk factors, additional research is needed, particularly studies 
that better define the severity of suicidal behaviors. It will be important for such studies to 
carefully distinguish suicide attempts and deliberate self-harm with an intent to die from 
self harm behaviors without suicidal intent. Investigation of the timing of sleep and 
suicidal acts may inform risk assessment procedures, emergency responding and 
surveillance, as well as treatment (Bernert & Joiner, 2007). There is an association between 
circadian rhythms and suicidality. This topic has always been investigated in terms of 
diurnal fluctuation of symptoms related to depression or Seasonal Affective Disorder 
(Wirz-Justice et al., 2009). Future research will also be necessary to thoroughly evaluate 
chronobiological correlates of suicidality in non-clinical samples for preventative 
purposes.  
6.3 Sleep homeostasis hypothesis and suicidality 
Sleep abnormalities are common in patients with suicidal behavior. Sleep complaints such 
as insomnia, hypersomnia, nightmare, and sleep panic attacks are frequent in suicidal 
adolescents and adults. Results from school-based survey in the USA indicate that whereas 
insomnia and hypersomnia independently increase risk for suicidal ideation in adolescents, 
the presence of both insomnia and hypersomnia incurs further increased suicidal risk in this 
population (Roberts et al., 2001). In another study, a significant and temporal relationship 
between sleep problems and completed suicide has been observed (Goldstein et al., 2008). 
Considerable evidence supports a strong link between sleep disturbances and suicidality 
but the pathway remains to be established (Sher, 2008). 
In 2003, an innovative theoretical model, called “sleep synaptic hypothesis”, reflecting on 
the significance of slow-wave activity and its homeostatic regulation was proposed (Tononi 
& Cirelli, 2003). According to this hypothesis, neuroplastic processes occurring during 
wakefulness result in a net increase in synaptic strength in many brain circuits. The role of 
sleep is to downscale synaptic strength to a baseline level that is energetically sustainable, 
makes efficient use of gray matter space, and is beneficial for learning and memory. Thus, 
sleep is the price we have to pay for plasticity, and its goal is the homeostatic regulation of 
the total synaptic weight impinging on neuron (Tononi & Cirelli, 2003, 2006). It has been 
suggested that wakefulness is associated with synaptic potentiation in several cortical 
circuits; synaptic potentiation is tied to the homeostatic regulation of slow-wave activity; 
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slow-wave activity is associated with synaptic downscaling; and active synaptic 
downscaling occurring during sleep is beneficial for cellular functions and is tied to 
overnight performance improvement. 
Hence, many aspects of behavioral performance improve after sleep and are negatively 
affected by sleep deprivation, and it is conceivable that avoiding synaptic overload by 
maintaining synaptic homeostasis would be beneficial for many cellular processes, such as 
energy metabolism and membrane maintenance. Clinically, sleep deprivation may affect 
fatigue complaints and the production of dreams, which is particularly important for 
adolescent’s development. It is possible that disruption of synaptic homeostasis underlies 
sleep abnormalities, leading or contributing to suicidal behavior. Serotonergic mechanisms 
may affect sleep regulation, are implicated in the pathophysiology of suicidal behavior, and 
may be involved in the relation between sleep abnormalities, synaptic homeostasis and 
suicidal behavior (Sher, 2008). Taken together, theoretically, sleep difficulties should be 
considered in prevention and intervention effort for patients at risk for suicide. Prevention 
effort should target good sleep hygiene and early detection and treatment of problematic 
sleep patterns in order to decrease risk for suicide (Liu & Buysse, 2006). Better 
understanding of the relationship between disturbed sleep and suicidality may serve to 
inform effort for suicide prevention.  
7. Nightmares  
7.1 Nightmare; Definition and epidemiology 
Both insomnia and nightmare showed classical and, at the same time, a novel symptomatic 
aspect in psychiatric epidemiology. Clinical observations have showed that nocturnal sleep 
disturbances, including insomnia and recurrent nightmares, represent common distressing 
sleep complaints that might have important prognostic and therapeutic implications in 
psychiatric patients. Epidemiological studies have demonstrated that insomnia, nightmares, 
and sleep insufficiency are associated with elevated risk for suicide (Hasler & Germain, 
2009). 
Dreams are a remarkable experiment in psychology and neuroscience, conducted every 
night in every sleeping person. They show that the human brain, disconnected from the 
environment, can generate an entire world of conscious experiences by itself (Nir & Tononi, 
2010). Both DSM-IV and ICSD-2 criteria converge on defining nightmares as intensely 
disturbing dreams that awaken the dreamer to a fully conscious state and generally occur in 
the latter half of the sleep period (Table 5.). 
Lifetime prevalence of nightmares in the general population is unknown, but large 
epidemiological studies indicate that about 85% of adults have experienced at least one 
nightmare within the past year (Levin & Nielsen, 2007). Further investigations suggest that 
the prevalence may almost approach 100%! The estimated frequency of clinically significant 
nightmares (occurring at least weekly) is 4–10% in the general population (Nielsen et al., 
2006). Similar rates are reported from different cultures. There is a significant gender 
difference in nightmare frequency, with women of all ages reporting nightmares more 
frequently than men. Age is also relevant: nightmares are less frequent among the elderly 
(Levin & Nielsen, 2007; Nielsen et al., 2006).  
Insomnia and Its Correlates:  




Nightmare Disorder  
 
A. Repeated occurrences of extended, extremely dysphoric and well-remembered dreams 
that usually involve efforts to avoid threats to survival, security or physical integrity 
and that generally occur during the second half of the major sleep episode.  
B. On awakening from the dysphoric dreams, the person rapidly becomes oriented and 
alert. 
C. The dream experience, or the sleep disturbance produced by awakening from it, causes 
clinically significant distress or impairment in social, occupational, or other important 
areas of functioning.  
D. The dysphoric dreams do not occur exclusively during the course of another mental 
disorder (e.g., a delirium, Posttraumatic Stress Disorder) and are not due to the direct 
physiological effects of a substance (e.g., a drug of abuse, a medication) or a general 
medical condition.  
 
Table 5. DSM-5 proposed criteria for nightmare disorder ([84], 2010). 
7.2 Nightmare; Etiology 
Because nightmares are often, but not necessarily, associated with PTSD, many specialists 
distinguish post-traumatic and non-traumatic (idiopathic) nightmares (Hasler & Germain, 
2009; Levin & Nielsen, 2009). Post-traumatic nightmares reflect the long-lasting effect of a 
wakeful traumatic experience, whereas the cause of non-traumatic nightmares is unknown. 
Numerous studies have found that nightmare frequency is associated with 
psychopathological symptoms (Levin & Nielsen, 2007), but because most of these studies do 
not strictly distinguish between post-traumatic and non-traumatic nightmares, the 
interpretation of the results is ambiguous. Levin & Nielsen described six broad 
psychopathological categories that are associated with nightmares: anxiety symptoms, 
neuroticism and global symptom reporting, schizophrenia-spectrum disorders, other 
psychiatric disorders, behavioral health problems and sleep disturbances, and PTSD (Levin 
& Nielsen, 2007). A common feature of these pathologies is notable waking emotional 
distress, suggesting that nightmares may play a role in processing of these experiences. The 
studied reviewed above also suggest that the connection between early experiences, brain 
development, and nightmare experiences might involve failures in emotion regulation 
(Nielsen et al, 2006; Levin & Nielsen, 2009). Current models of nightmare production seem 
to emphasize negative emotionality as having a central role in determining dream affects. 
Ağargün et al. previously reported that the prevalence of childhood traumatic experiences 
was higher among adult who ‘‘often’’ had nightmares than among adults who ‘‘sometimes’’ 
or ‘‘never’’ had nightmares (Ağargün et al., 2003). With regard to the associations between 
nightmares and mental health status, Nielsen et al. studied adolescents (aged 13–16) and 
reported a significant association between the frequency of nightmares and the level of 
anxiety (Nielsen et al., 2006). To date, very few studies have investigated the prevalence of 
nightmares in adolescents, compared to adults. In Japan, analyzing 90,081 nationwide 
adolescent sampled data, Munezawa et al. showed that the prevalence of nightmares was 
35.2% among Japanese adolescents (more than one third) (Munezawa et al., 2011). The 
results of this study should be considered in the prevention of nightmares among Japanese 
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slow-wave activity is associated with synaptic downscaling; and active synaptic 
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sleep patterns in order to decrease risk for suicide (Liu & Buysse, 2006). Better 
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psychiatric patients. Epidemiological studies have demonstrated that insomnia, nightmares, 
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Dreams are a remarkable experiment in psychology and neuroscience, conducted every 
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the prevalence may almost approach 100%! The estimated frequency of clinically significant 
nightmares (occurring at least weekly) is 4–10% in the general population (Nielsen et al., 
2006). Similar rates are reported from different cultures. There is a significant gender 
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Because nightmares are often, but not necessarily, associated with PTSD, many specialists 
distinguish post-traumatic and non-traumatic (idiopathic) nightmares (Hasler & Germain, 
2009; Levin & Nielsen, 2009). Post-traumatic nightmares reflect the long-lasting effect of a 
wakeful traumatic experience, whereas the cause of non-traumatic nightmares is unknown. 
Numerous studies have found that nightmare frequency is associated with 
psychopathological symptoms (Levin & Nielsen, 2007), but because most of these studies do 
not strictly distinguish between post-traumatic and non-traumatic nightmares, the 
interpretation of the results is ambiguous. Levin & Nielsen described six broad 
psychopathological categories that are associated with nightmares: anxiety symptoms, 
neuroticism and global symptom reporting, schizophrenia-spectrum disorders, other 
psychiatric disorders, behavioral health problems and sleep disturbances, and PTSD (Levin 
& Nielsen, 2007). A common feature of these pathologies is notable waking emotional 
distress, suggesting that nightmares may play a role in processing of these experiences. The 
studied reviewed above also suggest that the connection between early experiences, brain 
development, and nightmare experiences might involve failures in emotion regulation 
(Nielsen et al, 2006; Levin & Nielsen, 2009). Current models of nightmare production seem 
to emphasize negative emotionality as having a central role in determining dream affects. 
Ağargün et al. previously reported that the prevalence of childhood traumatic experiences 
was higher among adult who ‘‘often’’ had nightmares than among adults who ‘‘sometimes’’ 
or ‘‘never’’ had nightmares (Ağargün et al., 2003). With regard to the associations between 
nightmares and mental health status, Nielsen et al. studied adolescents (aged 13–16) and 
reported a significant association between the frequency of nightmares and the level of 
anxiety (Nielsen et al., 2006). To date, very few studies have investigated the prevalence of 
nightmares in adolescents, compared to adults. In Japan, analyzing 90,081 nationwide 
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adolescents. They concluded that it is important to maintain regular sleep habits for 
preventing this symptom, and proposed that health education about regular sleep habits 
should be promoted among Japanese adolescents in a near future.  
7.3 Nightmare and attachment 
Interestingly, from the viewpoint of both attachment theory and epidemiology, Csóka et al. 
have hypothesized that adults who experienced early maternal separation (before one year 
of age and lasting at least one month) would report more frequent nightmares and bad 
dreams (Csóka et al., 2011). In the frame of the Hungarostudy Epidemiological Panel, 5020 
subjects interviewed, significant associations were found between early maternal separation 
and both frequent nightmare experience in adulthood and increased frequency of 
oppressive and bad dreams. Current depression scores fully mediated the association 
between early separation and nightmares, but not the association between early separation 
and negative dream affects. The authors interpreted these findings as a trait-like 
enhancement of negative emotionality in adults who experienced early maternal separation. 
This enhancement influences the content of dreams and, when it takes the form of 
depression, also influences the frequency of nightmares. The effect of early maternal 
separation on nightmares and bad dreams is relevant, which merits further attention (Csóka 
et al., 2011). 
7.4 Nightmare and suicidality 
As we have mentioned above, frequent nightmares have been noted to be related to 
suicidality in depressed patients, particularly among women (Ağargün et al., 1998). A 
prospective follow-up study in a sample drawn from the general population also reported 
that the frequency of nightmares is directly related to the risk of suicide (Tanskanen et al., 
2001; Turvey et al., 2002; Bernert, et al., 2005; Sjöström et al., 2007; Nadorff et al., 2011). 
Among those, Bernert et al. directly addressed the real question regarding research 
indicating that sleep disturbances may be specifically linked to suicidal behaviors: Is this 
link largely explained by depressive symptoms or how are specific symptoms of sleep 
disturbances relate to suicidal symptoms when controlling for depression? The 176 
outpatients completed measures on sleep disturbances, suicidal symptoms. They 
controlled for depressive symptoms to establish a link between sleep disturbances and 
suicidality. They found that insomnia and nightmare symptoms were associated with 
both depressive symptoms and suicidality before controlling depressive symptoms. After 
controlling for depressive symptoms, only nightmares demonstrated an association with 
suicidal ideation. Another significant finding was that nightmares were particularly 
associated with suicidality among women compared to men. Before controlling for 
gender, a non-significant trend emerged between nightmare symptoms and suicidality, 
and this relationship remained after controlling for depression. After controlling for 
gender, the link between nightmare symptoms and suicidal ideation was statistically 
significant. This finding indicates that the association between nightmares and suicidality, 
while controlling for depression, was somewhat stronger among women versus among 
men (Bernert, et al., 2005).  
For more than three decades, sleep disturbance had been considered the hallmark of 
posttraumatic stress disorder. Since insomnia has been observed in 90% of PTSD cases and 
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nightmare related to the trauma in 70%, this is understandable (Hendin et al., 2008). Besides, 
recently, Nadorff et al. clearly showed that nightmare symptoms may be “more than” a 
marker of PTSD, and hence may be important in the identification of suicidal ideation 
following several previous literatures (Nadorff et al., 2011).  
8. Future remarks and treatment implications 
8.1 Acute insomnia, the emergence of sleep psychiatry 
Despite significant contributions made in the area of chronic insomnia, the area of acute 
insomnia has received comparatively little attention (Ellis et al., 2011). Overall, the findings 
from the review will highlight the need for a structured diagnosis of acute insomnia as the 
first step in a research and treatment strategy. Psychiatric and medical disorders are often 
associated with sleep disorders, especially acute insomnia which is a crucial element in 
clinical practices. Therefore, clinicians have to organize specific remedies for co-occurring 
acute insomnia itself. Recently the notion of sleep psychiatry (psychiatric therapeutic 
approach, both biologically and psychologically, based on sleep science) has gathered much 
attention worldwide (Goblin et al., 2004). Taking these points into account, when addressing 
potential treatment implications based on this conceptualisation of acute insomnia, three 
questions emerge: 1) Is it possible that acute insomnia can be identified and/or responded 
to in a timely manner?; 2) Is it possible that an intervention for acute insomnia has the 
potential to derail the occurrence of chronic insomnia?; 3) What would the optimal 
treatment approach be? Here, we will present a case study in order to show the possible 
efficiency of early sleep psychiatric intervention, mainly focusing on the subjective 
experience of the individual with acute insomnia (Abe et al., 2012). 
8.1.1 Case study 2 
Mr. T., a 25-year-old man, had a long history of OCD (Obsessive-Complusive Disorder) with 
recurrent obsessive thoughts of touching dirt and compulsive cleaning since his 
preadolescence. Firstly, at the age of 18, he consulted a psychiatrist for the purpose of 
treating his depressive symptoms after his father’s sudden death. His depressive symptoms 
improved and then stabilized for several years with the aid of pharmacologic treatment 
(sulpiride 30mg, clorazepate 7.5mg and paroxetine 20mg). After graduating from 
professional school, he was able to work as a computer engineer in an urban company in 
spite of the persistence of his obsessive symptoms. One winter, he was addressed to our 
outpatient clinic by his general practitioner. His symptoms had already stabilized because of 
the same medication as a long-term maintenance treatment for OCD. 
After four months of our follow-up, that spring, he was transferred to another section in his 
company. This change of social environment made him cogitate about his interpersonal 
relationship with other colleagues, which provoked acute insomnia symptoms, such as 
difficulty falling asleep and nighttime awaking. Additionally, he also suffered from daytime 
impairment related to his insomnia, especially hypersomnia and daytime sleepiness. He 
said, “I can’t concentrate on my work because I have to fight to get to sleep” and “I feel 
afraid of falling asleep”. Typically, the fear of insomnia was exacerbated. In other words, he 
was very afraid of losing his career position in his new section caused by the daytime 
impairments (e.g., losing concentration and diminished performance), which he attributed 
to his insomnia.  
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adolescents. They concluded that it is important to maintain regular sleep habits for 
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gender, a non-significant trend emerged between nightmare symptoms and suicidality, 
and this relationship remained after controlling for depression. After controlling for 
gender, the link between nightmare symptoms and suicidal ideation was statistically 
significant. This finding indicates that the association between nightmares and suicidality, 
while controlling for depression, was somewhat stronger among women versus among 
men (Bernert, et al., 2005).  
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clinical practices. Therefore, clinicians have to organize specific remedies for co-occurring 
acute insomnia itself. Recently the notion of sleep psychiatry (psychiatric therapeutic 
approach, both biologically and psychologically, based on sleep science) has gathered much 
attention worldwide (Goblin et al., 2004). Taking these points into account, when addressing 
potential treatment implications based on this conceptualisation of acute insomnia, three 
questions emerge: 1) Is it possible that acute insomnia can be identified and/or responded 
to in a timely manner?; 2) Is it possible that an intervention for acute insomnia has the 
potential to derail the occurrence of chronic insomnia?; 3) What would the optimal 
treatment approach be? Here, we will present a case study in order to show the possible 
efficiency of early sleep psychiatric intervention, mainly focusing on the subjective 
experience of the individual with acute insomnia (Abe et al., 2012). 
8.1.1 Case study 2 
Mr. T., a 25-year-old man, had a long history of OCD (Obsessive-Complusive Disorder) with 
recurrent obsessive thoughts of touching dirt and compulsive cleaning since his 
preadolescence. Firstly, at the age of 18, he consulted a psychiatrist for the purpose of 
treating his depressive symptoms after his father’s sudden death. His depressive symptoms 
improved and then stabilized for several years with the aid of pharmacologic treatment 
(sulpiride 30mg, clorazepate 7.5mg and paroxetine 20mg). After graduating from 
professional school, he was able to work as a computer engineer in an urban company in 
spite of the persistence of his obsessive symptoms. One winter, he was addressed to our 
outpatient clinic by his general practitioner. His symptoms had already stabilized because of 
the same medication as a long-term maintenance treatment for OCD. 
After four months of our follow-up, that spring, he was transferred to another section in his 
company. This change of social environment made him cogitate about his interpersonal 
relationship with other colleagues, which provoked acute insomnia symptoms, such as 
difficulty falling asleep and nighttime awaking. Additionally, he also suffered from daytime 
impairment related to his insomnia, especially hypersomnia and daytime sleepiness. He 
said, “I can’t concentrate on my work because I have to fight to get to sleep” and “I feel 
afraid of falling asleep”. Typically, the fear of insomnia was exacerbated. In other words, he 
was very afraid of losing his career position in his new section caused by the daytime 
impairments (e.g., losing concentration and diminished performance), which he attributed 
to his insomnia.  
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In order to improve acute insomnia symptoms, we treated him mainly with an early sleep 
psychiatric approach as a non-pharmacological intervention. Intentionally, we avoided 
increasing medication, because his principal concerns were strongly related with daytime 
impairment of insomnia. Adding another medication to improve sleep might run a risk of 
exacerbating daytime consequences of insomnia. In this situation, we treated him, making 
use of a home-monitoring actigraphy and an oxygen saturation tool. After two days of 
monitoring, the actigraphy always measured total sleep time and number of nighttime 
awakenings, so data showed that he had slept sufficiently during the night contrary to his 
complaints. As a first step, we supported him by showing him recorded sleep data, which 
suggested that his objective quality of sleep was different from his subjective complaining. 
This manifestation explained by itself a typical psychopathology of insomnia. This 
monitoring continued for a week. During this period, he was encouraged to visit our clinic 3 
times a week for evaluation. Over nights, his actigraphic records always suggested longer 
and more consolidated sleep efficiency compared with his subjective intensity of insomnia 
complaints. As a next step, one night he was asked to get installed a portable oxygen 
saturation tool. The obtained data showed that some presence of hypoxemia during his 
sleep, which could partially explain the fragility of his sleep function. Also, he was found 
drinking alcohol and smoking just before going to bed. Moreover, he often surfed the web in 
eating snacks during the night on weekends. Therefore, we considered this above data as 
important evidence to strongly stop him from smoking and drinking before bedtime, and 
urging him to keep regular habits even at the weekend. With this intervention equipped 
with the home-monitored objective data, also based on sleep hygiene education (e.g. avoid 
bedside drinking, smoking, snacking and surfing the internet), his anxiety and fear of 
insomnia diminished dramatically and he spontaneously recovered from acute insomnia. 
The lifetime prevalence of OCD is comparatively high at 2-3.5% of the population. While 
neither the core syndromal manifestations nor prominent associated features of OCD 
include sleep disturbances, patients suffering from OCD often complain about their sleep 
disturbance. Clinical observations show that their complaints are non-specific and persist. 
Previous sleep studies among patients with OCD are sparse and results inconsistent, often 
confounding with their comorbid depressive illness. Psychiatric disorders, such as neurotic 
disorders including OCD, are often associated with sleep disorders, especially insomnia 
which is a crucial element in clinical practices. Characteristically, insomniacs often complain 
about their sleep more than about the lack of it objectively measured. Therefore, we have to 
organize specific remedies for co-occurring acute insomnia itself. Possible other reasons for 
explaining his diminished quality of sleep in this case, were as follows; 1) presence of co-
occurring subclinical depressive symptoms, 2) negative consequences of core OCD 
symptoms of sleep habits, 3) concurrent diurnal side effects of long-term prescribed 
medication. Clinically, these aspects must always be taken into consideration for managing 
sleep disturbance comorbid with neurotic disorders including OCD. 
In this case, we attempted to have an early intervention in the vicious cycle of acute 
insomnia. This early sleep focused intervention prevented him from entering the chronic 
vicious cycle of psycho/physiological hyperarousal, which was supposed to play a central 
role in the pathophysiology of insomnia. We emphasize several suggestions about acute 
insomniac state. “I can’t sleep”, “I don’t get enough sleep”: This kind of complaints have 
often led to the easiest solution of direct prescriptions of hypnotics. The accumulation of 
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hypnotics has eventually had negative consequences in their everyday QOLs, such as 
daytime sleepiness and diminished concentration. Traditionally, Morita Therapy, a unique 
psychotherapy originated in Japan was devised for treating classical neurotic disorder. That 
concept has evolved the phenomenology of insomniacs as a subjective fabricated nature, 
claiming that clinicians are liable to make an error by just giving hypnotics to help the 
patient’s feeling of sleeplessness without attempting radical cure on him. In this case, 
theoretically we applied some conventional concepts of Morita therapy to the treatment, 
utilizing the latest home monitoring instruments. We have to understand the fundamental 
phenomenology of diminished quality of sleep, and then give feedback to the acute 
insomniacs themselves in an appropriate way. To explain this process in the Morita theory, 
we attempted to stop exacerbating “psychic interaction” of acute insomniacs. This way of 
feedback may have something in common with the current well-developing Mindful-Based 
Cognitive Behavioral Therapy for insomnia. Despite their nature of subjective-objective 
discrepancy, individuals suffering from acute insomnia are situated under a subjectively 
perceived overwhelming threat.  
We may stress that focusing on how sleep state misperception could be a particularly 
central aspect of insomnia within the context of OCD. From this case study, it appears that 
the treatment was largely successful because the actigraphic records helped to correct the 
patient's misperceptions. Perhaps, such a focused intervention has a non-specific and 
positive psychotherapeutic effect. This could also have implications about the possible 
application of actigraphy to treat sleep problems within anxiety disorders. A home 
monitoring system, such as actigraphy, not only provides satisfactory objective 
evaluation, but also a supportive psychotherapeutic effect in diminishing fear and anxiety 
related with acute insomnia. Getting an individual to recognize at an early stage, and 
providing him with treatment pathway guided by actigraph to deal with, were crucial in 
this case. 
8.2 Alcoholism and insomnia 
Some researchers have investigated between sleep disturbances in an adolescent period and 
its temporal development of substance abuse. The role of alcohol in the suicidal process 
warrants special attention (Gromov, I & Gromov, D, 2009; Wong et al., 2010). Adolescents 
may also be considered to choose drinking habits and substance abuse as a self-help sleep 
habit in order to escape negative suicide ideation. The association between insomnia and its 
self-medication with alcoholism has been acknowledged. The relationship between sleep 
problems and substance use/abuse has been demonstrated in both adults and adolescents. 
Insomnia has been shown to prospectively predict alcohol problems among some adults 
(Brower et al., 2001).  
One recent unpublished data in alcoholic groups in a psychiatric hospital in Japan also 
showed that the majority of middle-aged alcoholic patients entering treatment reported 
insomnia symptoms and recognized themselves their diminished quality of sleep (Asami et 
al., 2011). In the Epidemiological Catchment Area study in the USA (n= 7,954), individuals 
with persistent insomnia at baseline were more likely than individuals without insomnia to 
experience the first onset of alcohol abuse or dependence one year later (Ford & Kamerow, 
1989). 
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In order to improve acute insomnia symptoms, we treated him mainly with an early sleep 
psychiatric approach as a non-pharmacological intervention. Intentionally, we avoided 
increasing medication, because his principal concerns were strongly related with daytime 
impairment of insomnia. Adding another medication to improve sleep might run a risk of 
exacerbating daytime consequences of insomnia. In this situation, we treated him, making 
use of a home-monitoring actigraphy and an oxygen saturation tool. After two days of 
monitoring, the actigraphy always measured total sleep time and number of nighttime 
awakenings, so data showed that he had slept sufficiently during the night contrary to his 
complaints. As a first step, we supported him by showing him recorded sleep data, which 
suggested that his objective quality of sleep was different from his subjective complaining. 
This manifestation explained by itself a typical psychopathology of insomnia. This 
monitoring continued for a week. During this period, he was encouraged to visit our clinic 3 
times a week for evaluation. Over nights, his actigraphic records always suggested longer 
and more consolidated sleep efficiency compared with his subjective intensity of insomnia 
complaints. As a next step, one night he was asked to get installed a portable oxygen 
saturation tool. The obtained data showed that some presence of hypoxemia during his 
sleep, which could partially explain the fragility of his sleep function. Also, he was found 
drinking alcohol and smoking just before going to bed. Moreover, he often surfed the web in 
eating snacks during the night on weekends. Therefore, we considered this above data as 
important evidence to strongly stop him from smoking and drinking before bedtime, and 
urging him to keep regular habits even at the weekend. With this intervention equipped 
with the home-monitored objective data, also based on sleep hygiene education (e.g. avoid 
bedside drinking, smoking, snacking and surfing the internet), his anxiety and fear of 
insomnia diminished dramatically and he spontaneously recovered from acute insomnia. 
The lifetime prevalence of OCD is comparatively high at 2-3.5% of the population. While 
neither the core syndromal manifestations nor prominent associated features of OCD 
include sleep disturbances, patients suffering from OCD often complain about their sleep 
disturbance. Clinical observations show that their complaints are non-specific and persist. 
Previous sleep studies among patients with OCD are sparse and results inconsistent, often 
confounding with their comorbid depressive illness. Psychiatric disorders, such as neurotic 
disorders including OCD, are often associated with sleep disorders, especially insomnia 
which is a crucial element in clinical practices. Characteristically, insomniacs often complain 
about their sleep more than about the lack of it objectively measured. Therefore, we have to 
organize specific remedies for co-occurring acute insomnia itself. Possible other reasons for 
explaining his diminished quality of sleep in this case, were as follows; 1) presence of co-
occurring subclinical depressive symptoms, 2) negative consequences of core OCD 
symptoms of sleep habits, 3) concurrent diurnal side effects of long-term prescribed 
medication. Clinically, these aspects must always be taken into consideration for managing 
sleep disturbance comorbid with neurotic disorders including OCD. 
In this case, we attempted to have an early intervention in the vicious cycle of acute 
insomnia. This early sleep focused intervention prevented him from entering the chronic 
vicious cycle of psycho/physiological hyperarousal, which was supposed to play a central 
role in the pathophysiology of insomnia. We emphasize several suggestions about acute 
insomniac state. “I can’t sleep”, “I don’t get enough sleep”: This kind of complaints have 
often led to the easiest solution of direct prescriptions of hypnotics. The accumulation of 
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hypnotics has eventually had negative consequences in their everyday QOLs, such as 
daytime sleepiness and diminished concentration. Traditionally, Morita Therapy, a unique 
psychotherapy originated in Japan was devised for treating classical neurotic disorder. That 
concept has evolved the phenomenology of insomniacs as a subjective fabricated nature, 
claiming that clinicians are liable to make an error by just giving hypnotics to help the 
patient’s feeling of sleeplessness without attempting radical cure on him. In this case, 
theoretically we applied some conventional concepts of Morita therapy to the treatment, 
utilizing the latest home monitoring instruments. We have to understand the fundamental 
phenomenology of diminished quality of sleep, and then give feedback to the acute 
insomniacs themselves in an appropriate way. To explain this process in the Morita theory, 
we attempted to stop exacerbating “psychic interaction” of acute insomniacs. This way of 
feedback may have something in common with the current well-developing Mindful-Based 
Cognitive Behavioral Therapy for insomnia. Despite their nature of subjective-objective 
discrepancy, individuals suffering from acute insomnia are situated under a subjectively 
perceived overwhelming threat.  
We may stress that focusing on how sleep state misperception could be a particularly 
central aspect of insomnia within the context of OCD. From this case study, it appears that 
the treatment was largely successful because the actigraphic records helped to correct the 
patient's misperceptions. Perhaps, such a focused intervention has a non-specific and 
positive psychotherapeutic effect. This could also have implications about the possible 
application of actigraphy to treat sleep problems within anxiety disorders. A home 
monitoring system, such as actigraphy, not only provides satisfactory objective 
evaluation, but also a supportive psychotherapeutic effect in diminishing fear and anxiety 
related with acute insomnia. Getting an individual to recognize at an early stage, and 
providing him with treatment pathway guided by actigraph to deal with, were crucial in 
this case. 
8.2 Alcoholism and insomnia 
Some researchers have investigated between sleep disturbances in an adolescent period and 
its temporal development of substance abuse. The role of alcohol in the suicidal process 
warrants special attention (Gromov, I & Gromov, D, 2009; Wong et al., 2010). Adolescents 
may also be considered to choose drinking habits and substance abuse as a self-help sleep 
habit in order to escape negative suicide ideation. The association between insomnia and its 
self-medication with alcoholism has been acknowledged. The relationship between sleep 
problems and substance use/abuse has been demonstrated in both adults and adolescents. 
Insomnia has been shown to prospectively predict alcohol problems among some adults 
(Brower et al., 2001).  
One recent unpublished data in alcoholic groups in a psychiatric hospital in Japan also 
showed that the majority of middle-aged alcoholic patients entering treatment reported 
insomnia symptoms and recognized themselves their diminished quality of sleep (Asami et 
al., 2011). In the Epidemiological Catchment Area study in the USA (n= 7,954), individuals 
with persistent insomnia at baseline were more likely than individuals without insomnia to 
experience the first onset of alcohol abuse or dependence one year later (Ford & Kamerow, 
1989). 
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Recently, Pieters et al. have investigated the associations between pubertal development, 
sleep preference, sleep problems, and alcohol use in 431 early adolescents (Pieters et al., 
2010). Then, they studied whether the associations changed when controlling for adolescent 
internalizing and externalizing problems. Results showed that pubertal development was 
positively associated with sleep problems and more evening-type tendencies (e.g., favouring 
later bedtimes), which in turn were positively related to alcohol use. From this study, it can 
be concluded that both puberty and sleep regulation are important factors in explaining 
alcohol use in early adolescence. This research has shown again a possible bi-directional 
relation between alcohol use and sleep, while profound puberty-dependent transitions 
regarding sleep patterns take place in early adolescence. Moreover, puberty has been 
associated with an increase in alcohol use of adolescents. They provided valuable data to 
understand the relationship among puberty, sleep problems, and alcohol use. Questions 
regarding that association, the possible reciprocal relationships among circadian phase 
preference, sleep problems and alcohol use, mediators and moderators of such relationships, 
as well as potential gender differences on these relationships were discussed (Wong, 2010). 
To understand the relationships among pubertal development, sleep problems, and alcohol 
use, researchers need to be aware of the physiological changes that take place in puberty, as 
well as the psychosocial factors that are associated with such changes (Pieters et al., 2010).  
To the best of our knowledge, Wong et al. s’ several reports in the USA have been the only 
longitudinal study examining the relationship between childhood sleep problems and 
adolescent substance use (Wong et al., 2004, 2009, 2010). Following their early works from a 
community sample of high-risk families and controls (292 boys and 94 girls), they have also 
tested whether adolescent sleep problems and poor response inhibition mediated the 
relationship between childhood sleep problems and substance (alcohol and drug) outcomes 
in young adulthood (Wong et al., 2010). Eventually, longitudinal design should be useful. 
Prevention and intervention programs may want to consider the role of sleep problems and 
response inhibition on substance use and abuse. 
8.3 Insomnia and trauma in current Japanese society aftermath of tsunami disaster 
A massive 9.0-magnitude earthquake occurred in the Pacific Ocean near Northeast Japan 
on March 11, 2011, causing serious damage to Japan. The effect of the East Japan 
Earthquake will not terminate within months. Many survivors experienced observing the 
disaster of the tsunami wiping out everything, and those extraordinary experiences will 
surely cause trauma among many minors (children and adolescents) who survived this 
disaster (Takeda, 2011). Those affected adults and adolescents should be taken care of 
closely for the possible occurrence of post-traumatic stress disorder, in terms of daily 
stress coping and sleep hygiene parameters related with insomnia. How does such 
emotional affects predict insomnia and nightmare symptoms? Bereavement is a 
ubiquitous part of the human condition. Almost no person makes it through his or her life 
without having to cope with the loss of a loved one several different times. The loss of a 
parent, child, or grandparent can be very distressing. From now on, further research will 
be needed to investigate the relationship between bereavement, complicated grief and 
recovery sleep.  
Before concluding this discussion, we cited another provident remark, proposed by a French 
psychologist. She challenged to develop an analysis of various external and intrapsychic 
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factors related to adult insomnia (Dollander, 2002). The author suggests some preventive 
perspective to face the etiology of adult insomnia, and points out limits of pharmacological 
treatment. From a clinical viewpoint, she succeeded in making methodological propositions 
to test the four exposed psychodynamic assumptions: 1) insomnia should be a result of 
anguish excess related to intrapsychic conflicts which can’t lead to a mental elaboration; 2) 
insomnia should be a result of psychic functioning invalidation; 3) some insomnias are 
related to waking associated with repetitive nightmares, and 4) some insomnias are in 
relation with an impossibility to accept passive position. These aspects are still in a 
hypothetical model, but it should always be noted in constructing long-term treatment 
strategy targeting on insomnia especially in the aftermath of trauma. 
9. Brief summary and conclusion 
In summary, clinical and epidemiological studies suggest that sleep disturbances (insomnia) 
are closely associated with suicidality and other correlates both in adult, and probably more 
importantly, in adolescent. In some cases, this association appears to exist above and beyond 
depression and PTSD. Nightmare shows a unique association with suicide risk, whereas 
additional research is needed to clarify both pathophysiology and symptomatology of 
insomnia. Studies should also be undertaken to determine the effects of adequate sleep and 
sleep hygiene promotion on mental health and suicide prevention. As the association 
between alcohol use and sleep has also been well documented among adults, researchers 
need to be aware of the pubertal development that takes place in sleep problems and their 
coping strategies. Circadian and homeostatic factors drive sleep. The sleep focused 
intervention studies may help us learn more about the fundamental role and homeostatic 
process of sleep dynamics in psychiatric disorder. Issues regarding the relationship between 
puberty and insomnia, the possible reciprocal relationships among circadian phase 
preference, sleep problems and alcohol use, mediators and moderators of such relationships 
(i.e. risk, protective and resilient factors), as well as potential gender differences on these 
relationships were discussed in further research and clinical practices.  
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related to waking associated with repetitive nightmares, and 4) some insomnias are in 
relation with an impossibility to accept passive position. These aspects are still in a 
hypothetical model, but it should always be noted in constructing long-term treatment 
strategy targeting on insomnia especially in the aftermath of trauma. 
9. Brief summary and conclusion 
In summary, clinical and epidemiological studies suggest that sleep disturbances (insomnia) 
are closely associated with suicidality and other correlates both in adult, and probably more 
importantly, in adolescent. In some cases, this association appears to exist above and beyond 
depression and PTSD. Nightmare shows a unique association with suicide risk, whereas 
additional research is needed to clarify both pathophysiology and symptomatology of 
insomnia. Studies should also be undertaken to determine the effects of adequate sleep and 
sleep hygiene promotion on mental health and suicide prevention. As the association 
between alcohol use and sleep has also been well documented among adults, researchers 
need to be aware of the pubertal development that takes place in sleep problems and their 
coping strategies. Circadian and homeostatic factors drive sleep. The sleep focused 
intervention studies may help us learn more about the fundamental role and homeostatic 
process of sleep dynamics in psychiatric disorder. Issues regarding the relationship between 
puberty and insomnia, the possible reciprocal relationships among circadian phase 
preference, sleep problems and alcohol use, mediators and moderators of such relationships 
(i.e. risk, protective and resilient factors), as well as potential gender differences on these 
relationships were discussed in further research and clinical practices.  
10. Acknowledgment 
This work was partially supported by a Health Science Research Grant from the Ministry of 
Helth, Labour and Welfare. The authors report no other financial affiliation or relationship 
relevant to the subject of this article. The views expressed in this article are mainly those of 
one of the authors (Y.A) and do not necessarily reflect the official policy or position of the 
authors’ institutions. 
11. References  
[1] Abe, Y. & Mishima, K. (2008). The concepts and pathophysiology of insomnia. Brain 21, 
11, 62-68, [Article in Japanese]. 
[2] Abe, Y.; Mishima, K.; Kaneita, Y.; Li, L.; Ohida, T.; Nishikawa, T. & Uchiyama, M. (2011). 
Stress coping behaviors and sleep hygiene practices in a sample of Japanese adults 
with insomnia. Sleep and Biological Rhythm, 9, 35–45. 
 
Public Health – Methodology, Environmental and Systems Issues 
 
412 
[3] Abe, Y.; Nishimura, G. & Endo, T. Early sleep psychiatric intervention for acute 
insomnia: Implications from a case of Obsessive-Compulsive Disorder (2012).  
J. Clin. Sleep Med., in press.  
[4] Ağargün, M.Y.; Kara, H. & Solmaz, M. (1997). Subjective sleep quality and suicidality in 
patients with majour depression. J. Psychiatr. Res., 31, 377-381. 
[5] Ağargün, M.Y.; Cilli, A.S.; Kara, H.; Tarhan, N.; Kincir, F. & Oz, H. (1998). Repetitive and 
frightening dreams and suicidal behavior in patients with major depression. Compr. 
Psychiatry, 39, 198-202. 
[6] Ağargün, M.Y.; Kara, H.; Ozer, O.A..; Selvi, Y.; Kiran, U. & Kiran, S. (2003). Nightmares 
and dissociative experiences: The key role of childhood traumatic events. Psychiatry 
and Clin. Neurosciences, 57, 139–145.  
[7] Ağargün, M.Y. & Beşiroğlu, L. (2005). Sleep and suicidality: do sleep disturbances 
predict suicide risk? Sleep, 28, 1039-1040.  
[8] AASM (American Academy of Sleep Medicine). (2005). International Classification of Sleep 
Disorders, 2nd Ed.: Diagnostic and Coding Manual. American Academy of Sleep 
Medicine (ICSD-2). Westchester, IL. 
[9] American Psychiatric Association (APA). (2000). Diagnostic and Statistical Manual of 
Mental Disorders, 4th edn. Text revision. American Psychiatric Association: 
Washington, D.C. 
[10] Apter, A.; Gothelf, D.; Orbach, I.; Weizman, R.; Ratzoni, G.; Har-Even, D. & Tyano, S. 
(1995). Correlation of suicidal and violent behavior in different diagnostic 
categories in hospitalized adolescent patients. J. Am. Acad. Child Adolesc. Psychiatry, 
34, 912–918. 
[11] Asami, M.; Abe, Y.; Suzuki, R.; Hasuo, R.; Nirasawa, H.; Jukuroki, H. & Kakibuchi, Y. 
(2011). A study on the subjective sleep evaluation and the related factors in the 
alcoholic, presented at the 36th Annual Metting of Japanese Society of Sleep 
Research, Oct 16.  
[12] Bader, K.; Schäfer, V.; Schenkel, M.; Nissen, L. & Schwander, J. (2007). Adverse 
childhood experiences associated with sleep in primary insomnia. J. Sleep Res., 16, 
285-296. 
[13] Basta, M.; Chrousos, G.P.; Vela-Bueno, A. & Vgontzas, A.N. (2007). Chronic Insomnia 
and Stress System. Sleep Med. Clin., 2, 279-91.  
[14] Baglioni, C.; Spiegelhalder, K.; Lombardo, C. & Riemann, D. (2010). Sleep and 
emotions: a focus on insomnia. Sleep Med. Rev., 14, 4, 227-238.  
[15] Bastien, C. & Morin, C. M. (2000). Familial incidence of insomnia. J. Sleep Res., 9, 49–54.  
[16] Bastien, C. H.; Vallières, A. & Morin, C. M. (2004). Precipitating factors of insomnia. 
Behav. Sleep Med, 2, 50–62.  
[17] Beaulieu-Bonneau, S.; LeBlanc, M.; Merette, C.; Dauvilliers, Y. & Morin, C. (2007). 
Family history of insomnia in a population-based sample. Sleep, 30, 1739–1745.  
[18] Bernert, R.A.; Joiner, T.E. Jr.; Cukrowicz, KC; Schmidt, N.B. & Krakow B. (2005). 
Suicidality and sleep disturbances. Sleep, 28, 1135-1141.  
[19] Bernert, R. A. & Joiner, T.E. (2007). Sleep disturbances and suicide risk: A review of the 
literature. Neuropsychiatr. Dis. Treat., 3, 735-743.  
[20] Blenkiron, P; House, A. & Milnes, D. (2000). The timing of acts of deliberate self-harm: 
is there any relation with suicidal intent, mental disorder or psychiatric 
management? J. Psychosom. Res, 49, 3-6. 
Insomnia and Its Correlates:  
Current Concepts, Epidemiology, Pathophysiology and Future Remarks 
 
413 
[21] Bonnet, M.H. & Arand, D.L. (1995). 24-Hour metabolic rate in insomniacs and matched 
normal sleepers. Sleep, 18, 581–588.  
[22] Bonnet M.H. & Arand, D.L.  (2010). Hyperarousal and insomnia: state of the science. 
Sleep Med. Rev., 14, 9-15. 
[23] Brand, S.; Luethi, M.; von Planta, A; Hatzinger, M. & Holsboer-Trachsler, E. (2007). 
Romantic love, hypomania, and sleep pattern in adolescents. J. Adolesc. Health., 41, 
1, 69-76. 
[24] Brand, S. & Kirov, R. (2011). Sleep and its importance in adolescence and in common 
adolescent somatic and psychiatric conditions. Int. J. Gen. Med, 4, 425-442. 
[25] Bridge, J.A.; Goldstein, T.R. & Brent, D.A. (2006). Adolescent suicide and suicidal 
behavior. Journal of Child Psychology and Psychiatry, 47, 372-394.  
[26] Brower, K.J.; Aldrich, M.S.; Robinson, E.A.; Zucker, R.A. & Greden, J.F. (2001). 
Insomnia, self-medication, and relapse to alcoholism. Am. J. Psychiatry, 158, 399-
404. 
[27] Buysse, D.J. (2008). Chronic insomnia. Am. J. Psychiatry, 165, 678–686. 
[28] Buysse, DJ; Angst, J; Gamma, A; Ajdacic, V; Eich, D. & Rössler, W. (2008). Prevalence, 
course, and comorbidity of insomnia and depression in young adults. Sleep, 31, 
473–480. 
[29] Choquet, M. & Menke, H. (1990). Suicidal thoughts during early adolescence: 
prevalence, associated troubles and help-seeking behavior. Acta Psychiatr. Scand., 
81, 170-177. 
[30] Choquet, M.; Kovess, V. & Poutignat, N. (1993). Suicidal thoughts among adolescents: 
an intercultural approach. Adolescence, 28, 111, 649-659.  
[31] Csóka, S.; Simor, P.; Szabó, G.; Kopp, M.S. & Bódizs, R. (2011). Early maternal 
separation, nightmares, and bad dreams: results from the Hungarostudy 
Epidemiological Panel. Attach Hum Dev., 13, 125-140.  
[32] Dauvilliers, Y.; Morin, C.; Cervena, K.; Carlander, B.; Touchon, J.; Besset, A. & Billiard, 
M. (2005). Family studies in insomnia. J. Psychosom. Res., 58, 271–278.  
[33] Dollander, M. (2002). Etiology of adult insomnia. L’Encéphale, 28, 493-502 [Article in 
French]. 
[34] Drake, C.L.; Scofield, H. & Roth, T. (2008). Vulnerability to insomnia: the role of 
familial aggregation. Sleep Med., 9, 297–302. 
[35] Edinger, J.D., Means, M.; Carney, C. E. & Krystal, A.D. (2008). Psychomotor 
performance deficits and their relation to prior nights’ sleep among individuals 
with primary insomnia. Sleep, 31, 599–607.  
[36] Ellis, J.G.; Gehrman, P.; Espie, C.A.; Riemann, D. & Perlis, M.L. (2011). Acute insomnia: 
Current conceptualizations and future directions. Sleep Med. Rev., 
doi:10.1016/j.smr. 2011.02.002.  
[37] Endo, S. (1962). The Psychophysiological Study of Neurotic insomnia. Psychiatria et 
Neurologia Japonica, 64, 673-707.  
[38] Fawcett, J.; Scheftner, W.A.; Fogg, L.; Clark, D.C.; Young, M.A.; Hedeker, D. & 
Gibbons, R. (1990). Time-related predictors of suicide in major affective disorder. 
Am. J. Psychiatry, 147, 1189-1194. 
[39] Ford, D. E. & Kamerow, D. B. (1989). Epidemiologic study of sleep disturbances and 
psychiatric disorders: an opportunity for prevention? JAMA, 262: 1479–1484.  
 
Public Health – Methodology, Environmental and Systems Issues 
 
412 
[3] Abe, Y.; Nishimura, G. & Endo, T. Early sleep psychiatric intervention for acute 
insomnia: Implications from a case of Obsessive-Compulsive Disorder (2012).  
J. Clin. Sleep Med., in press.  
[4] Ağargün, M.Y.; Kara, H. & Solmaz, M. (1997). Subjective sleep quality and suicidality in 
patients with majour depression. J. Psychiatr. Res., 31, 377-381. 
[5] Ağargün, M.Y.; Cilli, A.S.; Kara, H.; Tarhan, N.; Kincir, F. & Oz, H. (1998). Repetitive and 
frightening dreams and suicidal behavior in patients with major depression. Compr. 
Psychiatry, 39, 198-202. 
[6] Ağargün, M.Y.; Kara, H.; Ozer, O.A..; Selvi, Y.; Kiran, U. & Kiran, S. (2003). Nightmares 
and dissociative experiences: The key role of childhood traumatic events. Psychiatry 
and Clin. Neurosciences, 57, 139–145.  
[7] Ağargün, M.Y. & Beşiroğlu, L. (2005). Sleep and suicidality: do sleep disturbances 
predict suicide risk? Sleep, 28, 1039-1040.  
[8] AASM (American Academy of Sleep Medicine). (2005). International Classification of Sleep 
Disorders, 2nd Ed.: Diagnostic and Coding Manual. American Academy of Sleep 
Medicine (ICSD-2). Westchester, IL. 
[9] American Psychiatric Association (APA). (2000). Diagnostic and Statistical Manual of 
Mental Disorders, 4th edn. Text revision. American Psychiatric Association: 
Washington, D.C. 
[10] Apter, A.; Gothelf, D.; Orbach, I.; Weizman, R.; Ratzoni, G.; Har-Even, D. & Tyano, S. 
(1995). Correlation of suicidal and violent behavior in different diagnostic 
categories in hospitalized adolescent patients. J. Am. Acad. Child Adolesc. Psychiatry, 
34, 912–918. 
[11] Asami, M.; Abe, Y.; Suzuki, R.; Hasuo, R.; Nirasawa, H.; Jukuroki, H. & Kakibuchi, Y. 
(2011). A study on the subjective sleep evaluation and the related factors in the 
alcoholic, presented at the 36th Annual Metting of Japanese Society of Sleep 
Research, Oct 16.  
[12] Bader, K.; Schäfer, V.; Schenkel, M.; Nissen, L. & Schwander, J. (2007). Adverse 
childhood experiences associated with sleep in primary insomnia. J. Sleep Res., 16, 
285-296. 
[13] Basta, M.; Chrousos, G.P.; Vela-Bueno, A. & Vgontzas, A.N. (2007). Chronic Insomnia 
and Stress System. Sleep Med. Clin., 2, 279-91.  
[14] Baglioni, C.; Spiegelhalder, K.; Lombardo, C. & Riemann, D. (2010). Sleep and 
emotions: a focus on insomnia. Sleep Med. Rev., 14, 4, 227-238.  
[15] Bastien, C. & Morin, C. M. (2000). Familial incidence of insomnia. J. Sleep Res., 9, 49–54.  
[16] Bastien, C. H.; Vallières, A. & Morin, C. M. (2004). Precipitating factors of insomnia. 
Behav. Sleep Med, 2, 50–62.  
[17] Beaulieu-Bonneau, S.; LeBlanc, M.; Merette, C.; Dauvilliers, Y. & Morin, C. (2007). 
Family history of insomnia in a population-based sample. Sleep, 30, 1739–1745.  
[18] Bernert, R.A.; Joiner, T.E. Jr.; Cukrowicz, KC; Schmidt, N.B. & Krakow B. (2005). 
Suicidality and sleep disturbances. Sleep, 28, 1135-1141.  
[19] Bernert, R. A. & Joiner, T.E. (2007). Sleep disturbances and suicide risk: A review of the 
literature. Neuropsychiatr. Dis. Treat., 3, 735-743.  
[20] Blenkiron, P; House, A. & Milnes, D. (2000). The timing of acts of deliberate self-harm: 
is there any relation with suicidal intent, mental disorder or psychiatric 
management? J. Psychosom. Res, 49, 3-6. 
Insomnia and Its Correlates:  
Current Concepts, Epidemiology, Pathophysiology and Future Remarks 
 
413 
[21] Bonnet, M.H. & Arand, D.L. (1995). 24-Hour metabolic rate in insomniacs and matched 
normal sleepers. Sleep, 18, 581–588.  
[22] Bonnet M.H. & Arand, D.L.  (2010). Hyperarousal and insomnia: state of the science. 
Sleep Med. Rev., 14, 9-15. 
[23] Brand, S.; Luethi, M.; von Planta, A; Hatzinger, M. & Holsboer-Trachsler, E. (2007). 
Romantic love, hypomania, and sleep pattern in adolescents. J. Adolesc. Health., 41, 
1, 69-76. 
[24] Brand, S. & Kirov, R. (2011). Sleep and its importance in adolescence and in common 
adolescent somatic and psychiatric conditions. Int. J. Gen. Med, 4, 425-442. 
[25] Bridge, J.A.; Goldstein, T.R. & Brent, D.A. (2006). Adolescent suicide and suicidal 
behavior. Journal of Child Psychology and Psychiatry, 47, 372-394.  
[26] Brower, K.J.; Aldrich, M.S.; Robinson, E.A.; Zucker, R.A. & Greden, J.F. (2001). 
Insomnia, self-medication, and relapse to alcoholism. Am. J. Psychiatry, 158, 399-
404. 
[27] Buysse, D.J. (2008). Chronic insomnia. Am. J. Psychiatry, 165, 678–686. 
[28] Buysse, DJ; Angst, J; Gamma, A; Ajdacic, V; Eich, D. & Rössler, W. (2008). Prevalence, 
course, and comorbidity of insomnia and depression in young adults. Sleep, 31, 
473–480. 
[29] Choquet, M. & Menke, H. (1990). Suicidal thoughts during early adolescence: 
prevalence, associated troubles and help-seeking behavior. Acta Psychiatr. Scand., 
81, 170-177. 
[30] Choquet, M.; Kovess, V. & Poutignat, N. (1993). Suicidal thoughts among adolescents: 
an intercultural approach. Adolescence, 28, 111, 649-659.  
[31] Csóka, S.; Simor, P.; Szabó, G.; Kopp, M.S. & Bódizs, R. (2011). Early maternal 
separation, nightmares, and bad dreams: results from the Hungarostudy 
Epidemiological Panel. Attach Hum Dev., 13, 125-140.  
[32] Dauvilliers, Y.; Morin, C.; Cervena, K.; Carlander, B.; Touchon, J.; Besset, A. & Billiard, 
M. (2005). Family studies in insomnia. J. Psychosom. Res., 58, 271–278.  
[33] Dollander, M. (2002). Etiology of adult insomnia. L’Encéphale, 28, 493-502 [Article in 
French]. 
[34] Drake, C.L.; Scofield, H. & Roth, T. (2008). Vulnerability to insomnia: the role of 
familial aggregation. Sleep Med., 9, 297–302. 
[35] Edinger, J.D., Means, M.; Carney, C. E. & Krystal, A.D. (2008). Psychomotor 
performance deficits and their relation to prior nights’ sleep among individuals 
with primary insomnia. Sleep, 31, 599–607.  
[36] Ellis, J.G.; Gehrman, P.; Espie, C.A.; Riemann, D. & Perlis, M.L. (2011). Acute insomnia: 
Current conceptualizations and future directions. Sleep Med. Rev., 
doi:10.1016/j.smr. 2011.02.002.  
[37] Endo, S. (1962). The Psychophysiological Study of Neurotic insomnia. Psychiatria et 
Neurologia Japonica, 64, 673-707.  
[38] Fawcett, J.; Scheftner, W.A.; Fogg, L.; Clark, D.C.; Young, M.A.; Hedeker, D. & 
Gibbons, R. (1990). Time-related predictors of suicide in major affective disorder. 
Am. J. Psychiatry, 147, 1189-1194. 
[39] Ford, D. E. & Kamerow, D. B. (1989). Epidemiologic study of sleep disturbances and 
psychiatric disorders: an opportunity for prevention? JAMA, 262: 1479–1484.  
 
Public Health – Methodology, Environmental and Systems Issues 
 
414 
[40] Franzen, P.L.& Buysse, D.J. (2008). Sleep disturbances and depression : risk 
relationships for sebsequent depression and therapeutic implications. Dialogues 
Clin. Neurosci., 10, 473-481. 
[41] Fujino, Y.; Mizoue, T; Tokui, N. & Yoshimura, T. (2005). Prospective cohort study of 
stress, life satisfaction, self-rated health, insomnia, and suicide death in Japan. 
Suicide Life-Threat Behav., 35, 2, 227–237. 
[42] Gangwisch, J.E.; Babiss, L.A.; Malaspina, D.; Turner, J.B.; Zammit, G.K. & Posner, K. 
(2010). Earlier parental set bedtimes as a protective factor against depression and 
suicidal ideation. Sleep, 33, 97-106.  
[43] Gau, S. F. & Soong, W.T. (1995). Sleep problems of junior high school students in 
Taipei. Sleep, 18, 667–673.  
[44] Germain. A.; Shear, K.; Monk, T.H.; Houck, P.R.; Reynolds, C.F.; Frank, E. & Buysse, 
D.J. (2006). Treating complicated grief: effects on sleep quality. Behav. Sleep Med., 4, 
3, 152-163.  
[45] Germain, A.; Buysse, D.J. & Nofzinger, E. (2008). Sleep-specific mechanisms 
underlying posttraumatic stress disorder: integrative review and neurobiological 
hypotheses. Sleep Med. Rev., 12, 3, 185-195.  
[46] Germain, A.; Hall, M.; Krakow, B.; Shear, K. M. & Buysse, D.J. (2005). A brief sleep 
scale for Posttraumatic Stress Disorder: Pittsburgh Sleep Quality Index Addendum 
for PTSD. J. Anxiety Disord., 19, 2, 233-244.  
[47] Goldstein, T. R.; Bridge, J.A. & Brent, D.A. (2008). Sleep disturbance preceding 
completed suicide in adolescents. J. Consult. Clin. Psychol., 76, 84-91.  
[48] Goblin, A.; Kravitz, H. & Keith, L. eds. (2004). Sleep Psychiatry. Taylor & Francis, 
London. 
[49] Gregory, A.M.; Caspi, A.; Moffitt, T.E. & Poulton R. (2006). Family conflict in 
childhood: a predictor of later insomnia. Sleep, 29, 1063-1067.  
[50] Gromov, I. & Gromov, D. (2009). Sleep and substance use and abuse in adolescents. 
Child. Adolesc. Psychiatr. Clin. N. Am., 18, 929-946.  
[51] Hasler, B. & Germain, A. (2009). Correlates and Treatments of Nightmares in Adults. 
Sleep Med Clin., 4, 507-517.  
[52] Hendin, H.; Maltsberger, J.T. & Szanto, K. (2008). The psychosocial context of trauma 
in treating PTSD patients. Am. J. Psychiatry, 165, 28-32.  
[53] Jefferson, C.D.; Drake, C.L.; Scofield, H.M., Myers, E.; McClure, T.; Roehrs, T. & Roth, 
T. (2005). Sleep hygiene practices in a population-based sample of insomniacs. 
Sleep, 28, 611–615.  
[54] Johnson, E.O.; Roth, T.; Schultz, L. & Breslau, N. (2006). Epidemiology of DSM-IV 
insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender 
difference. Pediatrics, 117, 247-256. 
[55] Kaneita, Y.; Ohida, T.; Osaki,Y.; Tanihata, T.; Minowa, M.; Suzuki, K.; Wada, K.; 
Kanda, H. & Hayashi, K. (2006). Insomnia among Japanese adolescents: 
anationwide representative survey. Sleep, 29, 1543–1550.  
[56] Krakow, B. ; Artar, A. & Warner, T.D. (2000). Sleep disorder, depression and suicidality 
in female sexual assault survivors. Crisis, 21, 163-170. 
[57] Krakow, B.; Ribeiro, J.D.; Ulibarri, V.A.; Krakow, J. & Joiner, T.E. Jr. (2011). Sleep 
disturbances and suicidal ideation in sleep medical center patients. J. Affect. Disord., 
131, 422-427. 
Insomnia and Its Correlates:  
Current Concepts, Epidemiology, Pathophysiology and Future Remarks 
 
415 
[58] LeBlanc, M.; Beaulieu-Bonneau, S.; Mérette, C.; Savard, J.; Ivers, H. & Morin, C.M. 
(2007). Psychological and health-related quality of life factors associated with 
insomnia in a population-based sample. J. Psychosom. Res., 63, 157–166.  
[59] Levin, R. & Nielsen, T.A. (2007). Disturbed dreaming, posttraumatic stress disorder, 
and affect distress: A review and neurocognitive model. Psychological Bulletin, 133, 
482–528. 
[60] Levin, R. & Nielsen, T. (2009). Nightmares, bad dreams and emotion dysregulation: A 
review and new neurocognitive model of dreaming. Current Directions in 
Psychological Science, 18, 84–88.  
[61] Li, S.X., Lam, S.P.; Yu, M.W.; Zhang, J. & Wing, Y.K. (2010). Nocturnal sleep 
disturbances as a predictor of suicide attempts among psychiatric outpatients: a 
clinical, epidemiologic, prospective study. J. Clin. Psychiatry, 71, 1440-1446.  
[62] Liu, X.C.; Uchiyama, M.; Okawa, M. & Kurita, H. (2000). Prevalence and correlates of 
self-reported sleep problems among Chinese adolescents. Sleep, 23, 27–34.  
[63] Liu, X. & Buysse, D.J. (2006). Sleep and youth suicidal behavior: a neglected field. Curr. 
Opin. Psychiatry, 19, 288-293.  
[64] Mahgoub, N. A. (2009). Insomnia and suicide risk. J. Neuropsychiatry Clin. Neurosci, 2, 
21, 232-233.  
[65] Mai, E. & Buysse, D.J. (2008). Insomnia: Prevalence, Impact, Pathogenesis, Differential 
Diagnosis, and Evaluation. Sleep Med. Clin., 3, 2, 167-174. 
[66] Morin, C.M.; Rodrigue, S. & Ivers, H. (2003). Role of stress, arousal, and coping skills in 
primary insomnia. Psychosom. Med., 65, 259–267.  
[67] Morin, C.M. & Espie, C. (2004). Insomnia: A Clinical Guide to Assessment and 
Treatment. Springer: New York. 
[68] Morin, C.M.; Leblanc, M.; Daley, M.; Gregoire, J.P. & Merette, C. (2006). Epidemiology 
of insomnia: prevalence, self-help treatments, consultations, and determinants of 
help-seeking behaviors. Sleep Med, 7, 123–130.  
[69] Morrison, D.N.; McGee, R. & Stanton, W.R. (1992). Sleep problems in adolescence.  
J. Am. Acad. Child. Adolesc. Psychiatry, 31, 94–99.  
[70] Motohashi, Y. (1990). Circadian variation in suicide attempts in Tokyo from 1978 to 
1985. Suicide Life Threat. Behav., 20, 533-539.  
[71] Munezawa, T.; Kaneita, Y.; Osaki, Y.; Kanda, H.; Ohtsu, T.; Suzuki, H.; Minowa, M.; 
Suzuki, K.; Higuchi, S.; Mori, J. & Ohida, T. (2011). Nightmare and sleep paralysis 
among Japanese adolescents: a nationwide representative survey. Sleep Med., 12, 
56-64. 
[72] Nadorff, M. R.; Nazem, S. & Fiske, A. (2011). Insomnia symptoms, nightmares, and 
suicidal ideation in a college student sample. Sleep, 34, 93-98. 
[73] National Institutes of Health (NIH). (2005). National Institutes of Health state of the 
science conference statement on manifestations and management of chronic 
insomnia in adults. June 13–15, 2005, Sleep, 28, 1049–1057.  
[74] Nielsen, T.A.; Stenstrom, P. & Levin, R. (2006). Nightmare frequency as a function of 
age, gender and September 11, 2001: Findings from an Internet questionnaire. 
Dreaming, 16, 145–158.  
[75] Nir, Y. & Tononi, G. (2010). Dreaming and the brain: from phenomenology to 
neurophysiology. Trends Cogn. Sci., 14, 2, 88-100.  
 
Public Health – Methodology, Environmental and Systems Issues 
 
414 
[40] Franzen, P.L.& Buysse, D.J. (2008). Sleep disturbances and depression : risk 
relationships for sebsequent depression and therapeutic implications. Dialogues 
Clin. Neurosci., 10, 473-481. 
[41] Fujino, Y.; Mizoue, T; Tokui, N. & Yoshimura, T. (2005). Prospective cohort study of 
stress, life satisfaction, self-rated health, insomnia, and suicide death in Japan. 
Suicide Life-Threat Behav., 35, 2, 227–237. 
[42] Gangwisch, J.E.; Babiss, L.A.; Malaspina, D.; Turner, J.B.; Zammit, G.K. & Posner, K. 
(2010). Earlier parental set bedtimes as a protective factor against depression and 
suicidal ideation. Sleep, 33, 97-106.  
[43] Gau, S. F. & Soong, W.T. (1995). Sleep problems of junior high school students in 
Taipei. Sleep, 18, 667–673.  
[44] Germain. A.; Shear, K.; Monk, T.H.; Houck, P.R.; Reynolds, C.F.; Frank, E. & Buysse, 
D.J. (2006). Treating complicated grief: effects on sleep quality. Behav. Sleep Med., 4, 
3, 152-163.  
[45] Germain, A.; Buysse, D.J. & Nofzinger, E. (2008). Sleep-specific mechanisms 
underlying posttraumatic stress disorder: integrative review and neurobiological 
hypotheses. Sleep Med. Rev., 12, 3, 185-195.  
[46] Germain, A.; Hall, M.; Krakow, B.; Shear, K. M. & Buysse, D.J. (2005). A brief sleep 
scale for Posttraumatic Stress Disorder: Pittsburgh Sleep Quality Index Addendum 
for PTSD. J. Anxiety Disord., 19, 2, 233-244.  
[47] Goldstein, T. R.; Bridge, J.A. & Brent, D.A. (2008). Sleep disturbance preceding 
completed suicide in adolescents. J. Consult. Clin. Psychol., 76, 84-91.  
[48] Goblin, A.; Kravitz, H. & Keith, L. eds. (2004). Sleep Psychiatry. Taylor & Francis, 
London. 
[49] Gregory, A.M.; Caspi, A.; Moffitt, T.E. & Poulton R. (2006). Family conflict in 
childhood: a predictor of later insomnia. Sleep, 29, 1063-1067.  
[50] Gromov, I. & Gromov, D. (2009). Sleep and substance use and abuse in adolescents. 
Child. Adolesc. Psychiatr. Clin. N. Am., 18, 929-946.  
[51] Hasler, B. & Germain, A. (2009). Correlates and Treatments of Nightmares in Adults. 
Sleep Med Clin., 4, 507-517.  
[52] Hendin, H.; Maltsberger, J.T. & Szanto, K. (2008). The psychosocial context of trauma 
in treating PTSD patients. Am. J. Psychiatry, 165, 28-32.  
[53] Jefferson, C.D.; Drake, C.L.; Scofield, H.M., Myers, E.; McClure, T.; Roehrs, T. & Roth, 
T. (2005). Sleep hygiene practices in a population-based sample of insomniacs. 
Sleep, 28, 611–615.  
[54] Johnson, E.O.; Roth, T.; Schultz, L. & Breslau, N. (2006). Epidemiology of DSM-IV 
insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender 
difference. Pediatrics, 117, 247-256. 
[55] Kaneita, Y.; Ohida, T.; Osaki,Y.; Tanihata, T.; Minowa, M.; Suzuki, K.; Wada, K.; 
Kanda, H. & Hayashi, K. (2006). Insomnia among Japanese adolescents: 
anationwide representative survey. Sleep, 29, 1543–1550.  
[56] Krakow, B. ; Artar, A. & Warner, T.D. (2000). Sleep disorder, depression and suicidality 
in female sexual assault survivors. Crisis, 21, 163-170. 
[57] Krakow, B.; Ribeiro, J.D.; Ulibarri, V.A.; Krakow, J. & Joiner, T.E. Jr. (2011). Sleep 
disturbances and suicidal ideation in sleep medical center patients. J. Affect. Disord., 
131, 422-427. 
Insomnia and Its Correlates:  
Current Concepts, Epidemiology, Pathophysiology and Future Remarks 
 
415 
[58] LeBlanc, M.; Beaulieu-Bonneau, S.; Mérette, C.; Savard, J.; Ivers, H. & Morin, C.M. 
(2007). Psychological and health-related quality of life factors associated with 
insomnia in a population-based sample. J. Psychosom. Res., 63, 157–166.  
[59] Levin, R. & Nielsen, T.A. (2007). Disturbed dreaming, posttraumatic stress disorder, 
and affect distress: A review and neurocognitive model. Psychological Bulletin, 133, 
482–528. 
[60] Levin, R. & Nielsen, T. (2009). Nightmares, bad dreams and emotion dysregulation: A 
review and new neurocognitive model of dreaming. Current Directions in 
Psychological Science, 18, 84–88.  
[61] Li, S.X., Lam, S.P.; Yu, M.W.; Zhang, J. & Wing, Y.K. (2010). Nocturnal sleep 
disturbances as a predictor of suicide attempts among psychiatric outpatients: a 
clinical, epidemiologic, prospective study. J. Clin. Psychiatry, 71, 1440-1446.  
[62] Liu, X.C.; Uchiyama, M.; Okawa, M. & Kurita, H. (2000). Prevalence and correlates of 
self-reported sleep problems among Chinese adolescents. Sleep, 23, 27–34.  
[63] Liu, X. & Buysse, D.J. (2006). Sleep and youth suicidal behavior: a neglected field. Curr. 
Opin. Psychiatry, 19, 288-293.  
[64] Mahgoub, N. A. (2009). Insomnia and suicide risk. J. Neuropsychiatry Clin. Neurosci, 2, 
21, 232-233.  
[65] Mai, E. & Buysse, D.J. (2008). Insomnia: Prevalence, Impact, Pathogenesis, Differential 
Diagnosis, and Evaluation. Sleep Med. Clin., 3, 2, 167-174. 
[66] Morin, C.M.; Rodrigue, S. & Ivers, H. (2003). Role of stress, arousal, and coping skills in 
primary insomnia. Psychosom. Med., 65, 259–267.  
[67] Morin, C.M. & Espie, C. (2004). Insomnia: A Clinical Guide to Assessment and 
Treatment. Springer: New York. 
[68] Morin, C.M.; Leblanc, M.; Daley, M.; Gregoire, J.P. & Merette, C. (2006). Epidemiology 
of insomnia: prevalence, self-help treatments, consultations, and determinants of 
help-seeking behaviors. Sleep Med, 7, 123–130.  
[69] Morrison, D.N.; McGee, R. & Stanton, W.R. (1992). Sleep problems in adolescence.  
J. Am. Acad. Child. Adolesc. Psychiatry, 31, 94–99.  
[70] Motohashi, Y. (1990). Circadian variation in suicide attempts in Tokyo from 1978 to 
1985. Suicide Life Threat. Behav., 20, 533-539.  
[71] Munezawa, T.; Kaneita, Y.; Osaki, Y.; Kanda, H.; Ohtsu, T.; Suzuki, H.; Minowa, M.; 
Suzuki, K.; Higuchi, S.; Mori, J. & Ohida, T. (2011). Nightmare and sleep paralysis 
among Japanese adolescents: a nationwide representative survey. Sleep Med., 12, 
56-64. 
[72] Nadorff, M. R.; Nazem, S. & Fiske, A. (2011). Insomnia symptoms, nightmares, and 
suicidal ideation in a college student sample. Sleep, 34, 93-98. 
[73] National Institutes of Health (NIH). (2005). National Institutes of Health state of the 
science conference statement on manifestations and management of chronic 
insomnia in adults. June 13–15, 2005, Sleep, 28, 1049–1057.  
[74] Nielsen, T.A.; Stenstrom, P. & Levin, R. (2006). Nightmare frequency as a function of 
age, gender and September 11, 2001: Findings from an Internet questionnaire. 
Dreaming, 16, 145–158.  
[75] Nir, Y. & Tononi, G. (2010). Dreaming and the brain: from phenomenology to 
neurophysiology. Trends Cogn. Sci., 14, 2, 88-100.  
 
Public Health – Methodology, Environmental and Systems Issues 
 
416 
[76] Nofzinger, E.A.; Buysse, D.J.; Germain, A.; Price, J.C.; Miewald, J.M. & Kupfer, D.J. 
(2004). Functional neuroimaging evidence for hyperarousal in insomnia. Am. J. 
Psychiatr, 161, 11, 2126-2128. 
[77] Ohayon, M.M. (2002). Epidemiology of insomnia: what we know and what we still 
need to learn. Sleep Med. Rev., 6, 97–111.  
[78] Ohayon, M. M. & Lemoine, P. (2004). Daytime consequences of insomnia complaints in 
the French general population. L’Encéphale, 222–227 [Article in French]. 
[79] Ohida, T.; Osaki, Y.; Doi, Y.; Tanihata, T.; Minowa, M.; Suzuki, K.; Wada, K.; Suzuki, K. 
& Kaneita, Y. (2004). An epidemiological study of self-reported sleepproblems 
among Japanese adolescents. Sleep, 27, 978–985.  
[80] Orff, H.J.; Drummond, S.P.; Nowakowski, S. & Perlis, M.L. (2007). Discrepancy 
between subjective symptomatology and objective neuropsychological 
performance in insomnia. Sleep, 30, 1205-1211.  
[81] Pandey, G. N. (2011). Neurobiology of adult and teenage suicide. Asian Journal of 
Psychiatry, 4, 2-13.  
[82] Pieters, S.; Van der Vorst, H.; Burk, W.J.; Wiers, R.W. & Engels, R.C. (2010). Puberty-
dependent sleep regulation and alcohol use in early adolescents. Alcohol Clin. Exp. 
Res., 34, 1512-1518.  
[83] Pigeon, W.R. & Caine, E.D. (2010). Insomnia and the risk for suicide: does sleep 
medicine have interventions that can make a difference? Sleep Med., 11, 9, 816-817.  
[84]  Proposed Draft Revisions to DSM-5 Disorders and Criteria. (2010). 
http://www.dsm5.org/.  
[85] Pronger, C.E. (1914). Insomnia and suicide. Lancet, 184: 1356–1359.  
[86] Riemann, D. & Voderholzer, U. (2003). Primary insomnia: a risk factor to develop 
depression? J. Affect. Disord. 76, 255–259.  
[87] Riemann, D.; Voderholzer, U.; Spiegelhalder, K.; Hornyak, M.; Buysse, D.J.; Nissen, C. ; 
Hennig, J.; Perlis, M.L.; van Elst, L.T. & Feige, B. (2007). Chronic insomnia and 
MRI-measured hippocampal volumes: a pilot study. Sleep, 30, 955–958.  
[88] Riemann, D.; Kloepfer, C. & Berger, M. (2009). Functional and structural brain 
alterations in insomnia: implications for pathophysiology. Eur. J. Neurosci., 29, 9, 
1754-1760.  
[89] Riemann, D.; Spiegelhalder, K.; Feige, B.; Voderholzer, U.; Berger, M.; Perlis, M. & 
Nissen, C. (2010). The hyperarousal model of insomnia: a review of the concept and 
its evidence. Sleep Med Rev. 14, 19-31.  
[90] Riemann, D.; Spiegelhalder, K.; Espie, C.; Pollmächer, T. ; Léger, D.; Bassetti, C. & van 
Someren, E. (2011). Chronic insomnia: clinical and research challenges--an agenda. 
Pharmacopsychiatry. 44, 1-14. 
[91] Roane B.M. & Taylor, D.J. (2008). Adolescent insomnia as a risk factor for early adult 
depression and substance abuse. Sleep, 31, 1351-1356. 
[92] Roberts, R. E.; Roberts, C.R. & Chen, I. G. (2001). Functioning of adolescents with 
symptoms of disturbed sleep. Journal of Youth and Adolescence, 30, 1-18. 
[93] Rosen, J.; Reynolds, C.F.3rd.; Yeager, A.L.; Houck, P.R. & Hurwitz, L.F. (1991). Sleep 
disturbances in survivors of the Nazi Holocaust. Am. J. Psychiatry, 148, 62-66.  
[94] Safer, D.J. (1997). Adolescent/adult differences in suicidal behavior and outcome. Ann. 
Clin. Psychiatry, 9, 61-66.  
Insomnia and Its Correlates:  
Current Concepts, Epidemiology, Pathophysiology and Future Remarks 
 
417 
[95] Selvi, Y.; Aydin, A.; Boysan, M., Atli, A.; Agargun, M.Y. & Besiroglu, L. (2010). 
Associations between chronotype, sleep quality, suicidality, and depressive 
symptoms in patients with major depression and healthy controls. Chronobiol Int., 
27, 1813-1828.  
[96] Shekleton, J. A.; Rogers, N. L. & Rajaratnam, S.M. (2010). Searching for the daytime 
impairments of primary insomnia. Sleep Med. Rev., 14, 1, 47-60.  
[97] Sher, L. (2008). Sleep disturbances, synaptic homeostasis and suicidal behaviour. Aust. 
N. Z. J. Psychiatry, 2008, 42, 1072-1073.  
[98] Singareddy, R. K. & Balon, R. (2001). Sleep and suicide in psychiatric patients. Ann. 
Clin. Psychiatry, 13, 93-101.  
[99] Sjöström, N.; Waern, M. & Hetta, J. (2007). Nightmares and sleep disturbances in 
relation to suicidality in suicide attempters. Sleep, 30, 91-95.  
[100] Soldatos, C.R.; Allaert, F.A.; Ohta, T. & Dikeos, D. G. (2005). How do individuals sleep 
around the world? Results from a single-day survey in ten contries. Sleep Med., 6, 
5–13. 
[101] Sompo Japan Research Institute Inc. Disease Management Reporter in Japan No. 17, 
May, 2010.  
[102] Spielman, A. J.; Caruso, L.S. & Glovinsky, P.B. (1987). A behavioral perspective on 
insomnia treatment. Psychiatr. Clin. North Am., 10, 541–553.  
[103] Tamas, Z.; Kovacs, M.; Gentzler, A.L.; Tepper, P.; Gadoros, J.; Kiss, E.; Kapornai, K. & 
Vetró, A. (2007). The relations of temperament and emotion self-regulation with 
suicidal behaviors in a clinical sample of depressed children in Hungary. J. Abnorm. 
Child Psychol., 35, 640-652.  
[104] Taylor, D. J. & Roane, B.M. (2010). Treatment of insomnia in adults and children: a 
practice-friendly review of research. J. Clin. Psychol., 66, 1137-1147.  
[105] Taylor, D. J.; Gardner, C.E; Bramoweth, A.D; Williams, J.M.; Roane, B. M.; Grieser, E. 
A. & Tatum, J. I. (2011). Insomnia and Mental Health in College Students. Behav. 
Sleep Med., 9, 107-116.  
[106] Tononi, G. & Cirelli, C. (2003). Sleep and synaptic homeostasis: a hypothesis. Brain Res. 
Bull., 62, 2, 143-150. 
[107] Tononi, G. & Cirelli, C. (2006). Sleep function and synaptic homeostasis. Sleep Med. 
Rev., 10, 49-62.  
[108] Tsuno, N.; Besset, A. & Ritchie, K. (2005). Sleep and depression. J. Clin. Psychiatry, 66, 
1254–1269. 
[109] Takeda, M. (2011). Mental health care and East Japan Great Earthquake. Psychiatry 
Clin. Neurosciences, 65, 207-212.  
[110] Tanskanen, A.; Tuomilehto, J.; Viinamäki, H.; Vartiainen, E.; Lehtonen, J. & Puska, P. 
(2001). Nightmares as predictors of suicide. Sleep, 24, 844-847. 
[111] Troxel, W.M. & Germain, A. (2011). Insecure attachment is an independent correlate  
of objective sleep disturbances in military veterans. Sleep Med., 
doi:10.1016/j.sleep.2011.07.005. 
[112] Turvey, C.L.; Conwell, Y.; Jones, M.P.; Phillips, C.; Simonsick, E.; Pearson J.L. & 
Wallace, R. (2002). Risk factors for late-life suicide: a prospective, community-based 
study. Am. J. Geriatr. Psychiatry, 10, 398-406.  
 
Public Health – Methodology, Environmental and Systems Issues 
 
416 
[76] Nofzinger, E.A.; Buysse, D.J.; Germain, A.; Price, J.C.; Miewald, J.M. & Kupfer, D.J. 
(2004). Functional neuroimaging evidence for hyperarousal in insomnia. Am. J. 
Psychiatr, 161, 11, 2126-2128. 
[77] Ohayon, M.M. (2002). Epidemiology of insomnia: what we know and what we still 
need to learn. Sleep Med. Rev., 6, 97–111.  
[78] Ohayon, M. M. & Lemoine, P. (2004). Daytime consequences of insomnia complaints in 
the French general population. L’Encéphale, 222–227 [Article in French]. 
[79] Ohida, T.; Osaki, Y.; Doi, Y.; Tanihata, T.; Minowa, M.; Suzuki, K.; Wada, K.; Suzuki, K. 
& Kaneita, Y. (2004). An epidemiological study of self-reported sleepproblems 
among Japanese adolescents. Sleep, 27, 978–985.  
[80] Orff, H.J.; Drummond, S.P.; Nowakowski, S. & Perlis, M.L. (2007). Discrepancy 
between subjective symptomatology and objective neuropsychological 
performance in insomnia. Sleep, 30, 1205-1211.  
[81] Pandey, G. N. (2011). Neurobiology of adult and teenage suicide. Asian Journal of 
Psychiatry, 4, 2-13.  
[82] Pieters, S.; Van der Vorst, H.; Burk, W.J.; Wiers, R.W. & Engels, R.C. (2010). Puberty-
dependent sleep regulation and alcohol use in early adolescents. Alcohol Clin. Exp. 
Res., 34, 1512-1518.  
[83] Pigeon, W.R. & Caine, E.D. (2010). Insomnia and the risk for suicide: does sleep 
medicine have interventions that can make a difference? Sleep Med., 11, 9, 816-817.  
[84]  Proposed Draft Revisions to DSM-5 Disorders and Criteria. (2010). 
http://www.dsm5.org/.  
[85] Pronger, C.E. (1914). Insomnia and suicide. Lancet, 184: 1356–1359.  
[86] Riemann, D. & Voderholzer, U. (2003). Primary insomnia: a risk factor to develop 
depression? J. Affect. Disord. 76, 255–259.  
[87] Riemann, D.; Voderholzer, U.; Spiegelhalder, K.; Hornyak, M.; Buysse, D.J.; Nissen, C. ; 
Hennig, J.; Perlis, M.L.; van Elst, L.T. & Feige, B. (2007). Chronic insomnia and 
MRI-measured hippocampal volumes: a pilot study. Sleep, 30, 955–958.  
[88] Riemann, D.; Kloepfer, C. & Berger, M. (2009). Functional and structural brain 
alterations in insomnia: implications for pathophysiology. Eur. J. Neurosci., 29, 9, 
1754-1760.  
[89] Riemann, D.; Spiegelhalder, K.; Feige, B.; Voderholzer, U.; Berger, M.; Perlis, M. & 
Nissen, C. (2010). The hyperarousal model of insomnia: a review of the concept and 
its evidence. Sleep Med Rev. 14, 19-31.  
[90] Riemann, D.; Spiegelhalder, K.; Espie, C.; Pollmächer, T. ; Léger, D.; Bassetti, C. & van 
Someren, E. (2011). Chronic insomnia: clinical and research challenges--an agenda. 
Pharmacopsychiatry. 44, 1-14. 
[91] Roane B.M. & Taylor, D.J. (2008). Adolescent insomnia as a risk factor for early adult 
depression and substance abuse. Sleep, 31, 1351-1356. 
[92] Roberts, R. E.; Roberts, C.R. & Chen, I. G. (2001). Functioning of adolescents with 
symptoms of disturbed sleep. Journal of Youth and Adolescence, 30, 1-18. 
[93] Rosen, J.; Reynolds, C.F.3rd.; Yeager, A.L.; Houck, P.R. & Hurwitz, L.F. (1991). Sleep 
disturbances in survivors of the Nazi Holocaust. Am. J. Psychiatry, 148, 62-66.  
[94] Safer, D.J. (1997). Adolescent/adult differences in suicidal behavior and outcome. Ann. 
Clin. Psychiatry, 9, 61-66.  
Insomnia and Its Correlates:  
Current Concepts, Epidemiology, Pathophysiology and Future Remarks 
 
417 
[95] Selvi, Y.; Aydin, A.; Boysan, M., Atli, A.; Agargun, M.Y. & Besiroglu, L. (2010). 
Associations between chronotype, sleep quality, suicidality, and depressive 
symptoms in patients with major depression and healthy controls. Chronobiol Int., 
27, 1813-1828.  
[96] Shekleton, J. A.; Rogers, N. L. & Rajaratnam, S.M. (2010). Searching for the daytime 
impairments of primary insomnia. Sleep Med. Rev., 14, 1, 47-60.  
[97] Sher, L. (2008). Sleep disturbances, synaptic homeostasis and suicidal behaviour. Aust. 
N. Z. J. Psychiatry, 2008, 42, 1072-1073.  
[98] Singareddy, R. K. & Balon, R. (2001). Sleep and suicide in psychiatric patients. Ann. 
Clin. Psychiatry, 13, 93-101.  
[99] Sjöström, N.; Waern, M. & Hetta, J. (2007). Nightmares and sleep disturbances in 
relation to suicidality in suicide attempters. Sleep, 30, 91-95.  
[100] Soldatos, C.R.; Allaert, F.A.; Ohta, T. & Dikeos, D. G. (2005). How do individuals sleep 
around the world? Results from a single-day survey in ten contries. Sleep Med., 6, 
5–13. 
[101] Sompo Japan Research Institute Inc. Disease Management Reporter in Japan No. 17, 
May, 2010.  
[102] Spielman, A. J.; Caruso, L.S. & Glovinsky, P.B. (1987). A behavioral perspective on 
insomnia treatment. Psychiatr. Clin. North Am., 10, 541–553.  
[103] Tamas, Z.; Kovacs, M.; Gentzler, A.L.; Tepper, P.; Gadoros, J.; Kiss, E.; Kapornai, K. & 
Vetró, A. (2007). The relations of temperament and emotion self-regulation with 
suicidal behaviors in a clinical sample of depressed children in Hungary. J. Abnorm. 
Child Psychol., 35, 640-652.  
[104] Taylor, D. J. & Roane, B.M. (2010). Treatment of insomnia in adults and children: a 
practice-friendly review of research. J. Clin. Psychol., 66, 1137-1147.  
[105] Taylor, D. J.; Gardner, C.E; Bramoweth, A.D; Williams, J.M.; Roane, B. M.; Grieser, E. 
A. & Tatum, J. I. (2011). Insomnia and Mental Health in College Students. Behav. 
Sleep Med., 9, 107-116.  
[106] Tononi, G. & Cirelli, C. (2003). Sleep and synaptic homeostasis: a hypothesis. Brain Res. 
Bull., 62, 2, 143-150. 
[107] Tononi, G. & Cirelli, C. (2006). Sleep function and synaptic homeostasis. Sleep Med. 
Rev., 10, 49-62.  
[108] Tsuno, N.; Besset, A. & Ritchie, K. (2005). Sleep and depression. J. Clin. Psychiatry, 66, 
1254–1269. 
[109] Takeda, M. (2011). Mental health care and East Japan Great Earthquake. Psychiatry 
Clin. Neurosciences, 65, 207-212.  
[110] Tanskanen, A.; Tuomilehto, J.; Viinamäki, H.; Vartiainen, E.; Lehtonen, J. & Puska, P. 
(2001). Nightmares as predictors of suicide. Sleep, 24, 844-847. 
[111] Troxel, W.M. & Germain, A. (2011). Insecure attachment is an independent correlate  
of objective sleep disturbances in military veterans. Sleep Med., 
doi:10.1016/j.sleep.2011.07.005. 
[112] Turvey, C.L.; Conwell, Y.; Jones, M.P.; Phillips, C.; Simonsick, E.; Pearson J.L. & 
Wallace, R. (2002). Risk factors for late-life suicide: a prospective, community-based 
study. Am. J. Geriatr. Psychiatry, 10, 398-406.  
 
Public Health – Methodology, Environmental and Systems Issues 
 
418 
[113] Vollath, M.; Wicki, W. & Angst, J. (1989). The Zurich Study VIII. Insomnia: association 
with depression, anxiety, somatic symptoms, and course of insomnia. Eur. Arch. 
Psychiatry Neurol. Sci., 239, 113–124. 
[114] Wirz-Justice, A.; Benedetti, F. & Terman, M. (2009). Chronotherapeutics for Affective 
Disorders: A Clinician's Manual for Light and Wake Therapy. Basel, Karger.  
[115] Wojnar, M.; Ilgen, M.A.; Wojnar, J.; McCammon, R.J.; Valenstein, M. & Brower, K.J. 
(2009). Sleep problems and suicidality in the National Comorbidity Survey 
Replication. J. Psychiatr. Res., 43, 526-531.  
[116] Wong, M.M; Brower, K.J.; Fitzgerald, H.E. & Zucker, R.A. (2004). Sleep problems in 
early childhood and early onset of alcohol and other drug use in adolescence. 
Alcohol. Clin. Exp. Res., 28, 578-587.  
[117] Wong, M. M.; Brower, K.J. & Zucker, R.A. (2009). Childhood sleep problems, early 
onset of substance use and behavioral problems in adolescence. Sleep Med., 10, 787-
796.  
[118] Wong, M. M.; Brower, K. J.; Nigg, J.T. & Zucker, R.A. (2010a). Childhood sleep 
problems, response inhibition, and alcohol and drug outcomes in adolescence and 
young adulthood. Alcohol. Clin. Exp. Res., 34, 1033-1044.  
[119] Wong, M, M. (2010b). Pubertal development, sleep problems, and alcohol use: a 
commentary. Alcohol. Clin. Exp. Res., 34, 2019-2021. 
[120] Wong, M.M.; Brower, K.J. & Zucker, R.A. (2011). Sleep problems, suicidal ideation, and 
self-harm behaviors in adolescence. J. Psychiatr. Res., 45, 505-511.  
[121] Yang, C.M.; Wu, C.H.; Hsieh, M. H.; Liu, M.H. & Lu, F.H. (2003). Coping with sleep 
disturbances among young adults: a survey of first-year college students in 
Taiwan. Behav. Med., 29, 133-138.  
20 
Saving More than Lives:  
A Gendered Analysis of the Importance  
of Fertility Preservation for Cancer Patients 
Lisa Campo-Engelstein1, Sarah Rodriguez2 and Shauna Gardino2,3 
1Alden March Bioethics Institute & Department of OBGYN,  
Albany Medical College, 




Cancer affects millions of Americans annually. Men’s lifetime risk of developing cancer for 
all sites is 50%; women’s lifetime risk is just over 33% (American Cancer Society, 2009).  
While cancer is generally perceived as a condition affecting people past their child-bearing 
years, nearly 10% of those diagnosed are under age 45 (Horner et al., 2009). Indeed, some of 
those diagnosed with cancer are still children. In 2006, an estimated 9,500 new cases of 
pediatric cancer were diagnosed in the United States (American Cancer Society, 2006). 
Because of recent breakthroughs and more aggressive treatments, the survival rate of those 
diagnosed with childhood cancer has risen to almost 80% (Clayman, Galvin, and Arnston, 
2007). One estimate is that by 2010 one of every 250 adults will be a survivor of childhood 
cancer (Kinahan, 2007). 
But while more aggressive treatments have meant more people survive cancer, these 
treatments have also resulted in impaired fertility or sterility for some. Given the numbers 
of children and adults within their child-bearing years diagnosed with, treated for, and 
surviving cancer, fertility concerns have emerged as a quality of life issue important to 
cancer survivors and their families. In one study of cancer survivors, 76% of those who were 
childless expressed a desire to have children in the future (Schover, 2009). Impaired fertility 
as a result of cancer treatment has physical as well as psychological effects. The existing 
literature on women whose fertility was impaired as a result of cancer treatment reveals an 
intense psychological distress; for these women, “psychological distress may result from, 
not only the loss of the physical ability to conceive, but also a symbolic loss of the option or 
idea of fertility, regardless of whether this would have been acted upon or achievable” 
(Carter et al, 2005, p. 93). Some studies on men have revealed similar levels of long-term 
distress over their impaired fertility as a result of cancer treatments (Schover, 2009) while 
other studies found that infertility is not nearly as devastating for men as it is for women.  
Though reproduction is valued by both women and men, as the conflicting responses to 
studies between women and men (and even among men) illustrate, there are often 
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Cancer affects millions of Americans annually. Men’s lifetime risk of developing cancer for 
all sites is 50%; women’s lifetime risk is just over 33% (American Cancer Society, 2009).  
While cancer is generally perceived as a condition affecting people past their child-bearing 
years, nearly 10% of those diagnosed are under age 45 (Horner et al., 2009). Indeed, some of 
those diagnosed with cancer are still children. In 2006, an estimated 9,500 new cases of 
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diagnosed with childhood cancer has risen to almost 80% (Clayman, Galvin, and Arnston, 
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surviving cancer, fertility concerns have emerged as a quality of life issue important to 
cancer survivors and their families. In one study of cancer survivors, 76% of those who were 
childless expressed a desire to have children in the future (Schover, 2009). Impaired fertility 
as a result of cancer treatment has physical as well as psychological effects. The existing 
literature on women whose fertility was impaired as a result of cancer treatment reveals an 
intense psychological distress; for these women, “psychological distress may result from, 
not only the loss of the physical ability to conceive, but also a symbolic loss of the option or 
idea of fertility, regardless of whether this would have been acted upon or achievable” 
(Carter et al, 2005, p. 93). Some studies on men have revealed similar levels of long-term 
distress over their impaired fertility as a result of cancer treatments (Schover, 2009) while 
other studies found that infertility is not nearly as devastating for men as it is for women.  
Though reproduction is valued by both women and men, as the conflicting responses to 
studies between women and men (and even among men) illustrate, there are often 
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differences in how women and men respond to infertility. Gender has been the focus of 
much analysis in ethics, but little work has been done looking at gendered narratives to 
analyze fertility concerns as a quality of life issue among men and women undergoing 
possible fertility-impairing treatment for cancer. Such an analysis is relevant in the current 
context because of the rise in the number of younger people being diagnosed with and 
surviving cancer and accompanying scientific and technological advances in fertility 
preservation techniques. In the context of cancer survivorship, fertility has become a distinct 
quality of life consideration, with an entire new field (oncofertility) now dedicated to 
promoting fertility preservation options for cancer patients and survivors. Since oncofertility 
is a novel discipline that bridges a variety of academic scholarships, existing conceptual 
frameworks are inadequate for analyses within this field. We propose a multidisciplinary 
approach to understand the gendered themes of infertility as a quality of life concern in the 
current context of oncofertility.  
In doing so, we argue that exploring common cultural conceptions of gender is essential to 
understanding cancer patients’ and their families’ fertility preservation decision making 
when confronting potential infertility. Our analysis begins at the patient level with a 
discussion of the existing literature that describes gender differences among cancer patients 
regarding fertility, cancer treatment, and the effects of both on their quality of life. Uniquely, 
we contextualize these existing social science studies within a historical context, using a new 
perspective to attempt to explain the sometimes divergent responses between women and 
men and among men by focusing on the different ways men and women have been treated 
for infertility broadly since the nineteenth century. We build on this historical framework by 
conducting a gendered analysis of infertility and fertility choices that is centered in the 
current cultural climate. In this way, we address gender, infertility, and fertility choices from 
three distinct levels—the individual level, the contextualizing historical level, and the 
broader current cultural level—creating our own multidisciplinary framework. Our analysis 
offers an insightful approach, creating a new framework within which we are able to draw 
meaningful conclusions about the impact gendered responses to infertility have on cancer 
patients’ medical care and how health care providers and researchers can incorporate this 
knowledge to improve patient care. 
2. Fertility preservation technologies 
The developing field of oncofertility is dedicated to providing fertility preservation options to 
cancer patients, and a number of alternatives currently exist for both men and women. 
Reproductively mature men confronting a cancer diagnosis can generate a sperm sample and 
cryopreserve (freeze) their gametes for later use. Ejaculation can be stimulated in young men 
and those too sick to produce a sperm sample, or an experimental testicular biopsy can be 
done; the resulting sample can be cryopreserved. The technology for freezing sperm is well-
established and successful, leaving these men with a viable option to become a biological 
father after cancer. Freezing sperm is relatively inexpensive and easy to accomplish, thus a 
feasible option for men of all socioeconomic backgrounds and cancer types. 
Women’s reproductive potential can also be jeopardized during cancer treatment. The only 
established method of fertility preservation for women is embryo banking, but this is often 
not a palatable option for young and/or single women. Egg banking is gaining popularity 
because there is no reliance on a male donor (known or anonymous); however, it is still 
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considered an experimental intervention by the American Society for Reproductive 
Medicine (ASRM). Neither embryo nor egg banking, however, are not good options for 
some newly diagnosed cancer patients because these procedures require a two-to-three 
week delay in cancer treatment and cannot be performed on those who have not yet reached 
puberty. For women or young girls for whom embryo or egg banking may not be an 
acceptable option, ovarian tissue cryopreservation offers another opportunity to protect 
their potential to parent. Ovarian tissue cryopreservation is a procedure in which one ovary 
is removed and ovarian tissue is frozen in small strips. Based on the woman’s treatment 
plan, the strips can be transplanted back and potentially restore ovarian function. 
Researchers are also currently working on another way to use the tissue: maturing the 
follicles from the cryopreserved ovarian tissue within the laboratory. As the functional unit 
of the ovary, the follicles would ideally mature into eggs and then be fertilized, with the 
resulting embryo implanted back into the woman when she desires pregnancy (Jeruss and 
Woodruff, 2009).  
3. Examining the existing research on QOL and fertility 
As we will discuss in-depth in the next section, infertility has historically been associated 
with women. Indeed, early studies of fertility concerns among cancer patients and survivors 
claim that women value fertility to a greater extent than men. In 1987, Wasserman, 
Thomspon, Wilimas, and Fairclough (1987) determined that attitudes toward possible 
sterility differed dramatically between female and male Hodgkin’s survivors, with females 
expressing much more concern about their childbearing potential than males. Five years 
later, Zelter published a literature review, concluding that women as a group seek more 
information and evaluation of their fertility status than men (Zelter, 1993). Schover, Rubicki, 
Martin, and Bringelsen (1999) followed up with another literature review, hypothesizing 
from gathered data that women are more distressed over infertility, more concerned about 
having children, and more likely to see parenthood as an integral part of their life goals 
when compared to men. Finally, Patridge et al (2004) found that women will even sacrifice 
the efficacy of cancer treatment to lessen their chances of infertility or sterility, describing 
how, if given a choice, young women with early-stage breast cancer may choose a less toxic 
regimen of chemotherapy even if it confers slightly less protection from recurrence of 
cancer.  
However, a handful of studies have recognized that male cancer patients and survivors 
value their fertility as well. A 1990 study by Reiker et al of 153 testicular cancer survivors 
indicated that distress about infertility is also prevalent among men, particularly among 
those who have cancer treatments that are likely to severely impair fertility (Reiker, 1990). 
Similarly, a 2003 study by Green, Galvin, and Horne confirmed that infertility can cause 
long-term distress among men with cancer. The literature regarding fertility concerns 
among male cancer patients is scarce when compared to the number of studies that 
demonstrate the importance of fertility among female cancer patients, but nonetheless this 
data should not be ignored. A growing body of more recent literature is beginning to 
recognize fertility concerns among male cancer patients, concluding that gender differences 
in fertility concerns may not be as prominent as once thought. 
Indeed, a 1999 study by Schover et al, which used a questionnaire to examine 283 young 
cancer survivors, found that about 80% of cancer survivors viewed themselves positively as 
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actual or potential parents, with no observed gender-related differences in the wish to have 
children or distress about fertility (Schover, et al, 1999). Similarly, a 2004 study by Zebrack, 
Casillas, Nohr, Adams, and Zelter used semi-structured interviews to assess the impact of 
cancer on long-term cancer survivors’ quality of life, concluding that both men and women 
expressed a desire to have children in the future (Zebrack, 2004). Finally, an exploratory 
qualitative study by Crawshaw (2010) found that fertility matters affected identity, well-
being and life planning as well as reproductive function, regardless of gender.  
Our literature review of gender differences in fertility concerns among cancer patients 
indicates that, at present, there is conflicting evidence, but understandings of these gendered 
differences may be changing. While older studies indicate that female cancer patients value 
their fertility more strongly than male cancer patients, newer research suggests that these 
attitudes may be changing as more male cancer patients are beginning to recognize and 
express their fertility-related distress. However, these disparate conclusions could also be 
explained by differing methodologies; the aforementioned studies range from semi-
structured interviews to questionnaires to literature reviews. As these studies are rooted in 
distinct and differing methodologies, drawing accurate comparisons between them may be 
complicated.  
In the rest of the paper we explore factors that may account for the aforementioned 
discrepancies in the literature relating to fertility concerns among female and male cancer 
patients, using both historical and cultural frameworks to explain how these attitudes are 
developed and derived.  
4. Historical foundations: Women and infertility  
In order to better understand the basis for the differing ways women and men may view 
infertility today, and the lack of consensus about the value of fertility among men, we need 
to explore the differences in the ways men and women have been medically treated for 
infertility in this country. As we will next describe, medical treatment for infertility in the 
United States reinforced and reflected prevailing cultural ideas about masculinity and 
femininity. 
Though Americans could consult medical guides in the late eighteenth century for recourse 
to alleviate an involuntarily childless marriage, it was during the nineteenth century when 
physicians became increasingly involved in treating, and patients began to increasingly seek 
medical intervention for, infertility (Marsh and Ronner, 1996). Almost always, however, the 
patients seeking treatment were women. Why? Though motherhood had earlier been a 
principal role for women, during the nineteenth century it increasingly became the defining 
role for women, especially white middle-class women (Apple, 1997; Marsh and Ronner, 
1996). By the early nineteenth century, American society began to draw clearer lines 
between family and community. These lines changed how families were seen and 
composed, both of which had profound implications for women’s conceptions of femininity 
and reproduction. During the course of the nineteenth century, biological parenthood rather 
than household composition came to define a family, and thus being a mother increasingly 
meant bearing one’s own children. As part of this shift, biological motherhood was 
increasingly regarded as the primary and principal role of women – in contrast to women in 
colonial America, where motherhood, though important, was seen as only one of a woman’s 
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roles (Marsh and Ronner, 1996). Being a mother, especially through pregnancy, began to be 
more strongly tied to being a woman. This change in the stress placed on biological 
motherhood as the core identifier for femininity, along with the rise in the profession of 
gynecology, prompted a change in the way involuntary childlessness was viewed, both 
popularly and medically. What had been regarded as barrenness, a personal misfortune, 
became infertility, a treatable condition. As Margaret Marsh and Wanda Ronner (1996) 
noted in their history of infertility in the United States, during the nineteenth century, 
involuntarily childless married women began to increasingly turn to medical expertise; by 
doing so, both clinicians and women accepted infertility as treatable. Infertility was now a 
recognized medical condition, but patients seeking treatment for it were still nearly all 
female (Marsh and Ronner, 1996). 
Beginning in the late nineteenth century, Marsh and Ronner argue, women willingly 
underwent often invasive treatments, including various surgeries, to correct an impairment 
of their bodies in order to provide them with a chance for motherhood. By doing so, they 
sought a surgical restoration not just of their reproductive functions but also of their 
feminine identity. The convergence of motherhood as defining femininity with the 
increasing reliance on physicians to treat involuntarily childless women enabled a 
perception that infertility was a problem of and with the female body. This was reinforced 
as only women sought medical attention for infertility. For the majority of the nineteenth 
century, it was women alone who were considered, culturally and medically, to be infertile; 
men were only considered infertile if they were impotent (Marsh and Ronner, 1996). 
Infertility was characterized as a disease of the female body, and it was a disease that 
impaired a woman’s ability to achieve her primary social role: motherhood (Apple, 1997; 
Marsh and Ronner, 1996). Women internalized infertility: a woman’s inability to biologically 
bear children challenged the prevailing cultural norm that motherhood was the natural role 
for a feminine woman. Infertility, then, affected the way women saw their feminine selves. 
As Marsh and Ronner (1996) found when they examined infertility in the late nineteenth 
and early twentieth centuries in the United States, doctors treated women across racial, 
ethnic, and class lines, suggesting the link between reproduction and femininity extended 
across the demographic spectrum. As the twentieth century wore on, increasing numbers of 
women sought medical expertise to enable them to conceive, with a sharp rise in infertility 
treatments accompanying the baby boom following World War II. During this intense 
pronatalist period in American history, to not be pregnant or have children within two years 
of marriage marked some women as odd – possibly even suggesting a lack of femininity. 
This tie between a woman’s ability to conceive and her femininity, though ebbing a bit in the 
1970s, remained strong through the course of the twentieth century (Marsh and Ronner, 
1996; May, 1995).  
5. Current cultural narratives: Women and infertility 
The cultural connection between a woman’s reproductive ability and her feminine identity 
has strong historical foundations in how women have been treated for infertility, 
foundations that continue to frame cultural conceptions of femininity as well as individual 
women’s conception of themselves as female. Women have, and continue to, internalize 
their infertility. The contemporary literature on women without a cancer diagnosis but with 
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impaired fertility reveals a significant amount of stress and depression due to their 
condition. Women who are infertile but otherwise healthy are twice as likely to be 
depressed as fertile healthy women; indeed, these women report levels of psychological 
distress comparable to women with life-threatening illnesses (Davis and Dearman, 1991; 
Domar, Zuttermeister, 1993; Luske and Vacc, 1993). In her exploration of women’s reactions 
to learning of their infertility, Gayle Letherby (2002) found that women experienced a 
profound shock to their sense of themselves, resulting in a challenge to their conception of 
identity as female. 
What happens, then, to a woman’s conception of herself when the option for biological 
motherhood is impaired or taken away because of her cancer diagnosis or cancer treatment? 
The existing literature on women whose fertility is impaired due to cancer treatment reveals 
similar psychological stress; for these women, “psychological distress may result from, not 
only the loss of the physical ability to conceive, but also a symbolic loss of the option or idea 
of fertility, regardless of whether this would have been acted upon or achievable” (Carter, et 
al., 2005, p. 93). The American Society of Clinical Oncology (ASCO) found that “surveys of 
cancer survivors have identified an increased risk of emotional distress on those who 
become infertile because of their treatment” (Lee et al., 2006, p. 2921). One study on young 
women with breast cancer found that “fertility concerns may complicate” their “treatment 
decision-making process” and that there is evidence these young women “may experience 
greater psychological distress and more difficulty with adjustment to the diagnosis and 
treatment of breast cancer” (Partridge, 2004, p. 4175). This actual or symbolic loss has 
potentially great implications for a woman’s perceptions of herself as female, for 
motherhood is a culturally significant role most women see themselves in and which cancer 
potentially interrupts. Women whose cancer treatments threaten their fertility still want the 
experience of motherhood, most often biological motherhood (Lee et al., 2006, p. 2921). This 
equation of femininity with reproductive ability remains culturally resonant. Women today, 
as in the past, quite often tie their feminine identities to their reproductive capabilities; a 
cancer diagnosis is a recent, and additionally culturally powerful, component of a longer 
story concerning women, infertility, and medical treatment. 
6. Historical foundations: Men and infertility 
Women, as was just explored, were much more likely in both the nineteenth and the 
twentieth centuries to seek medical treatment for infertility. While this gender discrepancy 
was at first an outgrowth of the idea that only women were barren, and then that only 
women were infertile, it persisted even as physicians noted that there could be a male factor 
involved in infertility. Indeed, by the late nineteenth century, some gynecologists began 
calling for husbands to be examined when wives came seeking a cure for their childlessness. 
But even as the concept of barrenness gave way to infertility for women in the nineteenth 
century, very few doctors asked to examine a patient’s husband, as most physicians still 
considered it rare for a virile man to be infertile (Marsh and Ronner, 1996). This cultural 
conception was reflected and reinforced medically in the nineteenth century. In the early 
twentieth century, after examining a young woman who had been married for six years and 
came to him for “relief” of her suffering from infertility, physician Gustavus Blech (1903) 
took a swab of semen from the young woman’s vagina and looked at it under a microscope. 
He found “not a spermatozoon in sight.” But though he noted this physiological matter, and 
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recommended to other physicians the need to look at the sperm of husbands’ when a 
woman came to them for the treatment of infertility, he also stressed the importance of 
whether or not the man was “capable of performing the sexual act” when analyzing if the 
infertility was male or female factor (Blech, 1903, 45-46). 
As the Blech case illustrates, male fertility was connected to virility through the twentieth 
century, even though physicians acknowledged that the viability of the semen was an 
identifiable factor. Though by the 1930s physicians recognized that infertility was 
comparable in both genders, and by the 1950s semen analysis had become a standard 
protocol for infertility intervention, women largely remained the focus of medical fertility 
treatment. More than one physician lamented in the first half of the twentieth century that 
too many of his peers were eager to first perform invasive procedures (such as surgery) on 
the wife before testing the viability of the husband’s sperm (Marsh and Ronner, 1996; May 
1995). But even with the knowledge that men were infertile as often as women, this gender 
difference in treatment continued for the course of the twentieth century. In 1963, the 
president of the American Society for the Study of Sterility (later called ASRM) explained at 
the group’s annual meeting that such a protocol remained justified because many infertility 
specialists believed men were rarely infertile. But just as important, since women usually 
initiated medical treatment, their husbands were often left unexamined (May, 1995). So 
while the physiological knowledge was there and the understanding that men were as likely 
to be infertile as women was available, women were the ones being treated because they 
sought the medical intervention. Even if a physician could not find a physiological reason 
on the woman’s body, both the woman and the physician frequently believed the 
impairment was with her body. From the nineteenth century to the present, women have 
most commonly sought medical intervention for infertility, often doing so in order to spare 
their husbands from possible humiliation – a humiliation based on the idea that an infertile 
man was an impotent man (Marsh and Ronner, 1996; May, 1995).  
While femininity was tied to reproduction, and this tie held both culturally and medically 
over the course of the twentieth century, masculinity, in contrast, was tied to sexual virility. 
Here we are extending the work of Marsh and Ronner (1996) in their history of infertility in 
the United States to argue that there is a historical basis for the current differences of 
fertility-related distress among male cancer patients compared to female cancer patients: 
men’s medical treatment was not so tied, and did not reinforce, infertility as an impairment 
of their bodies. When infertility was associated with men, it was generally seen as an 
impairment with virility.  
7. Current cultural narratives: Men and infertility 
Virility remains a significant component of cultural conceptions of masculinity and men’s 
gendered identities. Sexual prowess is often seen as a way of proving one’s masculinity. 
Furthermore, the male genitals are generally central to a man’s coherent sexual identity 
(Gurevich et al., 2004), and are associated with stereotypical masculine traits like “strength” 
and “courage” (Szasz, 1998). Because of the personal, as well as social, significance of the 
male genitals, having “misfunctioning” (e.g. impotent, prematurely ejaculating, infertile) 
genitals or genitals that look “abnormal” (e.g. small penis, missing a testicle) can diminish 
men’s sense of masculinity. For instance, in a ranking of the most humiliating experiences 
for college age men, the top three had to do with sexual function and the appearance of 
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impaired fertility reveals a significant amount of stress and depression due to their 
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genitals: 1. unable to maintain an erection during sex; 2. losing a testicle to cancer; 3. being 
teased about penis size (Mormon, 2000). 
This trend holds true for men facing cancer, especially those with cancer affecting the 
genitals: listing the second most humiliating experience as losing a testicle to cancer 
highlights the deleterious effects cancer can have on men’s self-worth and identity. A 
qualitative study on men with testicular cancer found that definitions of masculinity 
continue to be strongly tied to sexual performance and the appearance of “normal” genitals, 
both of which can be threatened by cancer and cancer treatments (Gurevich et al., 2004). 
Whereas the centrality of virility and male genitals to men’s sexual identity is supported in 
the literature (Gurevich, et al., 2004), the importance of fertility for men—the desire to have 
biological children and the role fertility plays in their identity—is not just ambiguous, but is 
often contradictory. As previously discussed, some studies found male cancer patients value 
their fertility as much as female cancer patients whereas other studies show that women 
value their fertility much more than men. Much of the broader literature on infertility in the 
general population, not just cancer patients, supports the latter finding. In his interviews 
with mainly white, middle-class, heterosexual married couples facing infertility,1 Arthur 
Greil (1991) found that the husbands were more likely to view the experience of infertility as 
disappointing, though not as a threat to their identity. The wives, in contrast, saw infertility 
as devastating, something that spoiled their identities and signified their role failure as 
woman, wife, and mother (Greil, 1991). Furthermore, in a review of the literature, Greil 
discusses how both qualitative and quantitative studies show that women react more 
negatively to infertility (e.g. have lower self-esteem, blame themselves for their infertility, 
feel defective, etc.) than men (Greil, 2010). Even when the couple is suffering from male 
factor infertility, most of the literature concludes that this does not seem to change men’s 
response to infertility (Greil, 1997).  
Given that infertility is not as devastating for men as impotence or abnormal genitals, it is 
not surprising that a diagnosis of sterility ranks lower (in fifth place) on the list of the most 
humiliating experiences for college men than experiences that are more closely connected to 
sexual performance and the appearance of “normal” genitals (Mormon, 2000).2 It is worth 
noting that men older than traditional college age students (18-22 years old) may have come 
up with a different ranking; while college age men are typically trying to avoid fatherhood 
and consequently do not value fertility as much at this stage in their lives, older men are 
probably more interested in becoming a father and thus may find a diagnosis of sterility 
more troubling.    
While sterility and infertility may not top the list as the most humiliating experience for 
young men, they are still negative experiences. A large reason for this is the close 
relationship between men’s virility and fertility (Inhorn, 2002). The historical association of 
infertility with impotence and the importance of virility to current conceptions of 
                                                 
1 White, middle-class, heterosexual married couples are the most common participants of many 
empirical studies on infertility in part because they are the social group most likely to seek out infertility 
treatment. In the last handful of years, however, more research has been done on people of color and 
infertility. See, for example, Becker et al., Jain, and White et al.  
2 Having a rectal exam ranks fourth. While this experience does not directly deal with male sexuality, 
being penetrated is usually associated with women, which is in part why this experience is humiliating. 
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masculinity result in cultural understandings of infertility as an indicator of emasculation. 
Cynthia Daniels (2006), a political scientist researching the politics of reproduction, asserts 
that “the ability to biologically father one’s children remains a hallmark of one’s manhood, 
and infertility remains a source of masculine shame” (p.161). Specifically, questions about 
the viability of sperm production incite questions about the viability of masculinity 
(Gurevich 2004; Daniels 2006) This association is reflected in the secrecy and stigma 
surrounding heterosexual couples using sperm donation and results in practices like 
“matching” sperm donors to the physical traits and characteristics of the social father to hide 
his infertility (Becker, 1994; Daniels, 2006).   
In addition to threatening masculinity, infertility may adversely affect men because it leaves 
their desire for biological children unfulfilled. Yet, this reason may play a smaller role for men 
than for women. The cultural pressure for women to have biological children and the fact that 
motherhood is an important part of many women’s identity are thought to be a significant 
factor in why infertility is so devastating to women. That “[t]here is, in American society, no 
‘fatherhood mandate’ with the same force and intensity as the ‘motherhood mandate’” may 
explain, at least in part, men’s less strong reaction to infertility (Greil 1991, p. 64).  
While there is still less pressure for men to be biological fathers compared to the pressure 
women feel to be mothers (at least in the U.S.), men are much more active in their children’s 
lives than even a generation ago. We see this change reflected in new concepts and policies. 
For example, the concept of a stay-at-home dad is relatively recent. This term probably did 
not exist, or at the very least was not ubiquitous, a couple of generations ago. Today, the 
U.S. Census Bureau estimates that there are 143,000 stay-at-home dads. Men’s involvement 
in primary caretaking of children is also seen in policies like extending maternity leave to 
men through paternity leave. A recent study shows that 89% of men took some time off after 
the birth of their child (Nepomnyaschy and Waldfogel, 2007).  
Men’s increased involvement in their children’s lives shows not only that fatherhood is 
extremely significant for many men, but also that men’s active participation in their 
children’s lives is becoming more socially acceptable. Indeed, gender norms surrounding 
fatherhood are changing, which influences the value men place on becoming biological 
fathers. Fatherhood today seems to play a greater role in men’s identity and their vision of 
an ideal life. This social change helps explain the mixed results on the importance of fertility 
to male cancer patients as illustrated in the quality of life surveys. We are in a time of 
transition in which more men are value active fatherhood, but there are still men who 
adhere to traditional gender roles. The survey results mirror this transition, as some surveys 
show that men are less interested in parenthood than women and other studies reveal that 
men’s and women’s interest in fertility are equivalent. If men’s interest in fatherhood 
continues to grow, we can expect that in the future, studies will uniformly find that women 
and men equally value parenthood.  
8. Clinical implications and conclusions 
The persistent gender bias – women’s bodies demand medical intervention while men’s 
bodies are left alone as long as there is a physical sign of sexual potency – is a historically 
important cultural phenomenon that continues to shape current conceptions of femininity, 
masculinity, and fertility. Understanding the history of the differences in medical treatment 
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of infertility provides a unique contextualization of contemporary cancer patients’ views on 
their fertility and the possibility of their future infertility. Quality of life studies consistently 
show that fertility is very important to female cancer patients and while the results for male 
cancer patients are mixed, many men do strongly value their fertility. These social science 
studies, however, are often not translated into clinical practice by health care providers. 
Instead, many providers continue to make assumptions “based on the patient’s age, sex, 
diagnosis, culture, and partnership status without checking with the patient” (Horden and 
Street, 2007, p. 227). Furthermore, providers’ personal characteristics (e.g. age, sex, etc.) can 
also influence whether they discuss fertility preservation treatment with their patients. For 
example, a recent study found that female oncologists were more likely to refer their 
patients to a reproductive endocrinologist or infertility specialist compared to male 
oncologists. While discussions and referrals for fertility preservation among adult cancer 
patients are improving, they remain suboptimal: only forty-seven percent of respondents 
always or often refer cancer patients of childbearing age to a reproductive endocrinologist 
or infertility specialist (Quinn, 2009). Health care providers need to openly address potential 
infertility as a consequence of cancer treatment so that their patients are informed about and 
offered fertility preservation options.   
By contextualizing female and male cancer patients’ views on infertility within a historical 
framework, we have shown that these differences in views are not innate, but rather are 
shaped by gender norms, both historical and current. Understanding the social factors that 
influence people’s views on infertility will enable health care providers to better aid their 
patients in their fertility preservation decision making. In other words, situating patients 
within their social environment, rather than seeing them as free floating individuals or 
reducing them to their diseases, allows providers to acknowledge the various social factors 
that contribute to and are at stake in decisions about fertility preservation treatment. 
Familiarity with gender norms as well as recognition they are changing (especially the role 
of fatherhood for men) equips providers with the ability to understand the discrepancy 
between women’s and men’s views and the discrepancy among men’s views on infertility. 
This can help providers be more empathetic to their patients’ needs and concerns, while at 
the same time not pigeonholing patients by sex/gender.  
Various health organizations, including ASCO and ASRM, have issued guidelines on fertility 
preservation to their practitioners for all cancer patients stating that “the available evidence 
suggests that fertility preservation is of great importance to many people diagnosed with 
cancer” (Lee, 2006, p. 2921; Ethics Committee of ASRM, 2005). While it is important for these 
organizations to set guidelines, the mere existence and dissemination of guidelines may not be 
enough to make substantial changes in provider referrals for fertility preservation treatment. A 
deeper appreciation for the social factors involved in patients’ views on infertility may 
engender greater change and specifically more referrals for fertility preservation treatment. 
Safeguarding fertility for cancer patients should be considered as important of a quality of life 
issue as breast reconstruction and hair replacement (Campo-Engelstein, 2010), and the options 
for fertility preservation should be part of the discussion regarding a patient’s cancer treatment 
– regardless of gender. Doing so respects both women’s and men’s desire to be – or at least 
retain the possibility of being – biological parents.  
The best way to ensure that these historical foundations and social factors are integrated 
into clinical care is through the development of an appropriate intervention. By creating 
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both provider and patient education materials that contextualize fertility preservation 
choices within the social environments in which they occur, as well as offering patients 
coping strategies that recognize their unique gendered responses, we can help address 
relevant patient concerns and enhance decision-making capabilities. Jordan et al. (1999) has 
recognized that significant gender differences exist in coping strategies for infertility, and 
these differences need to be addressed in the development of patient education materials 
that offer coping strategies (Jordan, 1999). Both historically and presently, infertility has 
been described as a devastating diagnosis for cancer patients, both female and male. 
Recognizing and outlining the historical influences that have contributed in creating this 
distress, as well as the current social factors that reinforce it, is a step in the right direction. 
Incorporating these analyses into the development of interdisciplinary patient and provider 
education materials is the next step towards translating these findings into clinical practice.  
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of infertility provides a unique contextualization of contemporary cancer patients’ views on 
their fertility and the possibility of their future infertility. Quality of life studies consistently 
show that fertility is very important to female cancer patients and while the results for male 
cancer patients are mixed, many men do strongly value their fertility. These social science 
studies, however, are often not translated into clinical practice by health care providers. 
Instead, many providers continue to make assumptions “based on the patient’s age, sex, 
diagnosis, culture, and partnership status without checking with the patient” (Horden and 
Street, 2007, p. 227). Furthermore, providers’ personal characteristics (e.g. age, sex, etc.) can 
also influence whether they discuss fertility preservation treatment with their patients. For 
example, a recent study found that female oncologists were more likely to refer their 
patients to a reproductive endocrinologist or infertility specialist compared to male 
oncologists. While discussions and referrals for fertility preservation among adult cancer 
patients are improving, they remain suboptimal: only forty-seven percent of respondents 
always or often refer cancer patients of childbearing age to a reproductive endocrinologist 
or infertility specialist (Quinn, 2009). Health care providers need to openly address potential 
infertility as a consequence of cancer treatment so that their patients are informed about and 
offered fertility preservation options.   
By contextualizing female and male cancer patients’ views on infertility within a historical 
framework, we have shown that these differences in views are not innate, but rather are 
shaped by gender norms, both historical and current. Understanding the social factors that 
influence people’s views on infertility will enable health care providers to better aid their 
patients in their fertility preservation decision making. In other words, situating patients 
within their social environment, rather than seeing them as free floating individuals or 
reducing them to their diseases, allows providers to acknowledge the various social factors 
that contribute to and are at stake in decisions about fertility preservation treatment. 
Familiarity with gender norms as well as recognition they are changing (especially the role 
of fatherhood for men) equips providers with the ability to understand the discrepancy 
between women’s and men’s views and the discrepancy among men’s views on infertility. 
This can help providers be more empathetic to their patients’ needs and concerns, while at 
the same time not pigeonholing patients by sex/gender.  
Various health organizations, including ASCO and ASRM, have issued guidelines on fertility 
preservation to their practitioners for all cancer patients stating that “the available evidence 
suggests that fertility preservation is of great importance to many people diagnosed with 
cancer” (Lee, 2006, p. 2921; Ethics Committee of ASRM, 2005). While it is important for these 
organizations to set guidelines, the mere existence and dissemination of guidelines may not be 
enough to make substantial changes in provider referrals for fertility preservation treatment. A 
deeper appreciation for the social factors involved in patients’ views on infertility may 
engender greater change and specifically more referrals for fertility preservation treatment. 
Safeguarding fertility for cancer patients should be considered as important of a quality of life 
issue as breast reconstruction and hair replacement (Campo-Engelstein, 2010), and the options 
for fertility preservation should be part of the discussion regarding a patient’s cancer treatment 
– regardless of gender. Doing so respects both women’s and men’s desire to be – or at least 
retain the possibility of being – biological parents.  
The best way to ensure that these historical foundations and social factors are integrated 
into clinical care is through the development of an appropriate intervention. By creating 
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both provider and patient education materials that contextualize fertility preservation 
choices within the social environments in which they occur, as well as offering patients 
coping strategies that recognize their unique gendered responses, we can help address 
relevant patient concerns and enhance decision-making capabilities. Jordan et al. (1999) has 
recognized that significant gender differences exist in coping strategies for infertility, and 
these differences need to be addressed in the development of patient education materials 
that offer coping strategies (Jordan, 1999). Both historically and presently, infertility has 
been described as a devastating diagnosis for cancer patients, both female and male. 
Recognizing and outlining the historical influences that have contributed in creating this 
distress, as well as the current social factors that reinforce it, is a step in the right direction. 
Incorporating these analyses into the development of interdisciplinary patient and provider 
education materials is the next step towards translating these findings into clinical practice.  
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